{"afaa4c5531e298412ff765a1fa12f8b46c6db982": [["Origin/DistributionEastern Purple Conefl ower is native to eastern North America.", [["Distribution", "OBSERVATION_MODIFIER", 7, 19], ["Eastern", "OBSERVATION_MODIFIER", 19, 26], ["Purple Conefl", "OBSERVATION", 27, 40]]], ["It is present to some extent in the wild in much of the eastern, southeastern and midwest United States.AgroecologyIn its native temperate range, it occurs in open woodlands, thickets, prairies, near waterways and roadsides.", [["some", "OBSERVATION_MODIFIER", 17, 21], ["extent", "OBSERVATION_MODIFIER", 22, 28], ["native", "OBSERVATION_MODIFIER", 122, 128], ["temperate range", "OBSERVATION_MODIFIER", 129, 144], ["open", "OBSERVATION_MODIFIER", 159, 163], ["woodlands", "OBSERVATION", 164, 173]]], ["It is extensively grown as ornamentals in gardens and parks and is also cultivated commercially as an herbal remedy.", [["an herbal remedy", "TREATMENT", 99, 115], ["grown", "OBSERVATION_MODIFIER", 18, 23]]], ["E. purpurea thrives best in full sun and is shade intolerant.", [["E. purpurea", "ORGANISM", 0, 11], ["E. purpurea", "SPECIES", 0, 11], ["E. purpurea", "SPECIES", 0, 11], ["shade intolerant", "PROBLEM", 44, 60], ["purpurea thrives", "OBSERVATION", 3, 19], ["shade intolerant", "OBSERVATION", 44, 60]]], ["It is not fastidious of soil pH but plant prefers loamy or sandy, well-drained soils.", [["soil pH", "PROBLEM", 24, 31], ["not", "UNCERTAINTY", 6, 9], ["fastidious", "OBSERVATION_MODIFIER", 10, 20], ["drained", "OBSERVATION", 71, 78]]], ["It is also quite drought tolerant.Edible Plant Parts and UsesThe petals are edible.", [["petals", "ANATOMY", 65, 71], ["petals", "ORGAN", 65, 71], ["Edible Plant Parts", "TREATMENT", 34, 52], ["drought tolerant", "OBSERVATION", 17, 33], ["Plant Parts", "OBSERVATION", 41, 52]]], ["Some dishes include echinacea Pane bagno (bathed bread) decorated with fresh echinacea petals and a wedge of lemon, American Indian savoury echinacea spread, echinacea and melon fruit salad (Roberts 2000 ) .", [["petals", "ANATOMY", 87, 93], ["bread", "ORGANISM_SUBDIVISION", 49, 54], ["lemon", "ORGANISM_SUBDIVISION", 109, 114], ["echinacea Pane bagno", "SPECIES", 20, 40], ["bread", "SPECIES", 49, 54], ["lemon", "SPECIES", 109, 114], ["savoury echinacea", "SPECIES", 132, 149], ["echinacea", "SPECIES", 158, 167], ["melon", "SPECIES", 172, 177], ["fruit", "SPECIES", 178, 183], ["American Indian savoury echinacea", "SPECIES", 116, 149], ["melon fruit salad (Roberts 2000 )", "SPECIES", 172, 205], ["Some dishes", "PROBLEM", 0, 11], ["echinacea Pane bagno", "TREATMENT", 20, 40], ["fresh echinacea petals", "TREATMENT", 71, 93], ["a wedge of lemon", "TREATMENT", 98, 114], ["echinacea Pane", "OBSERVATION", 20, 34], ["echinacea petals", "OBSERVATION", 77, 93], ["wedge", "OBSERVATION_MODIFIER", 100, 105]]], ["Petals are fried with watercress, onion and mustard leaves and spread over sweet potatoes.BotanyA herbaceous perennial 5-120 cm high with erect, branched brownish-green glabrous or hairy stems (Plate 1 ) and fi brous roots.", [["onion", "ANATOMY", 34, 39], ["leaves", "ANATOMY", 52, 58], ["hairy stems", "ANATOMY", 181, 192], ["roots", "ANATOMY", 217, 222], ["watercress, onion and mustard", "CHEMICAL", 22, 51], ["BotanyA", "CHEMICAL", 90, 97], ["onion", "TISSUE", 34, 39], ["potatoes", "ORGANISM_SUBDIVISION", 81, 89], ["glabrous", "TISSUE", 169, 177], ["brous roots", "MULTI-TISSUE_STRUCTURE", 211, 222], ["onion", "SPECIES", 34, 39], ["potatoes", "SPECIES", 81, 89], ["sweet potatoes", "SPECIES", 75, 89], ["BotanyA herbaceous perennial", "TEST", 90, 118], ["erect", "TEST", 138, 143], ["Plate", "TEST", 194, 199], ["herbaceous", "OBSERVATION_MODIFIER", 98, 108], ["perennial", "OBSERVATION_MODIFIER", 109, 118], ["120 cm", "OBSERVATION_MODIFIER", 121, 127], ["branched", "OBSERVATION_MODIFIER", 145, 153], ["brownish", "OBSERVATION", 154, 162], ["green glabrous", "ANATOMY", 163, 177], ["hairy stems", "OBSERVATION", 181, 192], ["fi", "ANATOMY_MODIFIER", 208, 210], ["brous roots", "ANATOMY", 211, 222]]], ["Leaves alternate, simple and lower leaves broader ovate (Plate 2 ) and petiolate with weakly winged petioles, lengths decreasing in upper leaves, lamina ovate lanceolate to narrolyl lanceolate, 5-30 by 5-12 cm, margins serrate, apex acute, base rounded to acute.", [["Leaves", "ANATOMY", 0, 6], ["petioles", "ANATOMY", 100, 108], ["leaves", "ANATOMY", 138, 144], ["narrolyl", "CHEMICAL", 173, 181], ["narrolyl", "CHEMICAL", 173, 181], ["petioles", "ORGANISM_SUBDIVISION", 100, 108], ["upper", "ORGANISM_SUBDIVISION", 132, 137], ["leaves", "ORGANISM_SUBDIVISION", 138, 144], ["lamina ovate lanceolate", "TISSUE", 146, 169], ["simple and lower leaves broader ovate (Plate", "TREATMENT", 18, 62], ["narrolyl lanceolate", "TREATMENT", 173, 192], ["apex acute, base rounded to acute", "PROBLEM", 228, 261], ["upper", "ANATOMY_MODIFIER", 132, 137], ["leaves", "ANATOMY", 138, 144], ["lamina", "ANATOMY", 146, 152], ["apex", "ANATOMY_MODIFIER", 228, 232], ["acute", "OBSERVATION_MODIFIER", 233, 238], ["base", "ANATOMY_MODIFIER", 240, 244], ["rounded", "OBSERVATION_MODIFIER", 245, 252], ["acute", "OBSERVATION_MODIFIER", 256, 261]]], ["Flowering heads solitary on stout terminal peduncle, 8-25 cm (Plates 1 , 3 and 4 ).", [["stout terminal peduncle", "ANATOMY", 28, 51], ["terminal peduncle", "MULTI-TISSUE_STRUCTURE", 34, 51], ["Plates", "TEST", 62, 68], ["heads", "OBSERVATION_MODIFIER", 10, 15], ["solitary", "OBSERVATION_MODIFIER", 16, 24], ["stout", "ANATOMY_MODIFIER", 28, 33], ["terminal", "ANATOMY_MODIFIER", 34, 42], ["peduncle", "ANATOMY_MODIFIER", 43, 51], ["8-25 cm", "OBSERVATION_MODIFIER", 53, 60]]], ["Involucral bracts linear to lanceolate.", [["Involucral bracts linear to lanceolate", "PROBLEM", 0, 38], ["bracts", "OBSERVATION_MODIFIER", 11, 17], ["linear", "OBSERVATION_MODIFIER", 18, 24]]], ["Receptacle with 9-15 mm palea, red orange tipped, slightly curve and pointed.", [["palea", "ANATOMY", 24, 29], ["red orange", "TEST", 31, 41], ["9-15 mm", "OBSERVATION_MODIFIER", 16, 23], ["red orange", "OBSERVATION_MODIFIER", 31, 41], ["tipped", "OBSERVATION_MODIFIER", 42, 48], ["slightly", "OBSERVATION_MODIFIER", 50, 58], ["curve", "OBSERVATION_MODIFIER", 59, 64]]], ["Discs conic to subglobose 1.4-45.5 by 2-4 cm, disc fl orets corolla greenish to pink or purple, 1.5-4.5 \u00d7 2-4 cm.", [["Discs conic", "TEST", 0, 11], ["subglobose", "TEST", 15, 25], ["disc fl orets corolla", "TEST", 46, 67], ["conic", "OBSERVATION_MODIFIER", 6, 11], ["disc", "ANATOMY", 46, 50], ["fl", "ANATOMY", 51, 53], ["corolla", "OBSERVATION_MODIFIER", 60, 67], ["greenish", "OBSERVATION_MODIFIER", 68, 76], ["pink", "OBSERVATION_MODIFIER", 80, 84], ["purple", "OBSERVATION_MODIFIER", 88, 94], ["1.5-4.5 \u00d7 2-4 cm", "OBSERVATION_MODIFIER", 96, 112]]], ["Ray fl orets corolla pink to purple pink to purple, laminae spreading to recurved, 3-8 cm \u00d7 0.8-2 cm, two-toothed at apex, sparsely hairy abaxially (Plates 1 , 3 and 4 ).", [["laminae", "ANATOMY", 52, 59], ["laminae", "TISSUE", 52, 59], ["Ray fl orets", "TEST", 0, 12], ["laminae spreading", "TEST", 52, 69], ["Plates", "TEST", 149, 155], ["fl", "ANATOMY", 4, 6], ["corolla", "OBSERVATION_MODIFIER", 13, 20], ["pink", "OBSERVATION_MODIFIER", 21, 25], ["purple", "OBSERVATION_MODIFIER", 29, 35], ["pink", "OBSERVATION_MODIFIER", 36, 40], ["to purple", "OBSERVATION_MODIFIER", 41, 50], ["laminae", "OBSERVATION_MODIFIER", 52, 59], ["spreading", "OBSERVATION_MODIFIER", 60, 69], ["3-8 cm \u00d7 0.8-2 cm", "OBSERVATION_MODIFIER", 83, 100], ["apex", "ANATOMY_MODIFIER", 117, 121], ["sparsely", "OBSERVATION_MODIFIER", 123, 131], ["hairy", "OBSERVATION_MODIFIER", 132, 137]]], ["Cypselae, 3-4 angled, glabrous, tan or bicoloured with a dark brown distal band, pappi persistent, 1.2 mm with 0-4 prominent teeth.Plant/Cell Culture PhytochemicalsTraces of pyrrolizidine alkaloids (0.006 %) tussilagine and isotussilagine were found in dried materials of Echinacea angustifolia and E. purpurea (Roder et al. 1984 ) .Plant/Cell Culture PhytochemicalsA 35-kDa water-soluble, acidic polysaccharide, 4-O -methyl-glucuronoarabinoxylan, was isolated from hemicellulosic fraction of E. purpurea and characterized by Wagner et al. ( 1984 Wagner et al. ( , 1985 and Proksch and Wagner ( 1987 ) .", [["glabrous", "ANATOMY", 22, 30], ["teeth", "ANATOMY", 125, 130], ["Cell", "ANATOMY", 137, 141], ["Cell", "ANATOMY", 339, 343], ["pyrrolizidine alkaloids", "CHEMICAL", 174, 197], ["tussilagine", "CHEMICAL", 208, 219], ["isotussilagine", "CHEMICAL", 224, 238], ["Echinacea angustifolia", "CHEMICAL", 272, 294], ["4-O -methyl-glucuronoarabinoxylan", "CHEMICAL", 413, 446], ["pyrrolizidine alkaloids", "CHEMICAL", 174, 197], ["tussilagine", "CHEMICAL", 208, 219], ["isotussilagine", "CHEMICAL", 224, 238], ["4-O -methyl-glucuronoarabinoxylan", "CHEMICAL", 413, 446], ["glabrous", "TISSUE", 22, 30], ["teeth", "ORGAN", 125, 130], ["Cell", "CELL", 137, 141], ["pyrrolizidine alkaloids", "SIMPLE_CHEMICAL", 174, 197], ["tussilagine", "SIMPLE_CHEMICAL", 208, 219], ["isotussilagine", "SIMPLE_CHEMICAL", 224, 238], ["Echinacea angustifolia", "ORGANISM", 272, 294], ["E. purpurea", "ORGANISM", 299, 310], ["Cell", "CELL", 339, 343], ["4-O -methyl-glucuronoarabinoxylan", "SIMPLE_CHEMICAL", 413, 446], ["E. purpurea", "ORGANISM", 493, 504], ["Echinacea angustifolia", "SPECIES", 272, 294], ["E. purpurea", "SPECIES", 299, 310], ["E. purpurea", "SPECIES", 493, 504], ["Echinacea angustifolia", "SPECIES", 272, 294], ["E. purpurea", "SPECIES", 299, 310], ["E. purpurea", "SPECIES", 493, 504], ["Cypselae", "TEST", 0, 8], ["a dark brown distal band", "PROBLEM", 55, 79], ["pappi", "TEST", 81, 86], ["Plant/Cell Culture", "TEST", 131, 149], ["pyrrolizidine alkaloids", "TREATMENT", 174, 197], ["tussilagine", "TREATMENT", 208, 219], ["isotussilagine", "TREATMENT", 224, 238], ["Echinacea angustifolia", "PROBLEM", 272, 294], ["Plant/Cell Culture", "TEST", 333, 351], ["PhytochemicalsA", "TEST", 352, 367], ["acidic polysaccharide", "TEST", 390, 411], ["methyl-glucuronoarabinoxylan", "TREATMENT", 418, 446], ["angled", "OBSERVATION_MODIFIER", 14, 20], ["glabrous", "ANATOMY", 22, 30], ["dark", "OBSERVATION_MODIFIER", 57, 61], ["brown", "OBSERVATION_MODIFIER", 62, 67], ["distal band", "OBSERVATION", 68, 79], ["persistent", "OBSERVATION_MODIFIER", 87, 97], ["1.2 mm", "OBSERVATION_MODIFIER", 99, 105], ["prominent", "OBSERVATION_MODIFIER", 115, 124], ["teeth", "OBSERVATION", 125, 130], ["Cell", "OBSERVATION", 137, 141], ["Echinacea angustifolia", "OBSERVATION", 272, 294], ["E. purpurea", "OBSERVATION", 493, 504]]], ["The polysaccharide contained a (1 \u2192 4)-linked \u03b2-D -xylan backbone with branching points at C-2 and C-3.", [["\u03b2-D -xylan", "CHEMICAL", 46, 56], ["\u03b2-D -xylan", "CHEMICAL", 46, 56], ["polysaccharide", "SIMPLE_CHEMICAL", 4, 18], ["(1 \u2192 4)", "SIMPLE_CHEMICAL", 31, 38], ["\u03b2-D -xylan backbone", "SIMPLE_CHEMICAL", 46, 65], ["C-2", "SIMPLE_CHEMICAL", 91, 94], ["C-3", "SIMPLE_CHEMICAL", 99, 102], ["The polysaccharide", "TEST", 0, 18], ["branching", "OBSERVATION_MODIFIER", 71, 80]]], ["Three homogeneous polysaccharides, two neutral fucogalactoxyloglucans with mean molecular weight of 10,000 and 25,000 and an acidic arabinogalactan with a mean molecular weight of 75,000 were isolated from the medium of Echinacea purpurea cell cultures ).", [["cell cultures", "ANATOMY", 239, 252], ["fucogalactoxyloglucans", "CHEMICAL", 47, 69], ["fucogalactoxyloglucans", "CHEMICAL", 47, 69], ["fucogalactoxyloglucans", "SIMPLE_CHEMICAL", 47, 69], ["Echinacea", "ORGANISM", 220, 229], ["purpurea cell cultures", "CELL", 230, 252], ["Echinacea purpurea cell cultures", "CELL_LINE", 220, 252], ["Echinacea purpurea", "SPECIES", 220, 238], ["Echinacea purpurea", "SPECIES", 220, 238], ["two neutral fucogalactoxyloglucans", "TEST", 35, 69], ["mean molecular weight", "TEST", 75, 96], ["an acidic arabinogalactan", "TEST", 122, 147], ["a mean molecular weight", "TEST", 153, 176], ["Echinacea purpurea cell cultures", "TEST", 220, 252], ["homogeneous", "OBSERVATION_MODIFIER", 6, 17], ["polysaccharides", "OBSERVATION", 18, 33]]], ["An arabinogalactan protein (AGP) with molecular weight 1.2 \u00d7 10 6 Da, from pressed juice of Echinacea purpurea , was isolated from a high molecular weight fraction by precipitation with the \u03b2-glucosyl Yariv reagent (Classen et al. 2000 ) .", [["juice", "ANATOMY", 83, 88], ["Echinacea purpurea", "CHEMICAL", 92, 110], ["\u03b2-glucosyl", "CHEMICAL", 190, 200], ["\u03b2-glucosyl", "CHEMICAL", 190, 200], ["arabinogalactan protein", "GENE_OR_GENE_PRODUCT", 3, 26], ["AGP", "GENE_OR_GENE_PRODUCT", 28, 31], ["juice", "ORGANISM_SUBSTANCE", 83, 88], ["Echinacea", "ORGANISM", 92, 101], ["purpurea", "ORGANISM", 102, 110], ["arabinogalactan protein", "PROTEIN", 3, 26], ["AGP", "PROTEIN", 28, 31], ["Echinacea purpurea", "SPECIES", 92, 110], ["Echinacea purpurea", "SPECIES", 92, 110], ["An arabinogalactan protein", "TEST", 0, 26], ["AGP", "TEST", 28, 31], ["molecular weight", "TEST", 38, 54], ["Echinacea purpurea", "PROBLEM", 92, 110], ["a high molecular weight fraction", "TREATMENT", 131, 163], ["the \u03b2-glucosyl Yariv reagent", "TREATMENT", 186, 214], ["arabinogalactan protein", "OBSERVATION", 3, 26], ["Echinacea purpurea", "OBSERVATION", 92, 110]]], ["It comprised a high amount of polysaccharide (83 %) with a ratio of galactose to arabinose of 1.8:1, some uronic acids (4-5 %) and a lowprotein content (7 %) with high levels of serine, alanine and hydroxyproline.", [["galactose", "CHEMICAL", 68, 77], ["arabinose", "CHEMICAL", 81, 90], ["uronic acids", "CHEMICAL", 106, 118], ["alanine", "CHEMICAL", 186, 193], ["hydroxyproline", "CHEMICAL", 198, 212], ["galactose", "CHEMICAL", 68, 77], ["arabinose", "CHEMICAL", 81, 90], ["uronic acids", "CHEMICAL", 106, 118], ["lowprotein", "CHEMICAL", 133, 143], ["serine", "CHEMICAL", 178, 184], ["alanine", "CHEMICAL", 186, 193], ["hydroxyproline", "CHEMICAL", 198, 212], ["polysaccharide", "SIMPLE_CHEMICAL", 30, 44], ["galactose", "SIMPLE_CHEMICAL", 68, 77], ["arabinose", "SIMPLE_CHEMICAL", 81, 90], ["1.8:1", "SIMPLE_CHEMICAL", 94, 99], ["uronic acids", "SIMPLE_CHEMICAL", 106, 118], ["lowprotein", "SIMPLE_CHEMICAL", 133, 143], ["serine", "AMINO_ACID", 178, 184], ["alanine", "AMINO_ACID", 186, 193], ["hydroxyproline", "SIMPLE_CHEMICAL", 198, 212], ["a high amount of polysaccharide", "PROBLEM", 13, 44], ["arabinose", "TEST", 81, 90], ["some uronic acids", "TEST", 101, 118], ["a lowprotein content", "TEST", 131, 151], ["high levels of serine", "PROBLEM", 163, 184], ["alanine", "TREATMENT", 186, 193], ["hydroxyproline", "TREATMENT", 198, 212], ["high", "OBSERVATION_MODIFIER", 15, 19], ["amount", "OBSERVATION_MODIFIER", 20, 26], ["polysaccharide", "OBSERVATION_MODIFIER", 30, 44], ["uronic acids", "OBSERVATION", 106, 118]]], ["The amino acid profi le in the arabinogalactan protein comprised serine 16 %, alanine 12.5 %, hydroxyproline 11.5 %, asparagine/aspartic acid 10.6 %, threonine 10.5 %, glutamine/glutamic acid 9.4 %, arginine 7.5 %, glycine 4.6 %, valine 4.1 %, histidine 3.7 %, lysine 3.3 %, leucine 2.5 %, isoleucine 2.2 % and phenylalanine 1,6 %.", [["amino acid", "CHEMICAL", 4, 14], ["alanine", "CHEMICAL", 78, 85], ["hydroxyproline", "CHEMICAL", 94, 108], ["asparagine", "CHEMICAL", 117, 127], ["aspartic acid", "CHEMICAL", 128, 141], ["threonine", "CHEMICAL", 150, 159], ["glutamine", "CHEMICAL", 168, 177], ["glutamic acid", "CHEMICAL", 178, 191], ["arginine", "CHEMICAL", 199, 207], ["glycine", "CHEMICAL", 215, 222], ["valine", "CHEMICAL", 230, 236], ["histidine", "CHEMICAL", 244, 253], ["lysine", "CHEMICAL", 261, 267], ["leucine", "CHEMICAL", 275, 282], ["isoleucine", "CHEMICAL", 290, 300], ["phenylalanine", "CHEMICAL", 311, 324], ["amino acid", "CHEMICAL", 4, 14], ["serine", "CHEMICAL", 65, 71], ["alanine", "CHEMICAL", 78, 85], ["hydroxyproline", "CHEMICAL", 94, 108], ["asparagine", "CHEMICAL", 117, 127], ["aspartic acid", "CHEMICAL", 128, 141], ["threonine", "CHEMICAL", 150, 159], ["glutamine", "CHEMICAL", 168, 177], ["glutamic acid", "CHEMICAL", 178, 191], ["arginine", "CHEMICAL", 199, 207], ["glycine", "CHEMICAL", 215, 222], ["valine", "CHEMICAL", 230, 236], ["histidine", "CHEMICAL", 244, 253], ["lysine", "CHEMICAL", 261, 267], ["leucine", "CHEMICAL", 275, 282], ["isoleucine", "CHEMICAL", 290, 300], ["phenylalanine", "CHEMICAL", 311, 324], ["amino acid", "AMINO_ACID", 4, 14], ["arabinogalactan", "GENE_OR_GENE_PRODUCT", 31, 46], ["serine", "AMINO_ACID", 65, 71], ["alanine", "AMINO_ACID", 78, 85], ["hydroxyproline", "SIMPLE_CHEMICAL", 94, 108], ["asparagine", "AMINO_ACID", 117, 127], ["aspartic acid", "AMINO_ACID", 128, 141], ["threonine", "AMINO_ACID", 150, 159], ["glutamine", "AMINO_ACID", 168, 177], ["glutamic acid", "AMINO_ACID", 178, 191], ["arginine", "AMINO_ACID", 199, 207], ["glycine", "AMINO_ACID", 215, 222], ["valine", "AMINO_ACID", 230, 236], ["histidine", "AMINO_ACID", 244, 253], ["lysine", "AMINO_ACID", 261, 267], ["leucine", "AMINO_ACID", 275, 282], ["isoleucine", "AMINO_ACID", 290, 300], ["phenylalanine", "AMINO_ACID", 311, 324], ["arabinogalactan protein", "PROTEIN", 31, 54], ["The amino acid profi le", "TREATMENT", 0, 23], ["alanine", "TEST", 78, 85], ["hydroxyproline", "TREATMENT", 94, 108], ["asparagine/aspartic acid", "TREATMENT", 117, 141], ["threonine", "TREATMENT", 150, 159], ["glutamine/glutamic acid", "TREATMENT", 168, 191], ["arginine", "TREATMENT", 199, 207], ["glycine", "TREATMENT", 215, 222], ["valine", "TREATMENT", 230, 236], ["histidine", "TREATMENT", 244, 253], ["lysine", "TREATMENT", 261, 267], ["leucine", "TREATMENT", 275, 282], ["isoleucine", "TREATMENT", 290, 300], ["phenylalanine", "TREATMENT", 311, 324]]], ["The monosaccharide profi le in the arabinogalactan protein comprised galactose 59.1, arabinose 33.2, glucosamine 4.0 %, mannose 2.6 % and rhamnose 1.1 %.", [["monosaccharide profi le", "CHEMICAL", 4, 27], ["galactose 59.1, arabinose 33.2,", "CHEMICAL", 69, 100], ["glucosamine", "CHEMICAL", 101, 112], ["mannose", "CHEMICAL", 120, 127], ["rhamnose", "CHEMICAL", 138, 146], ["monosaccharide", "CHEMICAL", 4, 18], ["galactose", "CHEMICAL", 69, 78], ["arabinose", "CHEMICAL", 85, 94], ["glucosamine", "CHEMICAL", 101, 112], ["mannose", "CHEMICAL", 120, 127], ["rhamnose", "CHEMICAL", 138, 146], ["galactose 59.1", "SIMPLE_CHEMICAL", 69, 83], ["arabinose 33.2", "SIMPLE_CHEMICAL", 85, 99], ["glucosamine", "SIMPLE_CHEMICAL", 101, 112], ["mannose", "SIMPLE_CHEMICAL", 120, 127], ["rhamnose", "SIMPLE_CHEMICAL", 138, 146], ["arabinogalactan protein", "PROTEIN", 35, 58], ["The monosaccharide profi le", "TEST", 0, 27], ["the arabinogalactan protein", "TEST", 31, 58], ["galactose", "TEST", 69, 78], ["arabinose", "TEST", 85, 94], ["glucosamine", "TEST", 101, 112], ["mannose", "TEST", 120, 127], ["rhamnose", "TEST", 138, 146]]], ["The molecular weight arabinogalactan protein (AGP) from the pressed juice of Echinacea purpurea was found to have hydroxyproline (42.9 % w/w) as the dominant amino acid and the major amino acid responsible for the binding between the protein and the arabinogalactan subunits via an O -glycosidic linkage (Volk et al. 2007 ).", [["juice", "ANATOMY", 68, 73], ["Echinacea purpurea", "CHEMICAL", 77, 95], ["hydroxyproline", "CHEMICAL", 114, 128], ["amino acid", "CHEMICAL", 158, 168], ["amino acid", "CHEMICAL", 183, 193], ["hydroxyproline", "CHEMICAL", 114, 128], ["amino acid", "CHEMICAL", 158, 168], ["amino acid", "CHEMICAL", 183, 193], ["O", "CHEMICAL", 282, 283], ["arabinogalactan protein", "GENE_OR_GENE_PRODUCT", 21, 44], ["AGP", "GENE_OR_GENE_PRODUCT", 46, 49], ["juice", "ORGANISM_SUBSTANCE", 68, 73], ["Echinacea purpurea", "ORGANISM", 77, 95], ["hydroxyproline", "SIMPLE_CHEMICAL", 114, 128], ["amino acid", "AMINO_ACID", 158, 168], ["amino acid", "AMINO_ACID", 183, 193], ["arabinogalactan protein", "PROTEIN", 21, 44], ["AGP", "PROTEIN", 46, 49], ["arabinogalactan subunits", "PROTEIN", 250, 274], ["Echinacea purpurea", "SPECIES", 77, 95], ["Echinacea purpurea", "SPECIES", 77, 95], ["The molecular weight arabinogalactan protein", "TEST", 0, 44], ["AGP", "TEST", 46, 49], ["Echinacea purpurea", "PROBLEM", 77, 95], ["hydroxyproline", "TEST", 114, 128], ["the dominant amino acid", "TREATMENT", 145, 168], ["the major amino acid", "PROBLEM", 173, 193], ["the arabinogalactan subunits", "TREATMENT", 246, 274], ["Echinacea purpurea", "OBSERVATION", 77, 95]]], ["Large amounts of glutamine/ glutamic acid (24.5 % w/w) and asparagine/ aspartic acid (17.3 % w/w) were also found.", [["glutamine", "CHEMICAL", 17, 26], ["glutamic acid", "CHEMICAL", 28, 41], ["asparagine", "CHEMICAL", 59, 69], ["aspartic acid", "CHEMICAL", 71, 84], ["glutamine", "CHEMICAL", 17, 26], ["glutamic acid", "CHEMICAL", 28, 41], ["asparagine", "CHEMICAL", 59, 69], ["aspartic acid", "CHEMICAL", 71, 84], ["glutamine", "AMINO_ACID", 17, 26], ["glutamic acid", "AMINO_ACID", 28, 41], ["asparagine", "AMINO_ACID", 59, 69], ["aspartic acid", "AMINO_ACID", 71, 84], ["glutamine/ glutamic acid", "TEST", 17, 41], ["asparagine/ aspartic acid", "TEST", 59, 84], ["amounts", "OBSERVATION_MODIFIER", 6, 13]]], ["Another arabinogalactan protein was purifi ed from E. purpurea suspension culture (Classen 2007 ) .", [["arabinogalactan", "GENE_OR_GENE_PRODUCT", 8, 23], ["arabinogalactan protein", "PROTEIN", 8, 31], ["E. purpurea", "SPECIES", 51, 62], ["E. purpurea", "SPECIES", 51, 62], ["Another arabinogalactan protein", "TEST", 0, 31], ["purpurea suspension culture", "TEST", 54, 81]]], ["It comprised high amount of polysaccharide (90 % w/w) with the dominating monosaccharides galactose and arabinose and some glucuronic acid and a small protein moiety (10 % w/w) with the main amino acids alanine, hydroxyproline, serine, glutamine/glutamic acid, asparagines/aspartic acid and threonine.", [["galactose", "CHEMICAL", 90, 99], ["arabinose", "CHEMICAL", 104, 113], ["glucuronic acid", "CHEMICAL", 123, 138], ["amino acids", "CHEMICAL", 191, 202], ["alanine", "CHEMICAL", 203, 210], ["hydroxyproline", "CHEMICAL", 212, 226], ["serine", "CHEMICAL", 228, 234], ["glutamine", "CHEMICAL", 236, 245], ["glutamic acid", "CHEMICAL", 246, 259], ["asparagines", "CHEMICAL", 261, 272], ["aspartic acid", "CHEMICAL", 273, 286], ["threonine", "CHEMICAL", 291, 300], ["galactose", "CHEMICAL", 90, 99], ["arabinose", "CHEMICAL", 104, 113], ["glucuronic acid", "CHEMICAL", 123, 138], ["amino acids", "CHEMICAL", 191, 202], ["alanine", "CHEMICAL", 203, 210], ["hydroxyproline", "CHEMICAL", 212, 226], ["serine", "CHEMICAL", 228, 234], ["glutamine", "CHEMICAL", 236, 245], ["glutamic acid", "CHEMICAL", 246, 259], ["asparagines", "CHEMICAL", 261, 272], ["aspartic acid", "CHEMICAL", 273, 286], ["threonine", "CHEMICAL", 291, 300], ["galactose", "SIMPLE_CHEMICAL", 90, 99], ["arabinose", "SIMPLE_CHEMICAL", 104, 113], ["glucuronic acid", "SIMPLE_CHEMICAL", 123, 138], ["amino acids", "AMINO_ACID", 191, 202], ["alanine", "AMINO_ACID", 203, 210], ["hydroxyproline", "SIMPLE_CHEMICAL", 212, 226], ["serine", "AMINO_ACID", 228, 234], ["glutamine", "AMINO_ACID", 236, 245], ["glutamic acid", "AMINO_ACID", 246, 259], ["asparagines", "SIMPLE_CHEMICAL", 261, 272], ["aspartic acid", "AMINO_ACID", 273, 286], ["threonine", "AMINO_ACID", 291, 300], ["polysaccharide", "TEST", 28, 42], ["the dominating monosaccharides galactose", "PROBLEM", 59, 99], ["arabinose", "TEST", 104, 113], ["some glucuronic acid", "TEST", 118, 138], ["a small protein moiety", "PROBLEM", 143, 165], ["the main amino acids alanine", "TREATMENT", 182, 210], ["hydroxyproline", "TREATMENT", 212, 226], ["serine", "TREATMENT", 228, 234], ["glutamine", "TREATMENT", 236, 245], ["glutamic acid", "TREATMENT", 246, 259], ["asparagines", "TREATMENT", 261, 272], ["aspartic acid", "TREATMENT", 273, 286], ["threonine", "TREATMENT", 291, 300], ["high", "OBSERVATION_MODIFIER", 13, 17], ["amount", "OBSERVATION_MODIFIER", 18, 24], ["polysaccharide", "OBSERVATION_MODIFIER", 28, 42], ["glucuronic acid", "OBSERVATION", 123, 138], ["small", "OBSERVATION_MODIFIER", 145, 150]]], ["The polysaccharide part was composed of a branched core-polysaccharide of 3-, 6-and 3,6-linked Galp residues with terminal Araf, Arap, Galp and GlcAp residues.", [["Galp", "CHEMICAL", 95, 99], ["Araf", "CHEMICAL", 123, 127], ["Arap", "CHEMICAL", 129, 133], ["Galp", "CHEMICAL", 135, 139], ["GlcAp", "CHEMICAL", 144, 149], ["3,6-linked Galp residues", "SIMPLE_CHEMICAL", 84, 108], ["terminal Araf", "SIMPLE_CHEMICAL", 114, 127], ["Arap", "SIMPLE_CHEMICAL", 129, 133], ["Galp", "SIMPLE_CHEMICAL", 135, 139], ["GlcAp", "SIMPLE_CHEMICAL", 144, 149], ["Galp residues", "PROTEIN", 95, 108], ["terminal Araf, Arap, Galp and GlcAp residues", "PROTEIN", 114, 158], ["polysaccharide", "TEST", 56, 70], ["terminal Araf", "TREATMENT", 114, 127], ["Galp and GlcAp residues", "TREATMENT", 135, 158], ["branched", "OBSERVATION_MODIFIER", 42, 50], ["Galp residues", "OBSERVATION", 95, 108], ["terminal Araf", "OBSERVATION", 114, 127], ["GlcAp residues", "OBSERVATION", 144, 158]]], ["Compared to an arabinogalactan protein from pressed juice of the aerial parts of Echinacea purpurea , differences particularly in terminal arabinose mono-and oligosaccharides in arabinogalactan (AG) side branches could be detected.Plant/Cell Culture PhytochemicalsTwo groups of minerals (I, Fe, Cu, Mn, Li and, II, Ca, Mg, Zn, Ni) were identifi ed in the aerial parts and roots of E. purpurea in Serbia (Razi\u0107 et al. 2003 ) .", [["juice", "ANATOMY", 52, 57], ["aerial parts", "ANATOMY", 65, 77], ["Cell", "ANATOMY", 237, 241], ["aerial parts", "ANATOMY", 355, 367], ["roots", "ANATOMY", 372, 377], ["arabinose", "CHEMICAL", 139, 148], ["arabinogalactan", "CHEMICAL", 178, 193], ["AG", "CHEMICAL", 195, 197], ["Fe", "CHEMICAL", 291, 293], ["Cu", "CHEMICAL", 295, 297], ["Mn", "CHEMICAL", 299, 301], ["Li", "CHEMICAL", 303, 305], ["Ca", "CHEMICAL", 315, 317], ["Mg", "CHEMICAL", 319, 321], ["Zn", "CHEMICAL", 323, 325], ["Ni", "CHEMICAL", 327, 329], ["arabinose", "CHEMICAL", 139, 148], ["I", "CHEMICAL", 288, 289], ["Fe", "CHEMICAL", 291, 293], ["Cu", "CHEMICAL", 295, 297], ["Mn", "CHEMICAL", 299, 301], ["Li", "CHEMICAL", 303, 305], ["II", "CHEMICAL", 311, 313], ["Ca", "CHEMICAL", 315, 317], ["Mg", "CHEMICAL", 319, 321], ["Zn", "CHEMICAL", 323, 325], ["Ni", "CHEMICAL", 327, 329], ["arabinogalactan", "GENE_OR_GENE_PRODUCT", 15, 30], ["juice", "ORGANISM_SUBSTANCE", 52, 57], ["Echinacea purpurea", "ORGANISM", 81, 99], ["arabinose", "SIMPLE_CHEMICAL", 139, 148], ["arabinogalactan (AG", "SIMPLE_CHEMICAL", 178, 197], ["Cell", "CELL", 237, 241], ["Fe", "SIMPLE_CHEMICAL", 291, 293], ["Cu", "SIMPLE_CHEMICAL", 295, 297], ["Mn", "SIMPLE_CHEMICAL", 299, 301], ["Li", "SIMPLE_CHEMICAL", 303, 305], ["Ca, Mg", "SIMPLE_CHEMICAL", 315, 321], ["Zn, Ni", "SIMPLE_CHEMICAL", 323, 329], ["aerial parts", "MULTI-TISSUE_STRUCTURE", 355, 367], ["roots", "ORGAN", 372, 377], ["E. purpurea", "ORGANISM", 381, 392], ["arabinogalactan protein", "PROTEIN", 15, 38], ["Echinacea purpurea", "SPECIES", 81, 99], ["E. purpurea", "SPECIES", 381, 392], ["Echinacea purpurea", "SPECIES", 81, 99], ["E. purpurea", "SPECIES", 381, 392], ["an arabinogalactan protein", "TEST", 12, 38], ["Echinacea purpurea", "PROBLEM", 81, 99], ["terminal arabinose mono", "TEST", 130, 153], ["oligosaccharides in arabinogalactan (AG) side branches", "TREATMENT", 158, 212], ["Plant/Cell Culture", "TEST", 231, 249], ["minerals", "TEST", 278, 286], ["Fe", "TEST", 291, 293], ["Mn", "TEST", 299, 301], ["Li", "TEST", 303, 305], ["Ca", "TEST", 315, 317], ["E. purpurea", "PROBLEM", 381, 392], ["Echinacea purpurea", "OBSERVATION", 81, 99], ["terminal", "OBSERVATION_MODIFIER", 130, 138], ["arabinose mono", "OBSERVATION", 139, 153], ["branches", "ANATOMY_MODIFIER", 204, 212], ["aerial", "ANATOMY_MODIFIER", 355, 361], ["roots", "ANATOMY_MODIFIER", 372, 377], ["E. purpurea", "OBSERVATION", 381, 392]]], ["The trace element profi les in the roots, stem, leaves and fl owers were found to differ signifi cantly.Plant/Cell Culture PhytochemicalsThe aerial parts of Echinacea purpurea afforded, in addition to known compounds, fi ve highly unsaturated acetylenic amides and a derivative of linolen (Bohlmann and Hoffmann 1983 ) .", [["roots", "ANATOMY", 35, 40], ["stem", "ANATOMY", 42, 46], ["leaves", "ANATOMY", 48, 54], ["Cell", "ANATOMY", 110, 114], ["aerial parts", "ANATOMY", 141, 153], ["Echinacea purpurea", "CHEMICAL", 157, 175], ["acetylenic amides", "CHEMICAL", 243, 260], ["linolen", "CHEMICAL", 281, 288], ["fi ve highly unsaturated acetylenic amides", "CHEMICAL", 218, 260], ["linolen", "CHEMICAL", 281, 288], ["roots", "ORGAN", 35, 40], ["stem", "TISSUE", 42, 46], ["leaves", "ORGANISM_SUBDIVISION", 48, 54], ["Cell Culture", "CELL", 110, 122], ["Echinacea purpurea", "ORGANISM", 157, 175], ["fi ve highly unsaturated acetylenic amides", "SIMPLE_CHEMICAL", 218, 260], ["linolen", "SIMPLE_CHEMICAL", 281, 288], ["Echinacea purpurea", "SPECIES", 157, 175], ["Echinacea purpurea", "SPECIES", 157, 175], ["Plant/Cell Culture", "TEST", 104, 122], ["Echinacea purpurea", "PROBLEM", 157, 175], ["known compounds", "PROBLEM", 201, 216], ["unsaturated acetylenic amides", "TREATMENT", 231, 260], ["a derivative of linolen (Bohlmann", "TREATMENT", 265, 298], ["trace", "OBSERVATION_MODIFIER", 4, 9], ["element", "OBSERVATION_MODIFIER", 10, 17], ["profi les", "OBSERVATION", 18, 27], ["roots", "ANATOMY", 35, 40], ["stem", "ANATOMY_MODIFIER", 42, 46], ["Cell", "OBSERVATION", 110, 114], ["Culture Phytochemicals", "OBSERVATION", 115, 137], ["Echinacea purpurea", "OBSERVATION", 157, 175], ["compounds", "OBSERVATION", 207, 216]]], ["The aerial parts of E. purpurea were found to contain different structural types of alkamides; the roots yielded similar alkamide pattern (Bauer and Reminger 1989 ) .", [["aerial parts", "ANATOMY", 4, 16], ["roots", "ANATOMY", 99, 104], ["alkamides", "CHEMICAL", 84, 93], ["alkamide", "CHEMICAL", 121, 129], ["alkamides", "CHEMICAL", 84, 93], ["alkamide", "CHEMICAL", 121, 129], ["E. purpurea", "ORGANISM", 20, 31], ["alkamides", "SIMPLE_CHEMICAL", 84, 93], ["roots", "ORGAN", 99, 104], ["alkamide", "SIMPLE_CHEMICAL", 121, 129], ["E. purpurea", "SPECIES", 20, 31], ["E. purpurea", "SPECIES", 20, 31], ["aerial", "ANATOMY_MODIFIER", 4, 10], ["purpurea", "OBSERVATION_MODIFIER", 23, 31], ["different", "OBSERVATION_MODIFIER", 54, 63], ["structural", "OBSERVATION_MODIFIER", 64, 74], ["types", "OBSERVATION_MODIFIER", 75, 80], ["roots", "ANATOMY", 99, 104]]], ["Alkamide levels differed signifi cantly among roots, rhizomes, stems, leaves and fl owers of E. purpurea (Perry et al. 1997) .", [["roots", "ANATOMY", 46, 51], ["rhizomes", "ANATOMY", 53, 61], ["stems", "ANATOMY", 63, 68], ["leaves", "ANATOMY", 70, 76], ["Alkamide", "CHEMICAL", 0, 8], ["Alkamide", "CHEMICAL", 0, 8], ["Alkamide", "SIMPLE_CHEMICAL", 0, 8], ["roots", "TISSUE", 46, 51], ["rhizomes", "TISSUE", 53, 61], ["stems", "TISSUE", 63, 68], ["leaves", "ORGANISM_SUBDIVISION", 70, 76], ["E. purpurea", "ORGANISM", 93, 104], ["E. purpurea", "SPECIES", 93, 104], ["E. purpurea", "SPECIES", 93, 104], ["Alkamide levels", "TEST", 0, 15]]], ["Roots were distinguished from other plant parts by higher levels of the C12 diene-diyne alkamides, whereas levels of the C12 tetraene alkamides and C11 diene-diynes were highest in vegetative stems.", [["vegetative stems", "ANATOMY", 181, 197], ["C12 diene-diyne", "CHEMICAL", 72, 87], ["alkamides", "CHEMICAL", 88, 97], ["C12 tetraene", "CHEMICAL", 121, 133], ["alkamides", "CHEMICAL", 134, 143], ["C11 diene-diynes", "CHEMICAL", 148, 164], ["C12 diene-diyne alkamides", "CHEMICAL", 72, 97], ["C12 tetraene alkamides", "CHEMICAL", 121, 143], ["C11 diene-diynes", "CHEMICAL", 148, 164], ["C12 diene-diyne alkamides", "SIMPLE_CHEMICAL", 72, 97], ["C12 tetraene alkamides", "SIMPLE_CHEMICAL", 121, 143], ["C11 diene-diynes", "SIMPLE_CHEMICAL", 148, 164], ["stems", "ORGAN", 192, 197], ["the C12 diene", "TREATMENT", 68, 81], ["the C12 tetraene alkamides", "TEST", 117, 143], ["vegetative stems", "OBSERVATION", 181, 197]]], ["The ratio of the 2 stereoisomeric C12 tetraene alkamides differed between fl owers and all other E. purpurea parts.", [["C12 tetraene", "CHEMICAL", 34, 46], ["alkamides", "CHEMICAL", 47, 56], ["C12 tetraene alkamides", "CHEMICAL", 34, 56], ["stereoisomeric C12 tetraene alkamides", "SIMPLE_CHEMICAL", 19, 56], ["E. purpurea", "SPECIES", 97, 108], ["The ratio", "TEST", 0, 9], ["the 2 stereoisomeric C12 tetraene alkamides", "TREATMENT", 13, 56], ["purpurea", "OBSERVATION", 100, 108]]], ["The alkylamides and cichoric acid in dried roots and aerial parts of E. purpurea grown in eastern Australia were determined as follows: total alkylamide concentration in root samples was 6.2 mg/g (range 1.2-12.1 mg/g) and in aerial samples was 1.0 mg/g (range 0.2-3.9 mg/g) (Wills and Stuart 1999 ) .", [["roots", "ANATOMY", 43, 48], ["aerial parts", "ANATOMY", 53, 65], ["root samples", "ANATOMY", 170, 182], ["aerial samples", "ANATOMY", 225, 239], ["alkylamides", "CHEMICAL", 4, 15], ["cichoric acid", "CHEMICAL", 20, 33], ["alkylamide", "CHEMICAL", 142, 152], ["alkylamides", "CHEMICAL", 4, 15], ["cichoric acid", "CHEMICAL", 20, 33], ["alkylamide", "CHEMICAL", 142, 152], ["alkylamides", "SIMPLE_CHEMICAL", 4, 15], ["cichoric acid", "SIMPLE_CHEMICAL", 20, 33], ["roots", "ORGAN", 43, 48], ["E. purpurea", "ORGANISM", 69, 80], ["alkylamide", "SIMPLE_CHEMICAL", 142, 152], ["root samples", "ORGANISM_SUBSTANCE", 170, 182], ["E. purpurea", "SPECIES", 69, 80], ["E. purpurea", "SPECIES", 69, 80], ["The alkylamides", "TREATMENT", 0, 15], ["cichoric acid in dried roots", "PROBLEM", 20, 48], ["E. purpurea", "PROBLEM", 69, 80], ["total alkylamide concentration", "TREATMENT", 136, 166], ["aerial samples", "TEST", 225, 239], ["cichoric acid", "OBSERVATION", 20, 33], ["dried roots", "OBSERVATION", 37, 48], ["aerial", "OBSERVATION_MODIFIER", 53, 59], ["parts", "OBSERVATION_MODIFIER", 60, 65], ["purpurea", "OBSERVATION_MODIFIER", 72, 80], ["grown", "OBSERVATION_MODIFIER", 81, 86]]], ["The cichoric acid concentration in root samples was 13.2 mg/g (range 1.4-20.5 mg/g) and in aerial samples was 12.9 mg/g (range 4.9-21.4 mg/g).", [["root samples", "ANATOMY", 35, 47], ["aerial samples", "ANATOMY", 91, 105], ["cichoric acid", "CHEMICAL", 4, 17], ["cichoric acid", "CHEMICAL", 4, 17], ["cichoric acid", "SIMPLE_CHEMICAL", 4, 17], ["root samples", "ORGANISM_SUBSTANCE", 35, 47], ["aerial samples", "ORGANISM_SUBSTANCE", 91, 105], ["The cichoric acid concentration", "TEST", 0, 31], ["root samples", "TEST", 35, 47], ["aerial samples", "TEST", 91, 105]]], ["Stuart and Wills ( 2000 ) found that total alkamide concentration in E. purpurea root, stem and leaf decreased throughout the fi rst growing season while the concentration in fl owers increased.", [["root", "ANATOMY", 81, 85], ["stem", "ANATOMY", 87, 91], ["leaf", "ANATOMY", 96, 100], ["alkamide", "CHEMICAL", 43, 51], ["alkamide", "CHEMICAL", 43, 51], ["alkamide", "SIMPLE_CHEMICAL", 43, 51], ["E. purpurea", "ORGANISM", 69, 80], ["root", "MULTI-TISSUE_STRUCTURE", 81, 85], ["stem", "TISSUE", 87, 91], ["leaf", "ORGAN", 96, 100], ["E. purpurea", "SPECIES", 69, 80], ["E. purpurea", "SPECIES", 69, 80], ["total alkamide concentration", "TREATMENT", 37, 65], ["stem and leaf", "PROBLEM", 87, 100], ["purpurea root", "OBSERVATION", 72, 85], ["stem", "ANATOMY_MODIFIER", 87, 91], ["leaf", "OBSERVATION_MODIFIER", 96, 100], ["decreased", "OBSERVATION_MODIFIER", 101, 110]]], ["In mature plants, the root contained about 70 % of the total plant alkamides with approximately 20 % in fl ower, 10 % in stem and 1 % in leaf tissue.", [["root", "ANATOMY", 22, 26], ["stem", "ANATOMY", 121, 125], ["leaf tissue", "ANATOMY", 137, 148], ["alkamides", "CHEMICAL", 67, 76], ["root", "ORGAN", 22, 26], ["alkamides", "SIMPLE_CHEMICAL", 67, 76], ["stem", "TISSUE", 121, 125], ["leaf tissue", "TISSUE", 137, 148], ["the total plant alkamides", "TREATMENT", 51, 76], ["mature", "OBSERVATION_MODIFIER", 3, 9], ["plants", "OBSERVATION", 10, 16], ["root", "OBSERVATION_MODIFIER", 22, 26], ["stem", "ANATOMY_MODIFIER", 121, 125], ["leaf tissue", "OBSERVATION", 137, 148]]], ["The relative proportion of individual alkamides in the root did not change during plant growth, but cichoric acid concentration in plant tissues did decrease during plant senescence.", [["root", "ANATOMY", 55, 59], ["tissues", "ANATOMY", 137, 144], ["alkamides", "CHEMICAL", 38, 47], ["cichoric acid", "CHEMICAL", 100, 113], ["alkamides", "CHEMICAL", 38, 47], ["cichoric acid", "CHEMICAL", 100, 113], ["alkamides", "GENE_OR_GENE_PRODUCT", 38, 47], ["root", "ORGAN", 55, 59], ["cichoric acid", "SIMPLE_CHEMICAL", 100, 113], ["plant tissues", "TISSUE", 131, 144], ["individual alkamides in the root", "PROBLEM", 27, 59], ["cichoric acid concentration in plant tissues", "PROBLEM", 100, 144], ["individual", "OBSERVATION_MODIFIER", 27, 37], ["alkamides", "OBSERVATION", 38, 47], ["root", "ANATOMY", 55, 59], ["growth", "OBSERVATION_MODIFIER", 88, 94], ["plant tissues", "OBSERVATION", 131, 144], ["decrease", "OBSERVATION_MODIFIER", 149, 157], ["plant senescence", "OBSERVATION", 165, 181]]], ["Similar concentrations of cichoric acid were measured in root, fl ower and leaf tissues, but stem levels were lower.", [["root", "ANATOMY", 57, 61], ["ower", "ANATOMY", 66, 70], ["leaf tissues", "ANATOMY", 75, 87], ["stem", "ANATOMY", 93, 97], ["cichoric acid", "CHEMICAL", 26, 39], ["cichoric acid", "CHEMICAL", 26, 39], ["cichoric acid", "SIMPLE_CHEMICAL", 26, 39], ["root", "TISSUE", 57, 61], ["leaf tissues", "TISSUE", 75, 87], ["stem", "CELL", 93, 97], ["cichoric acid", "PROBLEM", 26, 39], ["stem levels", "TEST", 93, 104], ["concentrations", "OBSERVATION_MODIFIER", 8, 22], ["cichoric acid", "OBSERVATION", 26, 39], ["root", "OBSERVATION_MODIFIER", 57, 61], ["fl ower", "OBSERVATION", 63, 70], ["leaf tissues", "OBSERVATION", 75, 87], ["stem levels", "OBSERVATION", 93, 104], ["lower", "OBSERVATION_MODIFIER", 110, 115]]], ["In mature plants, the fl ower and leaf each contained about 35 % of the total plant cichoric acid, while the root and stem contained approximately 20 and 10 %, respectively.", [["leaf", "ANATOMY", 34, 38], ["root", "ANATOMY", 109, 113], ["stem", "ANATOMY", 118, 122], ["cichoric acid", "CHEMICAL", 84, 97], ["cichoric acid", "CHEMICAL", 84, 97], ["fl ower", "ORGANISM", 22, 29], ["leaf", "ORGAN", 34, 38], ["cichoric acid", "SIMPLE_CHEMICAL", 84, 97], ["root", "TISSUE", 109, 113], ["stem", "TISSUE", 118, 122], ["mature", "OBSERVATION_MODIFIER", 3, 9], ["plants", "OBSERVATION", 10, 16], ["cichoric acid", "OBSERVATION", 84, 97], ["root", "ANATOMY_MODIFIER", 109, 113], ["stem", "ANATOMY_MODIFIER", 118, 122]]], ["Cichoric acid was the main phenolic in E. purpurea roots (mean 2.27 % summer, 1.68 % autumn) and tops (2.02 % summer, 0.52 % autumn) followed by caftaric acid was the other main phenolic compound in the roots (0.40 % summer, 0.35 % autumn) and tops (0.82 % sum-mer, 0.18 % autumn) (Perry et al. 2001 ) .", [["roots", "ANATOMY", 51, 56], ["roots", "ANATOMY", 203, 208], ["Cichoric acid", "CHEMICAL", 0, 13], ["caftaric acid", "CHEMICAL", 145, 158], ["Cichoric acid", "CHEMICAL", 0, 13], ["caftaric acid", "CHEMICAL", 145, 158], ["Cichoric acid", "SIMPLE_CHEMICAL", 0, 13], ["E. purpurea", "ORGANISM", 39, 50], ["roots", "ORGANISM", 51, 56], ["caftaric acid", "SIMPLE_CHEMICAL", 145, 158], ["roots", "ORGAN", 203, 208], ["E. purpurea", "SPECIES", 39, 50], ["E. purpurea", "SPECIES", 39, 50], ["Cichoric acid", "TEST", 0, 13], ["mean", "TEST", 58, 62], ["tops", "TEST", 97, 101], ["caftaric acid", "TEST", 145, 158], ["tops", "TEST", 244, 248], ["acid", "OBSERVATION_MODIFIER", 9, 13], ["main", "OBSERVATION_MODIFIER", 22, 26], ["phenolic", "OBSERVATION_MODIFIER", 27, 35], ["purpurea roots", "ANATOMY", 42, 56], ["main", "OBSERVATION_MODIFIER", 173, 177], ["phenolic compound", "OBSERVATION", 178, 195], ["roots", "ANATOMY", 203, 208]]], ["Autumngrown Echinacea purpurea plants in Taiwan produced more caffeoyl phenols, particularly cichoric acid and caftaric acid, in leaf and fl ower tissues than spring-grown plants (Chen et al. 2008 ) .", [["leaf", "ANATOMY", 129, 133], ["tissues", "ANATOMY", 146, 153], ["caffeoyl phenols", "CHEMICAL", 62, 78], ["cichoric acid", "CHEMICAL", 93, 106], ["caftaric acid", "CHEMICAL", 111, 124], ["caffeoyl phenols", "CHEMICAL", 62, 78], ["cichoric acid", "CHEMICAL", 93, 106], ["caftaric acid", "CHEMICAL", 111, 124], ["Autumngrown", "ORGANISM", 0, 11], ["Echinacea purpurea", "ORGANISM", 12, 30], ["caffeoyl phenols", "SIMPLE_CHEMICAL", 62, 78], ["cichoric acid", "SIMPLE_CHEMICAL", 93, 106], ["caftaric acid", "SIMPLE_CHEMICAL", 111, 124], ["leaf", "TISSUE", 129, 133], ["ower tissues", "TISSUE", 141, 153], ["Echinacea purpurea", "SPECIES", 12, 30], ["Echinacea purpurea", "SPECIES", 12, 30], ["Autumngrown Echinacea purpurea plants", "TREATMENT", 0, 37], ["caffeoyl phenols", "TREATMENT", 62, 78], ["cichoric acid and caftaric acid", "PROBLEM", 93, 124], ["Echinacea", "OBSERVATION_MODIFIER", 12, 21], ["purpurea plants", "OBSERVATION", 22, 37], ["leaf", "ANATOMY", 129, 133], ["fl", "ANATOMY", 138, 140]]], ["Iranian cultivated E. purpurea tops was found to have a high content of cichoric acid (3.5-5.7 %), followed by caftaric acid (3.1-4.5 %) and caffeic acid (0.6-1.1 %) with total polyphenol content of 7.9-10.9 %, (Iranshahi and Amanzadeh 2008 ) .", [["cichoric acid", "CHEMICAL", 72, 85], ["caftaric acid", "CHEMICAL", 111, 124], ["caffeic acid", "CHEMICAL", 141, 153], ["polyphenol", "CHEMICAL", 177, 187], ["cichoric acid", "CHEMICAL", 72, 85], ["caftaric acid", "CHEMICAL", 111, 124], ["caffeic acid", "CHEMICAL", 141, 153], ["polyphenol", "CHEMICAL", 177, 187], ["E. purpurea", "ORGANISM", 19, 30], ["cichoric acid", "SIMPLE_CHEMICAL", 72, 85], ["caftaric acid", "SIMPLE_CHEMICAL", 111, 124], ["caffeic acid", "SIMPLE_CHEMICAL", 141, 153], ["polyphenol", "SIMPLE_CHEMICAL", 177, 187], ["E. purpurea", "SPECIES", 19, 30], ["E. purpurea", "SPECIES", 19, 30], ["cichoric acid", "TEST", 72, 85], ["caftaric acid", "TEST", 111, 124], ["caffeic acid", "TEST", 141, 153], ["total polyphenol content", "TEST", 171, 195]]], ["After 2 hours of boiling water extraction, the content of cichoric acid was 5.7 %, whereas the content of this acid in 60:40 ethanol-water extraction did not exceed 3.9 %.Plant/Cell Culture PhytochemicalsFor total alkamides, concentrations (mg/g dry weight basis) among individual E. purpurea plants varied from 5.02 to 27.67 (mean = 14.4 %) in roots, from 0.62 to 3.42 (mean = 1.54) in nearly matured seed heads, and from 0.22 to 5.25 (mean = 0.77) in young tops (about \u00bd fl ower heads, \u00bc leaves, and \u00bc stems) (Qu et al. 2005 ) .", [["Cell", "ANATOMY", 177, 181], ["roots", "ANATOMY", 345, 350], ["seed heads", "ANATOMY", 402, 412], ["leaves", "ANATOMY", 490, 496], ["cichoric acid", "CHEMICAL", 58, 71], ["60:40 ethanol", "CHEMICAL", 119, 132], ["alkamides", "CHEMICAL", 214, 223], ["cichoric acid", "CHEMICAL", 58, 71], ["ethanol", "CHEMICAL", 125, 132], ["alkamides", "CHEMICAL", 214, 223], ["cichoric acid", "SIMPLE_CHEMICAL", 58, 71], ["ethanol", "SIMPLE_CHEMICAL", 125, 132], ["alkamides", "SIMPLE_CHEMICAL", 214, 223], ["E. purpurea", "ORGANISM", 281, 292], ["roots", "ORGAN", 345, 350], ["seed heads", "MULTI-TISSUE_STRUCTURE", 402, 412], ["E. purpurea", "SPECIES", 281, 292], ["E. purpurea", "SPECIES", 281, 292], ["boiling water extraction", "TREATMENT", 17, 41], ["cichoric acid", "TEST", 58, 71], ["this acid", "TREATMENT", 106, 115], ["water extraction", "TREATMENT", 133, 149], ["Plant/Cell Culture Phytochemicals", "TEST", 171, 204], ["total alkamides", "TREATMENT", 208, 223], ["concentrations (mg/g dry weight basis", "TREATMENT", 225, 262], ["individual E. purpurea plants", "TEST", 270, 299], ["mean", "TEST", 327, 331], ["mean", "TEST", 371, 375], ["mean", "TEST", 437, 441], ["roots", "ANATOMY_MODIFIER", 345, 350], ["seed", "OBSERVATION_MODIFIER", 402, 406], ["heads", "OBSERVATION_MODIFIER", 407, 412]]], ["For cichoric acid, concentrations among individual plants varied from 2.65 to 37.52 (mean = 8.95), from 2.03 to 31.58 (mean = 10.9) and from 4.79 to 38.55 (mean = 18.88) in the roots, the seed heads and the tops, respectively.", [["roots", "ANATOMY", 177, 182], ["seed heads", "ANATOMY", 188, 198], ["cichoric acid", "CHEMICAL", 4, 17], ["cichoric acid", "CHEMICAL", 4, 17], ["cichoric acid", "SIMPLE_CHEMICAL", 4, 17], ["roots", "ORGAN", 177, 182], ["seed heads", "MULTI-TISSUE_STRUCTURE", 188, 198], ["cichoric acid", "PROBLEM", 4, 17], ["individual plants", "TEST", 40, 57], ["mean", "TEST", 85, 89], ["mean", "TEST", 119, 123], ["mean", "TEST", 156, 160], ["roots", "ANATOMY_MODIFIER", 177, 182], ["seed", "OBSERVATION_MODIFIER", 188, 192], ["heads", "OBSERVATION_MODIFIER", 193, 198], ["tops", "ANATOMY_MODIFIER", 207, 211]]], ["Dodeca-2 E , 4 E , 8 Z , 10 E -tetraenoic acid isobutylamide and dodeca-2 E , 4 E , 8 Z , 10 Z -tetraenoic acid isobutylamide (alkamides 8/9) accounted for only 9.5 % of the total alkamides in roots but comprised 87.9 % in the seed heads and 76.6 % in the young tops.", [["roots", "ANATOMY", 193, 198], ["seed heads", "ANATOMY", 227, 237], ["Dodeca-2 E , 4 E , 8 Z , 10 E -tetraenoic acid", "CHEMICAL", 0, 46], ["isobutylamide", "CHEMICAL", 47, 60], ["dodeca-2 E , 4 E , 8 Z , 10 Z -tetraenoic acid isobutylamide", "CHEMICAL", 65, 125], ["alkamides", "CHEMICAL", 127, 136], ["alkamides", "CHEMICAL", 180, 189], ["Dodeca-2 E , 4 E , 8 Z , 10 E -tetraenoic acid isobutylamide", "CHEMICAL", 0, 60], ["dodeca-2 E , 4 E , 8 Z , 10 Z -tetraenoic acid isobutylamide", "CHEMICAL", 65, 125], ["alkamides", "CHEMICAL", 127, 136], ["alkamides", "CHEMICAL", 180, 189], ["Dodeca-2 E", "SIMPLE_CHEMICAL", 0, 10], ["4 E , 8 Z , 10 E -tetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 13, 60], ["dodeca-2 E , 4 E , 8 Z , 10 Z -tetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 65, 125], ["alkamides 8/9", "SIMPLE_CHEMICAL", 127, 140], ["alkamides", "SIMPLE_CHEMICAL", 180, 189], ["roots", "ORGAN", 193, 198], ["seed heads", "MULTI-TISSUE_STRUCTURE", 227, 237], ["Dodeca", "TEST", 0, 6], ["Z", "TEST", 21, 22], ["E", "TEST", 28, 29], ["tetraenoic acid isobutylamide", "TEST", 31, 60], ["dodeca", "TEST", 65, 71], ["E", "TEST", 80, 81], ["Z", "TEST", 86, 87], ["Z", "TEST", 93, 94], ["tetraenoic acid isobutylamide", "TEST", 96, 125], ["alkamides", "TEST", 127, 136], ["the total alkamides", "TEST", 170, 189]]], ["Two cinnamic acids, 2-O -caffeoyl-3-O -isoferuloyltartaric (3) and 2, 3-di-O -isoferuloyltartaric acid (5), along with three known caffeic acids, cichoric acid (1), 2-O -caffeoyl-3-O -feruloyltartaric acid (2) and 2-O -caffeoyl-3-Op -coumaroyltartaric acid (4), were isolated and purifi ed from Echinacea purpurea .", [["cinnamic acids", "CHEMICAL", 4, 18], ["2-O -caffeoyl-3-O -isoferuloyltartaric (3) and 2, 3-di-O -isoferuloyltartaric acid", "CHEMICAL", 20, 102], ["caffeic acids", "CHEMICAL", 131, 144], ["cichoric acid", "CHEMICAL", 146, 159], ["1), 2-O -caffeoyl-3-O -feruloyltartaric acid", "CHEMICAL", 161, 205], ["2-O -caffeoyl-3-Op -coumaroyltartaric acid", "CHEMICAL", 214, 256], ["cinnamic acids", "CHEMICAL", 4, 18], ["2-O -caffeoyl-3-O -isoferuloyltartaric", "CHEMICAL", 20, 58], ["2, 3-di-O -isoferuloyltartaric acid", "CHEMICAL", 67, 102], ["caffeic acids", "CHEMICAL", 131, 144], ["cichoric acid", "CHEMICAL", 146, 159], ["2-O -caffeoyl-3-O -feruloyltartaric acid", "CHEMICAL", 165, 205], ["2-O -caffeoyl-3-Op -coumaroyltartaric acid", "CHEMICAL", 214, 256], ["cinnamic acids", "SIMPLE_CHEMICAL", 4, 18], ["2-O -caffeoyl-3-O -isoferuloyltartaric (3)", "SIMPLE_CHEMICAL", 20, 62], ["2, 3-di-O -isoferuloyltartaric acid", "SIMPLE_CHEMICAL", 67, 102], ["5", "SIMPLE_CHEMICAL", 104, 105], ["caffeic acids", "SIMPLE_CHEMICAL", 131, 144], ["cichoric acid", "SIMPLE_CHEMICAL", 146, 159], ["1), 2-O -caffeoyl-3-O -feruloyltartaric acid (2)", "SIMPLE_CHEMICAL", 161, 209], ["2-O -caffeoyl-3-Op -coumaroyltartaric acid (4)", "SIMPLE_CHEMICAL", 214, 260], ["Echinacea purpurea", "ORGANISM", 295, 313], ["Echinacea purpurea", "SPECIES", 295, 313], ["Echinacea purpurea", "SPECIES", 295, 313], ["Two cinnamic acids", "TEST", 0, 18], ["caffeoyl", "TEST", 25, 33], ["isoferuloyltartaric acid", "TREATMENT", 78, 102], ["three known caffeic acids", "TREATMENT", 119, 144], ["cichoric acid", "TREATMENT", 146, 159], ["caffeoyl", "TREATMENT", 170, 178], ["feruloyltartaric acid", "TREATMENT", 184, 205], ["caffeoyl", "TREATMENT", 219, 227], ["Op -coumaroyltartaric acid", "TREATMENT", 230, 256], ["Echinacea purpurea", "PROBLEM", 295, 313], ["cinnamic acids", "OBSERVATION", 4, 18]]], ["From 250 mg of crude extracts, 65.1 mg of 1, 8.3 mg of 2, 4.0 mg of 3, 4.5 mg of 4 and 4.3 mg of 5 were isolated, with purities of 98.5, 97.7, 94.6, 94.3 and 98.6 %, respectively.", [["extracts", "ANATOMY", 21, 29], ["extracts", "ORGANISM_SUBSTANCE", 21, 29], ["crude extracts", "TREATMENT", 15, 29], ["purities", "TEST", 119, 127]]], ["Nineteen phenolics were identifi ed in the medium of E. purpurea cell cultures after elicitation with biotic elicitors Barz 2005 , 2006 ) .", [["cell cultures", "ANATOMY", 65, 78], ["phenolics", "CHEMICAL", 9, 18], ["identifi", "CHEMICAL", 24, 32], ["phenolics", "SIMPLE_CHEMICAL", 9, 18], ["purpurea cell cultures", "CELL", 56, 78], ["E. purpurea cell cultures", "CELL_LINE", 53, 78], ["E. purpurea", "SPECIES", 53, 64], ["E. purpurea", "SPECIES", 53, 64], ["Nineteen phenolics", "PROBLEM", 0, 18], ["E. purpurea cell cultures", "TEST", 53, 78], ["purpurea cell", "OBSERVATION", 56, 69]]], ["The medium contained lignan, neolignan and acetophenone derivatives as the main elicitorenhanced products.", [["lignan", "CHEMICAL", 21, 27], ["neolignan", "CHEMICAL", 29, 38], ["acetophenone", "CHEMICAL", 43, 55], ["lignan", "CHEMICAL", 21, 27], ["neolignan", "CHEMICAL", 29, 38], ["acetophenone", "CHEMICAL", 43, 55], ["lignan", "SIMPLE_CHEMICAL", 21, 27], ["neolignan", "SIMPLE_CHEMICAL", 29, 38], ["acetophenone derivatives", "SIMPLE_CHEMICAL", 43, 67], ["lignan", "TREATMENT", 21, 27], ["neolignan", "TREATMENT", 29, 38], ["acetophenone derivatives", "TREATMENT", 43, 67], ["the main elicitorenhanced products", "TREATMENT", 71, 105], ["lignan", "OBSERVATION_MODIFIER", 21, 27]]], ["E. purpurea cells mainly contained phenolic glycosides including a new compound \u03b1-O -\u03b2-D -glucopyranosyl-acetovanillone.Plant/Cell Culture PhytochemicalsConstitutive compounds identifi ed in the cell culture medium of E. purpurea included \u03b1-hydroxyacetovanillone (1), coniferyl alcohol (4), methyl ( E )p -coumarate (7), and 1-hydroxypinoresinol (8).", [["cells", "ANATOMY", 12, 17], ["Cell", "ANATOMY", 126, 130], ["cell", "ANATOMY", 195, 199], ["phenolic glycosides", "CHEMICAL", 35, 54], ["\u03b1-O -\u03b2-D -glucopyranosyl-acetovanillone", "CHEMICAL", 80, 119], ["\u03b1-hydroxyacetovanillone", "CHEMICAL", 239, 262], ["coniferyl alcohol", "CHEMICAL", 268, 285], ["methyl ( E )p -coumarate", "CHEMICAL", 291, 315], ["1-hydroxypinoresinol", "CHEMICAL", 325, 345], ["phenolic glycosides", "CHEMICAL", 35, 54], ["\u03b1-O -\u03b2-D -glucopyranosyl-acetovanillone", "CHEMICAL", 80, 119], ["\u03b1-hydroxyacetovanillone", "CHEMICAL", 239, 262], ["coniferyl alcohol", "CHEMICAL", 268, 285], ["methyl ( E )p -coumarate", "CHEMICAL", 291, 315], ["1-hydroxypinoresinol", "CHEMICAL", 325, 345], ["E. purpurea cells", "CELL", 0, 17], ["phenolic glycosides", "SIMPLE_CHEMICAL", 35, 54], ["\u03b1-O -\u03b2-D -glucopyranosyl-acetovanillone", "SIMPLE_CHEMICAL", 80, 119], ["Cell", "CELL", 126, 130], ["cell", "CELL", 195, 199], ["E. purpurea", "ORGANISM", 218, 229], ["\u03b1-hydroxyacetovanillone", "SIMPLE_CHEMICAL", 239, 262], ["coniferyl alcohol (4)", "SIMPLE_CHEMICAL", 268, 289], ["methyl ( E )p -coumarate (7)", "SIMPLE_CHEMICAL", 291, 319], ["1-hydroxypinoresinol", "SIMPLE_CHEMICAL", 325, 345], ["E. purpurea", "SPECIES", 0, 11], ["E. purpurea", "SPECIES", 218, 229], ["E. purpurea", "SPECIES", 0, 11], ["E. purpurea", "SPECIES", 218, 229], ["E. purpurea cells", "TEST", 0, 17], ["phenolic glycosides", "TREATMENT", 35, 54], ["a new compound \u03b1-O -\u03b2-D -glucopyranosyl-acetovanillone", "TREATMENT", 65, 119], ["Plant/Cell Culture", "TEST", 120, 138], ["Constitutive compounds", "PROBLEM", 153, 175], ["\u03b1-hydroxyacetovanillone", "TREATMENT", 239, 262], ["coniferyl alcohol", "TREATMENT", 268, 285], ["methyl ( E )p -coumarate", "TREATMENT", 291, 315], ["hydroxypinoresinol", "TREATMENT", 327, 345], ["purpurea cells", "OBSERVATION", 3, 17], ["phenolic glycosides", "OBSERVATION", 35, 54], ["Cell", "OBSERVATION", 126, 130]]], ["After elicitation of E. purpurea cell culture with yeast, the compounds found in the medium included \u03b1-hydrox yacetosyringone (2); 4-hydroxyacetophenone (3); 4,7,9,8\u2032-tetrahydroxy-3,3\u2032-5\u2032trimethoxy-8,4\u2032-oxy-9\u2032-norneolignan-7\u2032-one (5); 1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxy-4-[1-( E )-propen-3-ol]-phenoxy]-propane-1,3diol (6a,b); 4,7,9-trihydroxy-3,3\u2032,5\u2032-trimethoxy-8,4\u2032-oxy-9\u2032-norneolignan-7\u2032-one (9); and buddlenol B (10).", [["cell", "ANATOMY", 33, 37], ["\u03b1-hydrox yacetosyringone", "CHEMICAL", 101, 125], ["4-hydroxyacetophenone", "CHEMICAL", 131, 152], ["4,7,9,8\u2032-tetrahydroxy-3,3\u2032-5\u2032trimethoxy-8,4\u2032-oxy-9\u2032-norneolignan-7\u2032-one", "CHEMICAL", 158, 229], ["5); 1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxy-4-[1-( E )-propen-3-ol]-phenoxy", "CHEMICAL", 231, 309], ["4,7,9-trihydroxy-3,3\u2032,5\u2032-trimethoxy-8,4\u2032-oxy-9\u2032-norneolignan-7\u2032-one", "CHEMICAL", 335, 402], ["buddlenol B", "CHEMICAL", 412, 423], ["\u03b1-hydrox yacetosyringone", "CHEMICAL", 101, 125], ["4-hydroxyacetophenone", "CHEMICAL", 131, 152], ["4,7,9,8\u2032-tetrahydroxy-3,3\u2032-5\u2032trimethoxy-8,4\u2032-oxy-9\u2032-norneolignan-7\u2032-one", "CHEMICAL", 158, 229], ["1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxy-4-[1-( E )-propen-3-ol]-phenoxy]-propane-1,3diol", "CHEMICAL", 235, 326], ["4,7,9-trihydroxy-3,3\u2032,5\u2032-trimethoxy-8,4\u2032-oxy-9\u2032-norneolignan-7\u2032-one", "CHEMICAL", 335, 402], ["buddlenol B", "CHEMICAL", 412, 423], ["purpurea cell", "CELL", 24, 37], ["\u03b1-hydrox yacetosyringone (2); 4-hydroxyacetophenone (3); 4,7,9,8\u2032-tetrahydroxy-3,3\u2032-5\u2032trimethoxy-8,4\u2032-oxy-9\u2032-norneolignan-7\u2032-one (5); 1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxy-4-[1-( E )-propen-3-ol]-phenoxy]-propane-1,3diol (6a,b); 4,7,9-trihydroxy-3,3\u2032,5\u2032-trimethoxy-8,4\u2032-oxy-9\u2032-norneolignan-7\u2032-one (9)", "SIMPLE_CHEMICAL", 101, 406], ["buddlenol B (10)", "SIMPLE_CHEMICAL", 412, 428], ["E. purpurea cell culture", "CELL_LINE", 21, 45], ["E. purpurea", "SPECIES", 21, 32], ["yeast", "SPECIES", 51, 56], ["E. purpurea", "SPECIES", 21, 32], ["yeast", "SPECIES", 51, 56], ["E. purpurea cell culture", "TEST", 21, 45], ["yeast", "PROBLEM", 51, 56], ["the compounds", "PROBLEM", 58, 71], ["\u03b1-hydrox yacetosyringone", "TREATMENT", 101, 125], ["hydroxyacetophenone", "TREATMENT", 133, 152], ["tetrahydroxy", "TREATMENT", 167, 179], ["hydroxy", "TEST", 240, 247], ["methoxyphenyl", "TREATMENT", 250, 263], ["trihydroxy", "TEST", 341, 351], ["trimethoxy", "TREATMENT", 360, 370], ["purpurea cell", "OBSERVATION", 24, 37]]], ["Phenolics found in E. purpurea cells were 4-hydroxyacetophenone (3); scopoletin (11); 4-hydroxybenzoic acid glucose ester (12) (18); 1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxy-4-[1-( E )-propen-3-ol]-phenoxy]-propane-1,3diol (6a,b); and longiloroside (19) .", [["purpurea cells", "ANATOMY", 22, 36], ["Phenolics", "CHEMICAL", 0, 9], ["4-hydroxyacetophenone", "CHEMICAL", 42, 63], ["scopoletin", "CHEMICAL", 69, 79], ["4-hydroxybenzoic acid glucose ester", "CHEMICAL", 86, 121], ["1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxy-4-[1-( E )-propen-3-ol]-phenoxy]-propane-1,3diol", "CHEMICAL", 133, 224], ["longiloroside", "CHEMICAL", 237, 250], ["Phenolics", "CHEMICAL", 0, 9], ["4-hydroxyacetophenone", "CHEMICAL", 42, 63], ["scopoletin", "CHEMICAL", 69, 79], ["4-hydroxybenzoic acid glucose ester", "CHEMICAL", 86, 121], ["1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxy-4-[1-( E )-propen-3-ol]-phenoxy]-propane-1,3diol", "CHEMICAL", 133, 224], ["longiloroside", "CHEMICAL", 237, 250], ["Phenolics", "SIMPLE_CHEMICAL", 0, 9], ["E. purpurea cells", "CELL", 19, 36], ["4-hydroxyacetophenone", "SIMPLE_CHEMICAL", 42, 63], ["3)", "SIMPLE_CHEMICAL", 65, 67], ["scopoletin (11); 4-hydroxybenzoic acid glucose ester (12) (18); 1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxy-4-[1-( E )-propen-3-ol]-phenoxy]-propane-1,3diol", "SIMPLE_CHEMICAL", 69, 224], ["6a,b)", "SIMPLE_CHEMICAL", 226, 231], ["longiloroside", "SIMPLE_CHEMICAL", 237, 250], ["E. purpurea cells", "CELL_LINE", 19, 36], ["E. purpurea", "SPECIES", 19, 30], ["E. purpurea", "SPECIES", 19, 30], ["Phenolics", "TEST", 0, 9], ["purpurea cells", "TEST", 22, 36], ["hydroxyacetophenone", "TREATMENT", 44, 63], ["scopoletin", "TREATMENT", 69, 79], ["hydroxybenzoic acid glucose ester", "TREATMENT", 88, 121], ["hydroxy", "TEST", 138, 145], ["methoxyphenyl", "TREATMENT", 148, 161], ["phenoxy]-propane-1,3diol", "TREATMENT", 200, 224], ["purpurea cells", "OBSERVATION", 22, 36]]], ["The optima accumulation of Echinacea purpurea suspension culture biomass (73.6 g/l FW and 10.03 g/l DW), phenolics (61.14 mg/g DW) and fl avonoids (38.30 mg/g DW) was achieved in 0.5 MS (Murashige and Skoog) medium (Wu et al. 2007b ) .", [["Echinacea purpurea", "CHEMICAL", 27, 45], ["phenolics", "CHEMICAL", 105, 114], ["fl avonoids", "CHEMICAL", 135, 146], ["Echinacea", "ORGANISM", 27, 36], ["phenolics", "SIMPLE_CHEMICAL", 105, 114], ["fl avonoids", "SIMPLE_CHEMICAL", 135, 146], ["Echinacea purpurea", "SPECIES", 27, 45], ["Echinacea purpurea", "SPECIES", 27, 45], ["The optima accumulation", "PROBLEM", 0, 23], ["Echinacea purpurea suspension culture biomass", "TEST", 27, 72], ["FW", "TEST", 83, 85], ["g/l DW", "TEST", 96, 102], ["phenolics", "TEST", 105, 114], ["DW", "TEST", 127, 129], ["fl avonoids", "TEST", 135, 146], ["Echinacea", "OBSERVATION_MODIFIER", 27, 36], ["purpurea", "OBSERVATION_MODIFIER", 37, 45], ["suspension", "OBSERVATION_MODIFIER", 46, 56]]], ["High adventitious root biomasses (83.1 g/l FW and 15.30 g/l DW) were achieved with feeding of the 0.5 MS medium at the end of 2nd week.", [["root", "ANATOMY", 18, 22], ["root biomasses", "MULTI-TISSUE_STRUCTURE", 18, 32], ["High adventitious root biomasses", "PROBLEM", 0, 32], ["FW", "TEST", 43, 45], ["the 0.5 MS medium", "TREATMENT", 94, 111], ["adventitious", "OBSERVATION_MODIFIER", 5, 17], ["root biomasses", "OBSERVATION", 18, 32]]], ["This led to slight decreases in the total production of phenolics and fl avonoids; however, this feeding was responsible for increases in the accumulation of caftaric acid (5.76 mg/g DW) and cichoric acid (26.12 mg/g DW).Plant/Cell Culture PhytochemicalsBeside the above, many other studies had isolated and identifi ed alkamides and caffeic acid derivatives in E. pur purea plant, various plant parts and products Laasonen et al. 2002 ; M\u00f8lgaard et al. 2003 ) .", [["Cell", "ANATOMY", 227, 231], ["phenolics", "CHEMICAL", 56, 65], ["caftaric acid", "CHEMICAL", 158, 171], ["cichoric acid", "CHEMICAL", 191, 204], ["alkamides", "CHEMICAL", 320, 329], ["caffeic acid", "CHEMICAL", 334, 346], ["caftaric acid", "CHEMICAL", 158, 171], ["cichoric acid", "CHEMICAL", 191, 204], ["alkamides", "CHEMICAL", 320, 329], ["caffeic acid", "CHEMICAL", 334, 346], ["phenolics", "SIMPLE_CHEMICAL", 56, 65], ["fl avonoids", "SIMPLE_CHEMICAL", 70, 81], ["caftaric acid", "SIMPLE_CHEMICAL", 158, 171], ["cichoric acid", "SIMPLE_CHEMICAL", 191, 204], ["Cell Culture", "CELL", 227, 239], ["identifi ed alkamides", "SIMPLE_CHEMICAL", 308, 329], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 334, 358], ["E. pur purea", "ORGANISM", 362, 374], ["E. pur purea", "SPECIES", 362, 374], ["E. pur purea", "SPECIES", 362, 374], ["slight decreases", "PROBLEM", 12, 28], ["the total production of phenolics", "PROBLEM", 32, 65], ["fl avonoids", "PROBLEM", 70, 81], ["caftaric acid", "TREATMENT", 158, 171], ["cichoric acid", "TREATMENT", 191, 204], ["Plant/Cell Culture", "TEST", 221, 239], ["many other studies", "TEST", 272, 290], ["identifi ed alkamides", "TREATMENT", 308, 329], ["caffeic acid derivatives", "TREATMENT", 334, 358], ["slight", "OBSERVATION_MODIFIER", 12, 18], ["decreases", "OBSERVATION_MODIFIER", 19, 28], ["total", "OBSERVATION_MODIFIER", 36, 41], ["production", "OBSERVATION_MODIFIER", 42, 52]]], ["Ultrasonic extraction of dried samples of E. purpurea roots and aerial parts with methanolwater (7:3) or ethanol-water (7:3) gave good yields of cichoric acid, echinacoside and the alkamides, undeca-2 E ,4 Z -diene-8,10-diynoic acid isobutylamide and a mixture of dodeca-2 E ,4 E ,8 Z ,10 E/Z -tetraenoic acid isobutylamides (recoveries of 89, 85, 80 and 90 %, respectively) .", [["samples", "ANATOMY", 31, 38], ["roots", "ANATOMY", 54, 59], ["methanolwater", "CHEMICAL", 82, 95], ["ethanol", "CHEMICAL", 105, 112], ["cichoric acid", "CHEMICAL", 145, 158], ["echinacoside", "CHEMICAL", 160, 172], ["alkamides", "CHEMICAL", 181, 190], ["undeca-2 E ,4 Z -diene-8,10-diynoic acid isobutylamide", "CHEMICAL", 192, 246], ["dodeca-2 E ,4 E ,8 Z ,10 E/Z -tetraenoic acid isobutylamides", "CHEMICAL", 264, 324], ["methanolwater", "CHEMICAL", 82, 95], ["ethanol", "CHEMICAL", 105, 112], ["cichoric acid", "CHEMICAL", 145, 158], ["echinacoside", "CHEMICAL", 160, 172], ["alkamides", "CHEMICAL", 181, 190], ["undeca-2 E ,4 Z -diene-8,10-diynoic acid isobutylamide", "CHEMICAL", 192, 246], ["dodeca-2 E ,4 E ,8 Z ,10 E/Z -tetraenoic acid isobutylamides", "CHEMICAL", 264, 324], ["E. purpurea", "ORGANISM", 42, 53], ["roots", "ORGANISM", 54, 59], ["methanolwater", "SIMPLE_CHEMICAL", 82, 95], ["ethanol-water", "SIMPLE_CHEMICAL", 105, 118], ["cichoric acid", "SIMPLE_CHEMICAL", 145, 158], ["echinacoside", "SIMPLE_CHEMICAL", 160, 172], ["alkamides", "SIMPLE_CHEMICAL", 181, 190], ["undeca-2 E ,4 Z -diene-8,10-diynoic acid isobutylamide", "SIMPLE_CHEMICAL", 192, 246], ["dodeca-2 E ,4 E ,8 Z ,10 E/Z -tetraenoic acid isobutylamides", "SIMPLE_CHEMICAL", 264, 324], ["E. purpurea", "SPECIES", 42, 53], ["E. purpurea", "SPECIES", 42, 53], ["Ultrasonic extraction", "TREATMENT", 0, 21], ["dried samples", "TEST", 25, 38], ["E. purpurea roots", "PROBLEM", 42, 59], ["cichoric acid", "TREATMENT", 145, 158], ["echinacoside", "TEST", 160, 172], ["the alkamides", "TEST", 177, 190], ["undeca", "TEST", 192, 198], ["diynoic acid isobutylamide", "TREATMENT", 220, 246], ["dodeca", "TEST", 264, 270], ["Z", "TEST", 283, 284], ["Z", "TEST", 291, 292], ["tetraenoic acid isobutylamides", "TREATMENT", 294, 324], ["purpurea roots", "OBSERVATION", 45, 59], ["aerial", "ANATOMY_MODIFIER", 64, 70]]], ["The HPLC separation of the phenolic compounds cichoric acid, chlorogenic acid and echinacoside was also improved by careful attention to the pH of the mobile phase.", [["cichoric acid", "CHEMICAL", 46, 59], ["chlorogenic acid", "CHEMICAL", 61, 77], ["echinacoside", "CHEMICAL", 82, 94], ["cichoric acid", "CHEMICAL", 46, 59], ["chlorogenic acid", "CHEMICAL", 61, 77], ["echinacoside", "CHEMICAL", 82, 94], ["cichoric acid", "SIMPLE_CHEMICAL", 46, 59], ["chlorogenic acid", "SIMPLE_CHEMICAL", 61, 77], ["echinacoside", "SIMPLE_CHEMICAL", 82, 94], ["The HPLC", "TEST", 0, 8], ["chlorogenic acid", "TEST", 61, 77], ["the pH", "TEST", 137, 143], ["HPLC", "OBSERVATION_MODIFIER", 4, 8], ["separation", "OBSERVATION_MODIFIER", 9, 19], ["phenolic compounds", "OBSERVATION", 27, 45]]], ["The profi le of phenolic compounds (mean concentration \u03bcg/ml) in E. purpurea herb was determined as 0-767 \u03bcg caftaric acid, 0-45 \u03bcg chlorogenic acid, 0-220 \u03bcg caffeic acid, 0 \u03bcg cynarin, 0-2,879 \u03bcg cichoric acid, 0 \u03bcg echinacoside and 0-25 \u03bcg tet 8/9 (dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide) .Plant/Cell Culture PhytochemicalsStudies showed that the content of caffeic acid derivatives in E. purpurea aerial parts and roots reached its highest in the middle stage of full blossoming (Liu et al. 2007 ).", [["Cell", "ANATOMY", 320, 324], ["aerial parts", "ANATOMY", 422, 434], ["roots", "ANATOMY", 439, 444], ["caftaric acid", "CHEMICAL", 109, 122], ["chlorogenic acid", "CHEMICAL", 132, 148], ["caffeic acid", "CHEMICAL", 159, 171], ["cynarin", "CHEMICAL", 178, 185], ["cichoric acid", "CHEMICAL", 198, 211], ["echinacoside", "CHEMICAL", 218, 230], ["dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide", "CHEMICAL", 252, 311], ["caffeic acid", "CHEMICAL", 382, 394], ["caftaric acid", "CHEMICAL", 109, 122], ["chlorogenic acid", "CHEMICAL", 132, 148], ["caffeic acid", "CHEMICAL", 159, 171], ["cynarin", "CHEMICAL", 178, 185], ["cichoric acid", "CHEMICAL", 198, 211], ["echinacoside", "CHEMICAL", 218, 230], ["dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide", "CHEMICAL", 252, 311], ["caffeic acid", "CHEMICAL", 382, 394], ["phenolic compounds", "SIMPLE_CHEMICAL", 16, 34], ["E. purpurea", "ORGANISM", 65, 76], ["herb", "ORGANISM", 77, 81], ["caftaric acid", "SIMPLE_CHEMICAL", 109, 122], ["chlorogenic acid", "SIMPLE_CHEMICAL", 132, 148], ["caffeic acid", "SIMPLE_CHEMICAL", 159, 171], ["cynarin", "SIMPLE_CHEMICAL", 178, 185], ["cichoric acid", "SIMPLE_CHEMICAL", 198, 211], ["echinacoside", "SIMPLE_CHEMICAL", 218, 230], ["dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 252, 311], ["Cell Culture", "CELL", 320, 332], ["caffeic acid", "SIMPLE_CHEMICAL", 382, 394], ["E. purpurea", "ORGANISM", 410, 421], ["aerial parts", "MULTI-TISSUE_STRUCTURE", 422, 434], ["roots", "ORGAN", 439, 444], ["E. purpurea", "SPECIES", 65, 76], ["E. purpurea", "SPECIES", 410, 421], ["E. purpurea", "SPECIES", 65, 76], ["E. purpurea", "SPECIES", 410, 421], ["The profi le of phenolic compounds", "TREATMENT", 0, 34], ["mean concentration \u03bcg/ml", "TREATMENT", 36, 60], ["caftaric acid", "TEST", 109, 122], ["chlorogenic acid", "TEST", 132, 148], ["caffeic acid", "TEST", 159, 171], ["cynarin", "TEST", 178, 185], ["acid", "TEST", 207, 211], ["echinacoside", "TEST", 218, 230], ["tet", "TEST", 243, 246], ["dodeca", "TEST", 252, 258], ["Z", "TEST", 271, 272], ["Ztetraenoic acid isobutylamide", "TREATMENT", 281, 311], ["Plant/Cell Culture PhytochemicalsStudies", "TEST", 314, 354], ["caffeic acid derivatives", "TREATMENT", 382, 406], ["phenolic compounds", "OBSERVATION", 16, 34], ["caffeic acid derivatives", "OBSERVATION", 382, 406], ["purpurea", "OBSERVATION_MODIFIER", 413, 421], ["aerial", "OBSERVATION_MODIFIER", 422, 428], ["roots", "OBSERVATION_MODIFIER", 439, 444], ["highest", "OBSERVATION_MODIFIER", 457, 464], ["middle stage", "OBSERVATION_MODIFIER", 472, 484], ["full blossoming", "OBSERVATION", 488, 503]]], ["The content of caffeic acid derivatives in fresh raw material was generally higher than that in dried raw material.", [["caffeic acid", "CHEMICAL", 15, 27], ["caffeic acid", "CHEMICAL", 15, 27], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 15, 39], ["caffeic acid derivatives", "TREATMENT", 15, 39], ["fresh raw material", "PROBLEM", 43, 61], ["caffeic acid derivatives", "OBSERVATION", 15, 39], ["higher", "OBSERVATION_MODIFIER", 76, 82], ["dried raw", "OBSERVATION", 96, 105]]], ["The developmental pattern of total phenolics in E. purpurea was the same as that of caffeic acid derivatives.", [["phenolics", "CHEMICAL", 35, 44], ["caffeic acid", "CHEMICAL", 84, 96], ["caffeic acid", "CHEMICAL", 84, 96], ["phenolics", "SIMPLE_CHEMICAL", 35, 44], ["E. purpurea", "ORGANISM", 48, 59], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 84, 108], ["E. purpurea", "SPECIES", 48, 59], ["E. purpurea", "SPECIES", 48, 59], ["total phenolics in E. purpurea", "PROBLEM", 29, 59], ["caffeic acid derivatives", "TREATMENT", 84, 108], ["developmental", "OBSERVATION_MODIFIER", 4, 17], ["pattern", "OBSERVATION_MODIFIER", 18, 25], ["total phenolics", "OBSERVATION", 29, 44]]], ["The stage of mid-bloom was the optimal harvesting period for both caffeic acid derivatives and total phenolics.", [["caffeic acid", "CHEMICAL", 66, 78], ["phenolics", "CHEMICAL", 101, 110], ["caffeic acid", "CHEMICAL", 66, 78], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 66, 90], ["phenolics", "SIMPLE_CHEMICAL", 101, 110], ["both caffeic acid derivatives", "TREATMENT", 61, 90], ["total phenolics", "TREATMENT", 95, 110]]], ["There was no signifi cant difference in the content of caffeic acid derivatives among three Chinese geographical populations of E. purpurea .Plant/Cell Culture PhytochemicalsE. purpurea extracts stored for 18 months were found to contain caftaric acid, cichoric acid and undeca-2 Z ,4 E -diene-8,10-diynoic acid isobutylamide at concentrations of 0.7, 0.71 and 2.0 mg/ ml, respectively .", [["Cell", "ANATOMY", 147, 151], ["extracts", "ANATOMY", 186, 194], ["caffeic acid", "CHEMICAL", 55, 67], ["caftaric acid", "CHEMICAL", 238, 251], ["cichoric acid", "CHEMICAL", 253, 266], ["undeca-2 Z ,4 E -diene-8,10-diynoic acid isobutylamide", "CHEMICAL", 271, 325], ["caffeic acid", "CHEMICAL", 55, 67], ["caftaric acid", "CHEMICAL", 238, 251], ["cichoric acid", "CHEMICAL", 253, 266], ["undeca-2 Z ,4 E -diene-8,10-diynoic acid isobutylamide", "CHEMICAL", 271, 325], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 55, 79], ["E. purpurea", "ORGANISM", 128, 139], ["Cell", "CELL", 147, 151], ["purpurea extracts", "ORGANISM_SUBSTANCE", 177, 194], ["caftaric acid", "SIMPLE_CHEMICAL", 238, 251], ["cichoric acid", "SIMPLE_CHEMICAL", 253, 266], ["undeca-2 Z ,4 E -diene-8,10-diynoic acid isobutylamide", "SIMPLE_CHEMICAL", 271, 325], ["E. purpurea", "SPECIES", 128, 139], ["purpurea", "SPECIES", 177, 185], ["E. purpurea", "SPECIES", 128, 139], ["purpurea", "SPECIES", 177, 185], ["signifi cant difference", "PROBLEM", 13, 36], ["caffeic acid derivatives", "TREATMENT", 55, 79], ["E. purpurea", "PROBLEM", 128, 139], ["Plant/Cell Culture", "TEST", 141, 159], ["PhytochemicalsE", "TEST", 160, 175], ["purpurea extracts", "TEST", 177, 194], ["caftaric acid", "TEST", 238, 251], ["cichoric acid", "TEST", 253, 266], ["undeca", "TEST", 271, 277], ["Z", "TEST", 280, 281], ["diene", "TEST", 288, 293], ["diynoic acid isobutylamide", "TREATMENT", 299, 325], ["no", "UNCERTAINTY", 10, 12], ["E. purpurea", "OBSERVATION", 128, 139], ["Cell", "OBSERVATION", 147, 151], ["Culture PhytochemicalsE", "OBSERVATION", 152, 175]]], ["Using HPLC/ electrospray ionization mass spectrometry, isomeric isobutylamides and 2-methylbutylamides could be distinguished.", [["isobutylamides", "CHEMICAL", 64, 78], ["2-methylbutylamides", "CHEMICAL", 83, 102], ["isobutylamides", "CHEMICAL", 64, 78], ["2-methylbutylamides", "CHEMICAL", 83, 102], ["isobutylamides", "SIMPLE_CHEMICAL", 64, 78], ["2-methylbutylamides", "SIMPLE_CHEMICAL", 83, 102], ["HPLC/ electrospray ionization mass spectrometry", "TREATMENT", 6, 53], ["isomeric isobutylamides", "TREATMENT", 55, 78], ["methylbutylamides", "TREATMENT", 85, 102]]], ["The cichoric acid was the main phenolic compound detected in dried E. purpurea materials (fl owers, leaves, stems and roots), followed by caftaric acid (Lin et al. 2011 ) .", [["leaves", "ANATOMY", 100, 106], ["stems", "ANATOMY", 108, 113], ["roots", "ANATOMY", 118, 123], ["cichoric acid", "CHEMICAL", 4, 17], ["caftaric acid", "CHEMICAL", 138, 151], ["cichoric acid", "CHEMICAL", 4, 17], ["caftaric acid", "CHEMICAL", 138, 151], ["cichoric acid", "SIMPLE_CHEMICAL", 4, 17], ["leaves", "TISSUE", 100, 106], ["stems", "TISSUE", 108, 113], ["roots", "ORGAN", 118, 123], ["caftaric acid", "SIMPLE_CHEMICAL", 138, 151], ["E. purpurea", "SPECIES", 67, 78], ["E. purpurea", "SPECIES", 67, 78], ["The cichoric acid", "TEST", 0, 17], ["dried E. purpurea materials", "PROBLEM", 61, 88], ["acid", "OBSERVATION_MODIFIER", 13, 17], ["main", "OBSERVATION_MODIFIER", 26, 30], ["phenolic compound", "OBSERVATION", 31, 48], ["dried E.", "OBSERVATION_MODIFIER", 61, 69], ["purpurea materials", "OBSERVATION", 70, 88], ["stems", "ANATOMY", 108, 113], ["roots", "ANATOMY", 118, 123]]], ["The bioactive constituent contents in different plant parts were in the descending order: fl owers > leaves > stems > roots.", [["leaves", "ANATOMY", 101, 107], ["stems", "ANATOMY", 110, 115], ["roots", "ANATOMY", 118, 123], ["roots", "ORGAN", 118, 123], ["fl owers", "TEST", 90, 98], ["bioactive", "OBSERVATION_MODIFIER", 4, 13], ["constituent contents", "OBSERVATION", 14, 34], ["descending", "ANATOMY", 72, 82], ["stems", "ANATOMY_MODIFIER", 110, 115], ["roots", "ANATOMY_MODIFIER", 118, 123]]], ["Both caffeic acid derivatives and total phenolics contents were affected by drying method and storage/packing condition.", [["caffeic acid", "CHEMICAL", 5, 17], ["phenolics", "CHEMICAL", 40, 49], ["caffeic acid", "CHEMICAL", 5, 17], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 5, 29], ["phenolics", "SIMPLE_CHEMICAL", 40, 49], ["Both caffeic acid derivatives", "TREATMENT", 0, 29], ["total phenolics contents", "TREATMENT", 34, 58], ["storage/packing condition", "TREATMENT", 94, 119], ["caffeic", "OBSERVATION_MODIFIER", 5, 12], ["acid derivatives", "OBSERVATION", 13, 29]]], ["Cool wind-dried materials retained more bioactive constituents content (>85 %) compared to vacuum freeze-dried materials.Plant/Cell Culture PhytochemicalsThe storability results indicated that the freezedried E. purpurea materials sealed in polyethylene terephthalate/aluminium foil/polyethylene or nylon/polyethylene bags and stored under 10-20 \u00b0C and 40-60 % relative humidity without light conditions retained the highest content of bioactive compounds.Flower PhytochemicalsVolatiles in the headspace of E. purpurea fl owers were acetaldehyde, dimethyl sulphide, 2-methylpropanal and acetone, 2-butanone, 2-methylbutanal, 3-methylbutanal, unknown, \u03b1-pinene, camphene, hexanal, \u03b2-pinene, sabinene/ \u03b2-thujene, unknown, 2-methyl-4-pentenal, \u03b2-myrcene, \u03b1-terpinene, limonene, 2-hexenal ( trans ), ocimene, \u03b3-terpinene, trans -ocimene , p -cymene, \u03b1-terpinolene, unknown, 1-hexanol, allo -ocimene, 3-hexen-1-ol ( cis ), 2-hexen-1-ol ( trans ) and \u03b1-cubebene/\u03b1-copaene (Mazza and Cottrell 1999 ) .", [["Cell", "ANATOMY", 127, 131], ["polyethylene terephthalate", "CHEMICAL", 241, 267], ["aluminium foil/polyethylene or nylon/polyethylene bags", "CHEMICAL", 268, 322], ["Volatiles", "CHEMICAL", 477, 486], ["acetaldehyde", "CHEMICAL", 533, 545], ["dimethyl sulphide", "CHEMICAL", 547, 564], ["2-methylpropanal and acetone, 2-butanone", "CHEMICAL", 566, 606], ["2-methylbutanal", "CHEMICAL", 608, 623], ["3-methylbutanal", "CHEMICAL", 625, 640], ["\u03b1-pinene", "CHEMICAL", 651, 659], ["camphene", "CHEMICAL", 661, 669], ["hexanal", "CHEMICAL", 671, 678], ["\u03b2-pinene", "CHEMICAL", 680, 688], ["sabinene", "CHEMICAL", 690, 698], ["thujene", "CHEMICAL", 702, 709], ["2-methyl-4-pentenal, \u03b2-myrcene, \u03b1-terpinene, limonene, 2-hexenal", "CHEMICAL", 720, 784], ["ocimene", "CHEMICAL", 796, 803], ["\u03b3-terpinene", "CHEMICAL", 805, 816], ["trans -ocimene , p -cymene", "CHEMICAL", 818, 844], ["\u03b1-terpinolene", "CHEMICAL", 846, 859], ["1-hexanol", "CHEMICAL", 870, 879], ["allo -ocimene, 3-hexen-1-ol", "CHEMICAL", 881, 908], ["2-hexen-1-ol", "CHEMICAL", 918, 930], ["\u03b1-cubebene", "CHEMICAL", 945, 955], ["\u03b1-copaene", "CHEMICAL", 956, 965], ["polyethylene terephthalate", "CHEMICAL", 241, 267], ["aluminium", "CHEMICAL", 268, 277], ["polyethylene", "CHEMICAL", 283, 295], ["polyethylene", "CHEMICAL", 305, 317], ["acetaldehyde", "CHEMICAL", 533, 545], ["dimethyl sulphide", "CHEMICAL", 547, 564], ["2-methylpropanal", "CHEMICAL", 566, 582], ["acetone", "CHEMICAL", 587, 594], ["2-butanone", "CHEMICAL", 596, 606], ["2-methylbutanal", "CHEMICAL", 608, 623], ["3-methylbutanal", "CHEMICAL", 625, 640], ["\u03b1-pinene", "CHEMICAL", 651, 659], ["camphene", "CHEMICAL", 661, 669], ["hexanal", "CHEMICAL", 671, 678], ["\u03b2-pinene", "CHEMICAL", 680, 688], ["sabinene", "CHEMICAL", 690, 698], ["\u03b2-thujene", "CHEMICAL", 700, 709], ["2-methyl-4-pentenal", "CHEMICAL", 720, 739], ["\u03b2-myrcene", "CHEMICAL", 741, 750], ["\u03b1-terpinene", "CHEMICAL", 752, 763], ["limonene", "CHEMICAL", 765, 773], ["2-hexenal", "CHEMICAL", 775, 784], ["ocimene", "CHEMICAL", 796, 803], ["\u03b3-terpinene", "CHEMICAL", 805, 816], ["trans -ocimene", "CHEMICAL", 818, 832], ["p -cymene", "CHEMICAL", 835, 844], ["\u03b1-terpinolene", "CHEMICAL", 846, 859], ["1-hexanol", "CHEMICAL", 870, 879], ["allo -ocimene", "CHEMICAL", 881, 894], ["3-hexen-1-ol", "CHEMICAL", 896, 908], ["2-hexen-1-ol", "CHEMICAL", 918, 930], ["\u03b1-cubebene", "CHEMICAL", 945, 955], ["\u03b1-copaene", "CHEMICAL", 956, 965], ["Mazza", "CHEMICAL", 967, 972], ["Cell Culture", "CELL", 127, 139], ["E. purpurea", "ORGANISM", 209, 220], ["polyethylene terephthalate", "SIMPLE_CHEMICAL", 241, 267], ["aluminium foil", "SIMPLE_CHEMICAL", 268, 282], ["polyethylene", "SIMPLE_CHEMICAL", 283, 295], ["acetaldehyde", "SIMPLE_CHEMICAL", 533, 545], ["dimethyl sulphide", "SIMPLE_CHEMICAL", 547, 564], ["2-methylpropanal", "SIMPLE_CHEMICAL", 566, 582], ["acetone, 2-butanone", "SIMPLE_CHEMICAL", 587, 606], ["2-methylbutanal", "SIMPLE_CHEMICAL", 608, 623], ["3-methylbutanal", "SIMPLE_CHEMICAL", 625, 640], ["\u03b1-pinene", "SIMPLE_CHEMICAL", 651, 659], ["camphene", "SIMPLE_CHEMICAL", 661, 669], ["hexanal", "SIMPLE_CHEMICAL", 671, 678], ["\u03b2-pinene", "SIMPLE_CHEMICAL", 680, 688], ["sabinene/ \u03b2-thujene", "SIMPLE_CHEMICAL", 690, 709], ["2-methyl-4-pentenal", "SIMPLE_CHEMICAL", 720, 739], ["\u03b2-myrcene", "SIMPLE_CHEMICAL", 741, 750], ["\u03b1-terpinene", "SIMPLE_CHEMICAL", 752, 763], ["limonene", "SIMPLE_CHEMICAL", 765, 773], ["2-hexenal ( trans ), ocimene", "SIMPLE_CHEMICAL", 775, 803], ["\u03b3-terpinene", "SIMPLE_CHEMICAL", 805, 816], ["trans -ocimene", "SIMPLE_CHEMICAL", 818, 832], ["p -cymene", "SIMPLE_CHEMICAL", 835, 844], ["\u03b1-terpinolene", "SIMPLE_CHEMICAL", 846, 859], ["1-hexanol", "SIMPLE_CHEMICAL", 870, 879], ["allo -ocimene", "SIMPLE_CHEMICAL", 881, 894], ["3-hexen-1-ol ( cis ), 2-hexen-1-ol ( trans )", "SIMPLE_CHEMICAL", 896, 940], ["\u03b1-cubebene/\u03b1-copaene", "SIMPLE_CHEMICAL", 945, 965], ["Mazza", "SIMPLE_CHEMICAL", 967, 972], ["E. purpurea", "SPECIES", 209, 220], ["E. purpurea", "SPECIES", 507, 518], ["E. purpurea", "SPECIES", 209, 220], ["E. purpurea", "SPECIES", 507, 518], ["dried materials", "PROBLEM", 10, 25], ["Plant/Cell Culture", "TEST", 121, 139], ["the freezedried E. purpurea materials", "TREATMENT", 193, 230], ["polyethylene terephthalate/aluminium foil/polyethylene or nylon/polyethylene bags", "TREATMENT", 241, 322], ["light conditions", "PROBLEM", 387, 403], ["Flower Phytochemicals", "TEST", 456, 477], ["acetaldehyde", "TREATMENT", 533, 545], ["dimethyl sulphide", "TREATMENT", 547, 564], ["methylpropanal", "TREATMENT", 568, 582], ["acetone", "TREATMENT", 587, 594], ["butanone", "TREATMENT", 598, 606], ["methylbutanal", "TREATMENT", 610, 623], ["methylbutanal", "TREATMENT", 627, 640], ["\u03b1-pinene", "TREATMENT", 651, 659], ["camphene", "TREATMENT", 661, 669], ["hexanal", "TREATMENT", 671, 678], ["\u03b2-pinene", "TREATMENT", 680, 688], ["sabinene", "TREATMENT", 690, 698], ["thujene", "TREATMENT", 702, 709], ["methyl", "TREATMENT", 722, 728], ["pentenal", "TREATMENT", 731, 739], ["\u03b2-myrcene", "TREATMENT", 741, 750], ["\u03b1-terpinene", "TREATMENT", 752, 763], ["limonene", "TREATMENT", 765, 773], ["ocimene", "TREATMENT", 796, 803], ["\u03b3-terpinene", "TREATMENT", 805, 816], ["trans -ocimene", "TREATMENT", 818, 832], ["\u03b1-terpinolene", "TREATMENT", 846, 859], ["allo -ocimene", "TREATMENT", 881, 894], ["dried materials", "OBSERVATION_MODIFIER", 10, 25], ["bioactive", "OBSERVATION_MODIFIER", 40, 49], ["constituents content", "OBSERVATION_MODIFIER", 50, 70], ["vacuum freeze", "OBSERVATION_MODIFIER", 91, 104], ["purpurea materials", "OBSERVATION", 212, 230], ["polyethylene terephthalate", "OBSERVATION", 241, 267], ["polyethylene bags", "OBSERVATION", 305, 322], ["highest content", "OBSERVATION_MODIFIER", 417, 432], ["bioactive compounds", "OBSERVATION", 436, 455], ["PhytochemicalsVolatiles", "OBSERVATION", 463, 486]]], ["Major volatiles in headspace of fl ower tissues were myrcene 43 %, \u03b2-pinene 7.4 %, \u03b1-pinene 22.6 % and dimethyl sulphide 1.0 %.Flower PhytochemicalsThe essential oil of E. purpurea fl ower heads was found to contain 89 components of which 63 (monoterpene hydrocarbons, oxygenated monoterpenes, sesquiterpenes, oxygenated sesquiterpenes) were identifi ed comprising 92.8 % of the total oil yield (Diraz et al. 2012 ) .", [["tissues", "ANATOMY", 40, 47], ["oil", "ANATOMY", 162, 165], ["oil", "ANATOMY", 385, 388], ["myrcene", "CHEMICAL", 53, 60], ["\u03b2-pinene", "CHEMICAL", 67, 75], ["\u03b1-pinene", "CHEMICAL", 83, 91], ["dimethyl sulphide", "CHEMICAL", 103, 120], ["monoterpene hydrocarbons", "CHEMICAL", 243, 267], ["oxygenated monoterpenes, sesquiterpenes, oxygenated sesquiterpenes", "CHEMICAL", 269, 335], ["identifi", "CHEMICAL", 342, 350], ["myrcene", "CHEMICAL", 53, 60], ["\u03b2-pinene", "CHEMICAL", 67, 75], ["\u03b1-pinene", "CHEMICAL", 83, 91], ["dimethyl sulphide", "CHEMICAL", 103, 120], ["monoterpene hydrocarbons", "CHEMICAL", 243, 267], ["oxygenated monoterpenes", "CHEMICAL", 269, 292], ["sesquiterpenes", "CHEMICAL", 294, 308], ["oxygenated sesquiterpenes", "CHEMICAL", 310, 335], ["fl ower tissues", "TISSUE", 32, 47], ["myrcene", "SIMPLE_CHEMICAL", 53, 60], ["\u03b2-pinene", "SIMPLE_CHEMICAL", 67, 75], ["\u03b1-pinene", "SIMPLE_CHEMICAL", 83, 91], ["dimethyl sulphide", "SIMPLE_CHEMICAL", 103, 120], ["oil", "ORGANISM_SUBSTANCE", 162, 165], ["E. purpurea", "ORGANISM", 169, 180], ["fl ower heads", "ORGANISM", 181, 194], ["monoterpene hydrocarbons", "SIMPLE_CHEMICAL", 243, 267], ["oxygenated monoterpenes", "SIMPLE_CHEMICAL", 269, 292], ["sesquiterpenes", "SIMPLE_CHEMICAL", 294, 308], ["oxygenated sesquiterpenes", "SIMPLE_CHEMICAL", 310, 335], ["oil", "ORGANISM_SUBSTANCE", 385, 388], ["E. purpurea", "SPECIES", 169, 180], ["E. purpurea fl ower", "SPECIES", 169, 188], ["Major volatiles", "TEST", 0, 15], ["myrcene", "TEST", 53, 60], ["\u03b2-pinene", "TEST", 67, 75], ["\u03b1-pinene", "TREATMENT", 83, 91], ["dimethyl sulphide", "TREATMENT", 103, 120], ["monoterpene hydrocarbons", "TEST", 243, 267], ["oxygenated monoterpenes", "TREATMENT", 269, 292], ["sesquiterpenes", "TREATMENT", 294, 308], ["oxygenated sesquiterpenes", "TREATMENT", 310, 335], ["volatiles", "OBSERVATION_MODIFIER", 6, 15], ["essential", "OBSERVATION_MODIFIER", 152, 161], ["oil", "OBSERVATION_MODIFIER", 162, 165], ["purpurea fl", "OBSERVATION", 172, 183]]], ["The major components were germacrene D (11.3 %), caryophyllene oxide (8.7 %), \u03b2-caryophyllene (7.2 %) and \u03b1-cadinol (6.2 %).", [["germacrene D", "CHEMICAL", 26, 38], ["caryophyllene oxide", "CHEMICAL", 49, 68], ["\u03b2-caryophyllene", "CHEMICAL", 78, 93], ["\u03b1-cadinol", "CHEMICAL", 106, 115], ["germacrene D", "CHEMICAL", 26, 38], ["caryophyllene oxide", "CHEMICAL", 49, 68], ["\u03b2-caryophyllene", "CHEMICAL", 78, 93], ["\u03b1-cadinol", "CHEMICAL", 106, 115], ["germacrene D", "SIMPLE_CHEMICAL", 26, 38], ["caryophyllene oxide", "SIMPLE_CHEMICAL", 49, 68], ["\u03b2-caryophyllene", "SIMPLE_CHEMICAL", 78, 93], ["\u03b1-cadinol", "SIMPLE_CHEMICAL", 106, 115], ["germacrene D", "TEST", 26, 38], ["caryophyllene oxide", "TREATMENT", 49, 68], ["\u03b2-caryophyllene", "TREATMENT", 78, 93], ["\u03b1-cadinol", "TREATMENT", 106, 115]]], ["The other components higher than 1 % included \u03b2-pinene (1.3 %), \u03b1-phellandrene (2.9 %), p -cymene (2.65), \u03b2-elemene (2.1 %), a-cadinene (1.0 %), naphthalene, 1,2,3,5,6,8a-hexahydro-4,7-dimethyl-1-(1ethylethyl)-,(1 Scis )-(3.3 %), \u03b1-farnesene (1.0 %), 1,5 epoxysalvia-4(14)ene (3.3 %), naphthalene, 1,2,3,4,4a,7-hexahydro-1,6-dimethyl-4-1(1-methylethyl) -(1.6 %), \u03b1-bisabolene (2.3 %), bicylo[4.4.0]dec-1-ene,2-isopropyl-5-methyl-9methylene-(1.8 %), \u03b1-cadinene (2.0 %), decatone (1.5 %), ethyl oleate (1.6 %0, vulgarol B (1.9), aromadendrene oxide (1.1 %), 3,4,-difl oro-4-methoxybiphenyl (2.7 %), isoaromadendiene epoxide (1.9 %), trans ( Z )-\u03b1-bisabolene epoxide (2.3 %), benzenepropanoic acid, octadecyl ester (1.2 %) and diepi-\u03b1-cedrene epoxide (1.2 %).", [["\u03b2-pinene", "CHEMICAL", 46, 54], ["\u03b1-phellandrene", "CHEMICAL", 64, 78], ["p -cymene", "CHEMICAL", 88, 97], ["\u03b2-elemene", "CHEMICAL", 106, 115], ["a-cadinene", "CHEMICAL", 125, 135], ["naphthalene", "CHEMICAL", 145, 156], ["1,2,3,5,6,8a-hexahydro-4,7-dimethyl-1-(1ethylethyl)-,(1 Scis )-", "CHEMICAL", 158, 221], ["\u03b1-farnesene", "CHEMICAL", 230, 241], ["1,5 epoxysalvia-4(14)ene", "CHEMICAL", 251, 275], ["naphthalene", "CHEMICAL", 285, 296], ["1,2,3,4,4a,7-hexahydro-1,6-dimethyl-4-1(1-methylethyl) -", "CHEMICAL", 298, 354], ["\u03b1-bisabolene", "CHEMICAL", 363, 375], ["bicylo[4.4.0]dec-1-ene", "CHEMICAL", 385, 407], ["2-isopropyl-5-methyl-9methylene", "CHEMICAL", 408, 439], ["\u03b1-cadinene", "CHEMICAL", 449, 459], ["decatone", "CHEMICAL", 469, 477], ["ethyl oleate", "CHEMICAL", 487, 499], ["vulgarol B", "CHEMICAL", 509, 519], ["aromadendrene oxide", "CHEMICAL", 527, 546], ["3,4,-difl oro-4-methoxybiphenyl", "CHEMICAL", 556, 587], ["isoaromadendiene", "CHEMICAL", 597, 613], ["trans ( Z )-\u03b1-bisabolene epoxide", "CHEMICAL", 631, 663], ["benzenepropanoic acid", "CHEMICAL", 673, 694], ["octadecyl ester", "CHEMICAL", 696, 711], ["diepi-\u03b1-cedrene epoxide", "CHEMICAL", 724, 747], ["\u03b2-pinene", "CHEMICAL", 46, 54], ["\u03b1-phellandrene", "CHEMICAL", 64, 78], ["p -cymene", "CHEMICAL", 88, 97], ["\u03b2-elemene", "CHEMICAL", 106, 115], ["a-cadinene", "CHEMICAL", 125, 135], ["naphthalene", "CHEMICAL", 145, 156], ["1,2,3,5,6,8a-hexahydro-4,7-dimethyl-1-(1ethylethyl)-,(1 Scis )", "CHEMICAL", 158, 220], ["\u03b1-farnesene", "CHEMICAL", 230, 241], ["1,5 epoxysalvia-4(14)ene", "CHEMICAL", 251, 275], ["naphthalene", "CHEMICAL", 285, 296], ["1,2,3,4,4a,7-hexahydro-1,6-dimethyl-4-1(1-methylethyl)", "CHEMICAL", 298, 352], ["\u03b1-bisabolene", "CHEMICAL", 363, 375], ["bicylo[4.4.0]dec-1-ene", "CHEMICAL", 385, 407], ["2-isopropyl-5-methyl-9methylene", "CHEMICAL", 408, 439], ["\u03b1-cadinene", "CHEMICAL", 449, 459], ["decatone", "CHEMICAL", 469, 477], ["ethyl oleate", "CHEMICAL", 487, 499], ["vulgarol B", "CHEMICAL", 509, 519], ["aromadendrene oxide", "CHEMICAL", 527, 546], ["3,4,-difl oro-4-methoxybiphenyl", "CHEMICAL", 556, 587], ["isoaromadendiene epoxide", "CHEMICAL", 597, 621], ["trans ( Z )-\u03b1-bisabolene epoxide", "CHEMICAL", 631, 663], ["benzenepropanoic acid", "CHEMICAL", 673, 694], ["octadecyl ester", "CHEMICAL", 696, 711], ["diepi-\u03b1-cedrene epoxide", "CHEMICAL", 724, 747], ["\u03b2-pinene", "SIMPLE_CHEMICAL", 46, 54], ["\u03b1-phellandrene", "SIMPLE_CHEMICAL", 64, 78], ["p -cymene", "SIMPLE_CHEMICAL", 88, 97], ["\u03b2-elemene", "SIMPLE_CHEMICAL", 106, 115], ["a-cadinene", "SIMPLE_CHEMICAL", 125, 135], ["1.0 %), naphthalene, 1,2,3,5,6,8a-hexahydro-4,7-dimethyl-1-(1ethylethyl)-,(1 Scis )-(3.3 %), \u03b1-farnesene", "SIMPLE_CHEMICAL", 137, 241], ["1,5 epoxysalvia-4(14)ene", "SIMPLE_CHEMICAL", 251, 275], ["naphthalene", "SIMPLE_CHEMICAL", 285, 296], ["1,2,3,4,4a,7-hexahydro-1,6-dimethyl-4-1(1-methylethyl) -(1.6 %),", "SIMPLE_CHEMICAL", 298, 362], ["\u03b1-bisabolene", "SIMPLE_CHEMICAL", 363, 375], ["bicylo[4.4.0]dec-1-ene", "SIMPLE_CHEMICAL", 385, 407], ["2-isopropyl-5-methyl-9methylene-(1.8 %), \u03b1-cadinene", "SIMPLE_CHEMICAL", 408, 459], ["decatone", "SIMPLE_CHEMICAL", 469, 477], ["ethyl oleate", "SIMPLE_CHEMICAL", 487, 499], ["vulgarol B (1.9)", "SIMPLE_CHEMICAL", 509, 525], ["aromadendrene oxide", "SIMPLE_CHEMICAL", 527, 546], ["3,4,-difl oro-4-methoxybiphenyl", "SIMPLE_CHEMICAL", 556, 587], ["isoaromadendiene epoxide", "SIMPLE_CHEMICAL", 597, 621], ["trans ( Z )-\u03b1-bisabolene epoxide", "SIMPLE_CHEMICAL", 631, 663], ["benzenepropanoic acid", "SIMPLE_CHEMICAL", 673, 694], ["octadecyl ester", "SIMPLE_CHEMICAL", 696, 711], ["diepi-\u03b1-cedrene epoxide", "SIMPLE_CHEMICAL", 724, 747], ["The other components", "TEST", 0, 20], ["\u03b2-pinene", "TEST", 46, 54], ["\u03b1-phellandrene", "TEST", 64, 78], ["cymene", "TEST", 91, 97], ["\u03b2-elemene", "TEST", 106, 115], ["a-cadinene", "TEST", 125, 135], ["naphthalene", "TREATMENT", 145, 156], ["hexahydro", "TEST", 171, 180], ["\u03b1-farnesene", "TEST", 230, 241], ["epoxysalvia", "TEST", 255, 266], ["naphthalene", "TREATMENT", 285, 296], ["hexahydro", "TEST", 311, 320], ["dimethyl", "TEST", 325, 333], ["\u03b1-bisabolene", "TEST", 363, 375], ["bicylo", "TEST", 385, 391], ["isopropyl-5-methyl", "TREATMENT", 410, 428], ["9methylene", "TREATMENT", 429, 439], ["\u03b1-cadinene", "TREATMENT", 449, 459], ["decatone", "TREATMENT", 469, 477], ["ethyl oleate", "TREATMENT", 487, 499], ["aromadendrene oxide", "TREATMENT", 527, 546], ["difl oro", "TREATMENT", 561, 569], ["methoxybiphenyl", "TREATMENT", 572, 587], ["isoaromadendiene epoxide", "TREATMENT", 597, 621], ["trans ( Z )-\u03b1-bisabolene epoxide", "TREATMENT", 631, 663], ["benzenepropanoic acid, octadecyl ester", "TREATMENT", 673, 711], ["diepi-\u03b1-cedrene epoxide", "TREATMENT", 724, 747], ["components", "OBSERVATION_MODIFIER", 10, 20], ["higher", "OBSERVATION_MODIFIER", 21, 27]]], ["Earlier, 36 compounds comprising 70.9 % of sesquiterpenes and 6.4 % monoterpene hydrocarbons were identifi ed in the E. purpurea fl ower-head essential oil in Iran (Mirjalili et al. 2006 ) .", [["oil", "ANATOMY", 152, 155], ["sesquiterpenes", "CHEMICAL", 43, 57], ["monoterpene hydrocarbons", "CHEMICAL", 68, 92], ["identifi", "CHEMICAL", 98, 106], ["sesquiterpenes", "CHEMICAL", 43, 57], ["monoterpene hydrocarbons", "CHEMICAL", 68, 92], ["sesquiterpenes", "SIMPLE_CHEMICAL", 43, 57], ["monoterpene hydrocarbons", "SIMPLE_CHEMICAL", 68, 92], ["identifi", "SIMPLE_CHEMICAL", 98, 106], ["head", "ORGANISM_SUBDIVISION", 137, 141], ["oil", "ORGANISM_SUBSTANCE", 152, 155], ["E. purpurea", "SPECIES", 117, 128], ["E. purpurea", "SPECIES", 117, 128], ["sesquiterpenes", "TEST", 43, 57], ["6.4 % monoterpene hydrocarbons", "TREATMENT", 62, 92], ["head", "ANATOMY", 137, 141], ["oil", "OBSERVATION_MODIFIER", 152, 155]]], ["Germacrene D (57 %) was the major component.Flower PhytochemicalsRutin and nicotifl orin (3-O -rutinoside campherol) were isolated from the fl owers, the latter fl avonoid being dominant (Kurkin et al. 2011 ) .", [["Germacrene D", "CHEMICAL", 0, 12], ["PhytochemicalsRutin", "CHEMICAL", 51, 70], ["nicotifl orin", "CHEMICAL", 75, 88], ["3-O -rutinoside campherol", "CHEMICAL", 90, 115], ["Germacrene D", "CHEMICAL", 0, 12], ["PhytochemicalsRutin", "CHEMICAL", 51, 70], ["nicotifl orin", "CHEMICAL", 75, 88], ["3-O -rutinoside campherol", "CHEMICAL", 90, 115], ["Germacrene D", "SIMPLE_CHEMICAL", 0, 12], ["PhytochemicalsRutin", "SIMPLE_CHEMICAL", 51, 70], ["nicotifl orin (3-O -rutinoside campherol", "SIMPLE_CHEMICAL", 75, 115], ["Germacrene D", "TREATMENT", 0, 12], ["Flower PhytochemicalsRutin", "TREATMENT", 44, 70], ["nicotifl orin", "TREATMENT", 75, 88], ["major", "OBSERVATION_MODIFIER", 28, 33], ["component", "OBSERVATION_MODIFIER", 34, 43], ["dominant", "OBSERVATION_MODIFIER", 178, 186]]], ["The major anthocyanins of Echinacea purpurea and E. pallida were identifi ed as cyanidin 3-O -(\u03b2-D -glucopyranoside) and cyanidin 3-O -(6-O -malonyl-\u03b2-D -glucopyranoside) (Cheminat et al. 1989 ) .", [["anthocyanins of Echinacea purpurea", "CHEMICAL", 10, 44], ["cyanidin 3-O -(\u03b2-D -glucopyranoside", "CHEMICAL", 80, 115], ["cyanidin 3-O -(6-O -malonyl-\u03b2-D -glucopyranoside", "CHEMICAL", 121, 169], ["anthocyanins", "CHEMICAL", 10, 22], ["cyanidin 3-O -(\u03b2-D -glucopyranoside", "CHEMICAL", 80, 115], ["cyanidin 3-O -(6-O -malonyl-\u03b2-D -glucopyranoside", "CHEMICAL", 121, 169], ["anthocyanins", "SIMPLE_CHEMICAL", 10, 22], ["Echinacea purpurea", "ORGANISM", 26, 44], ["E. pallida", "ORGANISM", 49, 59], ["cyanidin 3-O -(\u03b2-D -glucopyranoside", "SIMPLE_CHEMICAL", 80, 115], ["cyanidin 3-O -(6-O -malonyl-\u03b2-D -glucopyranoside", "SIMPLE_CHEMICAL", 121, 169], ["Echinacea purpurea", "SPECIES", 26, 44], ["E. pallida", "SPECIES", 49, 59], ["Echinacea purpurea", "SPECIES", 26, 44], ["E. pallida", "SPECIES", 49, 59], ["Echinacea purpurea", "PROBLEM", 26, 44], ["E. pallida", "PROBLEM", 49, 59], ["cyanidin", "TEST", 80, 88], ["glucopyranoside", "TREATMENT", 100, 115], ["cyanidin", "TREATMENT", 121, 129], ["Echinacea purpurea", "OBSERVATION", 26, 44]]], ["Cyanidin 3-O -(\u03b2-D -glucopyranoside) (9.8 mg) and cyanidin 3-O -(6\u2033-O -\u03b2-D -glucopyranoside ) (14.3 mg) were obtained from 160 mg crude fl ower extract with a purity of 95.1 and 98.2 %, respectively .Flower PhytochemicalsThe profi le of phenolic compounds (mean concentration \u03bcg/ml) in E. purpurea fl ower was determined as 19-1,212 \u03bcg caftaric acid, 0-208 \u03bcg chlorogenic acid, 11-179 \u03bcg caffeic acid, 0-13 cynarin, 9-734 \u03bcg cichoric acid, 0 \u03bcg echinacoside, and 0-39 \u03bcg tet 8/9 (dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide) .", [["Cyanidin 3-O -(\u03b2-D -glucopyranoside", "CHEMICAL", 0, 35], ["cyanidin 3-O -(6\u2033-O -\u03b2-D -glucopyranoside", "CHEMICAL", 50, 91], ["caftaric acid", "CHEMICAL", 336, 349], ["chlorogenic acid", "CHEMICAL", 360, 376], ["caffeic acid", "CHEMICAL", 388, 400], ["0-13 cynarin, 9-734 \u03bcg cichoric acid", "CHEMICAL", 402, 438], ["echinacoside", "CHEMICAL", 445, 457], ["dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide", "CHEMICAL", 480, 539], ["Cyanidin 3-O -(\u03b2-D -glucopyranoside", "CHEMICAL", 0, 35], ["cyanidin 3-O -(6\u2033-O -\u03b2-D -glucopyranoside )", "CHEMICAL", 50, 93], ["caftaric acid", "CHEMICAL", 336, 349], ["chlorogenic acid", "CHEMICAL", 360, 376], ["caffeic acid", "CHEMICAL", 388, 400], ["cynarin", "CHEMICAL", 407, 414], ["cichoric acid", "CHEMICAL", 425, 438], ["echinacoside", "CHEMICAL", 445, 457], ["dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide", "CHEMICAL", 480, 539], ["Cyanidin 3-O -(\u03b2-D -glucopyranoside", "SIMPLE_CHEMICAL", 0, 35], ["cyanidin 3-O -(6\u2033-O -\u03b2-D -glucopyranoside", "SIMPLE_CHEMICAL", 50, 91], ["phenolic compounds", "SIMPLE_CHEMICAL", 237, 255], ["E. purpurea", "ORGANISM", 286, 297], ["fl ower", "ORGANISM", 298, 305], ["caftaric acid", "SIMPLE_CHEMICAL", 336, 349], ["chlorogenic acid", "SIMPLE_CHEMICAL", 360, 376], ["caffeic acid", "SIMPLE_CHEMICAL", 388, 400], ["cynarin", "SIMPLE_CHEMICAL", 407, 414], ["cichoric acid", "SIMPLE_CHEMICAL", 425, 438], ["echinacoside", "SIMPLE_CHEMICAL", 445, 457], ["dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 480, 539], ["E. purpurea", "SPECIES", 286, 297], ["E. purpurea", "SPECIES", 286, 297], ["Cyanidin", "TREATMENT", 0, 8], ["glucopyranoside)", "TREATMENT", 20, 36], ["cyanidin", "TREATMENT", 50, 58], ["D -glucopyranoside )", "TREATMENT", 73, 93], ["a purity", "TEST", 157, 165], ["Flower Phytochemicals", "TEST", 200, 221], ["The profi le of phenolic compounds", "TREATMENT", 221, 255], ["mean concentration \u03bcg/ml", "TREATMENT", 257, 281], ["caftaric acid", "TEST", 336, 349], ["chlorogenic acid", "TEST", 360, 376], ["caffeic acid", "TEST", 388, 400], ["cynarin", "TEST", 407, 414], ["cichoric acid", "TEST", 425, 438], ["echinacoside", "TEST", 445, 457], ["tet", "TEST", 471, 474], ["dodeca", "TEST", 480, 486], ["Z", "TEST", 499, 500], ["Ztetraenoic acid isobutylamide", "TREATMENT", 509, 539], ["Phytochemicals", "OBSERVATION", 207, 221], ["phenolic compounds", "OBSERVATION", 237, 255]]], ["In Echinacea purpurea cultivars Magnus and White Swan and line CLS-P2, harvested dry fl ower heads contained highest cichoric acid content and followed by caftaric acid and chlorogenic acid ).", [["cichoric acid", "CHEMICAL", 117, 130], ["caftaric acid", "CHEMICAL", 155, 168], ["chlorogenic acid", "CHEMICAL", 173, 189], ["cichoric acid", "CHEMICAL", 117, 130], ["caftaric acid", "CHEMICAL", 155, 168], ["chlorogenic acid", "CHEMICAL", 173, 189], ["Echinacea", "ORGANISM", 3, 12], ["line CLS-P2", "CELL", 58, 69], ["cichoric acid", "SIMPLE_CHEMICAL", 117, 130], ["caftaric acid", "SIMPLE_CHEMICAL", 155, 168], ["chlorogenic acid", "SIMPLE_CHEMICAL", 173, 189], ["Echinacea purpurea", "SPECIES", 3, 21], ["Echinacea purpurea", "SPECIES", 3, 21], ["Echinacea purpurea cultivars Magnus", "TREATMENT", 3, 38], ["White Swan", "TEST", 43, 53], ["line CLS", "TEST", 58, 66], ["highest cichoric acid content", "PROBLEM", 109, 138], ["caftaric acid", "TREATMENT", 155, 168], ["chlorogenic acid", "TREATMENT", 173, 189]]], ["The contents of cynarin and echinacoside in fl ower heads were relatively low as compared to cichoric acid, caftaric acid or chlorogenic acid.", [["cynarin", "CHEMICAL", 16, 23], ["echinacoside", "CHEMICAL", 28, 40], ["cichoric acid", "CHEMICAL", 93, 106], ["caftaric acid", "CHEMICAL", 108, 121], ["chlorogenic acid", "CHEMICAL", 125, 141], ["cynarin", "CHEMICAL", 16, 23], ["echinacoside", "CHEMICAL", 28, 40], ["cichoric acid", "CHEMICAL", 93, 106], ["caftaric acid", "CHEMICAL", 108, 121], ["chlorogenic acid", "CHEMICAL", 125, 141], ["cynarin", "SIMPLE_CHEMICAL", 16, 23], ["echinacoside", "SIMPLE_CHEMICAL", 28, 40], ["cichoric acid", "SIMPLE_CHEMICAL", 93, 106], ["caftaric acid", "SIMPLE_CHEMICAL", 108, 121], ["chlorogenic acid", "SIMPLE_CHEMICAL", 125, 141], ["cynarin", "TREATMENT", 16, 23], ["echinacoside in fl ower heads", "TEST", 28, 57], ["cichoric acid", "TEST", 93, 106], ["caftaric acid", "TEST", 108, 121], ["chlorogenic acid", "TREATMENT", 125, 141], ["low", "OBSERVATION_MODIFIER", 74, 77], ["chlorogenic acid", "OBSERVATION", 125, 141]]], ["Total caffeoyl derivatives content were 125.3, 116.7 and 145.5 mg/g dry weight for line CLS-P2, Magnus and White Swan, respectively.", [["caffeoyl", "CHEMICAL", 6, 14], ["caffeoyl", "CHEMICAL", 6, 14], ["caffeoyl derivatives", "SIMPLE_CHEMICAL", 6, 26], ["Total caffeoyl derivatives content", "TREATMENT", 0, 34], ["dry weight", "TEST", 68, 78], ["line CLS", "TEST", 83, 91], ["White Swan", "TEST", 107, 117], ["Magnus", "ANATOMY", 96, 102]]], ["The alkamides dodeca-2 E ,4 E ,8 Z ,10 E -tetraenoic acid isobutylamide (alkamide 8) and dodeca-2 E ,4 E ,8 Z ,10 Ztetraenoic acid isobutylamide (alkamide 9) were also found in the fl ower heads, but their content was much lower than in the roots.", [["roots", "ANATOMY", 241, 246], ["alkamides dodeca-2 E ,4 E ,8 Z ,10 E -tetraenoic acid isobutylamide", "CHEMICAL", 4, 71], ["alkamide 8) and dodeca-2 E ,4 E ,8 Z ,10 Ztetraenoic acid isobutylamide", "CHEMICAL", 73, 144], ["alkamide 9", "CHEMICAL", 146, 156], ["alkamides dodeca-2 E ,4 E ,8 Z ,10 E -tetraenoic acid isobutylamide", "CHEMICAL", 4, 71], ["alkamide", "CHEMICAL", 73, 81], ["dodeca-2 E ,4 E ,8 Z ,10 Ztetraenoic acid isobutylamide", "CHEMICAL", 89, 144], ["alkamide", "CHEMICAL", 146, 154], ["alkamides dodeca-2 E", "SIMPLE_CHEMICAL", 4, 24], ["4 E ,8 Z ,10 E -tetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 26, 71], ["alkamide 8)", "SIMPLE_CHEMICAL", 73, 84], ["dodeca-2 E ,4 E ,8 Z ,10 Ztetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 89, 144], ["alkamide 9", "SIMPLE_CHEMICAL", 146, 156], ["roots", "ORGAN", 241, 246], ["The alkamides dodeca", "TEST", 0, 20], ["Z", "TEST", 33, 34], ["E", "TEST", 39, 40], ["tetraenoic acid isobutylamide", "TREATMENT", 42, 71], ["alkamide", "TEST", 73, 81], ["dodeca", "TEST", 89, 95], ["Ztetraenoic acid isobutylamide", "TREATMENT", 114, 144], ["alkamide", "TREATMENT", 146, 154], ["fl", "ANATOMY", 181, 183], ["roots", "ANATOMY", 241, 246]]], ["No statistically signifi cant differences in fl ower-head alkamides 8 and 9 content were found among the tested E. purpurea cultivars and lines.Flower PhytochemicalsThe extraction yields of phenolics of freezedried E. purpurea fl owers were signifi cantly affected by the ethanol concentrations at 25 \u00b0C with water extraction giving the highest extraction yield (39.8 %) (Tsai et al. 2011 ) .", [["head", "ANATOMY", 53, 57], ["alkamides 8 and 9", "CHEMICAL", 58, 75], ["phenolics", "CHEMICAL", 190, 199], ["ethanol", "CHEMICAL", 272, 279], ["alkamides", "CHEMICAL", 58, 67], ["ethanol", "CHEMICAL", 272, 279], ["E. purpurea", "ORGANISM", 112, 123], ["lines", "CELL", 138, 143], ["phenolics", "SIMPLE_CHEMICAL", 190, 199], ["ethanol", "SIMPLE_CHEMICAL", 272, 279], ["E. purpurea", "SPECIES", 112, 123], ["E. purpurea", "SPECIES", 215, 226], ["E. purpurea", "SPECIES", 112, 123], ["E. purpurea", "SPECIES", 215, 226], ["statistically signifi cant differences", "PROBLEM", 3, 41], ["fl ower", "TEST", 45, 52], ["head alkamides", "TEST", 53, 67], ["The extraction", "TREATMENT", 165, 179], ["phenolics", "TREATMENT", 190, 199], ["the ethanol concentrations", "TREATMENT", 268, 294], ["water extraction", "TREATMENT", 309, 325], ["head", "ANATOMY", 53, 57], ["purpurea cultivars", "OBSERVATION", 115, 133], ["purpurea fl", "OBSERVATION", 218, 229]]], ["When the ethanol volume percentage in the solvent was increased from 25 % up to 95 %, the extraction yields were decreased from 36.9 to 3.3 %.", [["ethanol", "CHEMICAL", 9, 16], ["ethanol", "CHEMICAL", 9, 16], ["ethanol", "SIMPLE_CHEMICAL", 9, 16], ["the ethanol volume percentage", "TEST", 5, 34], ["the extraction", "TEST", 86, 100], ["decreased", "OBSERVATION_MODIFIER", 113, 122]]], ["Water extraction yielded 1,656 mg/g extract of caftaric acid, 0.14 mg chlorogenic acid, 0.53 mg echinoside, 37.23 mg cichoric acid, total caffeic acid derivatives 54.", [["caftaric acid", "CHEMICAL", 47, 60], ["chlorogenic acid", "CHEMICAL", 70, 86], ["echinoside", "CHEMICAL", 96, 106], ["cichoric acid", "CHEMICAL", 117, 130], ["caffeic acid", "CHEMICAL", 138, 150], ["caftaric acid", "CHEMICAL", 47, 60], ["chlorogenic acid", "CHEMICAL", 70, 86], ["echinoside", "CHEMICAL", 96, 106], ["cichoric acid", "CHEMICAL", 117, 130], ["caffeic acid", "CHEMICAL", 138, 150], ["caftaric acid", "SIMPLE_CHEMICAL", 47, 60], ["chlorogenic acid", "SIMPLE_CHEMICAL", 70, 86], ["echinoside", "SIMPLE_CHEMICAL", 96, 106], ["cichoric acid", "SIMPLE_CHEMICAL", 117, 130], ["caffeic acid", "SIMPLE_CHEMICAL", 138, 150], ["Water extraction", "TREATMENT", 0, 16], ["caftaric acid", "TREATMENT", 47, 60], ["chlorogenic acid", "TREATMENT", 70, 86], ["acid", "TEST", 126, 130], ["total caffeic acid derivatives", "TREATMENT", 132, 162]]], ["45 The content of cichoric acid and caftaric acids in dried E. purpurea fl owers were found to be signifi cantly affected by the drying methods used (Kim et al. 2000b ) .", [["cichoric acid", "CHEMICAL", 18, 31], ["caftaric acids", "CHEMICAL", 36, 50], ["cichoric acid", "CHEMICAL", 18, 31], ["caftaric acids", "CHEMICAL", 36, 50], ["cichoric acid", "SIMPLE_CHEMICAL", 18, 31], ["caftaric acids", "SIMPLE_CHEMICAL", 36, 50], ["E. purpurea", "SPECIES", 60, 71], ["E. purpurea fl owers", "SPECIES", 60, 80], ["cichoric acid", "TREATMENT", 18, 31], ["caftaric acids", "TREATMENT", 36, 50], ["the drying methods", "TREATMENT", 125, 143]]], ["Although signifi cant loss of cichoric acid was observed when fl owers were stored at high moisture, vacuum microwavedried fl owers with a low-moisture content retained the highest levels of cichoric acid and caftaric acid similar to freeze-dried fl owers.", [["cichoric acid", "CHEMICAL", 30, 43], ["cichoric acid", "CHEMICAL", 191, 204], ["caftaric acid", "CHEMICAL", 209, 222], ["cichoric acid", "CHEMICAL", 30, 43], ["cichoric acid", "CHEMICAL", 191, 204], ["caftaric acid", "CHEMICAL", 209, 222], ["cichoric acid", "SIMPLE_CHEMICAL", 30, 43], ["cichoric acid", "SIMPLE_CHEMICAL", 191, 204], ["caftaric acid", "SIMPLE_CHEMICAL", 209, 222], ["signifi cant loss of cichoric acid", "PROBLEM", 9, 43], ["a low-moisture content", "PROBLEM", 137, 159], ["cichoric acid", "TEST", 191, 204], ["caftaric acid", "TREATMENT", 209, 222]]], ["Flowers that were air-dried at 25 \u00b0C retained about 50 %, while those air-dried D at 70 \u00b0C had lowest retention of these acids.", [["these acids", "TREATMENT", 115, 126]]], ["Although fl owers air-dried at 40 \u00b0C retained relatively high amounts of cichoric acid and caftaric acid, the time (55 hours) required to reach optimal drying was considerably longer than that (47 minutes) for vacuum microwave drying.", [["cichoric acid", "CHEMICAL", 73, 86], ["caftaric acid", "CHEMICAL", 91, 104], ["cichoric acid", "CHEMICAL", 73, 86], ["caftaric acid", "CHEMICAL", 91, 104], ["cichoric acid", "SIMPLE_CHEMICAL", 73, 86], ["caftaric acid", "SIMPLE_CHEMICAL", 91, 104], ["fl owers air-dried", "PROBLEM", 9, 27], ["cichoric acid", "TREATMENT", 73, 86], ["caftaric acid", "TREATMENT", 91, 104], ["vacuum microwave drying", "TREATMENT", 210, 233]]], ["They also found that individual alkamide concentrations in roots and leaves were affected by the drying methods used (Kim et al. 2000a ) .", [["roots", "ANATOMY", 59, 64], ["leaves", "ANATOMY", 69, 75], ["alkamide", "CHEMICAL", 32, 40], ["alkamide", "CHEMICAL", 32, 40], ["alkamide", "SIMPLE_CHEMICAL", 32, 40], ["roots", "ORGAN", 59, 64], ["leaves", "ORGAN", 69, 75], ["individual alkamide concentrations in roots", "PROBLEM", 21, 64], ["roots", "OBSERVATION_MODIFIER", 59, 64]]], ["To preserve higher levels of total alkamides, freeze-drying was found to be the best method, vacuum microwave drying was a superior method for drying roots than air-drying at 70 \u00b0C, while air-drying at 50 \u00b0C was the preferred method for drying leaves of E. purpurea .Fruit (Achene)/Seed PhytochemicalsTwo major alkamide peaks were identifi ed in E. purpurea achenes as undeca-2 E ,4 Z -diene-8, 10-diynoic acid isobutylamide and dodeca-2 E , 4 E ,8 E ,10 E / Z tetraenoic acid isobutylamide (8/9) (He et al. 1998 ).", [["roots", "ANATOMY", 150, 155], ["alkamides", "CHEMICAL", 35, 44], ["alkamide", "CHEMICAL", 311, 319], ["undeca-2 E ,4 Z -diene-8, 10-diynoic acid isobutylamide", "CHEMICAL", 369, 424], ["dodeca-2 E , 4 E ,8 E ,10 E / Z tetraenoic acid isobutylamide", "CHEMICAL", 429, 490], ["alkamides", "CHEMICAL", 35, 44], ["alkamide", "CHEMICAL", 311, 319], ["undeca-2 E ,4 Z -diene-8, 10-diynoic acid isobutylamide", "CHEMICAL", 369, 424], ["dodeca-2 E , 4 E ,8 E ,10 E / Z tetraenoic acid isobutylamide", "CHEMICAL", 429, 490], ["alkamides", "SIMPLE_CHEMICAL", 35, 44], ["E. purpurea", "ORGANISM", 254, 265], ["Achene", "SIMPLE_CHEMICAL", 274, 280], ["alkamide", "SIMPLE_CHEMICAL", 311, 319], ["undeca-2 E", "SIMPLE_CHEMICAL", 369, 379], ["4 Z -diene-8, 10-diynoic acid isobutylamide", "SIMPLE_CHEMICAL", 381, 424], ["dodeca-2 E , 4 E ,8 E", "SIMPLE_CHEMICAL", 429, 450], ["10 E / Z tetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 452, 490], ["E. purpurea", "SPECIES", 254, 265], ["E. purpurea", "SPECIES", 346, 357], ["E. purpurea", "SPECIES", 254, 265], ["E. purpurea", "SPECIES", 346, 357], ["total alkamides", "TREATMENT", 29, 44], ["vacuum microwave drying", "TREATMENT", 93, 116], ["drying roots", "PROBLEM", 143, 155], ["E. purpurea", "PROBLEM", 254, 265], ["Two major alkamide peaks", "TEST", 301, 325], ["undeca", "TEST", 369, 375], ["diynoic acid isobutylamide", "TREATMENT", 398, 424], ["dodeca", "TEST", 429, 435], ["E", "TEST", 449, 450], ["E", "TEST", 455, 456], ["/ Z tetraenoic acid isobutylamide", "TREATMENT", 457, 490], ["E. purpurea", "OBSERVATION", 254, 265]]], ["The isomer pair, tetraene 8/9, was purifi ed as a standard for quantifi cation of alkamide content in E. purpurea achenes and roots.Fruit (Achene)/Seed PhytochemicalsSeed oil yields of E. angustifolia , E. pallida and E. purpurea , harvested in 1998 and 1999, ranged from 13 to 23 % (Oomah et al. 2006 ) .", [["achenes", "ANATOMY", 114, 121], ["roots", "ANATOMY", 126, 131], ["oil", "ANATOMY", 171, 174], ["tetraene", "CHEMICAL", 17, 25], ["alkamide", "CHEMICAL", 82, 90], ["tetraene", "CHEMICAL", 17, 25], ["alkamide", "CHEMICAL", 82, 90], ["tetraene 8/9", "SIMPLE_CHEMICAL", 17, 29], ["cation", "SIMPLE_CHEMICAL", 72, 78], ["alkamide", "SIMPLE_CHEMICAL", 82, 90], ["E. purpurea", "ORGANISM", 102, 113], ["achenes", "ORGANISM", 114, 121], ["roots", "ORGAN", 126, 131], ["Achene", "SIMPLE_CHEMICAL", 139, 145], ["oil", "ORGANISM_SUBSTANCE", 171, 174], ["E. angustifolia", "ORGANISM", 185, 200], ["E. pallida", "ORGANISM", 203, 213], ["E. purpurea", "ORGANISM", 218, 229], ["E. purpurea", "SPECIES", 102, 113], ["E. angustifolia", "SPECIES", 185, 200], ["E. pallida", "SPECIES", 203, 213], ["E. purpurea", "SPECIES", 218, 229], ["E. purpurea", "SPECIES", 102, 113], ["E. angustifolia", "SPECIES", 185, 200], ["E. pallida", "SPECIES", 203, 213], ["E. purpurea", "SPECIES", 218, 229], ["quantifi cation of alkamide content", "TREATMENT", 63, 98], ["E. angustifolia", "PROBLEM", 185, 200], ["E. pallida", "PROBLEM", 203, 213], ["purpurea achenes", "OBSERVATION", 105, 121], ["roots", "OBSERVATION_MODIFIER", 126, 131], ["E. angustifolia", "OBSERVATION_MODIFIER", 185, 200], ["pallida", "ANATOMY", 206, 213], ["purpurea", "OBSERVATION_MODIFIER", 221, 229]]], ["Vitamin E content of the oils ranged from 29 to 85 mg/100 g oil, with \u03b1-tocopherol constituting 83 % of the total tocopherol.", [["oils", "ANATOMY", 25, 29], ["oil", "ANATOMY", 60, 63], ["Vitamin E", "CHEMICAL", 0, 9], ["\u03b1-tocopherol", "CHEMICAL", 70, 82], ["tocopherol", "CHEMICAL", 114, 124], ["Vitamin E", "CHEMICAL", 0, 9], ["\u03b1-tocopherol", "CHEMICAL", 70, 82], ["tocopherol", "CHEMICAL", 114, 124], ["Vitamin E", "SIMPLE_CHEMICAL", 0, 9], ["oil", "ORGANISM_SUBSTANCE", 60, 63], ["\u03b1-tocopherol", "SIMPLE_CHEMICAL", 70, 82], ["tocopherol", "SIMPLE_CHEMICAL", 114, 124], ["Vitamin E content of the oils", "TREATMENT", 0, 29], ["\u03b1-tocopherol", "TREATMENT", 70, 82], ["the total tocopherol", "TREATMENT", 104, 124]]], ["The oil was highly polyunsaturated and abundant in linoleic, oleic and palmitic acids, together comprising 95 % of the total fatty acids.", [["oil", "ANATOMY", 4, 7], ["polyunsaturated", "CHEMICAL", 19, 34], ["linoleic, oleic and palmitic acids", "CHEMICAL", 51, 85], ["fatty acids", "CHEMICAL", 125, 136], ["linoleic, oleic and palmitic acids", "CHEMICAL", 51, 85], ["fatty acids", "CHEMICAL", 125, 136], ["oil", "ORGANISM_SUBSTANCE", 4, 7], ["linoleic", "SIMPLE_CHEMICAL", 51, 59], ["oleic", "SIMPLE_CHEMICAL", 61, 66], ["palmitic acids", "SIMPLE_CHEMICAL", 71, 85], ["fatty acids", "SIMPLE_CHEMICAL", 125, 136], ["palmitic acids", "TEST", 71, 85], ["the total fatty acids", "TEST", 115, 136], ["polyunsaturated", "OBSERVATION_MODIFIER", 19, 34], ["abundant", "OBSERVATION_MODIFIER", 39, 47], ["linoleic", "OBSERVATION_MODIFIER", 51, 59], ["palmitic acids", "OBSERVATION", 71, 85], ["fatty acids", "OBSERVATION", 125, 136]]], ["E. purpurea seed oils contained 66.5 % linoleic, 21.4 %, oleic and 8 % palmitic acids in the 1998 year harvest and 75.6 % linoleic, 12.2 % oleic and 7 % palmitic acids in the 1999 harvest.", [["seed oils", "ANATOMY", 12, 21], ["linoleic", "CHEMICAL", 39, 47], ["oleic", "CHEMICAL", 57, 62], ["palmitic acids", "CHEMICAL", 71, 85], ["linoleic", "CHEMICAL", 122, 130], ["oleic", "CHEMICAL", 139, 144], ["palmitic acids", "CHEMICAL", 153, 167], ["linoleic", "CHEMICAL", 39, 47], ["oleic", "CHEMICAL", 57, 62], ["palmitic acids", "CHEMICAL", 71, 85], ["linoleic", "CHEMICAL", 122, 130], ["oleic", "CHEMICAL", 139, 144], ["palmitic acids", "CHEMICAL", 153, 167], ["E. purpurea", "ORGANISM", 0, 11], ["seed oils", "ORGANISM_SUBSTANCE", 12, 21], ["linoleic", "SIMPLE_CHEMICAL", 39, 47], ["oleic", "SIMPLE_CHEMICAL", 57, 62], ["palmitic acids", "SIMPLE_CHEMICAL", 71, 85], ["linoleic", "SIMPLE_CHEMICAL", 122, 130], ["oleic", "SIMPLE_CHEMICAL", 139, 144], ["palmitic acids", "SIMPLE_CHEMICAL", 153, 167], ["E. purpurea", "SPECIES", 0, 11], ["E. purpurea", "SPECIES", 0, 11], ["E. purpurea seed oils", "TEST", 0, 21], ["linoleic", "TEST", 39, 47], ["oleic", "TEST", 57, 62], ["palmitic acids", "TEST", 71, 85], ["linoleic", "TEST", 122, 130], ["oleic", "TEST", 139, 144], ["palmitic acids", "TEST", 153, 167], ["1999 harvest", "OBSERVATION", 175, 187]]], ["Fruit (achenes) of E. purpurea was found to contain 33.6 % light yellow fatty oil comprising 78.4 % unsaturated fatty acids and 21.6 % saturated fatty acids; the major components were linoleic acid (58.2 %) and oleic (20.2 %) acid, and the equivalent iodine number was 121 (Vandyshev et al. 2009 ).", [["fatty oil", "ANATOMY", 72, 81], ["unsaturated fatty acids", "CHEMICAL", 100, 123], ["fatty acids", "CHEMICAL", 145, 156], ["linoleic acid", "CHEMICAL", 184, 197], ["oleic", "CHEMICAL", 211, 216], ["iodine", "CHEMICAL", 251, 257], ["fatty oil", "CHEMICAL", 72, 81], ["unsaturated fatty acids", "CHEMICAL", 100, 123], ["saturated fatty acids", "CHEMICAL", 135, 156], ["linoleic acid", "CHEMICAL", 184, 197], ["oleic", "CHEMICAL", 211, 216], ["iodine", "CHEMICAL", 251, 257], ["Fruit", "ORGANISM_SUBDIVISION", 0, 5], ["E. purpurea", "ORGANISM", 19, 30], ["oil", "ORGANISM_SUBSTANCE", 78, 81], ["unsaturated fatty acids", "SIMPLE_CHEMICAL", 100, 123], ["saturated fatty acids", "SIMPLE_CHEMICAL", 135, 156], ["linoleic acid", "SIMPLE_CHEMICAL", 184, 197], ["oleic", "SIMPLE_CHEMICAL", 211, 216], ["iodine", "SIMPLE_CHEMICAL", 251, 257], ["E. purpurea", "SPECIES", 19, 30], ["E. purpurea", "SPECIES", 19, 30], ["E. purpurea", "TEST", 19, 30], ["light yellow fatty oil", "TEST", 59, 81], ["unsaturated fatty acids", "TEST", 100, 123], ["saturated fatty acids", "TEST", 135, 156], ["linoleic acid", "TEST", 184, 197], ["oleic", "TEST", 211, 216], ["acid", "TEST", 226, 230], ["the equivalent iodine number", "TEST", 236, 264]]], ["Eighteen components were identified in E. purpurea seed oil, comprising 90.4 % of total area with petroleum ether solvent and 96 % with solvent n -hexane solvent (Diraz et al. 2012 ) .", [["seed oil", "ANATOMY", 51, 59], ["petroleum ether", "CHEMICAL", 98, 113], ["solvent n -hexane", "CHEMICAL", 136, 153], ["petroleum ether", "CHEMICAL", 98, 113], ["n -hexane", "CHEMICAL", 144, 153], ["E. purpurea", "ORGANISM", 39, 50], ["seed oil", "ORGANISM_SUBSTANCE", 51, 59], ["n -hexane", "SIMPLE_CHEMICAL", 144, 153], ["E. purpurea", "SPECIES", 39, 50], ["E. purpurea", "SPECIES", 39, 50], ["petroleum ether solvent", "TREATMENT", 98, 121], ["solvent n -hexane solvent", "TREATMENT", 136, 161], ["petroleum", "ANATOMY_MODIFIER", 98, 107]]], ["The most abundant fatty acids were palmitic acid, stearic acid, oleic acid, and linoleic acid.", [["fatty acids", "CHEMICAL", 18, 29], ["palmitic acid", "CHEMICAL", 35, 48], ["stearic acid", "CHEMICAL", 50, 62], ["oleic acid", "CHEMICAL", 64, 74], ["linoleic acid", "CHEMICAL", 80, 93], ["fatty acids", "CHEMICAL", 18, 29], ["palmitic acid", "CHEMICAL", 35, 48], ["stearic acid", "CHEMICAL", 50, 62], ["oleic acid", "CHEMICAL", 64, 74], ["linoleic acid", "CHEMICAL", 80, 93], ["fatty acids", "SIMPLE_CHEMICAL", 18, 29], ["palmitic acid", "SIMPLE_CHEMICAL", 35, 48], ["stearic acid", "SIMPLE_CHEMICAL", 50, 62], ["oleic acid", "SIMPLE_CHEMICAL", 64, 74], ["linoleic acid", "SIMPLE_CHEMICAL", 80, 93], ["palmitic acid", "TEST", 35, 48], ["stearic acid", "TEST", 50, 62], ["oleic acid", "TREATMENT", 64, 74], ["linoleic acid", "TREATMENT", 80, 93], ["abundant", "OBSERVATION_MODIFIER", 9, 17], ["fatty acids", "OBSERVATION", 18, 29]]], ["The fatty acid profi le using petroleum ether and n -hexane solvents were, respectively, as follows: oleic acid C18:1 (48 %, 29 %), palmitic acid C16:0 (16.6 %, 9.2 %), linoleic acid C18:2 (13.3 %; 51 %) , oxocol C13 (0.1 %, 0 %), myristic acid C14:0 (0.3 %, 0.2 %), pentadecanoic acid C15:0 (0.1 %, 0.1 %), palmitoleic acid C16:1Fruit (Achene)/Seed Phytochemicals(1 %, 0.4 %), carbonic acid C17:0 (0.2 %, 0.1 %), heptadecanoic acid C17:1 (0.2 %, 0 %), stearic acid C18:0 (5 %, 2.5 %) elaidic acid C18:1 (0.7 %, 0 %), linolelaidic acid C18:2 (0.8 %, 0 %), arachidic acid C20:0 (0.5 %, 0.6 %), gamma-linolenic acid C18:3 (0 %, 0.5 %), eicosenoic acid C20:1 (0.3 %, 0.5 %), behenic acid C22:0 (1.3 %, 0.7 %), tricosanoic acid C23:0 (0.1 %, 0.1 %), lignoceric acid C24:0 (0.6 %, 0.3 %) and oxiraneoctanoic acid C26 (0.8 %, 0.8 %).", [["fatty acid profi", "CHEMICAL", 4, 20], ["petroleum ether", "CHEMICAL", 30, 45], ["n -hexane", "CHEMICAL", 50, 59], ["oleic acid C18:1", "CHEMICAL", 101, 117], ["palmitic acid C16:0", "CHEMICAL", 132, 151], ["linoleic acid C18:2", "CHEMICAL", 169, 188], ["oxocol C13", "CHEMICAL", 206, 216], ["myristic acid", "CHEMICAL", 231, 244], ["C14:0", "CHEMICAL", 245, 250], ["pentadecanoic acid C15:0", "CHEMICAL", 267, 291], ["palmitoleic acid", "CHEMICAL", 308, 324], ["C16:1Fruit", "CHEMICAL", 325, 335], ["Achene", "CHEMICAL", 337, 343], ["carbonic acid", "CHEMICAL", 378, 391], ["C17:0", "CHEMICAL", 392, 397], ["heptadecanoic acid", "CHEMICAL", 414, 432], ["C17:1", "CHEMICAL", 433, 438], ["stearic acid C18:0", "CHEMICAL", 453, 471], ["elaidic acid C18:1", "CHEMICAL", 485, 503], ["linolelaidic acid C18:2", "CHEMICAL", 518, 541], ["arachidic acid", "CHEMICAL", 556, 570], ["C20:0", "CHEMICAL", 571, 576], ["gamma-linolenic acid", "CHEMICAL", 593, 613], ["C18:3", "CHEMICAL", 614, 619], ["eicosenoic acid C20:1", "CHEMICAL", 634, 655], ["behenic acid", "CHEMICAL", 672, 684], ["C22:0", "CHEMICAL", 685, 690], ["tricosanoic acid", "CHEMICAL", 707, 723], ["C23:0", "CHEMICAL", 724, 729], ["lignoceric acid", "CHEMICAL", 746, 761], ["C24:0", "CHEMICAL", 762, 767], ["oxiraneoctanoic acid C26", "CHEMICAL", 787, 811], ["fatty acid", "CHEMICAL", 4, 14], ["petroleum ether", "CHEMICAL", 30, 45], ["n -hexane", "CHEMICAL", 50, 59], ["oleic acid C18:1", "CHEMICAL", 101, 117], ["palmitic acid C16:0", "CHEMICAL", 132, 151], ["linoleic acid C18:2", "CHEMICAL", 169, 188], ["oxocol C13", "CHEMICAL", 206, 216], ["myristic acid C14:0", "CHEMICAL", 231, 250], ["pentadecanoic acid C15:0", "CHEMICAL", 267, 291], ["palmitoleic acid C16:1Fruit", "CHEMICAL", 308, 335], ["Achene", "CHEMICAL", 337, 343], ["carbonic acid C17:0", "CHEMICAL", 378, 397], ["heptadecanoic acid C17:1", "CHEMICAL", 414, 438], ["stearic acid C18:0", "CHEMICAL", 453, 471], ["elaidic acid C18:1", "CHEMICAL", 485, 503], ["linolelaidic acid C18:2", "CHEMICAL", 518, 541], ["arachidic acid C20:0", "CHEMICAL", 556, 576], ["gamma-linolenic acid C18:3", "CHEMICAL", 593, 619], ["eicosenoic acid C20:1", "CHEMICAL", 634, 655], ["behenic acid C22:0", "CHEMICAL", 672, 690], ["tricosanoic acid C23:0", "CHEMICAL", 707, 729], ["lignoceric acid C24:0", "CHEMICAL", 746, 767], ["oxiraneoctanoic acid C26", "CHEMICAL", 787, 811], ["fatty acid", "SIMPLE_CHEMICAL", 4, 14], ["petroleum ether", "SIMPLE_CHEMICAL", 30, 45], ["n -hexane", "SIMPLE_CHEMICAL", 50, 59], ["oleic acid C18:1", "SIMPLE_CHEMICAL", 101, 117], ["palmitic acid C16:0", "SIMPLE_CHEMICAL", 132, 151], ["linoleic acid C18:2", "SIMPLE_CHEMICAL", 169, 188], ["oxocol C13", "SIMPLE_CHEMICAL", 206, 216], ["myristic acid C14:0", "SIMPLE_CHEMICAL", 231, 250], ["pentadecanoic acid C15:0", "SIMPLE_CHEMICAL", 267, 291], ["palmitoleic acid C16:1Fruit", "SIMPLE_CHEMICAL", 308, 335], ["Achene", "SIMPLE_CHEMICAL", 337, 343], ["Seed Phytochemicals", "SIMPLE_CHEMICAL", 345, 364], ["carbonic acid C17:0", "SIMPLE_CHEMICAL", 378, 397], ["heptadecanoic acid C17:1", "SIMPLE_CHEMICAL", 414, 438], ["stearic acid C18:0", "SIMPLE_CHEMICAL", 453, 471], ["elaidic acid C18:1", "SIMPLE_CHEMICAL", 485, 503], ["linolelaidic acid C18:2", "SIMPLE_CHEMICAL", 518, 541], ["arachidic acid C20:0", "SIMPLE_CHEMICAL", 556, 576], ["gamma-linolenic acid C18:3", "SIMPLE_CHEMICAL", 593, 619], ["eicosenoic acid C20:1", "SIMPLE_CHEMICAL", 634, 655], ["behenic acid", "SIMPLE_CHEMICAL", 672, 684], ["C22:0", "SIMPLE_CHEMICAL", 685, 690], ["tricosanoic acid C23:0", "SIMPLE_CHEMICAL", 707, 729], ["lignoceric acid", "SIMPLE_CHEMICAL", 746, 761], ["C24:0", "SIMPLE_CHEMICAL", 762, 767], ["oxiraneoctanoic acid C26", "SIMPLE_CHEMICAL", 787, 811], ["The fatty acid profi", "TEST", 0, 20], ["petroleum ether", "TREATMENT", 30, 45], ["n -hexane solvents", "TREATMENT", 50, 68], ["oleic acid C18:1", "TEST", 101, 117], ["palmitic acid C16:0", "TEST", 132, 151], ["linoleic acid C18:2", "TEST", 169, 188], ["oxocol C13", "TEST", 206, 216], ["myristic acid C14:0", "TEST", 231, 250], ["pentadecanoic acid C15:0", "TEST", 267, 291], ["palmitoleic acid C16:1Fruit", "TEST", 308, 335], ["Seed Phytochemicals", "TEST", 345, 364], ["carbonic acid C17:0", "TEST", 378, 397], ["heptadecanoic acid C17:1", "TEST", 414, 438], ["stearic acid C18:0", "TEST", 453, 471], ["elaidic acid C18:1", "TEST", 485, 503], ["linolelaidic acid C18:2", "TEST", 518, 541], ["arachidic acid C20:0", "TEST", 556, 576], ["gamma", "TEST", 593, 598], ["linolenic acid C18:3", "TEST", 599, 619], ["eicosenoic acid C20:1", "TEST", 634, 655], ["behenic acid C22:0", "TEST", 672, 690], ["tricosanoic acid C23:0", "TEST", 707, 729], ["lignoceric acid C24:0", "TEST", 746, 767], ["oxiraneoctanoic acid C26", "TEST", 787, 811], ["fatty acid", "OBSERVATION", 4, 14], ["gamma", "ANATOMY", 593, 598]]], ["Oxocol, heptadecenoic acid, elaidic acid and linolelaidic acid could not be defi ned with solvent n -hexane.Leaf PhytochemicalsVolatiles in the headspace of E. purpurea leaf tissues were acetaldehyde, dimethyl sulphide, propanal, 2-methylbutanal, 3-methylbutanal, 2-ethylfuran, pentanl, \u03b1-pinene, \u03b1-thujene, camphene, hexanal, \u03b2-pinene, sabinene/ \u03b2-thujene, pentanal, 2-methyl-4-pentenal, \u03b2-myrcene, \u03b1-terpinene, limonene, 2-hexanal ( cis ), 2-hexenal ( trans ), ocimene, \u03b3-terpinene, trans -ocimene, p -cymene, hexyl acetate, \u03b1-terpinolene, 3-hexen-1-ol-acetate, 1-hexanol, allo -ocimene 3-hexen-1-ol ( cis ), \u03b1-ylangene, \u03b3-cadinene, trans -caryophyllene, calarene/\u03b1-copaene, germacrene D/\u03b1cubebene, 5-ethyl-2(5 H )-furanone, \u03b4-cadinene, \u03b2\u03b1-cubebine/\u03b3-cadinene and 2,2,3,3-tetramethyl hexane (Mazza and Cottrell 1999 ) .", [["leaf tissues", "ANATOMY", 169, 181], ["Oxocol", "CHEMICAL", 0, 6], ["heptadecenoic acid", "CHEMICAL", 8, 26], ["elaidic acid", "CHEMICAL", 28, 40], ["linolelaidic acid", "CHEMICAL", 45, 62], ["-hexane", "CHEMICAL", 100, 107], ["PhytochemicalsVolatiles", "CHEMICAL", 113, 136], ["acetaldehyde", "CHEMICAL", 187, 199], ["dimethyl sulphide", "CHEMICAL", 201, 218], ["propanal", "CHEMICAL", 220, 228], ["2-methylbutanal", "CHEMICAL", 230, 245], ["3-methylbutanal, 2-ethylfuran, pentanl, \u03b1-pinene, \u03b1-thujene, camphene, hexanal, \u03b2-pinene, sabinene/ \u03b2-thujene", "CHEMICAL", 247, 356], ["pentanal", "CHEMICAL", 358, 366], ["2-methyl-4-pentenal, \u03b2-myrcene, \u03b1-terpinene, limonene, 2-hexanal", "CHEMICAL", 368, 432], ["2-hexenal", "CHEMICAL", 442, 451], ["ocimene", "CHEMICAL", 463, 470], ["\u03b3-terpinene", "CHEMICAL", 472, 483], ["trans -ocimene, p -cymene, hexyl acetate", "CHEMICAL", 485, 525], ["\u03b1-terpinolene", "CHEMICAL", 527, 540], ["3-hexen-1-ol-acetate", "CHEMICAL", 542, 562], ["1-hexanol", "CHEMICAL", 564, 573], ["allo -ocimene 3-hexen-1-ol", "CHEMICAL", 575, 601], ["\u03b1-ylangene", "CHEMICAL", 611, 621], ["\u03b3-cadinene", "CHEMICAL", 623, 633], ["trans -caryophyllene", "CHEMICAL", 635, 655], ["calarene", "CHEMICAL", 657, 665], ["\u03b1-copaene", "CHEMICAL", 666, 675], ["germacrene D", "CHEMICAL", 677, 689], ["\u03b1cubebene", "CHEMICAL", 690, 699], ["5-ethyl-2(5 H )-furanone", "CHEMICAL", 701, 725], ["\u03b4-cadinene", "CHEMICAL", 727, 737], ["\u03b2\u03b1-cubebine/\u03b3-cadinene", "CHEMICAL", 739, 761], ["2,2,3,3-tetramethyl hexane", "CHEMICAL", 766, 792], ["Oxocol", "CHEMICAL", 0, 6], ["heptadecenoic acid", "CHEMICAL", 8, 26], ["elaidic acid", "CHEMICAL", 28, 40], ["linolelaidic acid", "CHEMICAL", 45, 62], ["-hexane", "CHEMICAL", 100, 107], ["acetaldehyde", "CHEMICAL", 187, 199], ["dimethyl sulphide", "CHEMICAL", 201, 218], ["propanal", "CHEMICAL", 220, 228], ["2-methylbutanal", "CHEMICAL", 230, 245], ["3-methylbutanal", "CHEMICAL", 247, 262], ["2-ethylfuran", "CHEMICAL", 264, 276], ["pentanl", "CHEMICAL", 278, 285], ["\u03b1-pinene", "CHEMICAL", 287, 295], ["\u03b1-thujene", "CHEMICAL", 297, 306], ["camphene", "CHEMICAL", 308, 316], ["hexanal", "CHEMICAL", 318, 325], ["\u03b2-pinene", "CHEMICAL", 327, 335], ["sabinene", "CHEMICAL", 337, 345], ["\u03b2-thujene", "CHEMICAL", 347, 356], ["pentanal", "CHEMICAL", 358, 366], ["2-methyl-4-pentenal", "CHEMICAL", 368, 387], ["\u03b2-myrcene", "CHEMICAL", 389, 398], ["\u03b1-terpinene", "CHEMICAL", 400, 411], ["limonene", "CHEMICAL", 413, 421], ["2-hexanal", "CHEMICAL", 423, 432], ["2-hexenal", "CHEMICAL", 442, 451], ["ocimene", "CHEMICAL", 463, 470], ["\u03b3-terpinene", "CHEMICAL", 472, 483], ["trans -ocimene", "CHEMICAL", 485, 499], ["p -cymene", "CHEMICAL", 501, 510], ["hexyl acetate", "CHEMICAL", 512, 525], ["\u03b1-terpinolene", "CHEMICAL", 527, 540], ["3-hexen-1-ol-acetate", "CHEMICAL", 542, 562], ["1-hexanol", "CHEMICAL", 564, 573], ["allo -ocimene 3-hexen-1-ol", "CHEMICAL", 575, 601], ["\u03b1-ylangene", "CHEMICAL", 611, 621], ["\u03b3-cadinene", "CHEMICAL", 623, 633], ["trans -caryophyllene", "CHEMICAL", 635, 655], ["calarene", "CHEMICAL", 657, 665], ["\u03b1-copaene", "CHEMICAL", 666, 675], ["germacrene D", "CHEMICAL", 677, 689], ["\u03b1cubebene", "CHEMICAL", 690, 699], ["5-ethyl-2(5 H )-furanone", "CHEMICAL", 701, 725], ["\u03b4-cadinene", "CHEMICAL", 727, 737], ["\u03b2\u03b1-cubebine", "CHEMICAL", 739, 750], ["\u03b3-cadinene", "CHEMICAL", 751, 761], ["2,2,3,3-tetramethyl hexane", "CHEMICAL", 766, 792], ["Mazza", "CHEMICAL", 794, 799], ["Oxocol", "SIMPLE_CHEMICAL", 0, 6], ["heptadecenoic acid", "SIMPLE_CHEMICAL", 8, 26], ["elaidic acid", "SIMPLE_CHEMICAL", 28, 40], ["linolelaidic acid", "SIMPLE_CHEMICAL", 45, 62], ["solvent n -hexane", "SIMPLE_CHEMICAL", 90, 107], ["E. purpurea", "ORGANISM", 157, 168], ["leaf tissues", "TISSUE", 169, 181], ["acetaldehyde", "SIMPLE_CHEMICAL", 187, 199], ["dimethyl sulphide", "SIMPLE_CHEMICAL", 201, 218], ["propanal", "SIMPLE_CHEMICAL", 220, 228], ["2-methylbutanal", "SIMPLE_CHEMICAL", 230, 245], ["3-methylbutanal", "SIMPLE_CHEMICAL", 247, 262], ["2-ethylfuran", "SIMPLE_CHEMICAL", 264, 276], ["pentanl", "SIMPLE_CHEMICAL", 278, 285], ["\u03b1-pinene", "SIMPLE_CHEMICAL", 287, 295], ["\u03b1-thujene", "SIMPLE_CHEMICAL", 297, 306], ["camphene", "SIMPLE_CHEMICAL", 308, 316], ["hexanal", "SIMPLE_CHEMICAL", 318, 325], ["\u03b2-pinene", "SIMPLE_CHEMICAL", 327, 335], ["sabinene/ \u03b2-thujene", "SIMPLE_CHEMICAL", 337, 356], ["pentanal", "SIMPLE_CHEMICAL", 358, 366], ["2-methyl-4-pentenal", "SIMPLE_CHEMICAL", 368, 387], ["\u03b2-myrcene", "SIMPLE_CHEMICAL", 389, 398], ["\u03b1-terpinene", "SIMPLE_CHEMICAL", 400, 411], ["limonene", "SIMPLE_CHEMICAL", 413, 421], ["2-hexanal ( cis ), 2-hexenal ( trans ), ocimene", "SIMPLE_CHEMICAL", 423, 470], ["\u03b3-terpinene", "SIMPLE_CHEMICAL", 472, 483], ["trans -ocimene", "SIMPLE_CHEMICAL", 485, 499], ["p -cymene", "SIMPLE_CHEMICAL", 501, 510], ["hexyl acetate", "SIMPLE_CHEMICAL", 512, 525], ["\u03b1-terpinolene", "SIMPLE_CHEMICAL", 527, 540], ["3-hexen-1-ol-acetate", "SIMPLE_CHEMICAL", 542, 562], ["1-hexanol", "SIMPLE_CHEMICAL", 564, 573], ["allo -ocimene 3-hexen-1-ol ( cis ), \u03b1-ylangene", "SIMPLE_CHEMICAL", 575, 621], ["\u03b3-cadinene", "SIMPLE_CHEMICAL", 623, 633], ["trans -caryophyllene", "SIMPLE_CHEMICAL", 635, 655], ["calarene", "SIMPLE_CHEMICAL", 657, 665], ["\u03b1-copaene", "SIMPLE_CHEMICAL", 666, 675], ["germacrene D/\u03b1cubebene", "SIMPLE_CHEMICAL", 677, 699], ["5-ethyl-2(5 H )-furanone", "SIMPLE_CHEMICAL", 701, 725], ["\u03b4-cadinene", "SIMPLE_CHEMICAL", 727, 737], ["\u03b2\u03b1-cubebine/\u03b3-cadinene", "SIMPLE_CHEMICAL", 739, 761], ["2,2,3,3-tetramethyl hexane", "SIMPLE_CHEMICAL", 766, 792], ["Mazza", "SIMPLE_CHEMICAL", 794, 799], ["E. purpurea", "SPECIES", 157, 168], ["E. purpurea", "SPECIES", 157, 168], ["Oxocol", "TREATMENT", 0, 6], ["heptadecenoic acid", "TREATMENT", 8, 26], ["elaidic acid", "TREATMENT", 28, 40], ["linolelaidic acid", "TREATMENT", 45, 62], ["solvent n -hexane", "TREATMENT", 90, 107], ["Leaf PhytochemicalsVolatiles", "TEST", 108, 136], ["acetaldehyde", "TREATMENT", 187, 199], ["dimethyl sulphide", "TREATMENT", 201, 218], ["propanal", "TREATMENT", 220, 228], ["methylbutanal", "TREATMENT", 232, 245], ["methylbutanal", "TREATMENT", 249, 262], ["ethylfuran", "TREATMENT", 266, 276], ["pentanl", "TREATMENT", 278, 285], ["\u03b1-pinene", "TREATMENT", 287, 295], ["thujene", "TREATMENT", 299, 306], ["camphene", "TREATMENT", 308, 316], ["hexanal", "TREATMENT", 318, 325], ["\u03b2-pinene", "TREATMENT", 327, 335], ["sabinene", "TREATMENT", 337, 345], ["thujene", "TREATMENT", 349, 356], ["pentanal", "TREATMENT", 358, 366], ["methyl", "TREATMENT", 370, 376], ["pentenal", "TREATMENT", 379, 387], ["\u03b2-myrcene", "TREATMENT", 389, 398], ["\u03b1-terpinene", "TREATMENT", 400, 411], ["limonene", "TREATMENT", 413, 421], ["ocimene", "TREATMENT", 463, 470], ["\u03b3-terpinene", "TREATMENT", 472, 483], ["trans -ocimene", "TREATMENT", 485, 499], ["hexyl acetate", "TREATMENT", 512, 525], ["\u03b1-terpinolene", "TREATMENT", 527, 540], ["hexen", "TREATMENT", 544, 549], ["acetate", "TREATMENT", 555, 562], ["hexanol", "TREATMENT", 566, 573], ["allo -ocimene", "TREATMENT", 575, 588], ["\u03b1-ylangene", "TREATMENT", 611, 621], ["\u03b3-cadinene", "TREATMENT", 623, 633], ["caryophyllene", "TREATMENT", 642, 655], ["calarene", "TREATMENT", 657, 665], ["copaene", "TREATMENT", 668, 675], ["germacrene D/\u03b1cubebene", "TREATMENT", 677, 699], ["furanone", "TREATMENT", 717, 725], ["\u03b4-cadinene", "TREATMENT", 727, 737], ["\u03b2\u03b1-cubebine", "TREATMENT", 739, 750], ["cadinene", "TREATMENT", 753, 761], ["tetramethyl hexane", "TREATMENT", 774, 792], ["headspace", "ANATOMY_MODIFIER", 144, 153], ["purpurea leaf tissues", "OBSERVATION", 160, 181]]], ["Major volatiles in headspace of leaf tissues were myrcene 27 %, \u03b2-pinene 1.9 %, \u03b1-pinene 12.1 %, dimethyl sulphide <1.0 % Total phenolic contents reported for E. purpurea (leaf) were 15.15 mg GAE/100 g DW (Wojdy\u0142o et al. 2007 ).", [["leaf tissues", "ANATOMY", 32, 44], ["myrcene", "CHEMICAL", 50, 57], ["\u03b2-pinene", "CHEMICAL", 64, 72], ["\u03b1-pinene", "CHEMICAL", 80, 88], ["dimethyl sulphide", "CHEMICAL", 97, 114], ["myrcene", "CHEMICAL", 50, 57], ["\u03b2-pinene", "CHEMICAL", 64, 72], ["\u03b1-pinene", "CHEMICAL", 80, 88], ["dimethyl sulphide", "CHEMICAL", 97, 114], ["leaf tissues", "TISSUE", 32, 44], ["myrcene", "SIMPLE_CHEMICAL", 50, 57], ["\u03b2-pinene", "SIMPLE_CHEMICAL", 64, 72], ["\u03b1-pinene", "SIMPLE_CHEMICAL", 80, 88], ["dimethyl sulphide", "SIMPLE_CHEMICAL", 97, 114], ["E. purpurea", "ORGANISM", 159, 170], ["leaf", "ORGAN", 172, 176], ["E. purpurea", "SPECIES", 159, 170], ["E. purpurea", "SPECIES", 159, 170], ["myrcene", "TEST", 50, 57], ["\u03b2-pinene", "TEST", 64, 72], ["\u03b1-pinene", "TEST", 80, 88], ["dimethyl sulphide", "TEST", 97, 114], ["E. purpurea (leaf)", "TREATMENT", 159, 177], ["volatiles", "OBSERVATION_MODIFIER", 6, 15], ["headspace", "ANATOMY_MODIFIER", 19, 28], ["leaf tissues", "ANATOMY", 32, 44]]], ["Major phenolic compounds (mg/100 g DW) found were phenolic acids, 620 mg caffeic acid, 115 mg neochlorogenic acid, 19.5 mg p -coumaric acid and 17.9 mg ferulic acid, and fl avonoids, 12.4 mg quercetin.Leaf PhytochemicalsIn Echinacea purpurea cultivars Magnus and White Swan and line CLS-P2, harvested dry leaves contained highest cichoric acid content and followed by caftaric acid and echinacoside ).", [["leaves", "ANATOMY", 305, 311], ["phenolic acids", "CHEMICAL", 50, 64], ["caffeic acid", "CHEMICAL", 73, 85], ["neochlorogenic acid", "CHEMICAL", 94, 113], ["p -coumaric acid", "CHEMICAL", 123, 139], ["ferulic acid", "CHEMICAL", 152, 164], ["quercetin", "CHEMICAL", 191, 200], ["cichoric acid", "CHEMICAL", 330, 343], ["caftaric acid", "CHEMICAL", 368, 381], ["echinacoside", "CHEMICAL", 386, 398], ["phenolic acids", "CHEMICAL", 50, 64], ["caffeic acid", "CHEMICAL", 73, 85], ["neochlorogenic acid", "CHEMICAL", 94, 113], ["p -coumaric acid", "CHEMICAL", 123, 139], ["ferulic acid", "CHEMICAL", 152, 164], ["quercetin", "CHEMICAL", 191, 200], ["cichoric acid", "CHEMICAL", 330, 343], ["caftaric acid", "CHEMICAL", 368, 381], ["echinacoside", "CHEMICAL", 386, 398], ["phenolic acids", "SIMPLE_CHEMICAL", 50, 64], ["caffeic acid", "SIMPLE_CHEMICAL", 73, 85], ["neochlorogenic acid", "SIMPLE_CHEMICAL", 94, 113], ["p -coumaric acid", "SIMPLE_CHEMICAL", 123, 139], ["ferulic acid", "SIMPLE_CHEMICAL", 152, 164], ["fl avonoids", "SIMPLE_CHEMICAL", 170, 181], ["quercetin", "SIMPLE_CHEMICAL", 191, 200], ["line CLS-P2", "CELL", 278, 289], ["cichoric acid", "SIMPLE_CHEMICAL", 330, 343], ["caftaric acid", "SIMPLE_CHEMICAL", 368, 381], ["echinacoside", "SIMPLE_CHEMICAL", 386, 398], ["Echinacea purpurea", "SPECIES", 223, 241], ["Echinacea purpurea", "SPECIES", 223, 241], ["Major phenolic compounds", "TREATMENT", 0, 24], ["phenolic acids", "TREATMENT", 50, 64], ["caffeic acid", "TREATMENT", 73, 85], ["neochlorogenic acid", "TREATMENT", 94, 113], ["coumaric acid", "TREATMENT", 126, 139], ["ferulic acid", "TEST", 152, 164], ["fl avonoids", "TREATMENT", 170, 181], ["quercetin", "TREATMENT", 191, 200], ["Leaf PhytochemicalsIn Echinacea purpurea cultivars Magnus", "TREATMENT", 201, 258], ["White Swan", "TEST", 263, 273], ["line CLS-P2", "TREATMENT", 278, 289], ["highest cichoric acid content", "PROBLEM", 322, 351], ["caftaric acid", "TREATMENT", 368, 381], ["phenolic compounds", "OBSERVATION", 6, 24]]], ["The contents of chlorogenic acid and cynarin in leaves were relatively low as compared to cichoric acid, caftaric acid and chlorogenic acid.", [["leaves", "ANATOMY", 48, 54], ["chlorogenic acid", "CHEMICAL", 16, 32], ["cynarin", "CHEMICAL", 37, 44], ["cichoric acid", "CHEMICAL", 90, 103], ["caftaric acid", "CHEMICAL", 105, 118], ["chlorogenic acid", "CHEMICAL", 123, 139], ["chlorogenic acid", "CHEMICAL", 16, 32], ["cynarin", "CHEMICAL", 37, 44], ["cichoric acid", "CHEMICAL", 90, 103], ["caftaric acid", "CHEMICAL", 105, 118], ["chlorogenic acid", "CHEMICAL", 123, 139], ["chlorogenic acid", "SIMPLE_CHEMICAL", 16, 32], ["cynarin", "SIMPLE_CHEMICAL", 37, 44], ["leaves", "ORGAN", 48, 54], ["cichoric acid", "SIMPLE_CHEMICAL", 90, 103], ["caftaric acid", "SIMPLE_CHEMICAL", 105, 118], ["chlorogenic acid", "SIMPLE_CHEMICAL", 123, 139], ["chlorogenic acid", "TEST", 16, 32], ["cichoric acid", "TEST", 90, 103], ["caftaric acid", "TREATMENT", 105, 118], ["chlorogenic acid", "TREATMENT", 123, 139], ["chlorogenic acid", "OBSERVATION", 16, 32], ["chlorogenic acid", "OBSERVATION", 123, 139]]], ["Among the fi ve caffeoyl derivatives examined, CLS-P2 leaves had greater cichoric acid, caftaric acid, cynarin and echinacoside levels than Magnus and White Swan.", [["cichoric acid", "CHEMICAL", 73, 86], ["caftaric acid", "CHEMICAL", 88, 101], ["cynarin", "CHEMICAL", 103, 110], ["echinacoside", "CHEMICAL", 115, 127], ["fi ve caffeoyl", "CHEMICAL", 10, 24], ["cichoric acid", "CHEMICAL", 73, 86], ["caftaric acid", "CHEMICAL", 88, 101], ["cynarin", "CHEMICAL", 103, 110], ["echinacoside", "CHEMICAL", 115, 127], ["fi ve caffeoyl derivatives", "SIMPLE_CHEMICAL", 10, 36], ["cichoric acid", "SIMPLE_CHEMICAL", 73, 86], ["caftaric acid", "SIMPLE_CHEMICAL", 88, 101], ["cynarin", "SIMPLE_CHEMICAL", 103, 110], ["echinacoside", "SIMPLE_CHEMICAL", 115, 127], ["the fi ve caffeoyl derivatives", "TREATMENT", 6, 36], ["greater cichoric acid", "TEST", 65, 86], ["caftaric acid", "TEST", 88, 101], ["echinacoside levels", "TEST", 115, 134], ["White Swan", "TEST", 151, 161]]], ["Total caffeoyl derivatives content were 61.73, 31.75 and 20.02 mg/g dry weight for line CLS-P2, cultivar Magnus and cultivar White Swan, respectively.", [["caffeoyl", "CHEMICAL", 6, 14], ["caffeoyl", "CHEMICAL", 6, 14], ["caffeoyl derivatives", "SIMPLE_CHEMICAL", 6, 26], ["Total caffeoyl derivatives content", "TREATMENT", 0, 34], ["line CLS", "TEST", 83, 91], ["cultivar Magnus", "TREATMENT", 96, 111], ["cultivar White Swan", "TEST", 116, 135], ["Magnus", "ANATOMY", 105, 111]]], ["Line CLS-P2 had the highest dodeca-2 E ,4 E ,8 Z ,10 E -tetraenoic acid isobutylamide (alkamide 8) and dodeca-2 E ,4 E ,8 Z ,10 Ztetraenoic acid isobutylamide (alkamide 9) content in dry leaves among the tested cultivars and line.", [["leaves", "ANATOMY", 187, 193], ["dodeca-2 E ,4 E ,8 Z ,10 E -tetraenoic acid isobutylamide", "CHEMICAL", 28, 85], ["alkamide 8", "CHEMICAL", 87, 97], ["dodeca-2 E ,4 E ,8 Z ,10 Ztetraenoic acid isobutylamide", "CHEMICAL", 103, 158], ["alkamide 9", "CHEMICAL", 160, 170], ["dodeca-2 E ,4 E ,8 Z ,10 E -tetraenoic acid isobutylamide", "CHEMICAL", 28, 85], ["alkamide", "CHEMICAL", 87, 95], ["dodeca-2 E ,4 E ,8 Z ,10 Ztetraenoic acid isobutylamide", "CHEMICAL", 103, 158], ["alkamide", "CHEMICAL", 160, 168], ["dodeca-2 E", "SIMPLE_CHEMICAL", 28, 38], ["4 E", "SIMPLE_CHEMICAL", 40, 43], ["8 Z", "SIMPLE_CHEMICAL", 45, 48], ["10 E -tetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 50, 85], ["alkamide 8)", "SIMPLE_CHEMICAL", 87, 98], ["dodeca-2 E ,4 E ,8 Z ,10 Ztetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 103, 158], ["alkamide 9)", "SIMPLE_CHEMICAL", 160, 171], ["Line CLS", "TEST", 0, 8], ["the highest dodeca", "TEST", 16, 34], ["Z", "TEST", 47, 48], ["E", "TEST", 53, 54], ["tetraenoic acid isobutylamide", "TREATMENT", 56, 85], ["alkamide", "TEST", 87, 95], ["dodeca", "TEST", 103, 109], ["Z", "TEST", 122, 123], ["Ztetraenoic acid isobutylamide (alkamide", "TREATMENT", 128, 168]]], ["The profi le of phenolic compounds (mean concentration \u03bcg/ml) in E. purpurea leaf and stem was determined as 0-1,174 \u03bcg caftaric acid, 0-63 \u03bcg chlorogenic acid, 0-421 \u03bcg caffeic acid, 0-5 cynarin, 0-6,001 \u03bcg cichoric acid, 0 \u03bcg echinacoside and 0.19 \u03bcg tet 8/9 (dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic acid isobutylamide) ).Stem PhytochemicalsVolatiles in the headspace of E. purpurea stem tissues were acetaldehyde, dimethyl sulphide, 2-methylpropanal and acetone, 2-methylbutanal, 3-methylbutanal, \u03b1-pinene, geranyl acetate, camphene, hexanal, \u03b2-pinene, sabinene/ \u03b2-thujene, unknown, 2-methyl-4-pentenal, \u03b2-myrcene, \u03b1-terpinene, limonene, 2-hexenal ( trans ), ocimene, \u03b3-terpinene, trans -ocimene, \u03b1-terpinolene, 3-hexen-1-ol-acetate, 1-hexanol, allo -ocimene, 3-hexen-1-ol ( cis ), 2-hexen-1-ol ( trans ), \u03b1-cubebene/\u03b1-copaene, \u03b1-ylangene, \u03b1-ylangene, germacrene D/\u03b1-cubebene, \u03b4-cadinene and \u03b2\u03b1-cubebine/\u03b3-cadinene (Mazza and Cottrell 1999 ) .", [["leaf", "ANATOMY", 77, 81], ["stem", "ANATOMY", 86, 90], ["stem tissues", "ANATOMY", 388, 400], ["caftaric acid", "CHEMICAL", 120, 133], ["chlorogenic acid", "CHEMICAL", 143, 159], ["caffeic acid", "CHEMICAL", 170, 182], ["0-5 cynarin, 0-6,001 \u03bcg cichoric acid", "CHEMICAL", 184, 221], ["echinacoside", "CHEMICAL", 228, 240], ["dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic acid isobutylamide", "CHEMICAL", 262, 323], ["acetaldehyde", "CHEMICAL", 406, 418], ["dimethyl sulphide", "CHEMICAL", 420, 437], ["2-methylpropanal", "CHEMICAL", 439, 455], ["acetone", "CHEMICAL", 460, 467], ["2-methylbutanal", "CHEMICAL", 469, 484], ["3-methylbutanal, \u03b1-pinene, geranyl acetate", "CHEMICAL", 486, 528], ["camphene", "CHEMICAL", 530, 538], ["hexanal", "CHEMICAL", 540, 547], ["\u03b2-pinene", "CHEMICAL", 549, 557], ["sabinene", "CHEMICAL", 559, 567], ["thujene", "CHEMICAL", 571, 578], ["2-methyl-4-pentenal, \u03b2-myrcene, \u03b1-terpinene, limonene, 2-hexenal", "CHEMICAL", 589, 653], ["ocimene", "CHEMICAL", 665, 672], ["\u03b3-terpinene", "CHEMICAL", 674, 685], ["\u03b1-terpinolene", "CHEMICAL", 703, 716], ["3-hexen-1-ol-acetate", "CHEMICAL", 718, 738], ["1-hexanol", "CHEMICAL", 740, 749], ["allo -ocimene, 3-hexen-1-ol", "CHEMICAL", 751, 778], ["2-hexen-1-ol", "CHEMICAL", 788, 800], ["\u03b1-cubebene", "CHEMICAL", 812, 822], ["\u03b1-ylangene", "CHEMICAL", 834, 844], ["\u03b1-ylangene", "CHEMICAL", 846, 856], ["germacrene D/\u03b1-cubebene", "CHEMICAL", 858, 881], ["\u03b4-cadinene", "CHEMICAL", 883, 893], ["\u03b2\u03b1-cubebine/\u03b3-cadinene", "CHEMICAL", 898, 920], ["caftaric acid", "CHEMICAL", 120, 133], ["chlorogenic acid", "CHEMICAL", 143, 159], ["caffeic acid", "CHEMICAL", 170, 182], ["cynarin", "CHEMICAL", 188, 195], ["cichoric acid", "CHEMICAL", 208, 221], ["echinacoside", "CHEMICAL", 228, 240], ["dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic acid isobutylamide", "CHEMICAL", 262, 323], ["acetaldehyde", "CHEMICAL", 406, 418], ["dimethyl sulphide", "CHEMICAL", 420, 437], ["2-methylpropanal", "CHEMICAL", 439, 455], ["acetone", "CHEMICAL", 460, 467], ["2-methylbutanal", "CHEMICAL", 469, 484], ["3-methylbutanal", "CHEMICAL", 486, 501], ["\u03b1-pinene", "CHEMICAL", 503, 511], ["geranyl acetate", "CHEMICAL", 513, 528], ["camphene", "CHEMICAL", 530, 538], ["hexanal", "CHEMICAL", 540, 547], ["\u03b2-pinene", "CHEMICAL", 549, 557], ["sabinene", "CHEMICAL", 559, 567], ["\u03b2-thujene", "CHEMICAL", 569, 578], ["2-methyl-4-pentenal", "CHEMICAL", 589, 608], ["\u03b2-myrcene", "CHEMICAL", 610, 619], ["\u03b1-terpinene", "CHEMICAL", 621, 632], ["limonene", "CHEMICAL", 634, 642], ["2-hexenal", "CHEMICAL", 644, 653], ["ocimene", "CHEMICAL", 665, 672], ["\u03b3-terpinene", "CHEMICAL", 674, 685], ["trans -ocimene", "CHEMICAL", 687, 701], ["\u03b1-terpinolene", "CHEMICAL", 703, 716], ["3-hexen-1-ol-acetate", "CHEMICAL", 718, 738], ["1-hexanol", "CHEMICAL", 740, 749], ["allo -ocimene", "CHEMICAL", 751, 764], ["3-hexen-1-ol", "CHEMICAL", 766, 778], ["2-hexen-1-ol", "CHEMICAL", 788, 800], ["\u03b1-cubebene", "CHEMICAL", 812, 822], ["\u03b1-copaene", "CHEMICAL", 823, 832], ["\u03b1-ylangene", "CHEMICAL", 834, 844], ["\u03b1-ylangene", "CHEMICAL", 846, 856], ["germacrene D", "CHEMICAL", 858, 870], ["\u03b1-cubebene", "CHEMICAL", 871, 881], ["\u03b4-cadinene", "CHEMICAL", 883, 893], ["\u03b2\u03b1-cubebine", "CHEMICAL", 898, 909], ["\u03b3-cadinene", "CHEMICAL", 910, 920], ["Mazza", "CHEMICAL", 922, 927], ["phenolic compounds", "SIMPLE_CHEMICAL", 16, 34], ["E. purpurea", "ORGANISM", 65, 76], ["leaf", "ORGANISM", 77, 81], ["stem", "CELL", 86, 90], ["caftaric acid", "SIMPLE_CHEMICAL", 120, 133], ["chlorogenic acid", "SIMPLE_CHEMICAL", 143, 159], ["caffeic acid", "SIMPLE_CHEMICAL", 170, 182], ["cynarin", "SIMPLE_CHEMICAL", 188, 195], ["cichoric acid", "SIMPLE_CHEMICAL", 208, 221], ["echinacoside", "SIMPLE_CHEMICAL", 228, 240], ["dodeca-2 E ,4 E ,8 Z", "SIMPLE_CHEMICAL", 262, 282], ["10 E / Z -tetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 284, 323], ["purpurea stem tissues", "TISSUE", 379, 400], ["acetaldehyde", "SIMPLE_CHEMICAL", 406, 418], ["dimethyl sulphide", "SIMPLE_CHEMICAL", 420, 437], ["2-methylpropanal", "SIMPLE_CHEMICAL", 439, 455], ["acetone", "SIMPLE_CHEMICAL", 460, 467], ["2-methylbutanal", "SIMPLE_CHEMICAL", 469, 484], ["3-methylbutanal", "SIMPLE_CHEMICAL", 486, 501], ["\u03b1-pinene", "SIMPLE_CHEMICAL", 503, 511], ["geranyl acetate", "SIMPLE_CHEMICAL", 513, 528], ["camphene", "SIMPLE_CHEMICAL", 530, 538], ["hexanal", "SIMPLE_CHEMICAL", 540, 547], ["\u03b2-pinene", "SIMPLE_CHEMICAL", 549, 557], ["sabinene/ \u03b2-thujene", "SIMPLE_CHEMICAL", 559, 578], ["2-methyl-4-pentenal", "SIMPLE_CHEMICAL", 589, 608], ["\u03b2-myrcene", "SIMPLE_CHEMICAL", 610, 619], ["\u03b1-terpinene", "SIMPLE_CHEMICAL", 621, 632], ["limonene", "SIMPLE_CHEMICAL", 634, 642], ["2-hexenal ( trans ), ocimene", "SIMPLE_CHEMICAL", 644, 672], ["\u03b3-terpinene", "SIMPLE_CHEMICAL", 674, 685], ["trans -ocimene", "SIMPLE_CHEMICAL", 687, 701], ["\u03b1-terpinolene", "SIMPLE_CHEMICAL", 703, 716], ["3-hexen-1-ol-acetate", "SIMPLE_CHEMICAL", 718, 738], ["1-hexanol", "SIMPLE_CHEMICAL", 740, 749], ["allo -ocimene", "SIMPLE_CHEMICAL", 751, 764], ["3-hexen-1-ol ( cis ), 2-hexen-1-ol ( trans ), \u03b1-cubebene/\u03b1-copaene", "SIMPLE_CHEMICAL", 766, 832], ["\u03b1-ylangene", "SIMPLE_CHEMICAL", 834, 844], ["\u03b1-ylangene", "SIMPLE_CHEMICAL", 846, 856], ["germacrene D/\u03b1-cubebene", "SIMPLE_CHEMICAL", 858, 881], ["\u03b4-cadinene", "SIMPLE_CHEMICAL", 883, 893], ["\u03b2\u03b1-cubebine/\u03b3-cadinene", "SIMPLE_CHEMICAL", 898, 920], ["Mazza", "SIMPLE_CHEMICAL", 922, 927], ["E. purpurea", "SPECIES", 65, 76], ["E. purpurea", "SPECIES", 376, 387], ["E. purpurea", "SPECIES", 65, 76], ["E. purpurea", "SPECIES", 376, 387], ["The profi le of phenolic compounds", "TREATMENT", 0, 34], ["mean concentration \u03bcg/ml", "TREATMENT", 36, 60], ["caftaric acid", "TEST", 120, 133], ["chlorogenic acid", "TEST", 143, 159], ["caffeic acid", "TEST", 170, 182], ["cynarin", "TEST", 188, 195], ["acid", "TEST", 217, 221], ["echinacoside", "TEST", 228, 240], ["tet", "TEST", 253, 256], ["dodeca", "TEST", 262, 268], ["Z", "TEST", 281, 282], ["Z", "TEST", 291, 292], ["tetraenoic acid isobutylamide", "TREATMENT", 294, 323], ["Stem PhytochemicalsVolatiles", "TEST", 327, 355], ["acetaldehyde", "TREATMENT", 406, 418], ["dimethyl sulphide", "TREATMENT", 420, 437], ["methylpropanal", "TREATMENT", 441, 455], ["acetone", "TREATMENT", 460, 467], ["methylbutanal", "TREATMENT", 471, 484], ["methylbutanal", "TREATMENT", 488, 501], ["\u03b1-pinene", "TREATMENT", 503, 511], ["geranyl acetate", "TREATMENT", 513, 528], ["camphene", "TREATMENT", 530, 538], ["hexanal", "TREATMENT", 540, 547], ["\u03b2-pinene", "TREATMENT", 549, 557], ["sabinene", "TREATMENT", 559, 567], ["thujene", "TREATMENT", 571, 578], ["methyl", "TREATMENT", 591, 597], ["pentenal", "TREATMENT", 600, 608], ["\u03b2-myrcene", "TREATMENT", 610, 619], ["\u03b1-terpinene", "TREATMENT", 621, 632], ["limonene", "TREATMENT", 634, 642], ["ocimene", "TREATMENT", 665, 672], ["\u03b3-terpinene", "TREATMENT", 674, 685], ["trans -ocimene", "TREATMENT", 687, 701], ["\u03b1-terpinolene", "TREATMENT", 703, 716], ["hexen", "TREATMENT", 720, 725], ["acetate", "TREATMENT", 731, 738], ["allo -ocimene", "TREATMENT", 751, 764], ["copaene", "TREATMENT", 825, 832], ["\u03b1-ylangene", "TREATMENT", 834, 844], ["\u03b1-ylangene", "TREATMENT", 846, 856], ["germacrene", "TREATMENT", 858, 868], ["cubebene", "TREATMENT", 873, 881], ["\u03b4-cadinene", "TREATMENT", 883, 893], ["\u03b2\u03b1-cubebine", "TREATMENT", 898, 909], ["cadinene", "TREATMENT", 912, 920], ["phenolic compounds", "OBSERVATION", 16, 34], ["purpurea leaf", "ANATOMY", 68, 81], ["stem", "ANATOMY", 86, 90], ["headspace", "ANATOMY_MODIFIER", 363, 372], ["purpurea stem tissues", "OBSERVATION", 379, 400]]], ["Major volatiles in headspace of stem tissues were myrcene 45 %, \u03b2-pinene 4.4 %, \u03b1-pinene 33.7 % and dimethyl sulphide <1.0 %.Root PhytochemicalsVolatiles in the headspace of E. purpurea roots were acetaldehyde, dimethyl sulphide, 2-methylpropanal and acetone, 2-propenal, 2-methylbutanal, 3-methylbutanal, ethanol, 1-methylpropyl acetate, trichloroacetic acid, \u03b1-pinene, camphene, hexanal, \u03b2-pinene, 2-methyl-1-propanol, sabinene/ \u03b2-thujene, \u03b1-phellandrene, \u03b1-terpinene, heptanal, limonene, 2-methyl-1-butanol, 3-methyl-1-butanol, ocimene, p -cymene, hexyl acetate, unknown, 6-methyl-5hepten-2-one, 1-hexanol and 1-octen-3-ol, benzaldehyde (Mazza and Cottrell 1999 ) .", [["stem tissues", "ANATOMY", 32, 44], ["roots", "ANATOMY", 186, 191], ["myrcene", "CHEMICAL", 50, 57], ["\u03b2-pinene", "CHEMICAL", 64, 72], ["\u03b1-pinene", "CHEMICAL", 80, 88], ["dimethyl sulphide", "CHEMICAL", 100, 117], ["Volatiles", "CHEMICAL", 144, 153], ["acetaldehyde", "CHEMICAL", 197, 209], ["dimethyl sulphide", "CHEMICAL", 211, 228], ["2-methylpropanal", "CHEMICAL", 230, 246], ["acetone", "CHEMICAL", 251, 258], ["2-propenal, 2-methylbutanal", "CHEMICAL", 260, 287], ["3-methylbutanal", "CHEMICAL", 289, 304], ["ethanol", "CHEMICAL", 306, 313], ["1-methylpropyl acetate", "CHEMICAL", 315, 337], ["trichloroacetic acid", "CHEMICAL", 339, 359], ["\u03b1-pinene", "CHEMICAL", 361, 369], ["camphene", "CHEMICAL", 371, 379], ["hexanal", "CHEMICAL", 381, 388], ["\u03b2-pinene", "CHEMICAL", 390, 398], ["2-methyl-1-propanol", "CHEMICAL", 400, 419], ["sabinene", "CHEMICAL", 421, 429], ["\u03b2-thujene", "CHEMICAL", 431, 440], ["\u03b1-phellandrene", "CHEMICAL", 442, 456], ["\u03b1-terpinene", "CHEMICAL", 458, 469], ["heptanal", "CHEMICAL", 471, 479], ["limonene", "CHEMICAL", 481, 489], ["2-methyl-1-butanol", "CHEMICAL", 491, 509], ["3-methyl-1-butanol", "CHEMICAL", 511, 529], ["ocimene", "CHEMICAL", 531, 538], ["p -cymene, hexyl acetate", "CHEMICAL", 540, 564], ["6-methyl-5hepten-2-one", "CHEMICAL", 575, 597], ["1-hexanol", "CHEMICAL", 599, 608], ["1-octen-3-ol", "CHEMICAL", 613, 625], ["benzaldehyde", "CHEMICAL", 627, 639], ["myrcene", "CHEMICAL", 50, 57], ["\u03b2-pinene", "CHEMICAL", 64, 72], ["\u03b1-pinene", "CHEMICAL", 80, 88], ["dimethyl sulphide", "CHEMICAL", 100, 117], ["acetaldehyde", "CHEMICAL", 197, 209], ["dimethyl sulphide", "CHEMICAL", 211, 228], ["2-methylpropanal", "CHEMICAL", 230, 246], ["acetone", "CHEMICAL", 251, 258], ["2-propenal", "CHEMICAL", 260, 270], ["2-methylbutanal", "CHEMICAL", 272, 287], ["3-methylbutanal", "CHEMICAL", 289, 304], ["ethanol", "CHEMICAL", 306, 313], ["1-methylpropyl acetate", "CHEMICAL", 315, 337], ["trichloroacetic acid", "CHEMICAL", 339, 359], ["\u03b1-pinene", "CHEMICAL", 361, 369], ["camphene", "CHEMICAL", 371, 379], ["hexanal", "CHEMICAL", 381, 388], ["\u03b2-pinene", "CHEMICAL", 390, 398], ["2-methyl-1-propanol", "CHEMICAL", 400, 419], ["sabinene", "CHEMICAL", 421, 429], ["\u03b2-thujene", "CHEMICAL", 431, 440], ["\u03b1-phellandrene", "CHEMICAL", 442, 456], ["\u03b1-terpinene", "CHEMICAL", 458, 469], ["heptanal", "CHEMICAL", 471, 479], ["limonene", "CHEMICAL", 481, 489], ["2-methyl-1-butanol", "CHEMICAL", 491, 509], ["3-methyl-1-butanol", "CHEMICAL", 511, 529], ["ocimene", "CHEMICAL", 531, 538], ["p -cymene", "CHEMICAL", 540, 549], ["hexyl acetate", "CHEMICAL", 551, 564], ["6-methyl-5hepten-2-one", "CHEMICAL", 575, 597], ["1-hexanol", "CHEMICAL", 599, 608], ["1-octen-3-ol", "CHEMICAL", 613, 625], ["benzaldehyde", "CHEMICAL", 627, 639], ["Mazza", "CHEMICAL", 641, 646], ["stem tissues", "TISSUE", 32, 44], ["myrcene", "SIMPLE_CHEMICAL", 50, 57], ["\u03b2-pinene", "SIMPLE_CHEMICAL", 64, 72], ["\u03b1-pinene", "SIMPLE_CHEMICAL", 80, 88], ["dimethyl sulphide", "SIMPLE_CHEMICAL", 100, 117], ["E. purpurea", "ORGANISM", 174, 185], ["roots", "ORGANISM", 186, 191], ["acetaldehyde", "SIMPLE_CHEMICAL", 197, 209], ["dimethyl sulphide", "SIMPLE_CHEMICAL", 211, 228], ["2-methylpropanal", "SIMPLE_CHEMICAL", 230, 246], ["acetone", "SIMPLE_CHEMICAL", 251, 258], ["2-propenal", "SIMPLE_CHEMICAL", 260, 270], ["2-methylbutanal", "SIMPLE_CHEMICAL", 272, 287], ["3-methylbutanal", "SIMPLE_CHEMICAL", 289, 304], ["ethanol", "SIMPLE_CHEMICAL", 306, 313], ["1-methylpropyl acetate", "SIMPLE_CHEMICAL", 315, 337], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 339, 359], ["\u03b1-pinene", "SIMPLE_CHEMICAL", 361, 369], ["camphene", "SIMPLE_CHEMICAL", 371, 379], ["hexanal", "SIMPLE_CHEMICAL", 381, 388], ["\u03b2-pinene", "SIMPLE_CHEMICAL", 390, 398], ["2-methyl-1-propanol", "SIMPLE_CHEMICAL", 400, 419], ["sabinene/ \u03b2-thujene", "SIMPLE_CHEMICAL", 421, 440], ["\u03b1-phellandrene", "SIMPLE_CHEMICAL", 442, 456], ["\u03b1-terpinene", "SIMPLE_CHEMICAL", 458, 469], ["heptanal", "SIMPLE_CHEMICAL", 471, 479], ["limonene", "SIMPLE_CHEMICAL", 481, 489], ["2-methyl-1-butanol", "SIMPLE_CHEMICAL", 491, 509], ["3-methyl-1-butanol", "SIMPLE_CHEMICAL", 511, 529], ["ocimene", "SIMPLE_CHEMICAL", 531, 538], ["p -cymene", "SIMPLE_CHEMICAL", 540, 549], ["hexyl acetate", "SIMPLE_CHEMICAL", 551, 564], ["6-methyl-5hepten-2-one", "SIMPLE_CHEMICAL", 575, 597], ["1-hexanol", "SIMPLE_CHEMICAL", 599, 608], ["1-octen-3-ol", "SIMPLE_CHEMICAL", 613, 625], ["benzaldehyde", "SIMPLE_CHEMICAL", 627, 639], ["Mazza", "SIMPLE_CHEMICAL", 641, 646], ["E. purpurea", "SPECIES", 174, 185], ["E. purpurea", "SPECIES", 174, 185], ["myrcene", "TEST", 50, 57], ["\u03b2-pinene", "TEST", 64, 72], ["\u03b1-pinene", "TREATMENT", 80, 88], ["dimethyl sulphide", "TREATMENT", 100, 117], ["acetaldehyde", "TREATMENT", 197, 209], ["dimethyl sulphide", "TREATMENT", 211, 228], ["methylpropanal", "TREATMENT", 232, 246], ["acetone", "TREATMENT", 251, 258], ["propenal", "TREATMENT", 262, 270], ["methylbutanal", "TREATMENT", 274, 287], ["methylbutanal", "TREATMENT", 291, 304], ["ethanol", "TREATMENT", 306, 313], ["methylpropyl acetate", "TREATMENT", 317, 337], ["trichloroacetic acid", "TREATMENT", 339, 359], ["\u03b1-pinene", "TREATMENT", 361, 369], ["camphene", "TREATMENT", 371, 379], ["hexanal", "TREATMENT", 381, 388], ["\u03b2-pinene", "TREATMENT", 390, 398], ["methyl", "TREATMENT", 402, 408], ["propanol", "TREATMENT", 411, 419], ["sabinene", "TREATMENT", 421, 429], ["thujene", "TREATMENT", 433, 440], ["\u03b1-phellandrene", "TREATMENT", 442, 456], ["\u03b1-terpinene", "TREATMENT", 458, 469], ["heptanal", "TREATMENT", 471, 479], ["limonene", "TREATMENT", 481, 489], ["methyl", "TREATMENT", 493, 499], ["butanol", "TREATMENT", 502, 509], ["methyl", "TREATMENT", 513, 519], ["butanol", "TREATMENT", 522, 529], ["ocimene", "TREATMENT", 531, 538], ["hexyl acetate", "TREATMENT", 551, 564], ["hexanol", "TREATMENT", 601, 608], ["stem tissues", "ANATOMY", 32, 44], ["purpurea roots", "ANATOMY", 177, 191]]], ["Major volatiles in headspace of root tissues were 0%, \u03b2-pinene 0.2 %, \u03b1-pinene 0.6 %, \u03b1-phellandrene 16.7 % and dimethyl sulphide 14.7 %.", [["root tissues", "ANATOMY", 32, 44], ["\u03b2-pinene", "CHEMICAL", 54, 62], ["\u03b1-pinene", "CHEMICAL", 70, 78], ["\u03b1-phellandrene", "CHEMICAL", 86, 100], ["dimethyl sulphide", "CHEMICAL", 112, 129], ["\u03b2-pinene", "CHEMICAL", 54, 62], ["\u03b1-pinene", "CHEMICAL", 70, 78], ["\u03b1-phellandrene", "CHEMICAL", 86, 100], ["dimethyl sulphide", "CHEMICAL", 112, 129], ["root tissues", "TISSUE", 32, 44], ["\u03b2-pinene", "SIMPLE_CHEMICAL", 54, 62], ["\u03b1-pinene", "SIMPLE_CHEMICAL", 70, 78], ["\u03b1-phellandrene", "SIMPLE_CHEMICAL", 86, 100], ["dimethyl sulphide", "SIMPLE_CHEMICAL", 112, 129], ["\u03b2-pinene", "TEST", 54, 62], ["\u03b1-pinene", "TREATMENT", 70, 78], ["\u03b1-phellandrene", "TREATMENT", 86, 100], ["dimethyl sulphide", "TREATMENT", 112, 129], ["volatiles", "OBSERVATION_MODIFIER", 6, 15], ["headspace", "ANATOMY_MODIFIER", 19, 28], ["root tissues", "ANATOMY", 32, 44]]], ["The seventeen lipophilic, volatile to semivolatile components, including the 11 alkamides known to E. purpurea roots, were identifi ed .", [["roots", "ANATOMY", 111, 116], ["alkamides", "CHEMICAL", 80, 89], ["alkamides", "CHEMICAL", 80, 89], ["alkamides", "SIMPLE_CHEMICAL", 80, 89], ["E. purpurea roots", "ORGANISM", 99, 116], ["E. purpurea", "SPECIES", 99, 110], ["E. purpurea", "SPECIES", 99, 110], ["seventeen", "OBSERVATION_MODIFIER", 4, 13], ["lipophilic", "OBSERVATION_MODIFIER", 14, 24], ["volatile", "OBSERVATION_MODIFIER", 26, 34], ["semivolatile components", "OBSERVATION", 38, 61], ["purpurea roots", "OBSERVATION", 102, 116]]], ["Cucumber mosaic cucumovirus infection was found to be responsible for signifi cant variations in the relative compositions of the major constituents, in particular germacrene D, dodeca-Root PhytochemicalsRoot extracts of E. purpurea root were found to contain (\u03bcg/ml) chlorogenic acid (0.0157 \u03bcg), caftaric acid (0.1568 \u03bcg), cafeic acid (trace), cichoric acid (1.0147 \u03bcg) alkamides 1 undeca-Root Phytochemicalsand undeca-2 E -ene-8,10-diynoic acid isobutylamide (0.0106 \u03bcg) (Bauer et al. 1988 ; Bauer and Reminger 1989 ; Binns et al. 2002b ; Perry et al. 2001 ; Hall 2003 ; Senchina et al. 2006 ; Pietta et al. 1998 ; Gotti et al. 2002 ; Pomponio et al. 2002 ; Solco 2007 ) .", [["extracts", "ANATOMY", 209, 217], ["root", "ANATOMY", 233, 237], ["cucumovirus infection", "DISEASE", 16, 37], ["germacrene D", "CHEMICAL", 164, 176], ["chlorogenic acid", "CHEMICAL", 268, 284], ["caftaric acid", "CHEMICAL", 298, 311], ["cafeic acid", "CHEMICAL", 325, 336], ["cichoric acid", "CHEMICAL", 346, 359], ["alkamides 1 undeca-Root Phytochemicalsand undeca-2 E -ene-8,10-diynoic acid isobutylamide", "CHEMICAL", 372, 461], ["germacrene D", "CHEMICAL", 164, 176], ["chlorogenic acid", "CHEMICAL", 268, 284], ["caftaric acid", "CHEMICAL", 298, 311], ["cafeic acid", "CHEMICAL", 325, 336], ["cichoric acid", "CHEMICAL", 346, 359], ["alkamides", "CHEMICAL", 372, 381], ["undeca-2 E -ene-8,10-diynoic acid isobutylamide", "CHEMICAL", 414, 461], ["Cucumber mosaic cucumovirus", "ORGANISM", 0, 27], ["germacrene D", "SIMPLE_CHEMICAL", 164, 176], ["dodeca-Root", "SIMPLE_CHEMICAL", 178, 189], ["Root extracts", "ORGANISM", 204, 217], ["E. purpurea", "ORGANISM", 221, 232], ["root", "ORGANISM", 233, 237], ["chlorogenic acid", "SIMPLE_CHEMICAL", 268, 284], ["caftaric acid", "SIMPLE_CHEMICAL", 298, 311], ["cafeic acid", "SIMPLE_CHEMICAL", 325, 336], ["cichoric acid", "SIMPLE_CHEMICAL", 346, 359], ["undeca-2 E -ene-8,10-diynoic acid isobutylamide", "SIMPLE_CHEMICAL", 414, 461], ["Cucumber", "SPECIES", 0, 8], ["E. purpurea", "SPECIES", 221, 232], ["Cucumber mosaic cucumovirus", "SPECIES", 0, 27], ["E. purpurea", "SPECIES", 221, 232], ["Cucumber mosaic cucumovirus infection", "PROBLEM", 0, 37], ["signifi cant variations", "PROBLEM", 70, 93], ["E. purpurea root", "TEST", 221, 237], ["chlorogenic acid", "TEST", 268, 284], ["caftaric acid", "TEST", 298, 311], ["cafeic acid", "TEST", 325, 336], ["cichoric acid", "TEST", 346, 359], ["alkamides", "TEST", 372, 381], ["undeca", "TEST", 384, 390], ["Phytochemicalsand", "TEST", 396, 413], ["undeca", "TEST", 414, 420], ["-ene", "TEST", 425, 429], ["diynoic acid isobutylamide", "TREATMENT", 435, 461], ["mosaic", "OBSERVATION_MODIFIER", 9, 15], ["cucumovirus", "OBSERVATION_MODIFIER", 16, 27], ["infection", "OBSERVATION", 28, 37], ["purpurea root", "ANATOMY", 224, 237]]], ["No cynarin and echinacoside were detected in the roots.", [["roots", "ANATOMY", 49, 54], ["cynarin", "CHEMICAL", 3, 10], ["echinacoside", "CHEMICAL", 15, 27], ["cynarin", "CHEMICAL", 3, 10], ["echinacoside", "CHEMICAL", 15, 27], ["cynarin", "SIMPLE_CHEMICAL", 3, 10], ["echinacoside", "SIMPLE_CHEMICAL", 15, 27], ["roots", "ORGAN", 49, 54], ["cynarin and echinacoside", "PROBLEM", 3, 27], ["cynarin", "OBSERVATION", 3, 10], ["echinacoside", "OBSERVATION", 15, 27], ["roots", "ANATOMY", 49, 54]]], ["Five alkylamides, undeca-2 E ,4 Z -dien-8,10-diynoic acid isobutyl-amide, dodeca-2 E ,4 Z -dien-8,10-diynoic acid isobutylamide, dodeca-2 E ,4 E ,10 E -trien-8-ynoic acid isobutylamide, dodeca-2 E ,4 E ,8 Z -trienoic acid isobutylamide and dodeca-2 E ,4 Z -dien-8,10-diynoic acid 2-methylbutylamide, were isolated from the roots (Bauer et al. 1988 ).", [["roots", "ANATOMY", 323, 328], ["alkylamides", "CHEMICAL", 5, 16], ["undeca-2 E ,4 Z -dien-8,10-diynoic acid isobutyl-amide", "CHEMICAL", 18, 72], ["dodeca-2 E ,4 Z -dien-8,10-diynoic acid isobutylamide", "CHEMICAL", 74, 127], ["dodeca-2 E ,4 E ,10 E -trien-8-ynoic acid isobutylamide", "CHEMICAL", 129, 184], ["dodeca-2 E ,4 E ,8 Z -trienoic acid isobutylamide", "CHEMICAL", 186, 235], ["dodeca-2 E ,4 Z -dien-8,10-diynoic acid 2-methylbutylamide", "CHEMICAL", 240, 298], ["alkylamides", "CHEMICAL", 5, 16], ["undeca-2 E ,4 Z -dien-8,10-diynoic acid isobutyl-amide", "CHEMICAL", 18, 72], ["dodeca-2 E ,4 Z -dien-8,10-diynoic acid isobutylamide", "CHEMICAL", 74, 127], ["dodeca-2 E ,4 E ,10 E -trien-8-ynoic acid isobutylamide", "CHEMICAL", 129, 184], ["dodeca-2 E ,4 E ,8 Z -trienoic acid isobutylamide", "CHEMICAL", 186, 235], ["dodeca-2 E ,4 Z -dien-8,10-diynoic acid 2-methylbutylamide", "CHEMICAL", 240, 298], ["alkylamides", "SIMPLE_CHEMICAL", 5, 16], ["undeca-2 E ,4 Z -dien-8,10-diynoic acid isobutyl-amide", "SIMPLE_CHEMICAL", 18, 72], ["dodeca-2 E ,4 Z -dien-8,10-diynoic acid isobutylamide", "SIMPLE_CHEMICAL", 74, 127], ["dodeca-2 E ,4 E ,10 E -trien-8-ynoic acid isobutylamide", "SIMPLE_CHEMICAL", 129, 184], ["dodeca-2 E ,4 E ,8 Z -trienoic acid isobutylamide", "SIMPLE_CHEMICAL", 186, 235], ["dodeca-2 E ,4 Z -dien-8,10-diynoic acid 2-methylbutylamide", "SIMPLE_CHEMICAL", 240, 298], ["roots", "ORGAN", 323, 328], ["alkylamides", "TEST", 5, 16], ["undeca", "TEST", 18, 24], ["Z", "TEST", 32, 33], ["diynoic acid isobutyl", "TREATMENT", 45, 66], ["dodeca", "TEST", 74, 80], ["diynoic acid isobutylamide", "TREATMENT", 101, 127], ["dodeca", "TEST", 129, 135], ["trien", "TEST", 152, 157], ["isobutylamide", "TEST", 171, 184], ["dodeca", "TEST", 186, 192], ["Z", "TEST", 205, 206], ["trienoic acid isobutylamide", "TREATMENT", 208, 235], ["dodeca", "TEST", 240, 246], ["diynoic acid", "TREATMENT", 267, 279], ["methylbutylamide", "TREATMENT", 282, 298], ["roots", "ANATOMY", 323, 328]]], ["Nine alkamides were identifi ed in the root of E. purpurea (He et al. 1998 ) similar to the fi ngerprint reported by Bauer and Remiger ( 1989 ) .", [["root", "ANATOMY", 39, 43], ["alkamides", "CHEMICAL", 5, 14], ["alkamides", "CHEMICAL", 5, 14], ["alkamides", "SIMPLE_CHEMICAL", 5, 14], ["root", "ORGAN", 39, 43], ["E. purpurea", "ORGANISM", 47, 58], ["E. purpurea", "SPECIES", 47, 58], ["E. purpurea", "SPECIES", 47, 58], ["Nine alkamides", "TREATMENT", 0, 14], ["E. purpurea", "PROBLEM", 47, 58], ["root", "ANATOMY", 39, 43]]], ["Several minor alkamides were also tentatively identifi ed.Root PhytochemicalsThe following alkamides were identifi ed in fresh and dry root extracts of E. purpurea (Spelman et al. 2009Root Phytochemicals; trideca-2 E ,7 Z -diene-8,10-diynoic acid isobutylamide (P); dodeca-2 E ,4 Zdiene-8,10-diynoic acid 2-methylbutylamide (Q); and dodeca-2,4,8,10-tetraenoic acid 2-methylbutylamide (R).", [["root extracts", "ANATOMY", 135, 148], ["alkamides", "CHEMICAL", 91, 100], ["identifi", "CHEMICAL", 106, 114], ["trideca-2 E ,7 Z -diene-8,10-diynoic acid isobutylamide", "CHEMICAL", 205, 260], ["dodeca-2 E ,4 Zdiene-8,10-diynoic acid 2-methylbutylamide", "CHEMICAL", 266, 323], ["dodeca-2,4,8,10-tetraenoic acid 2-methylbutylamide", "CHEMICAL", 333, 383], ["alkamides", "CHEMICAL", 14, 23], ["alkamides", "CHEMICAL", 91, 100], ["trideca-2 E ,7 Z -diene-8,10-diynoic acid isobutylamide", "CHEMICAL", 205, 260], ["dodeca-2 E ,4 Zdiene-8,10-diynoic acid 2-methylbutylamide", "CHEMICAL", 266, 323], ["dodeca-2,4,8,10-tetraenoic acid 2-methylbutylamide", "CHEMICAL", 333, 383], ["alkamides", "SIMPLE_CHEMICAL", 14, 23], ["alkamides", "SIMPLE_CHEMICAL", 91, 100], ["root extracts", "ORGANISM_SUBSTANCE", 135, 148], ["E. purpurea", "ORGANISM", 152, 163], ["trideca-2 E ,7 Z -diene-8,10-diynoic acid isobutylamide", "SIMPLE_CHEMICAL", 205, 260], ["dodeca-2 E ,4 Zdiene-8,10-diynoic acid 2-methylbutylamide (Q)", "SIMPLE_CHEMICAL", 266, 327], ["dodeca-2,4,8,10-tetraenoic acid 2-methylbutylamide", "SIMPLE_CHEMICAL", 333, 383], ["R", "SIMPLE_CHEMICAL", 385, 386], ["E. purpurea", "SPECIES", 152, 163], ["E. purpurea", "SPECIES", 152, 163], ["Several minor alkamides", "PROBLEM", 0, 23], ["Root Phytochemicals", "TEST", 58, 77], ["E. purpurea", "TREATMENT", 152, 163], ["Phytochemicals", "TEST", 189, 203], ["trideca", "TEST", 205, 212], ["diynoic acid isobutylamide", "TREATMENT", 234, 260], ["dodeca", "TEST", 266, 272], ["Zdiene", "TEST", 280, 286], ["diynoic acid", "TREATMENT", 292, 304], ["methylbutylamide", "TREATMENT", 307, 323], ["dodeca", "TREATMENT", 333, 339], ["tetraenoic acid", "TREATMENT", 349, 364], ["minor", "OBSERVATION_MODIFIER", 8, 13], ["alkamides", "OBSERVATION", 14, 23], ["Phytochemicals", "OBSERVATION", 63, 77], ["dry root", "ANATOMY", 131, 139]]], ["Quantities of the isomeric alkylamides K, L and M and alkylamide J in ethanol extracts of E. purpurea root were determined in terms of concentrations of the isomeric tetraenes (compounds K, L and M) and dodeca-2 E -ene-8,10-diynoic acid isobutylamide (compound J) per ml of solvent.", [["extracts", "ANATOMY", 78, 86], ["root", "ANATOMY", 102, 106], ["K", "CHEMICAL", 39, 40], ["alkylamide J", "CHEMICAL", 54, 66], ["ethanol", "CHEMICAL", 70, 77], ["tetraenes", "CHEMICAL", 166, 175], ["K", "CHEMICAL", 187, 188], ["dodeca-2 E -ene-8,10-diynoic acid isobutylamide", "CHEMICAL", 203, 250], ["alkylamides K, L and M", "CHEMICAL", 27, 49], ["alkylamide J", "CHEMICAL", 54, 66], ["ethanol", "CHEMICAL", 70, 77], ["tetraenes", "CHEMICAL", 166, 175], ["dodeca-2 E -ene-8,10-diynoic acid isobutylamide", "CHEMICAL", 203, 250], ["alkylamides K, L", "SIMPLE_CHEMICAL", 27, 43], ["M", "SIMPLE_CHEMICAL", 48, 49], ["alkylamide J", "SIMPLE_CHEMICAL", 54, 66], ["ethanol extracts", "ORGANISM_SUBSTANCE", 70, 86], ["E. purpurea", "ORGANISM", 90, 101], ["root", "ORGANISM", 102, 106], ["tetraenes", "SIMPLE_CHEMICAL", 166, 175], ["dodeca-2 E -ene-8,10-diynoic acid isobutylamide", "SIMPLE_CHEMICAL", 203, 250], ["E. purpurea", "SPECIES", 90, 101], ["E. purpurea", "SPECIES", 90, 101], ["the isomeric alkylamides K", "TEST", 14, 40], ["alkylamide J in ethanol extracts", "TREATMENT", 54, 86], ["E. purpurea root", "PROBLEM", 90, 106], ["K", "TEST", 187, 188], ["dodeca", "TEST", 203, 209], ["diynoic acid isobutylamide", "TREATMENT", 224, 250], ["purpurea root", "OBSERVATION", 93, 106]]], ["The three different Echinacea root extracts, fresh 1:2, dry 1:11 and dry 1:5, all contained these alkylamides.", [["root extracts", "ANATOMY", 30, 43], ["alkylamides", "CHEMICAL", 98, 109], ["alkylamides", "CHEMICAL", 98, 109], ["Echinacea", "ORGANISM", 20, 29], ["root extracts", "ORGANISM_SUBSTANCE", 30, 43], ["alkylamides", "SIMPLE_CHEMICAL", 98, 109], ["Echinacea", "SPECIES", 20, 29], ["The three different Echinacea root extracts", "TREATMENT", 0, 43], ["these alkylamides", "TREATMENT", 92, 109], ["three", "OBSERVATION_MODIFIER", 4, 9], ["different", "OBSERVATION_MODIFIER", 10, 19], ["Echinacea root extracts", "OBSERVATION", 20, 43]]], ["However, the dry 1:5 extract contained the greatest amount of these compounds.", [["the dry 1:5 extract", "TREATMENT", 9, 28], ["dry", "OBSERVATION_MODIFIER", 13, 16], ["greatest", "OBSERVATION_MODIFIER", 43, 51], ["amount", "OBSERVATION_MODIFIER", 52, 58], ["compounds", "OBSERVATION_MODIFIER", 68, 77]]], ["All three extraction techniques investigated here (fresh 1:2, dry 1:5 and dry 1:11) resulted in very similar alkylamide profi le and gave similar yields of alkylamides and of total dissolved solids.", [["alkylamide", "CHEMICAL", 109, 119], ["alkylamides", "CHEMICAL", 156, 167], ["alkylamide", "CHEMICAL", 109, 119], ["alkylamides", "CHEMICAL", 156, 167], ["alkylamide", "SIMPLE_CHEMICAL", 109, 119], ["alkylamides", "SIMPLE_CHEMICAL", 156, 167], ["alkylamides", "TREATMENT", 156, 167], ["total dissolved solids", "TREATMENT", 175, 197]]], ["The similarity in alkylamide content in fresh 1:2 and dry 1:11 extracts indicated that drying of root material at 50 \u00b0C did not result in a loss of alkylamides.", [["extracts", "ANATOMY", 63, 71], ["root material", "ANATOMY", 97, 110], ["alkylamide", "CHEMICAL", 18, 28], ["alkylamides", "CHEMICAL", 148, 159], ["alkylamide", "CHEMICAL", 18, 28], ["alkylamides", "CHEMICAL", 148, 159], ["alkylamide", "SIMPLE_CHEMICAL", 18, 28], ["root material", "MULTI-TISSUE_STRUCTURE", 97, 110], ["alkylamides", "SIMPLE_CHEMICAL", 148, 159], ["drying of root material", "PROBLEM", 87, 110], ["a loss of alkylamides", "TREATMENT", 138, 159], ["alkylamide content", "OBSERVATION", 18, 36], ["root", "OBSERVATION_MODIFIER", 97, 101]]], ["It was concluded that either fresh or dried roots could be used to prepare extracts with high alkylamide content, although the overall yield was slightly lower for fresh extracts.Root PhytochemicalsCaffeic acid derivatives, caftaric acid, chlorogenic acid, caffeic acid, cichoric acid and alka-Root Phytochemicalswere detected in the roots and extracts (Luo et al. 2003 ) .", [["roots", "ANATOMY", 44, 49], ["extracts", "ANATOMY", 75, 83], ["extracts", "ANATOMY", 170, 178], ["roots", "ANATOMY", 334, 339], ["extracts", "ANATOMY", 344, 352], ["alkylamide", "CHEMICAL", 94, 104], ["PhytochemicalsCaffeic acid", "CHEMICAL", 184, 210], ["caftaric acid, chlorogenic acid", "CHEMICAL", 224, 255], ["caffeic acid", "CHEMICAL", 257, 269], ["cichoric acid", "CHEMICAL", 271, 284], ["alka", "CHEMICAL", 289, 293], ["alkylamide", "CHEMICAL", 94, 104], ["PhytochemicalsCaffeic acid", "CHEMICAL", 184, 210], ["caftaric acid", "CHEMICAL", 224, 237], ["chlorogenic acid", "CHEMICAL", 239, 255], ["caffeic acid", "CHEMICAL", 257, 269], ["cichoric acid", "CHEMICAL", 271, 284], ["roots", "ORGAN", 44, 49], ["extracts", "ORGANISM_SUBSTANCE", 75, 83], ["alkylamide", "SIMPLE_CHEMICAL", 94, 104], ["extracts", "ORGANISM_SUBSTANCE", 170, 178], ["Root PhytochemicalsCaffeic acid derivatives", "SIMPLE_CHEMICAL", 179, 222], ["caftaric acid", "SIMPLE_CHEMICAL", 224, 237], ["chlorogenic acid", "SIMPLE_CHEMICAL", 239, 255], ["caffeic acid", "SIMPLE_CHEMICAL", 257, 269], ["cichoric acid", "SIMPLE_CHEMICAL", 271, 284], ["alka-Root", "SIMPLE_CHEMICAL", 289, 298], ["roots", "ORGAN", 334, 339], ["extracts", "ORGANISM_SUBSTANCE", 344, 352], ["fresh or dried roots", "PROBLEM", 29, 49], ["high alkylamide content", "PROBLEM", 89, 112], ["Root PhytochemicalsCaffeic acid derivatives", "TREATMENT", 179, 222], ["caftaric acid", "TREATMENT", 224, 237], ["chlorogenic acid", "TEST", 239, 255], ["caffeic acid", "TEST", 257, 269], ["cichoric acid", "TEST", 271, 284], ["alka", "TEST", 289, 293], ["Root Phytochemicalswere", "PROBLEM", 294, 317], ["dried roots", "OBSERVATION", 38, 49], ["acid derivatives", "OBSERVATION", 206, 222], ["Root Phytochemicalswere", "OBSERVATION", 294, 317], ["roots", "ANATOMY", 334, 339]]], ["Three alkamides and nitidanin diisovalerianate were identifi ed, together with 14 known alkamides and one sesquiterpene from the roots of Echinacea purpurea (Hohmann et al. 2011 ) .", [["roots", "ANATOMY", 129, 134], ["alkamides", "CHEMICAL", 6, 15], ["nitidanin diisovalerianate", "CHEMICAL", 20, 46], ["alkamides", "CHEMICAL", 88, 97], ["one sesquiterpene from the roots of Echinacea purpurea", "CHEMICAL", 102, 156], ["alkamides", "CHEMICAL", 6, 15], ["nitidanin diisovalerianate", "CHEMICAL", 20, 46], ["alkamides", "CHEMICAL", 88, 97], ["sesquiterpene", "CHEMICAL", 106, 119], ["alkamides", "SIMPLE_CHEMICAL", 6, 15], ["nitidanin diisovalerianate", "SIMPLE_CHEMICAL", 20, 46], ["alkamides", "SIMPLE_CHEMICAL", 88, 97], ["sesquiterpene", "SIMPLE_CHEMICAL", 106, 119], ["roots", "ORGAN", 129, 134], ["Echinacea purpurea", "ORGANISM", 138, 156], ["Echinacea purpurea", "SPECIES", 138, 156], ["Echinacea purpurea", "SPECIES", 138, 156], ["Three alkamides", "TREATMENT", 0, 15], ["nitidanin diisovalerianate", "TREATMENT", 20, 46], ["14 known alkamides", "TREATMENT", 79, 97], ["Echinacea purpurea", "PROBLEM", 138, 156], ["Echinacea purpurea", "OBSERVATION", 138, 156]]], ["Cichoric acid and verbascoside predominated in extracts of E. purpurea roots (Sloley et al. 2001 ) .", [["extracts", "ANATOMY", 47, 55], ["roots", "ANATOMY", 71, 76], ["Cichoric acid", "CHEMICAL", 0, 13], ["verbascoside", "CHEMICAL", 18, 30], ["Cichoric acid", "CHEMICAL", 0, 13], ["verbascoside", "CHEMICAL", 18, 30], ["Cichoric acid", "SIMPLE_CHEMICAL", 0, 13], ["verbascoside", "SIMPLE_CHEMICAL", 18, 30], ["extracts", "ORGANISM_SUBSTANCE", 47, 55], ["E. purpurea", "ORGANISM", 59, 70], ["roots", "ORGANISM", 71, 76], ["E. purpurea", "SPECIES", 59, 70], ["E. purpurea", "SPECIES", 59, 70], ["Cichoric acid", "TEST", 0, 13], ["verbascoside", "TREATMENT", 18, 30], ["verbascoside predominated", "OBSERVATION_MODIFIER", 18, 43], ["purpurea roots", "OBSERVATION", 62, 76]]], ["A total of 16 alkamides, three ketoalkenes, two ketoalkynes and four phenolic acids (echinacoside, cichoric acid, caftaric acid and chlorogenic acid) were identifi ed in aqueous ethanol (70 %) root extracts of Echinacea purpurea and Echinacea pallida (Thomsen et al. 2012 ).", [["root extracts", "ANATOMY", 193, 206], ["alkamides", "CHEMICAL", 14, 23], ["ketoalkenes", "CHEMICAL", 31, 42], ["ketoalkynes", "CHEMICAL", 48, 59], ["phenolic acids", "CHEMICAL", 69, 83], ["echinacoside, cichoric acid, caftaric acid and chlorogenic acid", "CHEMICAL", 85, 148], ["identifi", "CHEMICAL", 155, 163], ["ethanol", "CHEMICAL", 178, 185], ["Echinacea purpurea", "CHEMICAL", 210, 228], ["alkamides", "CHEMICAL", 14, 23], ["ketoalkenes", "CHEMICAL", 31, 42], ["ketoalkynes", "CHEMICAL", 48, 59], ["phenolic acids", "CHEMICAL", 69, 83], ["echinacoside", "CHEMICAL", 85, 97], ["cichoric acid", "CHEMICAL", 99, 112], ["caftaric acid", "CHEMICAL", 114, 127], ["chlorogenic acid", "CHEMICAL", 132, 148], ["ethanol", "CHEMICAL", 178, 185], ["alkamides", "SIMPLE_CHEMICAL", 14, 23], ["ketoalkenes", "SIMPLE_CHEMICAL", 31, 42], ["ketoalkynes", "SIMPLE_CHEMICAL", 48, 59], ["phenolic acids", "SIMPLE_CHEMICAL", 69, 83], ["echinacoside", "SIMPLE_CHEMICAL", 85, 97], ["cichoric acid", "SIMPLE_CHEMICAL", 99, 112], ["caftaric acid", "SIMPLE_CHEMICAL", 114, 127], ["chlorogenic acid", "SIMPLE_CHEMICAL", 132, 148], ["aqueous", "ORGANISM_SUBSTANCE", 170, 177], ["ethanol", "SIMPLE_CHEMICAL", 178, 185], ["root extracts", "ORGANISM_SUBSTANCE", 193, 206], ["Echinacea purpurea", "ORGANISM", 210, 228], ["Echinacea pallida", "ORGANISM", 233, 250], ["Echinacea purpurea", "SPECIES", 210, 228], ["Echinacea pallida", "SPECIES", 233, 250], ["Echinacea purpurea", "SPECIES", 210, 228], ["Echinacea pallida", "SPECIES", 233, 250], ["A total of 16 alkamides", "TREATMENT", 0, 23], ["three ketoalkenes", "TREATMENT", 25, 42], ["two ketoalkynes", "TREATMENT", 44, 59], ["four phenolic acids", "TREATMENT", 64, 83], ["echinacoside", "TREATMENT", 85, 97], ["cichoric acid", "TREATMENT", 99, 112], ["caftaric acid", "TREATMENT", 114, 127], ["chlorogenic acid", "TREATMENT", 132, 148], ["Echinacea purpurea", "PROBLEM", 210, 228], ["Echinacea pallida", "PROBLEM", 233, 250], ["Echinacea purpurea", "OBSERVATION", 210, 228], ["Echinacea pallida", "OBSERVATION", 233, 250]]], ["The major alkamides in the roots of E. purpurea were at their lowest concentration in the middle of autumn and early winter, while all of the major phenolic acids were at their highest concentrations in spring.", [["roots", "ANATOMY", 27, 32], ["alkamides", "CHEMICAL", 10, 19], ["phenolic acids", "CHEMICAL", 148, 162], ["alkamides", "CHEMICAL", 10, 19], ["phenolic acids", "CHEMICAL", 148, 162], ["alkamides", "SIMPLE_CHEMICAL", 10, 19], ["roots", "ORGAN", 27, 32], ["E. purpurea", "ORGANISM", 36, 47], ["phenolic acids", "SIMPLE_CHEMICAL", 148, 162], ["E. purpurea", "SPECIES", 36, 47], ["E. purpurea", "SPECIES", 36, 47], ["E. purpurea", "TREATMENT", 36, 47], ["major", "OBSERVATION_MODIFIER", 4, 9], ["alkamides", "OBSERVATION", 10, 19], ["roots", "OBSERVATION_MODIFIER", 27, 32], ["purpurea", "OBSERVATION_MODIFIER", 39, 47], ["middle", "ANATOMY_MODIFIER", 90, 96], ["autumn", "OBSERVATION", 100, 106], ["phenolic acids", "OBSERVATION", 148, 162]]], ["In E. purpurea root extract, the major alkamide, dodeca-2 E , 4 E , 8 Z , 10 E / Ztetraenoic acid isobutyl amide, was not significantly affected by storage at any of the temperatures (\u221220, 25 and 40 \u00b0C), but cichoric acid content declined signifi cantly at both 25 and 40 \u00b0C as compared to low-temperature storage (Livesey et al. 1999 ).", [["root extract", "ANATOMY", 15, 27], ["alkamide", "CHEMICAL", 39, 47], ["dodeca-2 E , 4 E , 8 Z , 10 E / Ztetraenoic acid isobutyl amide", "CHEMICAL", 49, 112], ["cichoric acid", "CHEMICAL", 208, 221], ["alkamide", "CHEMICAL", 39, 47], ["dodeca-2 E , 4 E , 8 Z , 10 E / Ztetraenoic acid isobutyl amide", "CHEMICAL", 49, 112], ["cichoric acid", "CHEMICAL", 208, 221], ["E. purpurea", "ORGANISM", 3, 14], ["alkamide", "SIMPLE_CHEMICAL", 39, 47], ["dodeca-2 E , 4 E", "SIMPLE_CHEMICAL", 49, 65], ["8 Z , 10 E / Ztetraenoic acid isobutyl amide", "SIMPLE_CHEMICAL", 68, 112], ["cichoric acid", "SIMPLE_CHEMICAL", 208, 221], ["E. purpurea", "SPECIES", 3, 14], ["E. purpurea", "SPECIES", 3, 14], ["the major alkamide", "TEST", 29, 47], ["dodeca", "TEST", 49, 55], ["Z", "TEST", 70, 71], ["Ztetraenoic acid isobutyl amide", "TREATMENT", 81, 112], ["the temperatures", "TEST", 166, 182], ["cichoric acid content", "TEST", 208, 229], ["purpurea root", "ANATOMY", 6, 19]]], ["In the root powder, the major alkamide showed a signifi cantly reduced level at 25 and 40 \u00b0C, while cichoric acid did not decline signifi cantly.Root PhytochemicalsBiomass accumulation and production of caffeic acid derivatives (caftaric acid, chlorogenic acid and cichoric acid) in Echinacea purpurea adventitious root cultures was optimal under incubation temperature of 20 \u00b0C among the different incubation temperatures tested (10, 15, 20, 25 and 30 \u00b0C) (Wu et al. 2007a ).", [["root powder", "ANATOMY", 7, 18], ["Root", "ANATOMY", 145, 149], ["root cultures", "ANATOMY", 315, 328], ["alkamide", "CHEMICAL", 30, 38], ["cichoric acid", "CHEMICAL", 100, 113], ["PhytochemicalsBiomass", "CHEMICAL", 150, 171], ["caffeic acid", "CHEMICAL", 203, 215], ["caftaric acid, chlorogenic acid", "CHEMICAL", 229, 260], ["cichoric acid", "CHEMICAL", 265, 278], ["alkamide", "CHEMICAL", 30, 38], ["cichoric acid", "CHEMICAL", 100, 113], ["caffeic acid", "CHEMICAL", 203, 215], ["caftaric acid", "CHEMICAL", 229, 242], ["chlorogenic acid", "CHEMICAL", 244, 260], ["cichoric acid", "CHEMICAL", 265, 278], ["alkamide", "SIMPLE_CHEMICAL", 30, 38], ["cichoric acid", "SIMPLE_CHEMICAL", 100, 113], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 203, 227], ["caftaric acid", "SIMPLE_CHEMICAL", 229, 242], ["chlorogenic acid", "SIMPLE_CHEMICAL", 244, 260], ["cichoric acid", "SIMPLE_CHEMICAL", 265, 278], ["Echinacea purpurea", "ORGANISM", 283, 301], ["root cultures", "CELL", 315, 328], ["Echinacea purpurea adventitious root cultures", "CELL_LINE", 283, 328], ["Echinacea purpurea", "SPECIES", 283, 301], ["Echinacea purpurea", "SPECIES", 283, 301], ["cichoric acid", "TEST", 100, 113], ["Root PhytochemicalsBiomass accumulation", "PROBLEM", 145, 184], ["caffeic acid derivatives", "TREATMENT", 203, 227], ["caftaric acid", "TREATMENT", 229, 242], ["chlorogenic acid", "TREATMENT", 244, 260], ["cichoric acid)", "TREATMENT", 265, 279], ["Echinacea purpurea adventitious root cultures", "TEST", 283, 328], ["incubation temperature", "TEST", 347, 369], ["the different incubation temperatures", "TEST", 385, 422], ["PhytochemicalsBiomass accumulation", "OBSERVATION", 150, 184], ["root", "OBSERVATION_MODIFIER", 315, 319]]], ["Biomass of adventitious roots was highest in cultures grown under dark, while accumulation of caffeic acid derivatives was optimum in the cultures grown under 3/21 hours light and dark cultural regimes.", [["roots", "ANATOMY", 24, 29], ["caffeic acid", "CHEMICAL", 94, 106], ["caffeic acid", "CHEMICAL", 94, 106], ["adventitious roots", "ORGAN", 11, 29], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 94, 118], ["Biomass of adventitious roots", "PROBLEM", 0, 29], ["cultures", "TEST", 45, 53], ["caffeic acid derivatives", "TREATMENT", 94, 118], ["the cultures", "TEST", 134, 146], ["dark cultural regimes", "TREATMENT", 180, 201], ["adventitious roots", "OBSERVATION", 11, 29], ["highest", "OBSERVATION_MODIFIER", 34, 41], ["caffeic acid derivatives", "OBSERVATION", 94, 118]]], ["Studies found that 15-day-old hairy root culture stimulated every 5 days by ultrasound for 6 minutes produced the highest amount of caffeic acid derivatives (CADs) after 30 days of culture among all ultrasound treatment experiments .", [["root culture", "ANATOMY", 36, 48], ["caffeic acid", "CHEMICAL", 132, 144], ["caffeic acid", "CHEMICAL", 132, 144], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 132, 156], ["CADs", "SIMPLE_CHEMICAL", 158, 162], ["Studies", "TEST", 0, 7], ["old hairy root culture", "PROBLEM", 26, 48], ["ultrasound", "TEST", 76, 86], ["caffeic acid derivatives", "TREATMENT", 132, 156], ["culture", "TEST", 181, 188], ["all ultrasound treatment experiments", "TREATMENT", 195, 231]]], ["The obvious increase of CADs production in E. purpurea hairy roots stimulated by ultrasound was related to the increase of both rolB-regulated endogenous indole-3-acetic acid biosynthesis and phenylalanine ammonium lyase (PAL) activity.Root PhytochemicalsIn Echinacea purpurea cultivars Magnus and White Swan and line CLS-P2, harvested dry roots contained highest cichoric acid content and then followed by caftaric acid, cynarin, echinacoside and chlorogenic acid ).", [["hairy roots", "ANATOMY", 55, 66], ["roots", "ANATOMY", 340, 345], ["CADs", "CHEMICAL", 24, 28], ["indole-3-acetic acid", "CHEMICAL", 154, 174], ["phenylalanine ammonium", "CHEMICAL", 192, 214], ["cichoric acid", "CHEMICAL", 364, 377], ["caftaric acid", "CHEMICAL", 407, 420], ["cynarin", "CHEMICAL", 422, 429], ["echinacoside", "CHEMICAL", 431, 443], ["chlorogenic acid", "CHEMICAL", 448, 464], ["CADs", "CHEMICAL", 24, 28], ["indole-3-acetic acid", "CHEMICAL", 154, 174], ["phenylalanine ammonium", "CHEMICAL", 192, 214], ["cichoric acid", "CHEMICAL", 364, 377], ["caftaric acid", "CHEMICAL", 407, 420], ["cynarin", "CHEMICAL", 422, 429], ["echinacoside", "CHEMICAL", 431, 443], ["chlorogenic acid", "CHEMICAL", 448, 464], ["CADs", "SIMPLE_CHEMICAL", 24, 28], ["E. purpurea", "ORGANISM", 43, 54], ["hairy roots", "ORGANISM", 55, 66], ["rolB", "SIMPLE_CHEMICAL", 128, 132], ["indole-3-acetic acid", "SIMPLE_CHEMICAL", 154, 174], ["phenylalanine ammonium lyase", "SIMPLE_CHEMICAL", 192, 220], ["PAL", "SIMPLE_CHEMICAL", 222, 225], ["line CLS-P2", "CELL", 313, 324], ["roots", "ORGAN", 340, 345], ["cichoric acid", "SIMPLE_CHEMICAL", 364, 377], ["caftaric acid", "SIMPLE_CHEMICAL", 407, 420], ["cynarin", "SIMPLE_CHEMICAL", 422, 429], ["echinacoside", "SIMPLE_CHEMICAL", 431, 443], ["chlorogenic acid", "SIMPLE_CHEMICAL", 448, 464], ["CADs", "PROTEIN", 24, 28], ["rolB", "PROTEIN", 128, 132], ["phenylalanine ammonium lyase", "PROTEIN", 192, 220], ["PAL", "PROTEIN", 222, 225], ["E. purpurea", "SPECIES", 43, 54], ["Echinacea purpurea", "SPECIES", 258, 276], ["E. purpurea", "SPECIES", 43, 54], ["Echinacea purpurea", "SPECIES", 258, 276], ["CADs production", "PROBLEM", 24, 39], ["ultrasound", "TEST", 81, 91], ["acetic acid biosynthesis", "TREATMENT", 163, 187], ["phenylalanine ammonium lyase", "TREATMENT", 192, 220], ["Root PhytochemicalsIn", "TEST", 236, 257], ["Echinacea purpurea cultivars Magnus", "TREATMENT", 258, 293], ["White Swan", "TEST", 298, 308], ["line CLS", "TEST", 313, 321], ["harvested dry roots", "PROBLEM", 326, 345], ["highest cichoric acid content", "PROBLEM", 356, 385], ["caftaric acid", "TREATMENT", 407, 420], ["cynarin", "TREATMENT", 422, 429], ["echinacoside", "TREATMENT", 431, 443], ["chlorogenic acid", "TREATMENT", 448, 464], ["obvious", "OBSERVATION_MODIFIER", 4, 11], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["CADs production", "OBSERVATION", 24, 39], ["purpurea", "OBSERVATION_MODIFIER", 46, 54], ["hairy roots", "OBSERVATION", 55, 66], ["line CLS", "OBSERVATION", 313, 321]]], ["The caffeoyl derivatives were 16.53, 19.71 and 27.40 mg/g dry weight for CLS-P2, Magnus and White Swan, respectively.", [["caffeoyl", "CHEMICAL", 4, 12], ["caffeoyl", "CHEMICAL", 4, 12], ["caffeoyl derivatives", "SIMPLE_CHEMICAL", 4, 24], ["The caffeoyl derivatives", "TREATMENT", 0, 24], ["CLS", "TEST", 73, 76], ["White Swan", "TEST", 92, 102], ["Magnus", "ANATOMY", 81, 87]]], ["Compared to fl owers and leaves, roots contained the highest content of alkamides, dodeca-2 E ,4 E ,8 Z ,10 E -tetraenoic acid isobutylamide (alkamide 8) and dodeca-2 E ,4 E ,8 Z ,10 Z -tetraenoic acid isobutylamide (alkamide 9).", [["leaves", "ANATOMY", 25, 31], ["roots", "ANATOMY", 33, 38], ["alkamides", "CHEMICAL", 72, 81], ["dodeca-2 E ,4 E ,8 Z ,10 E -tetraenoic acid isobutylamide", "CHEMICAL", 83, 140], ["alkamide 8) and dodeca-2 E ,4 E ,8 Z ,10 Z -tetraenoic acid isobutylamide", "CHEMICAL", 142, 215], ["alkamide 9", "CHEMICAL", 217, 227], ["alkamides", "CHEMICAL", 72, 81], ["dodeca-2 E ,4 E ,8 Z ,10 E -tetraenoic acid isobutylamide", "CHEMICAL", 83, 140], ["alkamide", "CHEMICAL", 142, 150], ["dodeca-2 E ,4 E ,8 Z ,10 Z -tetraenoic acid isobutylamide", "CHEMICAL", 158, 215], ["alkamide", "CHEMICAL", 217, 225], ["roots", "ORGAN", 33, 38], ["alkamides", "SIMPLE_CHEMICAL", 72, 81], ["dodeca-2 E", "SIMPLE_CHEMICAL", 83, 93], ["4 E ,8 Z ,10 E -tetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 95, 140], ["alkamide 8)", "SIMPLE_CHEMICAL", 142, 153], ["dodeca-2 E ,4 E ,8 Z ,10 Z -tetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 158, 215], ["alkamide 9", "SIMPLE_CHEMICAL", 217, 227], ["alkamides", "TEST", 72, 81], ["dodeca", "TEST", 83, 89], ["Z", "TEST", 102, 103], ["E", "TEST", 108, 109], ["tetraenoic acid isobutylamide", "TREATMENT", 111, 140], ["alkamide", "TEST", 142, 150], ["dodeca", "TEST", 158, 164], ["Z", "TEST", 177, 178], ["Z", "TEST", 183, 184], ["tetraenoic acid isobutylamide (alkamide", "TREATMENT", 186, 225], ["roots", "ANATOMY", 33, 38]]], ["White Swan accumulated considerably higher alkamides 8 and 9 content in dry roots than Magnum and line CLS-P2.Root PhytochemicalsHighly water-soluble fructans were isolated from E. purpurea roots (Wack and Blaschek 2006 ) .", [["roots", "ANATOMY", 76, 81], ["roots", "ANATOMY", 190, 195], ["alkamides 8 and 9", "CHEMICAL", 43, 60], ["alkamides", "CHEMICAL", 43, 52], ["alkamides", "SIMPLE_CHEMICAL", 43, 52], ["CLS-P2", "CELL", 103, 109], ["fructans", "SIMPLE_CHEMICAL", 150, 158], ["E. purpurea", "ORGANISM", 178, 189], ["roots", "ORGANISM", 190, 195], ["E. purpurea", "SPECIES", 178, 189], ["E. purpurea", "SPECIES", 178, 189], ["White Swan", "TEST", 0, 10], ["higher alkamides", "PROBLEM", 36, 52], ["Root Phytochemicals", "TEST", 110, 129], ["Highly water-soluble fructans", "TREATMENT", 129, 158], ["considerably", "OBSERVATION_MODIFIER", 23, 35], ["higher", "OBSERVATION_MODIFIER", 36, 42], ["dry roots", "ANATOMY", 72, 81], ["line CLS", "OBSERVATION", 98, 106], ["Phytochemicals", "OBSERVATION", 115, 129], ["purpurea roots", "OBSERVATION_MODIFIER", 181, 195]]], ["The fructans represented linear inulintype fructans with almost exclusively \u03b2-(2 \u2192 1)-linked fructosyl units, terminal glucose and terminal fructose.", [["glucose", "CHEMICAL", 119, 126], ["fructose", "CHEMICAL", 140, 148], ["fructosyl", "CHEMICAL", 93, 102], ["glucose", "CHEMICAL", 119, 126], ["fructose", "CHEMICAL", 140, 148], ["fructans", "SIMPLE_CHEMICAL", 4, 12], ["inulintype fructans", "SIMPLE_CHEMICAL", 32, 51], ["\u03b2-(2 \u2192 1)-linked fructosyl units", "SIMPLE_CHEMICAL", 76, 108], ["glucose", "SIMPLE_CHEMICAL", 119, 126], ["terminal fructose", "SIMPLE_CHEMICAL", 131, 148], ["linear inulintype fructans", "PROBLEM", 25, 51], ["terminal glucose and terminal fructose", "PROBLEM", 110, 148], ["linear", "OBSERVATION_MODIFIER", 25, 31], ["inulintype fructans", "OBSERVATION", 32, 51], ["terminal fructose", "OBSERVATION", 131, 148]]], ["Small proportions of \u03b2-(2 \u2192 1,2 \u2192 6)-linked branch point residues were detected.", [["\u03b2-(2 \u2192 1,2 \u2192 6", "CHEMICAL", 21, 35], ["\u03b2-(2 \u2192 1,2 \u2192 6", "SIMPLE_CHEMICAL", 21, 35], ["\u03b2", "TEST", 21, 22], ["linked branch point residues", "PROBLEM", 37, 65], ["proportions", "OBSERVATION_MODIFIER", 6, 17], ["branch", "OBSERVATION_MODIFIER", 44, 50], ["point residues", "OBSERVATION", 51, 65]]], ["80 % ethanol-insoluble fructan from E. purpurea showed an average mean degree of polymerization of 35, 60 % ethanolinsoluble fructan of 44, and 40 % ethanolinsoluble fructan of 55.Root PhytochemicalsCommercial Echinacea extracts are manufactured primarily from three Echinacea species, namely, Echinacea purpurea (herb, roots or seeds), E. angustifolia (roots) and E. pallida (roots) (Mahady et al. 2001 ) .", [["extracts", "ANATOMY", 220, 228], ["roots", "ANATOMY", 320, 325], ["seeds", "ANATOMY", 329, 334], ["roots", "ANATOMY", 354, 359], ["roots", "ANATOMY", 377, 382], ["ethanol", "CHEMICAL", 5, 12], ["fructan", "CHEMICAL", 23, 30], ["ethanolinsoluble fructan", "CHEMICAL", 108, 132], ["ethanolinsoluble fructan", "CHEMICAL", 149, 173], ["ethanol", "CHEMICAL", 5, 12], ["ethanol", "SIMPLE_CHEMICAL", 5, 12], ["fructan", "SIMPLE_CHEMICAL", 23, 30], ["E. purpurea", "ORGANISM", 36, 47], ["ethanolinsoluble fructan", "SIMPLE_CHEMICAL", 108, 132], ["ethanolinsoluble fructan", "SIMPLE_CHEMICAL", 149, 173], ["Echinacea", "ORGANISM", 210, 219], ["extracts", "ORGANISM_SUBSTANCE", 220, 228], ["Echinacea", "ORGANISM", 267, 276], ["Echinacea purpurea", "ORGANISM", 294, 312], ["herb", "ORGANISM_SUBDIVISION", 314, 318], ["roots", "ORGANISM_SUBDIVISION", 320, 325], ["seeds", "ORGANISM_SUBDIVISION", 329, 334], ["E. angustifolia", "ORGANISM", 337, 352], ["roots", "ORGAN", 354, 359], ["E. pallida", "ORGANISM", 365, 375], ["roots", "ORGAN", 377, 382], ["E. purpurea", "SPECIES", 36, 47], ["Echinacea", "SPECIES", 210, 219], ["Echinacea", "SPECIES", 267, 276], ["Echinacea purpurea", "SPECIES", 294, 312], ["E. angustifolia", "SPECIES", 337, 352], ["E. pallida", "SPECIES", 365, 375], ["E. purpurea", "SPECIES", 36, 47], ["Echinacea purpurea", "SPECIES", 294, 312], ["E. angustifolia", "SPECIES", 337, 352], ["E. pallida", "SPECIES", 365, 375], ["E. purpurea", "TEST", 36, 47], ["polymerization", "TEST", 81, 95], ["ethanolinsoluble fructan", "TEST", 108, 132], ["ethanolinsoluble fructan", "TEST", 149, 173], ["Root PhytochemicalsCommercial Echinacea extracts", "PROBLEM", 180, 228], ["three Echinacea species", "PROBLEM", 261, 284], ["Echinacea purpurea", "PROBLEM", 294, 312], ["average", "OBSERVATION_MODIFIER", 58, 65], ["mean degree", "OBSERVATION_MODIFIER", 66, 77], ["polymerization", "OBSERVATION_MODIFIER", 81, 95], ["Echinacea extracts", "OBSERVATION", 210, 228], ["Echinacea species", "OBSERVATION", 267, 284], ["Echinacea purpurea", "OBSERVATION", 294, 312], ["angustifolia", "OBSERVATION_MODIFIER", 340, 352]]], ["Current recommendations for use of these products include oral administration for the prophylaxis and treatment of the common cold, bronchitis, infl uenza and bacterial and viral infections of the respiratory tract.", [["oral", "ANATOMY", 58, 62], ["respiratory tract", "ANATOMY", 197, 214], ["bronchitis", "DISEASE", 132, 142], ["bacterial and viral infections of the respiratory tract", "DISEASE", 159, 214], ["oral", "ORGANISM_SUBDIVISION", 58, 62], ["respiratory tract", "ORGANISM_SUBDIVISION", 197, 214], ["these products", "TREATMENT", 35, 49], ["oral administration", "TREATMENT", 58, 77], ["the prophylaxis", "TREATMENT", 82, 97], ["treatment", "TREATMENT", 102, 111], ["the common cold", "PROBLEM", 115, 130], ["bronchitis", "PROBLEM", 132, 142], ["infl uenza", "PROBLEM", 144, 154], ["bacterial and viral infections of the respiratory tract", "PROBLEM", 159, 214], ["common cold", "ANATOMY", 119, 130], ["bronchitis", "OBSERVATION", 132, 142], ["bacterial", "OBSERVATION_MODIFIER", 159, 168], ["viral infections", "OBSERVATION", 173, 189], ["respiratory tract", "ANATOMY", 197, 214]]], ["However, based on existing data products containing pressed juice or hydroalcoholic extracts, Echinacea purpurea (leaf juice and roots) and E. pallida (roots) had the most convincing data supporting their use.", [["juice", "ANATOMY", 60, 65], ["extracts", "ANATOMY", 84, 92], ["leaf juice", "ANATOMY", 114, 124], ["roots", "ANATOMY", 129, 134], ["roots", "ANATOMY", 152, 157], ["Echinacea purpurea", "CHEMICAL", 94, 112], ["juice", "ORGANISM_SUBSTANCE", 60, 65], ["hydroalcoholic extracts", "ORGANISM_SUBSTANCE", 69, 92], ["Echinacea purpurea", "ORGANISM", 94, 112], ["leaf juice", "ORGANISM_SUBSTANCE", 114, 124], ["roots", "ORGAN", 129, 134], ["E. pallida", "ORGANISM", 140, 150], ["roots", "ORGAN", 152, 157], ["Echinacea purpurea", "SPECIES", 94, 112], ["juice", "SPECIES", 119, 124], ["E. pallida", "SPECIES", 140, 150], ["Echinacea purpurea", "SPECIES", 94, 112], ["E. pallida", "SPECIES", 140, 150], ["pressed juice", "TREATMENT", 52, 65], ["hydroalcoholic extracts", "TREATMENT", 69, 92], ["Echinacea purpurea (leaf juice and roots", "TREATMENT", 94, 134], ["roots", "ANATOMY", 129, 134]]], ["According to Spelman et al. ( 2009 ) , Echinacea purpurea , a top-selling botanical medicine, is currently of considerable interest due to immunomodulatory, antiinfl ammatory, antiviral and cannabinoid receptor 2 (CB 2 )-binding activities of its alkylamide constituents.", [["Echinacea purpurea", "CHEMICAL", 39, 57], ["alkylamide", "CHEMICAL", 247, 257], ["alkylamide", "CHEMICAL", 247, 257], ["Echinacea purpurea", "ORGANISM", 39, 57], ["antiinfl", "SIMPLE_CHEMICAL", 157, 165], ["cannabinoid receptor 2", "GENE_OR_GENE_PRODUCT", 190, 212], ["CB 2", "GENE_OR_GENE_PRODUCT", 214, 218], ["alkylamide", "SIMPLE_CHEMICAL", 247, 257], ["Echinacea purpurea", "SPECIES", 39, 57], ["Echinacea purpurea", "SPECIES", 39, 57], ["Echinacea purpurea", "PROBLEM", 39, 57], ["immunomodulatory, antiinfl ammatory", "TREATMENT", 139, 174], ["antiviral and cannabinoid receptor", "TREATMENT", 176, 210], ["its alkylamide constituents", "TREATMENT", 243, 270]]], ["It is an immunostimulating drug, containing multiple bioactive substances such as polysaccharides, caffeic acid derivatives (caffeic acid, cichoric acid, caftaric acid, chlorogenic acid), alkamides and glycoproteins (Man\u010dek and Kreft 2005 ) .", [["caffeic acid", "CHEMICAL", 99, 111], ["caffeic acid, cichoric acid, caftaric acid, chlorogenic acid", "CHEMICAL", 125, 185], ["alkamides", "CHEMICAL", 188, 197], ["caffeic acid", "CHEMICAL", 99, 111], ["caffeic acid", "CHEMICAL", 125, 137], ["cichoric acid", "CHEMICAL", 139, 152], ["caftaric acid", "CHEMICAL", 154, 167], ["chlorogenic acid", "CHEMICAL", 169, 185], ["alkamides", "CHEMICAL", 188, 197], ["polysaccharides", "SIMPLE_CHEMICAL", 82, 97], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 99, 123], ["caffeic acid", "SIMPLE_CHEMICAL", 125, 137], ["cichoric acid", "SIMPLE_CHEMICAL", 139, 152], ["caftaric acid", "SIMPLE_CHEMICAL", 154, 167], ["chlorogenic acid", "SIMPLE_CHEMICAL", 169, 185], ["alkamides", "SIMPLE_CHEMICAL", 188, 197], ["an immunostimulating drug", "TREATMENT", 6, 31], ["multiple bioactive substances", "TREATMENT", 44, 73], ["polysaccharides", "TREATMENT", 82, 97], ["caffeic acid derivatives", "TREATMENT", 99, 123], ["caffeic acid", "TREATMENT", 125, 137], ["cichoric acid", "TREATMENT", 139, 152], ["caftaric acid", "TREATMENT", 154, 167], ["chlorogenic acid", "TREATMENT", 169, 185], ["alkamides and glycoproteins", "TREATMENT", 188, 215], ["immunostimulating drug", "OBSERVATION", 9, 31], ["bioactive substances", "OBSERVATION", 53, 73]]], ["Among the many pharmacological properties reported for E. purpurea extracts, immunomodulation of macrophages had been demonstrated most convincingly (Barrett 2003 ) .", [["extracts", "ANATOMY", 67, 75], ["macrophages", "ANATOMY", 97, 108], ["E. purpurea", "ORGANISM", 55, 66], ["extracts", "ORGANISM_SUBSTANCE", 67, 75], ["macrophages", "CELL", 97, 108], ["macrophages", "CELL_TYPE", 97, 108], ["E. purpurea", "SPECIES", 55, 66], ["E. purpurea", "SPECIES", 55, 66], ["E. purpurea extracts", "TREATMENT", 55, 75], ["immunomodulation of macrophages", "PROBLEM", 77, 108], ["macrophages", "OBSERVATION", 97, 108]]], ["Several dozen clinical studies-including a number of blind randomized trials-had reported health benefi ts.", [["clinical studies", "TEST", 14, 30], ["blind randomized trials", "TREATMENT", 53, 76]]], ["The most robust data were from studies testing E. purpurea extracts in the treatment for acute upper respiratory infection.", [["extracts", "ANATOMY", 59, 67], ["respiratory", "ANATOMY", 101, 112], ["acute upper respiratory infection", "DISEASE", 89, 122], ["E. purpurea", "ORGANISM", 47, 58], ["extracts", "ORGANISM_SUBSTANCE", 59, 67], ["E. purpurea", "SPECIES", 47, 58], ["E. purpurea", "SPECIES", 47, 58], ["studies testing", "TEST", 31, 46], ["the treatment", "TREATMENT", 71, 84], ["acute upper respiratory infection", "PROBLEM", 89, 122], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["upper", "ANATOMY_MODIFIER", 95, 100], ["respiratory", "ANATOMY", 101, 112], ["infection", "OBSERVATION", 113, 122]]], ["Although indicative of modest benefi t, these studies were limited both in size and in methodological quality.", [["these studies", "TEST", 40, 53], ["indicative of", "UNCERTAINTY", 9, 22], ["modest", "OBSERVATION_MODIFIER", 23, 29], ["benefi", "OBSERVATION", 30, 36], ["size", "OBSERVATION_MODIFIER", 75, 79]]], ["Although a great deal of moderately good-quality scientifi c data regarding E. purpurea , effectiveness in treating illness or in enhancing human health exist, much has not yet been proven beyond a reasonable doubt.Root PhytochemicalsNumerous studies had shown that E. purpurea exhibited immunostimulating, antimicrobial, antiinflammatory, antioxidant, cytochrome enzyme inhibitory, antiandrogenic, cannabinoidomimetic, radioprotective and antitumorous activities (Gupta et al. 2012 ).Antioxidant ActivityThe mechanisms of antioxidant activity of extracts derived from E. angustifolia , E. pallida and E. purpurea roots included free radical scavenging and transition metal chelating (Hu and Kitts 2000 ) .", [["extracts", "ANATOMY", 547, 555], ["roots", "ANATOMY", 614, 619], ["illness", "DISEASE", 116, 123], ["transition metal", "CHEMICAL", 657, 673], ["E. purpurea", "ORGANISM", 76, 87], ["human", "ORGANISM", 140, 145], ["E. purpurea", "ORGANISM", 266, 277], ["cytochrome enzyme", "GENE_OR_GENE_PRODUCT", 353, 370], ["extracts", "ORGANISM_SUBSTANCE", 547, 555], ["E. angustifolia", "ORGANISM", 569, 584], ["E. pallida", "ORGANISM", 587, 597], ["E. purpurea", "ORGANISM", 602, 613], ["roots", "ORGANISM", 614, 619], ["free radical", "SIMPLE_CHEMICAL", 629, 641], ["E. purpurea", "SPECIES", 76, 87], ["human", "SPECIES", 140, 145], ["E. purpurea", "SPECIES", 266, 277], ["E. angustifolia", "SPECIES", 569, 584], ["E. pallida", "SPECIES", 587, 597], ["E. purpurea", "SPECIES", 602, 613], ["E. purpurea", "SPECIES", 76, 87], ["human", "SPECIES", 140, 145], ["E. purpurea", "SPECIES", 266, 277], ["E. angustifolia", "SPECIES", 569, 584], ["E. pallida", "SPECIES", 587, 597], ["E. purpurea", "SPECIES", 602, 613], ["E. purpurea", "PROBLEM", 76, 87], ["illness", "PROBLEM", 116, 123], ["Root PhytochemicalsNumerous studies", "TEST", 215, 250], ["E. purpurea", "PROBLEM", 266, 277], ["immunostimulating", "TREATMENT", 288, 305], ["antimicrobial", "TREATMENT", 307, 320], ["antiinflammatory", "TREATMENT", 322, 338], ["antioxidant", "TREATMENT", 340, 351], ["cytochrome enzyme inhibitory", "TREATMENT", 353, 381], ["antiandrogenic", "TREATMENT", 383, 397], ["cannabinoidomimetic", "TREATMENT", 399, 418], ["radioprotective", "TREATMENT", 420, 435], ["antioxidant activity of extracts", "PROBLEM", 523, 555], ["E. angustifolia", "PROBLEM", 569, 584], ["E. pallida", "PROBLEM", 587, 597], ["E. purpurea roots", "PROBLEM", 602, 619], ["free radical scavenging", "TREATMENT", 629, 652], ["transition metal chelating", "TREATMENT", 657, 683], ["antioxidant activity", "OBSERVATION", 523, 543], ["radical scavenging", "OBSERVATION", 634, 652]]], ["Root extracts of these Echinacea spp. were capable of scavenging hydroxyl, DPPH and ABTS radicals.", [["Root extracts", "ANATOMY", 0, 13], ["hydroxyl", "CHEMICAL", 65, 73], ["DPPH", "CHEMICAL", 75, 79], ["ABTS", "CHEMICAL", 84, 88], ["hydroxyl", "CHEMICAL", 65, 73], ["DPPH", "CHEMICAL", 75, 79], ["ABTS", "CHEMICAL", 84, 88], ["Root extracts", "ORGANISM_SUBSTANCE", 0, 13], ["Echinacea spp", "ORGANISM", 23, 36], ["hydroxyl", "SIMPLE_CHEMICAL", 65, 73], ["DPPH", "SIMPLE_CHEMICAL", 75, 79], ["ABTS radicals", "SIMPLE_CHEMICAL", 84, 97], ["Echinacea", "SPECIES", 23, 32], ["these Echinacea spp", "PROBLEM", 17, 36], ["scavenging hydroxyl", "TREATMENT", 54, 73], ["DPPH", "TREATMENT", 75, 79], ["ABTS radicals", "TREATMENT", 84, 97], ["Echinacea spp", "OBSERVATION", 23, 36]]], ["These root extracts delayed the formation of conjugated diene hydroperoxide induced by the thermal decomposition of 2, 2\u2032-azobis(2-amidinopropane) dihydrochloride and protracted the lag phase of peroxidation of soybean liposomes.", [["root extracts", "ANATOMY", 6, 19], ["diene hydroperoxide", "CHEMICAL", 56, 75], ["2, 2\u2032-azobis(2-amidinopropane) dihydrochloride", "CHEMICAL", 116, 162], ["diene hydroperoxide", "CHEMICAL", 56, 75], ["2, 2\u2032-azobis(2-amidinopropane) dihydrochloride", "CHEMICAL", 116, 162], ["root extracts", "ORGANISM_SUBSTANCE", 6, 19], ["conjugated diene hydroperoxide", "SIMPLE_CHEMICAL", 45, 75], ["2, 2\u2032-azobis(2-amidinopropane) dihydrochloride", "SIMPLE_CHEMICAL", 116, 162], ["soybean liposomes", "SIMPLE_CHEMICAL", 211, 228], ["soybean", "SPECIES", 211, 218], ["These root extracts", "PROBLEM", 0, 19], ["conjugated diene hydroperoxide", "TREATMENT", 45, 75], ["the thermal decomposition", "TREATMENT", 87, 112], ["amidinopropane", "TREATMENT", 131, 145], ["dihydrochloride", "TREATMENT", 147, 162], ["peroxidation of soybean liposomes", "TREATMENT", 195, 228], ["root", "OBSERVATION_MODIFIER", 6, 10], ["conjugated diene", "OBSERVATION", 45, 61], ["soybean liposomes", "OBSERVATION", 211, 228]]], ["These root extracts also suppressed the oxidation of human low-density lipoprotein, as evaluated by reduced agarose electrophoretic mobility following oxidative modifi cation by Cu 2+ .Antioxidant ActivityStudies showed that E. purpurea extracts had antioxidant activity similar to that of ascorbic acid but had no serious effect on inhibiting chicken's peripheral blood mononuclear cells viability (Lee et al. 2009 ), In 2,2-diphenyl-1-picril hydrazyl radical (DPPH) scavenging capacity, the ED 50 for the extract was measured at 0.23 mg/ml.", [["root extracts", "ANATOMY", 6, 19], ["extracts", "ANATOMY", 237, 245], ["peripheral blood mononuclear cells", "ANATOMY", 354, 388], ["extract", "ANATOMY", 507, 514], ["Cu", "CHEMICAL", 178, 180], ["ascorbic acid", "CHEMICAL", 290, 303], ["2,2-diphenyl-1-picril hydrazyl", "CHEMICAL", 422, 452], ["DPPH", "CHEMICAL", 462, 466], ["Cu 2+", "CHEMICAL", 178, 183], ["ascorbic acid", "CHEMICAL", 290, 303], ["In 2,2-diphenyl-1-picril hydrazyl", "CHEMICAL", 419, 452], ["DPPH", "CHEMICAL", 462, 466], ["root extracts", "ORGANISM_SUBSTANCE", 6, 19], ["human", "ORGANISM", 53, 58], ["low-density lipoprotein", "SIMPLE_CHEMICAL", 59, 82], ["agarose", "SIMPLE_CHEMICAL", 108, 115], ["cation", "SIMPLE_CHEMICAL", 168, 174], ["Cu 2+", "SIMPLE_CHEMICAL", 178, 183], ["E. purpurea", "ORGANISM", 225, 236], ["extracts", "ORGANISM_SUBSTANCE", 237, 245], ["ascorbic acid", "SIMPLE_CHEMICAL", 290, 303], ["chicken", "ORGANISM", 344, 351], ["peripheral blood mononuclear cells", "CELL", 354, 388], ["2,2-diphenyl-1-picril hydrazyl radical", "SIMPLE_CHEMICAL", 422, 460], ["DPPH", "SIMPLE_CHEMICAL", 462, 466], ["human low-density lipoprotein", "PROTEIN", 53, 82], ["peripheral blood mononuclear cells", "CELL_TYPE", 354, 388], ["human", "SPECIES", 53, 58], ["E. purpurea", "SPECIES", 225, 236], ["chicken", "SPECIES", 344, 351], ["human", "SPECIES", 53, 58], ["E. purpurea", "SPECIES", 225, 236], ["chicken", "SPECIES", 344, 351], ["reduced agarose electrophoretic mobility", "PROBLEM", 100, 140], ["oxidative modifi cation", "TREATMENT", 151, 174], ["Antioxidant ActivityStudies", "TEST", 185, 212], ["E. purpurea extracts", "PROBLEM", 225, 245], ["antioxidant activity", "PROBLEM", 250, 270], ["ascorbic acid", "TEST", 290, 303], ["serious effect", "PROBLEM", 315, 329], ["inhibiting chicken's peripheral blood mononuclear cells viability", "PROBLEM", 333, 398], ["diphenyl", "TREATMENT", 426, 434], ["picril hydrazyl radical", "TREATMENT", 437, 460], ["scavenging capacity", "TEST", 468, 487], ["root", "OBSERVATION_MODIFIER", 6, 10], ["density lipoprotein", "OBSERVATION", 63, 82], ["peripheral", "ANATOMY_MODIFIER", 354, 364], ["blood", "ANATOMY", 365, 370], ["mononuclear cells", "OBSERVATION", 371, 388]]], ["The superoxide anions scavenging capacity of the extract was nearly equivalent to ascorbic acid (91.1 % vs. 93.0 %) at the same concentration of 1.6 mg/ml, and ED 50 was 0.32 and 0.13 mg/ml, respectively.", [["extract", "ANATOMY", 49, 56], ["superoxide", "CHEMICAL", 4, 14], ["ascorbic acid", "CHEMICAL", 82, 95], ["superoxide", "CHEMICAL", 4, 14], ["ascorbic acid", "CHEMICAL", 82, 95], ["superoxide anions", "SIMPLE_CHEMICAL", 4, 21], ["ascorbic acid", "SIMPLE_CHEMICAL", 82, 95], ["The superoxide anions scavenging capacity", "PROBLEM", 0, 41], ["ascorbic acid", "TEST", 82, 95], ["scavenging capacity", "OBSERVATION", 22, 41]]], ["Reducing power of the extract increased linearly with its concentration, and the concentration at 2.0 mg/ml reached about 65 % of ascorbic acid at 0.3 mg/ml.", [["extract", "ANATOMY", 22, 29], ["ascorbic acid", "CHEMICAL", 130, 143], ["ascorbic acid", "CHEMICAL", 130, 143], ["ascorbic acid", "SIMPLE_CHEMICAL", 130, 143], ["the concentration", "TREATMENT", 77, 94], ["ascorbic acid", "TREATMENT", 130, 143], ["power", "OBSERVATION_MODIFIER", 9, 14], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["linearly", "OBSERVATION_MODIFIER", 40, 48]]], ["The chelating capacity of ferrous iron (Fe 2+ ) was 70 % as good as that of the synthetic metal chelater EDTA when added to 5.0 mg/ml of E. purpurea extract.", [["extract", "ANATOMY", 149, 156], ["ferrous iron", "CHEMICAL", 26, 38], ["Fe", "CHEMICAL", 40, 42], ["chelater EDTA", "CHEMICAL", 96, 109], ["ferrous iron", "CHEMICAL", 26, 38], ["Fe 2+ )", "CHEMICAL", 40, 47], ["EDTA", "CHEMICAL", 105, 109], ["ferrous iron", "SIMPLE_CHEMICAL", 26, 38], ["Fe 2+", "SIMPLE_CHEMICAL", 40, 45], ["metal chelater", "SIMPLE_CHEMICAL", 90, 104], ["EDTA", "SIMPLE_CHEMICAL", 105, 109], ["E. purpurea", "ORGANISM", 137, 148], ["E. purpurea", "SPECIES", 137, 148], ["E. purpurea", "SPECIES", 137, 148], ["The chelating capacity of ferrous iron (Fe", "TREATMENT", 0, 42], ["the synthetic metal chelater EDTA", "TREATMENT", 76, 109], ["chelating", "OBSERVATION_MODIFIER", 4, 13], ["capacity", "OBSERVATION_MODIFIER", 14, 22]]], ["The polysaccharides content of the extract was 159.8 mg/g dry weight (DW), and total phenolic compound was 11.0 mg gallic acid equivalent/g DW.", [["extract", "ANATOMY", 35, 42], ["phenolic compound", "CHEMICAL", 85, 102], ["gallic acid", "CHEMICAL", 115, 126], ["gallic acid", "CHEMICAL", 115, 126], ["polysaccharides", "SIMPLE_CHEMICAL", 4, 19], ["gallic acid", "SIMPLE_CHEMICAL", 115, 126], ["The polysaccharides content", "TEST", 0, 27], ["the extract", "TEST", 31, 42], ["dry weight", "TEST", 58, 68], ["DW", "TEST", 70, 72], ["total phenolic compound", "TREATMENT", 79, 102]]], ["Microculture tetrazolium assays showed extracts had 92 % cell viability at 1.6 mg/ml for chicken's peripheral blood mononuclear cells (PBMCs) and 84 % for RAW 264.7 macrophages, neither reaching the IC 50 level.Antioxidant ActivityExtracts of the roots and leaves of E. purpurea were found to have antioxidant properties in a free-radical scavenging assay and in a lipid peroxidation assay (Sloley et al. 2001 ).", [["extracts", "ANATOMY", 39, 47], ["cell", "ANATOMY", 57, 61], ["peripheral blood mononuclear cells", "ANATOMY", 99, 133], ["PBMCs", "ANATOMY", 135, 140], ["RAW 264.7 macrophages", "ANATOMY", 155, 176], ["roots", "ANATOMY", 247, 252], ["leaves", "ANATOMY", 257, 263], ["tetrazolium", "CHEMICAL", 13, 24], ["tetrazolium", "CHEMICAL", 13, 24], ["extracts", "ORGANISM_SUBSTANCE", 39, 47], ["cell", "CELL", 57, 61], ["chicken", "ORGANISM", 89, 96], ["peripheral blood mononuclear cells", "CELL", 99, 133], ["PBMCs", "CELL", 135, 140], ["RAW 264.7 macrophages", "CELL", 155, 176], ["roots", "ORGAN", 247, 252], ["leaves", "ORGANISM_SUBDIVISION", 257, 263], ["E. purpurea", "ORGANISM", 267, 278], ["lipid", "SIMPLE_CHEMICAL", 365, 370], ["peripheral blood mononuclear cells", "CELL_TYPE", 99, 133], ["PBMCs", "CELL_TYPE", 135, 140], ["RAW 264.7 macrophages", "CELL_LINE", 155, 176], ["chicken", "SPECIES", 89, 96], ["E. purpurea", "SPECIES", 267, 278], ["chicken", "SPECIES", 89, 96], ["E. purpurea", "SPECIES", 267, 278], ["Microculture tetrazolium assays", "TEST", 0, 31], ["extracts", "TEST", 39, 47], ["cell viability", "TEST", 57, 71], ["chicken's peripheral blood mononuclear cells", "TEST", 89, 133], ["PBMCs", "TEST", 135, 140], ["RAW", "TEST", 155, 158], ["macrophages", "TEST", 165, 176], ["Antioxidant ActivityExtracts of the roots", "TREATMENT", 211, 252], ["antioxidant properties", "TREATMENT", 298, 320], ["a lipid peroxidation assay", "TEST", 363, 389], ["mononuclear cells", "OBSERVATION", 116, 133], ["roots", "ANATOMY", 247, 252]]], ["The methanol root extract of E. purpurea , E. pallida and E. angustifolia exhibited DPPH antioxidant activity with EC 50 values of 134, 167 and 231 \u03bcg/ ml, respectively (Pellati et al. 2004 ).", [["root extract", "ANATOMY", 13, 25], ["methanol root extract of E. purpurea", "CHEMICAL", 4, 40], ["DPPH", "CHEMICAL", 84, 88], ["methanol", "CHEMICAL", 4, 12], ["DPPH", "CHEMICAL", 84, 88], ["methanol", "SIMPLE_CHEMICAL", 4, 12], ["E. purpurea", "ORGANISM", 29, 40], ["E. pallida", "ORGANISM", 43, 53], ["E. angustifolia", "ORGANISM", 58, 73], ["DPPH", "SIMPLE_CHEMICAL", 84, 88], ["EC", "CELL", 115, 117], ["E. purpurea", "SPECIES", 29, 40], ["E. pallida", "SPECIES", 43, 53], ["E. angustifolia", "SPECIES", 58, 73], ["E. purpurea", "SPECIES", 29, 40], ["E. pallida", "SPECIES", 43, 53], ["E. angustifolia", "SPECIES", 58, 73], ["The methanol root extract", "TEST", 0, 25], ["E. purpurea", "PROBLEM", 29, 40], ["E. pallida", "TEST", 43, 53], ["E. angustifolia", "TEST", 58, 73], ["DPPH antioxidant activity", "TEST", 84, 109], ["methanol root", "OBSERVATION", 4, 17], ["E. purpurea", "OBSERVATION_MODIFIER", 29, 40], ["pallida", "ANATOMY", 46, 53]]], ["The radical scavenging activity of Echinacea root extracts refl ected their phenolic content.", [["root extracts", "ANATOMY", 45, 58], ["Echinacea", "ORGANISM", 35, 44], ["phenolic", "SIMPLE_CHEMICAL", 76, 84], ["Echinacea", "SPECIES", 35, 44], ["The radical scavenging", "TREATMENT", 0, 22], ["Echinacea root extracts", "TEST", 35, 58], ["radical", "OBSERVATION_MODIFIER", 4, 11], ["scavenging activity", "OBSERVATION", 12, 31], ["Echinacea root", "OBSERVATION", 35, 49], ["phenolic content", "OBSERVATION", 76, 92]]], ["The total phenolic content was 23.23 mg/g for E. purpurea , 17.83 mg/g for E. pallida and 10.49 mg/g for E. angustifolia .", [["phenolic", "CHEMICAL", 10, 18], ["phenolic", "SIMPLE_CHEMICAL", 10, 18], ["E. purpurea", "ORGANISM", 46, 57], ["E. pallida", "ORGANISM", 75, 85], ["E. angustifolia", "ORGANISM", 105, 120], ["E. purpurea", "SPECIES", 46, 57], ["E. pallida", "SPECIES", 75, 85], ["E. angustifolia", "SPECIES", 105, 120], ["E. purpurea", "SPECIES", 46, 57], ["E. pallida", "SPECIES", 75, 85], ["E. angustifolia", "SPECIES", 105, 120], ["E. purpurea", "TREATMENT", 46, 57], ["E. angustifolia", "PROBLEM", 105, 120], ["total", "OBSERVATION_MODIFIER", 4, 9], ["phenolic content", "OBSERVATION", 10, 26]]], ["Caftaric acid, chlorogenic acid, caffeic acid, cynarin, echinacoside and cichoric acid were identifi ed and quantifi ed in Echinacea roots and derivatives.", [["roots", "ANATOMY", 133, 138], ["Caftaric acid", "CHEMICAL", 0, 13], ["chlorogenic acid", "CHEMICAL", 15, 31], ["caffeic acid", "CHEMICAL", 33, 45], ["cynarin", "CHEMICAL", 47, 54], ["echinacoside", "CHEMICAL", 56, 68], ["cichoric acid", "CHEMICAL", 73, 86], ["Caftaric acid", "CHEMICAL", 0, 13], ["chlorogenic acid", "CHEMICAL", 15, 31], ["caffeic acid", "CHEMICAL", 33, 45], ["cynarin", "CHEMICAL", 47, 54], ["echinacoside", "CHEMICAL", 56, 68], ["cichoric acid", "CHEMICAL", 73, 86], ["Caftaric acid", "SIMPLE_CHEMICAL", 0, 13], ["chlorogenic acid", "SIMPLE_CHEMICAL", 15, 31], ["caffeic acid", "SIMPLE_CHEMICAL", 33, 45], ["cynarin", "SIMPLE_CHEMICAL", 47, 54], ["echinacoside", "SIMPLE_CHEMICAL", 56, 68], ["cichoric acid", "SIMPLE_CHEMICAL", 73, 86], ["Echinacea", "ORGANISM", 123, 132], ["roots", "ORGAN", 133, 138], ["Echinacea", "SPECIES", 123, 132], ["Caftaric acid", "TREATMENT", 0, 13], ["chlorogenic acid", "TREATMENT", 15, 31], ["caffeic acid", "TREATMENT", 33, 45], ["cynarin", "TREATMENT", 47, 54], ["echinacoside", "TREATMENT", 56, 68], ["cichoric acid", "TREATMENT", 73, 86], ["derivatives", "TREATMENT", 143, 154], ["Echinacea roots", "OBSERVATION", 123, 138]]], ["Pure echinacoside had the highest capacity to quench DPPH radicals (EC 50 = 6.6 \u03bcM), while caftaric acid had the lowest (EC 50 = 20.5 \u03bcM).Antioxidant ActivityThe antioxidant activity of three extracts, one alkamide fraction, four polysaccharide-containing fractions, and three caffeic acid derivatives from Echinacea purpurea root was evaluated by measuring their inhibition of in-vitro Cu(II)-catalyzed oxidation of human low-density lipoprotein (LDL) (Dalby-Brown et al. 2005 ) .", [["extracts", "ANATOMY", 192, 200], ["root", "ANATOMY", 326, 330], ["echinacoside", "CHEMICAL", 5, 17], ["DPPH", "CHEMICAL", 53, 57], ["caftaric acid", "CHEMICAL", 91, 104], ["alkamide", "CHEMICAL", 206, 214], ["caffeic acid", "CHEMICAL", 277, 289], ["Echinacea purpurea", "CHEMICAL", 307, 325], ["Cu(II", "CHEMICAL", 387, 392], ["echinacoside", "CHEMICAL", 5, 17], ["DPPH", "CHEMICAL", 53, 57], ["caftaric acid", "CHEMICAL", 91, 104], ["alkamide", "CHEMICAL", 206, 214], ["caffeic acid", "CHEMICAL", 277, 289], ["Cu(II)", "CHEMICAL", 387, 393], ["echinacoside", "SIMPLE_CHEMICAL", 5, 17], ["DPPH radicals", "SIMPLE_CHEMICAL", 53, 66], ["caftaric acid", "SIMPLE_CHEMICAL", 91, 104], ["extracts", "ORGANISM_SUBSTANCE", 192, 200], ["alkamide", "SIMPLE_CHEMICAL", 206, 214], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 277, 301], ["Echinacea purpurea", "ORGANISM", 307, 325], ["root", "ORGAN", 326, 330], ["Cu(II)", "SIMPLE_CHEMICAL", 387, 393], ["human", "ORGANISM", 417, 422], ["low-density lipoprotein", "SIMPLE_CHEMICAL", 423, 446], ["LDL", "SIMPLE_CHEMICAL", 448, 451], ["human low-density lipoprotein", "PROTEIN", 417, 446], ["LDL", "PROTEIN", 448, 451], ["Echinacea purpurea", "SPECIES", 307, 325], ["human", "SPECIES", 417, 422], ["Echinacea purpurea", "SPECIES", 307, 325], ["human", "SPECIES", 417, 422], ["the highest capacity", "PROBLEM", 22, 42], ["DPPH radicals", "TEST", 53, 66], ["EC", "TEST", 68, 70], ["caftaric acid", "TEST", 91, 104], ["EC", "TEST", 121, 123], ["three caffeic acid derivatives", "TREATMENT", 271, 301], ["Echinacea purpurea root", "PROBLEM", 307, 330], ["human low-density lipoprotein (LDL)", "TREATMENT", 417, 452], ["purpurea root", "OBSERVATION", 317, 330]]], ["Among the extracts the 80 % aqueous ethanol extract exhibited ten times longer lag phase prolongation (LPP) than the 50 % ethanol extract, which in turn exhibited a longer LPP than the water extract.", [["extracts", "ANATOMY", 10, 18], ["ethanol", "CHEMICAL", 36, 43], ["ethanol", "CHEMICAL", 122, 129], ["ethanol", "CHEMICAL", 36, 43], ["ethanol", "CHEMICAL", 122, 129], ["extracts", "ORGANISM_SUBSTANCE", 10, 18], ["ethanol", "SIMPLE_CHEMICAL", 36, 43], ["ethanol", "SIMPLE_CHEMICAL", 122, 129], ["LPP", "SIMPLE_CHEMICAL", 172, 175], ["ten times longer lag phase prolongation", "PROBLEM", 62, 101]]], ["The antioxidant activity of the tested Echinacea extracts, fractions and isolated compounds was dose dependent.", [["extracts", "ANATOMY", 49, 57], ["Echinacea", "ORGANISM", 39, 48], ["extracts", "ORGANISM_SUBSTANCE", 49, 57], ["Echinacea", "SPECIES", 39, 48], ["the tested Echinacea extracts", "TREATMENT", 28, 57], ["isolated compounds", "PROBLEM", 73, 91], ["dose dependent", "PROBLEM", 96, 110], ["antioxidant activity", "OBSERVATION", 4, 24]]], ["Synergistic antioxidant effects of Echinacea constituents were found when cichoric acid (major caffeic acid derivative in E. purpurea ) or echinacoside (major caffeic acid derivative in Echinacea pallida and Echinacea angustifolia ) was combined with a natural mixture of alkamides and/or a water extract containing the high molecular weight compounds.Antioxidant ActivityThe extracts of the stems, leaves and roots of Echinacea purpure a and their constituent cichoric acid were found to be effi cient scavengers of DPPH radicals with an activity comparable to that of rosmarinic acid, a well-characterized antioxidant (Thygesen et al. 2007 ).", [["extracts", "ANATOMY", 376, 384], ["stems", "ANATOMY", 392, 397], ["leaves", "ANATOMY", 399, 405], ["roots", "ANATOMY", 410, 415], ["Echinacea", "CHEMICAL", 35, 44], ["cichoric acid", "CHEMICAL", 74, 87], ["caffeic acid", "CHEMICAL", 95, 107], ["echinacoside", "CHEMICAL", 139, 151], ["caffeic acid", "CHEMICAL", 159, 171], ["Echinacea pallida and Echinacea angustifolia", "CHEMICAL", 186, 230], ["alkamides", "CHEMICAL", 272, 281], ["purpure", "CHEMICAL", 429, 436], ["cichoric acid", "CHEMICAL", 461, 474], ["DPPH", "CHEMICAL", 517, 521], ["rosmarinic acid", "CHEMICAL", 570, 585], ["cichoric acid", "CHEMICAL", 74, 87], ["caffeic acid", "CHEMICAL", 95, 107], ["echinacoside", "CHEMICAL", 139, 151], ["caffeic acid", "CHEMICAL", 159, 171], ["alkamides", "CHEMICAL", 272, 281], ["cichoric acid", "CHEMICAL", 461, 474], ["DPPH", "CHEMICAL", 517, 521], ["rosmarinic acid", "CHEMICAL", 570, 585], ["Echinacea", "ORGANISM", 35, 44], ["cichoric acid", "SIMPLE_CHEMICAL", 74, 87], ["caffeic acid", "SIMPLE_CHEMICAL", 95, 107], ["E. purpurea", "ORGANISM", 122, 133], ["echinacoside", "SIMPLE_CHEMICAL", 139, 151], ["caffeic acid", "SIMPLE_CHEMICAL", 159, 171], ["Echinacea pallida", "ORGANISM", 186, 203], ["Echinacea angustifolia", "ORGANISM", 208, 230], ["alkamides", "SIMPLE_CHEMICAL", 272, 281], ["extracts", "ORGANISM_SUBSTANCE", 376, 384], ["stems", "ORGANISM_SUBDIVISION", 392, 397], ["leaves", "ORGANISM_SUBDIVISION", 399, 405], ["roots", "ORGANISM_SUBDIVISION", 410, 415], ["Echinacea", "ORGANISM", 419, 428], ["cichoric acid", "SIMPLE_CHEMICAL", 461, 474], ["DPPH", "SIMPLE_CHEMICAL", 517, 521], ["rosmarinic acid", "SIMPLE_CHEMICAL", 570, 585], ["E. purpurea", "SPECIES", 122, 133], ["Echinacea pallida", "SPECIES", 186, 203], ["Echinacea angustifolia", "SPECIES", 208, 230], ["Echinacea purpure", "SPECIES", 419, 436], ["E. purpurea", "SPECIES", 122, 133], ["Echinacea pallida", "SPECIES", 186, 203], ["Echinacea angustifolia", "SPECIES", 208, 230], ["Echinacea purpure", "SPECIES", 419, 436], ["Synergistic antioxidant effects", "TREATMENT", 0, 31], ["Echinacea constituents", "PROBLEM", 35, 57], ["cichoric acid", "TREATMENT", 74, 87], ["major caffeic acid derivative", "TREATMENT", 89, 118], ["E. purpurea", "TREATMENT", 122, 133], ["echinacoside", "TREATMENT", 139, 151], ["major caffeic acid derivative", "TREATMENT", 153, 182], ["Echinacea pallida", "PROBLEM", 186, 203], ["Echinacea angustifolia", "TREATMENT", 208, 230], ["alkamides", "TREATMENT", 272, 281], ["a water extract", "TREATMENT", 289, 304], ["Echinacea purpure", "TREATMENT", 419, 436], ["DPPH radicals", "TEST", 517, 530], ["rosmarinic acid", "TEST", 570, 585], ["stems", "ANATOMY_MODIFIER", 392, 397], ["roots", "OBSERVATION_MODIFIER", 410, 415]]], ["The effi cacy of the extracts in the reaction with DPPH correlated well with the amount of cichoric acid present in the various extracts.", [["extracts", "ANATOMY", 21, 29], ["extracts", "ANATOMY", 128, 136], ["DPPH", "CHEMICAL", 51, 55], ["cichoric acid", "CHEMICAL", 91, 104], ["DPPH", "CHEMICAL", 51, 55], ["cichoric acid", "CHEMICAL", 91, 104], ["extracts", "ORGANISM_SUBSTANCE", 21, 29], ["DPPH", "SIMPLE_CHEMICAL", 51, 55], ["cichoric acid", "SIMPLE_CHEMICAL", 91, 104], ["extracts", "ORGANISM_SUBSTANCE", 128, 136], ["the reaction", "PROBLEM", 33, 45], ["DPPH", "TREATMENT", 51, 55], ["cichoric acid", "PROBLEM", 91, 104], ["amount", "OBSERVATION_MODIFIER", 81, 87], ["cichoric acid", "OBSERVATION", 91, 104]]], ["The alkamides alone showed no antioxidant activity in any of the tests.", [["alkamides", "CHEMICAL", 4, 13], ["alkamides", "CHEMICAL", 4, 13], ["alkamides", "SIMPLE_CHEMICAL", 4, 13], ["The alkamides", "TEST", 0, 13], ["antioxidant activity", "PROBLEM", 30, 50], ["the tests", "TEST", 61, 70], ["no", "UNCERTAINTY", 27, 29], ["antioxidant activity", "OBSERVATION", 30, 50]]], ["Alkamides present in the extract increased, however, the antioxidative effect of cichoric acid in the peroxidation lipid emulsion assay.", [["extract", "ANATOMY", 25, 32], ["Alkamides", "CHEMICAL", 0, 9], ["cichoric acid", "CHEMICAL", 81, 94], ["Alkamides", "CHEMICAL", 0, 9], ["cichoric acid", "CHEMICAL", 81, 94], ["Alkamides", "SIMPLE_CHEMICAL", 0, 9], ["extract", "ORGANISM_SUBSTANCE", 25, 32], ["cichoric acid", "SIMPLE_CHEMICAL", 81, 94], ["Alkamides", "TREATMENT", 0, 9], ["cichoric acid", "PROBLEM", 81, 94], ["the peroxidation lipid emulsion assay", "TEST", 98, 135], ["extract", "OBSERVATION_MODIFIER", 25, 32], ["increased", "OBSERVATION_MODIFIER", 33, 42]]], ["Antioxidant activity in terms of TEAC (\u03bcM trolox/100 g DW) of E. purpurea leaves reported was 12.3 \u03bcM for ABTS, 75 \u03bcM for DPPH and 94.6 \u03bcM for FRAP (ferric reducing antioxidant power) assays (Wojdy\u0142o et al. 2007 ) .", [["leaves", "ANATOMY", 74, 80], ["TEAC", "CHEMICAL", 33, 37], ["trolox", "CHEMICAL", 42, 48], ["ABTS", "CHEMICAL", 106, 110], ["DPPH", "CHEMICAL", 122, 126], ["ferric", "CHEMICAL", 149, 155], ["trolox", "CHEMICAL", 42, 48], ["ABTS", "CHEMICAL", 106, 110], ["DPPH", "CHEMICAL", 122, 126], ["ferric", "CHEMICAL", 149, 155], ["TEAC", "SIMPLE_CHEMICAL", 33, 37], ["trolox", "SIMPLE_CHEMICAL", 42, 48], ["E. purpurea", "ORGANISM", 62, 73], ["leaves", "ORGANISM", 74, 80], ["ABTS", "SIMPLE_CHEMICAL", 106, 110], ["DPPH", "SIMPLE_CHEMICAL", 122, 126], ["FRAP", "SIMPLE_CHEMICAL", 143, 147], ["ferric", "SIMPLE_CHEMICAL", 149, 155], ["E. purpurea", "SPECIES", 62, 73], ["E. purpurea", "SPECIES", 62, 73], ["Antioxidant activity", "TREATMENT", 0, 20], ["TEAC (\u03bcM trolox", "TREATMENT", 33, 48], ["ABTS", "TEST", 106, 110], ["DPPH", "TEST", 122, 126], ["FRAP (ferric reducing antioxidant power", "TREATMENT", 143, 182]]], ["Total phenolic contents reported were 15.15 mg GAE/100 g DW.", [["phenolic contents", "OBSERVATION", 6, 23]]], ["The DPPH scavenging reached 93.6 %, and the values of EC 50 were (34.16) \u03bcg/ml and (65.48) \u03bcg/ml for the extracts obtained by the classical and ultrasound extractions, respectively (Stanisavljevi\u0107 et al. 2009 ).Antioxidant ActivityAt level of 10 \u03bcg/ml, the scavenging abilities of tested samples on DPPH radicals were in the descending order of ascorbic acid > BHA (butylated hydroxyanisole) > fl ower extract > \u03b1-tocopherol (Tsai et al. 2011 ) .", [["extracts", "ANATOMY", 105, 113], ["samples", "ANATOMY", 288, 295], ["DPPH", "CHEMICAL", 4, 8], ["DPPH", "CHEMICAL", 299, 303], ["ascorbic acid", "CHEMICAL", 345, 358], ["BHA", "CHEMICAL", 361, 364], ["butylated hydroxyanisole", "CHEMICAL", 366, 390], ["\u03b1-tocopherol", "CHEMICAL", 412, 424], ["DPPH", "CHEMICAL", 4, 8], ["DPPH", "CHEMICAL", 299, 303], ["ascorbic acid", "CHEMICAL", 345, 358], ["BHA", "CHEMICAL", 361, 364], ["butylated hydroxyanisole", "CHEMICAL", 366, 390], ["\u03b1-tocopherol", "CHEMICAL", 412, 424], ["DPPH", "SIMPLE_CHEMICAL", 4, 8], ["EC", "CELL", 54, 56], ["extracts", "ORGANISM_SUBSTANCE", 105, 113], ["DPPH radicals", "SIMPLE_CHEMICAL", 299, 312], ["ascorbic acid", "SIMPLE_CHEMICAL", 345, 358], ["BHA", "SIMPLE_CHEMICAL", 361, 364], ["butylated hydroxyanisole", "SIMPLE_CHEMICAL", 366, 390], ["fl ower extract", "SIMPLE_CHEMICAL", 394, 409], ["\u03b1-tocopherol", "SIMPLE_CHEMICAL", 412, 424], ["The DPPH scavenging", "TEST", 0, 19], ["EC", "TEST", 54, 56], ["the extracts", "TEST", 101, 113], ["ultrasound extractions", "TEST", 144, 166], ["Antioxidant ActivityAt level", "TEST", 211, 239], ["DPPH radicals", "TEST", 299, 312], ["ascorbic acid", "TEST", 345, 358], ["butylated hydroxyanisole", "TREATMENT", 366, 390], ["descending", "ANATOMY", 325, 335]]], ["At level of 30 \u03bcg/ ml, the fl ower extract and \u03b1-tocopherol showed 90.82 and 93.10 % scavenging abilities, respectively.", [["\u03b1-tocopherol", "CHEMICAL", 47, 59], ["\u03b1-tocopherol", "CHEMICAL", 47, 59], ["\u03b1-tocopherol", "SIMPLE_CHEMICAL", 47, 59], ["the fl ower extract", "TEST", 23, 42], ["\u03b1-tocopherol", "TEST", 47, 59], ["fl", "ANATOMY", 27, 29]]], ["The radical scavenging ability of E. purpurea fl ower extract could be attributable to the caffeic acid derivatives, especially cichoric acid with two adjacent hydroxyl groups of its phenolic rings showed the highest radical scavenging ability.", [["extract", "ANATOMY", 54, 61], ["caffeic acid", "CHEMICAL", 91, 103], ["cichoric acid", "CHEMICAL", 128, 141], ["hydroxyl", "CHEMICAL", 160, 168], ["caffeic acid", "CHEMICAL", 91, 103], ["cichoric acid", "CHEMICAL", 128, 141], ["hydroxyl", "CHEMICAL", 160, 168], ["E. purpurea", "ORGANISM", 34, 45], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 91, 115], ["cichoric acid", "SIMPLE_CHEMICAL", 128, 141], ["phenolic rings", "SIMPLE_CHEMICAL", 183, 197], ["radical", "SIMPLE_CHEMICAL", 217, 224], ["E. purpurea", "SPECIES", 34, 45], ["E. purpurea", "SPECIES", 34, 45], ["The radical scavenging", "TREATMENT", 0, 22], ["the caffeic acid derivatives", "TREATMENT", 87, 115], ["cichoric acid", "PROBLEM", 128, 141], ["its phenolic rings", "TREATMENT", 179, 197], ["the highest radical scavenging ability", "PROBLEM", 205, 243], ["radical", "OBSERVATION_MODIFIER", 4, 11], ["scavenging", "OBSERVATION_MODIFIER", 12, 22], ["purpurea fl", "OBSERVATION", 37, 48], ["caffeic acid derivatives", "OBSERVATION", 91, 115], ["hydroxyl groups", "OBSERVATION", 160, 175], ["phenolic rings", "OBSERVATION", 183, 197], ["highest", "OBSERVATION_MODIFIER", 209, 216], ["radical", "OBSERVATION_MODIFIER", 217, 224], ["scavenging ability", "OBSERVATION", 225, 243]]], ["The order of potency against DPPH radicals was the following: echinacoside > cichoric acid > chlorogenic acid > caffeic acid > caftaric acid.", [["DPPH", "CHEMICAL", 29, 33], ["echinacoside", "CHEMICAL", 62, 74], ["cichoric acid", "CHEMICAL", 77, 90], ["chlorogenic acid", "CHEMICAL", 93, 109], ["caffeic acid", "CHEMICAL", 112, 124], ["caftaric acid", "CHEMICAL", 127, 140], ["DPPH", "CHEMICAL", 29, 33], ["echinacoside", "CHEMICAL", 62, 74], ["cichoric acid", "CHEMICAL", 77, 90], ["chlorogenic acid", "CHEMICAL", 93, 109], ["caffeic acid", "CHEMICAL", 112, 124], ["caftaric acid", "CHEMICAL", 127, 140], ["DPPH radicals", "SIMPLE_CHEMICAL", 29, 42], ["echinacoside", "SIMPLE_CHEMICAL", 62, 74], ["cichoric acid", "SIMPLE_CHEMICAL", 77, 90], ["chlorogenic acid", "SIMPLE_CHEMICAL", 93, 109], ["caffeic acid", "SIMPLE_CHEMICAL", 112, 124], ["caftaric acid", "SIMPLE_CHEMICAL", 127, 140], ["DPPH radicals", "TEST", 29, 42], ["echinacoside", "TEST", 62, 74], ["cichoric acid", "TEST", 77, 90], ["chlorogenic acid", "TEST", 93, 109], ["caffeic acid", "TEST", 112, 124], ["caftaric acid", "TREATMENT", 127, 140]]], ["At the level of 100 \u03bcg/ml, the reducing power of samples was in the descending order of ascorbic acid > BHA > fl ower extract > \u03b1-tocopherol.", [["samples", "ANATOMY", 49, 56], ["ascorbic acid", "CHEMICAL", 88, 101], ["BHA", "CHEMICAL", 104, 107], ["\u03b1-tocopherol", "CHEMICAL", 128, 140], ["ascorbic acid", "CHEMICAL", 88, 101], ["BHA", "CHEMICAL", 104, 107], ["\u03b1-tocopherol", "CHEMICAL", 128, 140], ["ascorbic acid", "SIMPLE_CHEMICAL", 88, 101], ["BHA", "SIMPLE_CHEMICAL", 104, 107], ["fl ower extract", "SIMPLE_CHEMICAL", 110, 125], ["\u03b1-tocopherol", "SIMPLE_CHEMICAL", 128, 140], ["ascorbic acid", "TEST", 88, 101], ["BHA", "TEST", 104, 107], ["descending", "ANATOMY", 68, 78]]], ["The ascorbic acid, BHA, and fl ower extract attained the same maximum reducing power (2.3 AU) at 100, 200 and 400 \u03bcg/ml, respectively.", [["ascorbic acid", "CHEMICAL", 4, 17], ["BHA", "CHEMICAL", 19, 22], ["ascorbic acid", "CHEMICAL", 4, 17], ["BHA", "CHEMICAL", 19, 22], ["ascorbic acid", "SIMPLE_CHEMICAL", 4, 17], ["BHA", "SIMPLE_CHEMICAL", 19, 22], ["The ascorbic acid", "TEST", 0, 17], ["BHA", "TREATMENT", 19, 22], ["fl ower extract", "TREATMENT", 28, 43], ["ascorbic acid", "OBSERVATION", 4, 17]]], ["The fl ower extracts exerted an 81.88 % ferrous ions chelating effect at 3 mg/ml concentration when compared with the EDTA (ethylenediaminetetraacetic acid) concentration of 10 \u03bcg/ml.Immunomodulatory ActivityStudies found that the main immunostimulatory activity of Echinacea resided in the water-soluble materials rather than the lipoidal small molecules (Pillai et al. 2007 ).", [["extracts", "ANATOMY", 12, 20], ["ferrous", "CHEMICAL", 40, 47], ["ethylenediaminetetraacetic acid", "CHEMICAL", 124, 155], ["Echinacea", "CHEMICAL", 266, 275], ["ferrous", "CHEMICAL", 40, 47], ["EDTA", "CHEMICAL", 118, 122], ["ethylenediaminetetraacetic acid", "CHEMICAL", 124, 155], ["extracts", "ORGANISM_SUBSTANCE", 12, 20], ["ferrous ions", "SIMPLE_CHEMICAL", 40, 52], ["EDTA", "SIMPLE_CHEMICAL", 118, 122], ["ethylenediaminetetraacetic acid", "SIMPLE_CHEMICAL", 124, 155], ["Echinacea", "ORGANISM", 266, 275], ["The fl ower extracts", "TREATMENT", 0, 20], ["an 81.88 % ferrous ions chelating effect", "TREATMENT", 29, 69], ["the EDTA (ethylenediaminetetraacetic acid) concentration", "TREATMENT", 114, 170], ["Immunomodulatory ActivityStudies", "TEST", 183, 215], ["Echinacea", "PROBLEM", 266, 275], ["main", "OBSERVATION_MODIFIER", 231, 235], ["immunostimulatory activity", "OBSERVATION", 236, 262], ["Echinacea", "OBSERVATION_MODIFIER", 266, 275]]], ["The use of fl ow cytometry demonstrated a link between the polysaccharides in Echinacea and the biologic immunostimulatory effect.", [["Echinacea", "CHEMICAL", 78, 87], ["Echinacea", "ORGANISM", 78, 87], ["Echinacea", "SPECIES", 78, 87], ["fl ow cytometry", "TEST", 11, 26], ["the polysaccharides", "PROBLEM", 55, 74], ["Echinacea", "TREATMENT", 78, 87], ["the biologic immunostimulatory effect", "TREATMENT", 92, 129], ["immunostimulatory effect", "OBSERVATION", 105, 129]]], ["E. purpurea , E. pallida and E. angustifolia leaves, stems, fl owering tops and roots all produced substantial immunostimulatory activity .", [["leaves", "ANATOMY", 45, 51], ["stems", "ANATOMY", 53, 58], ["roots", "ANATOMY", 80, 85], ["E. purpurea", "ORGANISM", 0, 11], ["E. pallida", "ORGANISM", 14, 24], ["E. angustifolia", "ORGANISM", 29, 44], ["leaves", "ORGANISM", 45, 51], ["stems", "ORGANISM_SUBDIVISION", 53, 58], ["roots", "ORGAN", 80, 85], ["E. purpurea", "SPECIES", 0, 11], ["E. pallida", "SPECIES", 14, 24], ["E. angustifolia", "SPECIES", 29, 44], ["E. purpurea", "SPECIES", 0, 11], ["E. pallida", "SPECIES", 14, 24], ["E. angustifolia", "SPECIES", 29, 44], ["purpurea", "OBSERVATION_MODIFIER", 3, 11], ["pallida", "OBSERVATION_MODIFIER", 17, 24], ["angustifolia leaves", "OBSERVATION", 32, 51], ["stems", "OBSERVATION_MODIFIER", 53, 58], ["substantial", "OBSERVATION_MODIFIER", 99, 110], ["immunostimulatory activity", "OBSERVATION", 111, 137]]], ["In-vitro and in-vivo studies indicated that the therapeutic effects of Echinacea were due to a stimulation of cellular immune response (Mahady et al. 2001 ).In-Vitro StudiesPurifi ed polysaccharides (EPS) prepared from Echinacea purpurea were shown to strongly activate macrophages that developed pronounced extracellular cytotoxicity against tumour targets (Stimpel et al. 1984 ) .", [["cellular", "ANATOMY", 110, 118], ["macrophages", "ANATOMY", 270, 281], ["extracellular", "ANATOMY", 308, 321], ["tumour", "ANATOMY", 343, 349], ["Echinacea", "CHEMICAL", 71, 80], ["EPS", "CHEMICAL", 200, 203], ["tumour", "DISEASE", 343, 349], ["Echinacea", "ORGANISM", 71, 80], ["cellular", "CELL", 110, 118], ["StudiesPurifi ed polysaccharides", "SIMPLE_CHEMICAL", 166, 198], ["EPS", "SIMPLE_CHEMICAL", 200, 203], ["Echinacea purpurea", "ORGANISM", 219, 237], ["macrophages", "CELL", 270, 281], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 308, 321], ["tumour", "CANCER", 343, 349], ["macrophages", "CELL_TYPE", 270, 281], ["Echinacea purpurea", "SPECIES", 219, 237], ["Echinacea purpurea", "SPECIES", 219, 237], ["Echinacea", "TREATMENT", 71, 80], ["Echinacea purpurea", "TREATMENT", 219, 237], ["pronounced extracellular cytotoxicity against tumour targets", "PROBLEM", 297, 357]]], ["The splenic lymphocytes from mice treated with E. purpurea and Hypericum perforatum at the two dose levels used (30 and 100 mg/kg/day) were shown to be significantly more resistant to apoptosis than those from mice treated only with the vehicle (Di Carlo et al. 2003 ) .", [["splenic lymphocytes", "ANATOMY", 4, 23], ["Hypericum perforatum", "CHEMICAL", 63, 83], ["splenic lymphocytes", "CELL", 4, 23], ["mice", "ORGANISM", 29, 33], ["E. purpurea", "ORGANISM", 47, 58], ["Hypericum perforatum", "ORGANISM", 63, 83], ["mice", "ORGANISM", 210, 214], ["splenic lymphocytes", "CELL_TYPE", 4, 23], ["mice", "SPECIES", 29, 33], ["E. purpurea", "SPECIES", 47, 58], ["Hypericum perforatum", "SPECIES", 63, 83], ["mice", "SPECIES", 210, 214], ["mice", "SPECIES", 29, 33], ["E. purpurea", "SPECIES", 47, 58], ["Hypericum perforatum", "SPECIES", 63, 83], ["mice", "SPECIES", 210, 214], ["E. purpurea", "TREATMENT", 47, 58], ["Hypericum perforatum", "TREATMENT", 63, 83], ["apoptosis", "PROBLEM", 184, 193], ["splenic", "ANATOMY", 4, 11], ["lymphocytes", "OBSERVATION", 12, 23], ["purpurea", "OBSERVATION_MODIFIER", 50, 58], ["Hypericum perforatum", "OBSERVATION_MODIFIER", 63, 83], ["more resistant", "OBSERVATION_MODIFIER", 166, 180]]], ["Further, mice treated with these natural substances showed a decrease in Fas-Ag expression and an increase in Bcl-2 expression.In-Vitro StudiesThe 4-O -methyl-glucuronoarabinoxylan, isolated from E. purpurea showed immunestimulating activity in several in-vitro immunological test systems (Wagner et al. , 1985 Proksch and Wagner 1987 ) .", [["4-O -methyl-glucuronoarabinoxylan", "CHEMICAL", 147, 180], ["4-O -methyl-glucuronoarabinoxylan", "CHEMICAL", 147, 180], ["mice", "ORGANISM", 9, 13], ["Fas-Ag", "GENE_OR_GENE_PRODUCT", 73, 79], ["Bcl-2", "GENE_OR_GENE_PRODUCT", 110, 115], ["4-O -methyl-glucuronoarabinoxylan", "SIMPLE_CHEMICAL", 147, 180], ["E. purpurea", "ORGANISM", 196, 207], ["Fas-Ag", "PROTEIN", 73, 79], ["Bcl-2", "PROTEIN", 110, 115], ["mice", "SPECIES", 9, 13], ["E. purpurea", "SPECIES", 196, 207], ["mice", "SPECIES", 9, 13], ["E. purpurea", "SPECIES", 196, 207], ["these natural substances", "TREATMENT", 27, 51], ["a decrease in Fas-Ag expression", "PROBLEM", 59, 90], ["an increase in Bcl", "PROBLEM", 95, 113], ["methyl-glucuronoarabinoxylan", "TREATMENT", 152, 180], ["immunestimulating activity", "PROBLEM", 215, 241], ["decrease", "OBSERVATION_MODIFIER", 61, 69], ["Fas-Ag expression", "OBSERVATION", 73, 90], ["increase", "OBSERVATION_MODIFIER", 98, 106], ["Bcl", "OBSERVATION", 110, 113]]], ["The fucogalactoxyloglucan of mean molecular weight 25,000 isolated from E. purpurea cell culture enhanced phagocytosis in vitro and in-vivo ).", [["cell", "ANATOMY", 84, 88], ["fucogalactoxyloglucan", "CHEMICAL", 4, 25], ["fucogalactoxyloglucan", "CHEMICAL", 4, 25], ["fucogalactoxyloglucan", "SIMPLE_CHEMICAL", 4, 25], ["E. purpurea cell", "CELL", 72, 88], ["E. purpurea cell culture", "CELL_LINE", 72, 96], ["E. purpurea", "SPECIES", 72, 83], ["E. purpurea", "SPECIES", 72, 83], ["The fucogalactoxyloglucan", "TEST", 0, 25], ["mean molecular weight", "TEST", 29, 50], ["E. purpurea cell culture", "TEST", 72, 96], ["phagocytosis", "TEST", 106, 118], ["vitro", "TEST", 122, 127], ["purpurea cell", "OBSERVATION", 75, 88]]], ["The arabinogalactan specifi cally stimulated macrophages to excrete the tumour necrosis factor (TNF).", [["macrophages", "ANATOMY", 45, 56], ["necrosis", "DISEASE", 79, 87], ["macrophages", "CELL", 45, 56], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 72, 94], ["TNF", "GENE_OR_GENE_PRODUCT", 96, 99], ["arabinogalactan specifi cally stimulated macrophages", "CELL_TYPE", 4, 56], ["tumour necrosis factor", "PROTEIN", 72, 94], ["TNF", "PROTEIN", 96, 99], ["The arabinogalactan", "TREATMENT", 0, 19], ["the tumour necrosis factor", "PROBLEM", 68, 94], ["tumour necrosis", "OBSERVATION", 72, 87]]], ["The arabinogalactan protein (AGP) from pressed juice of the aerial parts of Echinacea purpurea demonstrated binding to lymphocytes, monocytes and granulocytes of different donors (Thude et al. 2006 ) .", [["juice", "ANATOMY", 47, 52], ["aerial parts", "ANATOMY", 60, 72], ["lymphocytes", "ANATOMY", 119, 130], ["monocytes", "ANATOMY", 132, 141], ["granulocytes", "ANATOMY", 146, 158], ["Echinacea purpurea", "CHEMICAL", 76, 94], ["arabinogalactan protein", "GENE_OR_GENE_PRODUCT", 4, 27], ["AGP", "GENE_OR_GENE_PRODUCT", 29, 32], ["juice", "ORGANISM_SUBSTANCE", 47, 52], ["Echinacea purpurea", "ORGANISM", 76, 94], ["lymphocytes", "CELL", 119, 130], ["monocytes", "CELL", 132, 141], ["granulocytes", "CELL", 146, 158], ["donors", "ORGANISM", 172, 178], ["arabinogalactan protein", "PROTEIN", 4, 27], ["AGP", "PROTEIN", 29, 32], ["lymphocytes", "CELL_TYPE", 119, 130], ["monocytes", "CELL_TYPE", 132, 141], ["granulocytes", "CELL_TYPE", 146, 158], ["Echinacea purpurea", "SPECIES", 76, 94], ["Echinacea purpurea", "SPECIES", 76, 94], ["The arabinogalactan protein (AGP", "TEST", 0, 32], ["pressed juice", "TEST", 39, 52], ["Echinacea purpurea", "TEST", 76, 94], ["lymphocytes", "TEST", 119, 130], ["monocytes", "TEST", 132, 141], ["granulocytes", "TEST", 146, 158], ["Echinacea purpurea", "OBSERVATION", 76, 94]]], ["A high molecular weight arabinogalactan protein (AGP) from the pressed juice of Echinacea purpurea , known to exhibit immunomodulatory properties in vitro, was characterized (Volk et al. 2007 ).", [["juice", "ANATOMY", 71, 76], ["Echinacea purpurea", "CHEMICAL", 80, 98], ["high molecular weight arabinogalactan protein", "GENE_OR_GENE_PRODUCT", 2, 47], ["AGP", "GENE_OR_GENE_PRODUCT", 49, 52], ["juice", "ORGANISM_SUBSTANCE", 71, 76], ["Echinacea purpurea", "ORGANISM", 80, 98], ["arabinogalactan protein", "PROTEIN", 24, 47], ["AGP", "PROTEIN", 49, 52], ["Echinacea purpurea", "SPECIES", 80, 98], ["Echinacea purpurea", "SPECIES", 80, 98], ["A high molecular weight arabinogalactan protein (AGP)", "PROBLEM", 0, 53], ["Echinacea purpurea", "PROBLEM", 80, 98], ["Echinacea purpurea", "OBSERVATION", 80, 98], ["immunomodulatory properties", "OBSERVATION", 118, 145]]], ["Normal human peripheral blood macrophages cultured in concentrations of Echinacea purpurea fresh pressed juice as low as 0.012 \u03bcg/ml produced significantly higher levels of IL-1, TNF-\u03b1, IL-6 and IL-10 than unstimulated cells (Burger et al. 1997 ) .", [["peripheral blood macrophages", "ANATOMY", 13, 41], ["juice", "ANATOMY", 105, 110], ["cells", "ANATOMY", 219, 224], ["human", "ORGANISM", 7, 12], ["peripheral blood macrophages", "CELL", 13, 41], ["Echinacea", "ORGANISM", 72, 81], ["juice", "ORGANISM_SUBSTANCE", 105, 110], ["IL-1", "GENE_OR_GENE_PRODUCT", 173, 177], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 179, 184], ["IL-6", "GENE_OR_GENE_PRODUCT", 186, 190], ["IL-10", "GENE_OR_GENE_PRODUCT", 195, 200], ["cells", "CELL", 219, 224], ["human peripheral blood macrophages", "CELL_TYPE", 7, 41], ["TNF", "PROTEIN", 179, 182], ["unstimulated cells", "CELL_TYPE", 206, 224], ["human", "SPECIES", 7, 12], ["Echinacea purpurea", "SPECIES", 72, 90], ["human", "SPECIES", 7, 12], ["Echinacea purpurea", "SPECIES", 72, 90], ["Echinacea purpurea fresh pressed juice", "TEST", 72, 110], ["IL", "TEST", 173, 175], ["TNF", "TEST", 179, 182], ["IL", "TEST", 186, 188], ["IL", "TEST", 195, 197], ["peripheral", "ANATOMY_MODIFIER", 13, 23], ["blood", "ANATOMY", 24, 29], ["macrophages", "OBSERVATION", 30, 41]]], ["The high levels of IL-1, TNF-\u03b1 and IL-10 induced by very low levels of echinacea were consistent with an immune-activated antiviral effect.", [["IL-1", "GENE_OR_GENE_PRODUCT", 19, 23], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 25, 30], ["IL-10", "GENE_OR_GENE_PRODUCT", 35, 40], ["echinacea", "SIMPLE_CHEMICAL", 71, 80], ["IL", "PROTEIN", 19, 21], ["TNF", "PROTEIN", 25, 28], ["IL-10", "PROTEIN", 35, 40], ["IL", "TEST", 19, 21], ["TNF", "TEST", 25, 28], ["IL", "TEST", 35, 37], ["very low levels of echinacea", "PROBLEM", 52, 80], ["activated antiviral effect", "PROBLEM", 112, 138], ["high", "OBSERVATION_MODIFIER", 4, 8], ["consistent with", "UNCERTAINTY", 86, 101], ["antiviral effect", "OBSERVATION", 122, 138]]], ["Echinacea induced lower levels of IL-6 in comparison to the other cytokines measured.", [["Echinacea", "CHEMICAL", 0, 9], ["Echinacea", "ORGANISM", 0, 9], ["IL-6", "GENE_OR_GENE_PRODUCT", 34, 38], ["IL-6", "PROTEIN", 34, 38], ["cytokines", "PROTEIN", 66, 75], ["Echinacea", "SPECIES", 0, 9], ["Echinacea induced lower levels of IL", "PROBLEM", 0, 36], ["the other cytokines", "TEST", 56, 75], ["lower", "ANATOMY_MODIFIER", 18, 23]]], ["Echinacea herb and root powders were found to stimulate murine macrophage cytokine secretion as well as to signifi cantly enhance the viability and/or proliferation of human peripheral blood mononuclear cells in vitro (Rininger et al. 2000 ) .", [["root powders", "ANATOMY", 19, 31], ["macrophage", "ANATOMY", 63, 73], ["peripheral blood mononuclear cells", "ANATOMY", 174, 208], ["Echinacea herb", "CHEMICAL", 0, 14], ["Echinacea", "ORGANISM", 0, 9], ["root powders", "ORGANISM_SUBSTANCE", 19, 31], ["murine", "ORGANISM", 56, 62], ["macrophage", "CELL", 63, 73], ["human", "ORGANISM", 168, 173], ["peripheral blood mononuclear cells", "CELL", 174, 208], ["cytokine", "PROTEIN", 74, 82], ["human peripheral blood mononuclear cells", "CELL_TYPE", 168, 208], ["Echinacea", "SPECIES", 0, 9], ["murine", "SPECIES", 56, 62], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["Echinacea herb", "TREATMENT", 0, 14], ["root powders", "TREATMENT", 19, 31], ["human peripheral blood mononuclear cells", "TREATMENT", 168, 208], ["mononuclear cells", "OBSERVATION", 191, 208]]], ["In contrast, echinacea extracts chemically standardized to phenolic acid or echinacoside content and fresh pressed juice preparations were found to be inactive as immunostimulatory agents but did display, to varying degrees, antiinfl ammatory and antioxidant properties.In-Vitro StudiesStudies showed that E. purpurea root and leaf-stem extract exhibited opposite (enhancing vs. inhibitory) modulatory effects on the expression of the CD83 marker in human dendritic cells (DCs) (Wang et al. 2006 ) Downregulation of mRNA expression of specifi c chemokines (e.g., CCL3 and CCL8) and their receptors (e.g., CCR1 and CCR9) was observed in stem-and leaftreated DCs.", [["extracts", "ANATOMY", 23, 31], ["juice", "ANATOMY", 115, 120], ["root", "ANATOMY", 318, 322], ["leaf-stem extract", "ANATOMY", 327, 344], ["dendritic cells", "ANATOMY", 456, 471], ["DCs", "ANATOMY", 473, 476], ["stem", "ANATOMY", 636, 640], ["DCs", "ANATOMY", 657, 660], ["phenolic acid", "CHEMICAL", 59, 72], ["echinacoside", "CHEMICAL", 76, 88], ["E. purpurea root and leaf-stem extract", "CHEMICAL", 306, 344], ["phenolic acid", "CHEMICAL", 59, 72], ["echinacoside", "CHEMICAL", 76, 88], ["echinacea extracts", "ORGANISM", 13, 31], ["phenolic acid", "SIMPLE_CHEMICAL", 59, 72], ["echinacoside", "SIMPLE_CHEMICAL", 76, 88], ["juice", "ORGANISM_SUBSTANCE", 115, 120], ["E. purpurea", "ORGANISM", 306, 317], ["root", "ORGANISM", 318, 322], ["leaf-stem", "CELL", 327, 336], ["CD83", "GENE_OR_GENE_PRODUCT", 435, 439], ["human", "ORGANISM", 450, 455], ["dendritic cells", "CELL", 456, 471], ["DCs", "CELL", 473, 476], ["specifi c chemokines", "GENE_OR_GENE_PRODUCT", 535, 555], ["CCL3", "GENE_OR_GENE_PRODUCT", 563, 567], ["CCL8", "GENE_OR_GENE_PRODUCT", 572, 576], ["CCR1", "GENE_OR_GENE_PRODUCT", 605, 609], ["CCR9", "GENE_OR_GENE_PRODUCT", 614, 618], ["stem", "CELL", 636, 640], ["DCs", "CELL", 657, 660], ["CD83", "PROTEIN", 435, 439], ["human dendritic cells", "CELL_TYPE", 450, 471], ["DCs", "CELL_TYPE", 473, 476], ["specifi c chemokines", "PROTEIN", 535, 555], ["CCL3", "PROTEIN", 563, 567], ["CCL8", "PROTEIN", 572, 576], ["CCR1", "PROTEIN", 605, 609], ["CCR9", "PROTEIN", 614, 618], ["stem-and leaftreated DCs", "CELL_LINE", 636, 660], ["E. purpurea", "SPECIES", 306, 317], ["human", "SPECIES", 450, 455], ["E. purpurea", "SPECIES", 306, 317], ["human", "SPECIES", 450, 455], ["echinacea extracts", "TREATMENT", 13, 31], ["phenolic acid", "TEST", 59, 72], ["echinacoside content", "PROBLEM", 76, 96], ["fresh pressed juice preparations", "TREATMENT", 101, 133], ["immunostimulatory agents", "TREATMENT", 163, 187], ["antiinfl ammatory and antioxidant properties", "TREATMENT", 225, 269], ["Vitro StudiesStudies", "TEST", 273, 293], ["E. purpurea root", "PROBLEM", 306, 322], ["opposite (enhancing vs. inhibitory) modulatory effects", "PROBLEM", 355, 409], ["mRNA expression of specifi c chemokines", "PROBLEM", 516, 555], ["CCL3", "TEST", 563, 567], ["CCR1", "TEST", 605, 609], ["CCR9", "TEST", 614, 618], ["phenolic acid", "OBSERVATION", 59, 72], ["purpurea root", "OBSERVATION", 309, 322], ["leaf", "OBSERVATION_MODIFIER", 327, 331], ["stem", "ANATOMY_MODIFIER", 332, 336], ["CD83 marker", "OBSERVATION", 435, 446], ["dendritic cells", "OBSERVATION", 456, 471]]], ["Other chemokines and regulatory molecules (e.g., CCL4 and CCL2) involved in the c-Jun pathway were found to be upregulated in root-treated DCs.", [["root", "ANATOMY", 126, 130], ["DCs", "ANATOMY", 139, 142], ["CCL4", "GENE_OR_GENE_PRODUCT", 49, 53], ["CCL2", "GENE_OR_GENE_PRODUCT", 58, 62], ["c-Jun", "GENE_OR_GENE_PRODUCT", 80, 85], ["root", "ORGAN", 126, 130], ["DCs", "CELL", 139, 142], ["chemokines", "PROTEIN", 6, 16], ["regulatory molecules", "PROTEIN", 21, 41], ["CCL4", "PROTEIN", 49, 53], ["CCL2", "PROTEIN", 58, 62], ["Jun", "PROTEIN", 82, 85], ["root-treated DCs", "CELL_LINE", 126, 142], ["root", "ANATOMY", 126, 130]]], ["In another study, following 48 hours exposure of dendritic cells from C57Bl/6 mice to E. purpurea root and leaf extracts, it was found that the polysaccharide-rich root extract increased the expression of MHC class II, CD86 and CD54 surface biomarkers whereas the alkylamide-rich leaf extract inhibited expression of these molecules (Benson et al. 2010 ).", [["dendritic cells", "ANATOMY", 49, 64], ["root", "ANATOMY", 98, 102], ["leaf extracts", "ANATOMY", 107, 120], ["root extract", "ANATOMY", 164, 176], ["surface", "ANATOMY", 233, 240], ["leaf extract", "ANATOMY", 280, 292], ["alkylamide-rich leaf extract", "CHEMICAL", 264, 292], ["alkylamide", "CHEMICAL", 264, 274], ["dendritic cells", "CELL", 49, 64], ["C57Bl/6 mice", "ORGANISM", 70, 82], ["E. purpurea", "ORGANISM", 86, 97], ["root", "TISSUE", 98, 102], ["leaf extracts", "ORGANISM_SUBSTANCE", 107, 120], ["polysaccharide", "SIMPLE_CHEMICAL", 144, 158], ["root extract", "ORGANISM_SUBSTANCE", 164, 176], ["MHC class II", "GENE_OR_GENE_PRODUCT", 205, 217], ["CD86", "GENE_OR_GENE_PRODUCT", 219, 223], ["CD54", "GENE_OR_GENE_PRODUCT", 228, 232], ["alkylamide", "SIMPLE_CHEMICAL", 264, 274], ["dendritic cells", "CELL_TYPE", 49, 64], ["MHC class II", "PROTEIN", 205, 217], ["CD86", "PROTEIN", 219, 223], ["CD54", "PROTEIN", 228, 232], ["mice", "SPECIES", 78, 82], ["E. purpurea", "SPECIES", 86, 97], ["mice", "SPECIES", 78, 82], ["E. purpurea", "SPECIES", 86, 97], ["another study", "TEST", 3, 16], ["dendritic cells", "PROBLEM", 49, 64], ["the polysaccharide", "TEST", 140, 158], ["CD86", "TEST", 219, 223], ["CD54 surface biomarkers", "TEST", 228, 251], ["dendritic cells", "OBSERVATION", 49, 64], ["purpurea root", "ANATOMY", 89, 102], ["leaf", "ANATOMY", 107, 111]]], ["Production of IL-6 and TNF-\u03b1 increased in a concentration-dependent manner with exposure to the root, but not leaf, extract.", [["root", "ANATOMY", 96, 100], ["leaf", "ANATOMY", 110, 114], ["extract", "ANATOMY", 116, 123], ["IL-6", "GENE_OR_GENE_PRODUCT", 14, 18], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 23, 28], ["root", "ORGAN", 96, 100], ["leaf", "ORGANISM_SUBDIVISION", 110, 114], ["IL-6", "PROTEIN", 14, 18], ["TNF", "PROTEIN", 23, 26], ["IL", "TEST", 14, 16], ["TNF", "TEST", 23, 26], ["IL", "OBSERVATION_MODIFIER", 14, 16], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["root", "ANATOMY", 96, 100], ["not", "UNCERTAINTY", 106, 109], ["leaf", "ANATOMY", 110, 114]]], ["In contrast, the leaf but not root extract inhibited the enzymatic activity of cyclooxygenase-2.", [["leaf", "ANATOMY", 17, 21], ["root extract", "ANATOMY", 30, 42], ["leaf", "ORGAN", 17, 21], ["root extract", "ORGANISM_SUBSTANCE", 30, 42], ["cyclooxygenase-2", "GENE_OR_GENE_PRODUCT", 79, 95], ["cyclooxygenase", "PROTEIN", 79, 93], ["root extract", "PROBLEM", 30, 42], ["cyclooxygenase", "TEST", 79, 93], ["leaf", "ANATOMY", 17, 21], ["enzymatic activity", "OBSERVATION", 57, 75]]], ["The leaf but not root extract inhibited the antigen-specifi c activation of na\u00efve CD4+ T cells from OT II/Thy1.1 mice.", [["leaf", "ANATOMY", 4, 8], ["root extract", "ANATOMY", 17, 29], ["na\u00efve CD4+ T cells", "ANATOMY", 76, 94], ["leaf", "ORGAN", 4, 8], ["root extract", "ORGANISM_SUBSTANCE", 17, 29], ["specifi c", "GENE_OR_GENE_PRODUCT", 52, 61], ["CD4", "GENE_OR_GENE_PRODUCT", 82, 85], ["OT II", "GENE_OR_GENE_PRODUCT", 100, 105], ["na\u00efve CD4+ T cells", "CELL_TYPE", 76, 94], ["mice", "SPECIES", 113, 117], ["root extract", "PROBLEM", 17, 29], ["the antigen", "TEST", 40, 51], ["OT II", "TEST", 100, 105], ["leaf", "ANATOMY", 4, 8], ["not", "UNCERTAINTY", 13, 16], ["root", "OBSERVATION_MODIFIER", 17, 21]]], ["These results suggested that E. purpurea could be immunostimulatory, immunosuppressive and/or antiinfl ammatory depending on the plant part and extraction method.In-Vitro StudiesE. purpurea extracted in a solvent mixture of 95:5 ethanol/water dose-dependently inhibited interleukin IL-2 production in human Jurkat T cells (Sasagawa et al. 2006 ).", [["Jurkat T cells", "ANATOMY", 307, 321], ["ethanol", "CHEMICAL", 229, 236], ["ethanol", "CHEMICAL", 229, 236], ["E. purpurea", "ORGANISM", 29, 40], ["purpurea", "ORGANISM", 181, 189], ["ethanol", "SIMPLE_CHEMICAL", 229, 236], ["water", "SIMPLE_CHEMICAL", 237, 242], ["interleukin IL-2", "GENE_OR_GENE_PRODUCT", 270, 286], ["human", "ORGANISM", 301, 306], ["Jurkat T cells", "CELL", 307, 321], ["interleukin IL-2", "PROTEIN", 270, 286], ["human Jurkat T cells", "CELL_LINE", 301, 321], ["E. purpurea", "SPECIES", 29, 40], ["purpurea", "SPECIES", 181, 189], ["human", "SPECIES", 301, 306], ["E. purpurea", "SPECIES", 29, 40], ["purpurea", "SPECIES", 181, 189], ["human", "SPECIES", 301, 306], ["E. purpurea", "PROBLEM", 29, 40], ["immunosuppressive", "TREATMENT", 69, 86], ["antiinfl ammatory", "TREATMENT", 94, 111], ["extraction method", "TREATMENT", 144, 161], ["purpurea", "PROBLEM", 181, 189], ["a solvent mixture", "TREATMENT", 203, 220], ["ethanol/water dose", "TREATMENT", 229, 247], ["dependently inhibited interleukin IL", "PROBLEM", 248, 284]]], ["This IL-2 inhibitory activity correlated with the presence of alkylamides but not caffeic acid derivatives.", [["alkylamides", "CHEMICAL", 62, 73], ["caffeic acid", "CHEMICAL", 82, 94], ["alkylamides", "CHEMICAL", 62, 73], ["caffeic acid", "CHEMICAL", 82, 94], ["IL-2", "GENE_OR_GENE_PRODUCT", 5, 9], ["alkylamides", "SIMPLE_CHEMICAL", 62, 73], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 82, 106], ["This IL", "TREATMENT", 0, 7], ["alkylamides", "TREATMENT", 62, 73], ["caffeic acid derivatives", "TREATMENT", 82, 106]]], ["E. purpurea extract was both IL-2 suppressive and cytotoxic at 50 and 100 \u03bcg/ml.", [["E. purpurea extract", "CHEMICAL", 0, 19], ["E. purpurea", "ORGANISM", 0, 11], ["IL-2", "GENE_OR_GENE_PRODUCT", 29, 33], ["E. purpurea", "SPECIES", 0, 11], ["E. purpurea", "SPECIES", 0, 11], ["both IL", "TREATMENT", 24, 31], ["cytotoxic", "TEST", 50, 59], ["purpurea", "OBSERVATION_MODIFIER", 3, 11]]], ["Lower concentrations from 6.25 to 25 \u03bcg/ml signifi cantly decreased IL-2 production, but not cell viability.", [["cell", "ANATOMY", 93, 97], ["IL-2", "GENE_OR_GENE_PRODUCT", 68, 72], ["cell", "CELL", 93, 97], ["IL", "PROTEIN", 68, 70], ["Lower concentrations", "PROBLEM", 0, 20], ["cantly decreased IL", "PROBLEM", 51, 70], ["decreased", "OBSERVATION_MODIFIER", 58, 67], ["IL", "OBSERVATION_MODIFIER", 68, 70], ["not", "UNCERTAINTY", 89, 92], ["cell viability", "OBSERVATION", 93, 107]]], ["Alkylamides at concentrations found in a 50 \u03bcg/ml extract decreased IL-2 production by approximately 50 %, but not cell viability in a dose-dependent manner.", [["extract", "ANATOMY", 50, 57], ["cell", "ANATOMY", 115, 119], ["Alkylamides", "CHEMICAL", 0, 11], ["Alkylamides", "CHEMICAL", 0, 11], ["Alkylamides", "SIMPLE_CHEMICAL", 0, 11], ["IL-2", "GENE_OR_GENE_PRODUCT", 68, 72], ["cell", "CELL", 115, 119], ["IL", "PROTEIN", 68, 70], ["Alkylamides", "TREATMENT", 0, 11], ["decreased IL", "PROBLEM", 58, 70], ["decreased", "OBSERVATION_MODIFIER", 58, 67], ["IL", "OBSERVATION_MODIFIER", 68, 70], ["not", "UNCERTAINTY", 111, 114], ["cell viability", "OBSERVATION", 115, 129]]], ["Echinacea and several of its phytochemical components were found to have opposing effects on NF\u03baB expression by Jurkat cells (a human T-cell line) (Matthias et al. 2008 ).", [["Jurkat cells", "ANATOMY", 112, 124], ["T-cell line", "ANATOMY", 134, 145], ["Echinacea", "CHEMICAL", 0, 9], ["Echinacea", "ORGANISM", 0, 9], ["NF\u03ba", "GENE_OR_GENE_PRODUCT", 93, 96], ["B", "GENE_OR_GENE_PRODUCT", 96, 97], ["Jurkat cells", "CELL", 112, 124], ["human", "ORGANISM", 128, 133], ["T-cell line", "CELL", 134, 145], ["NF\u03ba", "PROTEIN", 93, 96], ["Jurkat cells", "CELL_LINE", 112, 124], ["human T-cell line", "CELL_LINE", 128, 145], ["Echinacea", "SPECIES", 0, 9], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["Echinacea", "TREATMENT", 0, 9], ["a human T-cell line", "TREATMENT", 126, 145], ["Jurkat cells", "OBSERVATION", 112, 124]]], ["In the absence of stimulation, Echinacea and its components exerted no signifi cant effect on basal NF\u03baB expression levels.", [["Echinacea", "CHEMICAL", 31, 40], ["Echinacea", "ORGANISM", 31, 40], ["NF\u03ba", "GENE_OR_GENE_PRODUCT", 100, 103], ["B", "GENE_OR_GENE_PRODUCT", 103, 104], ["NF\u03ba", "PROTEIN", 100, 103], ["Echinacea", "TREATMENT", 31, 40], ["signifi cant effect", "PROBLEM", 71, 90], ["B expression levels", "TEST", 103, 122]]], ["In the presence of endotoxin (LPS), NF\u03baB expression was decreased.", [["endotoxin", "CHEMICAL", 19, 28], ["LPS", "CHEMICAL", 30, 33], ["endotoxin", "SIMPLE_CHEMICAL", 19, 28], ["LPS", "SIMPLE_CHEMICAL", 30, 33], ["NF\u03baB", "GENE_OR_GENE_PRODUCT", 36, 40], ["NF\u03baB", "PROTEIN", 36, 40], ["endotoxin (LPS", "TREATMENT", 19, 33], ["NF\u03baB expression", "TREATMENT", 36, 51], ["endotoxin", "OBSERVATION", 19, 28], ["decreased", "OBSERVATION_MODIFIER", 56, 65]]], ["However, this decrease was signifi cantly reversed by treatment with cichoric acid, an Echinacea root extract (prepared from both Echinacea angustifolia and Echinacea purpurea ) and the alkylamide fraction derived from this combination.", [["root extract", "ANATOMY", 97, 109], ["cichoric acid", "CHEMICAL", 69, 82], ["Echinacea root extract", "CHEMICAL", 87, 109], ["Echinacea angustifolia and Echinacea purpurea", "CHEMICAL", 130, 175], ["alkylamide", "CHEMICAL", 186, 196], ["cichoric acid", "CHEMICAL", 69, 82], ["alkylamide", "CHEMICAL", 186, 196], ["cichoric acid", "SIMPLE_CHEMICAL", 69, 82], ["Echinacea", "ORGANISM", 87, 96], ["Echinacea angustifolia", "ORGANISM", 130, 152], ["Echinacea purpurea", "ORGANISM", 157, 175], ["alkylamide", "SIMPLE_CHEMICAL", 186, 196], ["Echinacea", "SPECIES", 87, 96], ["Echinacea angustifolia", "SPECIES", 130, 152], ["Echinacea purpurea", "SPECIES", 157, 175], ["Echinacea angustifolia", "SPECIES", 130, 152], ["Echinacea purpurea", "SPECIES", 157, 175], ["cichoric acid", "TREATMENT", 69, 82], ["an Echinacea root extract", "PROBLEM", 84, 109], ["both Echinacea angustifolia", "TREATMENT", 125, 152], ["Echinacea purpurea", "TREATMENT", 157, 175], ["the alkylamide fraction", "TREATMENT", 182, 205], ["Echinacea root", "OBSERVATION", 87, 101]]], ["For the phorbol myristate acetate stimulation of Jurkat cells, effects on NF\u03baB expression were mixed.", [["Jurkat cells", "ANATOMY", 49, 61], ["phorbol myristate acetate", "CHEMICAL", 8, 33], ["phorbol myristate acetate", "CHEMICAL", 8, 33], ["phorbol myristate acetate", "SIMPLE_CHEMICAL", 8, 33], ["Jurkat cells", "CELL", 49, 61], ["NF\u03ba", "GENE_OR_GENE_PRODUCT", 74, 77], ["B", "GENE_OR_GENE_PRODUCT", 77, 78], ["Jurkat cells", "CELL_LINE", 49, 61], ["NF\u03ba", "PROTEIN", 74, 77], ["the phorbol myristate acetate stimulation of Jurkat cells", "TREATMENT", 4, 61], ["Jurkat cells", "OBSERVATION", 49, 61], ["mixed", "OBSERVATION_MODIFIER", 95, 100]]], ["Depending on the concentration, cichoric acid and a 2,4-diene alkylamide significantly induced NF\u03baB levels, whereas a 2-ene alkylamide caused a signifi cant inhibition.", [["cichoric acid", "CHEMICAL", 32, 45], ["2,4-diene", "CHEMICAL", 52, 61], ["alkylamide", "CHEMICAL", 62, 72], ["2-ene alkylamide", "CHEMICAL", 118, 134], ["cichoric acid", "CHEMICAL", 32, 45], ["2,4-diene alkylamide", "CHEMICAL", 52, 72], ["2-ene alkylamide", "CHEMICAL", 118, 134], ["cichoric acid", "SIMPLE_CHEMICAL", 32, 45], ["2,4-diene alkylamide", "SIMPLE_CHEMICAL", 52, 72], ["NF\u03ba", "GENE_OR_GENE_PRODUCT", 95, 98], ["B", "GENE_OR_GENE_PRODUCT", 98, 99], ["2-ene alkylamide", "SIMPLE_CHEMICAL", 118, 134], ["NF\u03ba", "PROTEIN", 95, 98], ["the concentration", "TEST", 13, 30], ["cichoric acid", "TEST", 32, 45], ["a 2,4-diene alkylamide", "TREATMENT", 50, 72], ["B levels", "TEST", 98, 106], ["a 2-ene alkylamide", "TREATMENT", 116, 134], ["a signifi cant inhibition", "TREATMENT", 142, 167]]], ["In contrast, both the Echinacea and the mixed alkylamide fraction exerted no effect.", [["Echinacea", "CHEMICAL", 22, 31], ["alkylamide", "CHEMICAL", 46, 56], ["alkylamide", "CHEMICAL", 46, 56], ["Echinacea", "ORGANISM", 22, 31], ["alkylamide", "SIMPLE_CHEMICAL", 46, 56], ["Echinacea", "SPECIES", 22, 31], ["the mixed alkylamide fraction", "TREATMENT", 36, 65], ["Echinacea", "OBSERVATION_MODIFIER", 22, 31], ["no", "UNCERTAINTY", 74, 76], ["effect", "OBSERVATION_MODIFIER", 77, 83]]], ["Pugh et al. ( 2012 ) found that differences in total bacterial load within Echinacea purpurea samples were strongly correlated with in-vitro macrophage activity (NF-\u03baB activation in THP-1 cells) and content of bacterial lipopolysaccharides in the extracts.", [["samples", "ANATOMY", 94, 101], ["macrophage", "ANATOMY", 141, 151], ["THP-1 cells", "ANATOMY", 182, 193], ["extracts", "ANATOMY", 247, 255], ["Echinacea purpurea", "ORGANISM", 75, 93], ["macrophage", "CELL", 141, 151], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 162, 167], ["THP-1 cells", "CELL", 182, 193], ["lipopolysaccharides", "SIMPLE_CHEMICAL", 220, 239], ["extracts", "ORGANISM_SUBSTANCE", 247, 255], ["NF-\u03baB", "PROTEIN", 162, 167], ["THP-1 cells", "CELL_LINE", 182, 193], ["Echinacea purpurea", "SPECIES", 75, 93], ["Echinacea purpurea", "SPECIES", 75, 93], ["total bacterial load", "PROBLEM", 47, 67], ["Echinacea purpurea samples", "TEST", 75, 101], ["NF", "TEST", 162, 164], ["bacterial lipopolysaccharides in the extracts", "PROBLEM", 210, 255], ["bacterial load", "OBSERVATION", 53, 67], ["macrophage activity", "OBSERVATION", 141, 160], ["bacterial lipopolysaccharides", "OBSERVATION", 210, 239]]], ["The results added to the growing body of evidence that bacteria within Echinacea were the main source of components responsible for enhancing innate immune function.Animal StudiesPolysaccharides purifi ed from large-scale Echinacea purpurea plant cell cultures were found to activate human phagocytes in vitro and in vivo and to induce acute-phase C reactions (Roesler et al. 1991b ).", [["cell cultures", "ANATOMY", 247, 260], ["phagocytes", "ANATOMY", 290, 300], ["Echinacea", "CHEMICAL", 71, 80], ["Echinacea", "ORGANISM", 71, 80], ["Echinacea", "ORGANISM", 222, 231], ["purpurea", "ORGANISM", 232, 240], ["cell cultures", "CELL", 247, 260], ["human", "ORGANISM", 284, 289], ["phagocytes", "CELL", 290, 300], ["Echinacea purpurea plant cell cultures", "CELL_LINE", 222, 260], ["human phagocytes", "CELL_TYPE", 284, 300], ["Echinacea", "SPECIES", 71, 80], ["Echinacea purpurea", "SPECIES", 222, 240], ["human", "SPECIES", 284, 289], ["Echinacea purpurea", "SPECIES", 222, 240], ["human", "SPECIES", 284, 289], ["bacteria within Echinacea", "PROBLEM", 55, 80], ["Animal Studies", "TEST", 165, 179], ["Polysaccharides", "TEST", 179, 194], ["Echinacea purpurea plant cell cultures", "TEST", 222, 260], ["human phagocytes", "TEST", 284, 300], ["acute-phase C reactions", "PROBLEM", 336, 359], ["bacteria", "OBSERVATION", 55, 63], ["immune function", "OBSERVATION", 149, 164], ["large", "OBSERVATION_MODIFIER", 210, 215], ["acute", "OBSERVATION_MODIFIER", 336, 341]]], ["These substances enhanced the spontaneous motility of polymorphonuclear leukocytes (PMN) under soft agar and increased the ability of these cells to kill staphylococci.", [["polymorphonuclear leukocytes", "ANATOMY", 54, 82], ["PMN", "ANATOMY", 84, 87], ["cells", "ANATOMY", 140, 145], ["staphylococci", "ANATOMY", 154, 167], ["staphylococci", "DISEASE", 154, 167], ["polymorphonuclear leukocytes", "CELL", 54, 82], ["PMN", "CELL", 84, 87], ["cells", "CELL", 140, 145], ["staphylococci", "CELL", 154, 167], ["polymorphonuclear leukocytes", "CELL_TYPE", 54, 82], ["PMN", "CELL_TYPE", 84, 87], ["polymorphonuclear leukocytes", "PROBLEM", 54, 82], ["soft agar", "TEST", 95, 104], ["kill staphylococci", "PROBLEM", 149, 167], ["spontaneous", "OBSERVATION_MODIFIER", 30, 41], ["motility", "OBSERVATION_MODIFIER", 42, 50], ["polymorphonuclear leukocytes", "OBSERVATION", 54, 82], ["soft agar", "OBSERVATION_MODIFIER", 95, 104]]], ["Monocytes were activated to secrete tumour necrosis factor alpha (TNF-\u03b1) and interleukins IL-6 and IL-1, whereas class II expression was unaffected.", [["Monocytes", "ANATOMY", 0, 9], ["necrosis", "DISEASE", 43, 51], ["Monocytes", "CELL", 0, 9], ["tumour necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 36, 64], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 66, 71], ["IL-6", "GENE_OR_GENE_PRODUCT", 90, 94], ["IL-1", "GENE_OR_GENE_PRODUCT", 99, 103], ["class II", "GENE_OR_GENE_PRODUCT", 113, 121], ["Monocytes", "CELL_TYPE", 0, 9], ["tumour necrosis factor alpha", "PROTEIN", 36, 64], ["TNF", "PROTEIN", 66, 69], ["interleukins", "PROTEIN", 77, 89], ["IL", "PROTEIN", 99, 101], ["Monocytes", "TEST", 0, 9], ["secrete tumour necrosis", "PROBLEM", 28, 51], ["alpha", "TEST", 59, 64], ["TNF", "TEST", 66, 69], ["interleukins IL", "TEST", 77, 92], ["IL", "TEST", 99, 101], ["secrete", "OBSERVATION_MODIFIER", 28, 35], ["tumour", "OBSERVATION_MODIFIER", 36, 42], ["necrosis", "OBSERVATION_MODIFIER", 43, 51]]], ["Intravenous application of the polysaccharides to test subjects immediately induced a fall in the number of PMN in the peripheral blood, indicating activation of adherence to endothelial cells.", [["PMN", "ANATOMY", 108, 111], ["peripheral blood", "ANATOMY", 119, 135], ["endothelial cells", "ANATOMY", 175, 192], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["PMN", "CELL", 108, 111], ["peripheral blood", "ORGANISM_SUBSTANCE", 119, 135], ["endothelial cells", "CELL", 175, 192], ["PMN", "CELL_TYPE", 108, 111], ["endothelial cells", "CELL_TYPE", 175, 192], ["the polysaccharides", "TREATMENT", 27, 46], ["a fall", "PROBLEM", 84, 90], ["endothelial cells", "PROBLEM", 175, 192], ["fall", "OBSERVATION", 86, 90], ["peripheral", "ANATOMY_MODIFIER", 119, 129], ["blood", "ANATOMY", 130, 135], ["endothelial cells", "OBSERVATION", 175, 192]]], ["This decline was followed by a leukocytosis due to an increase in the number of PMN and a lesser increase of monocytes.", [["PMN", "ANATOMY", 80, 83], ["monocytes", "ANATOMY", 109, 118], ["leukocytosis", "DISEASE", 31, 43], ["PMN", "CELL", 80, 83], ["monocytes", "CELL", 109, 118], ["PMN", "CELL_TYPE", 80, 83], ["monocytes", "CELL_TYPE", 109, 118], ["a leukocytosis", "PROBLEM", 29, 43], ["an increase in the number of PMN", "PROBLEM", 51, 83], ["a lesser increase of monocytes", "PROBLEM", 88, 118], ["leukocytosis", "OBSERVATION", 31, 43], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["lesser", "OBSERVATION_MODIFIER", 90, 96], ["increase", "OBSERVATION_MODIFIER", 97, 105], ["monocytes", "OBSERVATION", 109, 118]]], ["The acute-phase C-reactive protein (CRP) was induced, probably due to activation of monocytes and macrophages to produce IL-6.", [["monocytes", "ANATOMY", 84, 93], ["macrophages", "ANATOMY", 98, 109], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 16, 34], ["CRP", "GENE_OR_GENE_PRODUCT", 36, 39], ["monocytes", "CELL", 84, 93], ["macrophages", "CELL", 98, 109], ["IL-6", "GENE_OR_GENE_PRODUCT", 121, 125], ["acute-phase C-reactive protein", "PROTEIN", 4, 34], ["CRP", "PROTEIN", 36, 39], ["monocytes", "CELL_TYPE", 84, 93], ["macrophages", "CELL_TYPE", 98, 109], ["IL-6", "PROTEIN", 121, 125], ["The acute-phase C", "TEST", 0, 17], ["CRP", "TEST", 36, 39], ["activation of monocytes", "PROBLEM", 70, 93], ["macrophages", "PROBLEM", 98, 109], ["IL", "TEST", 121, 123], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["reactive protein", "OBSERVATION", 18, 34], ["probably due to", "UNCERTAINTY", 54, 69]]], ["Subsequent in-vivo studies found that the purifi ed polysaccharides (EP) from Echinacea purpurea plant cell cultures enhanced mice phagocytes' activities thus protecting against systemic infections with Listeria monocytogenes and Candida albicans (Roesler et al. 1991a ) .", [["cell cultures", "ANATOMY", 103, 116], ["phagocytes", "ANATOMY", 131, 141], ["EP", "CHEMICAL", 69, 71], ["systemic infections", "DISEASE", 178, 197], ["purifi ed polysaccharides", "SIMPLE_CHEMICAL", 42, 67], ["EP", "SIMPLE_CHEMICAL", 69, 71], ["Echinacea purpurea", "ORGANISM", 78, 96], ["cell cultures", "CELL", 103, 116], ["mice", "ORGANISM", 126, 130], ["phagocytes", "CELL", 131, 141], ["Listeria monocytogenes", "ORGANISM", 203, 225], ["Candida albicans", "ORGANISM", 230, 246], ["Echinacea purpurea plant cell cultures", "CELL_LINE", 78, 116], ["Echinacea purpurea", "SPECIES", 78, 96], ["mice", "SPECIES", 126, 130], ["Listeria monocytogenes", "SPECIES", 203, 225], ["Candida albicans", "SPECIES", 230, 246], ["Echinacea purpurea", "SPECIES", 78, 96], ["mice", "SPECIES", 126, 130], ["Listeria monocytogenes", "SPECIES", 203, 225], ["Candida albicans", "SPECIES", 230, 246], ["vivo studies", "TEST", 14, 26], ["the purifi ed polysaccharides", "PROBLEM", 38, 67], ["Echinacea purpurea plant cell cultures", "TEST", 78, 116], ["mice phagocytes' activities", "PROBLEM", 126, 153], ["systemic infections", "PROBLEM", 178, 197], ["Listeria monocytogenes", "PROBLEM", 203, 225], ["Candida albicans", "PROBLEM", 230, 246], ["Listeria monocytogenes", "OBSERVATION", 203, 225]]], ["They confi rmed their hypothesis that macrophages (M\u03c6) from different organ origin could be activated to produce IL-1, TNF\u03b1 and IL-6 to produce elevated amounts of reactive oxygen intermediates and to inhibit growth of Candida albicans in-vitro and that in-vivo the substances could induce increased proliferation of phagocytes in spleen and bone marrow and migration of granulocytes to the peripheral blood.", [["macrophages", "ANATOMY", 38, 49], ["M\u03c6", "ANATOMY", 51, 53], ["organ", "ANATOMY", 70, 75], ["phagocytes", "ANATOMY", 317, 327], ["spleen", "ANATOMY", 331, 337], ["bone marrow", "ANATOMY", 342, 353], ["granulocytes", "ANATOMY", 371, 383], ["peripheral blood", "ANATOMY", 391, 407], ["oxygen", "CHEMICAL", 173, 179], ["oxygen", "CHEMICAL", 173, 179], ["macrophages", "CELL", 38, 49], ["M\u03c6", "CELL", 51, 53], ["organ", "ORGAN", 70, 75], ["IL-1", "GENE_OR_GENE_PRODUCT", 113, 117], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 119, 123], ["IL-6", "GENE_OR_GENE_PRODUCT", 128, 132], ["reactive oxygen intermediates", "SIMPLE_CHEMICAL", 164, 193], ["Candida albicans", "ORGANISM", 219, 235], ["phagocytes", "CELL", 317, 327], ["spleen", "ORGAN", 331, 337], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 342, 353], ["granulocytes", "CELL", 371, 383], ["peripheral blood", "ORGANISM_SUBSTANCE", 391, 407], ["macrophages", "CELL_TYPE", 38, 49], ["M\u03c6", "CELL_TYPE", 51, 53], ["IL-1", "PROTEIN", 113, 117], ["TNF\u03b1", "PROTEIN", 119, 123], ["IL-6", "PROTEIN", 128, 132], ["phagocytes", "CELL_TYPE", 317, 327], ["granulocytes", "CELL_TYPE", 371, 383], ["Candida albicans", "SPECIES", 219, 235], ["Candida albicans", "SPECIES", 219, 235], ["IL", "TEST", 113, 115], ["TNF", "TEST", 119, 122], ["IL", "TEST", 128, 130], ["elevated amounts of reactive oxygen intermediates", "PROBLEM", 144, 193], ["Candida albicans", "PROBLEM", 219, 235], ["increased proliferation of phagocytes in spleen and bone marrow", "PROBLEM", 290, 353], ["migration of granulocytes", "PROBLEM", 358, 383], ["the peripheral blood", "TEST", 387, 407], ["macrophages", "OBSERVATION", 38, 49], ["reactive oxygen intermediates", "OBSERVATION", 164, 193], ["increased", "OBSERVATION_MODIFIER", 290, 299], ["proliferation", "OBSERVATION", 300, 313], ["phagocytes", "OBSERVATION_MODIFIER", 317, 327], ["spleen", "ANATOMY", 331, 337], ["bone marrow", "ANATOMY", 342, 353], ["peripheral", "ANATOMY_MODIFIER", 391, 401], ["blood", "ANATOMY", 402, 407]]], ["In a subsequent study, EP was found effective in activating peritoneal macrophages isolated from animals after administration of cyclophosphamide (CP) or cyclosporin A (CsA) (Steinm\u00fcller et al. 1993 ) .", [["peritoneal macrophages", "ANATOMY", 60, 82], ["EP", "CHEMICAL", 23, 25], ["cyclophosphamide", "CHEMICAL", 129, 145], ["CP", "CHEMICAL", 147, 149], ["cyclosporin A", "CHEMICAL", 154, 167], ["CsA", "CHEMICAL", 169, 172], ["cyclophosphamide", "CHEMICAL", 129, 145], ["cyclosporin A", "CHEMICAL", 154, 167], ["CsA", "CHEMICAL", 169, 172], ["peritoneal macrophages", "CELL", 60, 82], ["cyclophosphamide", "SIMPLE_CHEMICAL", 129, 145], ["CP", "SIMPLE_CHEMICAL", 147, 149], ["cyclosporin A", "SIMPLE_CHEMICAL", 154, 167], ["CsA", "SIMPLE_CHEMICAL", 169, 172], ["peritoneal macrophages", "CELL_TYPE", 60, 82], ["a subsequent study", "TEST", 3, 21], ["EP", "TEST", 23, 25], ["activating peritoneal macrophages", "PROBLEM", 49, 82], ["cyclophosphamide", "TREATMENT", 129, 145], ["CP", "PROBLEM", 147, 149], ["cyclosporin", "TREATMENT", 154, 165], ["peritoneal", "ANATOMY", 60, 70], ["macrophages", "OBSERVATION", 71, 82]]], ["EP-treated macrophages exhibited increased production of tumour necrosis factor-alpha (TNF) and enhanced cytotoxicity against tumour target WEHI 164 as well as against the intracellular parasite Leishmania enrietti .", [["macrophages", "ANATOMY", 11, 22], ["tumour", "ANATOMY", 126, 132], ["intracellular", "ANATOMY", 172, 185], ["EP", "CHEMICAL", 0, 2], ["necrosis", "DISEASE", 64, 72], ["tumour", "DISEASE", 126, 132], ["WEHI 164", "CHEMICAL", 140, 148], ["EP", "SIMPLE_CHEMICAL", 0, 2], ["macrophages", "CELL", 11, 22], ["tumour necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 57, 85], ["TNF", "GENE_OR_GENE_PRODUCT", 87, 90], ["tumour", "CANCER", 126, 132], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 172, 185], ["Leishmania enrietti", "ORGANISM", 195, 214], ["EP-treated macrophages", "CELL_LINE", 0, 22], ["tumour necrosis factor-alpha", "PROTEIN", 57, 85], ["TNF", "PROTEIN", 87, 90], ["Leishmania enrietti", "SPECIES", 195, 214], ["Leishmania enrietti", "SPECIES", 195, 214], ["EP", "TEST", 0, 2], ["macrophages", "PROBLEM", 11, 22], ["tumour necrosis factor", "PROBLEM", 57, 79], ["alpha (TNF)", "PROBLEM", 80, 91], ["enhanced cytotoxicity", "PROBLEM", 96, 117], ["tumour target WEHI", "TEST", 126, 144], ["the intracellular parasite Leishmania enrietti", "PROBLEM", 168, 214], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["production", "OBSERVATION_MODIFIER", 43, 53], ["tumour necrosis", "OBSERVATION", 57, 72], ["parasite", "OBSERVATION_MODIFIER", 186, 194], ["Leishmania enrietti", "OBSERVATION", 195, 214]]], ["After a CP-mediated reduction of leukocytes in the peripheral blood, the polysaccharides induced an earlier infl ux of neutrophil granulocytes as compared to PBS (phosphate buffer saline)-treated controls.", [["leukocytes", "ANATOMY", 33, 43], ["peripheral blood", "ANATOMY", 51, 67], ["neutrophil granulocytes", "ANATOMY", 119, 142], ["CP", "CHEMICAL", 8, 10], ["phosphate", "CHEMICAL", 163, 172], ["phosphate", "CHEMICAL", 163, 172], ["leukocytes", "CELL", 33, 43], ["peripheral blood", "ORGANISM_SUBSTANCE", 51, 67], ["polysaccharides", "SIMPLE_CHEMICAL", 73, 88], ["neutrophil granulocytes", "CELL", 119, 142], ["phosphate buffer saline", "SIMPLE_CHEMICAL", 163, 186], ["leukocytes", "CELL_TYPE", 33, 43], ["neutrophil granulocytes", "CELL_TYPE", 119, 142], ["leukocytes in the peripheral blood", "PROBLEM", 33, 67], ["the polysaccharides", "TEST", 69, 88], ["neutrophil granulocytes", "PROBLEM", 119, 142], ["PBS (phosphate buffer saline)", "TREATMENT", 158, 187], ["leukocytes", "OBSERVATION", 33, 43], ["peripheral", "ANATOMY_MODIFIER", 51, 61], ["blood", "ANATOMY", 62, 67], ["neutrophil granulocytes", "OBSERVATION", 119, 142]]], ["EP treatment of mice, immunosuppressed with CP or CsA, restored their resistance against lethal infections with the predominantly macrophage-dependent pathogen Listeria monocytogenes and predominantly granulocyte-dependent Candida albicans .Animal StudiesThe results of studies suggested that oral gavage with Echinacea preparations containing optimal concentrations of cichoric acid, polysaccharides and alkylamides were potentially effective in stimulating an in-vivo, nonspecifi c immune response in normal male Sprague-Dawley rats (Goel et al. 2002a , b ) .", [["oral", "ANATOMY", 293, 297], ["EP", "CHEMICAL", 0, 2], ["CP", "CHEMICAL", 44, 46], ["CsA", "CHEMICAL", 50, 53], ["infections", "DISEASE", 96, 106], ["Echinacea", "CHEMICAL", 310, 319], ["cichoric acid", "CHEMICAL", 370, 383], ["alkylamides", "CHEMICAL", 405, 416], ["CsA", "CHEMICAL", 50, 53], ["cichoric acid", "CHEMICAL", 370, 383], ["alkylamides", "CHEMICAL", 405, 416], ["EP", "SIMPLE_CHEMICAL", 0, 2], ["mice", "ORGANISM", 16, 20], ["CP", "SIMPLE_CHEMICAL", 44, 46], ["CsA", "SIMPLE_CHEMICAL", 50, 53], ["macrophage", "CELL", 130, 140], ["pathogen", "ORGANISM", 151, 159], ["Listeria monocytogenes", "ORGANISM", 160, 182], ["granulocyte", "CELL", 201, 212], ["Candida albicans", "ORGANISM", 223, 239], ["oral", "ORGANISM_SUBDIVISION", 293, 297], ["Echinacea", "ORGANISM", 310, 319], ["cichoric acid", "SIMPLE_CHEMICAL", 370, 383], ["polysaccharides", "SIMPLE_CHEMICAL", 385, 400], ["alkylamides", "SIMPLE_CHEMICAL", 405, 416], ["Sprague-Dawley rats", "ORGANISM", 515, 534], ["mice", "SPECIES", 16, 20], ["Listeria monocytogenes", "SPECIES", 160, 182], ["Candida albicans", "SPECIES", 223, 239], ["Sprague-Dawley rats", "SPECIES", 515, 534], ["mice", "SPECIES", 16, 20], ["Listeria monocytogenes", "SPECIES", 160, 182], ["Candida albicans", "SPECIES", 223, 239], ["Sprague-Dawley rats", "SPECIES", 515, 534], ["EP treatment", "TREATMENT", 0, 12], ["immunosuppressed", "PROBLEM", 22, 38], ["CP", "PROBLEM", 44, 46], ["CsA", "PROBLEM", 50, 53], ["lethal infections", "PROBLEM", 89, 106], ["dependent pathogen Listeria monocytogenes", "PROBLEM", 141, 182], ["dependent Candida albicans", "PROBLEM", 213, 239], ["Animal Studies", "TEST", 241, 255], ["studies", "TEST", 270, 277], ["oral gavage", "TREATMENT", 293, 304], ["Echinacea preparations", "TREATMENT", 310, 332], ["cichoric acid", "TREATMENT", 370, 383], ["polysaccharides", "TREATMENT", 385, 400], ["alkylamides", "TREATMENT", 405, 416], ["predominantly", "OBSERVATION_MODIFIER", 116, 129], ["macrophage", "OBSERVATION_MODIFIER", 130, 140], ["dependent", "OBSERVATION_MODIFIER", 141, 150], ["pathogen Listeria monocytogenes", "OBSERVATION", 151, 182], ["predominantly", "OBSERVATION_MODIFIER", 187, 200], ["granulocyte", "OBSERVATION", 201, 212], ["dependent", "OBSERVATION_MODIFIER", 213, 222], ["Candida albicans", "OBSERVATION", 223, 239]]], ["Among the components the alkylamides at the dose level of 12 \u03bcg/kg body weight/day signifi cantly increased the phagocytic activity as well as phagocytic index of the alveolar macrophages.", [["body", "ANATOMY", 67, 71], ["alveolar macrophages", "ANATOMY", 167, 187], ["alkylamides", "CHEMICAL", 25, 36], ["alkylamides", "CHEMICAL", 25, 36], ["alkylamides", "SIMPLE_CHEMICAL", 25, 36], ["body", "ORGANISM_SUBDIVISION", 67, 71], ["alveolar macrophages", "CELL", 167, 187], ["alveolar macrophages", "CELL_TYPE", 167, 187], ["the alkylamides", "TREATMENT", 21, 36], ["body weight", "TEST", 67, 78], ["the phagocytic activity", "TEST", 108, 131], ["phagocytic index", "TEST", 143, 159], ["phagocytic activity", "OBSERVATION", 112, 131], ["phagocytic index", "OBSERVATION", 143, 159], ["alveolar macrophages", "OBSERVATION", 167, 187]]], ["The alveolar macrophages obtained from this alkylamide-administered group also produced signifi cantly more TNF-\u03b1 and nitric oxide after an in-vitro stimulation with LPS than any other active component or the control.", [["alveolar macrophages", "ANATOMY", 4, 24], ["alkylamide", "CHEMICAL", 44, 54], ["nitric oxide", "CHEMICAL", 118, 130], ["LPS", "CHEMICAL", 166, 169], ["alkylamide", "CHEMICAL", 44, 54], ["nitric oxide", "CHEMICAL", 118, 130], ["alveolar macrophages", "CELL", 4, 24], ["alkylamide", "SIMPLE_CHEMICAL", 44, 54], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 108, 113], ["nitric oxide", "SIMPLE_CHEMICAL", 118, 130], ["LPS", "SIMPLE_CHEMICAL", 166, 169], ["alveolar macrophages", "CELL_TYPE", 4, 24], ["TNF", "PROTEIN", 108, 111], ["The alveolar macrophages", "PROBLEM", 0, 24], ["this alkylamide", "TREATMENT", 39, 54], ["TNF", "TREATMENT", 108, 111], ["nitric oxide", "TREATMENT", 118, 130], ["an in-vitro stimulation", "TREATMENT", 137, 160], ["LPS", "TREATMENT", 166, 169], ["alveolar macrophages", "OBSERVATION", 4, 24]]], ["The immunomodulatory effects of alkylamides appeared to be more pronounced in lungs than in spleen.", [["lungs", "ANATOMY", 78, 83], ["spleen", "ANATOMY", 92, 98], ["alkylamides", "CHEMICAL", 32, 43], ["alkylamides", "CHEMICAL", 32, 43], ["alkylamides", "SIMPLE_CHEMICAL", 32, 43], ["lungs", "ORGAN", 78, 83], ["spleen", "ORGAN", 92, 98], ["The immunomodulatory effects of alkylamides", "PROBLEM", 0, 43], ["immunomodulatory", "OBSERVATION_MODIFIER", 4, 20], ["more pronounced", "OBSERVATION_MODIFIER", 59, 74], ["lungs", "ANATOMY", 78, 83], ["spleen", "ANATOMY", 92, 98]]], ["Studies demonstrated Echinacea purpurea extracts to be potent activators of natural killer (NK) cells cytotoxicity (Gan et al. 2003 ) .", [["extracts", "ANATOMY", 40, 48], ["natural killer (NK) cells", "ANATOMY", 76, 101], ["Echinacea purpurea", "ORGANISM", 21, 39], ["extracts", "ORGANISM_SUBSTANCE", 40, 48], ["natural killer (NK) cells", "CELL", 76, 101], ["natural killer (NK) cells", "CELL_TYPE", 76, 101], ["Echinacea purpurea", "SPECIES", 21, 39], ["Echinacea purpurea", "SPECIES", 21, 39], ["Studies", "TEST", 0, 7], ["Echinacea purpurea extracts", "PROBLEM", 21, 48], ["cytotoxicity", "TEST", 102, 114], ["Echinacea purpurea", "OBSERVATION", 21, 39], ["natural killer", "OBSERVATION", 76, 90]]], ["NK cytotoxicity was augmented 100 % at the concentration of 0.1 \u03bcg/ml of Echinacea in a short time (4-hour) assay.", [["NK", "ANATOMY", 0, 2], ["Echinacea", "CHEMICAL", 73, 82], ["NK", "CELL", 0, 2], ["Echinacea", "ORGANISM", 73, 82], ["NK cytotoxicity", "TREATMENT", 0, 15], ["Echinacea", "TREATMENT", 73, 82]]], ["Echinacea augmented the frequency of NK target conjugates and activated the programming for lysis of NK cells.", [["NK", "ANATOMY", 37, 39], ["NK cells", "ANATOMY", 101, 109], ["Echinacea", "CHEMICAL", 0, 9], ["Echinacea", "ORGANISM", 0, 9], ["NK", "CELL", 37, 39], ["NK cells", "CELL", 101, 109], ["NK cells", "CELL_TYPE", 101, 109], ["Echinacea", "SPECIES", 0, 9], ["Echinacea", "TREATMENT", 0, 9], ["NK target conjugates", "TREATMENT", 37, 57], ["lysis of NK cells", "TREATMENT", 92, 109], ["NK cells", "OBSERVATION", 101, 109]]], ["In another study, dietary administration of E. purpurea (14 days) to aging, normal mice or thyroxin injection revealed that E. purpurea , but not thyroxin, had the capacity to increase natural killer (NK) cell numbers, in aging mice, refl ecting increased new NK cell production in their bone marrow generation site, leading to an increase in the absolute numbers of NK cells in the spleen, their primary destiny (Currier and Miller 2009 ) .", [["natural killer (NK) cell", "ANATOMY", 185, 209], ["NK cell", "ANATOMY", 260, 267], ["bone marrow", "ANATOMY", 288, 299], ["NK cells", "ANATOMY", 367, 375], ["spleen", "ANATOMY", 383, 389], ["thyroxin", "CHEMICAL", 91, 99], ["thyroxin", "CHEMICAL", 146, 154], ["thyroxin", "CHEMICAL", 91, 99], ["thyroxin", "CHEMICAL", 146, 154], ["E. purpurea", "ORGANISM", 44, 55], ["mice", "ORGANISM", 83, 87], ["thyroxin", "SIMPLE_CHEMICAL", 91, 99], ["E. purpurea", "ORGANISM", 124, 135], ["thyroxin", "SIMPLE_CHEMICAL", 146, 154], ["natural killer (NK) cell", "CELL", 185, 209], ["mice", "ORGANISM", 228, 232], ["NK cell", "CELL", 260, 267], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 288, 299], ["NK cells", "CELL", 367, 375], ["spleen", "ORGAN", 383, 389], ["natural killer (NK) cell", "CELL_TYPE", 185, 209], ["NK cells", "CELL_TYPE", 367, 375], ["E. purpurea", "SPECIES", 44, 55], ["mice", "SPECIES", 83, 87], ["E. purpurea", "SPECIES", 124, 135], ["mice", "SPECIES", 228, 232], ["E. purpurea", "SPECIES", 44, 55], ["mice", "SPECIES", 83, 87], ["E. purpurea", "SPECIES", 124, 135], ["mice", "SPECIES", 228, 232], ["another study", "TEST", 3, 16], ["E. purpurea", "PROBLEM", 44, 55], ["thyroxin injection", "TREATMENT", 91, 109], ["E. purpurea", "PROBLEM", 124, 135], ["thyroxin", "TREATMENT", 146, 154], ["the capacity", "PROBLEM", 160, 172], ["cell numbers", "TEST", 205, 217], ["increased new NK cell production", "PROBLEM", 246, 278], ["an increase", "PROBLEM", 328, 339], ["E. purpurea", "OBSERVATION_MODIFIER", 124, 135], ["increased", "OBSERVATION_MODIFIER", 246, 255], ["new", "OBSERVATION_MODIFIER", 256, 259], ["NK cell production", "OBSERVATION", 260, 278], ["bone", "ANATOMY", 288, 292], ["marrow", "OBSERVATION", 293, 299], ["increase", "OBSERVATION_MODIFIER", 331, 339], ["absolute", "OBSERVATION_MODIFIER", 347, 355], ["numbers", "OBSERVATION_MODIFIER", 356, 363], ["NK cells", "OBSERVATION", 367, 375], ["spleen", "ANATOMY", 383, 389]]], ["The E. purpurea -mediated increase in NK cell numbers was also paralleled by an increase in their antitumour, cytolytic functional capacity.", [["NK cell", "ANATOMY", 38, 45], ["antitumour", "ANATOMY", 98, 108], ["E. purpurea", "ORGANISM", 4, 15], ["NK cell", "CELL", 38, 45], ["antitumour", "CANCER", 98, 108], ["E. purpurea", "SPECIES", 4, 15], ["E. purpurea", "SPECIES", 4, 15], ["The E. purpurea", "TEST", 0, 15], ["NK cell numbers", "TEST", 38, 53], ["purpurea", "OBSERVATION_MODIFIER", 7, 15], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["NK cell numbers", "OBSERVATION", 38, 53], ["increase", "OBSERVATION_MODIFIER", 80, 88]]], ["In a recent study levamisole and Echinacea purpurea separately and together exerted a stimulant effect on the immune system in rats (Sadigh-Eteghad et al. 2011 ) .", [["immune system", "ANATOMY", 110, 123], ["levamisole", "CHEMICAL", 18, 28], ["Echinacea purpurea", "CHEMICAL", 33, 51], ["levamisole", "CHEMICAL", 18, 28], ["levamisole", "SIMPLE_CHEMICAL", 18, 28], ["Echinacea purpurea", "ORGANISM", 33, 51], ["immune system", "ANATOMICAL_SYSTEM", 110, 123], ["rats", "ORGANISM", 127, 131], ["Echinacea purpurea", "SPECIES", 33, 51], ["rats", "SPECIES", 127, 131], ["Echinacea purpurea", "SPECIES", 33, 51], ["a recent study levamisole", "TREATMENT", 3, 28], ["Echinacea purpurea", "TREATMENT", 33, 51], ["stimulant effect", "OBSERVATION", 86, 102]]], ["The gamma globulin level, white blood cells, neutrophil and monocyte counts and phagocyte activity increased significantly in comparison with normal saline group during the study.", [["white blood cells", "ANATOMY", 26, 43], ["neutrophil", "ANATOMY", 45, 55], ["monocyte", "ANATOMY", 60, 68], ["phagocyte", "ANATOMY", 80, 89], ["gamma globulin", "CHEMICAL", 4, 18], ["gamma globulin", "GENE_OR_GENE_PRODUCT", 4, 18], ["white blood cells", "CELL", 26, 43], ["neutrophil", "CELL", 45, 55], ["monocyte", "CELL", 60, 68], ["phagocyte", "CELL", 80, 89], ["saline", "SIMPLE_CHEMICAL", 149, 155], ["gamma globulin", "PROTEIN", 4, 18], ["white blood cells", "CELL_TYPE", 26, 43], ["neutrophil", "CELL_TYPE", 45, 55], ["The gamma globulin level", "TEST", 0, 24], ["white blood cells", "TEST", 26, 43], ["neutrophil", "TEST", 45, 55], ["monocyte counts", "TEST", 60, 75], ["phagocyte activity", "TEST", 80, 98], ["the study", "TEST", 169, 178], ["gamma globulin", "OBSERVATION", 4, 18], ["monocyte counts", "OBSERVATION", 60, 75], ["phagocyte activity", "OBSERVATION", 80, 98], ["increased", "OBSERVATION_MODIFIER", 99, 108]]], ["In the group that received Echinacea and levamisole simultaneously, these effects were synergistically increased.Animal StudiesMale rats were orally treated with two different doses (30 and 100 mg/kg) of extract of Echinacea purpurea (EP), Hypericum perforatum (HP) and Eleutherococcus senticosus (ES) drugs for 3 or 15 days (Di Carlo et al. 2005 ) .", [["extract", "ANATOMY", 204, 211], ["ES", "ANATOMY", 298, 300], ["Echinacea", "CHEMICAL", 27, 36], ["levamisole", "CHEMICAL", 41, 51], ["extract of Echinacea purpurea", "CHEMICAL", 204, 233], ["EP", "CHEMICAL", 235, 237], ["Hypericum perforatum", "CHEMICAL", 240, 260], ["levamisole", "CHEMICAL", 41, 51], ["Echinacea", "SIMPLE_CHEMICAL", 27, 36], ["levamisole", "SIMPLE_CHEMICAL", 41, 51], ["rats", "ORGANISM", 132, 136], ["Echinacea purpurea", "ORGANISM", 215, 233], ["Hypericum perforatum", "ORGANISM", 240, 260], ["HP", "ORGANISM", 262, 264], ["Eleutherococcus senticosus", "ORGANISM", 270, 296], ["rats", "SPECIES", 132, 136], ["Echinacea purpurea", "SPECIES", 215, 233], ["Hypericum perforatum", "SPECIES", 240, 260], ["Eleutherococcus senticosus", "SPECIES", 270, 296], ["Echinacea purpurea", "SPECIES", 215, 233], ["Hypericum perforatum", "SPECIES", 240, 260], ["Eleutherococcus senticosus", "SPECIES", 270, 296], ["Echinacea", "TREATMENT", 27, 36], ["levamisole", "TREATMENT", 41, 51], ["Echinacea purpurea", "PROBLEM", 215, 233], ["Hypericum perforatum", "PROBLEM", 240, 260], ["Eleutherococcus senticosus (ES) drugs", "TREATMENT", 270, 307], ["increased", "OBSERVATION_MODIFIER", 103, 112], ["Hypericum perforatum", "ANATOMY", 240, 260]]], ["A 3-day treatment was not able to modify prolactin serum levels, whereas a 15-day treatment with EP and HP at the higher dose signifi cantly inhibited prolactin production; prolactin had been reported to play an important role in immune system regulation.", [["serum", "ANATOMY", 51, 56], ["immune system", "ANATOMY", 230, 243], ["EP", "CHEMICAL", 97, 99], ["prolactin", "GENE_OR_GENE_PRODUCT", 41, 50], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["EP", "SIMPLE_CHEMICAL", 97, 99], ["HP", "SIMPLE_CHEMICAL", 104, 106], ["prolactin", "GENE_OR_GENE_PRODUCT", 151, 160], ["prolactin", "GENE_OR_GENE_PRODUCT", 173, 182], ["A 3-day treatment", "TREATMENT", 0, 17], ["prolactin serum levels", "TEST", 41, 63], ["EP", "TREATMENT", 97, 99], ["HP", "TREATMENT", 104, 106], ["prolactin production", "PROBLEM", 151, 171], ["prolactin", "TREATMENT", 173, 182]]], ["The treatment with ES was ineffective.", [["The treatment with ES", "TREATMENT", 0, 21]]], ["They suggested that a possible mechanism for this effect could be that both Echinacea purpurea and Hypericum perforatum extracts displayed a direct dopaminergic activity, although an involvement of the GABAergic system could not be excluded.Clinical StudiesYear-and-a-half old, dried Echinacea roots were found to retain cytokine-modulating capabilities in an in-vitro human older adult model of infl uenza vaccination (Senchina et al. 2006 ).", [["extracts", "ANATOMY", 120, 128], ["GABAergic system", "ANATOMY", 202, 218], ["roots", "ANATOMY", 294, 299], ["Echinacea purpurea and Hypericum perforatum", "CHEMICAL", 76, 119], ["Echinacea purpurea", "ORGANISM", 76, 94], ["Hypericum perforatum", "ORGANISM", 99, 119], ["extracts", "ORGANISM", 120, 128], ["Echinacea", "ORGANISM", 284, 293], ["roots", "ORGAN", 294, 299], ["human", "ORGANISM", 369, 374], ["infl uenza", "ORGANISM", 396, 406], ["cytokine", "PROTEIN", 321, 329], ["Echinacea purpurea", "SPECIES", 76, 94], ["Hypericum perforatum", "SPECIES", 99, 119], ["Echinacea", "SPECIES", 284, 293], ["human", "SPECIES", 369, 374], ["Echinacea purpurea", "SPECIES", 76, 94], ["Hypericum perforatum", "SPECIES", 99, 119], ["human", "SPECIES", 369, 374], ["both Echinacea purpurea", "TEST", 71, 94], ["Hypericum perforatum extracts", "PROBLEM", 99, 128], ["a direct dopaminergic activity", "PROBLEM", 139, 169], ["an involvement of the GABAergic system", "PROBLEM", 180, 218], ["Clinical Studies", "TEST", 241, 257], ["dried Echinacea roots", "PROBLEM", 278, 299], ["infl uenza vaccination", "TREATMENT", 396, 418], ["Hypericum", "OBSERVATION_MODIFIER", 99, 108], ["dopaminergic activity", "OBSERVATION", 148, 169], ["GABAergic system", "OBSERVATION", 202, 218], ["could not be excluded", "UNCERTAINTY", 219, 240]]], ["In this model, peripheral blood mononuclear cells were collected from subjects 6 months postvaccination and stimulated in vitro with the two type A infl uenza viruses contained in the trivalent 2004-2005 vaccine with a 50 % alcohol tincture prepared from the roots of one of seven Echinacea species: E. angustifolia , E. pallida , E. paradoxa , E. purpurea , E. sanguinea , E. simulata and E. tennesseensis .", [["peripheral blood mononuclear cells", "ANATOMY", 15, 49], ["roots", "ANATOMY", 259, 264], ["alcohol", "CHEMICAL", 224, 231], ["alcohol", "CHEMICAL", 224, 231], ["peripheral blood mononuclear cells", "CELL", 15, 49], ["infl uenza viruses", "ORGANISM", 148, 166], ["alcohol", "SIMPLE_CHEMICAL", 224, 231], ["roots", "ORGAN", 259, 264], ["Echinacea", "ORGANISM", 281, 290], ["E. angustifolia", "ORGANISM", 300, 315], ["E. pallida", "ORGANISM", 318, 328], ["E. paradoxa", "ORGANISM", 331, 342], ["E. purpurea", "ORGANISM", 345, 356], ["E. sanguinea", "ORGANISM", 359, 371], ["E. simulata", "ORGANISM", 374, 385], ["E. tennesseensis", "ORGANISM", 390, 406], ["peripheral blood mononuclear cells", "CELL_TYPE", 15, 49], ["Echinacea", "SPECIES", 281, 290], ["E. angustifolia", "SPECIES", 300, 315], ["E. pallida", "SPECIES", 318, 328], ["E. paradoxa", "SPECIES", 331, 342], ["E. purpurea", "SPECIES", 345, 356], ["E. sanguinea", "SPECIES", 359, 371], ["E. simulata", "SPECIES", 374, 385], ["E. tennesseensis", "SPECIES", 390, 406], ["A infl uenza viruses", "SPECIES", 146, 166], ["E. angustifolia", "SPECIES", 300, 315], ["E. pallida", "SPECIES", 318, 328], ["E. paradoxa", "SPECIES", 331, 342], ["E. purpurea", "SPECIES", 345, 356], ["E. sanguinea", "SPECIES", 359, 371], ["E. simulata", "SPECIES", 374, 385], ["E. tennesseensis", "SPECIES", 390, 406], ["peripheral blood mononuclear cells", "PROBLEM", 15, 49], ["a 50 % alcohol tincture", "TREATMENT", 217, 240], ["peripheral", "ANATOMY_MODIFIER", 15, 25], ["blood", "ANATOMY", 26, 31], ["mononuclear cells", "OBSERVATION", 32, 49]]], ["Four species ( E. angustifolia , E. purpurea , E. simulata , E. tennesseensis ) augmented interleukin IL-10 production, diminished IL-2 production, and had no effect on interferon IFN-gamma production.", [["E. angustifolia", "ORGANISM", 15, 30], ["E. purpurea", "ORGANISM", 33, 44], ["E. simulata", "ORGANISM", 47, 58], ["E. tennesseensis", "ORGANISM", 61, 77], ["interleukin IL-10", "GENE_OR_GENE_PRODUCT", 90, 107], ["IL-2", "GENE_OR_GENE_PRODUCT", 131, 135], ["IFN-gamma", "GENE_OR_GENE_PRODUCT", 180, 189], ["interleukin", "PROTEIN", 90, 101], ["IL", "PROTEIN", 131, 133], ["interferon IFN-gamma", "PROTEIN", 169, 189], ["E. angustifolia", "SPECIES", 15, 30], ["E. purpurea", "SPECIES", 33, 44], ["E. simulata", "SPECIES", 47, 58], ["E. tennesseensis", "SPECIES", 61, 77], ["E. angustifolia", "SPECIES", 15, 30], ["E. purpurea", "SPECIES", 33, 44], ["E. simulata", "SPECIES", 47, 58], ["E. tennesseensis", "SPECIES", 61, 77], ["Four species", "TEST", 0, 12], ["E. purpurea", "TEST", 33, 44], ["augmented interleukin IL", "TEST", 80, 104], ["diminished IL", "PROBLEM", 120, 133], ["interferon IFN", "TREATMENT", 169, 183], ["gamma production", "PROBLEM", 184, 200], ["diminished", "OBSERVATION_MODIFIER", 120, 130], ["no", "UNCERTAINTY", 156, 158]]], ["Parnham ( 1996 ) reported squeezed sap of E. purpurea , widely used in self-medication, to be well tolerated on long-term oral administration with no adverse event in healthy adults.", [["oral", "ANATOMY", 122, 126], ["E. purpurea", "ORGANISM", 42, 53], ["oral", "ORGANISM_SUBDIVISION", 122, 126], ["E. purpurea", "SPECIES", 42, 53], ["E. purpurea", "SPECIES", 42, 53], ["E. purpurea", "TREATMENT", 42, 53], ["self-medication", "TREATMENT", 71, 86], ["long-term oral administration", "TREATMENT", 112, 141]]], ["In contrast, parenteral administration of the squeezed sap of E. purpurea (Echinacin\u00ae) may be associated with symptoms of immunostimulation (shivering, fever, muscle weakness).", [["parenteral", "ANATOMY", 13, 23], ["muscle", "ANATOMY", 159, 165], ["Echinacin\u00ae", "CHEMICAL", 75, 85], ["shivering", "DISEASE", 141, 150], ["fever", "DISEASE", 152, 157], ["muscle weakness", "DISEASE", 159, 174], ["E. purpurea", "ORGANISM", 62, 73], ["Echinacin\u00ae", "SIMPLE_CHEMICAL", 75, 85], ["muscle", "ORGAN", 159, 165], ["E. purpurea", "SPECIES", 62, 73], ["E. purpurea", "SPECIES", 62, 73], ["parenteral administration", "TREATMENT", 13, 38], ["E. purpurea", "PROBLEM", 62, 73], ["symptoms", "PROBLEM", 110, 118], ["immunostimulation (shivering", "PROBLEM", 122, 150], ["fever", "PROBLEM", 152, 157], ["muscle weakness", "PROBLEM", 159, 174], ["muscle", "ANATOMY", 159, 165]]], ["Echinacin\u00ae had little or no effect on lymphocyte responses but had been reported to cause transient lymphopenia in some patients with infections of various etiologies.", [["lymphocyte", "ANATOMY", 38, 48], ["Echinacin\u00ae", "CHEMICAL", 0, 10], ["lymphopenia", "DISEASE", 100, 111], ["infections", "DISEASE", 134, 144], ["Echinacin\u00ae", "CHEMICAL", 0, 10], ["Echinacin\u00ae", "SIMPLE_CHEMICAL", 0, 10], ["lymphocyte", "CELL", 38, 48], ["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["Echinacin\u00ae", "TREATMENT", 0, 10], ["lymphocyte responses", "TEST", 38, 58], ["transient lymphopenia", "PROBLEM", 90, 111], ["infections of various etiologies", "PROBLEM", 134, 166], ["no", "UNCERTAINTY", 25, 27], ["effect", "OBSERVATION_MODIFIER", 28, 34], ["transient", "OBSERVATION_MODIFIER", 90, 99], ["lymphopenia", "OBSERVATION", 100, 111], ["some patients", "OBSERVATION_MODIFIER", 115, 128], ["infections", "OBSERVATION", 134, 144]]], ["In a double-blind placebo-controlled crossover design study with two treatment periods of 14 days involving 40 healthy male volunteers (age range 20-40 years), oral administration of Echinacea purpurea pressed juice for 1 and 2 weeks had only minor effects on two out of 12 lymphocyte subpopulations determined in the study (Schwarz et al. 2005 ).", [["oral", "ANATOMY", 160, 164], ["juice", "ANATOMY", 210, 215], ["lymphocyte", "ANATOMY", 274, 284], ["Echinacea purpurea", "CHEMICAL", 183, 201], ["volunteers", "ORGANISM", 124, 134], ["oral", "ORGANISM_SUBDIVISION", 160, 164], ["Echinacea", "ORGANISM", 183, 192], ["juice", "ORGANISM_SUBSTANCE", 210, 215], ["lymphocyte", "CELL", 274, 284], ["lymphocyte subpopulations", "CELL_TYPE", 274, 299], ["Echinacea purpurea", "SPECIES", 183, 201], ["Echinacea purpurea", "SPECIES", 183, 201], ["a double-blind placebo", "TREATMENT", 3, 25], ["oral administration of Echinacea purpurea pressed juice", "TREATMENT", 160, 215], ["lymphocyte subpopulations", "TEST", 274, 299], ["the study", "TEST", 314, 323]]], ["The small differences observed in the number of CD8+-T lymphocytes and natural killer cells were only of questionable physiological relevance.Clinical StudiesEchinacea purpurea was found to have immunomodulatory property.", [["CD8+-T lymphocytes", "ANATOMY", 48, 66], ["natural killer cells", "ANATOMY", 71, 91], ["CD8", "GENE_OR_GENE_PRODUCT", 48, 51], ["natural killer cells", "CELL", 71, 91], ["StudiesEchinacea purpurea", "ORGANISM", 151, 176], ["CD8+-T lymphocytes", "CELL_TYPE", 48, 66], ["natural killer cells", "CELL_TYPE", 71, 91], ["StudiesEchinacea purpurea", "SPECIES", 151, 176], ["StudiesEchinacea purpurea", "SPECIES", 151, 176], ["The small differences", "PROBLEM", 0, 21], ["natural killer cells", "TREATMENT", 71, 91], ["Clinical StudiesEchinacea purpurea", "PROBLEM", 142, 176], ["small", "OBSERVATION_MODIFIER", 4, 9], ["differences", "OBSERVATION_MODIFIER", 10, 21], ["natural killer cells", "OBSERVATION", 71, 91]]], ["Ritchie et al. ( 2011 ) found that a subgroup of volunteers who showed low pretreatment levels of the cytokines MCP-1, IL-8, IL-10 or IFN-\u03b3 ( n = 8) showed signifi cant stimulation of these factors upon Echinaforce\u00ae treatment ( E. purpurea ) (30-49 % increases), whereas the levels in subjects with higher pretreatment levels remained unaffected.", [["Echinaforce\u00ae", "CHEMICAL", 203, 215], ["Echinaforce\u00ae", "CHEMICAL", 203, 215], ["volunteers", "ORGANISM", 49, 59], ["MCP-1", "GENE_OR_GENE_PRODUCT", 112, 117], ["IL-8", "GENE_OR_GENE_PRODUCT", 119, 123], ["IL-10", "GENE_OR_GENE_PRODUCT", 125, 130], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 134, 139], ["Echinaforce\u00ae", "SIMPLE_CHEMICAL", 203, 215], ["E. purpurea", "ORGANISM", 228, 239], ["cytokines", "PROTEIN", 102, 111], ["MCP", "PROTEIN", 112, 115], ["IL-8", "PROTEIN", 119, 123], ["IL-10", "PROTEIN", 125, 130], ["IFN", "PROTEIN", 134, 137], ["E. purpurea", "SPECIES", 228, 239], ["E. purpurea", "SPECIES", 228, 239], ["low pretreatment levels", "PROBLEM", 71, 94], ["the cytokines MCP", "TEST", 98, 115], ["IL", "TEST", 119, 121], ["IL", "TEST", 125, 127], ["IFN", "TEST", 134, 137], ["signifi cant stimulation", "PROBLEM", 156, 180], ["these factors", "PROBLEM", 184, 197], ["Echinaforce\u00ae treatment", "TREATMENT", 203, 225], ["E. purpurea", "TEST", 228, 239], ["higher pretreatment levels", "PROBLEM", 299, 325]]], ["Volunteers who reported high stress levels ( n = 7) and more than 2 colds per year experienced a signifi cant transient increase in interferon IFN-\u03b3 upon Echinaforce\u00ae treatment (>50 %).", [["colds", "DISEASE", 68, 73], ["Echinaforce\u00ae", "CHEMICAL", 154, 166], ["Volunteers", "ORGANISM", 0, 10], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 143, 148], ["Echinaforce\u00ae", "SIMPLE_CHEMICAL", 154, 166], ["interferon", "PROTEIN", 132, 142], ["IFN", "PROTEIN", 143, 146], ["high stress levels", "PROBLEM", 24, 42], ["a signifi cant transient increase", "PROBLEM", 95, 128], ["interferon IFN", "TREATMENT", 132, 146], ["Echinaforce\u00ae treatment", "TREATMENT", 154, 176], ["increase", "OBSERVATION_MODIFIER", 120, 128], ["interferon IFN", "OBSERVATION", 132, 146]]], ["Subjects with low cortisol levels ( n = 11) showed signifi cant downregulation of the acute-phase proteins interleukin IL1-\u03b2, IL-6, IL-12 and TNF-\u03b1 by Echinaforce\u00ae (range, 13-25 %), while subjects with higher cortisol levels showed no such downregulation.", [["cortisol", "CHEMICAL", 18, 26], ["cortisol", "CHEMICAL", 209, 217], ["cortisol", "CHEMICAL", 18, 26], ["cortisol", "CHEMICAL", 209, 217], ["Subjects", "ORGANISM", 0, 8], ["cortisol", "GENE_OR_GENE_PRODUCT", 18, 26], ["interleukin IL1-\u03b2", "GENE_OR_GENE_PRODUCT", 107, 124], ["IL-6", "GENE_OR_GENE_PRODUCT", 126, 130], ["IL-12", "GENE_OR_GENE_PRODUCT", 132, 137], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 142, 147], ["Echinaforce\u00ae", "SIMPLE_CHEMICAL", 151, 163], ["cortisol", "GENE_OR_GENE_PRODUCT", 209, 217], ["acute-phase proteins", "PROTEIN", 86, 106], ["interleukin", "PROTEIN", 107, 118], ["IL1", "PROTEIN", 119, 122], ["\u03b2", "PROTEIN", 123, 124], ["IL-6", "PROTEIN", 126, 130], ["IL-12", "PROTEIN", 132, 137], ["TNF", "PROTEIN", 142, 145], ["low cortisol levels", "PROBLEM", 14, 33], ["signifi cant downregulation", "PROBLEM", 51, 78], ["IL1", "TEST", 119, 122], ["IL", "TEST", 126, 128], ["IL", "TEST", 132, 134], ["TNF", "TEST", 142, 145], ["Echinaforce\u00ae", "TEST", 151, 163], ["higher cortisol levels", "TEST", 202, 224], ["such downregulation", "PROBLEM", 235, 254], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["no", "UNCERTAINTY", 232, 234]]], ["The authors concluded that Echinaforce\u00ae thus regulated the production of chemokines and cytokines according to current immune status, such as responsiveness to exogenous stimuli, susceptibility to viral infection and exposure to stress.Review StudiesIn a review of immunomodulatory effi cacy of preparations containing extracts of Echinacea , 26 controlled clinical trials (18 randomized, 11 dou-ble blind) were identifi ed by Melchart et al. ( 1994 ) .", [["extracts", "ANATOMY", 319, 327], ["Echinaforce\u00ae", "CHEMICAL", 27, 39], ["viral infection", "DISEASE", 197, 212], ["Echinacea", "CHEMICAL", 331, 340], ["Echinaforce\u00ae", "SIMPLE_CHEMICAL", 27, 39], ["extracts", "ORGANISM_SUBSTANCE", 319, 327], ["Echinacea", "ORGANISM", 331, 340], ["chemokines", "PROTEIN", 73, 83], ["cytokines", "PROTEIN", 88, 97], ["Echinacea", "SPECIES", 331, 340], ["Echinaforce\u00ae", "TREATMENT", 27, 39], ["chemokines and cytokines", "TREATMENT", 73, 97], ["exogenous stimuli", "TEST", 160, 177], ["viral infection", "PROBLEM", 197, 212], ["stress", "PROBLEM", 229, 235], ["immunomodulatory effi cacy of preparations", "TREATMENT", 265, 307], ["Echinacea", "TREATMENT", 331, 340], ["viral infection", "OBSERVATION", 197, 212], ["Echinacea", "OBSERVATION_MODIFIER", 331, 340]]], ["Their study indicated that preparations containing extracts of Echinacea could be effi cacious immunomodulators.", [["extracts", "ANATOMY", 51, 59], ["Echinacea", "CHEMICAL", 63, 72], ["extracts", "ORGANISM_SUBSTANCE", 51, 59], ["Echinacea", "ORGANISM", 63, 72], ["Echinacea", "SPECIES", 63, 72], ["Their study", "TEST", 0, 11], ["Echinacea", "TREATMENT", 63, 72], ["immunomodulators", "TREATMENT", 95, 111]]], ["However, present evidence was still insuffi cient for clear therapeutic recommendations as to which preparation to use and which dose to employ for a specifi c indication.Antiviral ActivityThe roots of E. purpurea were found to induce a substance showing interferon-like activity (Skwarek et al. 1996 ) .", [["roots", "ANATOMY", 193, 198], ["roots", "ORGAN", 193, 198], ["E. purpurea", "ORGANISM", 202, 213], ["interferon", "GENE_OR_GENE_PRODUCT", 255, 265], ["interferon", "PROTEIN", 255, 265], ["E. purpurea", "SPECIES", 202, 213], ["E. purpurea", "SPECIES", 202, 213], ["roots", "ANATOMY", 193, 198]]], ["Biological activity studies showed that the protective titre (the largest dilution which protected cells by 50 % against virus infection) of the interferon-like materials was 1:6-1:15.", [["cells", "ANATOMY", 99, 104], ["infection", "DISEASE", 127, 136], ["cells", "CELL", 99, 104], ["interferon", "PROTEIN", 145, 155], ["Biological activity studies", "TEST", 0, 27], ["the protective titre", "TREATMENT", 40, 60], ["the largest dilution", "TREATMENT", 62, 82], ["virus infection", "PROBLEM", 121, 136]]], ["Echinacea purpurea and Panax ginseng extracts at concentrations \u22650.1 or 10 \u03bcg/kg, respectively, signifi cantly enhanced natural killer cell function against human erythromyeloblastoid leukaemia cell line, K562 cells in healthy subjects and chronic fatigue syndrome or acquired immunodefi ciency syndrome (AIDS) patients (See et al. 1997 ) .", [["extracts", "ANATOMY", 37, 45], ["natural killer cell", "ANATOMY", 120, 139], ["erythromyeloblastoid leukaemia cell line", "ANATOMY", 163, 203], ["K562 cells", "ANATOMY", 205, 215], ["Echinacea purpurea and Panax ginseng", "CHEMICAL", 0, 36], ["erythromyeloblastoid leukaemia", "DISEASE", 163, 193], ["chronic fatigue syndrome", "DISEASE", 240, 264], ["immunodefi ciency syndrome", "DISEASE", 277, 303], ["AIDS", "DISEASE", 305, 309], ["Echinacea purpurea", "ORGANISM", 0, 18], ["Panax", "ORGANISM", 23, 28], ["ginseng extracts", "ORGANISM_SUBSTANCE", 29, 45], ["natural killer cell", "CELL", 120, 139], ["human", "ORGANISM", 157, 162], ["erythromyeloblastoid leukaemia cell line", "CELL", 163, 203], ["K562 cells", "CELL", 205, 215], ["patients", "ORGANISM", 311, 319], ["natural killer cell", "CELL_TYPE", 120, 139], ["human erythromyeloblastoid leukaemia cell line", "CELL_LINE", 157, 203], ["K562 cells", "CELL_LINE", 205, 215], ["Echinacea purpurea", "SPECIES", 0, 18], ["Panax ginseng", "SPECIES", 23, 36], ["human", "SPECIES", 157, 162], ["patients", "SPECIES", 311, 319], ["Echinacea purpurea", "SPECIES", 0, 18], ["Panax ginseng", "SPECIES", 23, 36], ["human", "SPECIES", 157, 162], ["Echinacea purpurea", "TREATMENT", 0, 18], ["Panax ginseng extracts", "TREATMENT", 23, 45], ["human erythromyeloblastoid leukaemia cell line", "PROBLEM", 157, 203], ["chronic fatigue syndrome", "PROBLEM", 240, 264], ["acquired immunodefi ciency syndrome", "PROBLEM", 268, 303], ["natural killer cell", "OBSERVATION", 120, 139], ["leukaemia cell line", "OBSERVATION", 184, 203], ["K562 cells", "OBSERVATION", 205, 215], ["chronic", "OBSERVATION_MODIFIER", 240, 247], ["fatigue syndrome", "OBSERVATION", 248, 264]]], ["Similarly, the addition of either herb signifi cantly increased antibodydependent cellular cytotoxicity (ADCC) against human herpesvirus 6 infected H9 cells of peripheral blood mononuclear cells (PBMC) from all subject groups.", [["cellular", "ANATOMY", 82, 90], ["H9 cells", "ANATOMY", 148, 156], ["peripheral blood mononuclear cells", "ANATOMY", 160, 194], ["PBMC", "ANATOMY", 196, 200], ["antibodydependent cellular", "CELL", 64, 90], ["human", "ORGANISM", 119, 124], ["herpesvirus 6", "ORGANISM", 125, 138], ["H9 cells", "CELL", 148, 156], ["peripheral blood mononuclear cells", "CELL", 160, 194], ["PBMC", "CELL", 196, 200], ["human herpesvirus 6 infected H9 cells", "CELL_LINE", 119, 156], ["peripheral blood mononuclear cells", "CELL_TYPE", 160, 194], ["PBMC", "CELL_TYPE", 196, 200], ["human", "SPECIES", 119, 124], ["human herpesvirus 6", "SPECIES", 119, 138], ["herb signifi cantly increased antibodydependent cellular cytotoxicity", "PROBLEM", 34, 103], ["human herpesvirus", "PROBLEM", 119, 136], ["peripheral blood mononuclear cells", "PROBLEM", 160, 194], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["antibodydependent cellular cytotoxicity", "OBSERVATION", 64, 103], ["H9 cells", "OBSERVATION", 148, 156], ["peripheral", "ANATOMY_MODIFIER", 160, 170], ["blood", "ANATOMY", 171, 176], ["mononuclear cells", "OBSERVATION", 177, 194]]], ["Thus, extracts of Echinacea purpurea and Panax ginseng enhanced cellular immune function of PBMC both from normal individuals and patients with depressed cellular immunity.", [["extracts", "ANATOMY", 6, 14], ["cellular", "ANATOMY", 64, 72], ["PBMC", "ANATOMY", 92, 96], ["cellular", "ANATOMY", 154, 162], ["Echinacea purpurea", "CHEMICAL", 18, 36], ["depressed", "DISEASE", 144, 153], ["extracts", "ORGANISM_SUBSTANCE", 6, 14], ["Echinacea purpurea", "ORGANISM", 18, 36], ["Panax ginseng", "CELL", 41, 54], ["cellular", "CELL", 64, 72], ["PBMC", "CELL", 92, 96], ["patients", "ORGANISM", 130, 138], ["cellular", "CELL", 154, 162], ["PBMC", "CELL_TYPE", 92, 96], ["Echinacea purpurea", "SPECIES", 18, 36], ["Panax ginseng", "SPECIES", 41, 54], ["patients", "SPECIES", 130, 138], ["Echinacea purpurea", "SPECIES", 18, 36], ["Panax ginseng", "SPECIES", 41, 54], ["Echinacea purpurea", "PROBLEM", 18, 36], ["Panax ginseng", "TEST", 41, 54], ["PBMC", "TEST", 92, 96], ["depressed cellular immunity", "PROBLEM", 144, 171], ["Echinacea purpurea", "OBSERVATION", 18, 36], ["cellular immune", "OBSERVATION", 64, 79]]], ["Extracts of 8 taxa of the genus Echinacea were found to have antiviral activity against herpes simplex (HSV) virus type I in vitro when exposed to visible and UVA light (Binns et al. 2002a ) . n -Hexane extracts of roots containing alkenes and amides were more active in general than ethyl acetate extracts containing caffeic acids.", [["Extracts", "ANATOMY", 0, 8], ["extracts", "ANATOMY", 203, 211], ["roots", "ANATOMY", 215, 220], ["extracts", "ANATOMY", 298, 306], ["Echinacea", "CHEMICAL", 32, 41], ["herpes simplex (HSV) virus type I", "DISEASE", 88, 121], ["UVA", "CHEMICAL", 159, 162], ["n -Hexane", "CHEMICAL", 193, 202], ["alkenes", "CHEMICAL", 232, 239], ["amides", "CHEMICAL", 244, 250], ["ethyl acetate", "CHEMICAL", 284, 297], ["caffeic acids", "CHEMICAL", 318, 331], ["n -Hexane", "CHEMICAL", 193, 202], ["alkenes", "CHEMICAL", 232, 239], ["amides", "CHEMICAL", 244, 250], ["ethyl acetate", "CHEMICAL", 284, 297], ["caffeic acids", "CHEMICAL", 318, 331], ["Echinacea", "ORGANISM", 32, 41], ["herpes simplex (HSV) virus type I", "ORGANISM", 88, 121], ["roots", "ORGAN", 215, 220], ["alkenes", "SIMPLE_CHEMICAL", 232, 239], ["amides", "SIMPLE_CHEMICAL", 244, 250], ["ethyl acetate extracts", "SIMPLE_CHEMICAL", 284, 306], ["caffeic acids", "SIMPLE_CHEMICAL", 318, 331], ["Echinacea", "SPECIES", 32, 41], ["herpes simplex", "SPECIES", 88, 102], ["HSV) virus", "SPECIES", 104, 114], ["HSV", "SPECIES", 104, 107], ["Extracts", "TEST", 0, 8], ["antiviral activity", "PROBLEM", 61, 79], ["herpes simplex (HSV) virus type I", "PROBLEM", 88, 121], ["Hexane extracts", "TREATMENT", 196, 211], ["alkenes and amides", "TREATMENT", 232, 250], ["ethyl acetate extracts", "TREATMENT", 284, 306], ["caffeic acids", "TREATMENT", 318, 331], ["roots", "ANATOMY", 215, 220]]], ["Echinacea purpurea n -hexane root extract (MIC = 0.12 mg/ml) was one of the most potent inhibitors of HSV.Antiviral ActivityAqueous extracts of E. purpurea root contained a relatively potent activity against herpes simplex virus (HSV) and infl uenza virus (FV) but not against rhinovirus (RV) .Antiviral ActivityThese fractions had low amounts of caffeic acids and alkamides.", [["extracts", "ANATOMY", 132, 140], ["root", "ANATOMY", 156, 160], ["Echinacea purpurea n -hexane root extract", "CHEMICAL", 0, 41], ["MIC", "CHEMICAL", 43, 46], ["herpes simplex virus (HSV)", "DISEASE", 208, 234], ["caffeic acids", "CHEMICAL", 347, 360], ["alkamides", "CHEMICAL", 365, 374], ["n -hexane", "CHEMICAL", 19, 28], ["caffeic acids", "CHEMICAL", 347, 360], ["alkamides", "CHEMICAL", 365, 374], ["Echinacea", "ORGANISM", 0, 9], ["n -hexane", "SIMPLE_CHEMICAL", 19, 28], ["HSV", "ORGANISM", 102, 105], ["extracts", "ORGANISM_SUBSTANCE", 132, 140], ["E. purpurea", "ORGANISM", 144, 155], ["root", "ORGANISM", 156, 160], ["herpes simplex virus", "ORGANISM", 208, 228], ["HSV", "ORGANISM", 230, 233], ["infl uenza virus", "ORGANISM", 239, 255], ["FV", "ORGANISM", 257, 259], ["rhinovirus", "ORGANISM", 277, 287], ["caffeic acids", "SIMPLE_CHEMICAL", 347, 360], ["alkamides", "SIMPLE_CHEMICAL", 365, 374], ["Echinacea purpurea", "SPECIES", 0, 18], ["E. purpurea", "SPECIES", 144, 155], ["herpes simplex virus", "SPECIES", 208, 228], ["infl uenza virus", "SPECIES", 239, 255], ["Echinacea purpurea", "SPECIES", 0, 18], ["HSV", "SPECIES", 102, 105], ["E. purpurea", "SPECIES", 144, 155], ["herpes simplex virus", "SPECIES", 208, 228], ["HSV", "SPECIES", 230, 233], ["infl uenza virus", "SPECIES", 239, 255], ["FV", "SPECIES", 257, 259], ["RV", "SPECIES", 289, 291], ["Echinacea purpurea n -hexane root extract (MIC", "TREATMENT", 0, 46], ["HSV", "PROBLEM", 102, 105], ["Antiviral ActivityAqueous extracts", "TREATMENT", 106, 140], ["herpes simplex virus (HSV", "PROBLEM", 208, 233], ["infl uenza virus", "PROBLEM", 239, 255], ["rhinovirus", "PROBLEM", 277, 287], ["caffeic acids", "TREATMENT", 347, 360], ["alkamides", "TREATMENT", 365, 374], ["purpurea root", "OBSERVATION", 147, 160]]], ["The ethyl acetate fraction contained signifi cant but weak activity against both HSV and FV and contained signifi cant levels of cichoric acid.", [["ethyl acetate", "CHEMICAL", 4, 17], ["cichoric acid", "CHEMICAL", 129, 142], ["ethyl acetate", "CHEMICAL", 4, 17], ["cichoric acid", "CHEMICAL", 129, 142], ["ethyl acetate", "SIMPLE_CHEMICAL", 4, 17], ["HSV", "ORGANISM", 81, 84], ["FV", "MULTI-TISSUE_STRUCTURE", 89, 91], ["cichoric acid", "SIMPLE_CHEMICAL", 129, 142], ["HSV", "SPECIES", 81, 84], ["FV", "SPECIES", 89, 91], ["The ethyl acetate fraction", "TREATMENT", 0, 26], ["signifi cant", "PROBLEM", 37, 49], ["weak activity", "PROBLEM", 54, 67], ["cichoric acid", "PROBLEM", 129, 142], ["weak activity", "OBSERVATION_MODIFIER", 54, 67]]], ["All aqueous fractions of E. purpurea aerial parts contained potent activity against herpes simplex virus and infl uenza virus .", [["aqueous fractions", "ANATOMY", 4, 21], ["herpes simplex virus", "DISEASE", 84, 104], ["aqueous fractions", "ORGANISM_SUBSTANCE", 4, 21], ["E. purpurea", "ORGANISM", 25, 36], ["herpes simplex virus", "ORGANISM", 84, 104], ["infl uenza virus", "ORGANISM", 109, 125], ["E. purpurea", "SPECIES", 25, 36], ["herpes simplex virus", "SPECIES", 84, 104], ["uenza virus", "SPECIES", 114, 125], ["E. purpurea", "SPECIES", 25, 36], ["herpes simplex virus", "SPECIES", 84, 104], ["infl uenza virus", "SPECIES", 109, 125], ["All aqueous fractions of E. purpurea aerial parts", "TEST", 0, 49], ["herpes simplex virus", "PROBLEM", 84, 104], ["infl uenza virus", "PROBLEM", 109, 125], ["aqueous fractions", "OBSERVATION", 4, 21], ["purpurea aerial", "OBSERVATION", 28, 43], ["potent activity", "OBSERVATION_MODIFIER", 60, 75]]], ["The antiviral activity could partly be attributed to polysaccharide and cichoric acid components; their individual contributions could not account for the total antiviral activity.", [["cichoric acid", "CHEMICAL", 72, 85], ["cichoric acid", "CHEMICAL", 72, 85], ["polysaccharide", "SIMPLE_CHEMICAL", 53, 67], ["cichoric acid", "SIMPLE_CHEMICAL", 72, 85], ["The antiviral activity", "TREATMENT", 0, 22], ["polysaccharide and cichoric acid components", "PROBLEM", 53, 96], ["the total antiviral activity", "TREATMENT", 151, 179], ["antiviral activity", "OBSERVATION", 4, 22], ["antiviral activity", "OBSERVATION", 161, 179]]], ["Additionally, the ethanol-and ethyl acetate-soluble fractions from leaves and stem contained an uncharacterized but potent antiviral photosensitizer, which was absent from the fl ower extract.", [["leaves", "ANATOMY", 67, 73], ["stem", "ANATOMY", 78, 82], ["ethanol", "CHEMICAL", 18, 25], ["ethyl acetate", "CHEMICAL", 30, 43], ["ethanol", "CHEMICAL", 18, 25], ["ethyl acetate", "CHEMICAL", 30, 43], ["ethanol", "SIMPLE_CHEMICAL", 18, 25], ["ethyl acetate", "SIMPLE_CHEMICAL", 30, 43], ["leaves", "ORGANISM_SUBDIVISION", 67, 73], ["stem", "CELL", 78, 82], ["the ethanol-and ethyl acetate-soluble fractions", "TREATMENT", 14, 61], ["potent antiviral photosensitizer", "TREATMENT", 116, 148], ["stem", "ANATOMY", 78, 82], ["potent", "OBSERVATION_MODIFIER", 116, 122], ["antiviral photosensitizer", "OBSERVATION", 123, 148]]], ["None of the fractions, however, contained anti-rhinovirus.Antiviral ActivityStudies showed that exposure of a cultured line of human bronchial epithelial cells to rhinovirus 14 infection stimulated the release of at least 31 cytokine-related molecules, including several important chemokines known to attract infl ammatory cells.", [["bronchial epithelial cells", "ANATOMY", 133, 159], ["infl ammatory cells", "ANATOMY", 309, 328], ["infection", "DISEASE", 177, 186], ["human", "ORGANISM", 127, 132], ["bronchial epithelial cells", "CELL", 133, 159], ["rhinovirus 14", "ORGANISM", 163, 176], ["infl ammatory cells", "CELL", 309, 328], ["cultured line", "CELL_LINE", 110, 123], ["human bronchial epithelial cells", "CELL_TYPE", 127, 159], ["cytokine", "PROTEIN", 225, 233], ["chemokines", "PROTEIN", 281, 291], ["infl ammatory cells", "CELL_TYPE", 309, 328], ["human", "SPECIES", 127, 132], ["human", "SPECIES", 127, 132], ["anti-rhinovirus", "PROBLEM", 42, 57], ["Antiviral ActivityStudies", "TEST", 58, 83], ["a cultured line", "TREATMENT", 108, 123], ["human bronchial epithelial cells", "PROBLEM", 127, 159], ["rhinovirus 14 infection", "PROBLEM", 163, 186], ["bronchial", "ANATOMY", 133, 142], ["epithelial cells", "OBSERVATION", 143, 159]]], ["Most of these effects were reversed by simultaneous exposure to either of the two Echinacea extracts (Sharma et al. 2006a ) .", [["extracts", "ANATOMY", 92, 100], ["Echinacea", "ORGANISM", 82, 91]]], ["Rhinovirus infection of BEAS-2B cell line resulted in a more dramatic increase in multiple transcription factors including proinfl ammatory factors examined, such as NFkB, AP-1, AP-2 and STATs 1-6 (Sharma et al. 2006b ).", [["BEAS-2B cell line", "ANATOMY", 24, 41], ["infection", "DISEASE", 11, 20], ["BEAS-2B cell line", "CELL", 24, 41], ["proinfl ammatory factors", "GENE_OR_GENE_PRODUCT", 123, 147], ["NFkB", "GENE_OR_GENE_PRODUCT", 166, 170], ["AP-1", "GENE_OR_GENE_PRODUCT", 172, 176], ["AP-2", "GENE_OR_GENE_PRODUCT", 178, 182], ["STATs 1", "GENE_OR_GENE_PRODUCT", 187, 194], ["BEAS-2B cell line", "CELL_LINE", 24, 41], ["transcription factors", "PROTEIN", 91, 112], ["proinfl ammatory factors", "PROTEIN", 123, 147], ["NFkB", "PROTEIN", 166, 170], ["AP", "PROTEIN", 172, 174], ["AP", "PROTEIN", 178, 180], ["STATs 1-6", "PROTEIN", 187, 196], ["Rhinovirus infection", "PROBLEM", 0, 20], ["BEAS", "TEST", 24, 28], ["2B cell line", "TREATMENT", 29, 41], ["multiple transcription factors", "PROBLEM", 82, 112], ["proinfl ammatory factors", "PROBLEM", 123, 147], ["NFkB", "TEST", 166, 170], ["AP", "TEST", 172, 174], ["AP", "TEST", 178, 180], ["STATs", "TEST", 187, 192], ["infection", "OBSERVATION", 11, 20], ["2B cell line", "OBSERVATION", 29, 41], ["more", "OBSERVATION_MODIFIER", 56, 60], ["dramatic", "OBSERVATION_MODIFIER", 61, 69], ["increase", "OBSERVATION_MODIFIER", 70, 78], ["multiple", "OBSERVATION_MODIFIER", 82, 90], ["transcription factors", "OBSERVATION", 91, 112]]], ["However, when rhinovirus-infected cells were treated with either of the two Echinacea extracts, transcription factors levels were reduced to low levels, although the pattern of the reductions was different for the two extracts.", [["cells", "ANATOMY", 34, 39], ["extracts", "ANATOMY", 86, 94], ["extracts", "ANATOMY", 218, 226], ["rhinovirus-infected", "DISEASE", 14, 33], ["rhinovirus", "ORGANISM", 14, 24], ["cells", "CELL", 34, 39], ["Echinacea", "ORGANISM", 76, 85], ["extracts", "ORGANISM_SUBSTANCE", 86, 94], ["extracts", "ORGANISM_SUBSTANCE", 218, 226], ["rhinovirus-infected cells", "CELL_TYPE", 14, 39], ["transcription factors", "PROTEIN", 96, 117], ["rhinovirus", "PROBLEM", 14, 24], ["infected cells", "PROBLEM", 25, 39], ["the two Echinacea extracts", "TREATMENT", 68, 94], ["transcription factors levels", "TEST", 96, 124], ["infected cells", "OBSERVATION", 25, 39], ["low levels", "OBSERVATION_MODIFIER", 141, 151], ["reductions", "OBSERVATION_MODIFIER", 181, 191]]], ["The results could help to explain the benefi cial effects of Echinacea consumption.", [["Echinacea", "CHEMICAL", 61, 70], ["Echinacea", "ORGANISM", 61, 70], ["Echinacea consumption", "TREATMENT", 61, 82]]], ["All the viruses tested, rhinoviruses 1A and 14, infl uenza virus, respiratory syncytial virus, adenovirus types 3 and 11, and herpes simplex virus type 1, induced substantial secretion of IL-6 and IL-8 (CXCL8), in addition to several other chemokines, in a line of human bronchial epithelial cells (BEAS-2B) (Sharma et al. 2009 ).", [["bronchial epithelial cells", "ANATOMY", 271, 297], ["BEAS-2B", "ANATOMY", 299, 306], ["respiratory syncytial virus", "DISEASE", 66, 93], ["herpes simplex virus", "DISEASE", 126, 146], ["rhinoviruses 1A", "ORGANISM", 24, 39], ["14", "ORGANISM", 44, 46], ["infl uenza virus", "ORGANISM", 48, 64], ["respiratory syncytial virus", "ORGANISM", 66, 93], ["adenovirus types 3", "ORGANISM", 95, 113], ["herpes simplex virus type 1", "ORGANISM", 126, 153], ["IL-6", "GENE_OR_GENE_PRODUCT", 188, 192], ["IL-8", "GENE_OR_GENE_PRODUCT", 197, 201], ["CXCL8", "GENE_OR_GENE_PRODUCT", 203, 208], ["human", "ORGANISM", 265, 270], ["bronchial epithelial cells", "CELL", 271, 297], ["BEAS-2B", "CELL", 299, 306], ["IL-6", "PROTEIN", 188, 192], ["IL-8", "PROTEIN", 197, 201], ["CXCL8", "PROTEIN", 203, 208], ["chemokines", "PROTEIN", 240, 250], ["human bronchial epithelial cells", "CELL_TYPE", 265, 297], ["BEAS-2B", "CELL_LINE", 299, 306], ["uenza virus", "SPECIES", 53, 64], ["respiratory syncytial virus", "SPECIES", 66, 93], ["herpes simplex virus", "SPECIES", 126, 146], ["human", "SPECIES", 265, 270], ["infl uenza virus", "SPECIES", 48, 64], ["respiratory syncytial virus", "SPECIES", 66, 93], ["herpes simplex virus type 1", "SPECIES", 126, 153], ["human", "SPECIES", 265, 270], ["All the viruses", "TEST", 0, 15], ["rhinoviruses 1A", "TEST", 24, 39], ["infl uenza virus", "TEST", 48, 64], ["respiratory syncytial virus", "PROBLEM", 66, 93], ["adenovirus types", "TEST", 95, 111], ["herpes simplex virus type 1", "PROBLEM", 126, 153], ["IL", "TEST", 188, 190], ["IL", "TEST", 197, 199], ["several other chemokines", "PROBLEM", 226, 250], ["human bronchial epithelial cells", "TEST", 265, 297], ["BEAS", "TEST", 299, 303], ["viruses", "OBSERVATION", 8, 15], ["respiratory syncytial", "ANATOMY", 66, 87], ["substantial", "OBSERVATION_MODIFIER", 163, 174], ["secretion", "OBSERVATION", 175, 184], ["chemokines", "OBSERVATION", 240, 250], ["bronchial", "ANATOMY", 271, 280], ["epithelial cells", "OBSERVATION", 281, 297]]], ["In every case, however, Echinacea (Echinaforce, an ethanol extract of herb and roots of E. purpurea ) inhibited this induction.", [["herb", "ANATOMY", 70, 74], ["roots", "ANATOMY", 79, 84], ["Echinacea", "CHEMICAL", 24, 33], ["Echinaforce", "CHEMICAL", 35, 46], ["ethanol extract of herb and roots of E. purpurea", "CHEMICAL", 51, 99], ["ethanol", "CHEMICAL", 51, 58], ["Echinacea", "ORGANISM", 24, 33], ["Echinaforce", "SIMPLE_CHEMICAL", 35, 46], ["ethanol", "SIMPLE_CHEMICAL", 51, 58], ["herb", "ORGANISM_SUBDIVISION", 70, 74], ["roots", "ORGANISM_SUBDIVISION", 79, 84], ["E. purpurea", "ORGANISM", 88, 99], ["Echinacea", "SPECIES", 24, 33], ["E. purpurea", "SPECIES", 88, 99], ["E. purpurea", "SPECIES", 88, 99], ["Echinacea", "TEST", 24, 33], ["an ethanol extract", "TREATMENT", 48, 66], ["E. purpurea", "PROBLEM", 88, 99], ["this induction", "TREATMENT", 112, 126]]], ["The Echinacea preparation also showed potent virucidal activity against viruses with membranes, indicating the multifunctional potential of the herb.", [["membranes", "ANATOMY", 85, 94], ["Echinacea", "CHEMICAL", 4, 13], ["Echinacea", "ORGANISM", 4, 13], ["membranes", "CELLULAR_COMPONENT", 85, 94], ["Echinacea", "SPECIES", 4, 13], ["The Echinacea preparation", "TEST", 0, 25], ["potent virucidal activity against viruses with membranes", "PROBLEM", 38, 94], ["potent", "OBSERVATION_MODIFIER", 38, 44], ["virucidal activity", "OBSERVATION", 45, 63], ["herb", "OBSERVATION", 144, 148]]], ["The results supported the concept that certain Echinacea preparations could alleviate 'cold and fl u' symptoms, and possibly other respiratory disorders, by inhibiting viral growth and the secretion of proinfl ammatory cytokines.Antiviral ActivityIn a separate in-vitro study, human H1N1-type IV, highly pathogenic avian IV (HPAIV) of the H5-and H7-types, as well as swine origin IV (S-OIV, H1N1) were all inactivated in cell culture assays by the Echinacea purpurea (Echinaforce\u00ae, EF) preparation at concentrations ranging from the recommended dose for oral consumption to several orders of lower magnitude (Pleschka et al. 2009 ).", [["respiratory", "ANATOMY", 131, 142], ["cell", "ANATOMY", 421, 425], ["oral", "ANATOMY", 554, 558], ["Echinacea", "CHEMICAL", 47, 56], ["respiratory disorders", "DISEASE", 131, 152], ["Echinacea purpurea", "CHEMICAL", 448, 466], ["Echinacea", "ORGANISM", 47, 56], ["proinfl ammatory cytokines", "GENE_OR_GENE_PRODUCT", 202, 228], ["human", "ORGANISM", 277, 282], ["H1N1-type IV", "ORGANISM", 283, 295], ["avian IV", "ORGANISM", 315, 323], ["HPAIV", "ORGANISM", 325, 330], ["H7", "ORGANISM", 346, 348], ["S-OIV", "ORGANISM", 384, 389], ["H1N1", "ORGANISM", 391, 395], ["cell", "CELL", 421, 425], ["Echinacea", "ORGANISM", 448, 457], ["Echinaforce\u00ae", "SIMPLE_CHEMICAL", 468, 480], ["oral", "ORGANISM_SUBDIVISION", 554, 558], ["proinfl ammatory cytokines", "PROTEIN", 202, 228], ["human", "SPECIES", 277, 282], ["avian", "SPECIES", 315, 320], ["swine", "SPECIES", 367, 372], ["Echinacea purpurea", "SPECIES", 448, 466], ["human H1N1-type IV", "SPECIES", 277, 295], ["HPAIV", "SPECIES", 325, 330], ["OIV", "SPECIES", 386, 389], ["Echinacea purpurea", "SPECIES", 448, 466], ["Echinacea preparations", "TREATMENT", 47, 69], ["'cold and fl u' symptoms", "PROBLEM", 86, 110], ["other respiratory disorders", "PROBLEM", 125, 152], ["inhibiting viral growth", "PROBLEM", 157, 180], ["proinfl ammatory cytokines", "PROBLEM", 202, 228], ["Antiviral", "TREATMENT", 229, 238], ["vitro study", "TEST", 264, 275], ["human H1N1-type IV", "TREATMENT", 277, 295], ["the H5", "TREATMENT", 335, 341], ["H1N1", "PROBLEM", 391, 395], ["cell culture assays", "TEST", 421, 440], ["the Echinacea purpurea", "TREATMENT", 444, 466], ["oral consumption", "TREATMENT", 554, 570], ["respiratory disorders", "OBSERVATION", 131, 152], ["H5", "ANATOMY", 339, 341]]], ["Detailed studies with the H5N1 HPAIV strain indicated that direct contact between EF and virus was required, prior to infection, in order to obtain maximum inhibition in virus replication.", [["infection", "DISEASE", 118, 127], ["H5N1 HPAIV strain", "ORGANISM", 26, 43], ["EF", "PROTEIN", 82, 84], ["H5N1 HPAIV", "SPECIES", 26, 36], ["H5N1 HPAIV", "SPECIES", 26, 36], ["Detailed studies", "TEST", 0, 16], ["the H5N1 HPAIV strain", "PROBLEM", 22, 43], ["direct contact between EF and virus", "PROBLEM", 59, 94], ["infection", "PROBLEM", 118, 127], ["maximum inhibition in virus replication", "TREATMENT", 148, 187], ["infection", "OBSERVATION", 118, 127]]], ["Hemagglutination assays showed that the extract inhibited the receptorbinding activity of the virus, suggesting that the extract interferes with the viral entry into cells.", [["extract", "ANATOMY", 40, 47], ["extract", "ANATOMY", 121, 128], ["cells", "ANATOMY", 166, 171], ["cells", "CELL", 166, 171], ["Hemagglutination assays", "TEST", 0, 23], ["the extract", "PROBLEM", 36, 47], ["the virus", "PROBLEM", 90, 99], ["the extract", "PROBLEM", 117, 128], ["virus", "OBSERVATION", 94, 99]]], ["Recent studies reported that Echinaforce\u00ae the standardized extract of Echinacea purpurea exhibited immunomodulation and broad antiviral effects against respiratory tract viruses (Schapowal 2012 ) .", [["extract", "ANATOMY", 59, 66], ["Echinaforce\u00ae", "CHEMICAL", 29, 41], ["extract of Echinacea purpurea", "CHEMICAL", 59, 88], ["respiratory tract viruses", "DISEASE", 152, 177], ["Echinaforce\u00ae", "SIMPLE_CHEMICAL", 29, 41], ["Echinacea purpurea", "ORGANISM", 70, 88], ["respiratory tract viruses", "ORGANISM", 152, 177], ["Echinacea purpurea", "SPECIES", 70, 88], ["Echinacea purpurea", "SPECIES", 70, 88], ["Recent studies", "TEST", 0, 14], ["Echinacea purpurea", "PROBLEM", 70, 88], ["immunomodulation", "TREATMENT", 99, 115], ["broad antiviral effects", "TREATMENT", 120, 143], ["respiratory tract viruses", "PROBLEM", 152, 177], ["Echinacea purpurea", "OBSERVATION", 70, 88], ["broad", "OBSERVATION_MODIFIER", 120, 125], ["antiviral", "OBSERVATION", 126, 135]]], ["Haemagglutinin and neuraminidase were blocked.", [["Haemagglutinin", "CHEMICAL", 0, 14], ["Haemagglutinin", "CHEMICAL", 0, 14], ["Haemagglutinin", "GENE_OR_GENE_PRODUCT", 0, 14], ["neuraminidase", "GENE_OR_GENE_PRODUCT", 19, 32], ["Haemagglutinin", "PROTEIN", 0, 14], ["neuraminidase", "PROTEIN", 19, 32], ["Haemagglutinin", "TREATMENT", 0, 14], ["neuraminidase", "TREATMENT", 19, 32]]], ["In contrast to Oseltamivir no resistance was caused by Echinaforce\u00ae.", [["Oseltamivir", "CHEMICAL", 15, 26], ["Echinaforce\u00ae", "CHEMICAL", 55, 67], ["Oseltamivir", "CHEMICAL", 15, 26], ["Oseltamivir", "SIMPLE_CHEMICAL", 15, 26], ["Oseltamivir", "TREATMENT", 15, 26], ["resistance", "PROBLEM", 30, 40]]], ["A randomized, double-blind, placebo-controlled study over 4 months confi rmed that Echinaforce\u00ae supported the immune resistance and acted directly against a series of viruses.", [["Echinaforce\u00ae", "CHEMICAL", 83, 95], ["Echinaforce\u00ae", "SIMPLE_CHEMICAL", 83, 95], ["placebo-controlled study", "TEST", 28, 52], ["viruses", "PROBLEM", 167, 174], ["immune resistance", "OBSERVATION", 110, 127]]], ["He reported Echinaforce\u00ae to be effi cacious and safe in respiratory tract infections for long-term and short-term prevention as well as for acute treatment.Antiviral ActivityAn open-label, fi xed-sequence study of 15 HIV-infected patients showed that coadministration of E. purpurea root extract containing capsules with etravirine (a nonnucleoside reverse transcriptase inhibitor of HIV) was safe and well tolerated in HIV-infected patients (Molt\u00f3 et al. 2012 ) .", [["respiratory tract", "ANATOMY", 56, 73], ["root extract", "ANATOMY", 283, 295], ["respiratory tract infections", "DISEASE", 56, 84], ["HIV-infected", "DISEASE", 217, 229], ["E. purpurea root extract", "CHEMICAL", 271, 295], ["etravirine", "CHEMICAL", 321, 331], ["nonnucleoside reverse transcriptase inhibitor", "CHEMICAL", 335, 380], ["HIV-infected", "DISEASE", 420, 432], ["etravirine", "CHEMICAL", 321, 331], ["respiratory tract", "ORGANISM_SUBDIVISION", 56, 73], ["HIV", "ORGANISM", 217, 220], ["patients", "ORGANISM", 230, 238], ["E. purpurea", "ORGANISM", 271, 282], ["etravirine", "SIMPLE_CHEMICAL", 321, 331], ["nonnucleoside reverse transcriptase", "GENE_OR_GENE_PRODUCT", 335, 370], ["HIV", "ORGANISM", 384, 387], ["HIV", "ORGANISM", 420, 423], ["patients", "ORGANISM", 433, 441], ["nonnucleoside reverse transcriptase", "PROTEIN", 335, 370], ["HIV", "SPECIES", 217, 220], ["patients", "SPECIES", 230, 238], ["E. purpurea", "SPECIES", 271, 282], ["HIV", "SPECIES", 420, 423], ["patients", "SPECIES", 433, 441], ["HIV", "SPECIES", 217, 220], ["E. purpurea", "SPECIES", 271, 282], ["HIV", "SPECIES", 384, 387], ["HIV", "SPECIES", 420, 423], ["Echinaforce\u00ae", "PROBLEM", 12, 24], ["effi cacious", "PROBLEM", 31, 43], ["respiratory tract infections", "PROBLEM", 56, 84], ["short-term prevention", "TREATMENT", 103, 124], ["acute treatment", "TREATMENT", 140, 155], ["Antiviral", "TEST", 156, 165], ["fi xed-sequence study", "TEST", 189, 210], ["coadministration of E. purpurea root extract", "TREATMENT", 251, 295], ["etravirine", "TREATMENT", 321, 331], ["a nonnucleoside reverse transcriptase inhibitor", "TREATMENT", 333, 380], ["HIV", "PROBLEM", 384, 387], ["respiratory tract", "ANATOMY", 56, 73], ["purpurea root", "OBSERVATION", 274, 287]]], ["The geometric mean ratio for etravirine coadministered with E. purpurea relative to etravirine alone was 1.07 for the maximum concentration, 1.04 for the area under the concentration-time curve from 0 to 24 hours and 1.04 for the concentration at the end of the dosing interval.", [["etravirine", "CHEMICAL", 29, 39], ["etravirine", "CHEMICAL", 84, 94], ["etravirine", "CHEMICAL", 29, 39], ["etravirine", "CHEMICAL", 84, 94], ["etravirine", "SIMPLE_CHEMICAL", 29, 39], ["E. purpurea", "ORGANISM", 60, 71], ["etravirine", "SIMPLE_CHEMICAL", 84, 94], ["E. purpurea", "SPECIES", 60, 71], ["E. purpurea", "SPECIES", 60, 71], ["The geometric mean ratio", "TREATMENT", 0, 24], ["etravirine coadministered", "TREATMENT", 29, 54], ["E. purpurea", "TREATMENT", 60, 71], ["etravirine", "TREATMENT", 84, 94]]], ["The data suggested that no dose adjustment for etravirine was necessary.Antiviral ActivityRhinoviruses, infl uenza viruses, herpes viruses and calcivrus were found to be susceptible to E. purpurea ethanol extract and aqueous extract; respiratory syncytial virus, coronavirus (mouse) were susceptible only to E. purpurea ethanol extract, and polio virus was not susceptible to both extracts Vimalanathan et al. 2005 ; Pleschka et al. 2009 ; Hudson 2012 ).In-Vitro StudiesA standardized Echinacea extract (Echinaforce) was found to have dual action against several important respiratory bacteria, a killing effect and an antiinfl ammatory effect .", [["extracts", "ANATOMY", 381, 389], ["etravirine", "CHEMICAL", 47, 57], ["herpes viruses", "DISEASE", 124, 138], ["E. purpurea ethanol extract", "CHEMICAL", 185, 212], ["aqueous extract", "CHEMICAL", 217, 232], ["respiratory syncytial virus", "DISEASE", 234, 261], ["E. purpurea ethanol extract", "CHEMICAL", 308, 335], ["Echinacea extract", "CHEMICAL", 485, 502], ["Echinaforce", "CHEMICAL", 504, 515], ["etravirine", "CHEMICAL", 47, 57], ["ethanol", "CHEMICAL", 197, 204], ["ethanol", "CHEMICAL", 320, 327], ["etravirine", "SIMPLE_CHEMICAL", 47, 57], ["infl uenza viruses", "ORGANISM", 104, 122], ["herpes viruses", "ORGANISM", 124, 138], ["calcivrus", "ORGANISM", 143, 152], ["E. purpurea", "ORGANISM", 185, 196], ["ethanol", "SIMPLE_CHEMICAL", 197, 204], ["extract", "ORGANISM_SUBSTANCE", 205, 212], ["aqueous extract", "ORGANISM_SUBSTANCE", 217, 232], ["respiratory syncytial virus", "ORGANISM", 234, 261], ["coronavirus", "ORGANISM", 263, 274], ["mouse", "ORGANISM", 276, 281], ["E. purpurea", "ORGANISM", 308, 319], ["ethanol", "SIMPLE_CHEMICAL", 320, 327], ["polio virus", "ORGANISM", 341, 352], ["Echinacea", "ORGANISM", 485, 494], ["Echinaforce", "SIMPLE_CHEMICAL", 504, 515], ["herpes viruses", "SPECIES", 124, 138], ["E. purpurea", "SPECIES", 185, 196], ["respiratory syncytial virus", "SPECIES", 234, 261], ["coronavirus", "SPECIES", 263, 274], ["mouse", "SPECIES", 276, 281], ["E. purpurea", "SPECIES", 308, 319], ["Echinacea", "SPECIES", 485, 494], ["infl uenza viruses", "SPECIES", 104, 122], ["E. purpurea", "SPECIES", 185, 196], ["respiratory syncytial virus", "SPECIES", 234, 261], ["mouse", "SPECIES", 276, 281], ["E. purpurea", "SPECIES", 308, 319], ["polio virus", "SPECIES", 341, 352], ["dose adjustment", "TREATMENT", 27, 42], ["etravirine", "TREATMENT", 47, 57], ["Antiviral ActivityRhinoviruses", "TREATMENT", 72, 102], ["infl uenza viruses", "PROBLEM", 104, 122], ["herpes viruses", "PROBLEM", 124, 138], ["calcivrus", "TREATMENT", 143, 152], ["aqueous extract", "PROBLEM", 217, 232], ["respiratory syncytial virus", "PROBLEM", 234, 261], ["coronavirus", "PROBLEM", 263, 274], ["E. purpurea ethanol extract", "PROBLEM", 308, 335], ["polio virus", "PROBLEM", 341, 352], ["several important respiratory bacteria", "PROBLEM", 555, 593], ["a killing effect", "PROBLEM", 595, 611], ["an antiinfl ammatory effect", "TREATMENT", 616, 643], ["respiratory syncytial", "ANATOMY", 234, 255], ["respiratory bacteria", "OBSERVATION", 573, 593]]], ["It readily inactivated Streptococcus pyogenes , often associated with sore throat and more severe pulmonary infections, Haemophilus infl uenzae and Legionella pneumophila , and reversed their proinfl ammatory responses.", [["sore throat", "ANATOMY", 70, 81], ["pulmonary", "ANATOMY", 98, 107], ["Streptococcus pyogenes", "DISEASE", 23, 45], ["sore throat", "DISEASE", 70, 81], ["pulmonary infections", "DISEASE", 98, 118], ["Haemophilus infl uenzae", "DISEASE", 120, 143], ["Streptococcus pyogenes", "ORGANISM", 23, 45], ["throat", "ORGANISM_SUBDIVISION", 75, 81], ["pulmonary", "ORGAN", 98, 107], ["Haemophilus infl uenzae", "ORGANISM", 120, 143], ["Legionella pneumophila", "ORGANISM", 148, 170], ["Streptococcus pyogenes", "SPECIES", 23, 45], ["Haemophilus infl uenzae", "SPECIES", 120, 143], ["Legionella pneumophila", "SPECIES", 148, 170], ["Streptococcus pyogenes", "SPECIES", 23, 45], ["Haemophilus infl uenzae", "SPECIES", 120, 143], ["Legionella pneumophila", "SPECIES", 148, 170], ["Streptococcus pyogenes", "PROBLEM", 23, 45], ["sore throat", "PROBLEM", 70, 81], ["more severe pulmonary infections", "PROBLEM", 86, 118], ["Haemophilus infl uenzae", "PROBLEM", 120, 143], ["Legionella pneumophila", "PROBLEM", 148, 170], ["Streptococcus pyogenes", "OBSERVATION", 23, 45], ["severe", "OBSERVATION_MODIFIER", 91, 97], ["pulmonary", "ANATOMY", 98, 107], ["infections", "OBSERVATION", 108, 118], ["Legionella pneumophila", "OBSERVATION", 148, 170]]], ["Staphylococcus aureus (methicillin-resistant and sensitive strains) and Mycobacterium smegmatis were less sensitive to the bactericidal effects of Echinacea however, but their proinfl ammatory responses were still completely reversed.", [["Staphylococcus aureus", "CHEMICAL", 0, 21], ["methicillin", "CHEMICAL", 23, 34], ["Echinacea", "CHEMICAL", 147, 156], ["methicillin", "CHEMICAL", 23, 34], ["Staphylococcus aureus", "ORGANISM", 0, 21], ["Mycobacterium smegmatis", "GENE_OR_GENE_PRODUCT", 72, 95], ["Echinacea", "ORGANISM", 147, 156], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Mycobacterium smegmatis", "SPECIES", 72, 95], ["Staphylococcus aureus", "SPECIES", 0, 21], ["Mycobacterium smegmatis", "SPECIES", 72, 95], ["Staphylococcus aureus", "PROBLEM", 0, 21], ["methicillin", "TEST", 23, 34], ["sensitive strains)", "PROBLEM", 49, 67], ["Mycobacterium smegmatis", "PROBLEM", 72, 95], ["the bactericidal effects of Echinacea", "PROBLEM", 119, 156], ["aureus", "OBSERVATION", 15, 21], ["Mycobacterium smegmatis", "OBSERVATION", 72, 95]]], ["In contrast some other pathogens tested, including Candida albicans , were relatively resistant.", [["Candida albicans", "DISEASE", 51, 67], ["Candida albicans", "ORGANISM", 51, 67], ["Candida albicans", "SPECIES", 51, 67], ["Candida albicans", "SPECIES", 51, 67], ["Candida albicans", "PROBLEM", 51, 67], ["pathogens", "OBSERVATION", 23, 32], ["Candida albicans", "OBSERVATION", 51, 67]]], ["The results supported the concept of using a standardized Echinacea preparation to control symptoms associated with bacterial respiratory infections.In-Vitro StudiesThe alkylamides undeca-2 Z ,4 E -diene-8,10diynic acid isobutylamide, dodeca-2 E ,4 E ,8 Z , 10 E / Z -tetraenoic acid isobutylamide, dodeca-2 E ,4 E -dienoic acid isobutylamide, and undeca-2 E -ene-8,10-diynoic acid isobutylamide from E. purpurea suppressed production of TNF-\u03b1 and PGE2 from RAW 264.7 macrophage-like cells infected with the H1N1 infl uenza A strain PR/8/34 .", [["respiratory", "ANATOMY", 126, 137], ["RAW 264.7 macrophage-like cells", "ANATOMY", 458, 489], ["bacterial respiratory infections", "DISEASE", 116, 148], ["alkylamides undeca-2 Z ,4 E -diene-8,10diynic acid isobutylamide", "CHEMICAL", 169, 233], ["dodeca-2 E ,4 E ,8 Z , 10 E / Z -tetraenoic acid", "CHEMICAL", 235, 283], ["isobutylamide", "CHEMICAL", 284, 297], ["dodeca-2 E ,4 E -dienoic acid isobutylamide", "CHEMICAL", 299, 342], ["undeca-2 E -ene-8,10-diynoic acid", "CHEMICAL", 348, 381], ["isobutylamide", "CHEMICAL", 382, 395], ["PGE2", "CHEMICAL", 448, 452], ["alkylamides undeca-2 Z ,4 E -diene-8,10diynic acid isobutylamide", "CHEMICAL", 169, 233], ["dodeca-2 E ,4 E ,8 Z , 10 E / Z -tetraenoic acid isobutylamide", "CHEMICAL", 235, 297], ["dodeca-2 E ,4 E -dienoic acid isobutylamide", "CHEMICAL", 299, 342], ["undeca-2 E -ene-8,10-diynoic acid isobutylamide", "CHEMICAL", 348, 395], ["PGE2", "CHEMICAL", 448, 452], ["Echinacea", "ORGANISM", 58, 67], ["alkylamides undeca-2 Z ,4 E -diene-8,10diynic acid isobutylamide", "SIMPLE_CHEMICAL", 169, 233], ["dodeca-2 E ,4 E ,8 Z , 10 E / Z -tetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 235, 297], ["dodeca-2 E ,4 E -dienoic acid isobutylamide", "SIMPLE_CHEMICAL", 299, 342], ["undeca-2 E -ene-8,10-diynoic acid isobutylamide", "SIMPLE_CHEMICAL", 348, 395], ["E. purpurea", "ORGANISM", 401, 412], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 438, 443], ["PGE2", "SIMPLE_CHEMICAL", 448, 452], ["RAW 264.7 macrophage-like cells", "CELL", 458, 489], ["H1N1", "ORGANISM", 508, 512], ["infl uenza A", "ORGANISM", 513, 525], ["TNF", "PROTEIN", 438, 441], ["RAW 264.7 macrophage-like cells", "CELL_LINE", 458, 489], ["PR", "PROTEIN", 533, 535], ["E. purpurea", "SPECIES", 401, 412], ["E. purpurea", "SPECIES", 401, 412], ["H1N1 infl uenza A strain PR/8/34", "SPECIES", 508, 540], ["a standardized Echinacea preparation", "TREATMENT", 43, 79], ["symptoms", "PROBLEM", 91, 99], ["bacterial respiratory infections", "PROBLEM", 116, 148], ["alkylamides", "TEST", 169, 180], ["undeca", "TEST", 181, 187], ["Z", "TEST", 190, 191], ["diene", "TEST", 198, 203], ["isobutylamide", "TEST", 220, 233], ["dodeca", "TEST", 235, 241], ["Z", "TEST", 254, 255], ["Z", "TEST", 265, 266], ["tetraenoic acid", "TEST", 268, 283], ["isobutylamide", "TEST", 284, 297], ["dodeca", "TEST", 299, 305], ["dienoic acid isobutylamide", "TEST", 316, 342], ["undeca", "TEST", 348, 354], ["diynoic acid isobutylamide", "TREATMENT", 369, 395], ["TNF", "TEST", 438, 441], ["PGE2 from RAW", "TEST", 448, 461], ["macrophage", "TEST", 468, 478], ["like cells", "PROBLEM", 479, 489], ["bacterial", "OBSERVATION_MODIFIER", 116, 125], ["respiratory infections", "OBSERVATION", 126, 148]]], ["Dodeca-2 E ,4 Edienoic acid isobutylamide was especially effective at inhibiting production of these mediators and also strongly inhibited production of G-CSF, CCL2/MCP-1, CCL3/MIP-1\u03b1 and CCL5/ RANTES.", [["Dodeca-2 E ,4 Edienoic acid", "CHEMICAL", 0, 27], ["isobutylamide", "CHEMICAL", 28, 41], ["Dodeca-2 E ,4 Edienoic acid isobutylamide", "CHEMICAL", 0, 41], ["Dodeca-2 E", "SIMPLE_CHEMICAL", 0, 10], ["4 Edienoic acid isobutylamide", "SIMPLE_CHEMICAL", 12, 41], ["G-CSF", "GENE_OR_GENE_PRODUCT", 153, 158], ["CCL2", "GENE_OR_GENE_PRODUCT", 160, 164], ["MCP-1", "GENE_OR_GENE_PRODUCT", 165, 170], ["CCL3", "GENE_OR_GENE_PRODUCT", 172, 176], ["MIP-1\u03b1", "GENE_OR_GENE_PRODUCT", 177, 183], ["CCL5", "GENE_OR_GENE_PRODUCT", 188, 192], ["RANTES", "GENE_OR_GENE_PRODUCT", 194, 200], ["CSF", "PROTEIN", 155, 158], ["CCL2", "PROTEIN", 160, 164], ["MCP-1", "PROTEIN", 165, 170], ["CCL3", "PROTEIN", 172, 176], ["MIP-1\u03b1", "PROTEIN", 177, 183], ["CCL5", "PROTEIN", 188, 192], ["RANTES", "PROTEIN", 194, 200], ["Dodeca", "TEST", 0, 6], ["Edienoic acid isobutylamide", "TREATMENT", 14, 41], ["G-CSF", "TEST", 153, 158], ["CCL2", "TEST", 160, 164], ["MCP", "TEST", 165, 168], ["CCL3", "TEST", 172, 176], ["MIP", "TEST", 177, 180], ["CCL5/ RANTES", "TEST", 188, 200], ["CCL5", "ANATOMY", 188, 192]]], ["In contrast, the ethanol extracts (75 %), prepared from E. purpurea dormant roots, displayed a range of effects from suppression to stimulation of mediator production.", [["extracts", "ANATOMY", 25, 33], ["roots", "ANATOMY", 76, 81], ["ethanol", "CHEMICAL", 17, 24], ["ethanol", "CHEMICAL", 17, 24], ["ethanol extracts", "ORGANISM_SUBSTANCE", 17, 33], ["E. purpurea", "ORGANISM", 56, 67], ["roots", "ORGAN", 76, 81], ["E. purpurea", "SPECIES", 56, 67], ["E. purpurea", "SPECIES", 56, 67], ["the ethanol extracts", "TREATMENT", 13, 33], ["mediator production", "PROBLEM", 147, 166], ["purpurea", "OBSERVATION_MODIFIER", 59, 67], ["dormant roots", "OBSERVATION", 68, 81]]], ["Analysis of the extracts revealed slight variations in concentration of alkylamides, caftaric acid and cichoric acid, but the activity of the extracts did not strongly correlate with concentrations of these compounds.", [["extracts", "ANATOMY", 16, 24], ["extracts", "ANATOMY", 142, 150], ["alkylamides", "CHEMICAL", 72, 83], ["caftaric acid", "CHEMICAL", 85, 98], ["cichoric acid", "CHEMICAL", 103, 116], ["alkylamides", "CHEMICAL", 72, 83], ["caftaric acid", "CHEMICAL", 85, 98], ["cichoric acid", "CHEMICAL", 103, 116], ["extracts", "ORGANISM_SUBSTANCE", 16, 24], ["alkylamides", "SIMPLE_CHEMICAL", 72, 83], ["caftaric acid", "SIMPLE_CHEMICAL", 85, 98], ["cichoric acid", "SIMPLE_CHEMICAL", 103, 116], ["extracts", "ORGANISM_SUBSTANCE", 142, 150], ["Analysis of the extracts", "TEST", 0, 24], ["slight variations", "PROBLEM", 34, 51], ["alkylamides", "TREATMENT", 72, 83], ["caftaric acid and cichoric acid", "PROBLEM", 85, 116], ["slight", "OBSERVATION_MODIFIER", 34, 40], ["variations", "OBSERVATION_MODIFIER", 41, 51]]], ["The in-vitro studies suggested E. purpurea extracts to have the potential for use in alleviating the symptoms and pathology associated with infections with infl uenza A.Clinical/Human StudiesSome herbal preparations, including Echinacea purpurea , had been reported to improve cold symptoms in adults but ineffective in children (Fashner et al. 2012 ) .", [["extracts", "ANATOMY", 43, 51], ["infections", "DISEASE", 140, 150], ["Echinacea purpurea", "CHEMICAL", 227, 245], ["E. purpurea", "ORGANISM", 31, 42], ["extracts", "ORGANISM_SUBSTANCE", 43, 51], ["Human", "ORGANISM", 178, 183], ["Echinacea purpurea", "ORGANISM", 227, 245], ["children", "ORGANISM", 320, 328], ["E. purpurea", "SPECIES", 31, 42], ["Human", "SPECIES", 178, 183], ["Echinacea purpurea", "SPECIES", 227, 245], ["children", "SPECIES", 320, 328], ["E. purpurea", "SPECIES", 31, 42], ["Echinacea purpurea", "SPECIES", 227, 245], ["The in-vitro studies", "TEST", 0, 20], ["E. purpurea extracts", "PROBLEM", 31, 51], ["the symptoms", "PROBLEM", 97, 109], ["pathology", "PROBLEM", 114, 123], ["infections", "PROBLEM", 140, 150], ["Some herbal preparations", "TREATMENT", 191, 215], ["Echinacea purpurea", "PROBLEM", 227, 245], ["cold symptoms", "PROBLEM", 277, 290]]], ["Randolph et al. ( 2003 ) found that the overall gene expression pattern at 48 hours to 12 days after taking Echinacea product for cold and fl u by six healthy nonsmoking subjects (18-65 years of age)was consistent with an antiinfl ammatory response.", [["Echinacea", "CHEMICAL", 108, 117], ["Echinacea", "ORGANISM", 108, 117], ["Echinacea product", "TREATMENT", 108, 125]]], ["The expression of interleukin-1 beta, tumour necrosis factor-alpha, intracellular adhesion molecule and interleukin-8 was modestly decreased up through day 5, returning to baseline by day 12.", [["intracellular", "ANATOMY", 68, 81], ["necrosis", "DISEASE", 45, 53], ["interleukin-1 beta", "GENE_OR_GENE_PRODUCT", 18, 36], ["tumour necrosis factor-alpha", "GENE_OR_GENE_PRODUCT", 38, 66], ["intracellular adhesion molecule", "GENE_OR_GENE_PRODUCT", 68, 99], ["interleukin-8", "GENE_OR_GENE_PRODUCT", 104, 117], ["interleukin-1 beta", "PROTEIN", 18, 36], ["tumour necrosis factor-alpha", "PROTEIN", 38, 66], ["intracellular adhesion molecule", "PROTEIN", 68, 99], ["interleukin-8", "PROTEIN", 104, 117], ["interleukin", "TEST", 18, 29], ["tumour necrosis factor", "PROBLEM", 38, 60], ["alpha, intracellular adhesion molecule", "PROBLEM", 61, 99], ["interleukin", "TEST", 104, 115], ["tumour", "OBSERVATION_MODIFIER", 38, 44], ["necrosis", "OBSERVATION", 45, 53], ["alpha", "ANATOMY", 61, 66], ["intracellular", "ANATOMY_MODIFIER", 68, 81], ["adhesion molecule", "OBSERVATION", 82, 99], ["modestly", "OBSERVATION_MODIFIER", 122, 130], ["decreased", "OBSERVATION_MODIFIER", 131, 140]]], ["The expression of interferon-alpha steadily rose through day 12, consistent with an antiviral response.", [["interferon-alpha", "GENE_OR_GENE_PRODUCT", 18, 34], ["interferon-alpha", "PROTEIN", 18, 34], ["interferon", "TREATMENT", 18, 28], ["an antiviral response", "PROBLEM", 81, 102], ["interferon", "OBSERVATION", 18, 28], ["consistent with", "UNCERTAINTY", 65, 80], ["antiviral response", "OBSERVATION", 84, 102]]], ["The data presented a gene expression response pattern that was consistent with Echinacea 's reported ability to reduce both the duration and intensity of cold and fl u symptoms.Clinical/Human StudiesMixed results have been obtained in clinical studies on the effi cacy of E. purpurea in combating respiratory tract infections.", [["respiratory tract", "ANATOMY", 297, 314], ["respiratory tract infections", "DISEASE", 297, 325], ["Echinacea", "ORGANISM", 79, 88], ["Human", "ORGANISM", 186, 191], ["E. purpurea", "ORGANISM", 272, 283], ["respiratory tract", "ORGANISM_SUBDIVISION", 297, 314], ["Echinacea", "SPECIES", 79, 88], ["Human", "SPECIES", 186, 191], ["E. purpurea", "SPECIES", 272, 283], ["E. purpurea", "SPECIES", 272, 283], ["Echinacea 's", "PROBLEM", 79, 91], ["cold and fl u symptoms", "PROBLEM", 154, 176], ["Clinical/Human Studies", "TEST", 177, 199], ["clinical studies", "TEST", 235, 251], ["E. purpurea", "PROBLEM", 272, 283], ["respiratory tract infections", "PROBLEM", 297, 325], ["consistent with", "UNCERTAINTY", 63, 78], ["purpurea", "OBSERVATION", 275, 283], ["respiratory tract", "ANATOMY", 297, 314], ["infections", "OBSERVATION", 315, 325]]], ["In a randomized, double-blind, placebo-controlled study, 246 of 559 recruited healthy, adult volunteers contracted a common cold and took 3 times daily 2 tablets of either Echinaforce\u00ae ( Echinacea purpurea preparation from 95 % herba and 5 % radix), Echinacea purpurea concentrate (same preparation at 7 times higher concentration), special Echinacea purpurea radix preparation (totally different from that of Echinaforce\u00ae) or placebo until they felt healthy again but not longer than 7 days (Brinkeborn et al. 1999 ) .", [["Echinaforce\u00ae", "CHEMICAL", 172, 184], ["Echinacea purpurea", "CHEMICAL", 187, 205], ["Echinacea purpurea", "CHEMICAL", 250, 268], ["Echinacea purpurea radix", "CHEMICAL", 341, 365], ["Echinaforce\u00ae", "CHEMICAL", 410, 422], ["volunteers", "ORGANISM", 93, 103], ["radix", "ORGANISM_SUBDIVISION", 242, 247], ["Echinacea", "ORGANISM", 250, 259], ["Echinacea purpurea", "SPECIES", 187, 205], ["Echinacea purpurea", "SPECIES", 250, 268], ["Echinacea purpurea", "SPECIES", 341, 359], ["Echinacea purpurea", "SPECIES", 187, 205], ["Echinacea purpurea", "SPECIES", 250, 268], ["Echinacea purpurea", "SPECIES", 341, 359], ["placebo", "TREATMENT", 31, 38], ["Echinaforce\u00ae ( Echinacea purpurea preparation", "TREATMENT", 172, 217], ["herba", "TREATMENT", 228, 233], ["Echinacea purpurea concentrate", "TREATMENT", 250, 280], ["special Echinacea purpurea radix preparation", "TREATMENT", 333, 377], ["Echinaforce\u00ae", "TREATMENT", 410, 422], ["placebo", "TREATMENT", 427, 434]]], ["It was found that Echinaforce\u00ae and its concentrated preparation were signifi cantly more effective than the special Echinacea extract or placebo.", [["extract", "ANATOMY", 126, 133], ["Echinaforce\u00ae", "CHEMICAL", 18, 30], ["Echinacea extract", "CHEMICAL", 116, 133], ["Echinaforce\u00ae", "CHEMICAL", 18, 30], ["Echinaforce\u00ae", "SIMPLE_CHEMICAL", 18, 30], ["Echinacea", "ORGANISM", 116, 125], ["Echinacea", "SPECIES", 116, 125], ["Echinaforce\u00ae", "TREATMENT", 18, 30], ["the special Echinacea extract", "TREATMENT", 104, 133], ["placebo", "TREATMENT", 137, 144]]], ["All treatments were well tolerated.", [["All treatments", "TREATMENT", 0, 14]]], ["Among the Echinacea groups the frequency of adverse events was not signifi cantly higher than in the placebo group.", [["Echinacea", "ORGANISM", 10, 19], ["adverse events", "PROBLEM", 44, 58], ["Echinacea", "OBSERVATION_MODIFIER", 10, 19]]], ["They concluded that Echinacea concentrate as well as Echinaforce\u00ae represented a low-risk and effective alternative to the standard symptomatic medicines in the acute treatment of common cold.Clinical/Human StudiesIn a randomized, double-blind, placebocontrolled trial, 282 subjects aged 18-65 years, a total of 128 subjects contracted a common cold (59 echinacea, 69 placebo) (Goel et al. 2004 ).", [["Echinaforce\u00ae", "CHEMICAL", 53, 65], ["Echinacea", "ORGANISM", 20, 29], ["Human", "ORGANISM", 200, 205], ["subjects", "ORGANISM", 315, 323], ["Echinacea", "SPECIES", 20, 29], ["Human", "SPECIES", 200, 205], ["Echinacea concentrate", "TREATMENT", 20, 41], ["the standard symptomatic medicines", "TREATMENT", 118, 152], ["the acute treatment", "TREATMENT", 156, 175], ["common cold", "PROBLEM", 179, 190], ["acute", "OBSERVATION_MODIFIER", 160, 165]]], ["The total daily symptom scores were found to be 23.1 % lower in the echinacea group than in placebo in those who followed all elements of the study protocol.", [["echinacea", "CHEMICAL", 68, 77], ["echinacea", "CANCER", 68, 77], ["The total daily symptom scores", "TEST", 0, 30], ["the study protocol", "TEST", 138, 156]]], ["Throughout the treatment period, the response rate to treatments was greater in the echinacea group.", [["echinacea", "CHEMICAL", 84, 93], ["echinacea", "CANCER", 84, 93], ["treatments", "TREATMENT", 54, 64], ["greater", "OBSERVATION_MODIFIER", 69, 76]]], ["A few adverse event profi les were observed in both groups.", [["A few adverse event profi les", "PROBLEM", 0, 29], ["few", "OBSERVATION_MODIFIER", 2, 5], ["adverse", "OBSERVATION_MODIFIER", 6, 13]]], ["The researchers concluded that early intervention with a standardized formulation of echinacea resulted in reduced symptom severity in subjects with naturally acquired upper respiratory tract infection.", [["upper respiratory tract", "ANATOMY", 168, 191], ["echinacea", "CHEMICAL", 85, 94], ["upper respiratory tract infection", "DISEASE", 168, 201], ["echinacea", "SIMPLE_CHEMICAL", 85, 94], ["upper respiratory", "ORGANISM_SUBDIVISION", 168, 185], ["tract", "ORGANISM_SUBDIVISION", 186, 191], ["early intervention", "TREATMENT", 31, 49], ["a standardized formulation of echinacea", "TREATMENT", 55, 94], ["reduced symptom severity", "PROBLEM", 107, 131], ["naturally acquired upper respiratory tract infection", "PROBLEM", 149, 201], ["reduced", "OBSERVATION_MODIFIER", 107, 114], ["upper", "ANATOMY_MODIFIER", 168, 173], ["respiratory tract", "ANATOMY", 174, 191], ["infection", "OBSERVATION", 192, 201]]], ["In a clinical study, Echinilin (a formulation prepared from freshly harvested Echinacea purpurea plants and standardized on the basis of three known active components: alkamides, cichoric acid and polysaccharides) or placebo was administered to volunteers at the onset of their cold for a period of 7 days, with eight doses (5 ml/dose) on day 1 and three doses on subsequent days (Goel et al. 2005 ) .", [["Echinilin", "CHEMICAL", 21, 30], ["alkamides", "CHEMICAL", 168, 177], ["cichoric acid", "CHEMICAL", 179, 192], ["Echinilin", "CHEMICAL", 21, 30], ["alkamides", "CHEMICAL", 168, 177], ["cichoric acid", "CHEMICAL", 179, 192], ["Echinilin", "SIMPLE_CHEMICAL", 21, 30], ["alkamides", "SIMPLE_CHEMICAL", 168, 177], ["cichoric acid", "SIMPLE_CHEMICAL", 179, 192], ["polysaccharides", "SIMPLE_CHEMICAL", 197, 212], ["volunteers", "ORGANISM", 245, 255], ["Echinacea purpurea", "SPECIES", 78, 96], ["Echinacea purpurea", "SPECIES", 78, 96], ["a clinical study", "TEST", 3, 19], ["Echinilin", "TREATMENT", 21, 30], ["a formulation", "TREATMENT", 32, 45], ["freshly harvested Echinacea purpurea plants", "TREATMENT", 60, 103], ["alkamides", "TREATMENT", 168, 177], ["cichoric acid and polysaccharides", "TREATMENT", 179, 212], ["placebo", "TREATMENT", 217, 224]]], ["The decrease in total daily symptomatic score was more evident in the echinacea group than in the placebo group.", [["echinacea", "CHEMICAL", 70, 79], ["echinacea", "CANCER", 70, 79], ["The decrease in total daily symptomatic score", "PROBLEM", 0, 45], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["total", "OBSERVATION_MODIFIER", 16, 21], ["symptomatic", "OBSERVATION_MODIFIER", 28, 39]]], ["These effects of echinacea were associated with a signifi cant and sustained increase in the number of circulating total white blood cells, monocytes, neutrophils and natural killer cells.", [["white blood cells", "ANATOMY", 121, 138], ["monocytes", "ANATOMY", 140, 149], ["neutrophils", "ANATOMY", 151, 162], ["natural killer cells", "ANATOMY", 167, 187], ["echinacea", "CHEMICAL", 17, 26], ["echinacea", "SIMPLE_CHEMICAL", 17, 26], ["white blood cells", "CELL", 121, 138], ["monocytes", "CELL", 140, 149], ["neutrophils", "CELL", 151, 162], ["natural killer cells", "CELL", 167, 187], ["circulating total white blood cells", "CELL_TYPE", 103, 138], ["monocytes", "CELL_TYPE", 140, 149], ["neutrophils", "CELL_TYPE", 151, 162], ["natural killer cells", "CELL_TYPE", 167, 187], ["echinacea", "PROBLEM", 17, 26], ["a signifi cant", "PROBLEM", 48, 62], ["circulating total white blood cells", "TEST", 103, 138], ["monocytes", "TEST", 140, 149], ["neutrophils", "TEST", 151, 162], ["echinacea", "OBSERVATION", 17, 26], ["sustained", "OBSERVATION_MODIFIER", 67, 76], ["increase", "OBSERVATION_MODIFIER", 77, 85], ["natural killer cells", "OBSERVATION", 167, 187]]], ["In the later part of the cold, the echinacea treatment suppressed the cold-related increase in superoxide production by the neutrophils.", [["neutrophils", "ANATOMY", 124, 135], ["echinacea", "CHEMICAL", 35, 44], ["superoxide", "CHEMICAL", 95, 105], ["superoxide", "CHEMICAL", 95, 105], ["echinacea", "SIMPLE_CHEMICAL", 35, 44], ["superoxide", "SIMPLE_CHEMICAL", 95, 105], ["neutrophils", "CELL", 124, 135], ["neutrophils", "CELL_TYPE", 124, 135], ["the echinacea treatment", "TREATMENT", 31, 54], ["the cold-related increase in superoxide production", "PROBLEM", 66, 116], ["increase", "OBSERVATION_MODIFIER", 83, 91], ["superoxide production", "OBSERVATION", 95, 116], ["neutrophils", "ANATOMY", 124, 135]]], ["The results suggested that Echinilin, by enhancing the nonspecifi c immune response and eliciting free radical scavenging properties, may have led to a faster resolution of the cold symptoms.", [["Echinilin", "CHEMICAL", 27, 36], ["Echinilin", "CHEMICAL", 27, 36], ["Echinilin", "SIMPLE_CHEMICAL", 27, 36], ["Echinilin", "TREATMENT", 27, 36], ["eliciting free radical scavenging properties", "PROBLEM", 88, 132], ["the cold symptoms", "PROBLEM", 173, 190], ["free", "OBSERVATION_MODIFIER", 98, 102], ["radical scavenging", "OBSERVATION", 103, 121]]], ["Jawad et al. ( 2012 ) conducted a 4-month randomized, double-blind, placebo-controlled trial to investigate the safety (risk) and effi cacy (benefi t) of Echinacea purpurea (95 % herba and 5 % root) extract in the prevention of common cold episodes with 755 healthy subjects.", [["root", "ANATOMY", 193, 197], ["Echinacea purpurea", "CHEMICAL", 154, 172], ["effi cacy", "SIMPLE_CHEMICAL", 130, 139], ["Echinacea purpurea", "ORGANISM", 154, 172], ["root", "TISSUE", 193, 197], ["Echinacea purpurea", "SPECIES", 154, 172], ["Echinacea purpurea", "SPECIES", 154, 172], ["double-blind", "TREATMENT", 54, 66], ["placebo", "TREATMENT", 68, 75], ["Echinacea purpurea", "PROBLEM", 154, 172], ["common cold episodes", "PROBLEM", 228, 248], ["Echinacea purpurea", "ANATOMY", 154, 172]]], ["Echinacea extract found to reduce the total number of cold episodes, cumulated episode days within the group, and painkiller-medicated episodes.", [["Echinacea extract", "CHEMICAL", 0, 17], ["Echinacea", "ORGANISM", 0, 9], ["Echinacea", "SPECIES", 0, 9], ["Echinacea extract", "PROBLEM", 0, 17], ["cold episodes", "PROBLEM", 54, 67], ["painkiller-medicated episodes", "PROBLEM", 114, 143], ["total", "OBSERVATION_MODIFIER", 38, 43], ["number", "OBSERVATION_MODIFIER", 44, 50], ["cold episodes", "OBSERVATION_MODIFIER", 54, 67]]], ["Echinacea inhibited virally confi rmed colds and especially prevented enveloped virus infections.", [["Echinacea", "CHEMICAL", 0, 9], ["colds", "DISEASE", 39, 44], ["enveloped virus infections", "DISEASE", 70, 96], ["Echinacea", "ORGANISM", 0, 9], ["Echinacea", "SPECIES", 0, 9], ["Echinacea", "PROBLEM", 0, 9], ["virally confi rmed colds", "PROBLEM", 20, 44], ["enveloped virus infections", "PROBLEM", 70, 96], ["virus infections", "OBSERVATION", 80, 96]]], ["Echinacea showed maximal effects on recurrent infections, and preventive effects increased with therapy compliance and adherence to the protocol.", [["Echinacea", "CHEMICAL", 0, 9], ["infections", "DISEASE", 46, 56], ["Echinacea", "ORGANISM", 0, 9], ["Echinacea", "SPECIES", 0, 9], ["Echinacea", "TEST", 0, 9], ["maximal effects", "PROBLEM", 17, 32], ["recurrent infections", "PROBLEM", 36, 56], ["therapy compliance", "TREATMENT", 96, 114], ["the protocol", "TREATMENT", 132, 144], ["maximal effects", "OBSERVATION", 17, 32], ["recurrent", "OBSERVATION_MODIFIER", 36, 45], ["infections", "OBSERVATION", 46, 56]]], ["A total of 293 adverse events occurred with echinacea and 306 with placebo treatment.", [["echinacea", "CHEMICAL", 44, 53], ["adverse events", "PROBLEM", 15, 29], ["echinacea", "TREATMENT", 44, 53], ["placebo treatment", "TREATMENT", 67, 84]]], ["Nine and 10 % of participants experienced adverse events, which were at least possibly related to the study drug (adverse drug reactions).", [["adverse drug reactions", "DISEASE", 114, 136], ["participants", "ORGANISM", 17, 29], ["participants", "SPECIES", 17, 29], ["adverse events", "PROBLEM", 42, 56], ["the study drug", "PROBLEM", 98, 112], ["adverse drug reactions", "PROBLEM", 114, 136]]], ["Thus, the safety of Echinacea was noninferior to placebo.", [["Echinacea", "CHEMICAL", 20, 29], ["Echinacea", "ORGANISM", 20, 29], ["Echinacea", "TREATMENT", 20, 29], ["placebo", "TREATMENT", 49, 56]]], ["The study concluded that compliant prophylactic intake of E. purpurea over a 4-month period appeared to provide a positive risk to benefi t ratio In a randomized, placebo-controlled, doubleblind study, treatment with fl uid extract of Echinacea purpurea (widely used for the prevention and treatment of colds and respiratory infections), did not signifi cantly decrease the incidence, duration or severity of colds and respiratory infections compared to placebo (Grimm and M\u00fcller 1999 ) .", [["respiratory", "ANATOMY", 313, 324], ["respiratory", "ANATOMY", 419, 430], ["fl uid extract of Echinacea purpurea", "CHEMICAL", 217, 253], ["colds", "DISEASE", 303, 308], ["respiratory infections", "DISEASE", 313, 335], ["colds", "DISEASE", 409, 414], ["respiratory infections", "DISEASE", 419, 441], ["E. purpurea", "ORGANISM", 58, 69], ["fl uid", "SIMPLE_CHEMICAL", 217, 223], ["Echinacea purpurea", "ORGANISM", 235, 253], ["E. purpurea", "SPECIES", 58, 69], ["Echinacea purpurea", "SPECIES", 235, 253], ["E. purpurea", "SPECIES", 58, 69], ["Echinacea purpurea", "SPECIES", 235, 253], ["The study", "TEST", 0, 9], ["E. purpurea", "PROBLEM", 58, 69], ["placebo", "TREATMENT", 163, 170], ["doubleblind study", "TEST", 183, 200], ["treatment", "TREATMENT", 202, 211], ["fl uid extract", "TREATMENT", 217, 231], ["Echinacea purpurea", "TREATMENT", 235, 253], ["the prevention", "TREATMENT", 271, 285], ["treatment", "TREATMENT", 290, 299], ["colds", "PROBLEM", 303, 308], ["respiratory infections", "PROBLEM", 313, 335], ["colds", "PROBLEM", 409, 414], ["respiratory infections", "PROBLEM", 419, 441], ["respiratory", "ANATOMY", 313, 324], ["infections", "OBSERVATION", 325, 335], ["respiratory", "ANATOMY", 419, 430], ["infections", "OBSERVATION", 431, 441]]], ["During the 8-week treatment period, 35 (65 %) of 54 patients in the echinacea group and 40 (74 %) of 54 patients in the placebo group had at least one cold or respiratory infection.", [["respiratory", "ANATOMY", 159, 170], ["echinacea", "DISEASE", 68, 77], ["respiratory infection", "DISEASE", 159, 180], ["patients", "ORGANISM", 52, 60], ["echinacea", "CANCER", 68, 77], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 104, 112], ["respiratory infection", "PROBLEM", 159, 180], ["respiratory", "ANATOMY", 159, 170], ["infection", "OBSERVATION", 171, 180]]], ["The average number of colds and respiratory infections per patient was 0.78 in the echinacea group, and 0.93 in the placebo group.", [["respiratory", "ANATOMY", 32, 43], ["colds", "DISEASE", 22, 27], ["respiratory infections", "DISEASE", 32, 54], ["echinacea", "DISEASE", 83, 92], ["patient", "ORGANISM", 59, 66], ["echinacea", "CANCER", 83, 92], ["patient", "SPECIES", 59, 66], ["colds", "PROBLEM", 22, 27], ["respiratory infections", "PROBLEM", 32, 54], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["colds", "OBSERVATION", 22, 27], ["respiratory infections", "OBSERVATION", 32, 54]]], ["There were no signifi cant differences between treatment groups in the number of infections in each category of severity.", [["infections", "DISEASE", 81, 91], ["signifi cant differences", "PROBLEM", 14, 38], ["treatment groups", "TREATMENT", 47, 63], ["infections", "PROBLEM", 81, 91], ["no", "UNCERTAINTY", 11, 13], ["infections", "OBSERVATION", 81, 91]]], ["Side effects were observed in 11 patients (20 %) of the echinacea group and in seven patients (13 %) of the placebo group.", [["echinacea", "ANATOMY", 56, 65], ["echinacea", "DISEASE", 56, 65], ["patients", "ORGANISM", 33, 41], ["echinacea", "CANCER", 56, 65], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 85, 93], ["Side effects", "PROBLEM", 0, 12], ["the echinacea group", "TREATMENT", 52, 71], ["the placebo group", "TREATMENT", 104, 121]]], ["In a randomized, double-blind placebocontrolled trial of 175 adults travelling back from Australia to America, Europe or Africa for a period of 1-5 weeks on commercial fl ights via economy class, supplementation with standardized Echinacea tablets, taken before and during travel, may have preventive effects against the development of respiratory symptoms during travel involving long-haul fl ights (Tiralongo et al. 2012 ) .", [["respiratory", "ANATOMY", 336, 347], ["respiratory symptoms", "DISEASE", 336, 356], ["adults", "ORGANISM", 61, 67], ["Echinacea", "ORGANISM", 230, 239], ["double-blind placebocontrolled trial", "TREATMENT", 17, 53], ["supplementation", "TREATMENT", 196, 211], ["standardized Echinacea tablets", "TREATMENT", 217, 247], ["respiratory symptoms", "PROBLEM", 336, 356]]], ["In another study, 128 patients were enrolled within 24 hours of cold symptom onset in a randomized, double-blind, placebo-controlled design wherein patients received either 100 mg of E. purpurea (freeze-dried pressed juice from the aerial portion of the plant) or a lactose placebo 3 times daily until cold symptoms were relieved or until the end of 14 days, whichever came fi rst ( Yale and Liu 2004 ) .", [["juice", "ANATOMY", 217, 222], ["lactose", "CHEMICAL", 266, 273], ["lactose", "CHEMICAL", 266, 273], ["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 148, 156], ["E. purpurea", "ORGANISM", 183, 194], ["juice", "ORGANISM_SUBSTANCE", 217, 222], ["lactose", "SIMPLE_CHEMICAL", 266, 273], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 148, 156], ["E. purpurea", "SPECIES", 183, 194], ["E. purpurea", "SPECIES", 183, 194], ["another study", "TEST", 3, 16], ["cold symptom onset", "PROBLEM", 64, 82], ["double-blind", "TREATMENT", 100, 112], ["placebo", "TREATMENT", 114, 121], ["E. purpurea", "PROBLEM", 183, 194], ["a lactose placebo", "TREATMENT", 264, 281], ["cold symptoms", "PROBLEM", 302, 315]]], ["No statistically signifi cant difference was observed between treatment groups for either total symptom scores or mean individual symptom scores.", [["statistically signifi cant difference", "PROBLEM", 3, 40], ["treatment groups", "TREATMENT", 62, 78], ["total symptom scores", "PROBLEM", 90, 110], ["mean individual symptom scores", "PROBLEM", 114, 144], ["statistically", "OBSERVATION_MODIFIER", 3, 16], ["signifi", "OBSERVATION_MODIFIER", 17, 24]]], ["The time to resolution of symptoms was not statistically different.", [["symptoms", "PROBLEM", 26, 34]]], ["The effi cacy of E. purpurea in reducing common cold was not confi rmed.Clinical/Human StudiesIn a multicenter randomized placebo controlled trial, Echinacea purpurea was found ineffective for treating upper respiratory tract infections in children aged 2-11 years (Mainous 2004 ).", [["upper respiratory tract", "ANATOMY", 202, 225], ["Echinacea purpurea", "CHEMICAL", 148, 166], ["upper respiratory tract infections", "DISEASE", 202, 236], ["E. purpurea", "ORGANISM", 17, 28], ["Human", "ORGANISM", 81, 86], ["Echinacea", "ORGANISM", 148, 157], ["upper", "ORGANISM_SUBDIVISION", 202, 207], ["respiratory tract", "ORGANISM_SUBDIVISION", 208, 225], ["children", "ORGANISM", 240, 248], ["E. purpurea", "SPECIES", 17, 28], ["Human", "SPECIES", 81, 86], ["Echinacea purpurea", "SPECIES", 148, 166], ["children", "SPECIES", 240, 248], ["E. purpurea", "SPECIES", 17, 28], ["Echinacea purpurea", "SPECIES", 148, 166], ["E. purpurea", "PROBLEM", 17, 28], ["Clinical/Human Studies", "TEST", 72, 94], ["a multicenter randomized placebo controlled trial", "TREATMENT", 97, 146], ["Echinacea purpurea", "PROBLEM", 148, 166], ["upper respiratory tract infections", "PROBLEM", 202, 236], ["purpurea", "OBSERVATION_MODIFIER", 20, 28], ["upper", "ANATOMY_MODIFIER", 202, 207], ["respiratory tract", "ANATOMY", 208, 225]]], ["There was no signifi cant difference in duration or severity of symptoms with Echinacea purpurea compared with placebo in children with upper respiratory tract infection.", [["upper respiratory tract", "ANATOMY", 136, 159], ["Echinacea purpurea", "CHEMICAL", 78, 96], ["respiratory tract infection", "DISEASE", 142, 169], ["Echinacea purpurea", "ORGANISM", 78, 96], ["children", "ORGANISM", 122, 130], ["upper respiratory", "ORGANISM_SUBDIVISION", 136, 153], ["tract", "ORGANISM_SUBDIVISION", 154, 159], ["Echinacea purpurea", "SPECIES", 78, 96], ["children", "SPECIES", 122, 130], ["Echinacea purpurea", "SPECIES", 78, 96], ["signifi cant difference in duration", "PROBLEM", 13, 48], ["severity of symptoms", "PROBLEM", 52, 72], ["Echinacea purpurea", "PROBLEM", 78, 96], ["placebo", "TREATMENT", 111, 118], ["upper respiratory tract infection", "PROBLEM", 136, 169], ["no", "UNCERTAINTY", 10, 12], ["upper", "ANATOMY_MODIFIER", 136, 141], ["respiratory tract", "ANATOMY", 142, 159], ["infection", "OBSERVATION", 160, 169]]], ["In another randomized, double-blind, placebo-controlled trial of 407 children aged 2-11 years including 337 upper respiratory tract infections (URIs) treated with echinacea and 370 with placebo, Echinacea purpurea was found not effective in treating URI symptoms in these children, and its use was associated with an increased risk of rash (Taylor et al. 2003 ) .", [["upper respiratory tract", "ANATOMY", 108, 131], ["respiratory tract infections", "DISEASE", 114, 142], ["URIs", "DISEASE", 144, 148], ["echinacea", "CHEMICAL", 163, 172], ["Echinacea purpurea", "CHEMICAL", 195, 213], ["rash", "DISEASE", 335, 339], ["children", "ORGANISM", 69, 77], ["upper", "ORGANISM_SUBDIVISION", 108, 113], ["respiratory tract", "ORGANISM_SUBDIVISION", 114, 131], ["Echinacea purpurea", "ORGANISM", 195, 213], ["children", "ORGANISM", 272, 280], ["children", "SPECIES", 69, 77], ["Echinacea purpurea", "SPECIES", 195, 213], ["children", "SPECIES", 272, 280], ["Echinacea purpurea", "SPECIES", 195, 213], ["placebo", "TREATMENT", 37, 44], ["upper respiratory tract infections", "PROBLEM", 108, 142], ["echinacea", "TREATMENT", 163, 172], ["placebo", "TREATMENT", 186, 193], ["Echinacea purpurea", "PROBLEM", 195, 213], ["URI symptoms", "PROBLEM", 250, 262], ["rash", "PROBLEM", 335, 339], ["upper", "ANATOMY_MODIFIER", 108, 113], ["respiratory tract", "ANATOMY", 114, 131], ["increased", "OBSERVATION_MODIFIER", 317, 326], ["rash", "OBSERVATION", 335, 339]]], ["Scoop et al. (2006) conducted a meta-analysis on the therapeutic effectiveness of Echinacea in the treatment and the prevention of colds, wherein 3 suitable studies were selected for pooling of data, and 231 were excluded from the analysis because they related to studies of spontaneous common colds.", [["Echinacea", "CHEMICAL", 82, 91], ["colds", "DISEASE", 131, 136], ["colds", "DISEASE", 294, 299], ["Echinacea", "ORGANISM", 82, 91], ["Echinacea", "TREATMENT", 82, 91], ["the treatment", "TREATMENT", 95, 108], ["colds", "PROBLEM", 131, 136], ["pooling of data", "TEST", 183, 198], ["the analysis", "TEST", 227, 239], ["spontaneous common colds", "PROBLEM", 275, 299]]], ["The meta-analysis suggested that standardized extracts of Echinacea were effective in the prevention of symptoms of the common cold after clinical inoculation, compared with placebo.", [["extracts", "ANATOMY", 46, 54], ["Echinacea", "CHEMICAL", 58, 67], ["extracts", "ORGANISM_SUBSTANCE", 46, 54], ["Echinacea", "ORGANISM", 58, 67], ["Echinacea", "SPECIES", 58, 67], ["The meta-analysis", "TEST", 0, 17], ["Echinacea", "TREATMENT", 58, 67], ["symptoms", "PROBLEM", 104, 112], ["the common cold", "PROBLEM", 116, 131], ["clinical inoculation", "PROBLEM", 138, 158], ["placebo", "TREATMENT", 174, 181]]], ["However, more prospective, appropriately structured clinical studies were required to confi rm.", [["clinical studies", "TEST", 52, 68]]], ["Although Echinacea preparations tested in clinical trials differed greatly, there was some evidence that preparations based on the aerial parts of Echinacea purpurea might be effective for the early treatment of colds in adults but results were not fully consistent (Linde et al. 2006 ) .", [["Echinacea purpurea", "CHEMICAL", 147, 165], ["colds", "DISEASE", 212, 217], ["Echinacea", "ORGANISM", 9, 18], ["Echinacea purpurea", "ORGANISM", 147, 165], ["Echinacea", "SPECIES", 9, 18], ["Echinacea purpurea", "SPECIES", 147, 165], ["Echinacea purpurea", "SPECIES", 147, 165], ["Echinacea preparations", "TREATMENT", 9, 31], ["Echinacea purpurea", "TREATMENT", 147, 165], ["colds", "PROBLEM", 212, 217]]], ["Benefi cial effects of other Echinacea preparations and for preventative purposes might exist but had not been shown in independently replicated, rigorous, randomized trials.", [["Echinacea", "ORGANISM", 29, 38], ["Echinacea", "SPECIES", 29, 38], ["other Echinacea preparations", "TREATMENT", 23, 51], ["preventative purposes", "TREATMENT", 60, 81]]], ["A metaanalysis of 14 studies provided published evidence supporting Echinacea 's benefi t in decreasing the incidence and duration of the common cold (Shah et al. 2007 ).", [["Echinacea", "CHEMICAL", 68, 77], ["Echinacea", "ORGANISM", 68, 77], ["A metaanalysis of 14 studies", "TEST", 0, 28]]], ["Woelkart et al. ( 2008 ) stated that Echinacea preparations were more effective than no treatment, more effective than placebo or similarly effective to other treatments in the prevention and the treatment of the common cold.", [["Echinacea", "CHEMICAL", 37, 46], ["Echinacea", "ORGANISM", 37, 46], ["Echinacea", "SPECIES", 37, 46], ["Echinacea preparations", "TREATMENT", 37, 59], ["treatment", "TREATMENT", 88, 97], ["placebo", "TREATMENT", 119, 126], ["other treatments", "TREATMENT", 153, 169], ["the treatment", "TREATMENT", 192, 205], ["the common cold", "PROBLEM", 209, 224]]], ["In a more recent review on the effi cacy of Echinacea in cold prevention, Hart and Dey ( 2009 ) reiterated that in view of the residual uncertainty and the gaps between the evidence and the ways that this was summarized on webpages, it may prove diffi cult for consumers to assimilate the evidence.", [["Echinacea", "CHEMICAL", 44, 53], ["Echinacea", "ORGANISM", 44, 53], ["Echinacea", "SPECIES", 44, 53], ["the residual uncertainty", "PROBLEM", 123, 147]]], ["As well as undertaking high-quality trials in complementary medicine, there was a need to ensure precision in the reporting of uncertainty.Antimicrobial ActivityEchinacea (including E. purpurea ) were found to have phototoxic antimicrobial activity against fungi, including clinically relevant pathogenic fungi.", [["ActivityEchinacea", "CHEMICAL", 153, 170], ["ActivityEchinacea", "SIMPLE_CHEMICAL", 153, 170], ["E. purpurea", "ORGANISM", 182, 193], ["E. purpurea", "SPECIES", 182, 193], ["E. purpurea", "SPECIES", 182, 193], ["Antimicrobial ActivityEchinacea (including E. purpurea", "TREATMENT", 139, 193], ["phototoxic antimicrobial activity", "PROBLEM", 215, 248], ["fungi", "PROBLEM", 257, 262], ["clinically relevant pathogenic fungi", "PROBLEM", 274, 310]]], ["Results showed that hexane extracts of Echinacea variably inhibited growth of yeast strains of Saccharomyces cerevisiae , Candida shehata , C. kefyr , C. albicans , C. steatulytica and C. tropicalis under near UV irradiation (phototoxicity) and to a lower extent without irradiation (conventional antifungal activity) (Binns et al. 2000 ) .", [["extracts", "ANATOMY", 27, 35], ["hexane", "CHEMICAL", 20, 26], ["Echinacea", "CHEMICAL", 39, 48], ["hexane", "CHEMICAL", 20, 26], ["hexane extracts", "ORGANISM_SUBSTANCE", 20, 35], ["Echinacea", "ORGANISM", 39, 48], ["Saccharomyces cerevisiae", "ORGANISM", 95, 119], ["Candida shehata", "ORGANISM", 122, 137], ["C. kefyr", "ORGANISM", 140, 148], ["C. albicans", "ORGANISM", 151, 162], ["C. steatulytica", "ORGANISM", 165, 180], ["C. tropicalis", "ORGANISM", 185, 198], ["Echinacea", "SPECIES", 39, 48], ["yeast", "SPECIES", 78, 83], ["Saccharomyces cerevisiae", "SPECIES", 95, 119], ["Candida shehata", "SPECIES", 122, 137], ["C. kefyr", "SPECIES", 140, 148], ["C. albicans", "SPECIES", 151, 162], ["C. steatulytica", "SPECIES", 165, 180], ["C. tropicalis", "SPECIES", 185, 198], ["yeast", "SPECIES", 78, 83], ["Saccharomyces cerevisiae", "SPECIES", 95, 119], ["Candida shehata", "SPECIES", 122, 137], ["C. kefyr", "SPECIES", 140, 148], ["C. albicans", "SPECIES", 151, 162], ["C. steatulytica", "SPECIES", 165, 180], ["C. tropicalis", "SPECIES", 185, 198], ["hexane extracts", "TEST", 20, 35], ["Echinacea variably", "PROBLEM", 39, 57], ["yeast strains", "PROBLEM", 78, 91], ["Saccharomyces cerevisiae", "TREATMENT", 95, 119], ["Candida shehata", "TREATMENT", 122, 137], ["C. albicans", "PROBLEM", 151, 162], ["C. steatulytica", "PROBLEM", 165, 180], ["C. tropicalis", "PROBLEM", 185, 198], ["near UV irradiation", "TREATMENT", 205, 224], ["irradiation (conventional antifungal activity", "TREATMENT", 271, 316], ["yeast strains", "OBSERVATION", 78, 91], ["UV irradiation", "OBSERVATION", 210, 224], ["lower extent", "OBSERVATION_MODIFIER", 250, 262], ["without", "UNCERTAINTY", 263, 270], ["irradiation", "OBSERVATION", 271, 282]]], ["The presence of polyacetylenes and alkylamides in extracts of different organs was confi rmed in Echinacea purpurea and was related to phototoxic activity.", [["extracts", "ANATOMY", 50, 58], ["organs", "ANATOMY", 72, 78], ["polyacetylenes", "CHEMICAL", 16, 30], ["alkylamides", "CHEMICAL", 35, 46], ["Echinacea purpurea", "CHEMICAL", 97, 115], ["polyacetylenes", "CHEMICAL", 16, 30], ["alkylamides", "CHEMICAL", 35, 46], ["polyacetylenes", "SIMPLE_CHEMICAL", 16, 30], ["alkylamides", "SIMPLE_CHEMICAL", 35, 46], ["extracts", "ORGANISM_SUBSTANCE", 50, 58], ["organs", "ORGAN", 72, 78], ["Echinacea purpurea", "ORGANISM", 97, 115], ["Echinacea purpurea", "SPECIES", 97, 115], ["Echinacea purpurea", "SPECIES", 97, 115], ["polyacetylenes", "TREATMENT", 16, 30], ["alkylamides", "TREATMENT", 35, 46], ["different organs", "PROBLEM", 62, 78], ["confi", "PROBLEM", 83, 88], ["Echinacea purpurea", "PROBLEM", 97, 115], ["phototoxic activity", "PROBLEM", 135, 154], ["Echinacea purpurea", "OBSERVATION", 97, 115], ["phototoxic activity", "OBSERVATION", 135, 154]]], ["Significant phototoxicity was demonstrated by pure trideca-1-ene-3,5,7,9,10-pentayne from E. purpurea roots, while only minor phototoxicity was induced by the other two E. purpurea acetylenic compounds undeca-2 E ,4 Z -diene-8,10-diynoic acid isobutylamide and dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide.", [["roots", "ANATOMY", 102, 107], ["phototoxicity", "DISEASE", 12, 25], ["trideca-1-ene-3,5,7,9,10-pentayne", "CHEMICAL", 51, 84], ["phototoxicity", "DISEASE", 126, 139], ["undeca-2 E ,4 Z -diene-8,10-diynoic acid isobutylamide", "CHEMICAL", 202, 256], ["dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide", "CHEMICAL", 261, 320], ["trideca-1-ene-3,5,7,9,10-pentayne", "CHEMICAL", 51, 84], ["acetylenic", "CHEMICAL", 181, 191], ["undeca-2 E ,4 Z -diene-8,10-diynoic acid isobutylamide", "CHEMICAL", 202, 256], ["dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide", "CHEMICAL", 261, 320], ["trideca-1-ene-3,5,7,9,10-pentayne", "SIMPLE_CHEMICAL", 51, 84], ["E. purpurea", "ORGANISM", 90, 101], ["roots", "ORGAN", 102, 107], ["undeca-2 E ,4 Z -diene-8,10-diynoic acid isobutylamide", "SIMPLE_CHEMICAL", 202, 256], ["dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 261, 320], ["E. purpurea", "SPECIES", 90, 101], ["E. purpurea", "SPECIES", 90, 101], ["E. purpurea", "SPECIES", 169, 180], ["Significant phototoxicity", "PROBLEM", 0, 25], ["minor phototoxicity", "PROBLEM", 120, 139], ["undeca", "TEST", 202, 208], ["diynoic acid isobutylamide", "TREATMENT", 230, 256], ["dodeca", "TEST", 261, 267], ["Ztetraenoic acid isobutylamide", "TREATMENT", 290, 320], ["phototoxicity", "OBSERVATION", 12, 25], ["purpurea roots", "ANATOMY", 93, 107]]], ["Phototoxic activity of Echinacea spp. was primarily attributed to the ketoalkenes and ketoalkynes abundantly present in the roots.", [["roots", "ANATOMY", 124, 129], ["Echinacea spp.", "CHEMICAL", 23, 37], ["ketoalkenes", "CHEMICAL", 70, 81], ["ketoalkynes", "CHEMICAL", 86, 97], ["ketoalkenes", "CHEMICAL", 70, 81], ["ketoalkynes", "CHEMICAL", 86, 97], ["Echinacea spp.", "ORGANISM", 23, 37], ["ketoalkenes", "SIMPLE_CHEMICAL", 70, 81], ["ketoalkynes", "SIMPLE_CHEMICAL", 86, 97], ["roots", "ORGAN", 124, 129], ["Echinacea spp.", "SPECIES", 23, 37], ["Echinacea spp.", "SPECIES", 23, 37], ["Echinacea spp.", "PROBLEM", 23, 37], ["the ketoalkenes and ketoalkynes", "PROBLEM", 66, 97], ["roots", "ANATOMY", 124, 129]]], ["Root extracts of the eight Echinacea species including E. purpurea showed antifungal activity against most of the pathogenic fungi ( Trichophyton tonsurans , T. mentagrophytes , Microsporum gypseum , Pseudallescheria boydii , Cryptococcus neoformans and two Candida albicans isolates) (Merali et al. 2003 ) .", [["Root extracts", "ANATOMY", 0, 13], ["Trichophyton tonsurans", "DISEASE", 133, 155], ["Cryptococcus neoformans", "DISEASE", 226, 249], ["Root extracts", "ORGANISM_SUBSTANCE", 0, 13], ["Echinacea", "ORGANISM", 27, 36], ["E. purpurea", "ORGANISM", 55, 66], ["Trichophyton tonsurans", "ORGANISM", 133, 155], ["T. mentagrophytes", "ORGANISM", 158, 175], ["Microsporum gypseum", "ORGANISM", 178, 197], ["Pseudallescheria boydii", "ORGANISM", 200, 223], ["Cryptococcus neoformans", "ORGANISM", 226, 249], ["Candida albicans", "ORGANISM", 258, 274], ["Echinacea", "SPECIES", 27, 36], ["E. purpurea", "SPECIES", 55, 66], ["Trichophyton tonsurans", "SPECIES", 133, 155], ["T. mentagrophytes", "SPECIES", 158, 175], ["Microsporum gypseum", "SPECIES", 178, 197], ["Pseudallescheria boydii", "SPECIES", 200, 223], ["Cryptococcus neoformans", "SPECIES", 226, 249], ["Candida albicans", "SPECIES", 258, 274], ["E. purpurea", "SPECIES", 55, 66], ["Trichophyton tonsurans", "SPECIES", 133, 155], ["T. mentagrophytes", "SPECIES", 158, 175], ["Microsporum gypseum", "SPECIES", 178, 197], ["Pseudallescheria boydii", "SPECIES", 200, 223], ["Cryptococcus neoformans", "SPECIES", 226, 249], ["Candida albicans", "SPECIES", 258, 274], ["the eight Echinacea species", "TEST", 17, 44], ["E. purpurea", "TEST", 55, 66], ["antifungal activity", "PROBLEM", 74, 93], ["the pathogenic fungi", "PROBLEM", 110, 130], ["Trichophyton tonsurans", "TEST", 133, 155], ["T. mentagrophytes", "TEST", 158, 175], ["Microsporum gypseum", "PROBLEM", 178, 197], ["Pseudallescheria boydii", "PROBLEM", 200, 223], ["Cryptococcus neoformans", "TREATMENT", 226, 249], ["two Candida albicans isolates", "TREATMENT", 254, 283], ["antifungal activity", "OBSERVATION", 74, 93], ["Microsporum gypseum", "OBSERVATION", 178, 197], ["Pseudallescheria boydii", "OBSERVATION", 200, 223], ["Cryptococcus neoformans", "OBSERVATION", 226, 249]]], ["Recent studies on Echinacea purpurea had revealed that certain standardized preparations contain potent and selective antiviral and antimicrobial activities (Hudson 2012 ) .", [["Echinacea purpurea", "CHEMICAL", 18, 36], ["Echinacea purpurea", "ORGANISM", 18, 36], ["Echinacea purpurea", "SPECIES", 18, 36], ["Echinacea purpurea", "SPECIES", 18, 36], ["Recent studies", "TEST", 0, 14], ["Echinacea purpurea", "TEST", 18, 36], ["certain standardized preparations", "TREATMENT", 55, 88], ["selective antiviral and antimicrobial activities", "TREATMENT", 108, 156]]], ["In addition, they displayed multiple immunomodulatory activities, comprising stimulation of certain immune functions such as phagocytic activity of macrophages and suppression of the proinfl ammatory responses of epithelial cells to viruses and bacteria, which are manifested as alterations in secretion of various cytokines and chemokines.", [["macrophages", "ANATOMY", 148, 159], ["epithelial cells", "ANATOMY", 213, 229], ["macrophages", "CELL", 148, 159], ["epithelial cells", "CELL", 213, 229], ["macrophages", "CELL_TYPE", 148, 159], ["epithelial cells", "CELL_TYPE", 213, 229], ["cytokines", "PROTEIN", 315, 324], ["chemokines", "PROTEIN", 329, 339], ["multiple immunomodulatory activities", "PROBLEM", 28, 64], ["certain immune functions", "PROBLEM", 92, 116], ["phagocytic activity of macrophages", "PROBLEM", 125, 159], ["epithelial cells", "PROBLEM", 213, 229], ["viruses", "PROBLEM", 233, 240], ["bacteria", "PROBLEM", 245, 253], ["various cytokines", "TREATMENT", 307, 324], ["chemokines", "TREATMENT", 329, 339], ["multiple", "OBSERVATION_MODIFIER", 28, 36], ["immunomodulatory activities", "OBSERVATION", 37, 64], ["phagocytic activity", "OBSERVATION", 125, 144], ["macrophages", "OBSERVATION", 148, 159], ["epithelial cells", "OBSERVATION", 213, 229]]], ["E. purpurea dried aerial part ethanol extract showed a considerable growth inhibition on Candida albicans and Saccharomyces cerevisiae , while no growth inhibition zones were observed for Aspergillus niger (Stanisavljevi\u0107 et al. 2009 ).", [["ethanol extract", "CHEMICAL", 30, 45], ["ethanol", "CHEMICAL", 30, 37], ["E. purpurea", "ORGANISM", 0, 11], ["ethanol", "SIMPLE_CHEMICAL", 30, 37], ["Candida albicans", "ORGANISM", 89, 105], ["Saccharomyces cerevisiae", "ORGANISM", 110, 134], ["Aspergillus niger", "ORGANISM", 188, 205], ["E. purpurea", "SPECIES", 0, 11], ["Candida albicans", "SPECIES", 89, 105], ["Saccharomyces cerevisiae", "SPECIES", 110, 134], ["Aspergillus niger", "SPECIES", 188, 205], ["E. purpurea", "SPECIES", 0, 11], ["Candida albicans", "SPECIES", 89, 105], ["Saccharomyces cerevisiae", "SPECIES", 110, 134], ["Aspergillus niger", "SPECIES", 188, 205], ["E. purpurea dried aerial part ethanol extract", "TEST", 0, 45], ["a considerable growth inhibition", "PROBLEM", 53, 85], ["Candida albicans", "PROBLEM", 89, 105], ["Saccharomyces cerevisiae", "TREATMENT", 110, 134], ["growth inhibition zones", "PROBLEM", 146, 169], ["Aspergillus niger", "PROBLEM", 188, 205], ["purpurea", "OBSERVATION_MODIFIER", 3, 11], ["considerable", "OBSERVATION_MODIFIER", 55, 67], ["growth", "OBSERVATION_MODIFIER", 68, 74]]], ["In-vitro studies showed a standardized preparation of Echinacea purpurea (Echinaforce\u00ae) could provide a safe twofold benefi t to acne individuals by inhibiting proliferation of the Gram-positive bacterium Propionibacterium acnes and reversing the bacterial-induced infl ammation (Sharma et al. 2011 ).", [["Echinacea purpurea", "CHEMICAL", 54, 72], ["Echinaforce\u00ae", "CHEMICAL", 74, 86], ["acne", "DISEASE", 129, 133], ["Propionibacterium acnes", "CHEMICAL", 205, 228], ["Echinacea purpurea", "ORGANISM", 54, 72], ["Echinaforce\u00ae", "SIMPLE_CHEMICAL", 74, 86], ["Echinacea purpurea", "SPECIES", 54, 72], ["Propionibacterium acnes", "SPECIES", 205, 228], ["Echinacea purpurea", "SPECIES", 54, 72], ["Propionibacterium acnes", "SPECIES", 205, 228], ["vitro studies", "TEST", 3, 16], ["Echinacea purpurea", "PROBLEM", 54, 72], ["the Gram-positive bacterium Propionibacterium acnes", "PROBLEM", 177, 228], ["the bacterial", "TEST", 243, 256], ["Echinacea purpurea", "OBSERVATION", 54, 72], ["bacterial", "OBSERVATION_MODIFIER", 247, 256]]], ["E. purpurea completely reversed the bacterial increase in secretion of substantial amounts of several proinfl ammatory cytokines, including IL-6 and IL-8 (CXCL8), and brought the cytokine levels back to normal.Antiinfl ammatory ActivityRoot extracts of the three commercial species of Echinacea ( E. purpurea , E. pallida var.Antiinfl ammatory Activityangustifolia , E. pallida var. pallida ) inhibited the 5-lipoxygenase (5-LOX) enzyme (Merali et al. 2003 ) .", [["extracts", "ANATOMY", 241, 249], ["Echinacea", "CHEMICAL", 285, 294], ["5-lipoxygenase", "CHEMICAL", 407, 421], ["5-LOX", "CHEMICAL", 423, 428], ["E. purpurea", "ORGANISM", 0, 11], ["IL-6", "GENE_OR_GENE_PRODUCT", 140, 144], ["IL-8", "GENE_OR_GENE_PRODUCT", 149, 153], ["CXCL8", "GENE_OR_GENE_PRODUCT", 155, 160], ["Echinacea", "ORGANISM", 285, 294], ["E. purpurea", "ORGANISM", 297, 308], ["E. pallida", "ORGANISM", 311, 321], ["var", "ORGANISM", 322, 325], ["Antiinfl ammatory Activityangustifolia", "ORGANISM", 326, 364], ["E. pallida", "ORGANISM", 367, 377], ["var", "ORGANISM", 378, 381], ["pallida", "ORGANISM", 383, 390], ["5-lipoxygenase", "GENE_OR_GENE_PRODUCT", 407, 421], ["5-LOX", "SIMPLE_CHEMICAL", 423, 428], ["proinfl ammatory cytokines", "PROTEIN", 102, 128], ["IL-6", "PROTEIN", 140, 144], ["IL-8", "PROTEIN", 149, 153], ["CXCL8", "PROTEIN", 155, 160], ["cytokine", "PROTEIN", 179, 187], ["5-lipoxygenase (5-LOX) enzyme", "PROTEIN", 407, 436], ["E. purpurea", "SPECIES", 0, 11], ["Echinacea", "SPECIES", 285, 294], ["E. purpurea", "SPECIES", 297, 308], ["E. pallida", "SPECIES", 311, 321], ["E. pallida", "SPECIES", 367, 377], ["pallida", "SPECIES", 383, 390], ["E. purpurea", "SPECIES", 0, 11], ["E. purpurea", "SPECIES", 297, 308], ["E. pallida", "SPECIES", 311, 321], ["E. pallida", "SPECIES", 367, 377], ["pallida", "SPECIES", 383, 390], ["the bacterial increase", "PROBLEM", 32, 54], ["several proinfl ammatory cytokines", "PROBLEM", 94, 128], ["IL", "TEST", 140, 142], ["IL", "TEST", 149, 151], ["CXCL8", "TEST", 155, 160], ["the cytokine levels", "TEST", 175, 194], ["Antiinfl", "TREATMENT", 210, 218], ["Echinacea ( E. purpurea", "PROBLEM", 285, 308], ["enzyme", "TEST", 430, 436], ["purpurea", "OBSERVATION_MODIFIER", 3, 11], ["completely", "OBSERVATION_MODIFIER", 12, 22], ["reversed", "OBSERVATION", 23, 31], ["bacterial", "OBSERVATION_MODIFIER", 36, 45], ["increase", "OBSERVATION_MODIFIER", 46, 54], ["substantial", "OBSERVATION_MODIFIER", 71, 82], ["amounts", "OBSERVATION_MODIFIER", 83, 90], ["normal", "OBSERVATION", 203, 209], ["Echinacea", "ANATOMY", 285, 294], ["pallida var", "OBSERVATION", 314, 325], ["pallida var", "OBSERVATION", 370, 381]]], ["The results show that Echinacea spp. had signifi cant antiinfl ammatory activity.", [["Echinacea spp", "ORGANISM", 22, 35], ["Echinacea", "SPECIES", 22, 31], ["Echinacea spp", "PROBLEM", 22, 35], ["Echinacea spp", "OBSERVATION", 22, 35]]], ["Alcohol extracts of Echinacea angustifolia , Echinacea pallida and Echinacea purpurea signifi cantly inhibited NO production by lipopolysaccharide (LPS)-activated the RAW 264.7 macrophage cell line (Zhai et al. 2009 ).", [["extracts", "ANATOMY", 8, 16], ["RAW 264.7 macrophage cell line", "ANATOMY", 167, 197], ["Alcohol", "CHEMICAL", 0, 7], ["Echinacea angustifolia , Echinacea pallida", "CHEMICAL", 20, 62], ["NO", "CHEMICAL", 111, 113], ["lipopolysaccharide", "CHEMICAL", 128, 146], ["LPS", "CHEMICAL", 148, 151], ["Alcohol", "CHEMICAL", 0, 7], ["NO", "CHEMICAL", 111, 113], ["Alcohol extracts", "ORGANISM_SUBSTANCE", 0, 16], ["Echinacea angustifolia", "ORGANISM", 20, 42], ["Echinacea pallida", "ORGANISM", 45, 62], ["Echinacea purpurea", "ORGANISM", 67, 85], ["NO", "SIMPLE_CHEMICAL", 111, 113], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 128, 146], ["LPS", "SIMPLE_CHEMICAL", 148, 151], ["RAW 264.7 macrophage cell line", "CELL", 167, 197], ["Zhai et al. 2009", "CELL", 199, 215], ["RAW 264.7 macrophage cell line", "CELL_LINE", 167, 197], ["Echinacea angustifolia", "SPECIES", 20, 42], ["Echinacea pallida", "SPECIES", 45, 62], ["Echinacea purpurea", "SPECIES", 67, 85], ["signifi", "SPECIES", 86, 93], ["Echinacea angustifolia", "SPECIES", 20, 42], ["Echinacea pallida", "SPECIES", 45, 62], ["Echinacea purpurea signifi", "SPECIES", 67, 93], ["Echinacea angustifolia", "PROBLEM", 20, 42], ["Echinacea pallida", "PROBLEM", 45, 62], ["Echinacea purpurea", "TEST", 67, 85], ["LPS", "TEST", 148, 151], ["macrophage cell line", "TREATMENT", 177, 197], ["Echinacea angustifolia", "OBSERVATION", 20, 42], ["Echinacea pallida", "OBSERVATION", 45, 62], ["macrophage cell line", "OBSERVATION", 177, 197]]], ["Arginase activity of RAW 264.7 cells stimulated with 8-bromo-cAMP was signifi cantly increased by alcohol extracts of all three Echinacea species.", [["RAW 264.7 cells", "ANATOMY", 21, 36], ["extracts", "ANATOMY", 106, 114], ["8-bromo-cAMP", "CHEMICAL", 53, 65], ["alcohol", "CHEMICAL", 98, 105], ["8-bromo-cAMP", "CHEMICAL", 53, 65], ["alcohol", "CHEMICAL", 98, 105], ["Arginase", "GENE_OR_GENE_PRODUCT", 0, 8], ["RAW 264.7 cells", "CELL", 21, 36], ["8-bromo-cAMP", "SIMPLE_CHEMICAL", 53, 65], ["alcohol extracts", "ORGANISM_SUBSTANCE", 98, 114], ["Arginase", "PROTEIN", 0, 8], ["RAW 264.7 cells", "CELL_LINE", 21, 36], ["Echinacea", "SPECIES", 128, 137], ["Arginase activity", "TEST", 0, 17], ["Echinacea species", "OBSERVATION", 128, 145]]], ["The polar fraction containing caffeic acid derivatives enhanced arginase activity, while the lipophilic fraction containing alkamides exhibited a potential of inhibiting NO production and iNOS expression.", [["caffeic acid", "CHEMICAL", 30, 42], ["alkamides", "CHEMICAL", 124, 133], ["NO", "CHEMICAL", 170, 172], ["caffeic acid", "CHEMICAL", 30, 42], ["alkamides", "CHEMICAL", 124, 133], ["NO", "CHEMICAL", 170, 172], ["caffeic acid derivatives", "SIMPLE_CHEMICAL", 30, 54], ["arginase", "GENE_OR_GENE_PRODUCT", 64, 72], ["alkamides", "SIMPLE_CHEMICAL", 124, 133], ["NO", "SIMPLE_CHEMICAL", 170, 172], ["iNOS", "GENE_OR_GENE_PRODUCT", 188, 192], ["arginase", "PROTEIN", 64, 72], ["iNOS", "PROTEIN", 188, 192], ["The polar fraction", "TEST", 0, 18], ["caffeic acid derivatives", "TREATMENT", 30, 54], ["the lipophilic fraction", "TEST", 89, 112], ["iNOS expression", "PROBLEM", 188, 203], ["polar", "ANATOMY_MODIFIER", 4, 9], ["caffeic", "OBSERVATION", 30, 37], ["acid derivatives", "OBSERVATION", 38, 54], ["arginase activity", "OBSERVATION", 64, 81], ["lipophilic fraction", "OBSERVATION", 93, 112], ["iNOS expression", "OBSERVATION", 188, 203]]], ["The results suggested that the antiinfl ammatory activity of Echinace a might be due to multiple active metabolites, working together to switch macrophage activation from classical activation towards alternative activation.Antiinfl ammatory ActivityAt 100 g/ml, several E. purpurea alkamides, isolated from E. purpurea roots, inhibited cyclooxygenase COX-I and COX-II enzymes in the range of 36-60 % and 15-46 %, respectively, as compared to controls (Clifford et al. 2002 ) .", [["macrophage", "ANATOMY", 144, 154], ["roots", "ANATOMY", 319, 324], ["Echinace", "CHEMICAL", 61, 69], ["alkamides", "CHEMICAL", 282, 291], ["antiinfl", "GENE_OR_GENE_PRODUCT", 31, 39], ["Echinace", "SIMPLE_CHEMICAL", 61, 69], ["macrophage", "CELL", 144, 154], ["E. purpurea", "ORGANISM", 270, 281], ["alkamides", "SIMPLE_CHEMICAL", 282, 291], ["E. purpurea", "ORGANISM", 307, 318], ["roots", "ORGANISM", 319, 324], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 336, 350], ["COX-I", "GENE_OR_GENE_PRODUCT", 351, 356], ["COX-II", "GENE_OR_GENE_PRODUCT", 361, 367], ["cyclooxygenase COX-I and COX-II enzymes", "PROTEIN", 336, 375], ["E. purpurea", "SPECIES", 270, 281], ["E. purpurea", "SPECIES", 307, 318], ["E. purpurea", "SPECIES", 270, 281], ["E. purpurea", "SPECIES", 307, 318], ["multiple active metabolites", "PROBLEM", 88, 115], ["macrophage activation", "TREATMENT", 144, 165], ["Antiinfl ammatory ActivityAt", "TREATMENT", 223, 251], ["several E. purpurea alkamides", "TEST", 262, 291], ["E. purpurea roots", "PROBLEM", 307, 324], ["cyclooxygenase COX", "TEST", 336, 354], ["COX", "TEST", 361, 364], ["II enzymes", "TEST", 365, 375], ["purpurea roots", "OBSERVATION", 310, 324]]], ["Chicca et al. ( 2009 ) demonstrated that ethanol E. purpurea radix and herba extracts elicited synergistic pharmacological effects on the endocannabinoid system in vitro.", [["extracts", "ANATOMY", 77, 85], ["ethanol", "CHEMICAL", 41, 48], ["ethanol", "CHEMICAL", 41, 48], ["ethanol", "SIMPLE_CHEMICAL", 41, 48], ["E. purpurea", "ORGANISM", 49, 60], ["radix", "ORGANISM", 61, 66], ["herba extracts", "ORGANISM", 71, 85], ["endocannabinoid system", "ANATOMICAL_SYSTEM", 138, 160], ["E. purpurea radix", "SPECIES", 49, 66], ["E. purpurea", "SPECIES", 49, 60], ["ethanol E. purpurea radix", "TREATMENT", 41, 66], ["herba extracts", "TREATMENT", 71, 85], ["synergistic pharmacological effects", "PROBLEM", 95, 130]]], ["Supra-additive action of N -alkylamide combinations was observed at the level of intracellular calcium release as a function of cannabinoid receptor type-2 (CB 2 ) activation.", [["intracellular", "ANATOMY", 81, 94], ["N -alkylamide", "CHEMICAL", 25, 38], ["calcium", "CHEMICAL", 95, 102], ["N -alkylamide", "CHEMICAL", 25, 38], ["calcium", "CHEMICAL", 95, 102], ["N -alkylamide", "SIMPLE_CHEMICAL", 25, 38], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 81, 94], ["calcium", "SIMPLE_CHEMICAL", 95, 102], ["cannabinoid receptor type-2", "GENE_OR_GENE_PRODUCT", 128, 155], ["CB 2", "GENE_OR_GENE_PRODUCT", 157, 161], ["N -alkylamide combinations", "TREATMENT", 25, 51], ["intracellular calcium release", "TREATMENT", 81, 110]]], ["Likewise, synergism of the radix and herba tinctures was observed in LPS-stimulated cytokine expression from human PBMCs.", [["radix", "ANATOMY", 27, 32], ["PBMCs", "ANATOMY", 115, 120], ["LPS", "CHEMICAL", 69, 72], ["radix", "TISSUE", 27, 32], ["herba tinctures", "SIMPLE_CHEMICAL", 37, 52], ["LPS", "SIMPLE_CHEMICAL", 69, 72], ["human", "ORGANISM", 109, 114], ["PBMCs", "CELL", 115, 120], ["cytokine", "PROTEIN", 84, 92], ["human PBMCs", "CELL_TYPE", 109, 120], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["the radix", "TREATMENT", 23, 32], ["herba tinctures", "TREATMENT", 37, 52], ["human PBMCs", "TREATMENT", 109, 120], ["radix", "ANATOMY", 27, 32]]], ["While the expression of the antiinfl ammatory cytokine IL-10 was signifi cantly superstimulated, the expression of the proinfl ammatory TNF-\u03b1 protein was inhibited more strongly upon combination of the extracts.", [["extracts", "ANATOMY", 202, 210], ["antiinfl", "GENE_OR_GENE_PRODUCT", 28, 36], ["IL-10", "GENE_OR_GENE_PRODUCT", 55, 60], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 136, 141], ["extracts", "ORGANISM_SUBSTANCE", 202, 210], ["antiinfl ammatory cytokine IL-10", "PROTEIN", 28, 60], ["proinfl ammatory TNF-\u03b1 protein", "PROTEIN", 119, 149], ["the antiinfl ammatory cytokine IL", "TREATMENT", 24, 57], ["the proinfl ammatory TNF", "TEST", 115, 139], ["\u03b1 protein", "PROBLEM", 140, 149]]], ["They concluded that N -alkylamides in the extracts acted in concert to exert pleiotropic effects modulating the endocannabinoid system by simultaneously targeting the CB 2 receptor, endocannabinoid transport and degradation.", [["extracts", "ANATOMY", 42, 50], ["N -alkylamides", "CHEMICAL", 20, 34], ["N -alkylamides", "CHEMICAL", 20, 34], ["N -alkylamides", "SIMPLE_CHEMICAL", 20, 34], ["extracts", "ORGANISM_SUBSTANCE", 42, 50], ["CB 2 receptor", "GENE_OR_GENE_PRODUCT", 167, 180], ["endocannabinoid", "SIMPLE_CHEMICAL", 182, 197], ["CB 2 receptor", "PROTEIN", 167, 180], ["N -alkylamides in the extracts", "TREATMENT", 20, 50], ["endocannabinoid transport", "TREATMENT", 182, 207]]], ["Cannabinoid type-1 (CB 1 ) and CB 2 receptors belong to the family of G proteincoupled receptors and are the primary targets of the endogenous cannabinoids N -arachidonoyl ethanolamine and 2-arachidonoyl glycerol .", [["N -arachidonoyl ethanolamine", "CHEMICAL", 156, 184], ["2-arachidonoyl glycerol", "CHEMICAL", 189, 212], ["Cannabinoid", "CHEMICAL", 0, 11], ["N -arachidonoyl ethanolamine", "CHEMICAL", 156, 184], ["2-arachidonoyl glycerol", "CHEMICAL", 189, 212], ["Cannabinoid type-1 (CB 1", "GENE_OR_GENE_PRODUCT", 0, 24], ["CB 2 receptors", "GENE_OR_GENE_PRODUCT", 31, 45], ["G proteincoupled receptors", "GENE_OR_GENE_PRODUCT", 70, 96], ["cannabinoids N -arachidonoyl ethanolamine", "SIMPLE_CHEMICAL", 143, 184], ["2-arachidonoyl glycerol", "SIMPLE_CHEMICAL", 189, 212], ["Cannabinoid type-1 (CB 1 ) and CB 2 receptors", "PROTEIN", 0, 45], ["G proteincoupled receptors", "PROTEIN", 70, 96], ["Cannabinoid type-1 (CB", "TREATMENT", 0, 22], ["CB 2 receptors", "TREATMENT", 31, 45], ["G proteincoupled receptors", "TREATMENT", 70, 96], ["the endogenous cannabinoids", "TREATMENT", 128, 155], ["-arachidonoyl ethanolamine", "TREATMENT", 158, 184], ["2-arachidonoyl glycerol", "TREATMENT", 189, 212]]], ["CB 2 receptors are believed to play an important role in distinct pathophysiological processes, including metabolic dysregulation, infl ammation, pain and bone loss.Antiinfl ammatory ActivityA mitogen-induced murine skin infl ammation study suggested that alkamides were the active antiinfl ammatory components present in Echinace a plants (Hou et al. 2010 ) .", [["bone", "ANATOMY", 155, 159], ["skin", "ANATOMY", 216, 220], ["metabolic dysregulation", "DISEASE", 106, 129], ["pain", "DISEASE", 146, 150], ["bone loss", "DISEASE", 155, 164], ["alkamides", "CHEMICAL", 256, 265], ["alkamides", "CHEMICAL", 256, 265], ["CB 2 receptors", "GENE_OR_GENE_PRODUCT", 0, 14], ["bone", "TISSUE", 155, 159], ["murine", "ORGANISM", 209, 215], ["skin", "ORGAN", 216, 220], ["alkamides", "SIMPLE_CHEMICAL", 256, 265], ["CB 2 receptors", "PROTEIN", 0, 14], ["mitogen", "PROTEIN", 193, 200], ["murine", "SPECIES", 209, 215], ["metabolic dysregulation", "PROBLEM", 106, 129], ["infl ammation", "PROBLEM", 131, 144], ["pain", "PROBLEM", 146, 150], ["bone loss", "PROBLEM", 155, 164], ["Antiinfl", "TEST", 165, 173], ["murine skin infl ammation study", "TEST", 209, 240], ["alkamides", "PROBLEM", 256, 265], ["the active antiinfl ammatory components", "TREATMENT", 271, 310], ["metabolic dysregulation", "OBSERVATION", 106, 129], ["bone", "ANATOMY", 155, 159], ["loss", "OBSERVATION", 160, 164], ["skin", "ANATOMY", 216, 220], ["active", "OBSERVATION_MODIFIER", 275, 281]]], ["Mixed alkamides and the major component, dodeca-2 E ,4 E ,8 Z ,10 Z ( E )-tetraenoic acid isobutylamides (8/9), were then isolated from E. purpurea root extracts for further bioactivity elucidation.", [["extracts", "ANATOMY", 153, 161], ["alkamides", "CHEMICAL", 6, 15], ["dodeca-2 E ,4 E ,8 Z ,10 Z ( E )-tetraenoic acid isobutylamides", "CHEMICAL", 41, 104], ["alkamides", "CHEMICAL", 6, 15], ["dodeca-2 E ,4 E ,8 Z ,10 Z ( E )-tetraenoic acid isobutylamides", "CHEMICAL", 41, 104], ["alkamides", "SIMPLE_CHEMICAL", 6, 15], ["dodeca-2 E", "SIMPLE_CHEMICAL", 41, 51], ["4 E ,8 Z ,10 Z ( E )-tetraenoic acid isobutylamides", "SIMPLE_CHEMICAL", 53, 104], ["8/9", "SIMPLE_CHEMICAL", 106, 109], ["E. purpurea", "ORGANISM", 136, 147], ["root extracts", "ORGANISM_SUBSTANCE", 148, 161], ["E. purpurea", "SPECIES", 136, 147], ["E. purpurea", "SPECIES", 136, 147], ["Mixed alkamides", "PROBLEM", 0, 15], ["dodeca", "TEST", 41, 47], ["Z", "TEST", 60, 61], ["Z", "TEST", 66, 67], ["tetraenoic acid isobutylamides", "TEST", 74, 104], ["further bioactivity elucidation", "TEST", 166, 197]]], ["In macrophages, the alkamides signifi cantly inhibited cyclooxygenase 2 (COX-2) activity and the lipopolysaccharide-induced expression of COX-2, inducible nitric oxide synthase and specifi c cytokines or chemokines [i.e., TNF-\u03b1, interleukin (IL)-1\u03b1, IL-6, MCP-1, MIP-1\u03b2] but elevated heme oxygenase-1 protein expression.", [["macrophages", "ANATOMY", 3, 14], ["alkamides", "CHEMICAL", 20, 29], ["lipopolysaccharide", "CHEMICAL", 97, 115], ["nitric oxide", "CHEMICAL", 155, 167], ["alkamides", "CHEMICAL", 20, 29], ["nitric oxide", "CHEMICAL", 155, 167], ["macrophages", "CELL", 3, 14], ["alkamides", "SIMPLE_CHEMICAL", 20, 29], ["cyclooxygenase 2", "GENE_OR_GENE_PRODUCT", 55, 71], ["COX-2", "GENE_OR_GENE_PRODUCT", 73, 78], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 97, 115], ["COX-2", "GENE_OR_GENE_PRODUCT", 138, 143], ["inducible nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 145, 176], ["specifi c", "GENE_OR_GENE_PRODUCT", 181, 190], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 222, 227], ["interleukin (IL)-1\u03b1", "GENE_OR_GENE_PRODUCT", 229, 248], ["IL-6", "GENE_OR_GENE_PRODUCT", 250, 254], ["MCP-1", "GENE_OR_GENE_PRODUCT", 256, 261], ["MIP-1\u03b2", "GENE_OR_GENE_PRODUCT", 263, 269], ["heme oxygenase-1", "GENE_OR_GENE_PRODUCT", 284, 300], ["macrophages", "CELL_TYPE", 3, 14], ["cyclooxygenase 2", "PROTEIN", 55, 71], ["COX", "PROTEIN", 73, 76], ["COX-2", "PROTEIN", 138, 143], ["inducible nitric oxide synthase", "PROTEIN", 145, 176], ["specifi c cytokines", "PROTEIN", 181, 200], ["chemokines", "PROTEIN", 204, 214], ["TNF", "PROTEIN", 222, 225], ["interleukin (IL)-1\u03b1, IL-6", "PROTEIN", 229, 254], ["MCP", "PROTEIN", 256, 259], ["MIP-1\u03b2", "PROTEIN", 263, 269], ["heme oxygenase", "PROTEIN", 284, 298], ["the alkamides", "TEST", 16, 29], ["cyclooxygenase", "TEST", 55, 69], ["COX", "TEST", 73, 76], ["the lipopolysaccharide", "TREATMENT", 93, 115], ["COX", "TEST", 138, 141], ["inducible nitric oxide synthase", "TREATMENT", 145, 176], ["specifi c cytokines", "TREATMENT", 181, 200], ["chemokines", "TEST", 204, 214], ["TNF", "TEST", 222, 225], ["interleukin", "TEST", 229, 240], ["IL", "TEST", 242, 244], ["IL", "TEST", 250, 252], ["MCP", "TEST", 256, 259], ["MIP", "TEST", 263, 266], ["elevated heme oxygenase", "PROBLEM", 275, 298], ["macrophages", "OBSERVATION", 3, 14], ["heme oxygenase", "OBSERVATION", 284, 298], ["protein expression", "OBSERVATION", 301, 319]]], ["Cichoric acid, however, exhibited little or no effect.", [["Cichoric acid", "CHEMICAL", 0, 13], ["Cichoric acid", "CHEMICAL", 0, 13], ["Cichoric acid", "SIMPLE_CHEMICAL", 0, 13], ["Cichoric acid", "TEST", 0, 13], ["no", "UNCERTAINTY", 44, 46], ["effect", "OBSERVATION_MODIFIER", 47, 53]]], ["In another study, three alkamides and nitidanin diisovalerianate were identifi ed, together with 14 known alkamides and one sesquiterpene from the roots of Echinacea purpurea (Hohmann et al. 2011 ) .", [["roots", "ANATOMY", 147, 152], ["alkamides", "CHEMICAL", 24, 33], ["nitidanin", "CHEMICAL", 38, 47], ["diisovalerianate", "CHEMICAL", 48, 64], ["alkamides", "CHEMICAL", 106, 115], ["one sesquiterpene from the roots of Echinacea purpurea", "CHEMICAL", 120, 174], ["alkamides", "CHEMICAL", 24, 33], ["nitidanin diisovalerianate", "CHEMICAL", 38, 64], ["alkamides", "CHEMICAL", 106, 115], ["sesquiterpene", "CHEMICAL", 124, 137], ["alkamides", "SIMPLE_CHEMICAL", 24, 33], ["nitidanin diisovalerianate", "SIMPLE_CHEMICAL", 38, 64], ["alkamides", "SIMPLE_CHEMICAL", 106, 115], ["sesquiterpene", "SIMPLE_CHEMICAL", 124, 137], ["roots", "ORGAN", 147, 152], ["Echinacea purpurea", "ORGANISM", 156, 174], ["Echinacea purpurea", "SPECIES", 156, 174], ["Echinacea purpurea", "SPECIES", 156, 174], ["another study", "TEST", 3, 16], ["three alkamides", "TREATMENT", 18, 33], ["nitidanin diisovalerianate", "TREATMENT", 38, 64], ["14 known alkamides", "TREATMENT", 97, 115], ["Echinacea purpurea", "PROBLEM", 156, 174], ["Echinacea purpurea", "OBSERVATION", 156, 174]]], ["Their interaction with G-protein-coupled cannabinoid receptors was examined on rat brain membrane preparations.", [["brain membrane", "ANATOMY", 83, 97], ["G-protein-coupled cannabinoid receptors", "GENE_OR_GENE_PRODUCT", 23, 62], ["rat", "ORGANISM", 79, 82], ["brain membrane", "MULTI-TISSUE_STRUCTURE", 83, 97], ["G-protein-coupled cannabinoid receptors", "PROTEIN", 23, 62], ["rat", "SPECIES", 79, 82], ["rat", "SPECIES", 79, 82], ["rat brain membrane preparations", "TREATMENT", 79, 110]]], ["Both partial and inverse agonist compounds for cannabinoid (CB1) receptors were identifi ed among the metabolites, characterized by weak to moderate interactions with the G-protein signalling mechanisms.", [["cannabinoid (CB1) receptors", "GENE_OR_GENE_PRODUCT", 47, 74], ["G-protein", "GENE_OR_GENE_PRODUCT", 171, 180], ["cannabinoid (CB1) receptors", "PROTEIN", 47, 74], ["G-protein", "PROTEIN", 171, 180], ["weak to moderate interactions", "PROBLEM", 132, 161], ["partial", "OBSERVATION_MODIFIER", 5, 12], ["moderate", "OBSERVATION_MODIFIER", 140, 148]]], ["Upon coadministration with arachidonyl-2\u2032chloroethylamide, a number of them proved capable of inhibiting the stimulation of the pure agonist, thereby demonstrating cannabinoid receptor antagonist properties.", [["arachidonyl-2\u2032chloroethylamide", "CHEMICAL", 27, 57], ["arachidonyl-2\u2032chloroethylamide", "CHEMICAL", 27, 57], ["arachidonyl-2\u2032chloroethylamide", "SIMPLE_CHEMICAL", 27, 57], ["arachidonyl", "TREATMENT", 27, 38], ["cannabinoid receptor antagonist properties", "TREATMENT", 164, 206]]], ["In an earlier study, alkylamides, anandamide and SR144528 were found to potently inhibit lipopolysaccharideinduced infl ammation in human whole blood and exerted modulatory effects on cytokine expression, but these effects were not exclusively related to CB 2 binding .", [["whole blood", "ANATOMY", 138, 149], ["alkylamides", "CHEMICAL", 21, 32], ["anandamide", "CHEMICAL", 34, 44], ["SR144528", "CHEMICAL", 49, 57], ["alkylamides", "CHEMICAL", 21, 32], ["anandamide", "CHEMICAL", 34, 44], ["SR144528", "CHEMICAL", 49, 57], ["alkylamides", "SIMPLE_CHEMICAL", 21, 32], ["anandamide", "SIMPLE_CHEMICAL", 34, 44], ["SR144528", "SIMPLE_CHEMICAL", 49, 57], ["human", "ORGANISM", 132, 137], ["blood", "ORGANISM_SUBSTANCE", 144, 149], ["CB 2", "GENE_OR_GENE_PRODUCT", 255, 259], ["cytokine", "PROTEIN", 184, 192], ["human", "SPECIES", 132, 137], ["human", "SPECIES", 132, 137], ["an earlier study", "TEST", 3, 19], ["alkylamides", "TREATMENT", 21, 32], ["anandamide", "TEST", 34, 44], ["human whole blood", "PROBLEM", 132, 149], ["cytokine expression", "TREATMENT", 184, 203], ["CB 2 binding", "PROBLEM", 255, 267]]], ["The alkylamides dodeca-2 E ,4 E ,8 Z ,10 Z -tetraenoic acid isobutylamide (A1) and dodeca-2 E ,4 E -dienoic acid isobutylamide (A2) bound to the CB 2 receptor more strongly than the endogenous cannabinoids.", [["alkylamides dodeca-2 E ,4 E ,8 Z ,10 Z -tetraenoic acid isobutylamide", "CHEMICAL", 4, 73], ["dodeca-2 E ,4 E -dienoic acid isobutylamide", "CHEMICAL", 83, 126], ["alkylamides dodeca-2 E ,4 E ,8 Z ,10 Z -tetraenoic acid isobutylamide", "CHEMICAL", 4, 73], ["dodeca-2 E ,4 E -dienoic acid isobutylamide", "CHEMICAL", 83, 126], ["cannabinoids", "CHEMICAL", 193, 205], ["alkylamides dodeca-2 E ,4 E ,8 Z ,10 Z -tetraenoic acid isobutylamide", "SIMPLE_CHEMICAL", 4, 73], ["A1", "SIMPLE_CHEMICAL", 75, 77], ["dodeca-2 E ,4 E -dienoic acid isobutylamide", "SIMPLE_CHEMICAL", 83, 126], ["A2", "SIMPLE_CHEMICAL", 128, 130], ["CB 2 receptor", "GENE_OR_GENE_PRODUCT", 145, 158], ["CB 2 receptor", "PROTEIN", 145, 158], ["The alkylamides dodeca", "TEST", 0, 22], ["Z", "TEST", 35, 36], ["Z", "TEST", 41, 42], ["tetraenoic acid isobutylamide", "TEST", 44, 73], ["dodeca", "TEST", 83, 89], ["E", "TEST", 97, 98], ["dienoic acid isobutylamide", "TEST", 100, 126], ["the CB 2 receptor", "TEST", 141, 158], ["endogenous cannabinoids", "OBSERVATION", 182, 205]]], ["A1, A2, anandamide, the CB2 antagonist SR144528 (Ki < 10 nM), and also the non-CB 2 -binding alkylamide undeca-2 E -ene,8,10-diynoic acid isobutylamide all signifi cantly inhibited lipopolysaccharide-induced tumour necrosis factor alpha, IL-1beta and IL-12p70 expression (5-500 nM) in a CB 2 -independent manner.Anticancer ActivityAnimal studies found that dietary administration with E. purpurea preparations signifi cantly decreased prostate weight of rats and increased lymphocyte numbers after 8 weeks (Skaudickas et al. 2003 ) .", [["prostate", "ANATOMY", 435, 443], ["lymphocyte", "ANATOMY", 473, 483], ["anandamide", "CHEMICAL", 8, 18], ["SR144528", "CHEMICAL", 39, 47], ["alkylamide undeca-2 E -ene", "CHEMICAL", 93, 119], ["8,10-diynoic acid isobutylamide", "CHEMICAL", 120, 151], ["lipopolysaccharide", "CHEMICAL", 181, 199], ["necrosis", "DISEASE", 215, 223], ["anandamide", "CHEMICAL", 8, 18], ["SR144528", "CHEMICAL", 39, 47], ["alkylamide undeca-2 E -ene", "CHEMICAL", 93, 119], ["8,10-diynoic acid isobutylamide", "CHEMICAL", 120, 151], ["A2", "GENE_OR_GENE_PRODUCT", 4, 6], ["anandamide", "SIMPLE_CHEMICAL", 8, 18], ["SR144528", "SIMPLE_CHEMICAL", 39, 47], ["non-CB 2 -binding alkylamide undeca-2 E -ene", "SIMPLE_CHEMICAL", 75, 119], ["8,10-diynoic acid isobutylamide", "SIMPLE_CHEMICAL", 120, 151], ["signifi", "SIMPLE_CHEMICAL", 156, 163], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 181, 199], ["tumour necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 208, 236], ["IL-1beta", "GENE_OR_GENE_PRODUCT", 238, 246], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 251, 259], ["E. purpurea", "ORGANISM", 385, 396], ["prostate", "ORGAN", 435, 443], ["rats", "ORGANISM", 454, 458], ["lymphocyte", "CELL", 473, 483], ["tumour necrosis factor alpha", "PROTEIN", 208, 236], ["E. purpurea", "SPECIES", 385, 396], ["rats", "SPECIES", 454, 458], ["E. purpurea", "SPECIES", 385, 396], ["A1", "TEST", 0, 2], ["anandamide", "TEST", 8, 18], ["the CB2 antagonist", "TEST", 20, 38], ["Ki", "TEST", 49, 51], ["nM", "TEST", 57, 59], ["the non-CB", "TEST", 71, 81], ["alkylamide", "TEST", 93, 103], ["undeca", "TEST", 104, 110], ["diynoic acid isobutylamide", "TREATMENT", 125, 151], ["lipopolysaccharide", "TEST", 181, 199], ["tumour necrosis", "PROBLEM", 208, 223], ["alpha", "TEST", 231, 236], ["IL", "TEST", 238, 240], ["IL", "TEST", 251, 253], ["expression", "TEST", 260, 270], ["Anticancer ActivityAnimal studies", "TEST", 312, 345], ["dietary administration", "TREATMENT", 357, 379], ["E. purpurea preparations", "TREATMENT", 385, 409], ["increased lymphocyte numbers", "PROBLEM", 463, 491], ["tumour necrosis", "OBSERVATION", 208, 223], ["prostate", "ANATOMY", 435, 443], ["increased", "OBSERVATION_MODIFIER", 463, 472], ["lymphocyte", "OBSERVATION", 473, 483]]], ["Echinacea purpurea root hexane extract reduced cell viability of human pancreatic cancer MIA PaCa-2 and colon cancer COLO320 cell lines in a concentration-and time-dependent in vitro (Chicca et al. 2007 ).", [["extract", "ANATOMY", 31, 38], ["cell", "ANATOMY", 47, 51], ["pancreatic cancer MIA PaCa-2", "ANATOMY", 71, 99], ["colon cancer COLO320 cell lines", "ANATOMY", 104, 135], ["Echinacea purpurea root hexane extract", "CHEMICAL", 0, 38], ["pancreatic cancer", "DISEASE", 71, 88], ["colon cancer", "DISEASE", 104, 116], ["hexane", "CHEMICAL", 24, 30], ["Echinacea purpurea", "ORGANISM", 0, 18], ["root hexane extract", "ORGANISM_SUBSTANCE", 19, 38], ["cell", "CELL", 47, 51], ["human", "ORGANISM", 65, 70], ["pancreatic cancer MIA PaCa-2", "CELL", 71, 99], ["colon cancer COLO320 cell lines", "CELL", 104, 135], ["human pancreatic cancer MIA PaCa-2", "CELL_LINE", 65, 99], ["colon cancer COLO320 cell lines", "CELL_LINE", 104, 135], ["Echinacea purpurea", "SPECIES", 0, 18], ["human", "SPECIES", 65, 70], ["Echinacea purpurea", "SPECIES", 0, 18], ["human", "SPECIES", 65, 70], ["Echinacea purpurea root hexane", "TEST", 0, 30], ["human pancreatic cancer", "PROBLEM", 65, 88], ["MIA PaCa", "PROBLEM", 89, 97], ["colon cancer", "PROBLEM", 104, 116], ["cell lines", "TREATMENT", 125, 135], ["a concentration", "TREATMENT", 139, 154], ["purpurea", "OBSERVATION_MODIFIER", 10, 18], ["root", "OBSERVATION_MODIFIER", 19, 23], ["hexane", "OBSERVATION_MODIFIER", 24, 30], ["reduced", "OBSERVATION_MODIFIER", 39, 46], ["cell viability", "OBSERVATION", 47, 61], ["pancreatic", "ANATOMY", 71, 81], ["cancer", "OBSERVATION", 82, 88], ["colon", "ANATOMY", 104, 109], ["cancer", "OBSERVATION", 110, 116], ["COLO320 cell lines", "OBSERVATION", 117, 135]]], ["E. purpurea fl ower extract and cichoric acid signifi cantly inhibited proliferation in a dose-and time-dependent manner human colon cancer cells Caco-2 and HCT-116 (Tsai et al. 2012 ) .", [["extract", "ANATOMY", 20, 27], ["colon cancer cells Caco-2", "ANATOMY", 127, 152], ["HCT-116", "ANATOMY", 157, 164], ["cichoric acid", "CHEMICAL", 32, 45], ["colon cancer", "DISEASE", 127, 139], ["cichoric acid", "CHEMICAL", 32, 45], ["E. purpurea", "ORGANISM", 0, 11], ["cichoric acid signifi", "SIMPLE_CHEMICAL", 32, 53], ["human", "ORGANISM", 121, 126], ["colon cancer cells Caco-2", "CELL", 127, 152], ["HCT-116", "CELL", 157, 164], ["human colon cancer cells", "CELL_TYPE", 121, 145], ["HCT-116", "CELL_LINE", 157, 164], ["E. purpurea", "SPECIES", 0, 11], ["human", "SPECIES", 121, 126], ["E. purpurea fl ower", "SPECIES", 0, 19], ["human", "SPECIES", 121, 126], ["cichoric acid signifi cantly inhibited proliferation", "PROBLEM", 32, 84], ["dependent manner human colon cancer", "PROBLEM", 104, 139], ["Caco", "TEST", 146, 150], ["HCT", "TEST", 157, 160], ["purpurea fl", "OBSERVATION", 3, 14], ["proliferation", "OBSERVATION_MODIFIER", 71, 84], ["colon", "ANATOMY", 127, 132], ["cancer", "OBSERVATION", 133, 139]]], ["Cichoric acid treatment decreased telomerase activity in HCT-116 cells.", [["HCT-116 cells", "ANATOMY", 57, 70], ["Cichoric acid", "CHEMICAL", 0, 13], ["Cichoric acid", "CHEMICAL", 0, 13], ["Cichoric acid", "SIMPLE_CHEMICAL", 0, 13], ["telomerase", "GENE_OR_GENE_PRODUCT", 34, 44], ["HCT-116 cells", "CELL", 57, 70], ["telomerase", "PROTEIN", 34, 44], ["HCT-116 cells", "CELL_LINE", 57, 70], ["Cichoric acid treatment", "TREATMENT", 0, 23], ["telomerase activity", "TEST", 34, 53], ["HCT", "TEST", 57, 60]]], ["Further, cichoric acid effectively induced apoptosis in colon cancer cells, which were characterized by DNA fragmentation, activation of caspase-9, cleavage of PARP and downregulation of \u03b2-catenin.Anti-teratogenic ActivityStudies found that E. purpurea could stimulate immune system of mice more than levamisole and had better prophylactic effect against the teratogenic effect of phenytoin as evidenced by lower incidence of phenytoin-induced cleft palate, but it was not signifi cant (Mahabady et al. 2006 ) .", [["colon cancer cells", "ANATOMY", 56, 74], ["immune system", "ANATOMY", 269, 282], ["cleft palate", "ANATOMY", 444, 456], ["cichoric acid", "CHEMICAL", 9, 22], ["colon cancer", "DISEASE", 56, 68], ["levamisole", "CHEMICAL", 301, 311], ["phenytoin", "CHEMICAL", 381, 390], ["phenytoin", "CHEMICAL", 426, 435], ["cleft palate", "DISEASE", 444, 456], ["cichoric acid", "CHEMICAL", 9, 22], ["levamisole", "CHEMICAL", 301, 311], ["phenytoin", "CHEMICAL", 381, 390], ["phenytoin", "CHEMICAL", 426, 435], ["cichoric acid", "SIMPLE_CHEMICAL", 9, 22], ["colon cancer cells", "CELL", 56, 74], ["DNA", "CELLULAR_COMPONENT", 104, 107], ["caspase-9", "GENE_OR_GENE_PRODUCT", 137, 146], ["PARP", "GENE_OR_GENE_PRODUCT", 160, 164], ["\u03b2-catenin", "GENE_OR_GENE_PRODUCT", 187, 196], ["E. purpurea", "ORGANISM", 241, 252], ["immune system", "ANATOMICAL_SYSTEM", 269, 282], ["mice", "ORGANISM", 286, 290], ["levamisole", "SIMPLE_CHEMICAL", 301, 311], ["phenytoin", "SIMPLE_CHEMICAL", 381, 390], ["phenytoin", "SIMPLE_CHEMICAL", 426, 435], ["cleft", "ORGAN", 444, 449], ["palate", "ORGAN", 450, 456], ["colon cancer cells", "CELL_TYPE", 56, 74], ["caspase-9", "PROTEIN", 137, 146], ["PARP", "PROTEIN", 160, 164], ["\u03b2-catenin", "PROTEIN", 187, 196], ["E. purpurea", "SPECIES", 241, 252], ["mice", "SPECIES", 286, 290], ["E. purpurea", "SPECIES", 241, 252], ["mice", "SPECIES", 286, 290], ["cichoric acid effectively", "PROBLEM", 9, 34], ["apoptosis in colon cancer cells", "PROBLEM", 43, 74], ["DNA fragmentation", "PROBLEM", 104, 121], ["caspase", "TEST", 137, 144], ["PARP", "PROBLEM", 160, 164], ["downregulation of \u03b2-catenin", "TREATMENT", 169, 196], ["E. purpurea", "PROBLEM", 241, 252], ["levamisole", "TREATMENT", 301, 311], ["phenytoin", "TREATMENT", 381, 390], ["lower incidence of phenytoin", "PROBLEM", 407, 435], ["induced cleft palate", "PROBLEM", 436, 456], ["acid effectively", "OBSERVATION_MODIFIER", 18, 34], ["apoptosis", "OBSERVATION_MODIFIER", 43, 52], ["colon", "ANATOMY", 56, 61], ["cancer cells", "OBSERVATION", 62, 74], ["DNA fragmentation", "OBSERVATION", 104, 121], ["lower", "OBSERVATION_MODIFIER", 407, 412], ["phenytoin", "OBSERVATION", 426, 435], ["cleft palate", "ANATOMY", 444, 456]]], ["Cleft palate incidence was 16, 5.3 and 3.2 % in fetuses of mice that received only phenytoin, phenytoin with levamisole, and phenytoin with Echinacea extract, respectively.", [["Cleft palate", "ANATOMY", 0, 12], ["fetuses", "ANATOMY", 48, 55], ["Cleft palate", "DISEASE", 0, 12], ["phenytoin", "CHEMICAL", 83, 92], ["phenytoin", "CHEMICAL", 94, 103], ["levamisole", "CHEMICAL", 109, 119], ["phenytoin", "CHEMICAL", 125, 134], ["Echinacea extract", "CHEMICAL", 140, 157], ["phenytoin", "CHEMICAL", 83, 92], ["phenytoin", "CHEMICAL", 94, 103], ["levamisole", "CHEMICAL", 109, 119], ["phenytoin", "CHEMICAL", 125, 134], ["Cleft", "ORGAN", 0, 5], ["palate", "ORGAN", 6, 12], ["fetuses", "ORGANISM", 48, 55], ["mice", "ORGANISM", 59, 63], ["phenytoin", "SIMPLE_CHEMICAL", 83, 92], ["phenytoin", "SIMPLE_CHEMICAL", 94, 103], ["levamisole", "SIMPLE_CHEMICAL", 109, 119], ["phenytoin", "SIMPLE_CHEMICAL", 125, 134], ["Echinacea", "ORGANISM", 140, 149], ["mice", "SPECIES", 59, 63], ["Echinacea", "SPECIES", 140, 149], ["mice", "SPECIES", 59, 63], ["Cleft palate incidence", "TEST", 0, 22], ["phenytoin", "TREATMENT", 83, 92], ["phenytoin", "TREATMENT", 94, 103], ["levamisole", "TREATMENT", 109, 119], ["phenytoin", "TREATMENT", 125, 134], ["Echinacea extract", "TREATMENT", 140, 157], ["palate", "ANATOMY", 6, 12]]], ["Mean weight and length of fetuses of animals that received levamisole and Echinacea extract were signifi cantly greater than those that received only phenytoin.Hepatoprotective ActivityStudies showed that dodeca-2 E ,4 E ,8 Z ,10 Z ( E )tetraenoic acid isobutylamides (Alk-8/9), isolated from Echinacea purpurea roots, dose-dependently induced heme oxygenase (HO)-1 protein expression in lipopolysaccharide-stimulated murine macrophages that was likely regulated by the JNK-mediated pathway through increasing SAPK/JNK phosphorylation, c-Jun protein expression, and phosphorylation and transcription factor AP-1 binding consensus DNA activity (Hou et al. 2011 ).", [["fetuses", "ANATOMY", 26, 33], ["roots", "ANATOMY", 312, 317], ["macrophages", "ANATOMY", 425, 436], ["levamisole", "CHEMICAL", 59, 69], ["Echinacea extract", "CHEMICAL", 74, 91], ["phenytoin", "CHEMICAL", 150, 159], ["dodeca-2 E ,4 E ,8 Z ,10 Z ( E )tetraenoic acid", "CHEMICAL", 205, 252], ["isobutylamides", "CHEMICAL", 253, 267], ["Alk-8/9", "CHEMICAL", 269, 276], ["lipopolysaccharide", "CHEMICAL", 388, 406], ["levamisole", "CHEMICAL", 59, 69], ["phenytoin", "CHEMICAL", 150, 159], ["dodeca-2 E ,4 E ,8 Z ,10 Z ( E )tetraenoic acid isobutylamides", "CHEMICAL", 205, 267], ["Alk-8/9", "CHEMICAL", 269, 276], ["fetuses", "ORGANISM", 26, 33], ["levamisole", "SIMPLE_CHEMICAL", 59, 69], ["Echinacea", "ORGANISM", 74, 83], ["phenytoin", "SIMPLE_CHEMICAL", 150, 159], ["dodeca-2 E", "SIMPLE_CHEMICAL", 205, 215], ["4 E ,8 Z", "SIMPLE_CHEMICAL", 217, 225], ["10 Z ( E )tetraenoic acid isobutylamides", "SIMPLE_CHEMICAL", 227, 267], ["Alk-8/9", "SIMPLE_CHEMICAL", 269, 276], ["Echinacea purpurea", "ORGANISM", 293, 311], ["roots", "ORGANISM", 312, 317], ["heme oxygenase", "GENE_OR_GENE_PRODUCT", 344, 358], ["HO)-1", "GENE_OR_GENE_PRODUCT", 360, 365], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 388, 406], ["murine", "ORGANISM", 418, 424], ["macrophages", "CELL", 425, 436], ["JNK", "GENE_OR_GENE_PRODUCT", 470, 473], ["SAPK", "GENE_OR_GENE_PRODUCT", 510, 514], ["JNK", "GENE_OR_GENE_PRODUCT", 515, 518], ["c-Jun", "GENE_OR_GENE_PRODUCT", 536, 541], ["AP-1", "GENE_OR_GENE_PRODUCT", 607, 611], ["DNA", "CELLULAR_COMPONENT", 630, 633], ["heme oxygenase (HO)-1", "PROTEIN", 344, 365], ["lipopolysaccharide-stimulated murine macrophages", "CELL_LINE", 388, 436], ["JNK", "PROTEIN", 470, 473], ["SAPK", "PROTEIN", 510, 514], ["JNK", "PROTEIN", 515, 518], ["Jun", "PROTEIN", 538, 541], ["transcription factor", "PROTEIN", 586, 606], ["Echinacea", "SPECIES", 74, 83], ["Echinacea purpurea", "SPECIES", 293, 311], ["murine", "SPECIES", 418, 424], ["Echinacea purpurea", "SPECIES", 293, 311], ["Mean weight", "TEST", 0, 11], ["levamisole", "TREATMENT", 59, 69], ["Echinacea extract", "TREATMENT", 74, 91], ["phenytoin", "TREATMENT", 150, 159], ["Hepatoprotective ActivityStudies", "TEST", 160, 192], ["dodeca", "TEST", 205, 211], ["Z", "TEST", 224, 225], ["Z", "TEST", 230, 231], ["tetraenoic acid isobutylamides", "TEST", 237, 267], ["Alk", "TEST", 269, 272], ["Echinacea purpurea roots", "TEST", 293, 317], ["dependently induced heme oxygenase", "PROBLEM", 324, 358], ["HO)", "TEST", 360, 363], ["lipopolysaccharide", "TEST", 388, 406], ["stimulated murine macrophages", "PROBLEM", 407, 436], ["the JNK", "TEST", 466, 473], ["increasing SAPK/JNK phosphorylation", "PROBLEM", 499, 534], ["Jun protein expression", "TEST", 538, 560], ["phosphorylation", "PROBLEM", 566, 581], ["transcription factor AP", "TEST", 586, 609], ["length", "OBSERVATION_MODIFIER", 16, 22], ["purpurea roots", "OBSERVATION", 303, 317]]], ["Further, Alk-8/9 markedly induced c-Jun and HO-1 protein expression and suppressed serum aminotransferase activities, TNF-\u03b1 expression, and hepatocyte damage in liver tissues of lipopolysaccharide/ D -galactosamine -treated mice.", [["serum", "ANATOMY", 83, 88], ["hepatocyte", "ANATOMY", 140, 150], ["liver tissues", "ANATOMY", 161, 174], ["Alk-8/9", "CHEMICAL", 9, 16], ["lipopolysaccharide", "CHEMICAL", 178, 196], ["D -galactosamine", "CHEMICAL", 198, 214], ["Alk-8/9", "CHEMICAL", 9, 16], ["D -galactosamine", "CHEMICAL", 198, 214], ["Alk-8/9", "GENE_OR_GENE_PRODUCT", 9, 16], ["c-Jun", "GENE_OR_GENE_PRODUCT", 34, 39], ["HO-1", "GENE_OR_GENE_PRODUCT", 44, 48], ["serum", "ORGANISM_SUBSTANCE", 83, 88], ["aminotransferase", "SIMPLE_CHEMICAL", 89, 105], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 118, 123], ["hepatocyte", "CELL", 140, 150], ["liver tissues", "TISSUE", 161, 174], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 178, 196], ["D -galactosamine", "SIMPLE_CHEMICAL", 198, 214], ["mice", "ORGANISM", 224, 228], ["Jun", "PROTEIN", 36, 39], ["HO", "PROTEIN", 44, 46], ["serum aminotransferase", "PROTEIN", 83, 105], ["TNF", "PROTEIN", 118, 121], ["mice", "SPECIES", 224, 228], ["mice", "SPECIES", 224, 228], ["Alk", "TEST", 9, 12], ["HO", "TEST", 44, 46], ["protein expression", "TEST", 49, 67], ["serum aminotransferase activities", "TEST", 83, 116], ["TNF", "TEST", 118, 121], ["hepatocyte damage in liver tissues", "PROBLEM", 140, 174], ["lipopolysaccharide", "TEST", 178, 196], ["galactosamine", "TREATMENT", 201, 214], ["hepatocyte", "ANATOMY", 140, 150], ["damage", "OBSERVATION", 151, 157], ["liver", "ANATOMY", 161, 166]]], ["The results suggested a potential application of Echinacea , a top-selling herbal supplement, as a hepatoprotective agent.Antimutagenic ActivityThe 50 % ethanol fl ower extract did not show toxicity and mutagenicity towards Salmonella typhimurium TA98 and TA100 with or without S9 mix (Tsai et al. 2011 ).", [["Echinacea", "CHEMICAL", 49, 58], ["ethanol", "CHEMICAL", 153, 160], ["toxicity", "DISEASE", 190, 198], ["TA98", "CHEMICAL", 247, 251], ["TA100", "CHEMICAL", 256, 261], ["ethanol", "CHEMICAL", 153, 160], ["Echinacea", "ORGANISM", 49, 58], ["ethanol", "SIMPLE_CHEMICAL", 153, 160], ["Salmonella typhimurium", "ORGANISM", 224, 246], ["TA98", "ORGANISM", 247, 251], ["TA100", "SIMPLE_CHEMICAL", 256, 261], ["Salmonella typhimurium", "SPECIES", 224, 246], ["Salmonella typhimurium TA98", "SPECIES", 224, 251], ["TA100", "SPECIES", 256, 261], ["Echinacea", "TREATMENT", 49, 58], ["a top-selling herbal supplement", "TREATMENT", 61, 92], ["a hepatoprotective agent", "TREATMENT", 97, 121], ["Antimutagenic Activity", "TEST", 122, 144], ["toxicity", "PROBLEM", 190, 198], ["Salmonella typhimurium TA98", "TEST", 224, 251], ["TA100", "TEST", 256, 261], ["S9 mix", "TEST", 278, 284]]], ["The ethanol extract at 0.25-5 mg/plate exhibited a dose-dependent inhibitory effect against the mutagenicity of 2-aminoanthracene.", [["ethanol extract", "CHEMICAL", 4, 19], ["2-aminoanthracene", "CHEMICAL", 112, 129], ["ethanol", "CHEMICAL", 4, 11], ["2-aminoanthracene", "CHEMICAL", 112, 129], ["ethanol", "SIMPLE_CHEMICAL", 4, 11], ["2-aminoanthracene", "SIMPLE_CHEMICAL", 112, 129], ["The ethanol extract", "TREATMENT", 0, 19], ["a dose-dependent inhibitory effect", "TREATMENT", 49, 83], ["the mutagenicity", "TEST", 92, 108]]], ["They concluded that freeze-dried E. purpurea fl ower ethanol extract exhibited good antioxidant and antimutagenic activities.Radioprotective ActivityE. purpurea administration signifi cantly ameliorated the detrimental reduction effects of gamma rays on peripheral blood haemoglobin and the levels of red blood cells, differential white blood cells and bone marrow cells and antioxidant activity in mice (Abouelella et al. 2007 ).", [["peripheral blood", "ANATOMY", 254, 270], ["red blood cells", "ANATOMY", 301, 316], ["white blood cells", "ANATOMY", 331, 348], ["bone marrow cells", "ANATOMY", 353, 370], ["ethanol extract", "CHEMICAL", 53, 68], ["ethanol", "CHEMICAL", 53, 60], ["ethanol", "SIMPLE_CHEMICAL", 53, 60], ["purpurea", "ORGANISM", 152, 160], ["peripheral blood", "ORGANISM_SUBSTANCE", 254, 270], ["haemoglobin", "ORGANISM_SUBSTANCE", 271, 282], ["red blood cells", "CELL", 301, 316], ["white blood cells", "CELL", 331, 348], ["bone marrow cells", "CELL", 353, 370], ["mice", "ORGANISM", 399, 403], ["red blood cells", "CELL_TYPE", 301, 316], ["differential white blood cells", "CELL_TYPE", 318, 348], ["bone marrow cells", "CELL_TYPE", 353, 370], ["E. purpurea", "SPECIES", 33, 44], ["purpurea", "SPECIES", 152, 160], ["mice", "SPECIES", 399, 403], ["E. purpurea", "SPECIES", 33, 44], ["mice", "SPECIES", 399, 403], ["freeze", "TEST", 20, 26], ["ethanol extract", "TREATMENT", 53, 68], ["purpurea administration", "TREATMENT", 152, 175], ["gamma rays", "TEST", 240, 250], ["peripheral blood haemoglobin", "TEST", 254, 282], ["red blood cells", "TEST", 301, 316], ["white blood cells", "TEST", 331, 348], ["bone marrow cells", "TEST", 353, 370], ["antioxidant activity", "TEST", 375, 395], ["detrimental", "OBSERVATION_MODIFIER", 207, 218], ["reduction", "OBSERVATION_MODIFIER", 219, 228], ["gamma rays", "OBSERVATION", 240, 250], ["blood cells", "ANATOMY", 305, 316], ["bone", "ANATOMY", 353, 357], ["marrow cells", "OBSERVATION", 358, 370], ["antioxidant activity", "OBSERVATION", 375, 395]]], ["The radioprotection effectiveness was similar to the radio recovery curativeness in comparison to the control group in most of the tested parameters.Radioprotective ActivityThe radioprotection effi ciency was greater than the radio recovery in haemoglobin level during the fi rst 2 weeks, in lymphoid cell count and thiobarbituric acid-reactive substances (TBARs) level at the fourth week and in superoxide dismutase (SOD) activity during the fi rst 2 weeks, as compared to the levels of these parameters in the control group.Actoprotective/Adaptogenic ActivityPurple conefl ower tincture was found to improve both the work capacity and the endurance characteristics of white male mice in the conventional forced swim test (Kurkin et al. 2006 ).", [["lymphoid cell", "ANATOMY", 292, 305], ["thiobarbituric acid-reactive", "CHEMICAL", 316, 344], ["superoxide", "CHEMICAL", 396, 406], ["thiobarbituric acid-reactive", "CHEMICAL", 316, 344], ["superoxide", "CHEMICAL", 396, 406], ["haemoglobin", "GENE_OR_GENE_PRODUCT", 244, 255], ["lymphoid cell", "CELL", 292, 305], ["thiobarbituric acid-reactive substances", "SIMPLE_CHEMICAL", 316, 355], ["TBARs", "SIMPLE_CHEMICAL", 357, 362], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 396, 416], ["SOD", "GENE_OR_GENE_PRODUCT", 418, 421], ["mice", "ORGANISM", 681, 685], ["superoxide dismutase", "PROTEIN", 396, 416], ["SOD", "PROTEIN", 418, 421], ["mice", "SPECIES", 681, 685], ["mice", "SPECIES", 681, 685], ["The radioprotection effi ciency", "TEST", 173, 204], ["haemoglobin level", "TEST", 244, 261], ["lymphoid cell count", "TEST", 292, 311], ["thiobarbituric acid-reactive substances", "TEST", 316, 355], ["TBARs) level", "TEST", 357, 369], ["superoxide dismutase (SOD) activity", "PROBLEM", 396, 431], ["Actoprotective", "TREATMENT", 526, 540], ["Adaptogenic ActivityPurple conefl ower tincture", "TREATMENT", 541, 588], ["Activity", "OBSERVATION_MODIFIER", 165, 173], ["greater", "OBSERVATION_MODIFIER", 209, 216], ["lymphoid cell count", "OBSERVATION", 292, 311], ["thiobarbituric", "OBSERVATION", 316, 330], ["acid-reactive substances", "OBSERVATION", 331, 355]]], ["The actoprotective effect was attributed to a phenylpropanoid, echinacoside.Actoprotective/Adaptogenic ActivityIn a double-blind design placebo-controlled and self-administered study of 24 men (24.9 \u00b1 4.2 years) for 4 weeks, oral Echinacea supplementation resulted in signifi cant increases in erythropoietin (EPO), VO2max (maximal oxygen uptake) and running economy compared to placebo (Whitehead et al. 2012 ).Anti-Tyrosinase ActivityCichoric acid extracted from E. purpurea fl owers was found to have signifi cant tyrosinase inhibition activity in a broad range of concentration (10-20 mg/ml) (Jiang et al. 2012 ).Trypanocidal ActivityVarious Echinacea extracts could inhibit the proliferation of three species of trypanosomatids: Leishmania donovani , Leishmania major and Trypanosoma brucei (Canlas et al. 2010 ).", [["oral", "ANATOMY", 225, 229], ["extracts", "ANATOMY", 656, 664], ["phenylpropanoid", "CHEMICAL", 46, 61], ["echinacoside", "CHEMICAL", 63, 75], ["Echinacea", "CHEMICAL", 230, 239], ["oxygen", "CHEMICAL", 332, 338], ["Anti-Tyrosinase", "CHEMICAL", 412, 427], ["ActivityCichoric acid", "CHEMICAL", 428, 449], ["Echinacea", "CHEMICAL", 646, 655], ["Leishmania donovani", "DISEASE", 734, 753], ["phenylpropanoid", "CHEMICAL", 46, 61], ["echinacoside", "CHEMICAL", 63, 75], ["oxygen", "CHEMICAL", 332, 338], ["ActivityCichoric acid", "CHEMICAL", 428, 449], ["phenylpropanoid", "SIMPLE_CHEMICAL", 46, 61], ["echinacoside", "SIMPLE_CHEMICAL", 63, 75], ["men", "ORGANISM", 189, 192], ["oral", "ORGANISM_SUBDIVISION", 225, 229], ["Echinacea", "SIMPLE_CHEMICAL", 230, 239], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 294, 308], ["EPO", "SIMPLE_CHEMICAL", 310, 313], ["oxygen", "SIMPLE_CHEMICAL", 332, 338], ["Anti-Tyrosinase ActivityCichoric acid", "SIMPLE_CHEMICAL", 412, 449], ["E. purpurea", "ORGANISM", 465, 476], ["fl owers", "ORGANISM", 477, 485], ["tyrosinase", "GENE_OR_GENE_PRODUCT", 517, 527], ["Echinacea", "ORGANISM", 646, 655], ["extracts", "ORGANISM_SUBSTANCE", 656, 664], ["Leishmania donovani", "ORGANISM", 734, 753], ["Leishmania major", "ORGANISM", 756, 772], ["Trypanosoma brucei", "ORGANISM", 777, 795], ["erythropoietin", "PROTEIN", 294, 308], ["EPO", "PROTEIN", 310, 313], ["tyrosinase", "PROTEIN", 517, 527], ["men", "SPECIES", 189, 192], ["E. purpurea", "SPECIES", 465, 476], ["Echinacea", "SPECIES", 646, 655], ["Leishmania donovani", "SPECIES", 734, 753], ["Leishmania major", "SPECIES", 756, 772], ["Trypanosoma brucei", "SPECIES", 777, 795], ["E. purpurea fl owers", "SPECIES", 465, 485], ["Leishmania donovani", "SPECIES", 734, 753], ["Leishmania major", "SPECIES", 756, 772], ["Trypanosoma brucei", "SPECIES", 777, 795], ["The actoprotective effect", "PROBLEM", 0, 25], ["a phenylpropanoid", "TREATMENT", 44, 61], ["echinacoside", "TREATMENT", 63, 75], ["Actoprotective", "TREATMENT", 76, 90], ["Adaptogenic", "TREATMENT", 91, 102], ["a double-blind design placebo", "TREATMENT", 114, 143], ["oral Echinacea supplementation", "TREATMENT", 225, 255], ["signifi cant increases", "PROBLEM", 268, 290], ["erythropoietin (EPO", "TREATMENT", 294, 313], ["VO2max (maximal oxygen uptake", "TREATMENT", 316, 345], ["running economy", "TREATMENT", 351, 366], ["Anti-Tyrosinase", "TEST", 412, 427], ["ActivityCichoric acid", "TEST", 428, 449], ["E. purpurea fl owers", "TEST", 465, 485], ["signifi cant tyrosinase inhibition activity", "PROBLEM", 504, 547], ["Trypanocidal ActivityVarious Echinacea extracts", "TREATMENT", 617, 664], ["trypanosomatids", "PROBLEM", 717, 732], ["Leishmania donovani", "PROBLEM", 734, 753], ["Leishmania", "PROBLEM", 756, 766], ["Trypanosoma brucei", "PROBLEM", 777, 795], ["proliferation", "OBSERVATION_MODIFIER", 683, 696], ["Leishmania donovani", "OBSERVATION", 734, 753], ["Leishmania", "OBSERVATION_MODIFIER", 756, 766], ["Trypanosoma brucei", "OBSERVATION", 777, 795]]], ["The standardized ethanol extract of E. purpurea (L.)", [["ethanol extract of E. purpurea", "CHEMICAL", 17, 47], ["ethanol", "CHEMICAL", 17, 24], ["ethanol", "SIMPLE_CHEMICAL", 17, 24], ["E. purpurea", "ORGANISM", 36, 47], ["E. purpurea", "SPECIES", 36, 47], ["E. purpurea", "SPECIES", 36, 47]]], ["Moench reversed the proinfl ammatory activity (production of cytokines IL-6 and IL-8) of Leishmania donovani in human bronchial epithelial cells and in human skin fi broblasts.Larvicidal ActivitySeveral alkamides isolated from E. purpurea roots exhibited mosquitocidal activity causing 100 % mortality of Aedes aegypti larvae (Clifford et al. 2002 ) .Herb-Drug/Herb-Herb Interaction ActivityStudies showed Echinacea alkylamides were degraded in a time-and NADPH-dependent manner in microsomal fractions suggesting they were metabolized by cytochrome P450 (P450) enzymes in human liver ( Matthias et al. 2005b ).", [["bronchial epithelial cells", "ANATOMY", 118, 144], ["skin fi broblasts", "ANATOMY", 158, 175], ["roots", "ANATOMY", 239, 244], ["microsomal fractions", "ANATOMY", 482, 502], ["liver", "ANATOMY", 579, 584], ["alkamides", "CHEMICAL", 203, 212], ["Echinacea alkylamides", "CHEMICAL", 406, 427], ["NADPH", "CHEMICAL", 456, 461], ["alkamides", "CHEMICAL", 203, 212], ["alkylamides", "CHEMICAL", 416, 427], ["NADPH", "CHEMICAL", 456, 461], ["Moench", "SIMPLE_CHEMICAL", 0, 6], ["IL-6", "GENE_OR_GENE_PRODUCT", 71, 75], ["IL-8", "GENE_OR_GENE_PRODUCT", 80, 84], ["Leishmania donovani", "ORGANISM", 89, 108], ["human", "ORGANISM", 112, 117], ["bronchial epithelial cells", "CELL", 118, 144], ["human", "ORGANISM", 152, 157], ["skin fi broblasts", "CELL", 158, 175], ["Larvicidal ActivitySeveral alkamides", "SIMPLE_CHEMICAL", 176, 212], ["E. purpurea", "ORGANISM", 227, 238], ["roots", "ORGANISM", 239, 244], ["Aedes aegypti", "ORGANISM", 305, 318], ["Echinacea", "ORGANISM", 406, 415], ["alkylamides", "SIMPLE_CHEMICAL", 416, 427], ["NADPH", "SIMPLE_CHEMICAL", 456, 461], ["microsomal", "ORGANISM_SUBSTANCE", 482, 492], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 539, 554], ["P450", "GENE_OR_GENE_PRODUCT", 556, 560], ["human", "ORGANISM", 573, 578], ["liver", "ORGAN", 579, 584], ["cytokines IL-6", "PROTEIN", 61, 75], ["IL-8", "PROTEIN", 80, 84], ["human bronchial epithelial cells", "CELL_TYPE", 112, 144], ["cytochrome P450 (P450) enzymes", "PROTEIN", 539, 569], ["Leishmania donovani", "SPECIES", 89, 108], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 152, 157], ["E. purpurea", "SPECIES", 227, 238], ["Aedes aegypti", "SPECIES", 305, 318], ["Echinacea", "SPECIES", 406, 415], ["human", "SPECIES", 573, 578], ["Leishmania donovani", "SPECIES", 89, 108], ["human", "SPECIES", 112, 117], ["human", "SPECIES", 152, 157], ["E. purpurea", "SPECIES", 227, 238], ["Aedes aegypti", "SPECIES", 305, 318], ["human", "SPECIES", 573, 578], ["cytokines IL", "TEST", 61, 73], ["IL", "TEST", 80, 82], ["Leishmania donovani in human bronchial epithelial cells", "PROBLEM", 89, 144], ["Larvicidal ActivitySeveral alkamides", "TREATMENT", 176, 212], ["mosquitocidal activity", "PROBLEM", 255, 277], ["Aedes aegypti larvae", "PROBLEM", 305, 325], ["Echinacea alkylamides", "TREATMENT", 406, 427], ["NADPH", "TEST", 456, 461], ["microsomal fractions", "TEST", 482, 502], ["cytochrome P450", "TEST", 539, 554], ["enzymes", "TEST", 562, 569], ["Leishmania donovani", "OBSERVATION", 89, 108], ["human", "ANATOMY_MODIFIER", 112, 117], ["bronchial", "ANATOMY", 118, 127], ["epithelial cells", "OBSERVATION", 128, 144], ["human", "ANATOMY_MODIFIER", 152, 157], ["skin", "ANATOMY", 158, 162], ["fi broblasts", "OBSERVATION", 163, 175], ["liver", "ANATOMY", 579, 584]]], ["There was a difference in the susceptibility of 2-ene and 2,4diene pure synthetic alkylamides to microsomal degradation with (2 E )-N -isobutylundeca -2 -ene-8,10-diynamide metabolized to only a tenth the extent of (2 E ,4 E ,8 Z ,10 Z )-N -isobutyldodeca-2,4,8,10-tetraenamide under identical incubation conditions.", [["2-ene", "CHEMICAL", 48, 53], ["2,4diene", "CHEMICAL", 58, 66], ["alkylamides", "CHEMICAL", 82, 93], ["(2 E )-N -isobutylundeca -2 -ene-8,10-diynamide", "CHEMICAL", 125, 172], ["2 E ,4 E ,8 Z ,10 Z )-N -isobutyldodeca-2,4,8,10-tetraenamide", "CHEMICAL", 216, 277], ["2-ene", "CHEMICAL", 48, 53], ["2,4diene", "CHEMICAL", 58, 66], ["alkylamides", "CHEMICAL", 82, 93], ["(2 E )-N -isobutylundeca -2 -ene-8,10-diynamide", "CHEMICAL", 125, 172], ["(2 E ,4 E ,8 Z ,10 Z )-N -isobutyldodeca-2,4,8,10-tetraenamide", "CHEMICAL", 215, 277], ["2-ene", "SIMPLE_CHEMICAL", 48, 53], ["2,4diene pure synthetic alkylamides", "SIMPLE_CHEMICAL", 58, 93], ["microsomal", "SIMPLE_CHEMICAL", 97, 107], ["(2 E )-N -isobutylundeca -2 -ene-8,10-diynamide", "SIMPLE_CHEMICAL", 125, 172], ["(2 E ,4 E ,8 Z ,10 Z )-N -isobutyldodeca-2,4,8,10-tetraenamide", "SIMPLE_CHEMICAL", 215, 277], ["the susceptibility", "TEST", 26, 44], ["2,4diene pure synthetic alkylamides", "TREATMENT", 58, 93], ["microsomal degradation", "TEST", 97, 119], ["-isobutylundeca", "TEST", 134, 149], ["-isobutyldodeca", "TEST", 240, 255], ["tetraenamide", "TREATMENT", 265, 277], ["difference", "OBSERVATION_MODIFIER", 12, 22]]], ["Alkylamide metabolites were detected and found to be the predicted epoxidation, hydroxylation and dealkylation products.", [["Alkylamide", "CHEMICAL", 0, 10], ["Alkylamide", "CHEMICAL", 0, 10], ["Alkylamide", "SIMPLE_CHEMICAL", 0, 10], ["dealkylation products", "SIMPLE_CHEMICAL", 98, 119], ["Alkylamide metabolites", "TEST", 0, 22], ["hydroxylation", "TREATMENT", 80, 93], ["dealkylation products", "TREATMENT", 98, 119]]], ["These fi ndings suggested that Echinacea may affect the P450-mediated metabolism of other concurrently ingested pharmaceuticals.Herb-Drug/Herb-Herb Interaction ActivityCytochrome P450 enzymes (P450s) appeared to be the principal system responsible for the metabolism of Echinacea components and most of the main hepatic and some extrahepatic isoforms appeared to be involved (Toselli et al. 2009 ).", [["hepatic", "ANATOMY", 312, 319], ["extrahepatic", "ANATOMY", 329, 341], ["Echinacea", "CHEMICAL", 31, 40], ["Echinacea", "ORGANISM", 31, 40], ["P450", "GENE_OR_GENE_PRODUCT", 56, 60], ["ActivityCytochrome P450", "GENE_OR_GENE_PRODUCT", 160, 183], ["P450s", "GENE_OR_GENE_PRODUCT", 193, 198], ["Echinacea", "ORGANISM", 270, 279], ["hepatic", "ORGAN", 312, 319], ["extrahepatic", "MULTI-TISSUE_STRUCTURE", 329, 341], ["P450", "PROTEIN", 56, 60], ["ActivityCytochrome P450 enzymes", "PROTEIN", 160, 191], ["P450s", "PROTEIN", 193, 198], ["Echinacea", "SPECIES", 31, 40], ["Echinacea", "PROBLEM", 31, 40], ["the P450", "TEST", 52, 60], ["Herb", "TEST", 128, 132], ["P450 enzymes", "TEST", 179, 191], ["P450s", "TEST", 193, 198], ["Echinacea components", "PROBLEM", 270, 290], ["Echinacea", "OBSERVATION", 31, 40], ["Echinacea", "OBSERVATION", 270, 279], ["main", "ANATOMY_MODIFIER", 307, 311], ["hepatic", "ANATOMY", 312, 319], ["some", "ANATOMY_MODIFIER", 324, 328], ["extrahepatic", "ANATOMY", 329, 341]]], ["Epoxide formation, N-dealkylation and hydroxylation were reported as the main metabolic pathways mediated by P450s and interactions with P450s determined the circulating concentrations and duration of action of these phytochemicals as well as any potential interactions with other chemicals.", [["Epoxide", "CHEMICAL", 0, 7], ["N-dealkylation", "CHEMICAL", 19, 33], ["Epoxide", "CHEMICAL", 0, 7], ["N", "CHEMICAL", 19, 20], ["Epoxide", "SIMPLE_CHEMICAL", 0, 7], ["N-dealkylation", "SIMPLE_CHEMICAL", 19, 33], ["P450s", "GENE_OR_GENE_PRODUCT", 109, 114], ["P450s", "GENE_OR_GENE_PRODUCT", 137, 142], ["P450s", "PROTEIN", 109, 114], ["P450s", "PROTEIN", 137, 142], ["Epoxide formation", "TREATMENT", 0, 17], ["N-dealkylation", "TREATMENT", 19, 33], ["hydroxylation", "TREATMENT", 38, 51], ["the circulating concentrations", "PROBLEM", 154, 184], ["these phytochemicals", "TREATMENT", 211, 231]]], ["In-vivo studies in rats showed that E. purpurea may interact cytochrome P450 enzymes and induce signifi cant herb-drug interactions which may alter pharmacotherapy (Mrozikiewicz, et al. 2010 ).", [["rats", "ORGANISM", 19, 23], ["E. purpurea", "ORGANISM", 36, 47], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 61, 76], ["cytochrome P450 enzymes", "PROTEIN", 61, 84], ["rats", "SPECIES", 19, 23], ["E. purpurea", "SPECIES", 36, 47], ["E. purpurea", "SPECIES", 36, 47], ["E. purpurea", "PROBLEM", 36, 47], ["cytochrome P450 enzymes", "TEST", 61, 84], ["signifi cant herb", "PROBLEM", 96, 113], ["drug interactions", "PROBLEM", 114, 131]]], ["The Echinacea ethanol extract could potently inhibit the expression of CYP3A1 (41 %) and CYP3A2 (25 %) mRNAs.", [["Echinacea ethanol extract", "CHEMICAL", 4, 29], ["ethanol", "CHEMICAL", 14, 21], ["Echinacea", "ORGANISM", 4, 13], ["ethanol", "SIMPLE_CHEMICAL", 14, 21], ["CYP3A1", "GENE_OR_GENE_PRODUCT", 71, 77], ["CYP3A2", "GENE_OR_GENE_PRODUCT", 89, 95], ["CYP3A1 (41 %) and CYP3A2 (25 %) mRNAs", "RNA", 71, 108], ["Echinacea", "SPECIES", 4, 13], ["The Echinacea ethanol extract", "TREATMENT", 0, 29], ["CYP3A1", "TEST", 71, 77], ["CYP3A2", "TEST", 89, 95]]], ["A weaker inhibitory effect was observed for CYP2D2 by 15 % and CYP2C6 by 18 % after long application of the Echinacea ethanol extract.", [["Echinacea ethanol", "CHEMICAL", 108, 125], ["ethanol", "CHEMICAL", 118, 125], ["CYP2D2", "GENE_OR_GENE_PRODUCT", 44, 50], ["CYP2C6", "GENE_OR_GENE_PRODUCT", 63, 69], ["Echinacea", "ORGANISM", 108, 117], ["ethanol", "SIMPLE_CHEMICAL", 118, 125], ["CYP2D2", "PROTEIN", 44, 50], ["Echinacea", "SPECIES", 108, 117], ["A weaker inhibitory effect", "PROBLEM", 0, 26], ["CYP2D2", "TEST", 44, 50], ["CYP2C6", "TEST", 63, 69], ["the Echinacea ethanol extract", "TREATMENT", 104, 133], ["weaker", "OBSERVATION_MODIFIER", 2, 8], ["inhibitory effect", "OBSERVATION", 9, 26]]], ["CYP2D2 and CYP2C6 activities were also inhibited by extract but in a lesser degree than CYP3A1 activity.", [["extract", "ANATOMY", 52, 59], ["CYP2D2", "GENE_OR_GENE_PRODUCT", 0, 6], ["CYP2C6", "GENE_OR_GENE_PRODUCT", 11, 17], ["CYP3A1", "GENE_OR_GENE_PRODUCT", 88, 94], ["CYP3A1", "PROTEIN", 88, 94], ["CYP2D2", "TEST", 0, 6], ["lesser degree", "OBSERVATION_MODIFIER", 69, 82]]], ["The fi ndings suggested that Echinacea extract may infl uence the P450-mediated metabolism of different drugs and may initiate chemical carcinogenesis by activation of some compounds to their carcinogenic metabolites.Herb-Drug/Herb-Herb Interaction ActivityThe multiherbal product Sambucus Force containing Echinacea purpurea and Sambucus nigra as its main constituents was found to inhibit CYP3A4 activity with IC 50 value of 1,192 (1,091-1,302) \u03bcg/ml (Schr\u00f8der-Aasen et al. 2012 ) .", [["extract", "ANATOMY", 39, 46], ["Echinacea extract", "CHEMICAL", 29, 46], ["carcinogenesis", "DISEASE", 136, 150], ["Echinacea purpurea", "CHEMICAL", 307, 325], ["Echinacea", "ORGANISM", 29, 38], ["P450", "GENE_OR_GENE_PRODUCT", 66, 70], ["Sambucus", "ORGANISM", 281, 289], ["Echinacea purpurea", "ORGANISM", 307, 325], ["Sambucus nigra", "ORGANISM", 330, 344], ["CYP3A4", "GENE_OR_GENE_PRODUCT", 391, 397], ["CYP3A4", "PROTEIN", 391, 397], ["Echinacea", "SPECIES", 29, 38], ["Echinacea purpurea", "SPECIES", 307, 325], ["Sambucus nigra", "SPECIES", 330, 344], ["Echinacea purpurea", "SPECIES", 307, 325], ["Sambucus nigra", "SPECIES", 330, 344], ["Echinacea extract", "PROBLEM", 29, 46], ["different drugs", "TREATMENT", 94, 109], ["chemical carcinogenesis", "PROBLEM", 127, 150], ["Herb", "TREATMENT", 217, 221], ["The multiherbal product Sambucus Force", "TREATMENT", 257, 295], ["Echinacea purpurea", "PROBLEM", 307, 325], ["CYP3A4 activity", "TEST", 391, 406], ["IC", "TEST", 412, 414], ["Sambucus Force", "OBSERVATION", 281, 295], ["Echinacea purpurea", "OBSERVATION", 307, 325]]], ["The inhibitory potency appeared exclusively to be exerted by E. purpurea , implicating an insignifi cant inhibition by S. nigra.", [["E. purpurea", "ORGANISM", 61, 72], ["S. nigra", "ORGANISM", 119, 127], ["E. purpurea", "SPECIES", 61, 72], ["S. nigra", "SPECIES", 119, 127], ["E. purpurea", "SPECIES", 61, 72], ["S. nigra", "SPECIES", 119, 127], ["E. purpurea", "PROBLEM", 61, 72]]], ["Echinacea purpurea acted differently in the multiherbal product, which showed a dual inhibition profi le with both an uncompetitive (substrate-dependent) inhibition and a time-dependent (substrateindependent) inhibitory mechanism.", [["Echinacea purpurea", "CHEMICAL", 0, 18], ["Echinacea purpurea", "ORGANISM", 0, 18], ["Echinacea purpurea", "SPECIES", 0, 18], ["Echinacea purpurea", "SPECIES", 0, 18], ["Echinacea purpurea", "PROBLEM", 0, 18], ["a dual inhibition profi le", "PROBLEM", 78, 104], ["an uncompetitive (substrate-dependent) inhibition", "PROBLEM", 115, 164], ["a time-dependent (substrateindependent) inhibitory mechanism", "TREATMENT", 169, 229], ["purpurea", "OBSERVATION", 10, 18], ["uncompetitive", "OBSERVATION", 118, 131]]], ["These mechanistic differences were suggested to be caused by herb-herb interactions in the multiherbal product.Allergy ProblemsA woman with atopy experienced anaphylaxis after taking a commercial extract of Echinacea ; hypersensitivity was confi rmed by skin prick and RAST testing (Mullins 1998 ) .", [["skin", "ANATOMY", 254, 258], ["atopy", "DISEASE", 140, 145], ["anaphylaxis", "DISEASE", 158, 169], ["extract of Echinacea", "CHEMICAL", 196, 216], ["hypersensitivity", "DISEASE", 219, 235], ["woman", "ORGANISM", 129, 134], ["Echinacea", "ORGANISM", 207, 216], ["skin", "ORGAN", 254, 258], ["woman", "SPECIES", 129, 134], ["Echinacea", "SPECIES", 207, 216], ["atopy", "PROBLEM", 140, 145], ["anaphylaxis", "PROBLEM", 158, 169], ["a commercial extract of Echinacea", "TREATMENT", 183, 216], ["hypersensitivity", "PROBLEM", 219, 235], ["skin prick", "TEST", 254, 264], ["RAST testing", "TEST", 269, 281], ["skin", "ANATOMY", 254, 258]]], ["Regular ingestion of Echinacea by up to 5 % of surveyed patients with atopy, combined with detection of Echinacea -binding IgE in atopic subjects (19 % by skin testing; 20 % with moderate to strong reactivity by RAST testing), indicated the possibility of severe allergic reactions, even with fi rsttime use, due to cross-reactivity with other structurally similar allergens.Toxicity and Safety StudiesAccording to the review of Huntley et al. ( 2005 ) , despite the voluminous data availability on the effi cacy of Echinacea ( Echinacea spp. namely E. angustifolia , E. pallida and E. purpurea ), safety issues and the monitoring of adverse events had not been focused on.", [["skin", "ANATOMY", 155, 159], ["Echinacea", "CHEMICAL", 21, 30], ["atopy", "DISEASE", 70, 75], ["Echinacea", "CHEMICAL", 104, 113], ["atopic", "DISEASE", 130, 136], ["allergic reactions", "DISEASE", 263, 281], ["Toxicity", "DISEASE", 375, 383], ["Echinacea", "ORGANISM", 21, 30], ["patients", "ORGANISM", 56, 64], ["Echinacea", "ORGANISM", 104, 113], ["IgE", "GENE_OR_GENE_PRODUCT", 123, 126], ["skin", "ORGAN", 155, 159], ["Echinacea", "ORGANISM", 516, 525], ["Echinacea spp", "ORGANISM", 528, 541], ["E. angustifolia", "ORGANISM", 550, 565], ["E. pallida", "ORGANISM", 568, 578], ["E. purpurea", "ORGANISM", 583, 594], ["IgE", "PROTEIN", 123, 126], ["patients", "SPECIES", 56, 64], ["Echinacea", "SPECIES", 516, 525], ["Echinacea", "SPECIES", 528, 537], ["E. angustifolia", "SPECIES", 550, 565], ["E. pallida", "SPECIES", 568, 578], ["E. purpurea", "SPECIES", 583, 594], ["E. angustifolia", "SPECIES", 550, 565], ["E. pallida", "SPECIES", 568, 578], ["E. purpurea", "SPECIES", 583, 594], ["Echinacea", "TREATMENT", 21, 30], ["atopy", "PROBLEM", 70, 75], ["Echinacea", "TEST", 104, 113], ["binding IgE in atopic subjects", "PROBLEM", 115, 145], ["skin testing", "TEST", 155, 167], ["RAST testing", "TEST", 212, 224], ["severe allergic reactions", "PROBLEM", 256, 281], ["other structurally similar allergens", "PROBLEM", 338, 374], ["Echinacea ( Echinacea spp", "PROBLEM", 516, 541], ["the monitoring", "TEST", 616, 630], ["adverse events", "PROBLEM", 634, 648], ["Echinacea", "OBSERVATION_MODIFIER", 21, 30], ["possibility of", "UNCERTAINTY", 241, 255], ["severe", "OBSERVATION_MODIFIER", 256, 262], ["allergic", "OBSERVATION", 263, 271], ["allergens", "OBSERVATION", 365, 374], ["angustifolia", "OBSERVATION_MODIFIER", 553, 565]]], ["Short-term use of Echinacea was reported to be associated with a relatively good safety profi le, with a slight risk of transient, reversible, adverse events.", [["Echinacea", "CHEMICAL", 18, 27], ["Echinacea", "ORGANISM", 18, 27], ["Echinacea", "TREATMENT", 18, 27], ["transient, reversible, adverse events", "PROBLEM", 120, 157], ["transient", "OBSERVATION", 120, 129], ["reversible", "OBSERVATION_MODIFIER", 131, 141]]], ["The major adverse events reported with Echinacea products are allergic reactions, ranging from contact dermatitis to anaphylaxis (Mahady et al. 2001 ) .", [["Echinacea", "CHEMICAL", 39, 48], ["allergic reactions", "DISEASE", 62, 80], ["dermatitis", "DISEASE", 103, 113], ["anaphylaxis", "DISEASE", 117, 128], ["The major adverse events", "PROBLEM", 0, 24], ["Echinacea products", "TREATMENT", 39, 57], ["allergic reactions", "PROBLEM", 62, 80], ["contact dermatitis", "PROBLEM", 95, 113], ["anaphylaxis", "PROBLEM", 117, 128]]], ["Patients with an allergy to plants in the daisy family (Asteraceae) should be instructed not to use products containing Echinacea.", [["allergy", "DISEASE", 17, 24], ["Echinacea", "CHEMICAL", 120, 129], ["Patients", "ORGANISM", 0, 8], ["Echinacea", "ORGANISM", 120, 129], ["Patients", "SPECIES", 0, 8], ["Echinacea", "SPECIES", 120, 129], ["Echinacea", "TREATMENT", 120, 129]]], ["The use of Echinacea products during pregnancy and lactation would appear to be ill-advised in light of the paucity of data in this area.", [["Echinacea", "ORGANISM", 11, 20], ["Echinacea products", "TREATMENT", 11, 29], ["lactation", "TREATMENT", 51, 60]]], ["According to the review by Perri et al. ( 2006 ) there was good scientifi c evidence from a prospective cohort study that oral consumption of Echinacea during the fi rst trimester did not increase the risk for major malformations.", [["oral", "ANATOMY", 122, 126], ["Echinacea", "CHEMICAL", 142, 151], ["malformations", "DISEASE", 216, 229], ["oral", "ORGANISM_SUBDIVISION", 122, 126], ["Echinacea", "ORGANISM", 142, 151], ["a prospective cohort study", "TEST", 90, 116], ["Echinacea", "TREATMENT", 142, 151], ["major malformations", "PROBLEM", 210, 229], ["malformations", "OBSERVATION", 216, 229]]], ["Low-level evidence based on expert opinion showed oral consumption of Echinacea in recommended doses to be safe for use during pregnancy and lactation.", [["oral", "ANATOMY", 50, 54], ["Echinacea", "CHEMICAL", 70, 79], ["oral", "ORGANISM_SUBDIVISION", 50, 54], ["Echinacea", "ORGANISM", 70, 79], ["Echinacea", "TREATMENT", 70, 79]]], ["Echinacea was non-teratogenic when used during pregnancy.", [["Echinacea", "CHEMICAL", 0, 9], ["Echinacea", "ORGANISM", 0, 9], ["Echinacea", "SPECIES", 0, 9], ["Echinacea", "TREATMENT", 0, 9], ["non-teratogenic", "PROBLEM", 14, 29]]], ["However more quality studies were needed to determine its safety.Toxicity and Safety StudiesAfter 4 weeks of oral administration of expressed juice of E. purpurea in doses amounting to many times, the human therapeutic dose laboratory tests and necropsy fi ndings presented no evidence of any toxic effects in rats (Mengs et al. 1991 ) .", [["oral", "ANATOMY", 109, 113], ["juice", "ANATOMY", 142, 147], ["Toxicity", "DISEASE", 65, 73], ["oral", "ORGANISM_SUBDIVISION", 109, 113], ["juice", "ORGANISM_SUBSTANCE", 142, 147], ["E. purpurea", "ORGANISM", 151, 162], ["human", "ORGANISM", 201, 206], ["rats", "ORGANISM", 310, 314], ["E. purpurea", "SPECIES", 151, 162], ["human", "SPECIES", 201, 206], ["rats", "SPECIES", 310, 314], ["E. purpurea", "SPECIES", 151, 162], ["human", "SPECIES", 201, 206], ["more quality studies", "TEST", 8, 28], ["oral administration", "TREATMENT", 109, 128], ["E. purpurea", "TREATMENT", 151, 162], ["laboratory tests", "TEST", 224, 240], ["necropsy fi ndings", "TEST", 245, 263], ["any toxic effects in rats", "PROBLEM", 289, 314], ["no evidence of", "UNCERTAINTY", 274, 288], ["toxic", "OBSERVATION_MODIFIER", 293, 298]]], ["Tests for mutagenicity carried out in microorganisms and mammalian cells in-vitro and in mice all gave negative results.", [["mammalian cells", "ANATOMY", 57, 72], ["mammalian cells", "CELL", 57, 72], ["mice", "ORGANISM", 89, 93], ["mammalian cells", "CELL_TYPE", 57, 72], ["mice", "SPECIES", 89, 93], ["mice", "SPECIES", 89, 93], ["Tests", "TEST", 0, 5], ["mutagenicity", "TEST", 10, 22], ["microorganisms", "PROBLEM", 38, 52], ["mammalian cells", "TEST", 57, 72]]], ["In an in-vitro carcinogenicity study, E. purpurea did not produce malignant transformation in hamster embryo cells.Pharmacokinetic StudiesStudies showed that alkylamides from Echinacea species can readily be transported across Caco-2 monolayers indicating that they can be transported across the intestinal barrier and may contribute to the in-vivo effects of Echinacea preparations (Jager et al. 2002 ; Matthias et al. 2004 ) but not caffeic acid conjugates (Matthias et al. 2004 ).Pharmacokinetic StudiesStudies of nine healthy volunteers found that alkamides were rapidly absorbed and were measurable in plasma 20 minutes after Echinacea ( E. purpurea and E. angustifolia ) tablet ingestion after standard high-fat breakfast and remained detectable for up to 12 hours (Matthias et al. 2005a ) .", [["embryo cells", "ANATOMY", 102, 114], ["Caco-2 monolayers", "ANATOMY", 227, 244], ["intestinal barrier", "ANATOMY", 296, 314], ["plasma", "ANATOMY", 607, 613], ["malignant transformation", "DISEASE", 66, 90], ["alkylamides", "CHEMICAL", 158, 169], ["caffeic acid", "CHEMICAL", 435, 447], ["alkamides", "CHEMICAL", 552, 561], ["Echinacea", "CHEMICAL", 631, 640], ["alkylamides", "CHEMICAL", 158, 169], ["caffeic acid", "CHEMICAL", 435, 447], ["alkamides", "CHEMICAL", 552, 561], ["E. purpurea", "ORGANISM", 38, 49], ["hamster embryo cells", "CELL", 94, 114], ["alkylamides", "SIMPLE_CHEMICAL", 158, 169], ["Echinacea", "ORGANISM", 175, 184], ["Caco-2 monolayers", "CELL", 227, 244], ["intestinal barrier", "TISSUE", 296, 314], ["Echinacea", "ORGANISM", 360, 369], ["caffeic acid conjugates", "SIMPLE_CHEMICAL", 435, 458], ["volunteers", "ORGANISM", 530, 540], ["alkamides", "SIMPLE_CHEMICAL", 552, 561], ["plasma", "ORGANISM_SUBSTANCE", 607, 613], ["Echinacea", "ORGANISM", 631, 640], ["E. purpurea", "ORGANISM", 643, 654], ["E. angustifolia", "ORGANISM", 659, 674], ["hamster embryo cells", "CELL_TYPE", 94, 114], ["Caco-2 monolayers", "CELL_LINE", 227, 244], ["E. purpurea", "SPECIES", 38, 49], ["hamster", "SPECIES", 94, 101], ["E. purpurea", "SPECIES", 643, 654], ["E. angustifolia", "SPECIES", 659, 674], ["E. purpurea", "SPECIES", 38, 49], ["hamster", "SPECIES", 94, 101], ["E. purpurea", "SPECIES", 643, 654], ["E. angustifolia", "SPECIES", 659, 674], ["malignant transformation in hamster embryo cells", "PROBLEM", 66, 114], ["Pharmacokinetic StudiesStudies", "TEST", 115, 145], ["alkylamides", "PROBLEM", 158, 169], ["Echinacea species", "PROBLEM", 175, 192], ["Echinacea preparations", "TREATMENT", 360, 382], ["Pharmacokinetic StudiesStudies", "TEST", 483, 513], ["alkamides", "PROBLEM", 552, 561], ["Echinacea ( E. purpurea", "TREATMENT", 631, 654], ["standard high-fat breakfast", "TREATMENT", 700, 727], ["malignant", "OBSERVATION", 66, 75], ["hamster embryo cells", "OBSERVATION", 94, 114], ["Echinacea species", "OBSERVATION", 175, 192], ["intestinal", "ANATOMY", 296, 306]]], ["The maximal concentrations for the sum of alkamides in human plasma were reached within 2.3 hours post ingestion and averaged 336 ng eq/ml plasma.", [["plasma", "ANATOMY", 61, 67], ["plasma", "ANATOMY", 139, 145], ["alkamides", "CHEMICAL", 42, 51], ["alkamides", "CHEMICAL", 42, 51], ["alkamides", "SIMPLE_CHEMICAL", 42, 51], ["human", "ORGANISM", 55, 60], ["plasma", "ORGANISM_SUBSTANCE", 61, 67], ["plasma", "ORGANISM_SUBSTANCE", 139, 145], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["The maximal concentrations", "TREATMENT", 0, 26], ["human plasma", "TEST", 55, 67]]], ["No obvious differences were observed in the pharmacokinetics of individual or total alkamides.", [["alkamides", "CHEMICAL", 84, 93], ["alkamides", "CHEMICAL", 84, 93], ["alkamides", "SIMPLE_CHEMICAL", 84, 93], ["obvious differences", "PROBLEM", 3, 22], ["total alkamides", "TREATMENT", 78, 93], ["obvious", "OBSERVATION_MODIFIER", 3, 10], ["differences", "OBSERVATION_MODIFIER", 11, 22]]], ["Caffeic acid conjugates could not be identifi ed in any plasma sample at any time after tablet ingestion.Pharmacokinetic StudiesAlkamides dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic acid isobutylamides were found to be rapidly absorbed and measurable in plasma 10 minutes after administration of 0.21 and 0.9 mg Echinacea purpurea phytotherapeutic lozenges and remained detectable for 3 hours for the 0.21 mg lozenges and >3 hours for the 0.9 mg lozenges; 0.07 mg lozenges were measurable 20 minutes after administration and remained detectable for only 2 hours after the administration (Guiotto et al. 2008 ) .", [["plasma sample", "ANATOMY", 56, 69], ["plasma", "ANATOMY", 253, 259], ["Caffeic acid", "CHEMICAL", 0, 12], ["Alkamides dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic acid", "CHEMICAL", 128, 185], ["Caffeic acid", "CHEMICAL", 0, 12], ["Alkamides dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic acid isobutylamides", "CHEMICAL", 128, 200], ["Caffeic acid conjugates", "SIMPLE_CHEMICAL", 0, 23], ["plasma", "ORGANISM_SUBSTANCE", 56, 62], ["Alkamides dodeca-2 E", "SIMPLE_CHEMICAL", 128, 148], ["4 E ,8 Z ,10 E / Z -tetraenoic acid isobutylamides", "SIMPLE_CHEMICAL", 150, 200], ["plasma", "ORGANISM_SUBSTANCE", 253, 259], ["Echinacea purpurea", "SPECIES", 311, 329], ["Caffeic acid conjugates", "TREATMENT", 0, 23], ["Pharmacokinetic Studies", "TEST", 105, 128], ["Alkamides", "TEST", 128, 137], ["dodeca", "TEST", 138, 144], ["E", "TEST", 147, 148], ["E", "TEST", 152, 153], ["Z", "TEST", 157, 158], ["E", "TEST", 163, 164], ["Z", "TEST", 167, 168], ["tetraenoic acid isobutylamides", "TEST", 170, 200], ["Echinacea purpurea phytotherapeutic lozenges", "TREATMENT", 311, 355], ["the 0.9 mg lozenges", "TREATMENT", 434, 453]]], ["A signifi cant dose-independent downregulation of the proinfl ammatory cytokines IL-12p70, IL-8, IL-6, IL-10 and TNF was observed after 24 hours.", [["IL-12p70", "GENE_OR_GENE_PRODUCT", 81, 89], ["IL-8", "GENE_OR_GENE_PRODUCT", 91, 95], ["IL-6", "GENE_OR_GENE_PRODUCT", 97, 101], ["IL-10", "GENE_OR_GENE_PRODUCT", 103, 108], ["TNF", "GENE_OR_GENE_PRODUCT", 113, 116], ["proinfl ammatory cytokines", "PROTEIN", 54, 80], ["IL", "PROTEIN", 81, 83], ["IL", "PROTEIN", 103, 105], ["TNF", "PROTEIN", 113, 116], ["A signifi cant dose", "TEST", 0, 19], ["the proinfl ammatory cytokines IL", "TEST", 50, 83], ["IL", "TEST", 91, 93], ["IL", "TEST", 97, 99], ["IL", "TEST", 103, 105], ["TNF", "TREATMENT", 113, 116]]], ["The results demonstrated that pharmacokinetics of dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic isobutylamides were linear and that absorption was very rapid ( t 1/2 = 6 minutes) with apparently no lag time, thus indicating the possibility that a fraction of the drug was absorbed through the oral mucosa.", [["oral mucosa", "ANATOMY", 290, 301], ["dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic isobutylamides", "CHEMICAL", 50, 107], ["dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic isobutylamides", "CHEMICAL", 50, 107], ["dodeca-2 E", "SIMPLE_CHEMICAL", 50, 60], ["4 E ,8 Z", "SIMPLE_CHEMICAL", 62, 70], ["10 E / Z -tetraenoic isobutylamides", "SIMPLE_CHEMICAL", 72, 107], ["oral mucosa", "MULTI-TISSUE_STRUCTURE", 290, 301], ["pharmacokinetics", "TEST", 30, 46], ["dodeca", "TEST", 50, 56], ["Z", "TEST", 69, 70], ["Z", "TEST", 79, 80], ["indicating the possibility", "UNCERTAINTY", 210, 236], ["oral mucosa", "ANATOMY", 290, 301]]], ["In an earlier study, after oral ingestion, the arithmetic mean C (max) of dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic acid isobutylamides absorbed for Echinacea purpurea tincture was 0.40 ng/ml serum with 30 minutes t (max), while for the Echinacea tablet the t (max) of tablets was 45 minutes with a C (max) of 0.12 ng/ml (Woelkart et al. 2006 ) .", [["oral", "ANATOMY", 27, 31], ["serum", "ANATOMY", 193, 198], ["dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic acid isobutylamides", "CHEMICAL", 74, 136], ["Echinacea purpurea tincture", "CHEMICAL", 150, 177], ["dodeca-2 E ,4 E ,8 Z ,10 E / Z -tetraenoic acid isobutylamides", "CHEMICAL", 74, 136], ["oral", "ORGANISM_SUBDIVISION", 27, 31], ["dodeca-2 E", "SIMPLE_CHEMICAL", 74, 84], ["4 E", "SIMPLE_CHEMICAL", 86, 89], ["8 Z", "SIMPLE_CHEMICAL", 91, 94], ["10 E / Z -tetraenoic acid isobutylamides", "SIMPLE_CHEMICAL", 96, 136], ["Echinacea", "ORGANISM", 150, 159], ["serum", "ORGANISM_SUBSTANCE", 193, 198], ["Echinacea", "ORGANISM", 238, 247], ["Echinacea purpurea", "SPECIES", 150, 168], ["Echinacea purpurea", "SPECIES", 150, 168], ["an earlier study", "TEST", 3, 19], ["the arithmetic mean C", "TEST", 43, 64], ["dodeca", "TEST", 74, 80], ["Z", "TEST", 93, 94], ["Z", "TEST", 103, 104], ["tetraenoic acid isobutylamides", "TREATMENT", 106, 136], ["Echinacea purpurea tincture", "TREATMENT", 150, 177], ["the Echinacea tablet the t (max) of tablets", "TREATMENT", 234, 277], ["a C (max)", "TREATMENT", 298, 307]]], ["Both E. purpurea preparations led to the same effects on the immune system according to the concentration of proinfl ammatory cytokines TNF-alpha and IL-8.", [["immune system", "ANATOMY", 61, 74], ["E. purpurea", "ORGANISM", 5, 16], ["immune system", "ANATOMICAL_SYSTEM", 61, 74], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 136, 145], ["IL-8", "GENE_OR_GENE_PRODUCT", 150, 154], ["proinfl ammatory cytokines", "PROTEIN", 109, 135], ["TNF", "PROTEIN", 136, 139], ["IL-8", "PROTEIN", 150, 154], ["E. purpurea", "SPECIES", 5, 16], ["E. purpurea", "SPECIES", 5, 16], ["Both E. purpurea preparations", "TREATMENT", 0, 29], ["the immune system", "TREATMENT", 57, 74], ["proinfl ammatory cytokines", "TEST", 109, 135], ["TNF", "TEST", 136, 139], ["IL", "TEST", 150, 152], ["purpurea preparations", "OBSERVATION", 8, 29]]], ["Twenty-three hours after oral application a signifi cant downregulation of TNF-alpha and IL-8 in LPS pre-stimulated whole blood was found.", [["oral", "ANATOMY", 25, 29], ["whole blood", "ANATOMY", 116, 127], ["LPS", "CHEMICAL", 97, 100], ["oral", "ORGANISM_SUBDIVISION", 25, 29], ["TNF-alpha", "GENE_OR_GENE_PRODUCT", 75, 84], ["IL-8", "GENE_OR_GENE_PRODUCT", 89, 93], ["LPS", "SIMPLE_CHEMICAL", 97, 100], ["blood", "ORGANISM_SUBSTANCE", 122, 127], ["TNF-alpha", "PROTEIN", 75, 84], ["IL-8", "PROTEIN", 89, 93], ["oral application", "TREATMENT", 25, 41], ["a signifi cant downregulation of TNF", "TREATMENT", 42, 78], ["alpha and IL", "TREATMENT", 79, 91], ["TNF", "ANATOMY", 75, 78]]], ["However, no signifi cant changes in the concentration of IL-6 were observed.Pharmacokinetic StudiesThe alkylamide, undeca-2-ene-8,10-diynoic acid isobutylamide, a constituent of E. purpurea (Goel et al. 2011 ) and dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamides (DTAI), the most abundant alkylamide in E. purpurea , were successfully quantifi ed in the patients plasma after ingestion of E. purpurea extract by LC-MS/MS assay (Goey et al. 2012 ).Traditional Medicinal UsesEchinacea spp. are native to North America and were traditionally used by the Indian tribes for a variety of ailments, including mouth sores, colds and snakebites (Kindscher 1989 ) .", [["plasma", "ANATOMY", 375, 381], ["extract", "ANATOMY", 413, 420], ["mouth sores", "ANATOMY", 614, 625], ["alkylamide", "CHEMICAL", 103, 113], ["undeca-2-ene-8,10-diynoic acid isobutylamide", "CHEMICAL", 115, 159], ["dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamides", "CHEMICAL", 214, 274], ["DTAI", "CHEMICAL", 276, 280], ["alkylamide", "CHEMICAL", 301, 311], ["E. purpurea extract", "CHEMICAL", 401, 420], ["mouth sores", "DISEASE", 614, 625], ["colds", "DISEASE", 627, 632], ["snakebites", "DISEASE", 637, 647], ["alkylamide", "CHEMICAL", 103, 113], ["undeca-2-ene-8,10-diynoic acid isobutylamide", "CHEMICAL", 115, 159], ["dodeca-2 E ,4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamides", "CHEMICAL", 214, 274], ["DTAI", "CHEMICAL", 276, 280], ["alkylamide", "CHEMICAL", 301, 311], ["IL-6", "GENE_OR_GENE_PRODUCT", 57, 61], ["alkylamide", "SIMPLE_CHEMICAL", 103, 113], ["undeca-2-ene-8,10-diynoic acid isobutylamide", "SIMPLE_CHEMICAL", 115, 159], ["E. purpurea", "ORGANISM", 178, 189], ["dodeca-2 E", "SIMPLE_CHEMICAL", 214, 224], ["4 E ,8 Z ,10 E / Ztetraenoic acid isobutylamides", "SIMPLE_CHEMICAL", 226, 274], ["DTAI", "SIMPLE_CHEMICAL", 276, 280], ["alkylamide", "SIMPLE_CHEMICAL", 301, 311], ["E. purpurea", "ORGANISM", 315, 326], ["patients", "ORGANISM", 366, 374], ["plasma", "ORGANISM_SUBSTANCE", 375, 381], ["UsesEchinacea spp.", "ORGANISM", 481, 499], ["mouth", "ORGANISM_SUBDIVISION", 614, 619], ["IL-6", "PROTEIN", 57, 61], ["E. purpurea", "SPECIES", 178, 189], ["E. purpurea", "SPECIES", 315, 326], ["patients", "SPECIES", 366, 374], ["E. purpurea", "SPECIES", 401, 412], ["E. purpurea", "SPECIES", 178, 189], ["E. purpurea", "SPECIES", 315, 326], ["E. purpurea", "SPECIES", 401, 412], ["UsesEchinacea spp.", "SPECIES", 481, 499], ["signifi cant changes", "PROBLEM", 12, 32], ["the concentration of IL", "TREATMENT", 36, 59], ["Pharmacokinetic Studies", "TEST", 76, 99], ["The alkylamide", "TEST", 99, 113], ["undeca", "TEST", 115, 121], ["diynoic acid isobutylamide", "TREATMENT", 133, 159], ["E. purpurea", "TREATMENT", 178, 189], ["dodeca", "TEST", 214, 220], ["Ztetraenoic acid isobutylamides", "TREATMENT", 243, 274], ["MS assay", "TEST", 430, 438], ["mouth sores", "PROBLEM", 614, 625], ["colds", "PROBLEM", 627, 632], ["snakebites", "PROBLEM", 637, 647], ["no", "UNCERTAINTY", 9, 11], ["mouth", "ANATOMY", 614, 619]]], ["Traditional uses of E. purpurea , E. angustifolia and E. pallida include the following: respiratory infections, colds and fl u, bronchitis, strep throat, toothache; urinary tract infections, herpes sores and gonorrhoea; skin disorders, staph infections, cold sores, ulcers, wounds, burns, insect bites, eczema, allergies and others; and rheumatoid arthritis (Hudson 2012 ).Other UsesDried Echinacea purpurea (EP) can be used as a feed additive to improve the meat quality and oxidative status in Arbor Acres broilers (Lee et al. 2013 ).", [["respiratory", "ANATOMY", 88, 99], ["throat", "ANATOMY", 146, 152], ["urinary tract", "ANATOMY", 165, 178], ["skin", "ANATOMY", 220, 224], ["ulcers", "ANATOMY", 266, 272], ["wounds", "ANATOMY", 274, 280], ["meat", "ANATOMY", 459, 463], ["respiratory infections", "DISEASE", 88, 110], ["colds", "DISEASE", 112, 117], ["bronchitis", "DISEASE", 128, 138], ["strep throat", "DISEASE", 140, 152], ["toothache", "DISEASE", 154, 163], ["urinary tract infections", "DISEASE", 165, 189], ["herpes sores", "DISEASE", 191, 203], ["gonorrhoea", "DISEASE", 208, 218], ["skin disorders", "DISEASE", 220, 234], ["staph infections", "DISEASE", 236, 252], ["cold sores", "DISEASE", 254, 264], ["ulcers", "DISEASE", 266, 272], ["wounds", "DISEASE", 274, 280], ["burns", "DISEASE", 282, 287], ["insect bites", "DISEASE", 289, 301], ["eczema", "DISEASE", 303, 309], ["allergies", "DISEASE", 311, 320], ["rheumatoid arthritis", "DISEASE", 337, 357], ["UsesDried Echinacea purpurea", "CHEMICAL", 379, 407], ["EP", "CHEMICAL", 409, 411], ["E. purpurea", "ORGANISM", 20, 31], ["E. angustifolia", "ORGANISM", 34, 49], ["E. pallida", "ORGANISM", 54, 64], ["throat", "ORGANISM_SUBDIVISION", 146, 152], ["urinary tract", "ORGANISM_SUBDIVISION", 165, 178], ["skin", "ORGAN", 220, 224], ["ulcers", "PATHOLOGICAL_FORMATION", 266, 272], ["wounds", "PATHOLOGICAL_FORMATION", 274, 280], ["Echinacea purpurea", "ORGANISM", 389, 407], ["EP", "SIMPLE_CHEMICAL", 409, 411], ["meat", "ORGANISM_SUBDIVISION", 459, 463], ["E. purpurea", "SPECIES", 20, 31], ["E. angustifolia", "SPECIES", 34, 49], ["E. pallida", "SPECIES", 54, 64], ["Echinacea purpurea", "SPECIES", 389, 407], ["broilers", "SPECIES", 508, 516], ["E. purpurea", "SPECIES", 20, 31], ["E. angustifolia", "SPECIES", 34, 49], ["E. pallida", "SPECIES", 54, 64], ["Echinacea purpurea", "SPECIES", 389, 407], ["Arbor Acres broilers", "SPECIES", 496, 516], ["E. purpurea", "TREATMENT", 20, 31], ["respiratory infections", "PROBLEM", 88, 110], ["colds", "PROBLEM", 112, 117], ["fl u", "PROBLEM", 122, 126], ["bronchitis", "PROBLEM", 128, 138], ["strep throat", "PROBLEM", 140, 152], ["toothache", "PROBLEM", 154, 163], ["urinary tract infections", "PROBLEM", 165, 189], ["herpes sores", "PROBLEM", 191, 203], ["gonorrhoea", "PROBLEM", 208, 218], ["skin disorders", "PROBLEM", 220, 234], ["staph infections", "PROBLEM", 236, 252], ["cold sores", "PROBLEM", 254, 264], ["ulcers", "PROBLEM", 266, 272], ["wounds", "PROBLEM", 274, 280], ["burns", "PROBLEM", 282, 287], ["insect bites", "PROBLEM", 289, 301], ["eczema", "PROBLEM", 303, 309], ["allergies", "PROBLEM", 311, 320], ["rheumatoid arthritis", "PROBLEM", 337, 357], ["Other UsesDried Echinacea purpurea", "TREATMENT", 373, 407], ["a feed additive", "TREATMENT", 428, 443], ["respiratory", "ANATOMY", 88, 99], ["infections", "OBSERVATION", 100, 110], ["bronchitis", "OBSERVATION", 128, 138], ["throat", "ANATOMY", 146, 152], ["urinary tract", "ANATOMY", 165, 178], ["skin", "ANATOMY", 220, 224], ["staph infections", "OBSERVATION", 236, 252], ["cold sores", "OBSERVATION_MODIFIER", 254, 264], ["ulcers", "OBSERVATION", 266, 272], ["wounds", "ANATOMY", 274, 280], ["burns", "OBSERVATION", 282, 287], ["eczema", "OBSERVATION", 303, 309], ["rheumatoid arthritis", "OBSERVATION", 337, 357]]], ["The addition of 0.5 and 1.0 % EP signifi cantly increased water-holding capacity and decreased storage loss of breast and thigh fi llets at 35 days old.", [["breast", "ANATOMY", 111, 117], ["thigh fi llets", "ANATOMY", 122, 136], ["EP", "CHEMICAL", 30, 32], ["breast", "ORGANISM_SUBDIVISION", 111, 117], ["thigh", "ORGANISM_SUBDIVISION", 122, 127], ["decreased storage loss of breast and thigh fi llets", "TREATMENT", 85, 136], ["decreased", "OBSERVATION_MODIFIER", 85, 94], ["storage loss", "OBSERVATION", 95, 107], ["breast", "ANATOMY", 111, 117], ["thigh", "ANATOMY", 122, 127]]], ["Results for Trolox equivalent antioxidant capacity, catalase and superoxide dismutase were signifi cantly higher for the 0.5, 1.0 and 2.0 % EP supplemental groups than control group in serum.", [["serum", "ANATOMY", 185, 190], ["Trolox", "CHEMICAL", 12, 18], ["superoxide", "CHEMICAL", 65, 75], ["EP", "CHEMICAL", 140, 142], ["Trolox", "CHEMICAL", 12, 18], ["superoxide", "CHEMICAL", 65, 75], ["Trolox", "SIMPLE_CHEMICAL", 12, 18], ["catalase", "SIMPLE_CHEMICAL", 52, 60], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 65, 85], ["serum", "ORGANISM_SUBSTANCE", 185, 190], ["catalase", "PROTEIN", 52, 60], ["superoxide dismutase", "PROTEIN", 65, 85], ["Trolox equivalent antioxidant capacity", "TREATMENT", 12, 50], ["catalase", "TREATMENT", 52, 60], ["superoxide dismutase", "TEST", 65, 85], ["2.0 % EP supplemental groups", "TREATMENT", 134, 162]]], ["Liver and spleen tissues results showed that the antioxidative enzyme activities were higher with EP powder at 35 days of age.Other UsesStudies showed E. purpurea to have potential as immunostimulatory feed additive against Newcastle disease virus in laying hens and in fattening pigs by intermittent application (B\u00f6hmer et al. 2009 ).", [["Liver", "ANATOMY", 0, 5], ["spleen tissues", "ANATOMY", 10, 24], ["EP", "CHEMICAL", 98, 100], ["Newcastle disease virus", "DISEASE", 224, 247], ["Liver", "ORGAN", 0, 5], ["spleen tissues", "TISSUE", 10, 24], ["E. purpurea", "ORGANISM", 151, 162], ["Newcastle disease virus", "ORGANISM", 224, 247], ["pigs", "ORGANISM", 280, 284], ["E. purpurea", "SPECIES", 151, 162], ["hens", "SPECIES", 258, 262], ["pigs", "SPECIES", 280, 284], ["E. purpurea", "SPECIES", 151, 162], ["Newcastle disease virus", "SPECIES", 224, 247], ["pigs", "SPECIES", 280, 284], ["Liver and spleen tissues", "TEST", 0, 24], ["the antioxidative enzyme activities", "TEST", 45, 80], ["EP powder", "TREATMENT", 98, 107], ["E. purpurea", "PROBLEM", 151, 162], ["immunostimulatory feed", "TREATMENT", 184, 206], ["Newcastle disease virus", "PROBLEM", 224, 247], ["spleen", "ANATOMY", 10, 16]]], ["The performance of laying hens was not impacted with feed additive application of pressed E. purpurea (aerial parts) juice in ethanol or fermented juice.", [["juice", "ANATOMY", 117, 122], ["juice", "ANATOMY", 147, 152], ["ethanol", "CHEMICAL", 126, 133], ["ethanol", "CHEMICAL", 126, 133], ["hens", "ORGANISM", 26, 30], ["E. purpurea", "ORGANISM", 90, 101], ["juice", "ORGANISM_SUBSTANCE", 117, 122], ["ethanol", "SIMPLE_CHEMICAL", 126, 133], ["juice", "ORGANISM_SUBSTANCE", 147, 152], ["E. purpurea", "SPECIES", 90, 101], ["E. purpurea", "SPECIES", 90, 101], ["pressed E. purpurea", "TREATMENT", 82, 101]]], ["Signifi cant changes were found in the number of lymphocytes, phagocytosis rate and Newcastle Disease Virus (NDV) antibody titre.", [["lymphocytes", "ANATOMY", 49, 60], ["lymphocytes", "CELL", 49, 60], ["Newcastle Disease Virus", "ORGANISM", 84, 107], ["NDV", "ORGANISM", 109, 112], ["lymphocytes", "CELL_TYPE", 49, 60], ["Newcastle Disease Virus", "SPECIES", 84, 107], ["NDV", "SPECIES", 109, 112], ["Signifi cant changes", "PROBLEM", 0, 20], ["lymphocytes", "TEST", 49, 60], ["phagocytosis rate", "TEST", 62, 79], ["Newcastle Disease Virus", "PROBLEM", 84, 107], ["antibody titre", "TEST", 114, 128], ["lymphocytes", "ANATOMY", 49, 60]]], ["The number of lymphocytes was highest in the group receiving ethanol juice for fi ve consecutive days.", [["lymphocytes", "ANATOMY", 14, 25], ["juice", "ANATOMY", 69, 74], ["ethanol", "CHEMICAL", 61, 68], ["ethanol", "CHEMICAL", 61, 68], ["lymphocytes", "CELL", 14, 25], ["ethanol", "SIMPLE_CHEMICAL", 61, 68], ["juice", "ORGANISM_SUBSTANCE", 69, 74], ["lymphocytes", "CELL_TYPE", 14, 25], ["ethanol juice", "TREATMENT", 61, 74], ["number", "OBSERVATION_MODIFIER", 4, 10], ["lymphocytes", "OBSERVATION", 14, 25], ["highest", "OBSERVATION_MODIFIER", 30, 37]]], ["Phagocytosis was reduced in both groups provided with ethanol juice (2 or 5 days).", [["juice", "ANATOMY", 62, 67], ["ethanol", "CHEMICAL", 54, 61], ["ethanol", "CHEMICAL", 54, 61], ["ethanol", "SIMPLE_CHEMICAL", 54, 61], ["juice", "ORGANISM_SUBSTANCE", 62, 67], ["Phagocytosis", "PROBLEM", 0, 12], ["ethanol juice", "TREATMENT", 54, 67], ["reduced", "OBSERVATION_MODIFIER", 17, 24]]], ["Highest NDV antibody titres were seen in the groups receiving fermented juice for 2 days.", [["juice", "ANATOMY", 72, 77], ["NDV", "ORGANISM", 8, 11], ["juice", "ORGANISM_SUBSTANCE", 72, 77], ["NDV antibody", "PROTEIN", 8, 20], ["NDV", "SPECIES", 8, 11], ["Highest NDV antibody titres", "TEST", 0, 27], ["fermented juice", "TREATMENT", 62, 77], ["antibody titres", "OBSERVATION", 12, 27]]], ["Additionally, phagocytosis of granulocytes was determined in fattening pigs (80-100 kg) after 5 days of Echinacea application with ethanol or fermented juice.", [["granulocytes", "ANATOMY", 30, 42], ["juice", "ANATOMY", 152, 157], ["Echinacea", "CHEMICAL", 104, 113], ["ethanol", "CHEMICAL", 131, 138], ["ethanol", "CHEMICAL", 131, 138], ["granulocytes", "CELL", 30, 42], ["pigs", "ORGANISM", 71, 75], ["Echinacea", "ORGANISM", 104, 113], ["ethanol", "SIMPLE_CHEMICAL", 131, 138], ["juice", "ORGANISM_SUBSTANCE", 152, 157], ["granulocytes", "CELL_TYPE", 30, 42], ["pigs", "SPECIES", 71, 75], ["pigs", "SPECIES", 71, 75], ["phagocytosis of granulocytes", "PROBLEM", 14, 42], ["Echinacea application", "TREATMENT", 104, 125], ["fermented juice", "TREATMENT", 142, 157], ["granulocytes", "OBSERVATION", 30, 42]]], ["A signifi cant increase was found with both Echinacea formulations.", [["A signifi cant increase", "PROBLEM", 0, 23], ["both Echinacea formulations", "TREATMENT", 39, 66], ["increase", "OBSERVATION_MODIFIER", 15, 23]]], ["The number of lymphocytes was also increased signifi cantly in the groups provided with Echinacea .CommentsPurple conefl ower is easily propagated either from seeds or vegetatively by division, root cuttings and basal cuttings.", [["lymphocytes", "ANATOMY", 14, 25], ["seeds", "ANATOMY", 159, 164], ["root", "ANATOMY", 194, 198], ["Echinacea", "CHEMICAL", 88, 97], ["lymphocytes", "CELL", 14, 25], ["Echinacea", "ORGANISM", 88, 97], ["root cuttings", "MULTI-TISSUE_STRUCTURE", 194, 207], ["lymphocytes", "CELL_TYPE", 14, 25], ["Echinacea", "TREATMENT", 88, 97], ["root cuttings", "TEST", 194, 207], ["basal cuttings", "TREATMENT", 212, 226], ["number", "OBSERVATION_MODIFIER", 4, 10], ["lymphocytes", "OBSERVATION", 14, 25], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["signifi", "OBSERVATION_MODIFIER", 45, 52], ["Echinacea", "OBSERVATION", 88, 97], ["root cuttings", "OBSERVATION", 194, 207], ["basal cuttings", "OBSERVATION", 212, 226]]], ["It blooms throughout spring and summer and is pollinated by butterfl ies and bees.", [["blooms", "OBSERVATION", 3, 9]]]], "6c4ded01a201a2ece071739bd04893a226a4e60e": [["INTRODUCTIONThe term \"brittle diabetes\" was first described by Woodyatt in 1934 to describe individuals with large, unexplained changes in blood glucose concentrations (1) .", [["blood", "ANATOMY", 139, 144], ["diabetes", "DISEASE", 30, 38], ["glucose", "CHEMICAL", 145, 152], ["glucose", "CHEMICAL", 145, 152], ["blood", "ORGANISM_SUBSTANCE", 139, 144], ["glucose", "SIMPLE_CHEMICAL", 145, 152], ["brittle diabetes", "PROBLEM", 22, 38], ["large, unexplained changes in blood glucose concentrations", "PROBLEM", 109, 167], ["large", "OBSERVATION_MODIFIER", 109, 114]]], ["Over the years the definition evolved to characterize diabetes in a patient whose \"life was constantly disrupted by episodes of hypoglycemia or hyperglycemia\" (2) .", [["diabetes", "DISEASE", 54, 62], ["hypoglycemia", "DISEASE", 128, 140], ["hyperglycemia", "DISEASE", 144, 157], ["patient", "ORGANISM", 68, 75], ["patient", "SPECIES", 68, 75], ["diabetes", "PROBLEM", 54, 62], ["hypoglycemia", "PROBLEM", 128, 140], ["hyperglycemia\"", "PROBLEM", 144, 158], ["diabetes", "OBSERVATION", 54, 62]]], ["There have been many other subsequent definitions of brittle diabetes noting lability of glycemia, frequent hospitalizations for diabetic ketoacidosis (DKA) or hypoglycemia (Table 1) , and often poor patient outcomes.", [["diabetes", "DISEASE", 61, 69], ["glycemia", "DISEASE", 89, 97], ["diabetic ketoacidosis", "DISEASE", 129, 150], ["DKA", "DISEASE", 152, 155], ["hypoglycemia", "DISEASE", 160, 172], ["patient", "ORGANISM", 200, 207], ["patient", "SPECIES", 200, 207], ["brittle diabetes", "PROBLEM", 53, 69], ["lability of glycemia", "PROBLEM", 77, 97], ["diabetic ketoacidosis", "PROBLEM", 129, 150], ["DKA", "PROBLEM", 152, 155], ["hypoglycemia", "PROBLEM", 160, 172], ["brittle", "OBSERVATION_MODIFIER", 53, 60], ["diabetes", "OBSERVATION", 61, 69]]], ["In 1985 Schade and colleagues focused on the etiologies of severe disruptive glucose lability and noted that in 30 affected patients, 16 were found to have \"fictious disease\" or \"malingering\" (3) .", [["disruptive glucose lability", "DISEASE", 66, 93], ["malingering", "DISEASE", 179, 190], ["glucose", "CHEMICAL", 77, 84], ["glucose", "SIMPLE_CHEMICAL", 77, 84], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["severe disruptive glucose lability", "PROBLEM", 59, 93], ["\"fictious disease\"", "PROBLEM", 156, 174], ["severe", "OBSERVATION_MODIFIER", 59, 65]]], ["The term thus took on tones of a largely maladaptive patient coping response.INTRODUCTIONBrittle diabetes is still frequently noted by clinicians in a variety of clinical outpatient settings and often is included in hospital admission and discharge diagnoses, yet is actually a descriptive term and is not included in the classification of diabetes from either the American Diabetes Association or the World Health Organization.", [["diabetes", "DISEASE", 97, 105], ["diabetes", "DISEASE", 340, 348], ["Diabetes", "DISEASE", 374, 382], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["INTRODUCTIONBrittle diabetes", "PROBLEM", 77, 105], ["diabetes", "PROBLEM", 340, 348], ["diabetes", "OBSERVATION", 97, 105], ["diabetes", "OBSERVATION", 340, 348]]], ["It is also not a form of \"atypical diabetes\" as most individuals with brittle diabetes have either type 1 diabetes or severely insulin deficient type 2 diabetes.INTRODUCTIONClearly, as our medical knowledge has expanded, the old descriptive terminology is outdated.INTRODUCTIONWhile it is accurate to consider these patients as having life-changing disruptions due to severe glycemic dysregulation, classifying them as \"brittle\" may feel condescending to many patients and their families.", [["diabetes", "DISEASE", 35, 43], ["diabetes", "DISEASE", 78, 86], ["type 1 diabetes", "DISEASE", 99, 114], ["type 2 diabetes", "DISEASE", 145, 160], ["glycemic dysregulation", "DISEASE", 375, 397], ["insulin", "GENE_OR_GENE_PRODUCT", 127, 134], ["patients", "ORGANISM", 316, 324], ["patients", "ORGANISM", 460, 468], ["patients", "SPECIES", 316, 324], ["patients", "SPECIES", 460, 468], ["\"atypical diabetes\"", "PROBLEM", 25, 44], ["brittle diabetes", "PROBLEM", 70, 86], ["type 1 diabetes", "PROBLEM", 99, 114], ["severely insulin deficient type 2 diabetes", "PROBLEM", 118, 160], ["changing disruptions", "PROBLEM", 340, 360], ["severe glycemic dysregulation", "PROBLEM", 368, 397], ["not a form of", "UNCERTAINTY", 11, 24], ["atypical", "OBSERVATION_MODIFIER", 26, 34], ["diabetes", "OBSERVATION", 35, 43], ["insulin deficient", "OBSERVATION", 127, 144], ["diabetes", "OBSERVATION", 152, 160], ["severe", "OBSERVATION_MODIFIER", 368, 374], ["glycemic dysregulation", "OBSERVATION", 375, 397]]], ["Furthermore, the term can convey a sense of patient blame or maladjustment which may be either inaccurate or incomplete and blunts a more appropriate J o u r n a l P r e -p r o o f 4 impetus to search for treatable causes of this life-threatening condition and appropriate interventions to remedy it.INTRODUCTIONIn fact, most patients who have extreme difficulty controlling their diabetes have other conditions (sometimes undiagnosed) which may include mental health disorders, significant psycho-social stressors, a coexisting medical problem or factors of age, transitions and socioeconomic constraint.", [["maladjustment", "DISEASE", 61, 74], ["diabetes", "DISEASE", 381, 389], ["psycho-social stressors", "DISEASE", 491, 514], ["patient", "ORGANISM", 44, 51], ["patients", "ORGANISM", 326, 334], ["patient", "SPECIES", 44, 51], ["patients", "SPECIES", 326, 334], ["threatening condition", "PROBLEM", 235, 256], ["appropriate interventions", "TREATMENT", 261, 286], ["extreme difficulty controlling their diabetes", "PROBLEM", 344, 389], ["mental health disorders", "PROBLEM", 454, 477], ["a coexisting medical problem", "PROBLEM", 516, 544]]], ["Thus, unstable diabetes control may be a primary or secondary condition.", [["diabetes", "DISEASE", 15, 23], ["unstable diabetes control", "PROBLEM", 6, 31], ["secondary condition", "PROBLEM", 52, 71], ["unstable", "OBSERVATION_MODIFIER", 6, 14], ["diabetes", "OBSERVATION", 15, 23], ["secondary condition", "OBSERVATION", 52, 71]]], ["Whatever the causal factors these patients are at risk for many unfortunate consequences: poor glycemic control with its complications, more emergency room and hospital admissions, strains on relationships, and greater healthcare utilization and diabetes distress.INTRODUCTIONWe find it helpful to separate these patients with \"brittle diabetes\" into four groups which tend to cluster according to lifespan to some degree.", [["diabetes distress", "DISEASE", 246, 263], ["diabetes", "DISEASE", 336, 344], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 313, 321], ["its complications", "PROBLEM", 117, 134], ["diabetes distress", "PROBLEM", 246, 263], ["brittle diabetes\"", "PROBLEM", 328, 345]]], ["The first group, as described by Schade et al., (3) are often younger woman who are DKA-prone and have severe glycemic variability usually due to psycho-social instability and/or significant psychiatric disease and/or some form of an eating disorder which is often not being addressed.", [["DKA", "DISEASE", 84, 87], ["psychiatric disease", "DISEASE", 191, 210], ["eating disorder", "DISEASE", 234, 249], ["woman", "ORGANISM", 70, 75], ["woman", "SPECIES", 70, 75], ["DKA", "PROBLEM", 84, 87], ["severe glycemic variability", "PROBLEM", 103, 130], ["psycho-social instability", "PROBLEM", 146, 171], ["significant psychiatric disease", "PROBLEM", 179, 210], ["an eating disorder", "PROBLEM", 231, 249], ["severe", "OBSERVATION_MODIFIER", 103, 109], ["glycemic variability", "OBSERVATION", 110, 130]]], ["The second group would be those individuals who have another medical condition resulting in a major disruption of insulin sensitivity/utilization or a nutritional disease-causing insulin/ glucose mismatching.", [["nutritional disease", "DISEASE", 151, 170], ["glucose", "CHEMICAL", 188, 195], ["glucose", "CHEMICAL", 188, 195], ["insulin", "GENE_OR_GENE_PRODUCT", 114, 121], ["insulin", "GENE_OR_GENE_PRODUCT", 179, 186], ["glucose", "SIMPLE_CHEMICAL", 188, 195], ["another medical condition", "PROBLEM", 53, 78], ["insulin sensitivity", "PROBLEM", 114, 133], ["a nutritional disease", "PROBLEM", 149, 170], ["insulin/ glucose mismatching", "TREATMENT", 179, 207], ["glucose mismatching", "OBSERVATION", 188, 207]]], ["Identifying and treating co-existing morbidity can often resolve the lability of glycemia completely.", [["glycemia", "DISEASE", 81, 89], ["co-existing morbidity", "PROBLEM", 25, 46], ["the lability of glycemia", "PROBLEM", 65, 89], ["morbidity", "OBSERVATION", 37, 46]]], ["The third group has emerged as individuals with type 1 diabetes now living into older age and suffering various degrees of cognitive impairment and life-style transition resulting in inability to self-manage their diabetes.", [["type 1 diabetes", "DISEASE", 48, 63], ["cognitive impairment", "DISEASE", 123, 143], ["diabetes", "DISEASE", 214, 222], ["type 1 diabetes", "PROBLEM", 48, 63], ["cognitive impairment", "PROBLEM", 123, 143], ["life-style transition", "PROBLEM", 148, 169], ["their diabetes", "PROBLEM", 208, 222], ["diabetes", "OBSERVATION", 214, 222]]], ["\"Geriatric type 1 diabetes\" was rarely seen 30 years ago but with the longer life spans of these patients today we frequently now see severe glycemic instability J o u r n a l P r e -p r o o f 5 due to unintentional omission of insulin doses, confusion of insulin types and insulin amounts, dosing errors or repeated insulin doses.", [["diabetes", "DISEASE", 18, 26], ["glycemic instability", "DISEASE", 141, 161], ["confusion", "DISEASE", 243, 252], ["patients", "ORGANISM", 97, 105], ["insulin", "GENE_OR_GENE_PRODUCT", 228, 235], ["insulin", "GENE_OR_GENE_PRODUCT", 256, 263], ["insulin", "GENE_OR_GENE_PRODUCT", 274, 281], ["insulin", "GENE_OR_GENE_PRODUCT", 317, 324], ["patients", "SPECIES", 97, 105], ["Geriatric type 1 diabetes\"", "PROBLEM", 1, 27], ["severe glycemic instability", "PROBLEM", 134, 161], ["insulin doses", "TREATMENT", 228, 241], ["confusion", "PROBLEM", 243, 252], ["insulin types", "TREATMENT", 256, 269], ["insulin amounts", "TREATMENT", 274, 289], ["repeated insulin doses", "TREATMENT", 308, 330]]], ["Furthermore this population can experience failures to accurately utilize self-glucose monitoring technologies and due to coexisting impaired glucoregulatory responses become highly prone to severe hypoglycemic emergencies.", [["hypoglycemic emergencies", "DISEASE", 198, 222], ["glucose", "CHEMICAL", 79, 86], ["glucose", "SIMPLE_CHEMICAL", 79, 86], ["failures", "PROBLEM", 43, 51], ["self-glucose monitoring technologies", "TREATMENT", 74, 110], ["coexisting impaired glucoregulatory responses", "PROBLEM", 122, 167], ["severe hypoglycemic emergencies", "PROBLEM", 191, 222]]], ["A final condition which until recently was mostly seen in low-income countries but now is seen around the world, is lack of insulin access (in the United States due to cost) and food insecurity.", [["insulin", "GENE_OR_GENE_PRODUCT", 124, 131], ["insulin access", "TREATMENT", 124, 138]]], ["These patients also meet the definition of brittle diabetes due to the severe glycemic variability and incapacitation they experience repeatedly to the point of DKA.", [["diabetes", "DISEASE", 51, 59], ["incapacitation", "DISEASE", 103, 117], ["DKA", "DISEASE", 161, 164], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["brittle diabetes", "PROBLEM", 43, 59], ["the severe glycemic variability", "PROBLEM", 67, 98], ["incapacitation", "PROBLEM", 103, 117], ["DKA", "PROBLEM", 161, 164], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["glycemic variability", "OBSERVATION", 78, 98], ["DKA", "OBSERVATION", 161, 164]]], ["Each of these groups will be described.DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASEThese are the patients first described with brittle diabetes in the classic report by Schade et al. (3) .", [["DKA", "DISEASE", 39, 42], ["diabetes", "DISEASE", 141, 149], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["DKA", "PROBLEM", 39, 42], ["HYPOGYCEMIA", "PROBLEM", 43, 54], ["PSYCHOLOGICAL DISEASEThese", "PROBLEM", 68, 94], ["brittle diabetes", "PROBLEM", 133, 149]]], ["Of the 16 patients described, 14 were reported to have either \"factitious disease\" or \"malingering\" and were most often young women ranging in age from 8 to 33 years.", [["factitious disease", "DISEASE", 63, 81], ["malingering", "DISEASE", 87, 98], ["patients", "ORGANISM", 10, 18], ["women", "ORGANISM", 126, 131], ["patients", "SPECIES", 10, 18], ["women", "SPECIES", 126, 131], ["factitious disease\"", "PROBLEM", 63, 82]]], ["In the Tattersall report, there was no difference in gender for those with recurrent DKA, but these investigators also noted a group with recurrent severe hypoglycemia (2).", [["DKA", "DISEASE", 85, 88], ["hypoglycemia", "DISEASE", 155, 167], ["recurrent DKA", "PROBLEM", 75, 88], ["recurrent severe hypoglycemia", "PROBLEM", 138, 167], ["no", "UNCERTAINTY", 36, 38], ["DKA", "OBSERVATION", 85, 88], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["hypoglycemia", "OBSERVATION", 155, 167]]], ["Indeed, they described a group called \"mixed brittleness\" with recurrent DKA and severe hypoglycemia.DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASEWhile psycho-social stressors were usually the etiology of these hospital admissions, it is difficult to know how many in the severe hypoglycemia group had developed hypoglycemia unawareness which is better understood and treated today (4).DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASEJ o u r n a l P r e -p r o o f 6 Adolescence and young adulthood are a particularly challenging time for those with type 1 diabetes.", [["brittleness", "DISEASE", 45, 56], ["DKA", "DISEASE", 73, 76], ["hypoglycemia", "DISEASE", 88, 100], ["DKA", "DISEASE", 101, 104], ["hypoglycemia", "DISEASE", 284, 296], ["hypoglycemia", "DISEASE", 317, 329], ["unawareness", "DISEASE", 330, 341], ["DKA", "DISEASE", 391, 394], ["type 1 diabetes", "DISEASE", 557, 572], ["mixed brittleness", "PROBLEM", 39, 56], ["recurrent DKA", "PROBLEM", 63, 76], ["severe hypoglycemia", "PROBLEM", 81, 100], ["DKA", "PROBLEM", 101, 104], ["HYPOGYCEMIA", "PROBLEM", 105, 116], ["PSYCHOLOGICAL DISEASEWhile psycho-social stressors", "PROBLEM", 130, 180], ["the severe hypoglycemia group", "PROBLEM", 273, 302], ["hypoglycemia unawareness", "PROBLEM", 317, 341], ["DKA", "PROBLEM", 391, 394], ["HYPOGYCEMIA", "PROBLEM", 395, 406], ["type 1 diabetes", "PROBLEM", 557, 572], ["recurrent", "OBSERVATION_MODIFIER", 63, 72], ["DKA", "OBSERVATION", 73, 76], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["hypoglycemia", "OBSERVATION", 88, 100], ["diabetes", "OBSERVATION", 564, 572]]], ["Indeed, in the T1D Exchange the mean A1C for those 13 to 25 years of age was 9.3% and for those not using continuous glucose monitoring (CGM) or insulin pump therapy was 9.6% (5) .", [["T1D", "DISEASE", 15, 18], ["glucose", "CHEMICAL", 117, 124], ["glucose", "CHEMICAL", 117, 124], ["glucose", "SIMPLE_CHEMICAL", 117, 124], ["insulin pump", "GENE_OR_GENE_PRODUCT", 145, 157], ["the mean A1C", "TEST", 28, 40], ["continuous glucose monitoring", "TEST", 106, 135], ["CGM", "TEST", 137, 140], ["insulin pump therapy", "TREATMENT", 145, 165]]], ["Between 4 to 6% of these individuals had at least one episode of DKA or severe hypoglycemia during the 3 months before the survey.", [["DKA", "DISEASE", 65, 68], ["hypoglycemia", "DISEASE", 79, 91], ["individuals", "ORGANISM", 25, 36], ["DKA", "PROBLEM", 65, 68], ["severe hypoglycemia", "PROBLEM", 72, 91], ["DKA", "OBSERVATION", 65, 68], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["hypoglycemia", "OBSERVATION", 79, 91]]], ["It has long been acknowledged that this age group often struggles with adherence to prescribed insulin regimens (6) as they transition from childhood care to the requirements of selfcare in adolescence and young adulthood.DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASEIndeed, the more complex regimens for T1D today are vastly different from the one to two injections of previous eras.", [["DKA", "DISEASE", 222, 225], ["T1D", "DISEASE", 310, 313], ["insulin", "GENE_OR_GENE_PRODUCT", 95, 102], ["insulin regimens", "TREATMENT", 95, 111], ["DKA", "PROBLEM", 222, 225], ["HYPOGYCEMIA", "PROBLEM", 226, 237], ["PSYCHOLOGICAL DISEASEIndeed", "PROBLEM", 251, 278], ["T1D", "PROBLEM", 310, 313], ["previous eras", "TREATMENT", 375, 388]]], ["By definition, this group meets the criteria for brittle diabetes.", [["diabetes", "DISEASE", 57, 65], ["brittle diabetes", "PROBLEM", 49, 65], ["diabetes", "OBSERVATION", 57, 65]]], ["In the Schade report, 18 of the 30 patients were in this age group.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43]]], ["Thus, Voulgari notes when this population reports taking insulin doses of over 2.0 units/kg/day, medication non-adherence needs to be considered (6) .", [["insulin", "GENE_OR_GENE_PRODUCT", 57, 64], ["insulin doses", "TREATMENT", 57, 70], ["medication non-adherence", "TREATMENT", 97, 121]]], ["However, there are still other reasons for severe insulin resistance in young type 1 diabetes.", [["type 1 diabetes", "DISEASE", 78, 93], ["insulin", "GENE_OR_GENE_PRODUCT", 50, 57], ["severe insulin resistance", "PROBLEM", 43, 68], ["young type 1 diabetes", "PROBLEM", 72, 93], ["severe", "OBSERVATION_MODIFIER", 43, 49], ["insulin resistance", "OBSERVATION", 50, 68], ["diabetes", "OBSERVATION", 85, 93]]], ["Puberty, chronic infection, steroid administration, hormonal contraceptives, and menstrual fluctuations are obvious examples.", [["Puberty", "DISEASE", 0, 7], ["chronic infection", "DISEASE", 9, 26], ["steroid", "CHEMICAL", 28, 35], ["hormonal contraceptives", "CHEMICAL", 52, 75], ["steroid", "CHEMICAL", 28, 35], ["steroid", "SIMPLE_CHEMICAL", 28, 35], ["Puberty, chronic infection", "PROBLEM", 0, 26], ["steroid administration", "TREATMENT", 28, 50], ["hormonal contraceptives", "TREATMENT", 52, 75], ["menstrual fluctuations", "PROBLEM", 81, 103], ["chronic", "OBSERVATION_MODIFIER", 9, 16], ["infection", "OBSERVATION", 17, 26]]], ["There are also age-related causes of hypoglycemia including \"dieting\", irregular food intake, fear of weight gain, transitions from family eating to self-provided meals, intensive exercise with sports participation, recreational activities, drugs and alcohol use and occult eating disorders common in those with and without diabetes in the adolescent and young adult population.DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASESevere mental health problems contribute to brittle diabetes in all age groups (7, 8) .", [["hypoglycemia", "DISEASE", 37, 49], ["weight gain", "DISEASE", 102, 113], ["alcohol", "CHEMICAL", 251, 258], ["occult eating disorders", "DISEASE", 267, 290], ["diabetes", "DISEASE", 324, 332], ["DKA", "DISEASE", 378, 381], ["diabetes", "DISEASE", 480, 488], ["alcohol", "CHEMICAL", 251, 258], ["alcohol", "SIMPLE_CHEMICAL", 251, 258], ["hypoglycemia", "PROBLEM", 37, 49], ["weight gain", "PROBLEM", 102, 113], ["occult eating disorders", "PROBLEM", 267, 290], ["diabetes", "PROBLEM", 324, 332], ["DKA", "PROBLEM", 378, 381], ["HYPOGYCEMIA", "PROBLEM", 382, 393], ["PSYCHOLOGICAL DISEASESevere mental health problems", "PROBLEM", 407, 457], ["brittle diabetes", "PROBLEM", 472, 488], ["hypoglycemia", "OBSERVATION", 37, 49], ["brittle", "OBSERVATION_MODIFIER", 472, 479], ["diabetes", "OBSERVATION", 480, 488]]], ["Family dysfunction, eating disorders, and factious disease (particularly among health care professionals) and associated addictions to alcohol and drugs have all been described (9, 10).DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASEThe primary diabetes provider must have a high index of suspicion for these diagnoses, J o u r n a l P r e -p r o o f 7 (particularly eating disorders and factitious disease), and once a diagnosis is suspected a prompt referral should be made to an experienced psychiatrist, psychologist, or medical social worker familiar with the interaction of mental health and acute and chronic diabetes management.DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASEIt is important to note that most reports acknowledge the profound psychosocial problems that challenge all patients with diabetes.", [["Family dysfunction", "DISEASE", 0, 18], ["eating disorders", "DISEASE", 20, 36], ["factious disease", "DISEASE", 42, 58], ["alcohol", "CHEMICAL", 135, 142], ["DKA", "DISEASE", 185, 188], ["primary diabetes", "DISEASE", 239, 255], ["eating disorders", "DISEASE", 369, 385], ["factitious disease", "DISEASE", 390, 408], ["diabetes", "DISEASE", 618, 626], ["DKA", "DISEASE", 638, 641], ["diabetes", "DISEASE", 810, 818], ["alcohol", "CHEMICAL", 135, 142], ["alcohol", "SIMPLE_CHEMICAL", 135, 142], ["patients", "ORGANISM", 796, 804], ["patients", "SPECIES", 796, 804], ["Family dysfunction", "PROBLEM", 0, 18], ["eating disorders", "PROBLEM", 20, 36], ["factious disease", "PROBLEM", 42, 58], ["drugs", "TREATMENT", 147, 152], ["DKA", "PROBLEM", 185, 188], ["HYPOGYCEMIA", "PROBLEM", 189, 200], ["PSYCHOLOGICAL DISEASE", "PROBLEM", 214, 235], ["eating disorders", "PROBLEM", 369, 385], ["factitious disease", "PROBLEM", 390, 408], ["acute and chronic diabetes management", "TREATMENT", 600, 637], ["DKA", "PROBLEM", 638, 641], ["HYPOGYCEMIA", "PROBLEM", 642, 653], ["the profound psychosocial problems", "PROBLEM", 742, 776], ["diabetes", "PROBLEM", 810, 818], ["dysfunction", "OBSERVATION", 7, 18], ["DISEASE", "OBSERVATION", 228, 235], ["acute", "OBSERVATION_MODIFIER", 600, 605], ["chronic", "OBSERVATION_MODIFIER", 610, 617], ["diabetes", "OBSERVATION", 618, 626]]], ["There was an assessment comparing 42 subjects with brittle diabetes (\"severe life-disrupting glycemic instability of any kind\") and a case control group of 42 subjects with \"stable diabetes\" matched for age, gender, years of education, and diabetes duration.", [["diabetes", "DISEASE", 59, 67], ["glycemic instability", "DISEASE", 93, 113], ["diabetes", "DISEASE", 181, 189], ["diabetes", "DISEASE", 240, 248], ["an assessment", "TEST", 10, 23], ["brittle diabetes", "PROBLEM", 51, 67], ["\"stable diabetes", "PROBLEM", 173, 189], ["diabetes duration", "PROBLEM", 240, 257], ["diabetes", "OBSERVATION", 59, 67]]], ["Surprisingly, there were no differences noted in all primary symptom's dimensions and in the three global distress indices between the two groups (11) .", [["no", "UNCERTAINTY", 25, 27], ["global", "OBSERVATION_MODIFIER", 99, 105], ["distress", "OBSERVATION", 106, 114]]], ["Those with brittle diabetes did show higher percentages of borderline, histrionic, and narcissistic personality disorders however, these patients were older than those described in the Tattersall (12) .", [["diabetes", "DISEASE", 19, 27], ["narcissistic personality disorders", "DISEASE", 87, 121], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["brittle diabetes", "PROBLEM", 11, 27], ["borderline, histrionic", "PROBLEM", 59, 81], ["narcissistic personality disorders", "PROBLEM", 87, 121], ["brittle", "OBSERVATION_MODIFIER", 11, 18], ["diabetes", "OBSERVATION", 19, 27], ["borderline", "OBSERVATION_MODIFIER", 59, 69]]], ["How many of these would be considered to have \"brittle diabetes\"?", [["diabetes", "DISEASE", 55, 63], ["brittle diabetes\"", "PROBLEM", 47, 64]]], ["It would be ideal to have a more objective definition of this diagnosis to identify those who could benefit from referral for appropriate psychological therapy.DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASEJ o u r n a l P r e -p r o o f 8 Not surprisingly, the cost of brittle diabetes resulting in DKA is not trivial.", [["DKA", "DISEASE", 160, 163], ["diabetes", "DISEASE", 281, 289], ["DKA", "DISEASE", 303, 306], ["appropriate psychological therapy", "TREATMENT", 126, 159], ["DKA", "PROBLEM", 160, 163], ["HYPOGYCEMIA", "PROBLEM", 164, 175], ["a l P r e -p", "TREATMENT", 220, 232], ["brittle diabetes", "PROBLEM", 273, 289], ["DKA", "PROBLEM", 303, 306], ["diabetes", "OBSERVATION", 281, 289], ["DKA", "OBSERVATION", 303, 306]]], ["In a report from 2013 in the US the mean hospital cost for a pediatric DKA admission was over $7100 (12) .", [["DKA", "DISEASE", 71, 74], ["a pediatric DKA", "PROBLEM", 59, 74]]], ["It is more difficult to obtain cost data for hypoglycemia for this age group, but in an older population of insulin users the annualized medical cost of hypoglycemia by itself (emergency rooms and hospital admissions) was $3241 (13) .", [["hypoglycemia", "DISEASE", 45, 57], ["hypoglycemia", "DISEASE", 153, 165], ["insulin", "GENE_OR_GENE_PRODUCT", 108, 115], ["cost data", "TEST", 31, 40], ["hypoglycemia", "PROBLEM", 45, 57], ["insulin", "TREATMENT", 108, 115], ["hypoglycemia", "PROBLEM", 153, 165]]], ["Another report specifically addressing brittle diabetes noted costs were almost three-fold times the yearly costs for stable diabetes management (14) .DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASEIt is clear the financial cost of acute metabolic emergencies common in brittle diabetes is expensive.DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASETreatment of these patients can be challenging and frustrating.", [["diabetes", "DISEASE", 47, 55], ["diabetes", "DISEASE", 125, 133], ["DKA", "DISEASE", 151, 154], ["diabetes", "DISEASE", 281, 289], ["DKA", "DISEASE", 303, 306], ["patients", "ORGANISM", 372, 380], ["patients", "SPECIES", 372, 380], ["brittle diabetes", "PROBLEM", 39, 55], ["stable diabetes management", "TREATMENT", 118, 144], ["DKA", "PROBLEM", 151, 154], ["HYPOGYCEMIA", "PROBLEM", 155, 166], ["PSYCHOLOGICAL DISEASEIt", "PROBLEM", 180, 203], ["acute metabolic emergencies", "PROBLEM", 235, 262], ["brittle diabetes", "PROBLEM", 273, 289], ["DKA", "PROBLEM", 303, 306], ["HYPOGYCEMIA", "PROBLEM", 307, 318], ["stable", "OBSERVATION_MODIFIER", 118, 124], ["diabetes", "OBSERVATION", 125, 133], ["acute", "OBSERVATION_MODIFIER", 235, 240], ["metabolic emergencies", "OBSERVATION", 241, 262], ["brittle diabetes", "OBSERVATION", 273, 289]]], ["Each case is different and requires creative strategies (3, 10) .", [["creative strategies", "TREATMENT", 36, 55], ["different", "OBSERVATION_MODIFIER", 13, 22]]], ["Most important is referral to appropriate mental health providers, ideally knowledgeable in diabetes.", [["diabetes", "DISEASE", 92, 100], ["diabetes", "PROBLEM", 92, 100], ["diabetes", "OBSERVATION", 92, 100]]], ["In previous eras these patients were admitted to the hospital for therapy, but that is not generally realistic now.", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["therapy", "TREATMENT", 66, 73]]], ["There are reports of good results in the outpatient setting (15) .DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASEAs an example, a 24-year-old woman was referred for \"brittle diabetes\".", [["DKA", "DISEASE", 66, 69], ["diabetes", "DISEASE", 177, 185], ["woman", "ORGANISM", 145, 150], ["woman", "SPECIES", 145, 150], ["DKA", "PROBLEM", 66, 69], ["HYPOGYCEMIA", "PROBLEM", 70, 81], ["brittle diabetes\"", "PROBLEM", 169, 186]]], ["She developed her diabetes at the age of 19 years and had been hospitalized at her community hospital on A more common etiology for brittle diabetes is lipohypertrophy from repeated insulin injections in the same site (figure 2).", [["diabetes", "DISEASE", 18, 26], ["diabetes", "DISEASE", 140, 148], ["lipohypertrophy", "DISEASE", 152, 167], ["insulin", "GENE_OR_GENE_PRODUCT", 182, 189], ["her diabetes", "PROBLEM", 14, 26], ["brittle diabetes", "PROBLEM", 132, 148], ["lipohypertrophy", "PROBLEM", 152, 167], ["repeated insulin injections", "TREATMENT", 173, 200], ["diabetes", "OBSERVATION", 18, 26], ["diabetes", "OBSERVATION", 140, 148]]], ["Insulin injected into lipohypertrophic tissue can cause erratic insulin absorption resulting in fluctuating glucose levels resulting in both hypo-and hyperglycemia (24) .", [["lipohypertrophic tissue", "ANATOMY", 22, 45], ["Insulin", "CHEMICAL", 0, 7], ["glucose", "CHEMICAL", 108, 115], ["hyperglycemia", "DISEASE", 150, 163], ["glucose", "CHEMICAL", 108, 115], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["lipohypertrophic tissue", "TISSUE", 22, 45], ["insulin", "GENE_OR_GENE_PRODUCT", 64, 71], ["glucose", "SIMPLE_CHEMICAL", 108, 115], ["Insulin", "TREATMENT", 0, 7], ["erratic insulin absorption", "PROBLEM", 56, 82], ["fluctuating glucose levels", "PROBLEM", 96, 122], ["both hypo-and hyperglycemia", "PROBLEM", 136, 163], ["both", "OBSERVATION_MODIFIER", 136, 140], ["hypo-and", "OBSERVATION_MODIFIER", 141, 149], ["hyperglycemia", "OBSERVATION", 150, 163]]], ["As seen in figure 3 , simply injecting in new sites can make dramatic changes in blood glucose control.DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASEIn terms of hypoglycemia, one etiology for brittle diabetes is diabetic gastroparesis.", [["blood", "ANATOMY", 81, 86], ["glucose", "CHEMICAL", 87, 94], ["DKA", "DISEASE", 103, 106], ["hypoglycemia", "DISEASE", 165, 177], ["diabetes", "DISEASE", 204, 212], ["diabetic gastroparesis", "DISEASE", 216, 238], ["glucose", "CHEMICAL", 87, 94], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["glucose", "SIMPLE_CHEMICAL", 87, 94], ["dramatic changes", "PROBLEM", 61, 77], ["blood glucose control", "TREATMENT", 81, 102], ["DKA", "PROBLEM", 103, 106], ["HYPOGYCEMIA", "PROBLEM", 107, 118], ["PSYCHOLOGICAL DISEASEIn terms", "PROBLEM", 132, 161], ["hypoglycemia", "PROBLEM", 165, 177], ["brittle diabetes", "PROBLEM", 196, 212], ["diabetic gastroparesis", "PROBLEM", 216, 238], ["dramatic", "OBSERVATION_MODIFIER", 61, 69], ["hypoglycemia", "OBSERVATION", 165, 177], ["diabetes", "OBSERVATION", 204, 212], ["diabetic", "OBSERVATION_MODIFIER", 216, 224], ["gastroparesis", "OBSERVATION", 225, 238]]], ["In the T1D Exchange, almost 5% of the population (mean age 49 years) was diagnosed with gastroparesis (25) .", [["T1D", "DISEASE", 7, 10], ["gastroparesis", "DISEASE", 88, 101], ["gastroparesis", "PROBLEM", 88, 101], ["gastroparesis", "OBSERVATION", 88, 101]]], ["Severe hypoglycemia, defined as seizure or coma, occurred one or more times per year in 25% of those with gastroparesis compared to 11% of those without (25) .", [["hypoglycemia", "DISEASE", 7, 19], ["seizure", "DISEASE", 32, 39], ["coma", "DISEASE", 43, 47], ["gastroparesis", "DISEASE", 106, 119], ["Severe hypoglycemia", "PROBLEM", 0, 19], ["seizure", "PROBLEM", 32, 39], ["coma", "PROBLEM", 43, 47], ["gastroparesis", "PROBLEM", 106, 119], ["hypoglycemia", "OBSERVATION", 7, 19], ["gastroparesis", "OBSERVATION", 106, 119]]], ["Another cause of lifethreatening hypoglycemia is the type B insulin resistance syndrome (26) .", [["hypoglycemia", "DISEASE", 33, 45], ["insulin", "GENE_OR_GENE_PRODUCT", 60, 67], ["lifethreatening hypoglycemia", "PROBLEM", 17, 45], ["the type B insulin resistance syndrome", "PROBLEM", 49, 87], ["lifethreatening hypoglycemia", "OBSERVATION", 17, 45], ["insulin resistance", "OBSERVATION", 60, 78]]], ["This condition is classically seen in middle-aged black women with severe insulin resistance and intermittent hypoglycemia.DKA/HYPOGYCEMIA-PRONE DUE TO PSYCHOLOGICAL DISEASEThere are other cited etiologies for brittle diabetes that are not supported by the evidence.", [["hypoglycemia", "DISEASE", 110, 122], ["DKA", "DISEASE", 123, 126], ["diabetes", "DISEASE", 218, 226], ["women", "ORGANISM", 56, 61], ["insulin", "GENE_OR_GENE_PRODUCT", 74, 81], ["women", "SPECIES", 56, 61], ["severe insulin resistance", "PROBLEM", 67, 92], ["intermittent hypoglycemia", "PROBLEM", 97, 122], ["DKA", "PROBLEM", 123, 126], ["HYPOGYCEMIA", "PROBLEM", 127, 138], ["PSYCHOLOGICAL DISEASEThere", "PROBLEM", 152, 178], ["brittle diabetes", "PROBLEM", 210, 226], ["middle", "ANATOMY_MODIFIER", 38, 44], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["insulin resistance", "OBSERVATION", 74, 92], ["intermittent", "OBSERVATION_MODIFIER", 97, 109], ["hypoglycemia", "OBSERVATION", 110, 122], ["diabetes", "OBSERVATION", 218, 226]]], ["For example, pancreatic diabetes from pancreatectomy is not associated with brittle diabetes.", [["pancreatic", "ANATOMY", 13, 23], ["pancreatic diabetes", "DISEASE", 13, 32], ["diabetes", "DISEASE", 84, 92], ["pancreatic", "ORGAN", 13, 23], ["pancreatic diabetes", "PROBLEM", 13, 32], ["pancreatectomy", "TREATMENT", 38, 52], ["brittle diabetes", "PROBLEM", 76, 92], ["pancreatic", "ANATOMY", 13, 23], ["diabetes", "OBSERVATION", 24, 32], ["pancreatectomy", "OBSERVATION", 38, 52], ["not associated with", "UNCERTAINTY", 56, 75], ["brittle", "OBSERVATION_MODIFIER", 76, 83], ["diabetes", "OBSERVATION", 84, 92]]], ["One would think that the glucagon deficiency seen in this most severe form of pancreatic diabetes would result in more glycemic lability and hypoglycemia.", [["pancreatic", "ANATOMY", 78, 88], ["glucagon", "CHEMICAL", 25, 33], ["pancreatic diabetes", "DISEASE", 78, 97], ["glycemic lability", "DISEASE", 119, 136], ["hypoglycemia", "DISEASE", 141, 153], ["glucagon", "GENE_OR_GENE_PRODUCT", 25, 33], ["pancreatic", "ORGAN", 78, 88], ["the glucagon deficiency", "PROBLEM", 21, 44], ["pancreatic diabetes", "PROBLEM", 78, 97], ["glycemic lability", "PROBLEM", 119, 136], ["hypoglycemia", "PROBLEM", 141, 153], ["pancreatic", "ANATOMY", 78, 88], ["diabetes", "OBSERVATION", 89, 97]]], ["In fact, there are no differences in diabetes-specific outcomes after pancreatectomy compared to type 1 diabetes (27) .", [["diabetes", "DISEASE", 37, 45], ["type 1 diabetes", "DISEASE", 97, 112], ["diabetes", "PROBLEM", 37, 45], ["pancreatectomy", "TREATMENT", 70, 84], ["type 1 diabetes", "PROBLEM", 97, 112], ["no", "UNCERTAINTY", 19, 21], ["differences", "OBSERVATION_MODIFIER", 22, 33], ["diabetes", "OBSERVATION", 37, 45], ["pancreatectomy", "OBSERVATION", 70, 84]]], ["Alcohol is another etiology frequently noted as causing brittle diabetes due to hypoglycemia.", [["Alcohol", "CHEMICAL", 0, 7], ["diabetes", "DISEASE", 64, 72], ["hypoglycemia", "DISEASE", 80, 92], ["brittle diabetes", "PROBLEM", 56, 72], ["hypoglycemia", "PROBLEM", 80, 92], ["diabetes", "OBSERVATION", 64, 72], ["hypoglycemia", "OBSERVATION", 80, 92]]], ["While it has been appreciated for decades that alcohol suppresses hepatic gluconeogenesis increasing J o u r n a l P r e -p r o o f 12 hypoglycemia risk (28) , severe hypoglycemia does not frequently appear to be a sequala of alcohol intoxication (29) .GERIATRIC TYPE 1 DIABETESThe number of older adults with type 1 diabetes continues to increase.", [["hepatic", "ANATOMY", 66, 73], ["alcohol", "CHEMICAL", 47, 54], ["hypoglycemia", "DISEASE", 135, 147], ["hypoglycemia", "DISEASE", 167, 179], ["alcohol", "CHEMICAL", 226, 233], ["type 1 diabetes", "DISEASE", 310, 325], ["alcohol", "CHEMICAL", 47, 54], ["alcohol", "CHEMICAL", 226, 233], ["alcohol", "SIMPLE_CHEMICAL", 47, 54], ["hepatic", "ORGAN", 66, 73], ["alcohol", "SIMPLE_CHEMICAL", 226, 233], ["hepatic gluconeogenesis", "PROBLEM", 66, 89], ["hypoglycemia risk", "PROBLEM", 135, 152], ["severe hypoglycemia", "PROBLEM", 160, 179], ["alcohol intoxication", "PROBLEM", 226, 246], ["type 1 diabetes", "PROBLEM", 310, 325], ["hepatic", "ANATOMY", 66, 73], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["hypoglycemia", "OBSERVATION", 167, 179], ["diabetes", "OBSERVATION", 317, 325]]], ["First, life expectancy of those with type 1 diabetes continues to improve (30) .", [["type 1 diabetes", "DISEASE", 37, 52], ["type 1 diabetes", "PROBLEM", 37, 52]]], ["Even prior to the development of human insulin and its analogues, home blood glucose monitoring, insulin pumps, and certainly CGM, life expectancy improved to 69 years if diagnosis occurred between 1965 to 1980 (31) .", [["blood", "ANATOMY", 71, 76], ["glucose", "CHEMICAL", 77, 84], ["glucose", "CHEMICAL", 77, 84], ["human", "ORGANISM", 33, 38], ["insulin", "GENE_OR_GENE_PRODUCT", 39, 46], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["glucose", "SIMPLE_CHEMICAL", 77, 84], ["insulin", "GENE_OR_GENE_PRODUCT", 97, 104], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["human insulin", "TREATMENT", 33, 46], ["its analogues", "TREATMENT", 51, 64], ["home blood glucose monitoring", "TREATMENT", 66, 95], ["insulin pumps", "TREATMENT", 97, 110]]], ["In addition, we are now seeing an increasing number of people with type 1 diabetes diagnosed in adulthood and surviving to advanced ages.", [["type 1 diabetes", "DISEASE", 67, 82], ["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61], ["type 1 diabetes", "PROBLEM", 67, 82], ["increasing", "OBSERVATION_MODIFIER", 34, 44], ["diabetes", "OBSERVATION", 74, 82]]], ["One recent study showed 42% of newly diagnosed type 1 diabetes occurred between the ages of 31-60 years (32) .", [["diabetes", "DISEASE", 54, 62], ["One recent study", "TEST", 0, 16], ["newly diagnosed type 1 diabetes", "PROBLEM", 31, 62], ["diabetes", "OBSERVATION", 54, 62]]], ["It is not uncommon to see grandparents of children with type 1 diabetes develop the condition.", [["type 1 diabetes", "DISEASE", 56, 71], ["children", "ORGANISM", 42, 50], ["children", "SPECIES", 42, 50], ["type 1 diabetes develop the condition", "PROBLEM", 56, 93], ["not", "UNCERTAINTY", 6, 9]]], ["Prime Minister Theresa May developed her type 1 diabetes at the age of 57 years (33) , while comedian Jerry Lewis noted at the age of 90 that he had developed his type 1 diabetes late in his life (34) .GERIATRIC TYPE 1 DIABETESType 1 diabetes can be difficult at any age, but self-management for elderly patients can be particularly challenging.", [["diabetes", "DISEASE", 48, 56], ["type 1 diabetes", "DISEASE", 163, 178], ["diabetes", "DISEASE", 234, 242], ["patients", "ORGANISM", 304, 312], ["patients", "SPECIES", 304, 312], ["her type 1 diabetes", "PROBLEM", 37, 56], ["his type 1 diabetes", "PROBLEM", 159, 178], ["GERIATRIC TYPE 1 DIABETESType 1 diabetes", "PROBLEM", 202, 242], ["diabetes", "OBSERVATION", 48, 56], ["diabetes", "OBSERVATION", 234, 242]]], ["Concerns with remembering to administer insulin (or taking it twice) are a common problem that can result in enough disruption to meet the criteria of brittle diabetes.", [["insulin", "CHEMICAL", 40, 47], ["diabetes", "DISEASE", 159, 167], ["insulin", "GENE_OR_GENE_PRODUCT", 40, 47], ["insulin", "PROTEIN", 40, 47], ["insulin", "TREATMENT", 40, 47], ["brittle diabetes", "PROBLEM", 151, 167], ["diabetes", "OBSERVATION", 159, 167]]], ["As cognition declins with age, independent self-care of diabetes can become problematic for many.", [["diabetes", "DISEASE", 56, 64], ["diabetes", "PROBLEM", 56, 64]]], ["Often emergency department admissions for an acute glycemic emergency require family members to become more involved in their elder's daily care.GERIATRIC TYPE 1 DIABETESInexperienced family members, care givers and even skilled nursing facility staff often find J o u r n a l P r e -p r o o f 13 management of type 1 diabetes difficult and they also make insulin errors.", [["diabetes", "DISEASE", 318, 326], ["insulin", "GENE_OR_GENE_PRODUCT", 356, 363], ["management", "TREATMENT", 297, 307], ["type 1 diabetes", "PROBLEM", 311, 326]]], ["Mismatches of nutrition with insulin in terms both of dosing and timing are extremely common and a major cause of recurrent emergency room and hospital admissions in this group.GERIATRIC TYPE 1 DIABETESHypoglycemia is a major concern as in this age group as it is associated with more cardiovascular events and serious health outcomes (35) .", [["cardiovascular", "ANATOMY", 285, 299], ["DIABETESHypoglycemia", "DISEASE", 194, 214], ["insulin", "GENE_OR_GENE_PRODUCT", 29, 36], ["insulin", "TREATMENT", 29, 36], ["nutrition", "OBSERVATION", 14, 23]]], ["Using blinded CGM, older adults with type 1 diabetes (mean age 68 years) were found to be hypoglycemic, below 70 mg/dL and 50 mg/dL, for a median of 91 and 32 minutes each day, respectively.", [["type 1 diabetes", "DISEASE", 37, 52], ["hypoglycemic", "DISEASE", 90, 102], ["type 1 diabetes", "PROBLEM", 37, 52], ["hypoglycemic", "PROBLEM", 90, 102]]], ["Severe sequelae of both short-term and long-term effects of hypoglycemia have led to newer guidelines for this age group and advise avoidance of hypoglycemia by increasing glycemic targets and up-adjusting alarm settings (36) .GERIATRIC TYPE 1 DIABETESFortunately, CGM has been shown to be efficacious in this age group when used properly and in the United States CGM is covered by Medicare for insulin deficient patients meeting certain criteria.", [["hypoglycemia", "DISEASE", 60, 72], ["hypoglycemia", "DISEASE", 145, 157], ["insulin", "GENE_OR_GENE_PRODUCT", 395, 402], ["patients", "ORGANISM", 413, 421], ["patients", "SPECIES", 413, 421], ["Severe sequelae of both short-term", "PROBLEM", 0, 34], ["hypoglycemia", "PROBLEM", 60, 72], ["hypoglycemia", "PROBLEM", 145, 157], ["CGM", "TEST", 265, 268], ["insulin deficient patients", "TREATMENT", 395, 421], ["sequelae", "OBSERVATION_MODIFIER", 7, 15], ["both", "OBSERVATION_MODIFIER", 19, 23], ["short-term", "OBSERVATION_MODIFIER", 24, 34], ["long-term", "OBSERVATION_MODIFIER", 39, 48]]], ["In the Wireless Innovation for Seniors with Diabetes Mellitus (WISDM) study, 203 individuals with a median age of 68 years showed that when using real-time CGM hypoglycemic burden (below 70 mg/dL) was reduced by 27 minutes per day (37) .", [["Diabetes Mellitus", "DISEASE", 44, 61], ["hypoglycemic", "DISEASE", 160, 172], ["individuals", "ORGANISM", 81, 92], ["Diabetes Mellitus", "PROBLEM", 44, 61], ["hypoglycemic burden", "PROBLEM", 160, 179]]], ["Importantly, use of CGM was also found to result in less hypoglycemia below 54 mg/dL and less severe hypoglycemia (requiring the assistance of another person).", [["hypoglycemia", "DISEASE", 57, 69], ["hypoglycemia", "DISEASE", 101, 113], ["person", "SPECIES", 151, 157], ["CGM", "TEST", 20, 23], ["less hypoglycemia", "PROBLEM", 52, 69], ["less severe hypoglycemia", "PROBLEM", 89, 113], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["hypoglycemia", "OBSERVATION", 101, 113]]], ["Finally, while there is no consensus as to what degree of glycemic variability is ideal, let alone what degree results in brittle diabetes in the aged, those individuals using CGM had a coefficient of variation (CV) of 37% compared to 42% for those using blood glucose monitoring.GERIATRIC TYPE 1 DIABETESIt needs to be emphasized that despite the plethora of new tools, older patients with type 1 diabetes face specific challenges.", [["blood", "ANATOMY", 255, 260], ["diabetes", "DISEASE", 130, 138], ["glucose", "CHEMICAL", 261, 268], ["type 1 diabetes", "DISEASE", 391, 406], ["glucose", "CHEMICAL", 261, 268], ["blood", "ORGANISM_SUBSTANCE", 255, 260], ["glucose", "SIMPLE_CHEMICAL", 261, 268], ["patients", "ORGANISM", 377, 385], ["patients", "SPECIES", 377, 385], ["glycemic variability", "PROBLEM", 58, 78], ["brittle diabetes", "PROBLEM", 122, 138], ["CGM", "TEST", 176, 179], ["CV", "TEST", 212, 214], ["blood glucose monitoring", "TEST", 255, 279], ["type 1 diabetes face specific challenges", "PROBLEM", 391, 431], ["brittle", "OBSERVATION_MODIFIER", 122, 129], ["diabetes", "OBSERVATION", 130, 138]]], ["Cognitive losses of all degrees, challenges with dexterity, loss of vision and hearing, frequent depression often due to the loss of a spouse/partner or other family members, chemotherapy regimens, and many other co-morbidities can lead to frequent problems with day-to-day diabetes management.", [["Cognitive losses", "DISEASE", 0, 16], ["loss of vision", "DISEASE", 60, 74], ["depression", "DISEASE", 97, 107], ["diabetes", "DISEASE", 274, 282], ["Cognitive losses of all degrees", "PROBLEM", 0, 31], ["dexterity", "TREATMENT", 49, 58], ["loss of vision and hearing", "PROBLEM", 60, 86], ["frequent depression", "PROBLEM", 88, 107], ["chemotherapy regimens", "TREATMENT", 175, 196], ["many other co-morbidities", "PROBLEM", 202, 227], ["diabetes management", "TREATMENT", 274, 293], ["all degrees", "OBSERVATION_MODIFIER", 20, 31]]], ["Given the explosion in the number of seniors with type 1 diabetes we will be seeing in the next decade, greater effort is required in preparing providers and our health care systems in managing \"brittle diabetes\" in this population.INSULIN AND FOOD INSECURITYFrom a global viewpoint, lack of insulin access in low-income countries is a major cause of pediatric mortality (38) .", [["type 1 diabetes", "DISEASE", 50, 65], ["diabetes", "DISEASE", 203, 211], ["insulin", "GENE_OR_GENE_PRODUCT", 292, 299], ["type 1 diabetes", "PROBLEM", 50, 65], ["brittle diabetes\"", "PROBLEM", 195, 212], ["INSULIN", "TREATMENT", 232, 239], ["insulin access", "TREATMENT", 292, 306]]], ["Technically, this could be considered brittle diabetes since it meets the definition of constant disruption of life, in this case due to hyperglycemia and DKA.", [["diabetes", "DISEASE", 46, 54], ["hyperglycemia", "DISEASE", 137, 150], ["DKA", "DISEASE", 155, 158], ["brittle diabetes", "PROBLEM", 38, 54], ["constant disruption of life", "TREATMENT", 88, 115], ["hyperglycemia", "PROBLEM", 137, 150], ["DKA", "PROBLEM", 155, 158], ["diabetes", "OBSERVATION", 46, 54], ["hyperglycemia", "OBSERVATION", 137, 150], ["DKA", "OBSERVATION", 155, 158]]], ["While this is not what the Canadian discoverers of insulin envisioned almost 100 years ago, they would be even more appalled by the fact that insulin access and \"insecurity\" are now increasingly common and problematic in more affluent countries as well (38) .", [["insulin", "GENE_OR_GENE_PRODUCT", 51, 58], ["insulin", "GENE_OR_GENE_PRODUCT", 142, 149], ["insulin", "TREATMENT", 51, 58], ["insulin access", "TREATMENT", 142, 156]]], ["A 2018 report from the nonprofit T1International noted 26% of respondents from the United States acknowledged insulin rationing at least once in the previous year (40).", [["insulin", "GENE_OR_GENE_PRODUCT", 110, 117], ["insulin rationing", "TREATMENT", 110, 127]]], ["Deaths from insulin rationing are not uncommon even in this high-income country (41) , and it is unclear if the politicians will be able to rectify the problem.", [["insulin", "GENE_OR_GENE_PRODUCT", 12, 19], ["insulin rationing", "TREATMENT", 12, 29]]], ["While the original descriptions of brittle diabetes did not include insulin insecurity (1) (2) (3) (4) , it unfortunately must be considered a cause today and an increasing challenge for both those in low-income and high-income nations globally.INSULIN AND FOOD INSECURITYJ o u r n a l P r e -p r o o f 15 Food insecurity refers to the uncertain or limited access to adequate and safe foods and has had minimal attention compared to access to insulin.", [["diabetes", "DISEASE", 43, 51], ["insulin", "GENE_OR_GENE_PRODUCT", 68, 75], ["insulin", "GENE_OR_GENE_PRODUCT", 443, 450], ["insulin", "PROTEIN", 443, 450], ["brittle diabetes", "PROBLEM", 35, 51], ["insulin insecurity", "PROBLEM", 68, 86], ["an increasing challenge", "TREATMENT", 159, 182], ["INSULIN", "TREATMENT", 245, 252], ["insulin", "TREATMENT", 443, 450]]], ["Food insecurity is associated with higher A1C levels in both type 1 and type 2 diabetes (43, 44) .", [["type 2 diabetes", "DISEASE", 72, 87], ["A1C", "GENE_OR_GENE_PRODUCT", 42, 45], ["A1C", "PROTEIN", 42, 45], ["type 1", "SPECIES", 61, 67], ["Food insecurity", "PROBLEM", 0, 15], ["higher A1C levels", "PROBLEM", 35, 52], ["type 2 diabetes", "PROBLEM", 72, 87], ["insecurity", "OBSERVATION", 5, 15], ["diabetes", "OBSERVATION", 79, 87]]], ["For children whose parents are food insecure, there is a three-fold increase in yearly hospitalization compared to food secure families (30% vs. 10.5%, p=0.002) (44) .", [["food insecure", "DISEASE", 31, 44], ["children", "ORGANISM", 4, 12], ["children", "SPECIES", 4, 12]]], ["From this report, it isn't clear if this is for DKA or hypoglycemia, but given that high of a prevalence, most would agree that this meets the definition of brittle diabetes.", [["DKA", "DISEASE", 48, 51], ["hypoglycemia", "DISEASE", 55, 67], ["diabetes", "DISEASE", 165, 173], ["DKA", "PROBLEM", 48, 51], ["hypoglycemia", "PROBLEM", 55, 67], ["brittle diabetes", "PROBLEM", 157, 173], ["brittle diabetes", "OBSERVATION", 157, 173]]], ["Food and medication insecurity often co-exist (46), so a child or adult with type 1 diabetes in this situation is particularly challenged.INSULIN AND FOOD INSECURITYSince this is not a typical screening topic for clinicians, for many reasons (including time required) it is difficult to intervene for the most vulnerable patients.", [["type 1 diabetes", "DISEASE", 77, 92], ["patients", "ORGANISM", 321, 329], ["patients", "SPECIES", 321, 329], ["type 1 diabetes", "PROBLEM", 77, 92], ["INSULIN", "TREATMENT", 138, 145], ["diabetes", "OBSERVATION", 84, 92]]], ["Still, for many parents of children with diabetes, having the ability to discuss this sensitive topic is appreciated (47) .", [["diabetes", "DISEASE", 41, 49], ["children", "ORGANISM", 27, 35], ["children", "SPECIES", 27, 35], ["diabetes", "PROBLEM", 41, 49]]], ["This is an area that needs more effort and research as to how it contributes to brittle diabetes and how it can be prevented.CONCLUSIONSPhysicians have been classifying diabetes as \"brittle\" for decades to indicate a condition of instability of glycemic control requiring frequent hospitalizations and causing impaired quality 198 PubMed references about \"brittle diabetes\" suggesting this is not a common clinical challenge.", [["diabetes", "DISEASE", 88, 96], ["diabetes", "DISEASE", 169, 177], ["diabetes", "DISEASE", 364, 372], ["brittle diabetes", "PROBLEM", 80, 96], ["diabetes", "PROBLEM", 169, 177], ["glycemic control", "TREATMENT", 245, 261], ["brittle diabetes\"", "PROBLEM", 356, 373]]], ["However, considering all four groups described, the rising incidence of adolescent and young adult mental illnesses, the increasing prevalence of older adults with type 1 diabetes and insulin/food insecurity, brittle diabetes promises to only increase in the future.CONCLUSIONSIt is difficult to quantitate the degree of glucose instability between the four groups or between individuals.", [["adult mental illnesses", "DISEASE", 93, 115], ["type 1 diabetes", "DISEASE", 164, 179], ["food insecurity", "DISEASE", 192, 207], ["diabetes", "DISEASE", 217, 225], ["glucose instability", "DISEASE", 321, 340], ["glucose", "CHEMICAL", 321, 328], ["insulin", "GENE_OR_GENE_PRODUCT", 184, 191], ["glucose", "SIMPLE_CHEMICAL", 321, 328], ["young adult mental illnesses", "PROBLEM", 87, 115], ["type 1 diabetes", "PROBLEM", 164, 179], ["insulin/food insecurity", "PROBLEM", 184, 207], ["brittle diabetes promises", "PROBLEM", 209, 234], ["glucose instability", "PROBLEM", 321, 340], ["diabetes", "OBSERVATION", 171, 179], ["glucose instability", "OBSERVATION", 321, 340]]], ["One's degree of glucose variability, no matter the etiology, is to a large degree dependent on endogenous insulin secretion.", [["glucose", "CHEMICAL", 16, 23], ["glucose", "CHEMICAL", 16, 23], ["glucose", "SIMPLE_CHEMICAL", 16, 23], ["insulin", "GENE_OR_GENE_PRODUCT", 106, 113], ["glucose variability", "PROBLEM", 16, 35], ["a large degree dependent on endogenous insulin secretion", "PROBLEM", 67, 123], ["glucose variability", "OBSERVATION", 16, 35], ["no", "UNCERTAINTY", 37, 39], ["large degree", "OBSERVATION_MODIFIER", 69, 81], ["dependent", "OBSERVATION_MODIFIER", 82, 91], ["endogenous insulin secretion", "OBSERVATION", 95, 123]]], ["If someone with type 1 diabetes and no c-peptide secretion misses insulin injections frequently, glucose levels will surge to high levels and ketosis could potentially develop.", [["type 1 diabetes", "DISEASE", 16, 31], ["glucose", "CHEMICAL", 97, 104], ["ketosis", "DISEASE", 142, 149], ["glucose", "CHEMICAL", 97, 104], ["c-peptide", "GENE_OR_GENE_PRODUCT", 39, 48], ["insulin", "GENE_OR_GENE_PRODUCT", 66, 73], ["glucose", "SIMPLE_CHEMICAL", 97, 104], ["type 1 diabetes", "PROBLEM", 16, 31], ["c-peptide secretion", "PROBLEM", 39, 58], ["insulin injections", "TREATMENT", 66, 84], ["glucose levels", "TEST", 97, 111], ["ketosis", "PROBLEM", 142, 149]]], ["Alternatively, someone with type 2 diabetes and significant endogenous insulin production under these same circumstances would not have such dramatic consequences.", [["type 2 diabetes", "DISEASE", 28, 43], ["insulin", "GENE_OR_GENE_PRODUCT", 71, 78], ["type 2 diabetes", "PROBLEM", 28, 43], ["significant endogenous insulin production", "PROBLEM", 48, 89], ["diabetes", "OBSERVATION", 35, 43], ["significant", "OBSERVATION_MODIFIER", 48, 59], ["endogenous insulin", "OBSERVATION", 60, 78]]], ["Similarly, someone with severe insulin resistance requiring hundreds of units of insulin daily may not have the glycemic variability as seen in the more common type 1 diabetes, but under the right circumstance would be more prone to hospitalization for a hyperglycemic emergency.CONCLUSIONSPerhaps the term \"brittle diabetes\" will eventually be of historical interest only and be replaced by more accurate descriptions as \"unstable\" or \"dangerous\" diabetes or better yet by more accurate and specific etiologies.", [["diabetes", "DISEASE", 167, 175], ["diabetes", "DISEASE", 316, 324], ["diabetes", "DISEASE", 448, 456], ["insulin", "GENE_OR_GENE_PRODUCT", 31, 38], ["insulin", "GENE_OR_GENE_PRODUCT", 81, 88], ["severe insulin resistance", "PROBLEM", 24, 49], ["insulin", "TREATMENT", 81, 88], ["the glycemic variability", "PROBLEM", 108, 132], ["type 1 diabetes", "PROBLEM", 160, 175], ["a hyperglycemic emergency.CONCLUSIONSPerhaps", "PROBLEM", 253, 297], ["brittle diabetes", "PROBLEM", 308, 324], ["dangerous\" diabetes", "PROBLEM", 437, 456], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["insulin resistance", "OBSERVATION", 31, 49], ["diabetes", "OBSERVATION", 167, 175], ["right", "ANATOMY_MODIFIER", 191, 196]]], ["But no diagnosis, no matter what the etiology, should be associated with a disdainful connotation.", [["a disdainful connotation", "PROBLEM", 73, 97], ["no", "UNCERTAINTY", 4, 6]]], ["Patients with \"brittle diabetes\" are not failing, they are suffering, and they are at great risk.", [["diabetes", "DISEASE", 23, 31], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["brittle diabetes", "PROBLEM", 15, 31]]], ["It may be our medical care that is failing to help, to recognize, and to effectively address those unique scenarios of diabetes that are complex but potentially very treatable.", [["diabetes", "DISEASE", 119, 127], ["diabetes", "PROBLEM", 119, 127], ["diabetes", "OBSERVATION", 119, 127]]], ["We must utilize both old and new technologies as well as a wholistic approach that identifies the complex psychosocial environment of the individual with diabetes over a lifetime.", [["diabetes", "DISEASE", 154, 162], ["a wholistic approach", "TREATMENT", 57, 77], ["diabetes", "PROBLEM", 154, 162]]], ["An exhaustive search for the causes of this presentation of diabetes is imperative as it affects people with diabetes at any point along the lifespan and is often preventable, curable, or both.CONCLUSIONSWhile the nomenclature changes, we now have enough understanding about the various etiologies of unstable diabetes to appropriately identify, diagnose and treat these patients more successfully than previously.", [["diabetes", "DISEASE", 60, 68], ["diabetes", "DISEASE", 109, 117], ["diabetes", "DISEASE", 310, 318], ["people", "ORGANISM", 97, 103], ["patients", "ORGANISM", 371, 379], ["people", "SPECIES", 97, 103], ["patients", "SPECIES", 371, 379], ["diabetes", "PROBLEM", 60, 68], ["diabetes", "PROBLEM", 109, 117], ["unstable diabetes", "PROBLEM", 301, 318], ["diabetes", "OBSERVATION", 60, 68], ["unstable", "OBSERVATION_MODIFIER", 301, 309], ["diabetes", "OBSERVATION", 310, 318]]], ["Some of our treatments will be mostly medical, while others must be psychiatric and social and, in some cases, political and financial (insulin access and food insecurity) solutions must be sought.", [["psychiatric", "DISEASE", 68, 79], ["insulin", "GENE_OR_GENE_PRODUCT", 136, 143], ["political and financial (insulin access and food insecurity) solutions", "TREATMENT", 111, 181]]], ["The hope is that \"brittle diabetes\" should someday disappear.", [["diabetes", "DISEASE", 26, 34], ["brittle diabetes\"", "PROBLEM", 18, 35]]]], "abb0fe956deb7d423d73a82f8a7ec72343c02b65": [["IntroductionThis article reviews the current concepts for operatively managing and restoring carious lesions extending over one-third into dentine with adhesively-retaine ddirect composite resin.", [["carious lesions", "ANATOMY", 93, 108], ["dentine", "ANATOMY", 139, 146], ["carious lesions", "PATHOLOGICAL_FORMATION", 93, 108], ["dentine", "TISSUE", 139, 146], ["operatively managing", "TREATMENT", 58, 78], ["restoring carious lesions", "PROBLEM", 83, 108], ["retaine ddirect composite resin", "TREATMENT", 163, 194], ["carious", "OBSERVATION_MODIFIER", 93, 100], ["lesions", "OBSERVATION", 101, 108]]], ["The following topics will be discussed: operative management of caries extending into dentine, remineralisation with bioactive cements, bonding to caries-affected dentine including smear-layer modification using HOCl, creation of an acid-base resistance zone, steps to optimise the performance of all-in-one adhesives and incremental placement of direct composite resin to improve bond strengths to cavity floor dentine.", [["dentine", "ANATOMY", 86, 93], ["dentine", "ANATOMY", 163, 170], ["cavity floor dentine", "ANATOMY", 399, 419], ["caries", "DISEASE", 64, 70], ["caries", "DISEASE", 147, 153], ["HOCl", "CHEMICAL", 212, 216], ["HOCl", "CHEMICAL", 212, 216], ["dentine", "TISSUE", 86, 93], ["dentine", "TISSUE", 163, 170], ["HOCl", "SIMPLE_CHEMICAL", 212, 216], ["cavity floor dentine", "MULTI-TISSUE_STRUCTURE", 399, 419], ["operative management", "TREATMENT", 40, 60], ["caries", "PROBLEM", 64, 70], ["bioactive cements", "TREATMENT", 117, 134], ["affected dentine", "PROBLEM", 154, 170], ["smear", "TEST", 181, 186], ["HOCl", "TREATMENT", 212, 216], ["an acid-base resistance zone", "TREATMENT", 230, 258], ["one adhesives", "TREATMENT", 304, 317], ["incremental placement of direct composite resin", "TREATMENT", 322, 369], ["bioactive cements", "OBSERVATION", 117, 134]]], ["An understanding of how the phenomenon of colour-shifting at the composite resin-enamel/dentine restoration borders can help in creating near \"invisible\" restoration margins through a \"chameleon\" effect will also be addressed.", [["enamel", "ANATOMY", 81, 87], ["dentine", "ANATOMY", 88, 95], ["enamel", "TISSUE", 81, 87], ["dentine", "TISSUE", 88, 95], ["the composite resin-enamel/dentine restoration borders", "TREATMENT", 61, 115], ["restoration margins", "OBSERVATION", 154, 173]]], ["With the increased risks of transmission of Covid-19 when aerosol generating procedures are carried out in Dentistry, following a minimally invasive approach to managing dental caries should be given serious consideration with a heavy emphasis on prevention of caries by providing patients with appropriate dietary advice and oral hygiene instruction [1] .", [["oral", "ANATOMY", 326, 330], ["caries", "DISEASE", 177, 183], ["caries", "DISEASE", 261, 267], ["patients", "ORGANISM", 281, 289], ["oral", "ORGANISM_SUBDIVISION", 326, 330], ["patients", "SPECIES", 281, 289], ["Covid", "TEST", 44, 49], ["aerosol generating procedures", "TREATMENT", 58, 87], ["a minimally invasive approach", "TREATMENT", 128, 157], ["dental caries", "PROBLEM", 170, 183], ["caries", "PROBLEM", 261, 267]]], ["Should operative treatment be required, then reducing the amount of tooth structure that is removed, carrying out appropriate caries removaland use of a rubber dam will help lessen the quantity of aerosols generated, which might contain microorganisms that could be inhaled by dental staff involved with treatment [1] .", [["tooth", "ANATOMY", 68, 73], ["caries", "DISEASE", 126, 132], ["tooth", "ORGAN", 68, 73], ["operative treatment", "TREATMENT", 7, 26], ["tooth structure", "PROBLEM", 68, 83], ["a rubber dam", "TREATMENT", 151, 163]]], ["Advances have taken place in understanding how dentine can be remineralised, bonding to caries-affected dentine can be achieved and how the strength and acid resistance of the adhesive interface created by dental adhesives can be improved.", [["dentine", "ANATOMY", 47, 54], ["dentine", "ANATOMY", 104, 111], ["caries", "DISEASE", 88, 94], ["dentine", "TISSUE", 47, 54], ["dentine", "TISSUE", 104, 111], ["affected dentine", "PROBLEM", 95, 111], ["the adhesive interface", "TREATMENT", 172, 194], ["dental adhesives", "TREATMENT", 206, 222]]], ["These factors can aid the clinical success of adhesive direct composite restorations, which when combined with the adoption of a minimally invasive approach now allow us to minimise the intervention required and these will be discussed in more detail.Operative caries managementCarious lesions extending beyond one third from the enameldentine junction (EDJ) into dentine will require operative management [2] .", [["Carious lesions", "ANATOMY", 278, 293], ["enameldentine junction", "ANATOMY", 330, 352], ["EDJ", "ANATOMY", 354, 357], ["dentine", "ANATOMY", 364, 371], ["caries", "DISEASE", 261, 267], ["Carious lesions", "CANCER", 278, 293], ["enameldentine junction", "MULTI-TISSUE_STRUCTURE", 330, 352], ["dentine", "TISSUE", 364, 371], ["adhesive direct composite restorations", "TREATMENT", 46, 84], ["a minimally invasive approach", "TREATMENT", 127, 156], ["the intervention", "TREATMENT", 182, 198], ["Operative caries management", "TREATMENT", 251, 278], ["Carious lesions", "PROBLEM", 278, 293], ["operative management", "TREATMENT", 385, 405], ["caries", "OBSERVATION", 261, 267], ["lesions", "OBSERVATION", 286, 293], ["enameldentine junction", "ANATOMY", 330, 352]]], ["Operative management should aim to preserve as much tooth structure as possible.", [["tooth", "ANATOMY", 52, 57], ["tooth", "ORGAN", 52, 57], ["Operative management", "TREATMENT", 0, 20]]], ["This can be achieved by carefully accessing the dentine caries with as little removal of tooth structure as possible and understanding the pathology of the carious process together with the published research on the clinical management.", [["dentine", "ANATOMY", 48, 55], ["tooth", "ANATOMY", 89, 94], ["caries", "DISEASE", 56, 62], ["dentine", "TISSUE", 48, 55], ["tooth", "ORGAN", 89, 94], ["the dentine caries", "TREATMENT", 44, 62], ["little removal of tooth structure", "TREATMENT", 71, 104], ["the clinical management", "TREATMENT", 212, 235], ["carious", "OBSERVATION", 156, 163]]], ["Fusayama's classification of carious dentine into the two zones of \"caries-infected\" dentine and \"caries-affected\" dentine has https://doi.org/10.1016/j.jdsr.2020.08.003 1882-7616/\u00a9 2020 The Author.", [["dentine", "ANATOMY", 37, 44], ["dentine", "ANATOMY", 85, 92], ["caries", "DISEASE", 68, 74], ["caries", "DISEASE", 98, 104], ["carious dentine", "TISSUE", 29, 44], ["dentine", "TISSUE", 85, 92], ["dentine", "TISSUE", 115, 122], ["carious dentine", "PROBLEM", 29, 44], ["infected\" dentine and \"caries", "PROBLEM", 75, 104], ["carious dentine", "OBSERVATION", 29, 44], ["caries", "OBSERVATION", 68, 74], ["infected", "OBSERVATION", 75, 83]]], ["This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). provided important guidance on how the histology of the dentine carious lesion can be related to the clinical situation [3] .", [["carious lesion", "ANATOMY", 178, 192], ["CC", "CHEMICAL", 41, 43], ["dentine", "TISSUE", 170, 177], ["the dentine carious lesion", "PROBLEM", 166, 192], ["lesion", "OBSERVATION", 186, 192]]], ["Fusayama advocated removing caries-infected dentine, which is substantially demineralised and is physiologically un-remineralisable [3] .", [["dentine", "ANATOMY", 44, 51], ["Fusayama", "CHEMICAL", 0, 8], ["caries-infected dentine", "DISEASE", 28, 51], ["Fusayama", "SIMPLE_CHEMICAL", 0, 8], ["dentine", "TISSUE", 44, 51], ["infected dentine", "PROBLEM", 35, 51], ["infected dentine", "OBSERVATION", 35, 51]]], ["This dentine consists of irreversibly denatured collagen fibrils and to leave behind the caries-affected dentine, which in contrast is minimally infected with bacteria, partially demineralised and physiologically remineralisable [3] .Operative caries managementIt is not easy clinically to differentiate between caries-infected dentine and caries-affected dentine and it may not matter so much if the floor of the cavity is still caries-infected dentine rather than caries-affected dentine if a seal can be created after restoration.", [["dentine", "ANATOMY", 5, 12], ["dentine", "ANATOMY", 105, 112], ["dentine", "ANATOMY", 328, 335], ["dentine", "ANATOMY", 356, 363], ["dentine", "ANATOMY", 446, 453], ["dentine", "ANATOMY", 482, 489], ["caries", "DISEASE", 89, 95], ["caries", "DISEASE", 244, 250], ["caries-infected dentine", "DISEASE", 312, 335], ["caries", "DISEASE", 340, 346], ["caries", "DISEASE", 430, 436], ["caries", "DISEASE", 466, 472], ["dentine", "TISSUE", 5, 12], ["collagen fibrils", "GENE_OR_GENE_PRODUCT", 48, 64], ["dentine", "TISSUE", 105, 112], ["dentine", "TISSUE", 328, 335], ["dentine", "TISSUE", 356, 363], ["cavity", "ORGAN", 414, 420], ["dentine", "TISSUE", 446, 453], ["dentine", "TISSUE", 482, 489], ["collagen fibrils", "PROTEIN", 48, 64], ["irreversibly denatured collagen fibrils", "PROBLEM", 25, 64], ["affected dentine", "PROBLEM", 96, 112], ["minimally infected", "PROBLEM", 135, 153], ["bacteria", "PROBLEM", 159, 167], ["Operative caries management", "TREATMENT", 234, 261], ["caries", "PROBLEM", 312, 318], ["infected dentine and caries", "PROBLEM", 319, 346], ["affected dentine", "PROBLEM", 347, 363], ["still caries", "PROBLEM", 424, 436], ["infected dentine", "PROBLEM", 437, 453], ["affected dentine", "PROBLEM", 473, 489], ["a seal", "TREATMENT", 493, 499], ["irreversibly", "OBSERVATION_MODIFIER", 25, 37], ["denatured", "OBSERVATION", 38, 47], ["collagen fibrils", "OBSERVATION", 48, 64], ["caries", "OBSERVATION", 89, 95], ["minimally", "OBSERVATION_MODIFIER", 135, 144], ["infected", "OBSERVATION", 145, 153], ["bacteria", "OBSERVATION", 159, 167], ["caries", "OBSERVATION", 244, 250], ["infected", "OBSERVATION", 319, 327], ["cavity", "ANATOMY", 414, 420], ["infected", "OBSERVATION", 437, 445]]], ["There is no solid evidence that it is necessary to remove all the caries-infected dentine and if present, even all the soft, wet carious dentine.", [["dentine", "ANATOMY", 82, 89], ["dentine", "ANATOMY", 137, 144], ["caries", "DISEASE", 66, 72], ["dentine", "TISSUE", 82, 89], ["carious dentine", "TISSUE", 129, 144], ["infected dentine", "PROBLEM", 73, 89], ["wet carious dentine", "PROBLEM", 125, 144], ["no", "UNCERTAINTY", 9, 11], ["solid", "OBSERVATION_MODIFIER", 12, 17], ["caries", "OBSERVATION", 66, 72], ["infected", "OBSERVATION", 73, 81], ["soft", "ANATOMY", 119, 123], ["carious dentine", "OBSERVATION", 129, 144]]], ["If there is enamel present at the cavity margins then the deeper caries can be \"sealed\" after removal of superficial soft cariesif an adhesive restorative material is used [4] .", [["enamel", "ANATOMY", 12, 18], ["caries", "DISEASE", 65, 71], ["enamel", "TISSUE", 12, 18], ["cavity margins", "MULTI-TISSUE_STRUCTURE", 34, 48], ["enamel present at the cavity margins", "PROBLEM", 12, 48], ["removal", "TREATMENT", 94, 101], ["superficial soft cariesif an adhesive restorative material", "TREATMENT", 105, 163], ["cavity", "OBSERVATION_MODIFIER", 34, 40], ["margins", "OBSERVATION_MODIFIER", 41, 48], ["deeper", "OBSERVATION_MODIFIER", 58, 64], ["caries", "OBSERVATION", 65, 71], ["superficial", "OBSERVATION_MODIFIER", 105, 116], ["soft cariesif", "OBSERVATION_MODIFIER", 117, 130], ["adhesive restorative", "OBSERVATION", 134, 154]]], ["The classic study by Mertz-Fairhurst's group adhesively bonded composite and amalgam over soft carious dentine that was present even adjacent to the EDJ and although only 50% of the patients presented at recall 10 years later, this approach led to a similar outcome as conventional caries removal [5] .", [["dentine", "ANATOMY", 103, 110], ["caries", "DISEASE", 282, 288], ["carious dentine", "TISSUE", 95, 110], ["EDJ", "CANCER", 149, 152], ["patients", "ORGANISM", 182, 190], ["patients", "SPECIES", 182, 190], ["The classic study", "TEST", 0, 17], ["Mertz", "TEST", 21, 26], ["Fairhurst's group adhesively bonded composite", "TREATMENT", 27, 72], ["soft carious dentine", "PROBLEM", 90, 110], ["conventional caries removal", "TREATMENT", 269, 296], ["soft carious", "OBSERVATION_MODIFIER", 90, 102], ["dentine", "OBSERVATION", 103, 110]]], ["It is accepted that removal of \"softened\" carious dentine using hand excavators, initially adjacent to the enamel-dentine junction, keeping away from the deeper caries, will lessen the likelihood of a pulp exposure [6] .", [["dentine", "ANATOMY", 50, 57], ["hand", "ANATOMY", 64, 68], ["enamel-dentine junction", "ANATOMY", 107, 130], ["pulp", "ANATOMY", 201, 205], ["caries", "DISEASE", 161, 167], ["carious dentine", "TISSUE", 42, 57], ["enamel", "TISSUE", 107, 113], ["pulp", "TISSUE", 201, 205], ["removal", "TREATMENT", 20, 27], ["\"softened\" carious dentine", "TREATMENT", 31, 57], ["hand excavators", "TREATMENT", 64, 79], ["a pulp exposure", "PROBLEM", 199, 214], ["dentine junction", "ANATOMY", 114, 130]]], ["However, it is important to understand that it is not necessary for the cavity to be completely caries-free as this will result in sound dentine being present on the cavity floor, which will lead to the exposure of dentinal tubules that will cause pain for the patient.Operative caries managementWhat has been sometimes forgotten is that Fusayama as well as advocating that complete caries removal is not necessary, also introduced the concept of \"painless dentistry\" [7] .", [["dentine", "ANATOMY", 137, 144], ["cavity floor", "ANATOMY", 166, 178], ["dentinal tubules", "ANATOMY", 215, 231], ["caries", "DISEASE", 96, 102], ["pain", "DISEASE", 248, 252], ["caries", "DISEASE", 279, 285], ["caries", "DISEASE", 383, 389], ["dentine", "TISSUE", 137, 144], ["cavity floor", "ORGANISM_SUBDIVISION", 166, 178], ["dentinal tubules", "TISSUE", 215, 231], ["patient", "ORGANISM", 261, 268], ["patient", "SPECIES", 261, 268], ["sound dentine", "PROBLEM", 131, 144], ["dentinal tubules", "PROBLEM", 215, 231], ["pain", "PROBLEM", 248, 252], ["Operative caries management", "TREATMENT", 269, 296], ["complete caries removal", "TREATMENT", 374, 397], ["caries", "OBSERVATION", 279, 285]]], ["He advocated leaving the cavity floor consisting of caries-affected dentine, where the tubules are filled with whitlockite crystals formed by reprecipitation of calcium and phosphate ions lost during the carious process that can re-mineralise and forms a so-called \"barrier\" to the underlying pulp.", [["cavity floor", "ANATOMY", 25, 37], ["dentine", "ANATOMY", 68, 75], ["tubules", "ANATOMY", 87, 94], ["pulp", "ANATOMY", 293, 297], ["caries", "DISEASE", 52, 58], ["calcium", "CHEMICAL", 161, 168], ["phosphate", "CHEMICAL", 173, 182], ["calcium", "CHEMICAL", 161, 168], ["phosphate", "CHEMICAL", 173, 182], ["dentine", "TISSUE", 68, 75], ["tubules", "TISSUE", 87, 94], ["calcium", "SIMPLE_CHEMICAL", 161, 168], ["phosphate ions", "SIMPLE_CHEMICAL", 173, 187], ["barrier", "TISSUE", 266, 273], ["pulp", "TISSUE", 293, 297], ["caries-affected dentine", "PROBLEM", 52, 75], ["whitlockite crystals", "TREATMENT", 111, 131], ["calcium and phosphate ions", "TREATMENT", 161, 187], ["the carious process", "PROBLEM", 200, 219], ["caries", "OBSERVATION", 52, 58], ["pulp", "ANATOMY", 293, 297]]], ["He wrote in 1991, \"although dentists have heretofore believed that dental caries treatment must surely be accompanied by pain, our new concept of dental caries pathology reveals that the pain is caused by removing tissue that should not be removed\", thereby introducing the concept of \"painless\" dentistry [7] .", [["tissue", "ANATOMY", 214, 220], ["caries", "DISEASE", 74, 80], ["pain", "DISEASE", 121, 125], ["caries", "DISEASE", 153, 159], ["pain", "DISEASE", 187, 191], ["tissue", "TISSUE", 214, 220], ["dental caries treatment", "TREATMENT", 67, 90], ["pain", "PROBLEM", 121, 125], ["dental caries pathology", "PROBLEM", 146, 169], ["the pain", "PROBLEM", 183, 191]]], ["Removing \"soft\" caries carefully with an excavator that will be caries-infected dentine can be often accomplished without causing pain to the patient and this is all the operative intervention that is required on the carious dentine.", [["dentine", "ANATOMY", 80, 87], ["dentine", "ANATOMY", 225, 232], ["caries", "DISEASE", 16, 22], ["caries-infected dentine", "DISEASE", 64, 87], ["pain", "DISEASE", 130, 134], ["dentine", "TISSUE", 80, 87], ["patient", "ORGANISM", 142, 149], ["carious dentine", "TISSUE", 217, 232], ["patient", "SPECIES", 142, 149], ["soft\" caries", "TREATMENT", 10, 22], ["an excavator", "TREATMENT", 38, 50], ["infected dentine", "PROBLEM", 71, 87], ["pain", "PROBLEM", 130, 134], ["the operative intervention", "TREATMENT", 166, 192]]], ["This will also minimise the risk of post-operative sensitivity.", [["post-operative sensitivity", "PROBLEM", 36, 62], ["post-operative sensitivity", "OBSERVATION", 36, 62]]], ["It is not recommended that caries removal should be taken any further from a biological point of view [6] .", [["caries", "DISEASE", 27, 33], ["caries removal", "TREATMENT", 27, 41]]], ["We should be thinking biologically and aiming to preserve pulp vitality at all costs ( Fig. 1) .Operative caries managementWith the increased risks of virus diffusion when carrying out aerosol generating procedures on patients who may have been infected with Covid-19 [1] , access cavities for caries ought to be kept as small as possible if using an air turbine, followed by careful excavation of only superficial, soft, wet, \"infected\" carious dentine.It could be argued that a clinician managing caries for the first time on a tooth carries a great responsibility to preserve as much healthy tooth tissue as possible.", [["pulp", "ANATOMY", 58, 62], ["dentine", "ANATOMY", 446, 453], ["tooth", "ANATOMY", 530, 535], ["tooth tissue", "ANATOMY", 595, 607], ["caries", "DISEASE", 106, 112], ["caries", "DISEASE", 294, 300], ["caries", "DISEASE", 499, 505], ["pulp", "TISSUE", 58, 62], ["patients", "ORGANISM", 218, 226], ["carious dentine", "TISSUE", 438, 453], ["tooth", "ORGAN", 530, 535], ["tooth tissue", "TISSUE", 595, 607], ["patients", "SPECIES", 218, 226], ["Operative caries", "TREATMENT", 96, 112], ["virus diffusion", "PROBLEM", 151, 166], ["aerosol generating procedures", "TREATMENT", 185, 214], ["Covid", "TEST", 259, 264], ["access cavities", "TREATMENT", 274, 289], ["caries", "PROBLEM", 294, 300], ["an air turbine", "TREATMENT", 348, 362], ["soft, wet, \"infected\" carious dentine", "PROBLEM", 416, 453], ["increased", "OBSERVATION_MODIFIER", 132, 141], ["air turbine", "OBSERVATION", 351, 362], ["superficial", "ANATOMY", 403, 414], ["soft", "ANATOMY", 416, 420], ["carious dentine", "OBSERVATION", 438, 453]]], ["Opting if possible, for a restorative material such as an adhesive direct composite resin restoration in the first instance after accessing and managing the caries.", [["caries", "DISEASE", 157, 163], ["a restorative material", "TREATMENT", 24, 46], ["an adhesive direct composite resin restoration", "TREATMENT", 55, 101]]], ["This often only requires minor subsequent cavity modifications and there have been several papers published showing its long-term clinical success over a period of 25 years or more [8, 9] .", [["minor subsequent cavity modifications", "TREATMENT", 25, 62], ["cavity", "OBSERVATION", 42, 48]]], ["On the other-hand, if instead an indirect restoration is chosen, tooth tissue will need to be removed to create a cavity with diverging cavity walls, which is likely to give rise to additional loss of peripheral enamel and most likely sound dentine.", [["tooth tissue", "ANATOMY", 65, 77], ["cavity walls", "ANATOMY", 136, 148], ["peripheral enamel", "ANATOMY", 201, 218], ["dentine", "ANATOMY", 241, 248], ["loss of peripheral enamel", "DISEASE", 193, 218], ["tooth tissue", "TISSUE", 65, 77], ["cavity walls", "MULTI-TISSUE_STRUCTURE", 136, 148], ["peripheral enamel", "MULTI-TISSUE_STRUCTURE", 201, 218], ["dentine", "TISSUE", 241, 248], ["an indirect restoration", "TREATMENT", 30, 53], ["tooth tissue", "PROBLEM", 65, 77], ["diverging cavity walls", "PROBLEM", 126, 148], ["additional loss of peripheral enamel", "PROBLEM", 182, 218], ["sound dentine", "PROBLEM", 235, 248], ["cavity", "OBSERVATION", 114, 120], ["cavity", "OBSERVATION", 136, 142], ["loss", "OBSERVATION", 193, 197], ["peripheral enamel", "OBSERVATION_MODIFIER", 201, 218], ["most likely", "UNCERTAINTY", 223, 234], ["sound dentine", "OBSERVATION", 235, 248]]], ["Cutting of sound dentine exposes denti-nal tubules causing the patient pain and must be sealed to prevent post-operative sensitivity.", [["dentine", "ANATOMY", 17, 24], ["denti-nal tubules", "ANATOMY", 33, 50], ["pain", "DISEASE", 71, 75], ["dentine", "TISSUE", 17, 24], ["denti-nal tubules", "TISSUE", 33, 50], ["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70], ["denti-nal tubules", "PROBLEM", 33, 50], ["the patient pain", "PROBLEM", 59, 75], ["post-operative sensitivity", "PROBLEM", 106, 132], ["sound", "OBSERVATION_MODIFIER", 11, 16], ["dentine", "OBSERVATION", 17, 24], ["denti-nal tubules", "OBSERVATION", 33, 50]]], ["This could create an additional clinical problem that might otherwise be avoided.", [["an additional clinical problem", "PROBLEM", 18, 48]]], ["This approach therefore does not make sense from a biological point of view where only \"diseased\" tooth tissue is removed and as much healthy tooth tissue as possible is retained thus ensuring the tooth has the best possible chance of long-term survival.Remineralisation of cavity-floor carious dentineCaries that has extended into dentine most likely leads to the pulp becoming \"stressed\".", [["tooth tissue", "ANATOMY", 98, 110], ["tooth tissue", "ANATOMY", 142, 154], ["tooth", "ANATOMY", 197, 202], ["dentine", "ANATOMY", 332, 339], ["pulp", "ANATOMY", 365, 369], ["tooth tissue", "TISSUE", 98, 110], ["tooth tissue", "TISSUE", 142, 154], ["tooth", "ORGAN", 197, 202], ["cavity", "PATHOLOGICAL_FORMATION", 274, 280], ["dentine", "TISSUE", 332, 339], ["pulp", "TISSUE", 365, 369], ["\"diseased\" tooth tissue", "PROBLEM", 87, 110], ["long-term survival", "TREATMENT", 235, 253], ["Remineralisation of cavity", "PROBLEM", 254, 280], ["floor carious dentineCaries", "PROBLEM", 281, 308], ["diseased", "OBSERVATION", 88, 96], ["tooth tissue", "OBSERVATION", 98, 110], ["cavity", "OBSERVATION", 274, 280], ["pulp", "ANATOMY", 365, 369]]], ["In 1982, Abou-Rass introduced the \"stressed\" pulp as a clinical concept in which the pulp should be considered to be \"stressed\" if it has been subjected to repeated challenges to pathological changes such as caries [10] .", [["pulp", "ANATOMY", 45, 49], ["pulp", "ANATOMY", 85, 89], ["Abou-Rass", "CHEMICAL", 9, 18], ["caries", "DISEASE", 208, 214], ["pulp", "TISSUE", 45, 49], ["pulp", "TISSUE", 85, 89], ["pulp", "ANATOMY", 85, 89]]], ["Nowadays, if we believe this to be the case, it would make sense to consider placing a \"bioactive\" restorative material that may promote repair and remineralisation of the demineralised carious dentine left on the cavity floor, such as a glass-ionomer based or calcium-silicate based material [11] .", [["dentine", "ANATOMY", 194, 201], ["cavity floor", "ANATOMY", 214, 226], ["calcium-silicate", "CHEMICAL", 261, 277], ["calcium-silicate", "CHEMICAL", 261, 277], ["cavity floor", "ORGANISM_SUBDIVISION", 214, 226], ["calcium-silicate", "SIMPLE_CHEMICAL", 261, 277], ["a \"bioactive\" restorative material", "TREATMENT", 85, 119], ["repair", "TREATMENT", 137, 143], ["remineralisation", "TREATMENT", 148, 164], ["the demineralised carious dentine", "PROBLEM", 168, 201], ["a glass-ionomer based", "TREATMENT", 236, 257], ["calcium-silicate based material", "TREATMENT", 261, 292], ["repair", "OBSERVATION", 137, 143], ["left", "ANATOMY_MODIFIER", 202, 206], ["cavity floor", "ANATOMY", 214, 226]]], ["The setting reaction of glass-ionomer based materials and calcium-silicate materials are unlikely to stress the pulp further and the calcium-silicate cement, Biodentine TM (Septodont, Saint-Maur-des-Foss\u00e9, France) in particular may have a therapeutic effect of 'pulp-healing\" [12] (Fig. 2 ).", [["pulp", "ANATOMY", 112, 116], ["pulp", "ANATOMY", 262, 266], ["glass-ionomer", "CHEMICAL", 24, 37], ["calcium-silicate", "CHEMICAL", 58, 74], ["calcium-silicate", "CHEMICAL", 133, 149], ["Biodentine", "CHEMICAL", 158, 168], ["calcium-silicate", "CHEMICAL", 58, 74], ["calcium-silicate", "CHEMICAL", 133, 149], ["glass-ionomer", "SIMPLE_CHEMICAL", 24, 37], ["calcium-silicate materials", "SIMPLE_CHEMICAL", 58, 84], ["pulp", "TISSUE", 112, 116], ["calcium", "SIMPLE_CHEMICAL", 133, 140], ["Biodentine TM", "SIMPLE_CHEMICAL", 158, 171], ["pulp", "TISSUE", 262, 266], ["glass-ionomer based materials", "TREATMENT", 24, 53], ["calcium-silicate materials", "TREATMENT", 58, 84], ["the calcium-silicate cement", "TREATMENT", 129, 156], ["Biodentine TM", "TREATMENT", 158, 171], ["pulp", "ANATOMY", 112, 116], ["silicate cement", "OBSERVATION", 141, 156]]], ["Biodentine TM (Septodont, Saint-Maur-des-Foss\u00e9, France) or glass-ionomer provisional restorations should be cut back and layered with direct composite resin to provide a durable occluding surface [13] .", [["surface", "ANATOMY", 188, 195], ["Biodentine", "CHEMICAL", 0, 10], ["Saint-Maur-des-Foss\u00e9", "SPECIES", 26, 46], ["Biodentine TM", "TREATMENT", 0, 13], ["Maur-des", "TREATMENT", 32, 40], ["glass-ionomer provisional restorations", "TREATMENT", 59, 97], ["direct composite resin", "TREATMENT", 134, 156], ["a durable occluding surface", "TREATMENT", 168, 195]]], ["This could be as little as 1.5-2.0 mm, which could be pain-free for the patient if sound dentine is not cut.", [["dentine", "ANATOMY", 89, 96], ["pain", "DISEASE", 54, 58], ["patient", "ORGANISM", 72, 79], ["dentine", "TISSUE", 89, 96], ["patient", "SPECIES", 72, 79], ["pain", "PROBLEM", 54, 58], ["sound dentine", "PROBLEM", 83, 96], ["little", "OBSERVATION_MODIFIER", 17, 23], ["1.5-2.0 mm", "OBSERVATION_MODIFIER", 27, 37]]], ["The cut-back restorative material will act as a \"dentine\" replacement and the overlying direct composite resin material as the enamel replacement (Fig. 3) .Remineralisation of cavity-floor carious dentineClinically, a decision has to be made therefore after managing a tooth with deep caries into dentine.", [["dentine", "ANATOMY", 49, 56], ["enamel", "ANATOMY", 127, 133], ["tooth", "ANATOMY", 269, 274], ["dentine", "ANATOMY", 297, 304], ["caries", "DISEASE", 285, 291], ["dentine", "TISSUE", 49, 56], ["enamel", "TISSUE", 127, 133], ["tooth", "ORGAN", 269, 274], ["dentine", "TISSUE", 297, 304], ["The cut-back restorative material", "TREATMENT", 0, 33], ["a \"dentine\" replacement", "TREATMENT", 46, 69], ["the overlying direct composite resin material", "TREATMENT", 74, 119], ["the enamel replacement", "TREATMENT", 123, 145], ["a tooth with deep caries into dentine", "PROBLEM", 267, 304], ["cavity", "OBSERVATION", 176, 182]]], ["The options are to proceed straightaway with a directly bonded resin composite restoration, which will create a \"seal\" and a durable, aesthetic restoration, or to adopt a two visit technique in which an attempt is made to manage the remaining carious dentine and potentially \"stressed\" pulp biologically.Adhesion to caries-affected dentinePartial caries removal and cavity preparation using excavators and burs will leave a smear layer and caries-affected dentine as the substrates at the base of the cavity, which should be managed appropriately prior to applying a dentine adhesive.", [["dentine", "ANATOMY", 251, 258], ["pulp", "ANATOMY", 286, 290], ["dentinePartial", "ANATOMY", 332, 346], ["smear layer", "ANATOMY", 424, 435], ["dentine", "ANATOMY", 456, 463], ["cavity", "ANATOMY", 501, 507], ["dentine", "ANATOMY", 567, 574], ["caries", "DISEASE", 316, 322], ["caries", "DISEASE", 347, 353], ["caries", "DISEASE", 440, 446], ["carious dentine", "TISSUE", 243, 258], ["pulp", "TISSUE", 286, 290], ["dentine", "TISSUE", 456, 463], ["cavity", "ORGAN", 501, 507], ["dentine", "TISSUE", 567, 574], ["a directly bonded resin composite restoration", "TREATMENT", 45, 90], ["a \"seal\"", "TREATMENT", 110, 118], ["the remaining carious dentine", "PROBLEM", 229, 258], ["Adhesion to caries", "PROBLEM", 304, 322], ["affected dentinePartial caries removal", "TREATMENT", 323, 361], ["cavity preparation", "TREATMENT", 366, 384], ["excavators and burs", "TREATMENT", 391, 410], ["a smear layer and caries-affected dentine", "PROBLEM", 422, 463], ["a dentine adhesive", "TREATMENT", 565, 583], ["carious dentine", "OBSERVATION", 243, 258], ["caries", "OBSERVATION", 316, 322], ["affected", "OBSERVATION_MODIFIER", 323, 331], ["dentinePartial", "OBSERVATION_MODIFIER", 332, 346], ["caries", "OBSERVATION", 347, 353], ["cavity", "OBSERVATION_MODIFIER", 366, 372], ["base", "ANATOMY_MODIFIER", 489, 493], ["cavity", "ANATOMY", 501, 507]]], ["Nakajima's group have reported that caries-affected dentine compared to sound dentine is softer even though the dentinal tubules are occluded with mineral deposits [14] .", [["dentine", "ANATOMY", 52, 59], ["dentine", "ANATOMY", 78, 85], ["dentinal tubules", "ANATOMY", 112, 128], ["caries", "DISEASE", 36, 42], ["dentine", "TISSUE", 52, 59], ["dentine", "TISSUE", 78, 85], ["dentinal tubules", "MULTI-TISSUE_STRUCTURE", 112, 128], ["Nakajima's group", "TREATMENT", 0, 16], ["caries-affected dentine", "PROBLEM", 36, 59], ["mineral deposits", "PROBLEM", 147, 163], ["softer", "OBSERVATION", 89, 95], ["dentinal tubules", "ANATOMY", 112, 128], ["occluded", "OBSERVATION", 133, 141]]], ["Moreover, Nakajima described the smear layer created on caries-affected dentine as being thicker and more enriched with organic components than the smear layer created on sound dentine because the caries-affected dentine is partially demineralised compared to normal dentine [14] .", [["smear layer", "ANATOMY", 33, 44], ["dentine", "ANATOMY", 72, 79], ["smear layer", "ANATOMY", 148, 159], ["dentine", "ANATOMY", 177, 184], ["dentine", "ANATOMY", 213, 220], ["caries", "DISEASE", 56, 62], ["caries", "DISEASE", 197, 203], ["dentine", "TISSUE", 72, 79], ["dentine", "TISSUE", 177, 184], ["dentine", "TISSUE", 213, 220], ["the smear layer", "PROBLEM", 29, 44], ["affected dentine", "PROBLEM", 63, 79], ["organic components", "PROBLEM", 120, 138], ["the smear layer", "PROBLEM", 144, 159], ["sound dentine", "PROBLEM", 171, 184], ["affected dentine", "PROBLEM", 204, 220], ["partially demineralised", "PROBLEM", 224, 247], ["layer", "OBSERVATION_MODIFIER", 39, 44], ["more enriched", "OBSERVATION_MODIFIER", 101, 114]]], ["The remaining caries-affected dentine on the cavity floor is a challenging substrate to bond to.", [["dentine", "ANATOMY", 30, 37], ["cavity floor", "ANATOMY", 45, 57], ["caries", "DISEASE", 14, 20], ["dentine", "TISSUE", 30, 37], ["cavity floor", "ORGANISM_SUBDIVISION", 45, 57], ["affected dentine", "PROBLEM", 21, 37], ["remaining", "OBSERVATION_MODIFIER", 4, 13], ["caries", "OBSERVATION", 14, 20]]], ["In the era of evidence-based dentistry it is poignant to appreciate that the majority of research on dentine adhesives has been carried out on extracted molars or bovine teeth with sound dentine.", [["molars", "ANATOMY", 153, 159], ["teeth", "ANATOMY", 170, 175], ["dentine", "ANATOMY", 187, 194], ["dentine", "TISSUE", 101, 108], ["molars", "ORGAN", 153, 159], ["bovine", "ORGANISM", 163, 169], ["teeth", "ORGAN", 170, 175], ["dentine", "TISSUE", 187, 194], ["bovine", "SPECIES", 163, 169], ["dentine adhesives", "TREATMENT", 101, 118], ["sound dentine", "PROBLEM", 181, 194]]], ["However, research on bonding to caries-affected dentine is limited.", [["dentine", "ANATOMY", 48, 55], ["caries", "DISEASE", 32, 38], ["dentine", "TISSUE", 48, 55]]], ["The clinician has various choices with regards to dentine adhesives and there are two broad groups: etch and rinse adhesives and self-etching adhesives.Adhesion to caries-affected dentineWith regards to the \"etch-and-rinse\" adhesives, the phosphoric acid etchant will dissolve the smear layer and demineralise the surface dentine.", [["dentine", "ANATOMY", 50, 57], ["smear layer", "ANATOMY", 281, 292], ["surface dentine", "ANATOMY", 314, 329], ["caries", "DISEASE", 164, 170], ["phosphoric acid", "CHEMICAL", 239, 254], ["phosphoric acid", "CHEMICAL", 239, 254], ["dentine", "TISSUE", 50, 57], ["phosphoric acid", "SIMPLE_CHEMICAL", 239, 254], ["surface dentine", "CELLULAR_COMPONENT", 314, 329], ["dentine adhesives", "TREATMENT", 50, 67], ["rinse adhesives", "TREATMENT", 109, 124], ["self-etching adhesives", "TREATMENT", 129, 151], ["Adhesion to caries", "PROBLEM", 152, 170], ["the \"etch", "TREATMENT", 203, 212], ["rinse\" adhesives", "TREATMENT", 217, 233], ["the phosphoric acid etchant", "TREATMENT", 235, 262], ["caries", "OBSERVATION", 164, 170]]], ["It can be difficult for the resin monomers to infiltrate to the full depth of demineralised dentine and when a \"wet bonding\" technique is used, water will also compete with the resin monomers to penetrate to the full depth of demineralisation [14] .", [["dentine", "ANATOMY", 92, 99], ["dentine", "TISSUE", 92, 99], ["the resin monomers", "TREATMENT", 24, 42], ["infiltrate", "PROBLEM", 46, 56], ["demineralised dentine", "PROBLEM", 78, 99], ["a \"wet bonding\" technique", "TREATMENT", 109, 134], ["the resin monomers", "TREATMENT", 173, 191], ["infiltrate", "OBSERVATION", 46, 56], ["full depth", "OBSERVATION_MODIFIER", 64, 74]]], ["The occluded dentinal tubules in the caries affected dentine cannot be completely dissolved by phosphoric acid and this makes them acid resistant [14] .", [["dentinal tubules", "ANATOMY", 13, 29], ["dentine", "ANATOMY", 53, 60], ["caries", "DISEASE", 37, 43], ["phosphoric acid", "CHEMICAL", 95, 110], ["phosphoric acid", "CHEMICAL", 95, 110], ["dentinal tubules", "MULTI-TISSUE_STRUCTURE", 13, 29], ["dentine", "TISSUE", 53, 60], ["phosphoric acid", "SIMPLE_CHEMICAL", 95, 110], ["The occluded dentinal tubules in the caries affected dentine", "PROBLEM", 0, 60], ["phosphoric acid", "TEST", 95, 110], ["occluded", "OBSERVATION", 4, 12], ["dentinal tubules", "OBSERVATION", 13, 29], ["caries", "OBSERVATION", 37, 43], ["cannot be", "UNCERTAINTY", 61, 70]]], ["However, because the caries-affected dentine is less mineralised compared to normal dentine, a deeper zone of demineralised dentine is created after phosphoric acid etching, which will result in a thicker hybrid layer after resin infiltration [15] .", [["dentine", "ANATOMY", 37, 44], ["dentine", "ANATOMY", 84, 91], ["dentine", "ANATOMY", 124, 131], ["caries", "DISEASE", 21, 27], ["phosphoric acid", "CHEMICAL", 149, 164], ["phosphoric acid", "CHEMICAL", 149, 164], ["dentine", "TISSUE", 37, 44], ["dentine", "TISSUE", 84, 91], ["dentine", "TISSUE", 124, 131], ["phosphoric acid", "SIMPLE_CHEMICAL", 149, 164], ["affected dentine", "PROBLEM", 28, 44], ["demineralised dentine", "PROBLEM", 110, 131], ["phosphoric acid etching", "TREATMENT", 149, 172], ["a thicker hybrid layer after resin infiltration", "TREATMENT", 195, 242], ["less mineralised", "OBSERVATION_MODIFIER", 48, 64]]], ["On the other hand, beneath the hybrid zone there will be a porous region of dentine that has been created because of the greater depth of demineralisation and the mineral deposits present in the tubules [16] .", [["dentine", "ANATOMY", 76, 83], ["tubules", "ANATOMY", 195, 202], ["dentine", "TISSUE", 76, 83], ["tubules", "TISSUE", 195, 202], ["a porous region of dentine", "PROBLEM", 57, 83], ["demineralisation", "PROBLEM", 138, 154], ["the mineral deposits", "PROBLEM", 159, 179], ["greater", "OBSERVATION_MODIFIER", 121, 128], ["depth", "OBSERVATION_MODIFIER", 129, 134], ["demineralisation", "OBSERVATION", 138, 154], ["mineral deposits", "OBSERVATION", 163, 179]]], ["The net result of this is a reduction in resin-dentin bond strengths to caries-affected dentine compared to sound dentine.", [["dentine", "ANATOMY", 88, 95], ["dentine", "ANATOMY", 114, 121], ["caries", "DISEASE", 72, 78], ["dentine", "TISSUE", 88, 95], ["dentine", "TISSUE", 114, 121], ["a reduction in resin-dentin bond strengths", "TREATMENT", 26, 68], ["affected dentine", "PROBLEM", 79, 95]]], ["This porous zone of weakness below the hybrid layer can be potentially strengthened by the addition of chemical cross linkers, which mechanically strengthen this incompletely resin-infiltrated zone [14] .Adhesion to caries-affected dentineSelf-etching adhesives, in particular the two-step self-etching systems, offer the advantage of not requiring dentine to be etched by phosphoric acid and the acidic self-etching primer will dissolve the smear layer and demineralise a thin zone of underlying dentine.", [["smear layer", "ANATOMY", 442, 453], ["dentine", "ANATOMY", 497, 504], ["caries", "DISEASE", 216, 222], ["phosphoric acid", "CHEMICAL", 373, 388], ["phosphoric acid", "CHEMICAL", 373, 388], ["dentineSelf", "SIMPLE_CHEMICAL", 232, 243], ["dentine", "TISSUE", 349, 356], ["phosphoric acid", "SIMPLE_CHEMICAL", 373, 388], ["dentine", "TISSUE", 497, 504], ["This porous zone of weakness", "PROBLEM", 0, 28], ["chemical cross linkers", "TREATMENT", 103, 125], ["Adhesion to caries", "PROBLEM", 204, 222], ["affected dentineSelf", "PROBLEM", 223, 243], ["etching adhesives", "TREATMENT", 244, 261], ["self-etching systems", "TREATMENT", 290, 310], ["dentine", "PROBLEM", 349, 356], ["phosphoric acid", "TREATMENT", 373, 388], ["the acidic self-etching primer", "TREATMENT", 393, 423], ["the smear layer", "PROBLEM", 438, 453], ["underlying dentine", "PROBLEM", 486, 504], ["porous", "OBSERVATION_MODIFIER", 5, 11], ["zone", "OBSERVATION_MODIFIER", 12, 16], ["weakness", "OBSERVATION", 20, 28], ["caries", "OBSERVATION", 216, 222], ["etching adhesives", "OBSERVATION", 244, 261], ["thin zone", "OBSERVATION_MODIFIER", 473, 482], ["dentine", "OBSERVATION", 497, 504]]], ["The zone of demineralisation is not as deep in normal dentine as that created by phosphoric acid, which makes it easier for the subsequently applied bonding resin to infiltrate the demineralised dentine resulting in a thin but \"high quality\" hybrid layer [14] .", [["dentine", "ANATOMY", 54, 61], ["dentine", "ANATOMY", 195, 202], ["phosphoric acid", "CHEMICAL", 81, 96], ["phosphoric acid", "CHEMICAL", 81, 96], ["dentine", "TISSUE", 54, 61], ["phosphoric acid", "SIMPLE_CHEMICAL", 81, 96], ["dentine", "TISSUE", 195, 202], ["demineralisation", "PROBLEM", 12, 28], ["phosphoric acid", "TEST", 81, 96], ["bonding resin", "TREATMENT", 149, 162], ["infiltrate the demineralised dentine", "PROBLEM", 166, 202], ["a thin but \"high quality\" hybrid layer", "PROBLEM", 216, 254], ["zone", "OBSERVATION_MODIFIER", 4, 8], ["demineralisation", "OBSERVATION", 12, 28], ["not as", "UNCERTAINTY", 32, 38], ["normal dentine", "OBSERVATION_MODIFIER", 47, 61], ["infiltrate", "OBSERVATION", 166, 176]]], ["However, in caries-affected dentine, the hybrid layer created by a self-etching adhesive is thicker, though not as thick when an \"etch and rinse\" adhesive is used, and a porous zone has been observed beneath the hybrid layer created by a self-etching adhesive [14] .", [["dentine", "ANATOMY", 28, 35], ["caries", "DISEASE", 12, 18], ["dentine", "TISSUE", 28, 35], ["affected dentine", "PROBLEM", 19, 35], ["the hybrid layer", "PROBLEM", 37, 53], ["a self-etching adhesive", "TREATMENT", 65, 88], ["a porous zone", "PROBLEM", 168, 181], ["a self-etching adhesive", "TREATMENT", 236, 259]]], ["A deeper zone of demineralisation is created in caries-affected dentine and resin infiltration is also hampered by the thicker smear layer, which the mildly acidic self-etching primer is not able to fully dissolve.", [["dentine", "ANATOMY", 64, 71], ["smear layer", "ANATOMY", 127, 138], ["caries", "DISEASE", 48, 54], ["dentine", "TISSUE", 64, 71], ["A deeper zone of demineralisation", "PROBLEM", 0, 33], ["affected dentine", "PROBLEM", 55, 71], ["resin infiltration", "PROBLEM", 76, 94], ["the thicker smear layer", "PROBLEM", 115, 138], ["the mildly acidic self-etching primer", "PROBLEM", 146, 183], ["deeper", "OBSERVATION_MODIFIER", 2, 8], ["zone", "OBSERVATION_MODIFIER", 9, 13], ["demineralisation", "OBSERVATION", 17, 33], ["caries", "OBSERVATION", 48, 54], ["dentine", "OBSERVATION_MODIFIER", 64, 71], ["resin infiltration", "OBSERVATION", 76, 94], ["layer", "OBSERVATION_MODIFIER", 133, 138], ["mildly", "OBSERVATION_MODIFIER", 150, 156], ["acidic", "OBSERVATION_MODIFIER", 157, 163]]], ["This results in the self-etching adhesives having lower bond strengths to caries-affected dentine compared to sound dentine [14] .Adhesion to caries-affected dentineIn order to improve the bonding of self-etching adhesives to caries-affected dentine, researchers have looked at modifying the thicker smear layer present on caries-affected dentine [14] .", [["dentine", "ANATOMY", 90, 97], ["dentine", "ANATOMY", 242, 249], ["smear layer", "ANATOMY", 300, 311], ["dentine", "ANATOMY", 339, 346], ["caries", "DISEASE", 74, 80], ["caries", "DISEASE", 142, 148], ["caries", "DISEASE", 226, 232], ["caries", "DISEASE", 323, 329], ["dentine", "TISSUE", 90, 97], ["dentine", "TISSUE", 242, 249], ["dentine", "TISSUE", 339, 346], ["the self-etching adhesives", "TREATMENT", 16, 42], ["affected dentine", "PROBLEM", 81, 97], ["Adhesion to caries", "PROBLEM", 130, 148], ["self-etching adhesives", "TREATMENT", 200, 222], ["affected dentine", "PROBLEM", 233, 249], ["affected dentine", "PROBLEM", 330, 346], ["caries", "OBSERVATION", 142, 148]]], ["Initially, sodium hypochlorite solution was investigated as this solution can dissolve organic substances and when applied to smear-layer covered caries-affected dentine at a concentration of 6% for 15 s, it was shown that the smear layer was thinned down and dissolved away resulting in significant improvements of the bond strengths of one and two-step self-etching adhesives [17] .", [["dentine", "ANATOMY", 162, 169], ["smear layer", "ANATOMY", 227, 238], ["sodium hypochlorite", "CHEMICAL", 11, 30], ["caries", "DISEASE", 146, 152], ["sodium hypochlorite", "CHEMICAL", 11, 30], ["sodium hypochlorite", "SIMPLE_CHEMICAL", 11, 30], ["dentine", "TISSUE", 162, 169], ["sodium hypochlorite solution", "TREATMENT", 11, 39], ["this solution", "TREATMENT", 60, 73], ["organic substances", "TREATMENT", 87, 105], ["smear", "TEST", 126, 131], ["layer covered caries", "PROBLEM", 132, 152], ["affected dentine", "PROBLEM", 153, 169], ["the smear layer", "PROBLEM", 223, 238], ["self-etching adhesives", "TREATMENT", 355, 377], ["caries", "OBSERVATION", 146, 152], ["layer", "OBSERVATION_MODIFIER", 233, 238], ["significant", "OBSERVATION_MODIFIER", 288, 299], ["improvements", "OBSERVATION_MODIFIER", 300, 312]]], ["Further research by the same research group has investigated the application of a mild acidic solution of HOCl (Comfosy, HaccpperAdvantec Corp., Tokyo, Japan), which has antimicrobial, deproteinising and low cytotoxicity properties on caries-affected dentine and observed that a better quality of hybrid layer was created as well as more stable bond strengths [18] .Acid-base resistant zone-creation of \"super dentine\"It has been mentioned earlier that phosphoric acid etching of dentine may result in the phenomenon of \"over-etched\" dentine, whereby the resin is unable to fully penetrate to the full depth of demineralisation resulting in a zone of potential weakness beneath the hybrid layer [14] .", [["dentine", "ANATOMY", 251, 258], ["dentine", "ANATOMY", 480, 487], ["dentine", "ANATOMY", 534, 541], ["HOCl", "CHEMICAL", 106, 110], ["caries", "DISEASE", 235, 241], ["phosphoric acid", "CHEMICAL", 453, 468], ["HOCl", "CHEMICAL", 106, 110], ["phosphoric acid", "CHEMICAL", 453, 468], ["HOCl", "SIMPLE_CHEMICAL", 106, 110], ["Comfosy", "SIMPLE_CHEMICAL", 112, 119], ["dentine", "TISSUE", 251, 258], ["Acid", "SIMPLE_CHEMICAL", 366, 370], ["phosphoric acid", "SIMPLE_CHEMICAL", 453, 468], ["dentine", "TISSUE", 480, 487], ["dentine", "TISSUE", 534, 541], ["a mild acidic solution of HOCl", "TREATMENT", 80, 110], ["antimicrobial", "PROBLEM", 170, 183], ["low cytotoxicity properties on caries", "PROBLEM", 204, 241], ["affected dentine", "PROBLEM", 242, 258], ["Acid", "TEST", 366, 370], ["phosphoric acid etching of dentine", "TREATMENT", 453, 487], ["demineralisation", "PROBLEM", 611, 627], ["potential weakness", "PROBLEM", 651, 669], ["mild", "OBSERVATION_MODIFIER", 82, 86], ["low cytotoxicity", "OBSERVATION_MODIFIER", 204, 220], ["base", "ANATOMY_MODIFIER", 371, 375], ["resistant", "OBSERVATION_MODIFIER", 376, 385], ["zone", "OBSERVATION_MODIFIER", 386, 390], ["zone", "OBSERVATION_MODIFIER", 643, 647], ["weakness", "OBSERVATION", 661, 669]]], ["This zone will be demineralised and not be fully infiltrated with resin and could influence the longevity of a composite resin restoration particularly if placed in a tooth subjected to high occlusal stress.", [["tooth", "ANATOMY", 167, 172], ["tooth", "ORGAN", 167, 172], ["resin", "TREATMENT", 66, 71], ["a composite resin restoration", "TREATMENT", 109, 138], ["a tooth", "PROBLEM", 165, 172], ["high occlusal stress", "PROBLEM", 186, 206]]], ["On the otherhand, self-etching adhesive systems do not require prior phosphoric acid etching of dentine and therefore, \"aggressive\" etching of dentine is avoided [19] .", [["dentine", "ANATOMY", 143, 150], ["phosphoric acid", "CHEMICAL", 69, 84], ["phosphoric acid", "CHEMICAL", 69, 84], ["phosphoric acid", "SIMPLE_CHEMICAL", 69, 84], ["dentine", "TISSUE", 96, 103], ["dentine", "TISSUE", 143, 150], ["self-etching adhesive systems", "TREATMENT", 18, 47], ["prior phosphoric acid etching of dentine", "TREATMENT", 63, 103], ["aggressive\" etching of dentine", "TREATMENT", 120, 150]]], ["Nikaido previously discovered an \"acid-base resistant\" zone beneath the hybrid layer, when bonded dentine-composite resin discs were subjected to an artificial secondary caries attack [19] .", [["hybrid layer", "ANATOMY", 72, 84], ["caries", "DISEASE", 170, 176], ["dentine", "TISSUE", 98, 105], ["an \"acid-base resistant\" zone", "PROBLEM", 30, 59], ["bonded dentine", "PROBLEM", 91, 105], ["composite resin discs", "TREATMENT", 106, 127], ["an artificial secondary caries attack", "PROBLEM", 146, 183], ["resistant", "OBSERVATION_MODIFIER", 44, 53], ["hybrid layer", "OBSERVATION", 72, 84]]], ["His research group investigated a two-step, self-etching adhesive, Clearfil SE Bond (Kuraray Noritake Dental Inc., Japan), and observed that the hybrid layerwas approximately 1 m thick after argon ion etching in sound dentine and was slightly thicker in caries-affected dentine [20] .", [["dentine", "ANATOMY", 218, 225], ["dentine", "ANATOMY", 270, 277], ["caries", "DISEASE", 254, 260], ["dentine", "TISSUE", 218, 225], ["dentine", "TISSUE", 270, 277], ["self-etching adhesive", "TREATMENT", 44, 65], ["argon ion etching", "TREATMENT", 191, 208], ["sound dentine", "PROBLEM", 212, 225], ["slightly thicker in caries", "PROBLEM", 234, 260], ["affected dentine", "PROBLEM", 261, 277]]], ["Beneath the hybrid layer of this adhesive, an acid-base resistant zone was observed in both sound and caries-affected dentine bonded specimens, which was observed to be 1 m thick in the sound dentine and 1.5 m thick in the caries-affected dentine [20] .", [["dentine", "ANATOMY", 118, 125], ["specimens", "ANATOMY", 133, 142], ["dentine", "ANATOMY", 192, 199], ["dentine", "ANATOMY", 239, 246], ["caries", "DISEASE", 102, 108], ["caries", "DISEASE", 223, 229], ["dentine", "TISSUE", 118, 125], ["dentine", "TISSUE", 192, 199], ["dentine", "TISSUE", 239, 246], ["this adhesive", "TREATMENT", 28, 41], ["an acid-base resistant zone", "PROBLEM", 43, 70], ["affected dentine bonded specimens", "PROBLEM", 109, 142], ["affected dentine", "PROBLEM", 230, 246], ["hybrid", "OBSERVATION_MODIFIER", 12, 18], ["layer", "OBSERVATION_MODIFIER", 19, 24]]], ["This zone was not observed to be present for adhesive systems that required prior etching with phosphoric acid.", [["phosphoric acid", "CHEMICAL", 95, 110], ["phosphoric acid", "CHEMICAL", 95, 110], ["phosphoric acid", "SIMPLE_CHEMICAL", 95, 110], ["adhesive systems", "PROBLEM", 45, 61], ["prior etching with phosphoric acid", "TREATMENT", 76, 110]]], ["It was reasoned that this was because phosphoric acid aggressively etched the dentine and created a zone of demineralisation that was too deep for resin to fully infiltrate [20] .", [["dentine", "ANATOMY", 78, 85], ["phosphoric acid", "CHEMICAL", 38, 53], ["phosphoric acid", "CHEMICAL", 38, 53], ["phosphoric acid", "SIMPLE_CHEMICAL", 38, 53], ["dentine", "TISSUE", 78, 85], ["phosphoric acid", "PROBLEM", 38, 53], ["the dentine", "PROBLEM", 74, 85], ["a zone of demineralisation", "PROBLEM", 98, 124], ["fully infiltrate", "PROBLEM", 156, 172], ["infiltrate", "OBSERVATION", 162, 172]]], ["This is potentially significant in that secondary caries will occur at the margins of restorations between the dentine and resin restoration and therefore the presence of an acid-base resistant zone may help prevent secondary caries around a restoration.Acid-base resistant zone-creation of \"super dentine\"It is relevant at this point to mention that in 1985, Nakabayashi described the resin infiltration of tooth structure as follows; \"the resin reinforced dentine and enamel is a hybrid of natural tissue and artificial material and is valuable in the prevention of secondary caries after restoration\" [21] .", [["dentine", "ANATOMY", 111, 118], ["tooth", "ANATOMY", 408, 413], ["dentine", "ANATOMY", 458, 465], ["enamel", "ANATOMY", 470, 476], ["tissue", "ANATOMY", 500, 506], ["caries", "DISEASE", 50, 56], ["caries", "DISEASE", 226, 232], ["caries", "DISEASE", 578, 584], ["dentine", "TISSUE", 111, 118], ["Acid", "SIMPLE_CHEMICAL", 254, 258], ["tooth", "ORGAN", 408, 413], ["dentine", "TISSUE", 458, 465], ["enamel", "ORGAN", 470, 476], ["tissue", "TISSUE", 500, 506], ["secondary caries", "PROBLEM", 40, 56], ["restorations", "TREATMENT", 86, 98], ["the dentine", "TREATMENT", 107, 118], ["resin restoration", "TREATMENT", 123, 140], ["an acid-base resistant zone", "TREATMENT", 171, 198], ["secondary caries", "PROBLEM", 216, 232], ["a restoration", "TREATMENT", 240, 253], ["Acid-base resistant zone", "PROBLEM", 254, 278], ["the resin infiltration of tooth structure", "PROBLEM", 382, 423], ["the resin reinforced dentine", "TREATMENT", 437, 465], ["artificial material", "TREATMENT", 511, 530], ["secondary caries", "PROBLEM", 568, 584], ["potentially", "UNCERTAINTY", 8, 19], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["secondary", "OBSERVATION_MODIFIER", 40, 49], ["caries", "OBSERVATION", 50, 56], ["resin restoration", "OBSERVATION", 123, 140], ["base", "ANATOMY_MODIFIER", 259, 263], ["resistant", "OBSERVATION_MODIFIER", 264, 273], ["zone", "OBSERVATION_MODIFIER", 274, 278], ["resin infiltration", "OBSERVATION", 386, 404], ["tooth", "ANATOMY", 408, 413]]], ["And so, even though it was thirty-five years ago when prevention of secondary caries by hybrid layer formation was first proposed, it is interesting that discussion on the effectiveness of the hybrid layer to prevent secondary caries is sometimes omitted in the scientific discussions when adhesive performance is discussed.Acid-base resistant zone-creation of \"super dentine\"Nikaido described the acid-base resistant zone as a combination of dentine and the adjacent hybrid layer which, because it is effectively reinforced, has suggested this region of the adhesive interface should be called \"super dentine\", which possesses an ability to prevent primary and secondary caries [22] .", [["dentine", "ANATOMY", 443, 450], ["dentine", "ANATOMY", 602, 609], ["caries", "DISEASE", 78, 84], ["caries", "DISEASE", 227, 233], ["primary and secondary caries", "DISEASE", 650, 678], ["Acid", "SIMPLE_CHEMICAL", 324, 328], ["dentine", "TISSUE", 443, 450], ["dentine", "TISSUE", 602, 609], ["secondary caries", "PROBLEM", 68, 84], ["the hybrid layer", "TREATMENT", 189, 205], ["secondary caries", "PROBLEM", 217, 233], ["Acid-base resistant zone", "PROBLEM", 324, 348], ["\"super dentine", "PROBLEM", 361, 375], ["the acid-base resistant zone", "PROBLEM", 394, 422], ["dentine", "PROBLEM", 443, 450], ["the adjacent hybrid layer", "PROBLEM", 455, 480], ["the adhesive interface", "TREATMENT", 555, 577], ["primary and secondary caries", "PROBLEM", 650, 678], ["base", "ANATOMY_MODIFIER", 329, 333], ["resistant", "OBSERVATION_MODIFIER", 334, 343], ["zone", "OBSERVATION_MODIFIER", 344, 348], ["hybrid layer", "OBSERVATION", 468, 480]]], ["This is because it is superior to sound dentine mechanically, chemically and biologically.", [["dentine", "TISSUE", 40, 47]]], ["Nikaido's proposal is arguably, a further development and extrapolation of the concept of that the hybrid layer can prevent secondary caries formation, as was first described by Nakabayashi in 1985 [21, 22] .Acid-base resistant zone-creation of \"super dentine\"Having now discussed how we could provide \"painless\" dentistry by careful removal of soft, caries-infected dentine, seal the cavity and prevent caries progression by adhesive enamel bonding and how the hybrid layer and an acid-base resistant zone offer the ability to prevent primary and secondary caries, it is clear that carefully applied adhesive direct composite resin restorations can offer the patient additional benefits by their ability to fill minimally prepared cavities, offer aesthetically pleasing results and good long-term durability [8] .", [["dentine", "ANATOMY", 367, 374], ["enamel", "ANATOMY", 435, 441], ["caries", "DISEASE", 134, 140], ["caries", "DISEASE", 351, 357], ["caries", "DISEASE", 404, 410], ["caries", "DISEASE", 558, 564], ["Acid", "SIMPLE_CHEMICAL", 208, 212], ["dentine", "TISSUE", 367, 374], ["cavity", "ORGAN", 385, 391], ["enamel", "TISSUE", 435, 441], ["patient", "ORGANISM", 660, 667], ["patient", "SPECIES", 660, 667], ["Nikaido's proposal", "TREATMENT", 0, 18], ["the hybrid layer", "PROBLEM", 95, 111], ["secondary caries formation", "PROBLEM", 124, 150], ["Acid-base resistant zone", "PROBLEM", 208, 232], ["painless\" dentistry", "TREATMENT", 303, 322], ["careful removal", "TREATMENT", 326, 341], ["soft, caries", "PROBLEM", 345, 357], ["infected dentine", "PROBLEM", 358, 374], ["seal the cavity", "TREATMENT", 376, 391], ["caries progression", "PROBLEM", 404, 422], ["adhesive enamel bonding", "TREATMENT", 426, 449], ["the hybrid layer", "TREATMENT", 458, 474], ["an acid-base resistant zone", "TREATMENT", 479, 506], ["primary and secondary caries", "PROBLEM", 536, 564], ["adhesive direct composite resin restorations", "TREATMENT", 601, 645], ["secondary", "OBSERVATION_MODIFIER", 124, 133], ["caries", "OBSERVATION", 134, 140], ["base", "ANATOMY_MODIFIER", 213, 217], ["resistant", "OBSERVATION_MODIFIER", 218, 227], ["zone", "OBSERVATION_MODIFIER", 228, 232], ["cavity", "ANATOMY", 385, 391]]], ["While the words \"minimally invasive dentistry\" are mentioned nowadays as if it was a new treatment modality, it's origins are surely in the mid 1980s with the work of Fusayama and Nakabayashi who suggested that caries can be prevented by hybrid layer formation at the adhesive interface of direct composite resin restorations.", [["caries", "DISEASE", 211, 217], ["a new treatment modality", "TREATMENT", 83, 107], ["caries", "PROBLEM", 211, 217], ["direct composite resin restorations", "TREATMENT", 290, 325], ["resin restorations", "OBSERVATION", 307, 325]]], ["The remainder of this article will discuss some key aspects of direct composite resin placement to obtain good adhesion and colour matching.Options for improving adhesive performance at the cavity floor and marginsThere are multiple choices for the clinician when selecting which direct composite resin materials should be used as a restorative material.", [["cavity floor", "ANATOMY", 190, 202], ["cavity floor", "MULTI-TISSUE_STRUCTURE", 190, 202], ["direct composite resin placement", "TREATMENT", 63, 95], ["improving adhesive performance", "TREATMENT", 152, 182], ["direct composite resin materials", "TREATMENT", 280, 312], ["a restorative material", "TREATMENT", 331, 353], ["margins", "OBSERVATION_MODIFIER", 207, 214], ["multiple", "OBSERVATION_MODIFIER", 224, 232]]], ["An initial question might be whether a thin layer of a \"flowable\" composite resin should be placed initially in the cavity?", [["cavity", "ORGANISM_SUBDIVISION", 116, 122], ["a \"flowable\" composite resin", "TREATMENT", 53, 81], ["cavity", "ANATOMY", 116, 122]]], ["The rationale of placing a low-viscosity or flowable composite resin as an initial thin layer after curing of the adhesive is that this may dissipate contraction stresses that are created when the composite resin is light-cured by the creating of a stress-absorbing layer that helps preserve the integrity of the bonded adhesive interface [23] .Options for improving adhesive performance at the cavity floor and marginsIn 2003, Reis and colleagues looked at the effect of filling techniques and a low-viscosity composite liner on bond strength to class II cavities prepared in extracted human third-molar teeth and found that bond strengths were not improved when a low-viscosity composite resin was used but an incremental filling technique improved bond strengths [24] .Options for improving adhesive performance at the cavity floor and marginsResearch was then focussed on whether a particular type of adhesive might benefit from a subsequent application of a thin layer of flowable composite resin and work by De Goes' group tried to answer this question by looking at 4 adhesives representing the four classes of adhesives at that time [25] .", [["cavity floor", "ANATOMY", 395, 407], ["teeth", "ANATOMY", 605, 610], ["cavity floor", "ANATOMY", 822, 834], ["cavity floor", "MULTI-TISSUE_STRUCTURE", 395, 407], ["human", "ORGANISM", 587, 592], ["teeth", "ORGAN", 605, 610], ["cavity floor", "MULTI-TISSUE_STRUCTURE", 822, 834], ["human", "SPECIES", 587, 592], ["human", "SPECIES", 587, 592], ["a low-viscosity or flowable composite resin", "TREATMENT", 25, 68], ["an initial thin layer", "TREATMENT", 72, 93], ["the adhesive", "TREATMENT", 110, 122], ["contraction stresses", "PROBLEM", 150, 170], ["the composite resin", "TREATMENT", 193, 212], ["a stress-absorbing layer", "PROBLEM", 247, 271], ["improving adhesive performance", "TREATMENT", 357, 387], ["filling techniques", "TREATMENT", 472, 490], ["a low-viscosity composite liner", "TREATMENT", 495, 526], ["a low-viscosity composite resin", "TREATMENT", 664, 695], ["an incremental filling technique", "TREATMENT", 709, 741], ["improving adhesive performance", "TREATMENT", 784, 814], ["a thin layer of flowable composite resin", "TREATMENT", 961, 1001], ["adhesives", "TREATMENT", 1118, 1127], ["contraction stresses", "OBSERVATION", 150, 170], ["margins", "OBSERVATION_MODIFIER", 412, 419], ["improved", "OBSERVATION_MODIFIER", 650, 658], ["margins", "OBSERVATION_MODIFIER", 839, 846]]], ["The occlusal surfaces of extracted third molars were ground to expose dentine and were treated with one of four adhesives: 3-Step etch-andrinse (ScotchBond Multi-Purpose, 3 M, USA); 2-step etch-and-rinse (SingleBond, 3 M, USA); All-in-one self-etching adhesive (Adper Prompt, 3 M, USA); 2-step self-etching adhesive (Clearfil SE Bond, Kuraray Noritake Dental Inc., Japan) [25] .", [["third molars", "ANATOMY", 35, 47], ["dentine", "ANATOMY", 70, 77], ["molars", "ORGAN", 41, 47], ["dentine", "TISSUE", 70, 77], ["extracted third molars", "PROBLEM", 25, 47], ["self-etching adhesive", "TREATMENT", 239, 260], ["self-etching adhesive (Clearfil SE Bond", "TREATMENT", 294, 333], ["occlusal", "OBSERVATION_MODIFIER", 4, 12], ["surfaces", "OBSERVATION_MODIFIER", 13, 21], ["third", "OBSERVATION_MODIFIER", 35, 40], ["molars", "OBSERVATION", 41, 47]]], ["Their results showed that application of an intermediate flowable composite layer improved the bond strength of all four adhesives and this was significant for Clearfil SE Bond (Kuraray Noritake Dental Inc., Japan) [25] .Options for improving adhesive performance at the cavity floor and marginsEarly all-one-adhesives such as Adper PromptL-Pop (3 M, USA) contained a functional monomer that dissociated into a hydrolytically unstable monomer because of the presence of water at a concentration of 30%-50%.", [["cavity floor", "ANATOMY", 271, 283], ["cavity floor", "MULTI-TISSUE_STRUCTURE", 271, 283], ["water", "SIMPLE_CHEMICAL", 470, 475], ["an intermediate flowable composite layer", "TREATMENT", 41, 81], ["all four adhesives", "TREATMENT", 112, 130], ["Clearfil SE Bond (Kuraray Noritake Dental", "TREATMENT", 160, 201], ["improving adhesive performance", "TREATMENT", 233, 263], ["adhesives", "TREATMENT", 309, 318], ["a functional monomer", "PROBLEM", 366, 386], ["a hydrolytically unstable monomer", "PROBLEM", 409, 442], ["layer", "OBSERVATION_MODIFIER", 76, 81], ["bond strength", "OBSERVATION", 95, 108], ["margins", "OBSERVATION_MODIFIER", 288, 295], ["functional monomer", "OBSERVATION", 368, 386]]], ["This allowed fluid penetration through the adhesive and led to the hybrid layer being susceptible to cracking after polymerisation of the overlying composite resin [26, 27] (Fig. 4) .", [["fluid", "ANATOMY", 13, 18], ["fluid penetration", "TREATMENT", 13, 30], ["the adhesive", "TREATMENT", 39, 51], ["the hybrid layer", "TREATMENT", 63, 79], ["polymerisation of the overlying composite resin", "TREATMENT", 116, 163], ["fluid penetration", "OBSERVATION", 13, 30], ["cracking", "OBSERVATION_MODIFIER", 101, 109]]], ["The simplicity of all-in-one adhesives led many researchers to look at ways of improving the durability of the adhesive bond and the mechanical properties of the adhesive interface to withstand the contraction stresses of the overlying composite resin as it polymerised and manufacturers to look at new compositions.", [["the adhesive bond", "TREATMENT", 107, 124], ["the adhesive interface", "TREATMENT", 158, 180], ["the overlying composite resin", "TREATMENT", 222, 251], ["adhesive interface", "OBSERVATION", 162, 180], ["contraction stresses", "OBSERVATION", 198, 218]]], ["The expiry of the patent in 2003 for MDP, which was held by Kuraray Noritake Dental Inc. Japan, has led to several manufacturers, developing new adhesives that contain MDP as the functional adhesive monomer and their terminology has also evolved to \"universal adhesives\" [28] .", [["MDP", "CHEMICAL", 37, 40], ["MDP", "CHEMICAL", 168, 171], ["MDP", "CHEMICAL", 37, 40], ["MDP", "CHEMICAL", 168, 171], ["MDP", "SIMPLE_CHEMICAL", 37, 40], ["MDP", "SIMPLE_CHEMICAL", 168, 171], ["MDP", "TEST", 37, 40], ["new adhesives", "TREATMENT", 141, 154], ["patent", "OBSERVATION", 18, 24], ["new", "OBSERVATION_MODIFIER", 141, 144], ["adhesives", "OBSERVATION", 145, 154]]], ["MDP has been shown to exhibit ionic bonding to hydroxyapatite more effectively than other adhesive monomers such as 4-MET through the creation of an MDP-Ca salt deposition and nanolayering [29] .Options for improving adhesive performance at the cavity floor and marginsApplying the all-in-one adhesive as a double application before curing has been investigated using four, one-step self-etching adhesives (iBond SE, Kulzer GmbH, Germany; Clearfil S 3 Bond,(Kuraray Noritake Dental Inc., Japan; XenoV, Dentsply Sirona, USA; and Scotchbond Universal, 3 M, USA) with extracted human third molars as the bonding substrate under different storage conditions [30] .", [["cavity floor", "ANATOMY", 245, 257], ["molars", "ANATOMY", 587, 593], ["MDP", "CHEMICAL", 0, 3], ["hydroxyapatite", "CHEMICAL", 47, 61], ["4-MET", "CHEMICAL", 116, 121], ["MDP", "CHEMICAL", 149, 152], ["Ca", "CHEMICAL", 153, 155], ["SE", "DISEASE", 413, 415], ["MDP", "CHEMICAL", 0, 3], ["hydroxyapatite", "CHEMICAL", 47, 61], ["4-MET", "CHEMICAL", 116, 121], ["MDP", "CHEMICAL", 149, 152], ["Ca", "CHEMICAL", 153, 155], ["MDP", "SIMPLE_CHEMICAL", 0, 3], ["hydroxyapatite", "SIMPLE_CHEMICAL", 47, 61], ["4-MET", "SIMPLE_CHEMICAL", 116, 121], ["MDP-Ca salt", "SIMPLE_CHEMICAL", 149, 160], ["cavity floor", "MULTI-TISSUE_STRUCTURE", 245, 257], ["human", "ORGANISM", 575, 580], ["molars", "ORGAN", 587, 593], ["human", "SPECIES", 575, 580], ["human", "SPECIES", 575, 580], ["ionic bonding", "PROBLEM", 30, 43], ["hydroxyapatite", "TREATMENT", 47, 61], ["other adhesive monomers", "TREATMENT", 84, 107], ["an MDP", "TEST", 146, 152], ["Ca salt deposition", "TREATMENT", 153, 171], ["improving adhesive performance", "TREATMENT", 207, 237], ["a double application", "TREATMENT", 305, 325], ["self-etching adhesives", "TREATMENT", 383, 405], ["XenoV", "TREATMENT", 495, 500], ["extracted human third molars", "TREATMENT", 565, 593], ["margins", "OBSERVATION_MODIFIER", 262, 269]]], ["It was found that iBond SE, Clearfil S 3 Bond and XenoV exhibited significantly higher bond strengths when they were applied as a double layer before light-curing [30] .Options for improving adhesive performance at the cavity floor and marginsAnother adhesive application technique, \"scrubbing\"the dentin surface with a micro-sponge, has been suggested for certain onestep self-etching adhesives to increase the bond strength [31] .", [["cavity floor", "ANATOMY", 219, 231], ["dentin surface", "ANATOMY", 298, 312], ["SE", "DISEASE", 24, 26], ["XenoV", "CHEMICAL", 50, 55], ["XenoV", "SIMPLE_CHEMICAL", 50, 55], ["cavity floor", "MULTI-TISSUE_STRUCTURE", 219, 231], ["Clearfil S", "TEST", 28, 38], ["a double layer", "TREATMENT", 128, 142], ["improving adhesive performance", "TREATMENT", 181, 211], ["Another adhesive application technique", "TREATMENT", 243, 281], ["a micro-sponge", "TREATMENT", 318, 332], ["onestep self-etching adhesives", "TREATMENT", 365, 395], ["significantly", "OBSERVATION_MODIFIER", 66, 79], ["higher", "OBSERVATION_MODIFIER", 80, 86], ["bond strengths", "OBSERVATION", 87, 101], ["margins", "OBSERVATION_MODIFIER", 236, 243], ["adhesive", "OBSERVATION_MODIFIER", 251, 259]]], ["The effect of scrubbing dentine during application was investigated using two, one-step self-etching adhesives on extracted third molar teeth (SE One, Kuraray Noritake Dental Inc., Japan; and Scotchbond Universal, 3 M, USA) and it was found that scrubbing improved etching ability and significantly improved the bond strength of Scotchbond Universal (3 M, USA) [31] .Options for improving adhesive performance at the cavity floor and marginsOne more technique proposed to improve the bond strength of universal adhesives is to apply a subsequent coating of a thin layer of a hydrophobic resin, thereby converting the adhesive strategy to a two-step self-etching one [32] .", [["dentine", "ANATOMY", 24, 31], ["teeth", "ANATOMY", 136, 141], ["cavity floor", "ANATOMY", 417, 429], ["SE", "DISEASE", 143, 145], ["dentine", "TISSUE", 24, 31], ["teeth", "ORGAN", 136, 141], ["cavity floor", "MULTI-TISSUE_STRUCTURE", 417, 429], ["scrubbing dentine", "PROBLEM", 14, 31], ["one-step self-etching adhesives", "TREATMENT", 79, 110], ["extracted third molar teeth", "TREATMENT", 114, 141], ["improving adhesive performance", "TREATMENT", 379, 409], ["universal adhesives", "TREATMENT", 501, 520], ["a hydrophobic resin", "TREATMENT", 573, 592], ["the adhesive strategy", "TREATMENT", 613, 634], ["a two-step self-etching", "TREATMENT", 638, 661], ["scrubbing dentine", "OBSERVATION", 14, 31], ["margins", "OBSERVATION_MODIFIER", 434, 441]]], ["Extracted third molar teeth were used and when a layer of Heliobond (IvoclarVivadent AG, Liechtenstein) was applied to three universal adhesives (All-Bond Universal, Bisco, USA; G-Bond Plus, GC Corporation, Japan; and ScotchBond Universal, 3 M, USA) in their self-etching mode, adhesive performance was improved [32] .Options for improving adhesive performance at the cavity floor and marginsWhat this means for clinical practice is that while the abovementioned studies using universal adhesives all used extracted third molars, their results do indicate that if a universal adhesive has been chosen by the clinician, then thought should be given not only to its application technique, be it by \"scrubbing\" or as a double-coat, but whether consideration should be given to applying an additional thin layer of hydrophobic resin before applying the composite resin or a flowable composite resin material.Composite resin placementIt has been established that shrinkage stresses develop in composite resin during polymerisation and if the cavities increase in size then volumetric shrinkage may also increase [33] .", [["teeth", "ANATOMY", 22, 27], ["cavity floor", "ANATOMY", 368, 380], ["third molars", "ANATOMY", 516, 528], ["teeth", "ORGAN", 22, 27], ["cavity floor", "MULTI-TISSUE_STRUCTURE", 368, 380], ["molars", "ORGAN", 522, 528], ["Extracted third molar teeth", "PROBLEM", 0, 27], ["Heliobond (IvoclarVivadent AG, Liechtenstein)", "TREATMENT", 58, 103], ["universal adhesives", "TREATMENT", 125, 144], ["GC Corporation", "TREATMENT", 191, 205], ["improving adhesive performance", "TREATMENT", 330, 360], ["the abovementioned studies", "TEST", 444, 470], ["universal adhesives", "TREATMENT", 477, 496], ["third molars", "PROBLEM", 516, 528], ["a universal adhesive", "TREATMENT", 564, 584], ["a double-coat", "TREATMENT", 714, 727], ["an additional thin layer of hydrophobic resin", "TREATMENT", 783, 828], ["the composite resin", "TREATMENT", 845, 864], ["a flowable composite resin material", "TREATMENT", 868, 903], ["Composite resin placement", "TREATMENT", 904, 929], ["shrinkage stresses", "PROBLEM", 958, 976], ["composite resin during polymerisation", "TREATMENT", 988, 1025], ["the cavities", "PROBLEM", 1033, 1045], ["volumetric shrinkage", "PROBLEM", 1068, 1088], ["third", "OBSERVATION_MODIFIER", 10, 15], ["molar teeth", "OBSERVATION", 16, 27], ["margins", "OBSERVATION_MODIFIER", 385, 392], ["resin material", "OBSERVATION", 889, 903], ["resin placement", "OBSERVATION", 914, 929], ["shrinkage", "OBSERVATION_MODIFIER", 958, 967], ["stresses", "OBSERVATION_MODIFIER", 968, 976], ["cavities", "OBSERVATION_MODIFIER", 1037, 1045], ["increase", "OBSERVATION_MODIFIER", 1046, 1054], ["size", "OBSERVATION_MODIFIER", 1058, 1062], ["increase", "OBSERVATION_MODIFIER", 1098, 1106]]], ["Polymerisation shrinkage cannot be avoided, and the adhesive system must possess sufficient mechanical strength to avoid being weakened [34] .", [["Polymerisation shrinkage", "TREATMENT", 0, 24], ["the adhesive system", "TREATMENT", 48, 67]]], ["Research using simulated occlusal cavities in resin and occlusal cavities cut in extracted human molarsshowed that an incremental filling technique was more effective in improving adhesion to the cavity floor than a bulk filling technique [34, 35] .Colour adjustment at the restoration-tooth borderFor patients, a good aesthetic outcome is often important and direct composite resin can give excellent results if attention is paid to shade matching with the surrounding tooth structure.", [["cavity floor", "ANATOMY", 196, 208], ["tooth", "ANATOMY", 286, 291], ["tooth", "ANATOMY", 470, 475], ["human", "ORGANISM", 91, 96], ["patients", "ORGANISM", 302, 310], ["tooth", "ORGAN", 470, 475], ["human", "SPECIES", 91, 96], ["patients", "SPECIES", 302, 310], ["human", "SPECIES", 91, 96], ["simulated occlusal cavities in resin and occlusal cavities", "TREATMENT", 15, 73], ["an incremental filling technique", "TREATMENT", 115, 147], ["a bulk filling technique", "TEST", 214, 238], ["Colour adjustment", "PROBLEM", 249, 266], ["direct composite resin", "TREATMENT", 360, 382], ["occlusal cavities", "OBSERVATION", 25, 42], ["occlusal cavities", "OBSERVATION", 56, 73], ["cavity", "ANATOMY", 196, 202], ["tooth", "ANATOMY", 286, 291], ["border", "ANATOMY_MODIFIER", 292, 298]]], ["The colour of the resin composite is influenced and perceived by various factors; colour elements of hue value and chroma; and optical properties.", [["hue value", "TEST", 101, 110], ["colour", "OBSERVATION_MODIFIER", 4, 10], ["resin composite", "OBSERVATION", 18, 33]]], ["The optical properties include light transmission characteristics (straight-line and diffusion), translucency, fluorescence, and opalescence, along with the surface characteristics of the composite resin [36] .", [["surface", "ANATOMY", 157, 164], ["translucency", "PROBLEM", 97, 109], ["opalescence", "PROBLEM", 129, 140], ["opalescence", "OBSERVATION_MODIFIER", 129, 140]]], ["Composite resin and enamel are translucent materials, which can reflect colours from adjoining substrates, leading to the colour shifting between each other [36] .", [["enamel", "ANATOMY", 20, 26], ["enamel", "TISSUE", 20, 26], ["Composite resin", "TREATMENT", 0, 15], ["translucent materials", "PROBLEM", 31, 52], ["translucent materials", "OBSERVATION", 31, 52]]], ["Obtaining a near \"invisible\" restoration margin through good colour matching with the adjacent tooth structure can help ensure a pleasing result for the patient (Fig. 5) .", [["tooth", "ANATOMY", 95, 100], ["tooth", "ORGAN", 95, 100], ["patient", "ORGANISM", 153, 160], ["patient", "SPECIES", 153, 160], ["a near \"invisible\" restoration margin", "PROBLEM", 10, 47], ["margin", "OBSERVATION_MODIFIER", 41, 47], ["good colour", "OBSERVATION", 56, 67]]], ["Several factors come into play when considering how best to get a good colour match with a synthetic restorative material to natural living tooth structure.Colour adjustment at the restoration-tooth borderExtracted human premolar teeth and four different composite resin restorative materials (Clearfil AP-X, Kuraray Noritake Dental Inc., Japan; Clearfil Majesty, Kuraray Noritake Dental Inc., Japan; Tetric N Ceram, IvoclarVivadent AG, Liechtenstein; and Ceram X mono, Dentsply Sirona, USA) have been used to look at the colour differences in four regions: the resin composite restorations, within the tooth, at the composite border area and at the tooth border area [37] .", [["tooth", "ANATOMY", 140, 145], ["tooth", "ANATOMY", 193, 198], ["premolar teeth", "ANATOMY", 221, 235], ["tooth", "ANATOMY", 603, 608], ["border area", "ANATOMY", 627, 638], ["tooth border area", "ANATOMY", 650, 667], ["tooth", "ORGAN", 140, 145], ["human", "ORGANISM", 215, 220], ["premolar teeth", "MULTI-TISSUE_STRUCTURE", 221, 235], ["tooth", "ORGAN", 603, 608], ["human", "SPECIES", 215, 220], ["human", "SPECIES", 215, 220], ["a synthetic restorative material", "TREATMENT", 89, 121], ["Colour adjustment", "PROBLEM", 156, 173], ["Extracted human premolar teeth", "PROBLEM", 205, 235], ["four different composite resin restorative materials", "TREATMENT", 240, 292], ["Clearfil Majesty", "TREATMENT", 346, 362], ["Tetric N Ceram", "TREATMENT", 401, 415], ["IvoclarVivadent AG, Liechtenstein", "TREATMENT", 417, 450], ["Ceram X mono", "TREATMENT", 456, 468], ["the resin composite restorations", "TREATMENT", 558, 590], ["the tooth", "PROBLEM", 599, 608], ["tooth", "ANATOMY", 193, 198], ["border", "ANATOMY_MODIFIER", 199, 205], ["premolar teeth", "OBSERVATION", 221, 235], ["restorations", "OBSERVATION", 578, 590], ["tooth", "ANATOMY", 603, 608], ["tooth", "ANATOMY", 650, 655], ["border", "ANATOMY_MODIFIER", 656, 662]]], ["It was found that colour changes occurred at the borders of the composite resin restoration with the adjacent tooth structure and on both sides of the restoration border, within the tooth structure and the composite restoration [37] .", [["tooth", "ANATOMY", 110, 115], ["tooth", "ANATOMY", 182, 187], ["tooth", "ORGAN", 110, 115], ["tooth", "ORGAN", 182, 187], ["colour changes", "PROBLEM", 18, 32], ["the composite resin restoration", "TREATMENT", 60, 91], ["colour", "OBSERVATION", 18, 24], ["borders", "OBSERVATION_MODIFIER", 49, 56], ["composite", "OBSERVATION_MODIFIER", 64, 73], ["resin restoration", "OBSERVATION", 74, 91], ["tooth structure", "OBSERVATION", 110, 125], ["restoration", "OBSERVATION", 151, 162], ["border", "OBSERVATION_MODIFIER", 163, 169], ["tooth", "ANATOMY", 182, 187], ["composite", "OBSERVATION_MODIFIER", 206, 215], ["restoration", "OBSERVATION_MODIFIER", 216, 227]]], ["Colour changes in the tooth structure adjacent to the restoration border were therefore due to colour reflection from the composite restoration.", [["tooth", "ANATOMY", 22, 27], ["tooth", "ORGAN", 22, 27], ["Colour changes in the tooth structure", "PROBLEM", 0, 37], ["the composite restoration", "PROBLEM", 118, 143], ["tooth", "ANATOMY", 22, 27], ["restoration", "OBSERVATION", 54, 65], ["composite restoration", "OBSERVATION", 122, 143]]], ["Colour changes within the border of the composite restoration were due to colour reflection from the tooth structure.", [["tooth", "ANATOMY", 101, 106], ["tooth", "ORGAN", 101, 106], ["Colour changes", "PROBLEM", 0, 14], ["the composite restoration", "TREATMENT", 36, 61], ["border", "OBSERVATION_MODIFIER", 26, 32], ["composite restoration", "OBSERVATION", 40, 61], ["colour reflection", "OBSERVATION", 74, 91], ["tooth", "ANATOMY", 101, 106]]], ["Colour changes in the tooth structure adjacent to the restoration border, were larger than the colour changes in the composite restoration adjacent to the border [37] .", [["tooth", "ANATOMY", 22, 27], ["tooth", "ORGAN", 22, 27], ["Colour changes in the tooth structure", "PROBLEM", 0, 37], ["tooth", "ANATOMY", 22, 27], ["restoration", "OBSERVATION_MODIFIER", 54, 65], ["border", "OBSERVATION_MODIFIER", 66, 72], ["larger", "OBSERVATION_MODIFIER", 79, 85], ["composite", "OBSERVATION_MODIFIER", 117, 126], ["restoration", "OBSERVATION", 127, 138], ["border", "ANATOMY_MODIFIER", 155, 161]]], ["A goniophotometer was also used to investigate how light was transmitted through the four resin composite materials [37] .", [["A goniophotometer", "TREATMENT", 0, 17]]], ["Ceram-X and Clearfil Majesty showed that light diffused more within the composite material than within Clearfil AP-X and Tetric N Ceram.", [["Ceram-X", "GENE_OR_GENE_PRODUCT", 0, 7], ["Ceram", "TEST", 0, 5], ["Clearfil Majesty", "TEST", 12, 28], ["Tetric N Ceram", "TREATMENT", 121, 135], ["light diffused", "OBSERVATION_MODIFIER", 41, 55]]], ["Different depths of cavity preparation (1.5 mm and 3 mm) were also investigated [37] .", [["Different depths of cavity preparation", "TREATMENT", 0, 38], ["depths", "OBSERVATION_MODIFIER", 10, 16], ["cavity", "OBSERVATION_MODIFIER", 20, 26], ["1.5 mm", "OBSERVATION_MODIFIER", 40, 46]]], ["For the 3 mm-deep cavities, the values for light diffusivity were compared with the colour differences measured for each material at the different border regions and it was concluded that the materials exhibiting good light diffusivity within the composite resin are able to create a chameleon effect as result of reflection of the surrounding tooth colour and projection of its own colour into the surrounding tooth structure, which would result in good colour matching [37] .", [["tooth", "ANATOMY", 344, 349], ["tooth", "ANATOMY", 411, 416], ["tooth", "ORGAN", 344, 349], ["tooth", "ORGAN", 411, 416], ["the 3 mm-deep cavities", "PROBLEM", 4, 26], ["light diffusivity", "TEST", 43, 60], ["a chameleon effect", "PROBLEM", 282, 300], ["the surrounding tooth colour", "PROBLEM", 328, 356], ["3 mm", "OBSERVATION_MODIFIER", 8, 12], ["deep", "ANATOMY_MODIFIER", 13, 17], ["cavities", "OBSERVATION", 18, 26], ["tooth colour", "OBSERVATION", 344, 356], ["tooth", "ANATOMY", 411, 416]]], ["On the otherhand, in the cavities that were 1.5 mm deep, it was found that light diffusivity had less influence on the colour changes and the colour rendition of the composite restorations was more influenced by the colour of the cavity floor.", [["cavity floor", "ANATOMY", 230, 242], ["cavity floor", "ORGANISM_SUBDIVISION", 230, 242], ["light diffusivity", "PROBLEM", 75, 92], ["the colour changes", "PROBLEM", 115, 133], ["the composite restorations", "PROBLEM", 162, 188], ["cavities", "ANATOMY_MODIFIER", 25, 33], ["1.5 mm", "OBSERVATION_MODIFIER", 44, 50], ["deep", "OBSERVATION_MODIFIER", 51, 55], ["light", "OBSERVATION_MODIFIER", 75, 80], ["diffusivity", "OBSERVATION_MODIFIER", 81, 92], ["composite restorations", "OBSERVATION", 166, 188], ["cavity", "ANATOMY", 230, 236]]], ["In the shallower cavity, the materials which exhibited better straight-line light transmission through the resin in this case, Tetric N Ceram, reflected the background colour better [37] .Colour adjustment at the restoration-tooth borderThe clinical relevance of these findings is that in order to successfully colour match a composite restoration with the surrounding tooth structure, consideration must be given to the surrounding tooth structure, which might have to be masked.", [["tooth", "ANATOMY", 225, 230], ["tooth", "ANATOMY", 369, 374], ["tooth", "ANATOMY", 433, 438], ["tooth", "ORGAN", 369, 374], ["tooth", "ORGAN", 433, 438], ["Tetric N Ceram", "TREATMENT", 127, 141], ["Colour adjustment", "PROBLEM", 188, 205], ["a composite restoration", "TREATMENT", 324, 347], ["shallower cavity", "ANATOMY", 7, 23], ["tooth", "ANATOMY", 225, 230], ["border", "ANATOMY_MODIFIER", 231, 237], ["composite restoration", "OBSERVATION", 326, 347], ["tooth structure", "OBSERVATION", 369, 384]]], ["Moreover, the straight-line and diffused light transmission properties of the composite resin materials must be considered.Further work has been carried out on how the colour of the surrounding tooth structure might influence the colour of the composite restoration border [38] .Effect of tooth age on colourHow the age of the tooth, in particular colour changes that occur in dentine with aging, through factors such as physiological aging and the creation of transparent dentine as a result of mineral deposition in the dentinal tubules, might influence the colour of the restoration at the borders has been investigated [38] .", [["tooth", "ANATOMY", 194, 199], ["tooth", "ANATOMY", 289, 294], ["tooth", "ANATOMY", 327, 332], ["dentine", "ANATOMY", 377, 384], ["dentine", "ANATOMY", 473, 480], ["dentinal tubules", "ANATOMY", 522, 538], ["tooth", "ORGAN", 194, 199], ["tooth", "ORGAN", 289, 294], ["tooth", "ORGAN", 327, 332], ["dentine", "TISSUE", 377, 384], ["dentine", "TISSUE", 473, 480], ["mineral", "TISSUE", 496, 503], ["dentinal tubules", "MULTI-TISSUE_STRUCTURE", 522, 538], ["the straight-line", "TREATMENT", 10, 27], ["the composite resin materials", "TREATMENT", 74, 103], ["the tooth", "PROBLEM", 323, 332], ["physiological aging", "TREATMENT", 421, 440], ["transparent dentine", "PROBLEM", 461, 480], ["mineral deposition in the dentinal tubules", "PROBLEM", 496, 538], ["straight", "OBSERVATION_MODIFIER", 14, 22], ["diffused", "OBSERVATION_MODIFIER", 32, 40], ["light", "OBSERVATION_MODIFIER", 41, 46], ["resin materials", "OBSERVATION", 88, 103], ["must be considered", "UNCERTAINTY", 104, 122], ["tooth", "ANATOMY", 327, 332], ["mineral deposition", "OBSERVATION", 496, 514], ["dentinal tubules", "ANATOMY", 522, 538], ["restoration", "OBSERVATION", 574, 585]]], ["Human premolars extracted for orthodontic reasons (younger teeth, age 20-28 years) and premolar teeth extracted for periodontal reasons (older teeth, age 45-69 years) were used along with four direct composite resins, Kalore (GC Corporation, Japan), Solare (GC Corporation, Japan), Clearfil Majesty (Kuraray Noritake Dental Inc., Japan) and Beautiful II (Shofu, Japan)) all of shade A2 [38] .", [["premolars", "ANATOMY", 6, 15], ["teeth", "ANATOMY", 59, 64], ["premolar teeth", "ANATOMY", 87, 101], ["periodontal", "ANATOMY", 116, 127], ["teeth", "ANATOMY", 143, 148], ["Human", "ORGANISM", 0, 5], ["premolars", "ORGAN", 6, 15], ["teeth", "ORGAN", 59, 64], ["premolar", "MULTI-TISSUE_STRUCTURE", 87, 95], ["teeth", "ORGAN", 96, 101], ["teeth", "ORGAN", 143, 148], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human premolars", "TREATMENT", 0, 15], ["premolar teeth", "PROBLEM", 87, 101], ["periodontal reasons", "PROBLEM", 116, 135], ["four direct composite resins", "TREATMENT", 188, 216], ["Kalore (GC Corporation", "TREATMENT", 218, 240], ["Solare (GC Corporation", "TREATMENT", 250, 272], ["Clearfil", "TREATMENT", 282, 290], ["premolar teeth", "ANATOMY", 87, 101]]], ["All four materials exhibited colour differences between the restoration borders and the dentine and composite resin in both the \"younger\" and \"older\" teeth, indicating \"colour shifting\" had occurred at the restoration borders [38] .", [["dentine", "ANATOMY", 88, 95], ["teeth", "ANATOMY", 150, 155], ["dentine", "TISSUE", 88, 95], ["teeth", "ORGAN", 150, 155], ["colour shifting\"", "PROBLEM", 169, 185], ["colour", "OBSERVATION_MODIFIER", 29, 35], ["differences", "OBSERVATION_MODIFIER", 36, 47], ["restoration", "OBSERVATION_MODIFIER", 60, 71], ["borders", "OBSERVATION_MODIFIER", 72, 79]]], ["However, when the \"younger\" and \"older\" teeth were looked at, colour differences in the older teeth at the restoration borders were greater than those for the \"younger\" teeth, indicating that potential for colour adjustment in older teeth would be less than it would be for younger teeth [38] .", [["teeth", "ANATOMY", 40, 45], ["teeth", "ANATOMY", 94, 99], ["teeth", "ANATOMY", 169, 174], ["teeth", "ANATOMY", 233, 238], ["teeth", "ANATOMY", 282, 287], ["teeth", "ORGAN", 40, 45], ["teeth", "ORGAN", 94, 99], ["teeth", "ORGAN", 169, 174], ["teeth", "ORGAN", 233, 238], ["teeth", "ORGAN", 282, 287], ["colour adjustment in older teeth", "PROBLEM", 206, 238], ["restoration", "OBSERVATION_MODIFIER", 107, 118], ["borders", "OBSERVATION_MODIFIER", 119, 126], ["greater", "OBSERVATION_MODIFIER", 132, 139]]], ["The straight-line and diffusivity light transmission properties of the young and old dentine were also investigated.", [["dentine", "ANATOMY", 85, 92], ["dentine", "TISSUE", 85, 92], ["The straight-line", "TREATMENT", 0, 17], ["old dentine", "PROBLEM", 81, 92], ["straight", "OBSERVATION_MODIFIER", 4, 12], ["line", "OBSERVATION", 13, 17]]], ["The older dentine exhibited higher straightline light transmission values than younger dentine, indicating better light transmission, whereas the younger dentine exhibited better light diffusion values, indicating less light transmission [38] .", [["dentine", "ANATOMY", 10, 17], ["dentine", "ANATOMY", 87, 94], ["dentine", "ANATOMY", 154, 161], ["dentine", "TISSUE", 10, 17], ["dentine", "TISSUE", 87, 94], ["dentine", "TISSUE", 154, 161], ["higher", "OBSERVATION_MODIFIER", 28, 34]]], ["Clinically, this would mean that better colour matching would be required when restoring older teeth compared to younger teeth.Effect of enamel margins on tooth colourThe effect of the enamel margin on colour adjustment has also been investigated [39] .", [["teeth", "ANATOMY", 95, 100], ["teeth", "ANATOMY", 121, 126], ["enamel", "ANATOMY", 137, 143], ["tooth", "ANATOMY", 155, 160], ["enamel", "ANATOMY", 185, 191], ["teeth", "ORGAN", 95, 100], ["teeth", "ORGAN", 121, 126], ["enamel margins", "MULTI-TISSUE_STRUCTURE", 137, 151], ["tooth", "ORGAN", 155, 160], ["enamel margin", "MULTI-TISSUE_STRUCTURE", 185, 198], ["restoring older teeth", "PROBLEM", 79, 100], ["enamel margins", "PROBLEM", 137, 151], ["tooth colour", "TEST", 155, 167], ["the enamel margin", "PROBLEM", 181, 198], ["colour adjustment", "TREATMENT", 202, 219], ["enamel margins", "OBSERVATION", 137, 151], ["tooth colour", "OBSERVATION_MODIFIER", 155, 167], ["enamel", "OBSERVATION_MODIFIER", 185, 191], ["margin", "OBSERVATION_MODIFIER", 192, 198]]], ["Three types of enamel margin (non-bevel, 45-degree bevel and 45-degree reverse-bevel) and four composite resin materials (Estelite Asteria A2B, Tokuyama Dental Corp., Japan; Estelite Pro A2E, Tokuyama Dental Corp., Japan; Kalore E2, GC Corporation, Japan; and Clearfil Majesty ES-2 Premium A2E, Kuraray Noritake Dental Inc., Japan) were studied in bovine enamel [39] .", [["enamel margin", "ANATOMY", 15, 28], ["enamel", "ANATOMY", 355, 361], ["enamel margin", "MULTI-TISSUE_STRUCTURE", 15, 28], ["bovine", "ORGANISM", 348, 354], ["bovine", "SPECIES", 348, 354], ["bevel", "TEST", 34, 39], ["bevel", "TEST", 51, 56], ["four composite resin materials", "TREATMENT", 90, 120], ["Kalore E2", "TREATMENT", 222, 231], ["GC Corporation", "TREATMENT", 233, 247], ["enamel", "OBSERVATION_MODIFIER", 15, 21], ["margin", "OBSERVATION_MODIFIER", 22, 28]]], ["The study found that the enamel margin configuration affected colour adjustment at the borders of the restoration with the bevel preparation improving colour adjustment at the borders [39] .", [["enamel margin", "ANATOMY", 25, 38], ["enamel", "TISSUE", 25, 31], ["The study", "TEST", 0, 9], ["the enamel margin configuration", "PROBLEM", 21, 52], ["the bevel preparation", "TREATMENT", 119, 140], ["enamel", "OBSERVATION_MODIFIER", 25, 31], ["margin", "OBSERVATION_MODIFIER", 32, 38], ["configuration", "OBSERVATION_MODIFIER", 39, 52], ["affected", "OBSERVATION_MODIFIER", 53, 61], ["colour", "OBSERVATION_MODIFIER", 62, 68], ["adjustment", "OBSERVATION_MODIFIER", 69, 79], ["borders", "OBSERVATION_MODIFIER", 87, 94], ["restoration", "OBSERVATION", 102, 113]]], ["With regards to the four composite resin materials, they had different values for straight-line light transmission and light diffusivity within the materials and the degree of colour adjustment at the borders of the restoration was material dependent [39] .Effect of enamel margins on tooth colourIf a cavity involved the labial aspect of the tooth, which is likely to be highly visible to the patient, then the orientation of the enamel prisms would differ depending on whether the cavity margin was in coronal or cervical regions of the enamel.", [["enamel", "ANATOMY", 267, 273], ["tooth", "ANATOMY", 285, 290], ["cavity", "ANATOMY", 302, 308], ["labial aspect", "ANATOMY", 322, 335], ["tooth", "ANATOMY", 343, 348], ["enamel", "ANATOMY", 431, 437], ["coronal", "ANATOMY", 504, 511], ["cervical", "ANATOMY", 515, 523], ["enamel", "ANATOMY", 539, 545], ["enamel margins", "MULTI-TISSUE_STRUCTURE", 267, 281], ["tooth", "ORGAN", 285, 290], ["cavity", "ORGAN", 302, 308], ["labial", "ORGAN", 322, 328], ["tooth", "ORGAN", 343, 348], ["patient", "ORGANISM", 394, 401], ["cavity margin", "MULTI-TISSUE_STRUCTURE", 483, 496], ["cervical", "ORGAN", 515, 523], ["enamel", "TISSUE", 539, 545], ["patient", "SPECIES", 394, 401], ["the four composite resin materials", "TREATMENT", 16, 50], ["straight-line light transmission", "TREATMENT", 82, 114], ["light diffusivity within the materials", "PROBLEM", 119, 157], ["colour adjustment", "PROBLEM", 176, 193], ["material dependent", "PROBLEM", 232, 250], ["enamel margins", "PROBLEM", 267, 281], ["tooth colour", "TEST", 285, 297], ["a cavity", "PROBLEM", 300, 308], ["light diffusivity", "OBSERVATION_MODIFIER", 119, 136], ["colour adjustment", "OBSERVATION", 176, 193], ["borders", "OBSERVATION_MODIFIER", 201, 208], ["restoration", "OBSERVATION", 216, 227], ["enamel margins", "OBSERVATION", 267, 281], ["tooth colour", "OBSERVATION_MODIFIER", 285, 297], ["cavity", "OBSERVATION", 302, 308], ["labial", "ANATOMY_MODIFIER", 322, 328], ["tooth", "ANATOMY", 343, 348], ["likely to be", "UNCERTAINTY", 359, 371], ["cervical", "ANATOMY", 515, 523], ["regions", "ANATOMY_MODIFIER", 524, 531]]], ["Enamel prisms are the most important structure in enamel for influencing light scattering, an important optical property.The effect of enamel prism orientation on colour shifting at the border of composite resin restorations was investigated using bovine enameland four composite resin materials (Estelite Asteria A2B, Estelite Pro A2E, Kalore E2 and Clearfil Majesty ES-2 Premium A2E) bonded using a one -step self-etching adhesive (Clearfil SE One) [40] .", [["enamel", "ANATOMY", 50, 56], ["enamel", "ANATOMY", 135, 141], ["Kalore E2", "CHEMICAL", 337, 346], ["enamel", "TISSUE", 50, 56], ["enamel", "TISSUE", 135, 141], ["bovine", "ORGANISM", 248, 254], ["bovine", "SPECIES", 248, 254], ["bovine", "SPECIES", 248, 254], ["Enamel prisms", "PROBLEM", 0, 13], ["enamel prism orientation", "PROBLEM", 135, 159], ["colour shifting", "PROBLEM", 163, 178], ["composite resin restorations", "TREATMENT", 196, 224], ["bovine enameland four composite resin materials", "TREATMENT", 248, 295], ["Estelite", "TEST", 297, 305], ["A2B", "TEST", 314, 317], ["Estelite Pro A2E", "TREATMENT", 319, 335], ["Kalore E2", "TREATMENT", 337, 346], ["a one -step self-etching adhesive (Clearfil SE", "TREATMENT", 399, 445], ["most important", "OBSERVATION_MODIFIER", 22, 36], ["resin restorations", "OBSERVATION", 206, 224]]], ["In the coronal enamel, the prisms would be cut diagonally, whereas in the cervical region, they would have been cut longitudinally [40] .", [["coronal enamel", "ANATOMY", 7, 21], ["cervical region", "ANATOMY", 74, 89], ["coronal enamel", "MULTI-TISSUE_STRUCTURE", 7, 21], ["cervical", "ORGAN", 74, 82], ["cervical", "ANATOMY", 74, 82], ["region", "ANATOMY_MODIFIER", 83, 89]]], ["Two sizes of composite restoration in enamel were prepared; 1 mm wide and 3 mm wide, both 1 mm thick.", [["enamel", "ANATOMY", 38, 44], ["enamel", "ORGAN", 38, 44], ["composite restoration in enamel", "TREATMENT", 13, 44], ["sizes", "OBSERVATION_MODIFIER", 4, 9], ["composite restoration", "OBSERVATION", 13, 34], ["enamel", "ANATOMY", 38, 44], ["3 mm", "OBSERVATION_MODIFIER", 74, 78], ["wide", "OBSERVATION_MODIFIER", 79, 83], ["1 mm", "OBSERVATION_MODIFIER", 90, 94]]], ["The colour shift in the L* value was greater in the enamel side of the restoration [40] .", [["enamel", "ANATOMY", 52, 58], ["The colour shift", "TEST", 0, 16], ["the L* value", "TEST", 20, 32], ["colour", "OBSERVATION_MODIFIER", 4, 10], ["shift", "OBSERVATION_MODIFIER", 11, 16], ["L", "ANATOMY_MODIFIER", 24, 25], ["greater", "OBSERVATION_MODIFIER", 37, 44]]], ["The colour shift in the L* value was also significantly greater at the cervical border than the coronal border and the difference in value was also larger in the small cavity [40] .", [["cervical border", "ANATOMY", 71, 86], ["coronal border", "ANATOMY", 96, 110], ["cervical border", "MULTI-TISSUE_STRUCTURE", 71, 86], ["coronal border", "MULTI-TISSUE_STRUCTURE", 96, 110], ["The colour shift", "TEST", 0, 16], ["the L* value", "TEST", 20, 32], ["colour", "OBSERVATION_MODIFIER", 4, 10], ["shift", "OBSERVATION", 11, 16], ["L", "ANATOMY_MODIFIER", 24, 25], ["significantly", "OBSERVATION_MODIFIER", 42, 55], ["greater", "OBSERVATION_MODIFIER", 56, 63], ["cervical", "ANATOMY", 71, 79], ["border", "ANATOMY_MODIFIER", 80, 86], ["difference", "OBSERVATION_MODIFIER", 119, 129], ["larger", "OBSERVATION_MODIFIER", 148, 154], ["small", "OBSERVATION_MODIFIER", 162, 167], ["cavity", "OBSERVATION_MODIFIER", 168, 174]]], ["Clinically this would indicate that the potential for colour adjustment, particularly lightness, is greater in the coronal border region of a composite restoration because the gentle colour shifting and larger area of colour shifting would make the restoration border less obvious.Effect of layering composite resin on colourWith regards to placement of the composite resin, as mentioned previously, placing the composite resin in increments can aid colour matching, ensure adequate polymerisation of the increment and minimize the effect of contraction stress on adhesion to cavity walls [41] .", [["colour adjustment", "PROBLEM", 54, 71], ["a composite restoration", "TREATMENT", 140, 163], ["the gentle colour shifting", "PROBLEM", 172, 198], ["colour shifting", "PROBLEM", 218, 233], ["layering composite resin", "TREATMENT", 291, 315], ["placement of the composite resin", "TREATMENT", 341, 373], ["the composite resin in increments", "TREATMENT", 408, 441], ["contraction stress", "PROBLEM", 542, 560], ["greater", "OBSERVATION_MODIFIER", 100, 107], ["composite restoration", "OBSERVATION", 142, 163], ["gentle", "OBSERVATION_MODIFIER", 176, 182], ["colour", "OBSERVATION_MODIFIER", 183, 189], ["shifting", "OBSERVATION_MODIFIER", 190, 198], ["larger", "OBSERVATION_MODIFIER", 203, 209], ["area", "OBSERVATION_MODIFIER", 210, 214], ["colour shifting", "OBSERVATION", 218, 233], ["layering", "OBSERVATION_MODIFIER", 291, 299], ["composite", "OBSERVATION_MODIFIER", 300, 309], ["resin", "OBSERVATION_MODIFIER", 310, 315]]], ["The effect of layering composite resin using both conventional and bulk-filling techniques on translucency and colour appearance has been investigated [41] .", [["layering composite resin", "TREATMENT", 14, 38], ["both conventional and bulk-filling techniques", "TREATMENT", 45, 90], ["translucency", "TEST", 94, 106], ["layering", "OBSERVATION_MODIFIER", 14, 22], ["composite", "OBSERVATION_MODIFIER", 23, 32], ["resin", "OBSERVATION_MODIFIER", 33, 38], ["filling techniques", "OBSERVATION", 72, 90]]], ["Three resin composites (Estelite Sigma, Tokuyama Dental Corp., Japan; Beautiful II, Shofu, Japan; Clearfil Majesty, Kuraray Noritake Dental Inc., Japan) in both A2 and OA2 shades were evaluated [41] .", [["Three resin composites", "TREATMENT", 0, 22]]], ["The universal (A2) shade specimens exhibited higher translucency than the opaque-shade (OA2) specimens, which would indicate that the OA2 shades would be better for masking colour [41] .", [["specimens", "ANATOMY", 25, 34], ["specimens", "ANATOMY", 93, 102], ["The universal (A2) shade specimens", "TEST", 0, 34], ["higher translucency", "PROBLEM", 45, 64], ["the OA2 shades", "PROBLEM", 130, 144], ["masking colour", "TEST", 165, 179], ["higher translucency", "OBSERVATION", 45, 64]]], ["In addition, layering in 1 mm-thick incre-ments resulted in less transparency than a 2mm-thick increment indicating light diffusion occurring at the composite-composite joint [41] .", [["layering in 1 mm-thick incre-ments", "PROBLEM", 13, 47], ["a 2mm-thick increment", "PROBLEM", 83, 104], ["light diffusion", "PROBLEM", 116, 131], ["layering", "OBSERVATION_MODIFIER", 13, 21], ["1 mm", "OBSERVATION_MODIFIER", 25, 29], ["less", "OBSERVATION_MODIFIER", 60, 64], ["transparency", "OBSERVATION_MODIFIER", 65, 77], ["light diffusion", "OBSERVATION_MODIFIER", 116, 131], ["composite joint", "ANATOMY", 159, 174]]], ["Clinically this means that after a shade of composite resin is chosen, the final colour might change depending on how thick the increments of composite resin were when they were placed.Effect of layering composite resin on colourFinally, a restoration will be viewed by the patient from many directions and the effect of the direction of the light illuminating a direct composite restoration has been investigated [36] .", [["patient", "ORGANISM", 274, 281], ["patient", "SPECIES", 274, 281], ["a shade of composite resin", "TREATMENT", 33, 59], ["composite resin", "TREATMENT", 142, 157], ["layering composite resin", "PROBLEM", 195, 219], ["a restoration", "TREATMENT", 238, 251], ["a direct composite restoration", "TREATMENT", 361, 391], ["layering", "OBSERVATION_MODIFIER", 195, 203], ["composite", "OBSERVATION_MODIFIER", 204, 213], ["resin", "OBSERVATION_MODIFIER", 214, 219]]], ["It was found that the colour appearance at the border of composite resin restorations is influenced by the light illuminating direction in conjunction with the enamel rod orientation [36] .", [["enamel", "ANATOMY", 160, 166], ["the colour appearance", "PROBLEM", 18, 39], ["composite resin restorations", "TREATMENT", 57, 85], ["colour", "OBSERVATION_MODIFIER", 22, 28], ["border", "OBSERVATION_MODIFIER", 47, 53], ["composite", "OBSERVATION", 57, 66], ["resin restorations", "OBSERVATION", 67, 85], ["enamel rod", "OBSERVATION", 160, 170]]], ["In other words, the appearance of a patient's restoration around the cavity margin, particularly towards the coronal aspect, will differ depending on the angle at which it is viewed by another person.Conflicts of interestNone.", [["cavity margin", "ANATOMY", 69, 82], ["patient", "ORGANISM", 36, 43], ["cavity margin", "MULTI-TISSUE_STRUCTURE", 69, 82], ["patient", "SPECIES", 36, 43], ["person", "SPECIES", 193, 199], ["a patient's restoration", "PROBLEM", 34, 57], ["cavity", "OBSERVATION_MODIFIER", 69, 75], ["margin", "OBSERVATION_MODIFIER", 76, 82]]]], "cc65f691d7506313b318e2107babc52794b212bd": [["Patients were dying of respiratory failure.", [["respiratory", "ANATOMY", 23, 34], ["respiratory failure", "DISEASE", 23, 42], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["respiratory failure", "PROBLEM", 23, 42], ["respiratory failure", "OBSERVATION", 23, 42]]], ["At Blegdam Hospital, Copenhagen in 1952, Bj\u00f8rn Ibsen's use of invasive positive pressure ventilation, then revolutionary, saved countless lives from polio and initiated the development of intensive care units (ICUs) [1] .Dear Editor,In 2020, ICUs around the world are flooded with coronavirus disease 2019 (COVID-19).", [["polio", "DISEASE", 149, 154], ["coronavirus disease", "DISEASE", 281, 300], ["invasive positive pressure ventilation", "TREATMENT", 62, 100], ["polio", "TREATMENT", 149, 154], ["coronavirus disease", "PROBLEM", 281, 300], ["COVID", "TEST", 307, 312], ["pressure ventilation", "OBSERVATION", 80, 100], ["coronavirus disease", "OBSERVATION", 281, 300]]], ["The response to this pandemic has focused on increasing availability of intensivists, ICU beds, and ventilators.", [["ICU beds", "TREATMENT", 86, 94], ["ventilators", "TREATMENT", 100, 111]]], ["So, in keeping with Maslow's law of the hammer, these patients are generally being treated as if they have acute respiratory distress syndrome (ARDS).Dear Editor,However, the ' ARDS' caused by COVID-19 is atypical [2, 3] .", [["respiratory", "ANATOMY", 113, 124], ["acute respiratory distress syndrome", "DISEASE", 107, 142], ["ARDS", "DISEASE", 144, 148], ["ARDS", "DISEASE", 177, 181], ["COVID-19", "CHEMICAL", 193, 201], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["acute respiratory distress syndrome", "PROBLEM", 107, 142], ["ARDS", "PROBLEM", 144, 148], ["the ' ARDS'", "PROBLEM", 171, 182], ["COVID", "TEST", 193, 198], ["acute", "OBSERVATION_MODIFIER", 107, 112], ["respiratory distress", "OBSERVATION", 113, 133]]], ["They describe two distinct patterns of respiratory COVID-19 (type L, low elastance and type H, high elastance) [2] .", [["respiratory COVID", "TEST", 39, 56], ["type L, low elastance", "PROBLEM", 61, 82], ["type H, high elastance)", "PROBLEM", 87, 110], ["distinct", "OBSERVATION_MODIFIER", 18, 26], ["respiratory COVID", "OBSERVATION", 39, 56], ["low elastance", "OBSERVATION_MODIFIER", 69, 82]]], ["However, there is a 'hole' in their argument.", [["a 'hole'", "TREATMENT", 18, 26]]], ["A series of patients with COVID-19, also described by Gattinoni's group; had a mean shunt fraction of 0.50 \u00b1 0.11 despite relatively preserved pulmonary compliance (50.2 \u00b1 14.3 ml/cmH 2 O) [3] .Dear Editor,The cause of this shunt is likely to be multifactorial.", [["pulmonary", "ANATOMY", 143, 152], ["patients", "ORGANISM", 12, 20], ["pulmonary", "ORGAN", 143, 152], ["patients", "SPECIES", 12, 20], ["COVID", "TEST", 26, 31], ["a mean shunt fraction", "TEST", 77, 98], ["this shunt", "TREATMENT", 219, 229], ["pulmonary", "ANATOMY", 143, 152], ["shunt", "OBSERVATION", 224, 229], ["likely to be", "UNCERTAINTY", 233, 245], ["multifactorial", "OBSERVATION_MODIFIER", 246, 260]]], ["Right-to-left (RTL) shunt may be extrapulmonary (EPS) and/or intrapulmonary (IPS).", [["extrapulmonary", "ANATOMY", 33, 47], ["intrapulmonary", "ANATOMY", 61, 75], ["extrapulmonary", "DISEASE", 33, 47], ["EPS", "DISEASE", 49, 52], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 61, 75], ["Right-to-left (RTL) shunt", "TREATMENT", 0, 25], ["intrapulmonary (IPS)", "TREATMENT", 61, 81], ["left", "ANATOMY_MODIFIER", 9, 13], ["shunt", "OBSERVATION", 20, 25], ["may be", "UNCERTAINTY", 26, 32], ["extrapulmonary", "OBSERVATION", 33, 47], ["intrapulmonary", "ANATOMY", 61, 75]]], ["A degree of IPS is inevitable.", [["A degree of IPS", "TREATMENT", 0, 15], ["degree", "OBSERVATION_MODIFIER", 2, 8], ["IPS", "OBSERVATION", 12, 15]]], ["However, EPS may be present in some patients with COVID-19.Dear Editor,Extrapulmonary shunt is often intracardiac (ICS) [4] .", [["intracardiac", "ANATOMY", 101, 113], ["EPS", "CHEMICAL", 9, 12], ["COVID-19", "CHEMICAL", 50, 58], ["EPS", "SIMPLE_CHEMICAL", 9, 12], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["EPS", "TEST", 9, 12], ["COVID", "TEST", 50, 55], ["Extrapulmonary shunt", "TREATMENT", 71, 91], ["Extrapulmonary", "ANATOMY", 71, 85], ["shunt", "OBSERVATION", 86, 91]]], ["Echocardiography with bubble contrast, a minimally invasive bedside test, can be used to detect ICS [4] .", [["Echocardiography", "TEST", 0, 16], ["bubble contrast", "TEST", 22, 37], ["a minimally invasive bedside test", "TEST", 39, 72]]], ["This is most commonly due to patent foramen ovale (PFO) [4] .", [["patent foramen ovale", "DISEASE", 29, 49], ["PFO", "DISEASE", 51, 54], ["foramen ovale", "SIMPLE_CHEMICAL", 36, 49], ["patent foramen ovale", "PROBLEM", 29, 49], ["most commonly due to", "UNCERTAINTY", 8, 28], ["patent", "OBSERVATION", 29, 35], ["foramen", "ANATOMY_MODIFIER", 36, 43], ["ovale", "OBSERVATION", 44, 49]]], ["Hypoxia is an uncommon complication of PFO unless a precipitant such as COVID-19 initiates RTLICS.", [["Hypoxia", "DISEASE", 0, 7], ["PFO", "DISEASE", 39, 42], ["COVID-19", "CHEMICAL", 72, 80], ["COVID-19", "CHEMICAL", 72, 80], ["Hypoxia", "PROBLEM", 0, 7], ["an uncommon complication", "PROBLEM", 11, 35], ["PFO", "PROBLEM", 39, 42], ["COVID", "TEST", 72, 77], ["uncommon", "OBSERVATION_MODIFIER", 14, 22], ["complication", "OBSERVATION", 23, 35], ["PFO", "OBSERVATION", 39, 42]]], ["However, because the prevalence of PFO in the general population is 20-30%, EPS may be relevant to many patients with COVID-19 worldwide.Dear Editor,We therefore suggest that respiratory failure should be classified into four dynamic phenotypes based on total shunt (i.e. IPS \u00b1 EPS) and lung mechanics:Dear Editor,Type L respiratory failure \u2022 due to IPS alone (Subtype LPS) \u2022 due to IPS and EPS (Subtype LES)Dear Editor,Type H respiratory failure \u2022 due to IPS alone (Subtype HPS) \u2022 due to IPS and EPS (Subtype HES)Dear Editor,Worsening pulmonary pathology progresses from Type L to H. Increasing airway pressures could induce HES [5] .", [["respiratory", "ANATOMY", 175, 186], ["lung", "ANATOMY", 287, 291], ["pulmonary", "ANATOMY", 536, 545], ["airway", "ANATOMY", 596, 602], ["PFO", "DISEASE", 35, 38], ["EPS", "DISEASE", 76, 79], ["respiratory failure", "DISEASE", 175, 194], ["Type L respiratory failure", "DISEASE", 314, 340], ["EPS", "DISEASE", 391, 394], ["respiratory failure", "DISEASE", 427, 446], ["HPS", "DISEASE", 475, 478], ["EPS", "DISEASE", 497, 500], ["HES", "DISEASE", 626, 629], ["IPS", "CHEMICAL", 350, 353], ["patients", "ORGANISM", 104, 112], ["lung", "ORGAN", 287, 291], ["pulmonary", "ORGAN", 536, 545], ["airway", "MULTI-TISSUE_STRUCTURE", 596, 602], ["patients", "SPECIES", 104, 112], ["PFO", "PROBLEM", 35, 38], ["EPS", "TEST", 76, 79], ["COVID", "TEST", 118, 123], ["respiratory failure", "PROBLEM", 175, 194], ["total shunt", "TREATMENT", 254, 265], ["IPS \u00b1 EPS", "TREATMENT", 272, 281], ["Type L respiratory failure", "PROBLEM", 314, 340], ["IPS alone", "TREATMENT", 350, 359], ["IPS", "PROBLEM", 383, 386], ["Type H respiratory failure", "PROBLEM", 420, 446], ["IPS", "PROBLEM", 456, 459], ["IPS", "PROBLEM", 489, 492], ["Worsening pulmonary pathology", "PROBLEM", 526, 555], ["airway pressures", "TREATMENT", 596, 612], ["PFO", "OBSERVATION", 35, 38], ["respiratory failure", "OBSERVATION", 175, 194], ["lung", "ANATOMY", 287, 291], ["respiratory", "ANATOMY", 321, 332], ["failure", "OBSERVATION", 333, 340], ["respiratory", "ANATOMY", 427, 438], ["failure", "OBSERVATION", 439, 446], ["Worsening", "OBSERVATION_MODIFIER", 526, 535], ["pulmonary", "ANATOMY", 536, 545], ["pathology", "OBSERVATION", 546, 555], ["airway", "ANATOMY", 596, 602], ["pressures", "OBSERVATION", 603, 612]]], ["There are few data to guide management of patients with EPS.", [["EPS", "DISEASE", 56, 59], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["EPS", "TEST", 56, 59]]], ["However, the standard approach to refractory hypoxia may exacerbate RTLICS whilst trying to reduce IPS [5] .", [["hypoxia", "DISEASE", 45, 52], ["RTLICS", "DISEASE", 68, 74], ["refractory hypoxia", "PROBLEM", 34, 52]]], ["The patients with RTLICS respond poorly to positive end expiratory pressure are ventilated longer, and stay longer in ICU [5] .", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["RTLICS", "TREATMENT", 18, 24], ["positive end expiratory pressure", "TREATMENT", 43, 75]]], ["Reducing airway pressures may allow reversion to HPS.", [["airway", "ANATOMY", 9, 15], ["HPS", "DISEASE", 49, 52], ["airway", "MULTI-TISSUE_STRUCTURE", 9, 15], ["Reducing airway pressures", "TREATMENT", 0, 25], ["HPS", "PROBLEM", 49, 52], ["airway", "ANATOMY", 9, 15], ["pressures", "OBSERVATION", 16, 25]]], ["As the lung injury resolves, both total shunt and lung mechanics may normalise.", [["lung", "ANATOMY", 7, 11], ["lung", "ANATOMY", 50, 54], ["lung injury", "DISEASE", 7, 18], ["lung", "ORGAN", 7, 11], ["lung", "ORGAN", 50, 54], ["the lung injury", "PROBLEM", 3, 18], ["both total shunt", "TREATMENT", 29, 45], ["lung", "ANATOMY", 7, 11], ["injury", "OBSERVATION", 12, 18], ["total", "OBSERVATION_MODIFIER", 34, 39], ["shunt", "OBSERVATION", 40, 45], ["lung", "ANATOMY", 50, 54], ["mechanics", "OBSERVATION", 55, 64]]]], "PMC549591": [["IntroductionDuring infectious disease outbreaks, due to either new or established agents, extensive information gathering is required to enable identification of the source, transmission routes, and the effect of containment policies.", [["infectious disease outbreaks", "DISEASE", 19, 47], ["IntroductionDuring infectious disease outbreaks", "PROBLEM", 0, 47], ["containment policies", "TREATMENT", 213, 233]]], ["It is becoming increasingly clear that traditional approaches based on travel and contact tracing are not sufficient for tracking an outbreak.", [["contact tracing", "TEST", 82, 97], ["increasingly", "OBSERVATION_MODIFIER", 15, 27], ["clear", "OBSERVATION", 28, 33]]], ["New sequence-based techniques for pathogen detection and identification have the potential to become perhaps the most important component of these investigations, as demonstrated in the recent worldwide effort in fighting the epidemic of severe acute respiratory syndrome (SARS).", [["acute respiratory syndrome", "DISEASE", 245, 271], ["SARS", "DISEASE", 273, 277], ["pathogen detection", "TEST", 34, 52], ["these investigations", "TEST", 141, 161], ["severe acute respiratory syndrome", "PROBLEM", 238, 271], ["severe", "OBSERVATION_MODIFIER", 238, 244], ["acute", "OBSERVATION_MODIFIER", 245, 250], ["respiratory syndrome", "OBSERVATION", 251, 271]]], ["The discovery of the SARS coronavirus (SARS-CoV) as the etiological agent for SARS was a major breakthrough [1], which was quickly followed by the successful sequencing of the whole genome of the virus [2,3].", [["SARS coronavirus", "DISEASE", 21, 37], ["SARS", "DISEASE", 39, 43], ["SARS", "DISEASE", 78, 82], ["SARS coronavirus", "ORGANISM", 21, 37], ["SARS-CoV", "ORGANISM", 39, 47], ["SARS coronavirus", "SPECIES", 21, 37], ["SARS-CoV", "SPECIES", 39, 47], ["the SARS coronavirus", "PROBLEM", 17, 37], ["SARS", "PROBLEM", 78, 82]]], ["Genome sequence comparison between this new coronavirus and the three known classes of coronavirus revealed a similar genome structure, but minimum homology at the amino acid level, strongly suggesting that the SARS-CoV was a new class of coronavirus [2,3,4].", [["amino acid", "CHEMICAL", 164, 174], ["SARS", "DISEASE", 211, 215], ["amino acid", "CHEMICAL", 164, 174], ["coronavirus", "ORGANISM", 44, 55], ["coronavirus", "ORGANISM", 87, 98], ["amino acid", "AMINO_ACID", 164, 174], ["SARS-CoV", "ORGANISM", 211, 219], ["coronavirus", "ORGANISM", 239, 250], ["coronavirus", "SPECIES", 44, 55], ["SARS-CoV", "SPECIES", 211, 219], ["this new coronavirus", "PROBLEM", 35, 55], ["coronavirus", "PROBLEM", 87, 98], ["the amino acid level", "TEST", 160, 180], ["the SARS-CoV", "PROBLEM", 207, 219], ["coronavirus", "PROBLEM", 239, 250], ["genome structure", "OBSERVATION", 118, 134]]], ["A comparative sequence analysis of 14 SARS isolates from different countries suggested a moderate genetic diversity among the SARS isolates and thus implied a slow evolution of the SARS-CoV genome [5].", [["SARS", "DISEASE", 38, 42], ["SARS", "DISEASE", 126, 130], ["SARS", "DISEASE", 181, 185], ["SARS-CoV", "ORGANISM", 181, 189], ["SARS-CoV genome", "DNA", 181, 196], ["SARS-CoV", "SPECIES", 181, 189], ["A comparative sequence analysis", "TEST", 0, 31], ["SARS isolates", "TEST", 38, 51], ["a moderate genetic diversity", "PROBLEM", 87, 115], ["the SARS isolates", "PROBLEM", 122, 139], ["the SARS", "PROBLEM", 177, 185], ["moderate", "OBSERVATION_MODIFIER", 89, 97]]], ["Furthermore, sequence variation analyses of SARS-CoV isolates demonstrated that common genetic variations in the SARS-CoV genome could be used as \u201cmolecular fingerprints\u201d to partition the viral isolates into different genetic lineages, track the transmission of a specific viral lineage, and infer the origin of infection [5,6].", [["SARS", "DISEASE", 113, 117], ["infection", "DISEASE", 312, 321], ["SARS-CoV", "ORGANISM", 44, 52], ["SARS-CoV", "ORGANISM", 113, 121], ["SARS-CoV genome", "DNA", 113, 128], ["viral lineage", "CELL_TYPE", 273, 286], ["SARS-CoV", "SPECIES", 44, 52], ["SARS-CoV", "SPECIES", 113, 121], ["sequence variation analyses", "TEST", 13, 40], ["SARS", "PROBLEM", 44, 48], ["CoV isolates", "TEST", 49, 61], ["common genetic variations", "PROBLEM", 80, 105], ["the SARS", "PROBLEM", 109, 117], ["CoV genome", "TREATMENT", 118, 128], ["the viral isolates into different genetic lineages", "PROBLEM", 184, 234], ["a specific viral lineage", "PROBLEM", 262, 286], ["infection", "PROBLEM", 312, 321], ["viral lineage", "OBSERVATION", 273, 286], ["infection", "OBSERVATION", 312, 321]]], ["Therefore, the characterization of SARS-CoV's genetic variations is not only instrumental for understanding its genetic diversity and genome evolution but also important for tracking its transmission and understanding its epidemiological pattern in human populations.IntroductionDirect sequence analysis of a pathogen in a large number of clinical samples, particularly at a population level, is generally cumbersome, technically challenging, and expensive.", [["samples", "ANATOMY", 348, 355], ["SARS", "DISEASE", 35, 39], ["SARS-CoV", "ORGANISM", 35, 43], ["human", "ORGANISM", 249, 254], ["samples", "CANCER", 348, 355], ["human", "SPECIES", 249, 254], ["SARS-CoV", "SPECIES", 35, 43], ["human", "SPECIES", 249, 254], ["the characterization", "TEST", 11, 31], ["SARS", "PROBLEM", 35, 39], ["CoV's genetic variations", "PROBLEM", 40, 64], ["IntroductionDirect sequence analysis", "TEST", 267, 303], ["a pathogen", "PROBLEM", 307, 317], ["clinical samples", "TEST", 339, 355], ["large", "OBSERVATION_MODIFIER", 323, 328]]], ["Therefore, a rapid, sensitive, high-throughput, and cost-effective screening method would greatly facilitate large-scale characterization of genetic variation of pathogens at a population level.", [["cost-effective screening method", "TEST", 52, 83], ["pathogens", "PROBLEM", 162, 171]]], ["A mass spectrometry (MS)\u2013based method for detecting single nucleotide polymorphisms has been routinely used as a high-throughput method for genotyping human samples, and, thus, we sought to extend this methodology to detect pathogen sequence variations.", [["samples", "ANATOMY", 157, 164], ["human", "ORGANISM", 151, 156], ["samples", "CANCER", 157, 164], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["A mass spectrometry (MS)\u2013based method", "PROBLEM", 0, 37], ["single nucleotide polymorphisms", "PROBLEM", 52, 83], ["genotyping human samples", "TEST", 140, 164], ["pathogen sequence variations", "TEST", 224, 252], ["mass", "OBSERVATION", 2, 6]]], ["Here, we demonstrate the high sensitivity of the MS-based analysis in detecting SARS-CoV sequence variations and apply it to analyzing both cultured viral isolates and uncultured tissue samples of SARS-CoV.Patients and Samples ::: MethodsThe SARS-CoV samples used in the sensitivity study were previously described [7].", [["tissue samples", "ANATOMY", 179, 193], ["SARS", "DISEASE", 197, 201], ["tissue samples", "TISSUE", 179, 193], ["SARS-CoV", "ORGANISM", 197, 205], ["Patients", "ORGANISM", 206, 214], ["SARS-CoV sequence", "DNA", 80, 97], ["Patients", "SPECIES", 206, 214], ["SARS-CoV", "SPECIES", 80, 88], ["SARS-CoV", "SPECIES", 197, 205], ["SARS-CoV", "SPECIES", 242, 250], ["the MS", "TEST", 45, 51], ["based analysis", "TEST", 52, 66], ["SARS", "PROBLEM", 80, 84], ["CoV sequence variations", "TREATMENT", 85, 108], ["viral isolates", "TEST", 149, 163], ["uncultured tissue samples", "TEST", 168, 193], ["SARS", "PROBLEM", 197, 201], ["CoV", "PROBLEM", 202, 205], ["Methods", "TREATMENT", 231, 238], ["The SARS-CoV samples", "TEST", 238, 258], ["the sensitivity study", "TEST", 267, 288]]], ["Briefly, five in vitro samples were generated by spiking 200-\u03bcl human whole-blood samples with SARS-CoV virus obtained from a Vero E6 cell culture of an anonymous Singapore patient.Patients and Samples ::: MethodsVero cell cultured viral isolates were obtained from 13 Singapore patients: the presumed index case (patient Sin2500) of the Singapore SARS outbreak, whose date of illness onset was 25 February 2004; three primary contacts (patients Sin2677, Sin2774, and Sin2748), whose dates of onset were 9 March 2004 (Sin2677 and Sin2774) and 14 March 2004 (Sin2748); one secondary contact (patient Sin2679), who was believed to have contracted SARS from index patient Sin2500 through another primary contact not included in this study and whose date of illness onset was 15 March 2004; and another eight patients (Sin842, Sin845, Sin846, Sin847, Sin848, Sin849, Sin850, and Sin852), who were believed to be the fifth- or six-generation contacts of index patient Sin2500 (based on contact tracing records) and whose dates of illness onset ranged from 2 April to 14 April 2004.", [["samples", "ANATOMY", 23, 30], ["whole-blood samples", "ANATOMY", 70, 89], ["cell", "ANATOMY", 134, 138], ["Vero cell", "ANATOMY", 213, 222], ["SARS", "DISEASE", 348, 352], ["illness", "DISEASE", 377, 384], ["SARS", "DISEASE", 645, 649], ["illness", "DISEASE", 754, 761], ["illness", "DISEASE", 1025, 1032], ["Sin842", "CHEMICAL", 815, 821], ["Sin845", "CHEMICAL", 823, 829], ["Sin846", "CHEMICAL", 831, 837], ["Sin847", "CHEMICAL", 839, 845], ["Sin848", "CHEMICAL", 847, 853], ["Sin849", "CHEMICAL", 855, 861], ["Sin850", "CHEMICAL", 863, 869], ["Sin852", "CHEMICAL", 875, 881], ["human", "ORGANISM", 64, 69], ["blood samples", "ORGANISM_SUBSTANCE", 76, 89], ["SARS-CoV virus", "ORGANISM", 95, 109], ["Vero E6 cell", "CELL", 126, 138], ["patient", "ORGANISM", 173, 180], ["Patients", "ORGANISM", 181, 189], ["Vero cell", "CELL", 213, 222], ["patients", "ORGANISM", 279, 287], ["patient", "ORGANISM", 314, 321], ["patients", "ORGANISM", 437, 445], ["patient", "ORGANISM", 591, 598], ["patient", "ORGANISM", 661, 668], ["patients", "ORGANISM", 805, 813], ["Sin842", "GENE_OR_GENE_PRODUCT", 815, 821], ["Sin845", "GENE_OR_GENE_PRODUCT", 823, 829], ["Sin846", "GENE_OR_GENE_PRODUCT", 831, 837], ["Sin847", "GENE_OR_GENE_PRODUCT", 839, 845], ["Sin848", "GENE_OR_GENE_PRODUCT", 847, 853], ["Sin849", "GENE_OR_GENE_PRODUCT", 855, 861], ["Sin850", "GENE_OR_GENE_PRODUCT", 863, 869], ["patient", "ORGANISM", 955, 962], ["Vero E6 cell culture", "CELL_LINE", 126, 146], ["human", "SPECIES", 64, 69], ["patient", "SPECIES", 173, 180], ["Patients", "SPECIES", 181, 189], ["patients", "SPECIES", 279, 287], ["patient", "SPECIES", 314, 321], ["patients", "SPECIES", 437, 445], ["patient", "SPECIES", 591, 598], ["patient", "SPECIES", 661, 668], ["patients", "SPECIES", 805, 813], ["patient", "SPECIES", 955, 962], ["human", "SPECIES", 64, 69], ["SARS-CoV virus", "SPECIES", 95, 109], ["Vero E6", "SPECIES", 126, 133], ["blood samples", "TEST", 76, 89], ["SARS", "PROBLEM", 95, 99], ["CoV virus", "PROBLEM", 100, 109], ["a Vero E6 cell culture", "TEST", 124, 146], ["Methods", "TREATMENT", 206, 213], ["Vero cell cultured viral isolates", "TEST", 213, 246], ["contracted SARS", "PROBLEM", 634, 649], ["this study", "TEST", 725, 735], ["illness onset", "PROBLEM", 1025, 1038], ["viral isolates", "OBSERVATION", 232, 246]]], ["All the patients fitted the World Health Organization case definition for probable SARS [8].", [["SARS", "DISEASE", 83, 87], ["patients", "ORGANISM", 8, 16], ["patients", "SPECIES", 8, 16], ["SARS", "PROBLEM", 83, 87]]], ["The virus was cultured in vero cells following isolation from respiratory samples (three endotracheal tube swabs, three throat swabs, one nasal swab, two nasopharyngeal aspirates, and four lung tissues) obtained from the patients between 0 and 11 d after onset of symptoms.", [["vero cells", "ANATOMY", 26, 36], ["respiratory samples", "ANATOMY", 62, 81], ["endotracheal tube swabs", "ANATOMY", 89, 112], ["throat swabs", "ANATOMY", 120, 132], ["nasal swab", "ANATOMY", 138, 148], ["nasopharyngeal aspirates", "ANATOMY", 154, 178], ["lung tissues", "ANATOMY", 189, 201], ["vero cells", "CELL", 26, 36], ["endotracheal tube swabs", "MULTI-TISSUE_STRUCTURE", 89, 112], ["nasal swab", "MULTI-TISSUE_STRUCTURE", 138, 148], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 154, 178], ["lung tissues", "TISSUE", 189, 201], ["patients", "ORGANISM", 221, 229], ["vero cells", "CELL_LINE", 26, 36], ["patients", "SPECIES", 221, 229], ["The virus", "PROBLEM", 0, 9], ["respiratory samples", "TEST", 62, 81], ["three endotracheal tube swabs", "TREATMENT", 83, 112], ["three throat swabs", "TEST", 114, 132], ["one nasal swab", "TEST", 134, 148], ["two nasopharyngeal aspirates", "TEST", 150, 178], ["symptoms", "PROBLEM", 264, 272], ["virus", "OBSERVATION", 4, 9], ["vero cells", "OBSERVATION", 26, 36], ["nasopharyngeal", "ANATOMY", 154, 168], ["aspirates", "OBSERVATION", 169, 178], ["lung tissues", "ANATOMY", 189, 201]]], ["Uncultured lung tissue samples were also obtained from patients Sin842, Sin848, Sin849, and Sin852.", [["lung tissue samples", "ANATOMY", 11, 30], ["Sin849", "CHEMICAL", 80, 86], ["Sin852", "CHEMICAL", 92, 98], ["lung tissue samples", "TISSUE", 11, 30], ["patients", "ORGANISM", 55, 63], ["Sin842", "GENE_OR_GENE_PRODUCT", 64, 70], ["Sin848", "GENE_OR_GENE_PRODUCT", 72, 78], ["Sin849", "GENE_OR_GENE_PRODUCT", 80, 86], ["Sin852", "GENE_OR_GENE_PRODUCT", 92, 98], ["patients", "SPECIES", 55, 63], ["Uncultured lung tissue samples", "TEST", 0, 30], ["lung", "ANATOMY", 11, 15]]], ["Bronchoalveolar lavage material was obtained from a serologically confirmed German patient with SARS who had been traveling on the same flight as an early Singaporean patient with SARS who was later hospitalized in Germany [9].", [["Bronchoalveolar lavage", "ANATOMY", 0, 22], ["SARS", "DISEASE", 96, 100], ["SARS", "DISEASE", 180, 184], ["Bronchoalveolar lavage material", "ORGANISM_SUBSTANCE", 0, 31], ["patient", "ORGANISM", 83, 90], ["patient", "ORGANISM", 167, 174], ["patient", "SPECIES", 83, 90], ["patient", "SPECIES", 167, 174], ["Bronchoalveolar lavage material", "TEST", 0, 31]]], ["Virus could not be isolated from the sample owing to its inappropriate storage.RNA Extraction and cDNA Synthesis ::: MethodsFor the spiked human blood samples, RNA was extracted from 200 \u03bcl of blood into 50 \u03bcl of water using a HighPure RNA kit (Roche, Basel, Switzerland).", [["sample", "ANATOMY", 37, 43], ["blood samples", "ANATOMY", 145, 158], ["blood", "ANATOMY", 193, 198], ["Virus", "ORGANISM", 0, 5], ["human", "ORGANISM", 139, 144], ["blood samples", "ORGANISM_SUBSTANCE", 145, 158], ["blood", "ORGANISM_SUBSTANCE", 193, 198], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 139, 144], ["Virus", "PROBLEM", 0, 5], ["Methods", "TREATMENT", 117, 124], ["the spiked human blood samples", "TEST", 128, 158], ["RNA", "TEST", 160, 163], ["could not be", "UNCERTAINTY", 6, 18]]], ["For the clinical samples, RNA was extracted into 30 \u03bcl of water using a QiAmp viral RNA mini kit (Qiagen, Valencia, California, United States).", [["samples", "ANATOMY", 17, 24], ["the clinical samples", "TEST", 4, 24], ["RNA", "TEST", 26, 29], ["a QiAmp viral RNA mini kit", "TREATMENT", 70, 96]]], ["RNA samples were reverse transcribed into cDNA using 2 \u03bcl of RNA as template, a SuperScript kit (Invitrogen, Carlsbad, California, United States), and 13 sequence-specific primers [10].", [["samples", "ANATOMY", 4, 11], ["cDNA", "DNA", 42, 46], ["RNA samples", "TEST", 0, 11], ["RNA", "TREATMENT", 61, 64]]], ["All cDNA products were purified by ethanol precipitation and then resuspended in 20 \u03bcl of water.Real-Time Quantitative PCR Analysis ::: MethodsReal-time quantitative PCR analyses of the RNA samples from spiked human blood were performed using a Lightcycler Sars-CoV quantification kit (Roche).", [["samples", "ANATOMY", 190, 197], ["blood", "ANATOMY", 216, 221], ["ethanol", "CHEMICAL", 35, 42], ["ethanol", "CHEMICAL", 35, 42], ["ethanol", "SIMPLE_CHEMICAL", 35, 42], ["human", "ORGANISM", 210, 215], ["blood", "ORGANISM_SUBSTANCE", 216, 221], ["cDNA products", "DNA", 4, 17], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 210, 215], ["Sars-CoV", "SPECIES", 257, 265], ["All cDNA products", "TREATMENT", 0, 17], ["ethanol precipitation", "TREATMENT", 35, 56], ["MethodsReal", "TEST", 136, 147], ["the RNA samples", "TEST", 182, 197], ["spiked human blood", "TEST", 203, 221], ["a Lightcycler", "TEST", 243, 256]]], ["Each analysis was done using 1 \u03bcl of RNA and in accordance with the manufacturers' instructions.Single Nucleotide Variations of SARS-CoV ::: MethodsTwenty-one single nucleotide variations (SNVs) of SARS-CoV were analyzed in this study.", [["SARS", "DISEASE", 198, 202], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 198, 206], ["SARS-CoV", "SPECIES", 128, 136], ["SARS-CoV", "SPECIES", 198, 206], ["Each analysis", "TEST", 0, 13], ["1 \u03bcl of RNA", "TREATMENT", 29, 40], ["SARS", "PROBLEM", 128, 132], ["Methods", "TEST", 141, 148], ["SARS", "PROBLEM", 198, 202], ["CoV", "PROBLEM", 203, 206], ["this study", "TEST", 224, 234]]], ["Eight of these were identified from our previous sequence analysis of five Singapore SARS-CoV viral isolates and represent variations [5], and 13 SNVs were identified from a more recent genome sequence analysis of additional Singapore SARS-CoV viral isolates.", [["SARS", "DISEASE", 85, 89], ["Singapore", "ORGANISM", 75, 84], ["SARS-CoV", "ORGANISM", 85, 93], ["Singapore", "ORGANISM", 225, 234], ["SARS-CoV viral", "ORGANISM", 235, 249], ["Singapore SARS-CoV", "SPECIES", 75, 93], ["Singapore SARS-CoV", "SPECIES", 225, 243], ["our previous sequence analysis", "TEST", 36, 66], ["CoV viral isolates", "PROBLEM", 90, 108], ["SNVs", "TEST", 146, 150], ["CoV viral isolates", "TREATMENT", 240, 258]]], ["The former eight SNVs were used in evaluating the sensitivity of MS-based genotyping analysis in detecting SARS-CoV viral genotypes, and the later 13 SNVs, as well as five of the former eight SNVs, were used to genotype the patient-derived samples.SNV Analysis ::: MethodsA primer extension genotyping assay was designed for each SARS-CoV SNV using SpectroDesigner software (Sequenom, San Diego, California, United States) and analyzed using the MassARRAY system (Sequenom) and the recommended protocol for the MADLI-TOF (matrix-assisted laser desorption ionization/time-of-flight) MS-based genotyping analysis [11].", [["samples", "ANATOMY", 240, 247], ["SARS-CoV", "ORGANISM", 107, 115], ["patient", "ORGANISM", 224, 231], ["SARS-CoV viral genotypes", "DNA", 107, 131], ["patient", "SPECIES", 224, 231], ["SARS-CoV", "SPECIES", 107, 115], ["SARS-CoV SNV", "SPECIES", 330, 342], ["MS", "TEST", 65, 67], ["based genotyping analysis", "TEST", 68, 93], ["SARS", "TEST", 107, 111], ["CoV viral genotypes", "TEST", 112, 131], ["SNVs", "TEST", 150, 154], ["SNV Analysis", "TEST", 248, 260], ["MethodsA primer extension genotyping assay", "TEST", 265, 307], ["the MassARRAY system", "TEST", 442, 462], ["the MADLI-TOF (matrix-assisted laser desorption ionization", "TREATMENT", 507, 565], ["MS", "TEST", 582, 584], ["genotyping analysis", "TEST", 591, 610]]], ["One microliter of cDNA (equivalent to 0.1 \u03bcl of RNA from 1 \u03bcl of spiked human blood) was used as template in each analysis.Statistical Analysis of Sensitivity ::: MethodsThe analytical detection limit of the combined RNA preparation/RT-PCR/MALDI-TOF MS system was determined by probit analysis [12] using the Statgraphics Plus 5.0 software package (Statistical Graphics, Jena, Germany).Sensitivity for Detecting SARS-CoV SNVs ::: ResultsPrior to determining viral sequence variants in clinical samples, we measured the sensitivity of the MS-based assay for detecting SARS-CoV sequence variations by analyzing eight SNVs in in vitro human blood samples spiked with SARS-CoV.", [["blood", "ANATOMY", 78, 83], ["samples", "ANATOMY", 494, 501], ["blood samples", "ANATOMY", 638, 651], ["human", "ORGANISM", 72, 77], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["human", "ORGANISM", 632, 637], ["blood samples", "ORGANISM_SUBSTANCE", 638, 651], ["SARS-CoV", "ORGANISM", 664, 672], ["cDNA", "DNA", 18, 22], ["SARS-CoV SNVs", "DNA", 412, 425], ["viral sequence variants", "DNA", 458, 481], ["SARS-CoV sequence", "DNA", 567, 584], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 632, 637], ["human", "SPECIES", 72, 77], ["SARS-CoV", "SPECIES", 412, 420], ["SARS-CoV", "SPECIES", 567, 575], ["human", "SPECIES", 632, 637], ["SARS-CoV", "SPECIES", 664, 672], ["RNA", "TREATMENT", 48, 51], ["template in each analysis", "TEST", 97, 122], ["Methods", "TREATMENT", 163, 170], ["the combined RNA preparation", "TREATMENT", 204, 232], ["RT", "TEST", 233, 235], ["PCR", "TEST", 236, 239], ["MALDI", "TEST", 240, 245], ["probit analysis", "TEST", 278, 293], ["the Statgraphics", "TREATMENT", 305, 321], ["Sensitivity", "TEST", 386, 397], ["viral sequence variants", "PROBLEM", 458, 481], ["the MS", "TEST", 534, 540], ["SARS", "PROBLEM", 567, 571], ["CoV sequence variations", "TEST", 572, 595], ["analyzing eight SNVs", "TEST", 599, 619], ["vitro human blood samples", "TEST", 626, 651], ["SARS", "PROBLEM", 664, 668], ["CoV", "PROBLEM", 669, 672]]], ["The viral RNA copy numbers in five spiked human blood samples were quantified by real-time PCR analysis and determined to be 1.64 \u00d7 106 (SB1), 3.84 \u00d7 103 (SB2), 2.17 \u00d7 103 (SB3), 6.21 \u00d7 102 (SB4), and 1.20 \u00d7 102 (SB5) copies per microliter (Figure S1).", [["blood samples", "ANATOMY", 48, 61], ["human", "ORGANISM", 42, 47], ["blood samples", "ORGANISM_SUBSTANCE", 48, 61], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["The viral RNA copy numbers", "TEST", 0, 26], ["human blood samples", "TEST", 42, 61], ["PCR analysis", "TEST", 91, 103], ["SB1", "TEST", 137, 140], ["SB2", "TEST", 155, 158], ["SB3", "TEST", 173, 176], ["SB4", "TEST", 191, 194], ["SB5", "TEST", 213, 216], ["viral RNA", "OBSERVATION", 4, 13]]], ["The three samples (SB3, SB4, and SB5) with the lowest virus copy numbers were used to determine the sensitivity of the MS-based assay.Sensitivity for Detecting SARS-CoV SNVs ::: ResultsWe were able to successfully type the virus in 16 of the 16 analyses of the SB3 sample (equivalent to 217 RNA copies per reaction), 12 of the 15 analyses of the SB4 sample (equivalent to 62 RNA copies per reaction), and six of the 15 analyses of the SB5 sample (equivalent to 12 RNA copies per reaction).", [["samples", "ANATOMY", 10, 17], ["SB3 sample", "ANATOMY", 261, 271], ["SB4 sample", "ANATOMY", 346, 356], ["SB5 sample", "ANATOMY", 435, 445], ["SB4", "GENE_OR_GENE_PRODUCT", 24, 27], ["SB5", "GENE_OR_GENE_PRODUCT", 33, 36], ["SARS-CoV SNVs", "DNA", 160, 173], ["SARS-CoV", "SPECIES", 160, 168], ["The three samples", "TEST", 0, 17], ["SB3", "TEST", 19, 22], ["SB4", "TEST", 24, 27], ["the lowest virus copy numbers", "TEST", 43, 72], ["the MS", "TEST", 115, 121], ["Sensitivity", "TEST", 134, 145], ["type the virus", "PROBLEM", 214, 228], ["the SB3 sample", "TEST", 257, 271], ["the SB4 sample", "TEST", 342, 356], ["the SB5 sample", "TEST", 431, 445]]], ["According to probit analysis, this corresponds to a 95% probability of detection when at least 75 copies of viral RNA (95% confidence interval, 59\u2013107 copies) are present per reaction, and still a 50% detection chance at 38 copies of virus RNA per reaction (95% confidence interval, 29\u201353 copies).", [["viral RNA", "RNA", 108, 117], ["virus RNA", "RNA", 234, 243], ["probit analysis", "TEST", 13, 28], ["viral RNA", "PROBLEM", 108, 117], ["interval", "TEST", 134, 142], ["viral RNA", "OBSERVATION", 108, 117]]], ["All 64 sham spiked samples gave negative genotype calls.Sequence Variant Determination of SARS-CoV in Viral Isolates ::: ResultsHaving demonstrated the high sensitivity of the MS-based analysis, we typed 18 SARS-CoV SNVs in the cultured viral isolates from nine Singapore patients, including five early Singapore cases (Sin2500, Sin2774, Sin2748, Sin2677, and Sin2679) and four later Singapore cases (Sin842, Sin848, Sin849, and Sin852).Sequence Variant Determination of SARS-CoV in Viral Isolates ::: ResultsOf the 18 SNVs analyzed, nine were detected in at least two SARS isolates (Table 1).", [["samples", "ANATOMY", 19, 26], ["SARS", "DISEASE", 569, 573], ["Sin852", "CHEMICAL", 429, 435], ["SARS-CoV", "ORGANISM", 90, 98], ["Viral", "ORGANISM", 102, 107], ["patients", "ORGANISM", 272, 280], ["Sin849", "GENE_OR_GENE_PRODUCT", 417, 423], ["SARS-CoV", "ORGANISM", 471, 479], ["Viral", "ORGANISM", 483, 488], ["SARS-CoV SNVs", "DNA", 207, 220], ["patients", "SPECIES", 272, 280], ["SARS-CoV", "SPECIES", 90, 98], ["SARS-CoV", "SPECIES", 207, 215], ["SARS-CoV", "SPECIES", 471, 479], ["SARS", "PROBLEM", 90, 94], ["the MS", "TEST", 172, 178], ["CoV SNVs", "TEST", 212, 220], ["SARS", "PROBLEM", 471, 475], ["the 18 SNVs", "TEST", 512, 523], ["Viral Isolates", "OBSERVATION", 102, 116]]], ["Assuming that a common sequence variation originated through a single mutation in a host and was then propagated by subsequent infection to others, the sharing of a specific sequence variant by different viral isolates suggests that either these viral isolates share a common ancestor or they have direct ancestor\u2013descendant relationship.", [["infection", "DISEASE", 127, 136], ["a common sequence variation", "PROBLEM", 14, 41], ["a single mutation", "PROBLEM", 61, 78], ["subsequent infection", "PROBLEM", 116, 136], ["a specific sequence variant", "PROBLEM", 163, 190], ["different viral isolates", "PROBLEM", 194, 218], ["these viral isolates", "PROBLEM", 240, 260], ["infection", "OBSERVATION", 127, 136]]], ["Sequence variants at the nine common SNV sites were used to reconstruct the molecular relationship among the nine viral isolates.", [["SNV sites", "DNA", 37, 46], ["Sequence variants", "TEST", 0, 17], ["common SNV", "ANATOMY", 30, 40], ["viral isolates", "OBSERVATION", 114, 128]]], ["The pattern of the shared variants among the nine viral isolates (Table 1) clearly indicated two major molecular lineages of isolate (Figure 1).", [["the shared variants", "PROBLEM", 15, 34], ["molecular lineages", "OBSERVATION", 103, 121]]], ["One lineage includes the four early isolates from patients Sin2500, Sin2774, Sin2748, and Sin2677, and the other includes the early isolate from patient Sin2679 and the four later isolates.", [["patients", "ORGANISM", 50, 58], ["Sin2500", "GENE_OR_GENE_PRODUCT", 59, 66], ["Sin2774", "GENE_OR_GENE_PRODUCT", 68, 75], ["Sin2748", "GENE_OR_GENE_PRODUCT", 77, 84], ["Sin2677", "GENE_OR_GENE_PRODUCT", 90, 97], ["patient", "ORGANISM", 145, 152], ["Sin2679", "CANCER", 153, 160], ["patients", "SPECIES", 50, 58], ["patient", "SPECIES", 145, 152], ["lineage", "OBSERVATION_MODIFIER", 4, 11]]], ["The first lineage is defined by the sequence variant T:C:T at SNV positions19,084, 23,174, and 28,268, whereas the second lineage is defined by the sequence variant C:T:C. Both the variants are distinct from the presumed ancestral sequence variant C:C:C observed in the Urbani viral isolate.", [["C:C:C", "GENE_OR_GENE_PRODUCT", 248, 253], ["Urbani viral", "ORGANISM", 270, 282], ["SNV positions", "TEST", 62, 75], ["C", "PROBLEM", 252, 253], ["the Urbani viral isolate", "TREATMENT", 266, 290]]], ["The later Singapore isolates were also differentiated from the early isolates by the sequence variant pattern at SNV positions 22,549 and 23,735.Sequence Variant Determination of SARS-CoV in Viral Isolates ::: ResultsIn addition, the sequence variant sharing pattern at SNVs 28,008, 548, 1,727, and 13,347 can further differentiate the four fifth- and six-generation isolates into three different sub-lineages (Figure 1) defined by three distinct variants: C:T:T:C in the isolate from patient Sin842, T:T:T:C in the isolate from patient Sin849, and T:C:C:T in the isolates from patients Sin852 and Sin848 (Table 1).", [["SARS-CoV", "ORGANISM", 179, 187], ["Viral", "ORGANISM", 191, 196], ["C:T:T:C", "GENE_OR_GENE_PRODUCT", 457, 464], ["patient", "ORGANISM", 485, 492], ["T:T:T:C", "GENE_OR_GENE_PRODUCT", 501, 508], ["patient", "ORGANISM", 529, 536], ["Sin849", "GENE_OR_GENE_PRODUCT", 537, 543], ["T:C:", "ORGANISM", 549, 553], ["C:T", "GENE_OR_GENE_PRODUCT", 553, 556], ["patients", "ORGANISM", 578, 586], ["patient", "SPECIES", 485, 492], ["patient", "SPECIES", 529, 536], ["patients", "SPECIES", 578, 586], ["SARS-CoV", "SPECIES", 179, 187], ["SARS", "PROBLEM", 179, 183], ["SNVs", "TEST", 270, 274], ["Viral Isolates", "OBSERVATION", 191, 205]]], ["To further confirm this three-sub-lineage pattern observed in the later Singapore isolates, we typed another four later Singapore isolates, from patients Sin845, Sin846, Sin847, and Sin850, at five critical SNVs (19,084, 28,008, 548, 1,727, and 13,347).", [["patients", "ORGANISM", 145, 153], ["Sin845", "GENE_OR_GENE_PRODUCT", 154, 160], ["Sin846", "GENE_OR_GENE_PRODUCT", 162, 168], ["Sin847", "GENE_OR_GENE_PRODUCT", 170, 176], ["Sin850", "GENE_OR_GENE_PRODUCT", 182, 188], ["patients", "SPECIES", 145, 153]]], ["The detected sequence variations in the four new isolates supported the three-sub-lineage pattern in the later Singapore isolates (Table 2; Figure 1).", [["The detected sequence variations", "PROBLEM", 0, 32], ["lineage pattern", "OBSERVATION", 82, 97]]], ["The second and third sub-lineages are more closely related to each other than to the first one, as all the members of the latter two sub-lineages show the variant T at SNV position 28,008, whereas the two members of the first sub-lineage show the variant C.Sequence Variant Determination of SARS-CoV in Viral Isolates ::: ResultsThe molecular relationship among the viral isolates derived from MS-based viral sequence analysis is consistent with the one derived from the whole-genome sequence analysis of the same isolates [13], clearly demonstrating that a small subset of commonly shared variances can be used as \u201cmolecular signature\u201d to differentiate and thus track viral isolates.Direct Sequence Variation Determination of SARS-CoV in Primary Lung Tissue Samples ::: ResultsWe also typed the 18 SNVs in four uncultured lung tissue samples from patients Sin842, Sin848, Sin849, and Sin852, and compared their sequence variations with their matched cultured isolates (Table 3).Direct Sequence Variation Determination of SARS-CoV in Primary Lung Tissue Samples ::: ResultsOf the 72 direct sequence variation comparisons (18 SNVs in four sample pairs), nine differences were identified.", [["Lung", "ANATOMY", 747, 751], ["lung tissue samples", "ANATOMY", 823, 842], ["SARS", "DISEASE", 291, 295], ["SARS-CoV", "ORGANISM", 291, 299], ["Viral", "ORGANISM", 303, 308], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 727, 735], ["Primary Lung Tissue", "CANCER", 739, 758], ["lung tissue samples", "TISSUE", 823, 842], ["patients", "ORGANISM", 848, 856], ["Sin842", "GENE_OR_GENE_PRODUCT", 857, 863], ["Sin848", "GENE_OR_GENE_PRODUCT", 865, 871], ["Sin849", "GENE_OR_GENE_PRODUCT", 873, 879], ["Sin852", "GENE_OR_GENE_PRODUCT", 885, 891], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 1022, 1030], ["patients", "SPECIES", 848, 856], ["SARS-CoV", "SPECIES", 291, 299], ["SARS-CoV", "SPECIES", 727, 735], ["SARS-CoV", "SPECIES", 1022, 1030], ["The second and third sub-lineages", "PROBLEM", 0, 33], ["SARS", "PROBLEM", 291, 295], ["the viral isolates", "TEST", 362, 380], ["MS-based viral sequence analysis", "TEST", 394, 426], ["a small subset of commonly shared variances", "PROBLEM", 556, 599], ["track viral isolates", "PROBLEM", 663, 683], ["Direct Sequence Variation", "TEST", 684, 709], ["SARS", "PROBLEM", 727, 731], ["Direct Sequence Variation", "TEST", 979, 1004], ["SARS", "PROBLEM", 1022, 1026], ["direct sequence variation comparisons", "TEST", 1083, 1120], ["SNVs", "TEST", 1125, 1129], ["third", "OBSERVATION_MODIFIER", 15, 20], ["sub", "OBSERVATION_MODIFIER", 21, 24], ["lineages", "OBSERVATION", 25, 33], ["consistent with", "UNCERTAINTY", 430, 445], ["small", "OBSERVATION_MODIFIER", 558, 563], ["Lung Tissue", "ANATOMY", 747, 758], ["lung tissue", "ANATOMY", 823, 834], ["Lung Tissue", "ANATOMY", 1042, 1053]]], ["Six of these were due to heterogeneous sequences in primary tissue samples.", [["primary tissue samples", "ANATOMY", 52, 74], ["tissue samples", "TISSUE", 60, 74], ["heterogeneous sequences in primary tissue samples", "PROBLEM", 25, 74], ["heterogeneous", "OBSERVATION_MODIFIER", 25, 38], ["primary tissue", "OBSERVATION", 52, 66]]], ["For example, the cultured isolate from patient Sin849 showed the sequence variant T:T:C at SNV positions 548, 1,727, and 13,347, a subset of the heterogeneous T/C:T/C:T/C variant observed in the matched lung tissue sample from the same patient.", [["lung tissue sample", "ANATOMY", 203, 221], ["patient", "ORGANISM", 39, 46], ["Sin849", "GENE_OR_GENE_PRODUCT", 47, 53], ["T:T:C", "GENE_OR_GENE_PRODUCT", 82, 87], ["T/C", "GENE_OR_GENE_PRODUCT", 159, 162], ["T/C", "GENE_OR_GENE_PRODUCT", 167, 170], ["lung tissue", "TISSUE", 203, 214], ["patient", "ORGANISM", 236, 243], ["Sin849", "DNA", 47, 53], ["patient", "SPECIES", 39, 46], ["patient", "SPECIES", 236, 243], ["the cultured isolate", "TEST", 13, 33], ["SNV positions", "TEST", 91, 104], [":T", "TEST", 162, 164], ["T/C variant", "PROBLEM", 167, 178], ["heterogeneous", "OBSERVATION_MODIFIER", 145, 158], ["lung", "ANATOMY", 203, 207], ["tissue", "OBSERVATION", 208, 214]]], ["Direct comparison of the MS spectrums of the three different sequence variants (T, T/C, and C) at SNV position 1,727 in Figure 2 clearly ruled out the possibility of variant miscall.", [["SNV position 1,727", "DNA", 98, 116], ["the MS spectrums", "TEST", 21, 37], ["T", "TEST", 80, 81], ["SNV position", "TEST", 98, 110], ["variant miscall", "PROBLEM", 166, 181], ["ruled out the possibility of", "UNCERTAINTY", 137, 165], ["variant miscall", "OBSERVATION", 166, 181]]], ["More interestingly, the heterogeneous variant T/C:T/C:T/C in the primary lung tissue sample revealed both of the two existing variants of T:T:C and C:C:T seen in other cultured and lung tissue samples (Table 3).Direct Sequence Variation Determination of SARS-CoV in Primary Lung Tissue Samples ::: ResultsIn addition, another three sequence variant differences were observed between the paired cultured and tissue samples from patient Sin848 at SNV positions14,807, 26,205, and 26,509, where the tissue sample showed the sequence variant C:C:T, but the matched culture isolate showed the variant T:T:C (Table 3).", [["primary lung tissue sample", "ANATOMY", 65, 91], ["lung tissue samples", "ANATOMY", 181, 200], ["Lung", "ANATOMY", 274, 278], ["tissue samples", "ANATOMY", 407, 421], ["tissue sample", "ANATOMY", 496, 509], ["T/C", "GENE_OR_GENE_PRODUCT", 54, 57], ["lung tissue", "TISSUE", 73, 84], ["T:T:C", "GENE_OR_GENE_PRODUCT", 138, 143], ["C:C:T", "GENE_OR_GENE_PRODUCT", 148, 153], ["lung tissue samples", "TISSUE", 181, 200], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 254, 262], ["Primary Lung Tissue", "CANCER", 266, 285], ["tissue samples", "TISSUE", 407, 421], ["patient", "ORGANISM", 427, 434], ["Sin848", "GENE_OR_GENE_PRODUCT", 435, 441], ["tissue", "TISSUE", 496, 502], ["patient", "SPECIES", 427, 434], ["SARS-CoV", "SPECIES", 254, 262], ["T/C", "TEST", 54, 57], ["the primary lung tissue sample", "TEST", 61, 91], ["T", "PROBLEM", 152, 153], ["lung tissue samples", "TEST", 181, 200], ["Direct Sequence Variation", "TEST", 211, 236], ["SARS", "PROBLEM", 254, 258], ["tissue samples", "TEST", 407, 421], ["the tissue sample", "TEST", 492, 509], ["the matched culture isolate", "TEST", 549, 576], ["heterogeneous", "OBSERVATION_MODIFIER", 24, 37], ["lung tissue", "ANATOMY", 73, 84], ["lung tissue", "ANATOMY", 181, 192], ["Lung Tissue", "ANATOMY", 274, 285]]], ["In all three SNV positions, the cultured isolate showed novel sequence variants, whereas the primary lung tissue showed the Urbani isolate's variants (see Table 3).Confirmation of the Singapore Origin of a German SARS-CoV Isolate ::: ResultsThe application of tagging and thus tracking of SARS-CoV strains using viral lineage- and/or strain-specific sequence variants was further demonstrated in our investigation of a clinical sample from a German patient.", [["primary lung tissue", "ANATOMY", 93, 112], ["SARS", "DISEASE", 213, 217], ["SARS", "DISEASE", 289, 293], ["lung tissue", "TISSUE", 101, 112], ["SARS-CoV strains", "ORGANISM", 289, 305], ["patient", "ORGANISM", 449, 456], ["SNV positions", "DNA", 13, 26], ["patient", "SPECIES", 449, 456], ["German SARS-CoV", "SPECIES", 206, 221], ["SARS-CoV", "SPECIES", 289, 297], ["the cultured isolate", "TEST", 28, 48], ["novel sequence variants", "PROBLEM", 56, 79], ["the primary lung tissue", "TEST", 89, 112], ["the Urbani isolate's variants", "PROBLEM", 120, 149], ["tagging", "TREATMENT", 260, 267], ["SARS", "PROBLEM", 289, 293], ["CoV strains", "PROBLEM", 294, 305], ["viral lineage", "TEST", 312, 325], ["SNV positions", "OBSERVATION", 13, 26], ["lung tissue", "ANATOMY", 101, 112]]], ["This patient stayed in Hanoi, Vietnam, before sharing an airplane flight with an early Singapore SARS patient on his way to New York via Frankfurt [9].", [["SARS", "DISEASE", 97, 101], ["patient", "ORGANISM", 5, 12], ["patient", "ORGANISM", 102, 109], ["patient", "SPECIES", 5, 12], ["patient", "SPECIES", 102, 109]]], ["German health authorities assumed that this patient was infected somewhere in Hanoi, Vietnam, although the possibility of him being infected by a Singapore SARS-CoV strain during his flight to New York could not be ruled out.Confirmation of the Singapore Origin of a German SARS-CoV Isolate ::: ResultsWe genotyped the virus directly from a brochoalveolar lavage specimen from the German patient at four SNV positions (19,084, 23,792, 26,428, and 27,111) that were distinctive for the early Singapore SARS-CoV isolates (see Table 1).", [["brochoalveolar lavage specimen", "ANATOMY", 341, 371], ["SARS", "DISEASE", 156, 160], ["SARS", "DISEASE", 274, 278], ["SARS", "DISEASE", 501, 505], ["patient", "ORGANISM", 44, 51], ["Singapore SARS-CoV", "ORGANISM", 146, 164], ["brochoalveolar lavage specimen", "TISSUE", 341, 371], ["patient", "ORGANISM", 388, 395], ["patient", "SPECIES", 44, 51], ["patient", "SPECIES", 388, 395], ["Singapore SARS-CoV", "SPECIES", 146, 164], ["German SARS-CoV", "SPECIES", 267, 282], ["SARS-CoV", "SPECIES", 501, 509], ["CoV strain", "PROBLEM", 161, 171], ["the virus", "PROBLEM", 315, 324], ["a brochoalveolar lavage specimen", "TEST", 339, 371]]], ["The sequence of the isolate from the German patient was determined to be T:C:G:A at these SNV positions.", [["patient", "ORGANISM", 44, 51], ["G:A", "GENE_OR_GENE_PRODUCT", 77, 80], ["patient", "SPECIES", 44, 51]]], ["The detection of the variant T at SNV position 19,084 in the isolate from the German patient strongly suggested that this patient was indeed infected by an early Singapore SARS-CoV strain, as the T sequence variant at position 19,084 was detected only in the early Singapore isolates [5,6] and is clearly different from the C variant at position 19,084 observed in the Vietnam-originated isolates [6,14].", [["SARS", "DISEASE", 172, 176], ["patient", "ORGANISM", 85, 92], ["patient", "ORGANISM", 122, 129], ["SARS-CoV", "ORGANISM", 172, 180], ["SNV position 19,084", "DNA", 34, 53], ["patient", "SPECIES", 85, 92], ["patient", "SPECIES", 122, 129], ["Singapore SARS-CoV", "SPECIES", 162, 180], ["CoV strain", "PROBLEM", 177, 187], ["the T sequence variant", "TEST", 192, 214]]], ["Furthermore, this German isolate's sequence variant, T:C:G:A, was detected only in the isolate from the Singapore primary case Sin2748, suggesting that this German patient was probably infected by a SARS-CoV strain originating from or closely related to the SARS-CoV strain of the Singapore primary case Sin2748 and not from the Hanoi outbreak.", [["SARS-CoV strain", "DISEASE", 199, 214], ["SARS", "DISEASE", 258, 262], ["T:C:G:A", "GENE_OR_GENE_PRODUCT", 53, 60], ["patient", "ORGANISM", 164, 171], ["SARS-CoV strain", "ORGANISM", 199, 214], ["SARS-CoV", "ORGANISM", 258, 266], ["patient", "SPECIES", 164, 171], ["SARS-CoV", "SPECIES", 199, 207], ["SARS-CoV", "SPECIES", 258, 266], ["a SARS-CoV strain", "PROBLEM", 197, 214], ["the SARS", "PROBLEM", 254, 262]]], ["Indeed, the T:C:G:A variant is also present in the Frankfurt-1 isolate [15], which was contracted from the early Singaporean patient traveling on the same flight as the German patient.DiscussionThrough the application of this MS mini-sequencing approach to the SARS outbreak in Singapore we have demonstrated the precision that pathogen sequence data can add to an epidemiological investigation.", [["SARS", "DISEASE", 261, 265], ["T:C", "GENE_OR_GENE_PRODUCT", 12, 15], ["G:A", "GENE_OR_GENE_PRODUCT", 16, 19], ["patient", "ORGANISM", 125, 132], ["patient", "ORGANISM", 176, 183], ["patient", "SPECIES", 125, 132], ["patient", "SPECIES", 176, 183], ["Frankfurt-1", "SPECIES", 51, 62], ["this MS mini-sequencing approach", "TREATMENT", 221, 253], ["pathogen sequence data", "TEST", 328, 350], ["an epidemiological investigation", "TEST", 362, 394]]], ["We analyzed 18 SARS-CoV SNVs and determined the molecular relationship among the viral isolates from 13 Singapore SARS patients (see Figure 1) from different stages of the Singapore outbreak.", [["SARS", "DISEASE", 114, 118], ["patients", "ORGANISM", 119, 127], ["SARS-CoV SNVs", "DNA", 15, 28], ["patients", "SPECIES", 119, 127], ["SARS-CoV", "SPECIES", 15, 23], ["CoV SNVs", "TEST", 20, 28]]], ["The molecular relationship among the patients' viral isolates derived from our MS-based viral sequence analysis is not consistent with the current understanding of the clinical transmission relations between these patients.", [["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 214, 222], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 214, 222], ["the patients' viral isolates", "PROBLEM", 33, 61], ["our MS", "TEST", 75, 81], ["based viral sequence analysis", "TEST", 82, 111], ["not consistent with", "UNCERTAINTY", 115, 134]]], ["According to contact tracing records, patient Sin2500 was believed to have been the index case of the Singapore SARS outbreak and to have introduced the SARS-CoV virus into the Singapore population following a visit to the Hotel M (Hong Kong) [5,6].", [["SARS", "DISEASE", 112, 116], ["SARS", "DISEASE", 153, 157], ["patient", "ORGANISM", 38, 45], ["Sin2500", "GENE_OR_GENE_PRODUCT", 46, 53], ["SARS-CoV virus", "ORGANISM", 153, 167], ["patient", "SPECIES", 38, 45], ["CoV virus", "SPECIES", 158, 167], ["SARS-CoV virus", "SPECIES", 153, 167]]], ["Patients Sin2774, 2748, and Sin2677 were believed to have been infected directly by the index case Sin2500, and patient Sin2679 was believed to have been infected by the index case through another, unidentified, primary patient [5].", [["Patients", "ORGANISM", 0, 8], ["Sin2677", "GENE_OR_GENE_PRODUCT", 28, 35], ["patient", "ORGANISM", 112, 119], ["patient", "ORGANISM", 220, 227], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 112, 119], ["patient", "SPECIES", 220, 227], ["infected", "OBSERVATION", 63, 71], ["infected", "OBSERVATION", 154, 162]]], ["Given the pattern of sequence variations observed in the viral isolates, in order for this presumed clinical transmission relationship among these five patients to be correct, one has to assume that during viral transmission from index case Sin2500 to secondary case Sin2679 via an unidentified primary case (two human-to-human transmissions), two reverse mutations at SNV positions 19,084 and 28,268 and one novel mutation at SNV position 23,174 occurred.", [["Sin2679", "CHEMICAL", 267, 274], ["patients", "ORGANISM", 152, 160], ["human", "ORGANISM", 313, 318], ["human", "ORGANISM", 322, 327], ["SNV position 23,174", "DNA", 427, 446], ["patients", "SPECIES", 152, 160], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 322, 327], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 322, 327], ["sequence variations", "PROBLEM", 21, 40], ["the viral isolates", "TEST", 53, 71], ["SNV positions", "TEST", 369, 382], ["viral isolates", "OBSERVATION", 57, 71]]], ["Although this is not impossible, it is unlikely considering the observed mutation rate among the post\u2013Hotel M SARS-CoV isolates [5,16,17].", [["SARS-CoV", "SPECIES", 110, 118], ["the observed mutation rate", "PROBLEM", 60, 86]]], ["A more parsimonious explanation would be a single-mutation scenario in which, instead of contracting the virus from the presumed index case Sin2500, the secondary patient Sin2679 and all the later Singapore cases were infected by a virus strain from the Hotel M cluster through another, as yet unidentified, route, and during this transmission, a novel mutation occurred at SNV position 23,174.", [["Sin2500", "GENE_OR_GENE_PRODUCT", 140, 147], ["patient", "ORGANISM", 163, 170], ["SNV position 23,174", "DNA", 374, 393], ["patient", "SPECIES", 163, 170], ["a single-mutation scenario", "PROBLEM", 41, 67], ["contracting the virus", "PROBLEM", 89, 110], ["a virus strain", "PROBLEM", 230, 244], ["a novel mutation", "PROBLEM", 345, 361]]], ["Thus, patient Sin2679 or another unidentified Singapore patient from whom patient Sin2679 contracted SARS should be the index case of all the late-generation Singapore SARS patients.", [["SARS", "DISEASE", 101, 105], ["SARS", "DISEASE", 168, 172], ["patient", "ORGANISM", 6, 13], ["Sin2679", "GENE_OR_GENE_PRODUCT", 14, 21], ["patient", "ORGANISM", 56, 63], ["patient", "ORGANISM", 74, 81], ["patients", "ORGANISM", 173, 181], ["patient", "SPECIES", 6, 13], ["patient", "SPECIES", 56, 63], ["patient", "SPECIES", 74, 81], ["patients", "SPECIES", 173, 181]]], ["Further viral genetic characterization of additional Singapore SARS cases, especially early-generation ones, may shed light on this hypothesis.", [["SARS", "DISEASE", 63, 67]]], ["Unidentified secondary SARS-CoV infection routes from Guangdong to Hong Kong were also suggested by the genetic characterization of SARS-CoV isolates, although none of these contributed substantially to the subsequent Hong Kong outbreak [6,18].DiscussionA further application of MS-based viral sequence variation analysis in tracking the virus strain and thus the transmission of SARS-CoV was demonstrated by our confirmation of the Singapore origin of a SARS-CoV isolate from a German patient.", [["SARS", "DISEASE", 23, 27], ["infection", "DISEASE", 32, 41], ["SARS", "DISEASE", 132, 136], ["SARS", "DISEASE", 380, 384], ["SARS", "DISEASE", 455, 459], ["SARS-CoV", "ORGANISM", 132, 140], ["SARS-CoV", "ORGANISM", 380, 388], ["SARS-CoV", "ORGANISM", 455, 463], ["patient", "ORGANISM", 486, 493], ["patient", "SPECIES", 486, 493], ["SARS-CoV", "SPECIES", 23, 31], ["SARS-CoV", "SPECIES", 132, 140], ["SARS-CoV", "SPECIES", 380, 388], ["SARS-CoV", "SPECIES", 455, 463], ["secondary SARS", "PROBLEM", 13, 27], ["CoV infection", "PROBLEM", 28, 41], ["CoV isolates", "TEST", 137, 149], ["MS", "TEST", 279, 281], ["based viral sequence variation analysis", "TEST", 282, 321], ["the virus strain", "PROBLEM", 334, 350], ["SARS", "PROBLEM", 380, 384], ["CoV", "PROBLEM", 385, 388], ["a SARS", "PROBLEM", 453, 459], ["secondary", "OBSERVATION_MODIFIER", 13, 22], ["SARS", "OBSERVATION", 23, 27], ["CoV", "OBSERVATION_MODIFIER", 28, 31], ["infection", "OBSERVATION", 32, 41]]], ["Travel and contact tracing records for this German patient indicated more than one potential exposure to SARS-CoV, and because virus could not be cultured from the patient, it was difficult to pinpoint the origin of his infection by classical sequencing methods that require virus enrichment by culture.", [["SARS", "DISEASE", 105, 109], ["infection", "DISEASE", 220, 229], ["patient", "ORGANISM", 51, 58], ["SARS-CoV", "ORGANISM", 105, 113], ["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 51, 58], ["patient", "SPECIES", 164, 171], ["SARS-CoV", "SPECIES", 105, 113], ["SARS", "PROBLEM", 105, 109], ["CoV", "PROBLEM", 110, 113], ["virus", "PROBLEM", 127, 132], ["his infection", "PROBLEM", 216, 229], ["classical sequencing methods", "PROBLEM", 233, 261], ["virus enrichment", "TREATMENT", 275, 291], ["culture", "TEST", 295, 302], ["infection", "OBSERVATION", 220, 229]]], ["By genotyping the four SNV positions that showed unique variants in the early Singapore SARS-CoV isolates, we confirmed that this German patient was indeed infected by an early Singapore virus strain, most likely in a hitherto unnoticed aircraft transmission event from an early Singaporean patient who was later hospitalized with SARS in Germany [9].", [["SARS", "DISEASE", 331, 335], ["Singapore SARS-CoV", "ORGANISM", 78, 96], ["patient", "ORGANISM", 137, 144], ["Singapore virus", "ORGANISM", 177, 192], ["patient", "ORGANISM", 291, 298], ["SNV positions", "DNA", 23, 36], ["patient", "SPECIES", 137, 144], ["patient", "SPECIES", 291, 298], ["Singapore SARS-CoV", "SPECIES", 78, 96], ["Singapore virus", "SPECIES", 177, 192], ["unique variants", "PROBLEM", 49, 64], ["an early Singapore virus strain", "PROBLEM", 168, 199], ["SARS", "PROBLEM", 331, 335], ["most likely", "UNCERTAINTY", 201, 212]]], ["Therefore, our results clearly demonstrate the usefulness of the sequence variation information as molecular fingerprint in \u201ctagging\u201d SARS-CoV viral strains.DiscussionDirect viral sequence variation analysis of uncultured lung tissue samples identified cases of heterogeneous viral sequences in single patient samples.", [["lung tissue samples", "ANATOMY", 222, 241], ["samples", "ANATOMY", 310, 317], ["SARS-CoV viral", "ORGANISM", 134, 148], ["lung tissue samples", "CANCER", 222, 241], ["patient", "ORGANISM", 302, 309], ["viral sequences", "DNA", 276, 291], ["patient", "SPECIES", 302, 309], ["SARS-CoV", "SPECIES", 134, 142], ["molecular fingerprint", "TEST", 99, 120], ["SARS", "PROBLEM", 134, 138], ["CoV viral strains", "PROBLEM", 139, 156], ["DiscussionDirect viral sequence variation analysis", "TEST", 157, 207], ["uncultured lung tissue samples", "TEST", 211, 241], ["heterogeneous viral sequences", "PROBLEM", 262, 291], ["lung", "ANATOMY", 222, 226], ["heterogeneous", "OBSERVATION_MODIFIER", 262, 275], ["viral", "OBSERVATION", 276, 281]]], ["As the SARS-CoV virus is a single-strand RNA virus, the discovery of different sequences in a single tissue sample suggests the presence of multiple viral sequence variants, or quasispsecies, within the host when the sample was retrieved.", [["tissue sample", "ANATOMY", 101, 114], ["SARS", "DISEASE", 7, 11], ["SARS-CoV virus", "ORGANISM", 7, 21], ["tissue", "TISSUE", 101, 107], ["viral sequence variants", "DNA", 149, 172], ["CoV virus", "SPECIES", 12, 21], ["SARS-CoV virus", "SPECIES", 7, 21], ["the SARS-CoV virus", "PROBLEM", 3, 21], ["a single-strand RNA virus", "PROBLEM", 25, 50], ["a single tissue sample", "TEST", 92, 114], ["multiple viral sequence variants", "PROBLEM", 140, 172], ["multiple", "OBSERVATION_MODIFIER", 140, 148], ["viral", "OBSERVATION", 149, 154]]], ["Our result has further confirmed a recent observation of SARS-CoV quasispecies in individual patients [19] and is consistent with observations in other viral infections.", [["SARS", "DISEASE", 57, 61], ["viral infections", "DISEASE", 152, 168], ["SARS-CoV", "ORGANISM", 57, 65], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["SARS-CoV", "SPECIES", 57, 65], ["SARS", "PROBLEM", 57, 61], ["CoV quasispecies", "PROBLEM", 62, 78], ["other viral infections", "PROBLEM", 146, 168], ["consistent with", "UNCERTAINTY", 114, 129], ["viral", "OBSERVATION_MODIFIER", 152, 157], ["infections", "OBSERVATION", 158, 168]]], ["Furthermore, direct comparison between cultured and uncultured samples from the same patient confirmed the existence of the heterogeneous viral sequences only in the uncultured tissue sample, which suggests that of the two initial variants in the human host, only one survived in the vero cell culture.", [["samples", "ANATOMY", 63, 70], ["tissue sample", "ANATOMY", 177, 190], ["cell", "ANATOMY", 289, 293], ["samples", "CANCER", 63, 70], ["patient", "ORGANISM", 85, 92], ["tissue", "TISSUE", 177, 183], ["human", "ORGANISM", 247, 252], ["vero cell", "CELL", 284, 293], ["viral sequences", "DNA", 138, 153], ["vero cell culture", "CELL_LINE", 284, 301], ["patient", "SPECIES", 85, 92], ["human", "SPECIES", 247, 252], ["human", "SPECIES", 247, 252], ["uncultured samples", "TEST", 52, 70], ["the heterogeneous viral sequences", "PROBLEM", 120, 153], ["the two initial variants in the human host", "PROBLEM", 215, 257], ["the vero cell culture", "TEST", 280, 301], ["heterogeneous", "OBSERVATION_MODIFIER", 124, 137], ["viral", "OBSERVATION", 138, 143], ["uncultured tissue", "OBSERVATION_MODIFIER", 166, 183], ["human host", "OBSERVATION_MODIFIER", 247, 257], ["vero cell", "OBSERVATION", 284, 293]]], ["This raises a concern that viral genetic characterization in cultured viral isolates may not capture the whole sequence variation spectrum of a virus in a patient population.DiscussionOur study has clearly demonstrated the advantages of MS-based genetic analysis as a method for large-scale viral genetic characterization in clinical samples.", [["samples", "ANATOMY", 334, 341], ["patient", "ORGANISM", 155, 162], ["samples", "CANCER", 334, 341], ["patient", "SPECIES", 155, 162], ["viral genetic characterization", "TEST", 27, 57], ["cultured viral isolates", "PROBLEM", 61, 84], ["a virus", "PROBLEM", 142, 149], ["DiscussionOur study", "TEST", 174, 193], ["MS", "TEST", 237, 239], ["genetic analysis", "TEST", 246, 262], ["a method", "TEST", 266, 274]]], ["Firstly, MS-based analysis has high sensitivity, providing successful detection of virus more than 95% of the time at virus concentrations as low as 75 RNA copies per reaction (equivalent to a detection sensitivity of 103\u2013104 RNA copies per milliliter), which is close to the detection limit of real-time RT-PCR based diagnostic tests (demonstrated to be 5\u201385 copies of viral RNA per reaction) [7,20,21,22] and within the concentration range reported for SARS-CoV in respiratory and plasma samples [9,20,22,23,24].", [["respiratory", "ANATOMY", 467, 478], ["plasma samples", "ANATOMY", 483, 497], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 455, 463], ["plasma samples", "ORGANISM_SUBSTANCE", 483, 497], ["viral RNA", "RNA", 370, 379], ["SARS-CoV", "SPECIES", 455, 463], ["MS", "TEST", 9, 11], ["high sensitivity", "PROBLEM", 31, 47], ["virus", "PROBLEM", 83, 88], ["virus concentrations", "TEST", 118, 138], ["a detection sensitivity", "TEST", 191, 214], ["diagnostic tests", "TEST", 318, 334], ["SARS", "PROBLEM", 455, 459], ["CoV in respiratory and plasma samples", "TEST", 460, 497], ["respiratory", "ANATOMY", 467, 478]]], ["Typical RT-PCR sequencing usually requires as many as 1,000 copies of template, as large PCR fragments are typically amplified with less efficiency than the small fragments (about 100 bp) that are commonly used in MS-based analysis.", [["PCR fragments", "DNA", 89, 102], ["small fragments", "DNA", 157, 172], ["Typical RT-PCR sequencing", "TREATMENT", 0, 25], ["template", "TREATMENT", 70, 78], ["large PCR fragments", "PROBLEM", 83, 102], ["the small fragments", "PROBLEM", 153, 172], ["large", "OBSERVATION_MODIFIER", 83, 88], ["PCR fragments", "OBSERVATION", 89, 102], ["less efficiency", "OBSERVATION_MODIFIER", 132, 147], ["small", "OBSERVATION_MODIFIER", 157, 162], ["fragments", "OBSERVATION", 163, 172]]], ["Secondly, our detection of heterogeneous viral sequences in single clinical samples demonstrated the accuracy of the MS-based assay in characterizing SARS-CoV sequence variations.", [["samples", "ANATOMY", 76, 83], ["viral sequences", "DNA", 41, 56], ["SARS-CoV sequence", "DNA", 150, 167], ["SARS-CoV", "SPECIES", 150, 158], ["heterogeneous viral sequences", "PROBLEM", 27, 56], ["the MS", "TEST", 113, 119], ["heterogeneous", "OBSERVATION_MODIFIER", 27, 40], ["viral", "OBSERVATION", 41, 46]]], ["Thirdly, MS-based assay requires only a small amount of starting material for genetic characterization, 0.1 \u03bcl of RNA per reaction in the present study.", [["genetic characterization", "TEST", 78, 102], ["the present study", "TEST", 134, 151]]], ["Currently, MS-based genotyping analysis of human genetic variation is routinely done in a multiplex fashion, where multiple single nucleotide polymorphisms are genotyped simultaneously in a single assay.", [["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["MS", "TEST", 11, 13], ["multiple single nucleotide polymorphisms", "PROBLEM", 115, 155]]], ["It is thus conceivable that the development of a multiplexing MS-based SNV assay for SARS-CoV could further reduce the required amount of starting material, which would be especially beneficial for analyzing uncultured clinical samples, in which viral materials are often limited.", [["samples", "ANATOMY", 228, 235], ["SARS", "DISEASE", 85, 89], ["SARS-CoV", "ORGANISM", 85, 93], ["SARS-CoV", "SPECIES", 85, 93], ["a multiplexing MS", "TEST", 47, 64], ["SNV assay", "TEST", 71, 80], ["SARS", "PROBLEM", 85, 89], ["CoV", "PROBLEM", 90, 93], ["analyzing uncultured clinical samples", "TEST", 198, 235], ["viral materials", "OBSERVATION", 246, 261]]], ["Multiplexing analysis of MS-based assays also greatly reduces the cost of analysis to about US$0.10\u2013$0.20 per analysis (depending on the level of multiplexing), which is much cheaper than conventional sequence analysis, whose cost is typically a few dollars per analysis.", [["Multiplexing analysis", "TEST", 0, 21], ["MS", "TEST", 25, 27], ["based assays", "TEST", 28, 40], ["US", "TEST", 92, 94], ["analysis", "TEST", 110, 118], ["conventional sequence analysis", "TEST", 188, 218]]], ["Therefore, MS-based sequence variation analysis is a sensitive, accurate, cost-effective, and high-throughput method for confirming putative variations and characterizing known variations in clinical samples, especially for large-scale population studies.DiscussionMS-based sequence variation analysis is complementary to the identification of new sequence variation by direct sequence analysis and is particularly suitable for investigating agents for which there is already extensive sequence information.", [["samples", "ANATOMY", 200, 207], ["MS-based sequence variation analysis", "TEST", 11, 47], ["putative variations", "PROBLEM", 132, 151], ["known variations in clinical samples", "PROBLEM", 171, 207], ["large-scale population studies", "TEST", 224, 254], ["based sequence variation analysis", "TEST", 268, 301], ["direct sequence analysis", "TEST", 370, 394]]], ["Direct sequence analysis is still the \u201cgold standard\u201d for identifying new sequence variations, but it is inefficient and is not necessary for characterizing known sequence variations in a large number of samples.", [["samples", "ANATOMY", 204, 211], ["samples", "CANCER", 204, 211], ["Direct sequence analysis", "TEST", 0, 24], ["new sequence variations", "TEST", 70, 93], ["known sequence variations", "PROBLEM", 157, 182], ["large", "OBSERVATION_MODIFIER", 188, 193]]], ["A combination of initial characterization of genome sequence by direct sequence analysis in a subset of samples and the subsequent analysis of informative genetic variations via a MS-based approach is more efficient and suitable for large-scale population investigations.", [["samples", "ANATOMY", 104, 111], ["samples", "CANCER", 104, 111], ["direct sequence analysis", "TEST", 64, 88], ["the subsequent analysis", "TEST", 116, 139], ["a MS-based approach", "TREATMENT", 178, 197], ["large-scale population investigations", "TEST", 233, 270]]], ["The genome sequences of a wide variety of pathogens and strains are being rapidly accumulated.", [["pathogens", "PROBLEM", 42, 51], ["strains", "PROBLEM", 56, 63], ["wide", "OBSERVATION_MODIFIER", 26, 30], ["variety", "OBSERVATION_MODIFIER", 31, 38], ["pathogens", "OBSERVATION", 42, 51]]], ["In bacterial pathogens, strain sequence information is frequently limited to a relatively small number of genes (where using all of them simultaneously might be appropriate), whereas in viruses such as influenza, extensive genomic knowledge is accumulating.", [["influenza", "DISEASE", 202, 211], ["bacterial pathogens", "PROBLEM", 3, 22], ["strain sequence information", "TEST", 24, 51], ["influenza", "PROBLEM", 202, 211], ["bacterial pathogens", "OBSERVATION", 3, 22], ["small", "OBSERVATION_MODIFIER", 90, 95]]], ["Such accumulation of both partial- and whole-genome sequence information for pathogens will further extend the usefulness of this approach.DiscussionIn summary, our reassessment of the SARS-CoV transmission route in Singapore using MS-based viral sequence variation analysis highlighted the limitation of conventional epidemiological analysis based on travel and contact tracing, and the importance of informing clinical and epidemiological investigation of pathogen transmission by genetic analysis.", [["SARS", "DISEASE", 185, 189], ["SARS-CoV", "SPECIES", 185, 193], ["pathogens", "PROBLEM", 77, 86], ["this approach", "TREATMENT", 125, 138], ["MS", "TEST", 232, 234], ["based viral sequence variation analysis", "TEST", 235, 274], ["conventional epidemiological analysis", "TEST", 305, 342], ["contact tracing", "TEST", 363, 378], ["genetic analysis", "TEST", 483, 499], ["both", "OBSERVATION_MODIFIER", 21, 25], ["partial", "OBSERVATION_MODIFIER", 26, 33]]], ["With its demonstrated high throughput [25], sensitivity, accuracy, and cost effectiveness in determining viral sequence variations, MS-based genetic analysis can greatly facilitate the large-scale epidemiological investigations of SARS-CoV and other agents of infectious disease, and may allow for real-time investigation in outbreak situations.", [["SARS-CoV", "DISEASE", 231, 239], ["infectious disease", "DISEASE", 260, 278], ["SARS-CoV", "ORGANISM", 231, 239], ["SARS-CoV", "SPECIES", 231, 239], ["accuracy", "TEST", 57, 65], ["viral sequence variations", "TEST", 105, 130], ["MS", "TEST", 132, 134], ["genetic analysis", "TEST", 141, 157], ["SARS", "PROBLEM", 231, 235], ["infectious disease", "PROBLEM", 260, 278], ["high", "OBSERVATION_MODIFIER", 22, 26], ["infectious", "OBSERVATION", 260, 270]]]], "4b7c49425b70860e6488a36fb8ebe38c20b28d1e": [["IntroductionSingle-cell RNA sequencing (scRNA-seq) has found many important biological applications, from discovery of new cell types 1 to mapping the transcriptional landscape of human embryonic stem cells 2 .", [["cell", "ANATOMY", 123, 127], ["embryonic stem cells", "ANATOMY", 186, 206], ["cell", "CELL", 123, 127], ["human", "ORGANISM", 180, 185], ["embryonic stem cells 2", "CELL", 186, 208], ["human embryonic stem cells 2", "CELL_TYPE", 180, 208], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 180, 185], ["RNA sequencing", "TEST", 24, 38], ["new cell types", "PROBLEM", 119, 133], ["new cell", "OBSERVATION", 119, 127], ["human embryonic stem cells", "OBSERVATION", 180, 206]]], ["Droplet-based scRNA-seq technologies, such as Drop-seq 3 and 10X Chromium 4 , are particularly powerful due to their high throughput: thousands of single cells can be analyzed in a single experiment.", [["cells", "ANATOMY", 154, 159], ["Chromium", "CHEMICAL", 65, 73], ["Chromium 4", "CHEMICAL", 65, 75], ["cells", "CELL", 154, 159], ["single cells", "CELL_TYPE", 147, 159], ["Droplet", "TEST", 0, 7], ["single cells", "PROBLEM", 147, 159]]], ["However, even with these high-throughput techniques, analyzing rare cell populations remains a challenging task, often requiring protein-based enrichment for the cell population of interest before scRNA-seq 5 .", [["cell", "ANATOMY", 68, 72], ["cell", "ANATOMY", 162, 166], ["cell populations", "CELL", 68, 84], ["cell", "CELL", 162, 166], ["scRNA-seq 5", "PROTEIN", 197, 208], ["analyzing rare cell populations", "PROBLEM", 53, 84], ["protein-based enrichment", "TREATMENT", 129, 153], ["the cell population", "TREATMENT", 158, 177], ["rare", "OBSERVATION_MODIFIER", 63, 67], ["cell populations", "OBSERVATION", 68, 84]]], ["Some cell types can be enriched using cell surface markers and fluorescent-activated cell sorting (FACS), while others require intracellular protein staining instead.", [["cell", "ANATOMY", 5, 9], ["cell surface", "ANATOMY", 38, 50], ["cell", "ANATOMY", 85, 89], ["intracellular", "ANATOMY", 127, 140], ["cell", "CELL", 5, 9], ["cell", "CELL", 38, 42], ["cell", "CELL", 85, 89], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 127, 140], ["cell surface markers", "PROTEIN", 38, 58], ["Some cell types", "PROBLEM", 0, 15], ["cell surface markers", "TEST", 38, 58], ["intracellular protein staining", "TREATMENT", 127, 157], ["cell types", "OBSERVATION", 5, 15], ["protein staining", "OBSERVATION", 141, 157]]], ["For example, Foxp3 is an intracellular marker of regulatory T cells 6 , and Oct4 and Nanog are intracellular reprogramming markers of induced pluripotent stem cells 7 .IntroductionIntracellular protein staining requires cell fixation, which is usually achieved with methanol or paraformaldehyde (PFA) fixation.", [["intracellular", "ANATOMY", 25, 38], ["regulatory T cells", "ANATOMY", 49, 67], ["intracellular", "ANATOMY", 95, 108], ["pluripotent stem cells", "ANATOMY", 142, 164], ["Intracellular", "ANATOMY", 180, 193], ["cell", "ANATOMY", 220, 224], ["methanol", "CHEMICAL", 266, 274], ["paraformaldehyde", "CHEMICAL", 278, 294], ["PFA", "CHEMICAL", 296, 299], ["Foxp3", "GENE_OR_GENE_PRODUCT", 13, 18], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 25, 38], ["T cells 6", "CELL", 60, 69], ["Oct4", "GENE_OR_GENE_PRODUCT", 76, 80], ["Nanog", "GENE_OR_GENE_PRODUCT", 85, 90], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 108], ["pluripotent stem cells 7", "CELL", 142, 166], ["Intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 180, 193], ["cell", "CELL", 220, 224], ["methanol", "SIMPLE_CHEMICAL", 266, 274], ["paraformaldehyde", "SIMPLE_CHEMICAL", 278, 294], ["PFA", "SIMPLE_CHEMICAL", 296, 299], ["Foxp3", "PROTEIN", 13, 18], ["regulatory T cells 6", "CELL_TYPE", 49, 69], ["Oct4", "PROTEIN", 76, 80], ["Nanog", "PROTEIN", 85, 90], ["induced pluripotent stem cells 7", "CELL_LINE", 134, 166], ["an intracellular marker", "TEST", 22, 45], ["Oct4", "TEST", 76, 80], ["induced pluripotent stem cells", "PROBLEM", 134, 164], ["Intracellular protein staining", "TREATMENT", 180, 210], ["cell fixation", "TREATMENT", 220, 233], ["methanol or paraformaldehyde (PFA) fixation", "TREATMENT", 266, 309], ["Foxp3", "OBSERVATION", 13, 18], ["intracellular", "OBSERVATION_MODIFIER", 25, 38], ["marker", "OBSERVATION_MODIFIER", 39, 45], ["regulatory T cells", "OBSERVATION", 49, 67], ["intracellular reprogramming markers", "OBSERVATION", 95, 130], ["pluripotent stem cells", "OBSERVATION", 142, 164], ["protein staining", "OBSERVATION", 194, 210], ["cell fixation", "OBSERVATION", 220, 233]]], ["Drop-seq and 10X have been shown to be compatible with methanol-fixed cells 8, 9 .", [["cells", "ANATOMY", 70, 75], ["methanol", "CHEMICAL", 55, 63], ["Drop-seq", "GENE_OR_GENE_PRODUCT", 0, 8], ["10X", "SIMPLE_CHEMICAL", 13, 16], ["methanol", "SIMPLE_CHEMICAL", 55, 63], ["cells", "CELL", 70, 75], ["methanol-fixed cells", "TREATMENT", 55, 75]]], ["In many intracellular staining applications, however, PFA fixation is necessary to increase the signal-to-background ratio [9] [10] [11] .", [["intracellular", "ANATOMY", 8, 21], ["PFA", "CHEMICAL", 54, 57], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 8, 21], ["PFA", "SIMPLE_CHEMICAL", 54, 57], ["many intracellular staining applications", "TREATMENT", 3, 43], ["PFA fixation", "TREATMENT", 54, 66], ["the signal", "TEST", 92, 102], ["intracellular", "OBSERVATION_MODIFIER", 8, 21], ["staining", "OBSERVATION", 22, 30]]], ["PFA fixation is also a common method for cell and tissue preservation.", [["cell", "ANATOMY", 41, 45], ["tissue", "ANATOMY", 50, 56], ["PFA", "CHEMICAL", 0, 3], ["PFA", "SIMPLE_CHEMICAL", 0, 3], ["cell", "CELL", 41, 45], ["tissue", "TISSUE", 50, 56], ["PFA fixation", "TREATMENT", 0, 12], ["cell and tissue preservation", "TREATMENT", 41, 69], ["fixation", "OBSERVATION", 4, 12]]], ["PFA fixation presents more challenges for RNA sequencing than alcohol-based fixation because the nucleic acids are chemically cross-linked to the intracellular proteins 5, 9 .", [["intracellular", "ANATOMY", 146, 159], ["alcohol", "CHEMICAL", 62, 69], ["nucleic acids", "CHEMICAL", 97, 110], ["PFA", "CHEMICAL", 0, 3], ["alcohol", "CHEMICAL", 62, 69], ["PFA", "SIMPLE_CHEMICAL", 0, 3], ["alcohol", "SIMPLE_CHEMICAL", 62, 69], ["nucleic acids", "SIMPLE_CHEMICAL", 97, 110], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 146, 159], ["intracellular proteins 5, 9", "PROTEIN", 146, 173], ["PFA fixation", "TREATMENT", 0, 12], ["RNA sequencing", "TEST", 42, 56], ["alcohol-based fixation", "TREATMENT", 62, 84], ["the nucleic acids", "TEST", 93, 110], ["the intracellular proteins", "TEST", 142, 168], ["fixation", "OBSERVATION", 4, 12], ["fixation", "OBSERVATION", 76, 84]]], ["In order to retrieve high quality RNA from single PFA-fixed cells, an appropriate cross-link reversal protocol that maintains RNA integrity and minimizes RNA loss is crucial.", [["cells", "ANATOMY", 60, 65], ["PFA", "CHEMICAL", 50, 53], ["PFA", "SIMPLE_CHEMICAL", 50, 53], ["cells", "CELL", 60, 65], ["PFA-fixed cells", "CELL_LINE", 50, 65], ["high quality RNA", "PROBLEM", 21, 37], ["an appropriate cross-link reversal protocol", "TREATMENT", 67, 110], ["RNA loss", "PROBLEM", 154, 162], ["RNA integrity", "OBSERVATION", 126, 139], ["RNA loss", "OBSERVATION", 154, 162]]], ["Here we describe FD-seq (Fixed Droplet RNA sequencing), a method based on Drop-seq for RNA sequencing of PFA-fixed, stained and sorted single cells.", [["cells", "ANATOMY", 142, 147], ["PFA", "CHEMICAL", 105, 108], ["PFA", "SIMPLE_CHEMICAL", 105, 108], ["cells", "CELL", 142, 147], ["FD-seq", "DNA", 17, 23], ["PFA-fixed, stained and sorted single cells", "CELL_LINE", 105, 147], ["FD", "TEST", 17, 19], ["Fixed Droplet RNA sequencing", "TEST", 25, 53], ["a method", "TEST", 56, 64], ["Drop", "TEST", 74, 78], ["RNA sequencing", "TEST", 87, 101], ["PFA", "TEST", 105, 108], ["single cells", "OBSERVATION", 135, 147]]], ["We show that the relative RNA expression profile of fixed cells obtained by FD-seq is similar to that of live cells obtained by Drop-seq.", [["cells", "ANATOMY", 58, 63], ["cells", "ANATOMY", 110, 115], ["cells", "CELL", 58, 63], ["cells", "CELL", 110, 115], ["live cells", "CELL_TYPE", 105, 115], ["fixed cells", "PROBLEM", 52, 63]]], ["FD-seq can also detect unspliced mRNA, allowing for advanced data analysis methods such as RNA velocity 12 in fixed single cells.IntroductionWe used our method to study two important problems in virology.", [["cells", "ANATOMY", 123, 128], ["cells", "CELL", 123, 128], ["unspliced mRNA", "RNA", 23, 37], ["fixed single cells", "CELL_TYPE", 110, 128], ["unspliced mRNA", "PROBLEM", 23, 37], ["advanced data analysis methods", "TEST", 52, 82], ["RNA velocity", "TEST", 91, 103], ["IntroductionWe", "TREATMENT", 129, 143]]], ["First, we investigated the host factors that influence Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation in tumor cells.", [["tumor cells", "ANATOMY", 118, 129], ["Kaposi's sarcoma", "DISEASE", 55, 71], ["tumor", "DISEASE", 118, 123], ["Kaposi's sarcoma-associated herpesvirus", "ORGANISM", 55, 94], ["KSHV", "ORGANISM", 96, 100], ["tumor cells", "CELL", 118, 129], ["tumor cells", "CELL_TYPE", 118, 129], ["Kaposi's sarcoma-associated herpesvirus", "SPECIES", 55, 94], ["Kaposi's sarcoma-associated herpesvirus", "SPECIES", 55, 94], ["KSHV", "SPECIES", 96, 100], ["the host factors", "PROBLEM", 23, 39], ["Kaposi's sarcoma", "PROBLEM", 55, 71], ["herpesvirus (KSHV) reactivation in tumor cells", "PROBLEM", 83, 129], ["sarcoma", "OBSERVATION", 64, 71], ["tumor cells", "OBSERVATION", 118, 129]]], ["KSHV, also known as human herpesvirus type 8 (HHV-8), is a human gammaherpesvirus that causes a number of malignancies such as Kaposi's sarcoma, primary effusion lymphoma and multicentric Castleman's disease 13, 14 .", [["malignancies", "ANATOMY", 106, 118], ["Kaposi's sarcoma", "ANATOMY", 127, 143], ["primary effusion lymphoma", "ANATOMY", 145, 170], ["malignancies", "DISEASE", 106, 118], ["Kaposi's sarcoma", "DISEASE", 127, 143], ["primary effusion lymphoma", "DISEASE", 145, 170], ["Castleman's disease", "DISEASE", 188, 207], ["KSHV", "ORGANISM", 0, 4], ["human herpesvirus type 8", "ORGANISM", 20, 44], ["HHV-8", "ORGANISM", 46, 51], ["human", "ORGANISM", 59, 64], ["malignancies", "CANCER", 106, 118], ["Kaposi's sarcoma", "CANCER", 127, 143], ["primary effusion lymphoma", "CANCER", 145, 170], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 59, 64], ["KSHV", "SPECIES", 0, 4], ["human herpesvirus type 8 (HHV-8", "SPECIES", 20, 51], ["human gammaherpesvirus", "SPECIES", 59, 81], ["human herpesvirus type", "TEST", 20, 42], ["HHV", "TEST", 46, 49], ["a human gammaherpesvirus", "PROBLEM", 57, 81], ["malignancies", "PROBLEM", 106, 118], ["Kaposi's sarcoma", "PROBLEM", 127, 143], ["primary effusion lymphoma", "PROBLEM", 145, 170], ["multicentric Castleman's disease", "PROBLEM", 175, 207], ["human gammaherpesvirus", "OBSERVATION", 59, 81], ["malignancies", "OBSERVATION", 106, 118], ["Kaposi", "ANATOMY", 127, 133], ["sarcoma", "OBSERVATION", 136, 143], ["effusion lymphoma", "OBSERVATION", 153, 170], ["multicentric", "OBSERVATION_MODIFIER", 175, 187], ["Castleman", "OBSERVATION", 188, 197]]], ["There is a considerable interest in unraveling the molecular details of the host factors that modulate KSHV latency and reactivation, because both latency and low-level reactivation are known to contribute to viral tumorigenesis 15 , and therapeutic induction of reactivation could sensitize latently-infected cells to currently available anti-herpesvirus drugs 16 .", [["cells", "ANATOMY", 310, 315], ["latently-infected", "DISEASE", 292, 309], ["KSHV", "ORGANISM", 103, 107], ["cells", "CELL", 310, 315], ["latently-infected cells", "CELL_TYPE", 292, 315], ["KSHV", "SPECIES", 103, 107], ["KSHV latency", "PROBLEM", 103, 115], ["reactivation", "PROBLEM", 120, 132], ["both latency", "PROBLEM", 142, 154], ["low-level reactivation", "PROBLEM", 159, 181], ["viral tumorigenesis", "PROBLEM", 209, 228], ["reactivation", "PROBLEM", 263, 275], ["infected cells", "PROBLEM", 301, 315], ["anti-herpesvirus drugs", "TREATMENT", 339, 361], ["considerable", "OBSERVATION_MODIFIER", 11, 23], ["interest", "OBSERVATION_MODIFIER", 24, 32], ["KSHV latency", "OBSERVATION", 103, 115]]], ["Using FD-seq, we present a single-cell transcriptomic analysis of reactivated human primary effusion lymphoma (PEL) cells.", [["cell", "ANATOMY", 34, 38], ["primary effusion lymphoma (PEL) cells", "ANATOMY", 84, 121], ["primary effusion lymphoma", "DISEASE", 84, 109], ["cell", "CELL", 34, 38], ["human", "ORGANISM", 78, 83], ["effusion lymphoma", "CANCER", 92, 109], ["PEL) cells", "CELL", 111, 121], ["FD-seq", "DNA", 6, 12], ["reactivated human primary effusion lymphoma (PEL) cells", "CELL_LINE", 66, 121], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["reactivated human primary effusion lymphoma (PEL) cells", "PROBLEM", 66, 121], ["primary", "OBSERVATION_MODIFIER", 84, 91], ["effusion lymphoma", "OBSERVATION", 92, 109]]], ["We found that in reactivated cells, the expression levels of viral genes were extremely heterogeneous.", [["cells", "ANATOMY", 29, 34], ["cells", "CELL", 29, 34], ["reactivated cells", "CELL_TYPE", 17, 34], ["viral genes", "DNA", 61, 72], ["reactivated cells", "PROBLEM", 17, 34], ["the expression levels of viral genes", "PROBLEM", 36, 72], ["reactivated cells", "OBSERVATION", 17, 34], ["viral genes", "OBSERVATION", 61, 72], ["extremely", "OBSERVATION_MODIFIER", 78, 87], ["heterogeneous", "OBSERVATION_MODIFIER", 88, 101]]], ["Additionally, we found four host genes, CDH1, CORO1C, ISCU and TMEM119, whose levels correlated with the state of viral reactivation.", [["CDH1", "GENE_OR_GENE_PRODUCT", 40, 44], ["CORO1C", "GENE_OR_GENE_PRODUCT", 46, 52], ["ISCU", "GENE_OR_GENE_PRODUCT", 54, 58], ["TMEM119", "GENE_OR_GENE_PRODUCT", 63, 70], ["host genes", "DNA", 28, 38], ["CDH1", "DNA", 40, 44], ["CORO1C", "DNA", 46, 52], ["ISCU", "DNA", 54, 58], ["TMEM119", "DNA", 63, 70], ["CDH1", "PROBLEM", 40, 44], ["whose levels", "TEST", 72, 84], ["viral reactivation", "PROBLEM", 114, 132], ["host genes", "OBSERVATION", 28, 38], ["CDH1", "OBSERVATION", 40, 44], ["viral reactivation", "OBSERVATION", 114, 132]]], ["Using live cell imaging and time-course study of viral gene expression, we found that ectopic expression of TMEM119 gene induced KSHV reactivation, whereas its silencing led to lower reactivation.", [["cell", "ANATOMY", 11, 15], ["cell", "CELL", 11, 15], ["TMEM119", "GENE_OR_GENE_PRODUCT", 108, 115], ["KSHV", "ORGANISM", 129, 133], ["TMEM119 gene", "DNA", 108, 120], ["KSHV", "SPECIES", 129, 133], ["live cell imaging", "TEST", 6, 23], ["ectopic expression", "PROBLEM", 86, 104], ["KSHV reactivation", "PROBLEM", 129, 146], ["lower reactivation", "PROBLEM", 177, 195], ["KSHV reactivation", "OBSERVATION", 129, 146], ["lower", "OBSERVATION_MODIFIER", 177, 182], ["reactivation", "OBSERVATION", 183, 195]]], ["Bulk RNA-seq on TMEM119 transfected cells showed that upregulated genes were enriched in the mitogen-activated protein kinase (MAPK) signaling pathway.", [["cells", "ANATOMY", 36, 41], ["cells", "CELL", 36, 41], ["mitogen-activated protein kinase", "GENE_OR_GENE_PRODUCT", 93, 125], ["MAPK", "GENE_OR_GENE_PRODUCT", 127, 131], ["TMEM119 transfected cells", "CELL_LINE", 16, 41], ["mitogen-activated protein kinase", "PROTEIN", 93, 125], ["MAPK", "PROTEIN", 127, 131], ["Bulk RNA", "TEST", 0, 8], ["transfected cells", "TEST", 24, 41], ["upregulated genes", "PROBLEM", 54, 71], ["the mitogen", "TEST", 89, 100], ["activated protein kinase", "TEST", 101, 125], ["upregulated genes", "OBSERVATION", 54, 71]]], ["4 We then studied the immune response of human lung cells infected by OC43 coronavirus.IntroductionThe current coronavirus disease 2019 (COVID-19) pandemic has resulted in more than 500,000 deaths worldwide.", [["lung cells", "ANATOMY", 47, 57], ["coronavirus disease", "DISEASE", 111, 130], ["COVID-19", "CHEMICAL", 137, 145], ["deaths", "DISEASE", 190, 196], ["human", "ORGANISM", 41, 46], ["lung cells", "CELL", 47, 57], ["OC43 coronavirus", "ORGANISM", 70, 86], ["coronavirus", "ORGANISM", 111, 122], ["COVID-19", "ORGANISM", 137, 145], ["human lung cells", "CELL_TYPE", 41, 57], ["human", "SPECIES", 41, 46], ["coronavirus", "SPECIES", 75, 86], ["human", "SPECIES", 41, 46], ["OC43 coronavirus", "SPECIES", 70, 86], ["human lung cells", "PROBLEM", 41, 57], ["OC43 coronavirus", "PROBLEM", 70, 86], ["The current coronavirus disease", "PROBLEM", 99, 130], ["COVID", "TEST", 137, 142], ["pandemic", "PROBLEM", 147, 155], ["lung", "ANATOMY", 47, 51], ["cells infected", "OBSERVATION", 52, 66], ["OC43 coronavirus", "OBSERVATION", 70, 86], ["coronavirus disease", "OBSERVATION", 111, 130]]], ["Studying SARS-CoV-2, the etiological agent of COVID-19, requires Biosafety level 3 (BSL-3) facilities, which are often not readily available.", [["SARS-CoV-2", "ORGANISM", 9, 19], ["SARS-CoV", "SPECIES", 9, 17], ["Studying SARS", "TEST", 0, 13], ["COVID", "TEST", 46, 51]]], ["In addition, time from sample collection (for example from a patient in a hospital) to analysis could pose a problem for maintaining cell viability and RNA quality.", [["sample", "ANATOMY", 23, 29], ["cell", "ANATOMY", 133, 137], ["patient", "ORGANISM", 61, 68], ["cell", "CELL", 133, 137], ["patient", "SPECIES", 61, 68], ["sample collection", "TEST", 23, 40], ["cell viability", "OBSERVATION", 133, 147]]], ["To make studying this virus more convenient, and to facilitate international collaboration, researchers can inactivate the patient cells with PFA so that the samples can be handled in BSL-2 facilities, and/or the samples can be preserved and transported internationally.", [["cells", "ANATOMY", 131, 136], ["samples", "ANATOMY", 158, 165], ["samples", "ANATOMY", 213, 220], ["PFA", "CHEMICAL", 142, 145], ["patient", "ORGANISM", 123, 130], ["cells", "CELL", 131, 136], ["PFA", "SIMPLE_CHEMICAL", 142, 145], ["patient", "SPECIES", 123, 130], ["this virus", "PROBLEM", 17, 27], ["PFA", "TREATMENT", 142, 145]]], ["In this study, we also show a possible application of FD-seq in the current pandemic by studying PFA-fixed cells that had been infected with OC43, a relative of SARS-CoV-2.", [["cells", "ANATOMY", 107, 112], ["PFA", "CHEMICAL", 97, 100], ["PFA", "SIMPLE_CHEMICAL", 97, 100], ["cells", "CELL", 107, 112], ["OC43", "GENE_OR_GENE_PRODUCT", 141, 145], ["SARS-CoV-2", "ORGANISM", 161, 171], ["PFA-fixed cells", "CELL_LINE", 97, 112], ["SARS-CoV", "SPECIES", 161, 169], ["this study", "TEST", 3, 13], ["fixed cells", "PROBLEM", 101, 112], ["OC43", "PROBLEM", 141, 145], ["SARS", "TEST", 161, 165], ["CoV", "TEST", 166, 169], ["fixed cells", "OBSERVATION", 101, 112], ["infected", "OBSERVATION_MODIFIER", 127, 135]]], ["OC43, like SARS-CoV-2, belongs to the family of betacoronaviruses, and is a major human pathogen that causes the common cold.", [["OC43", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV-2", "ORGANISM", 11, 21], ["betacoronaviruses", "GENE_OR_GENE_PRODUCT", 48, 65], ["human", "ORGANISM", 82, 87], ["OC43", "PROTEIN", 0, 4], ["human", "SPECIES", 82, 87], ["SARS-CoV", "SPECIES", 11, 19], ["human", "SPECIES", 82, 87], ["a major human pathogen", "PROBLEM", 74, 96]]], ["OC43 has been successfully used to discover drugs that inhibit SARS-CoV-2 replication in vitro 17 .", [["OC43", "CHEMICAL", 0, 4], ["OC43", "GENE_OR_GENE_PRODUCT", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 63, 73], ["OC43", "PROTEIN", 0, 4], ["drugs", "TREATMENT", 44, 49], ["SARS", "PROBLEM", 63, 67], ["CoV", "TEST", 68, 71]]], ["We found that human lung cells infected by OC43 were composed of two subpopulations with either low or high viral gene expression.IntroductionInterestingly, pro-inflammatory immune signaling pathways, such as IL-17 and TNF signaling pathways, were upregulated in bystander cells that showed low or no viral gene expression.", [["lung cells", "ANATOMY", 20, 30], ["OC43", "ANATOMY", 43, 47], ["bystander cells", "ANATOMY", 263, 278], ["human", "ORGANISM", 14, 19], ["lung cells", "CELL", 20, 30], ["OC43", "CELL", 43, 47], ["IL-17", "GENE_OR_GENE_PRODUCT", 209, 214], ["TNF", "GENE_OR_GENE_PRODUCT", 219, 222], ["bystander cells", "CELL", 263, 278], ["human lung cells", "CELL_TYPE", 14, 30], ["TNF", "PROTEIN", 219, 222], ["bystander cells", "CELL_TYPE", 263, 278], ["human", "SPECIES", 14, 19], ["human", "SPECIES", 14, 19], ["human lung cells", "PROBLEM", 14, 30], ["OC43", "PROBLEM", 43, 47], ["low or high viral gene expression", "PROBLEM", 96, 129], ["IL", "TEST", 209, 211], ["TNF signaling pathways", "TEST", 219, 241], ["bystander cells", "TEST", 263, 278], ["viral gene expression", "PROBLEM", 301, 322], ["lung", "ANATOMY", 20, 24], ["cells infected", "OBSERVATION", 25, 39], ["two", "OBSERVATION_MODIFIER", 65, 68], ["subpopulations", "OBSERVATION_MODIFIER", 69, 83], ["low", "OBSERVATION_MODIFIER", 96, 99], ["high", "OBSERVATION_MODIFIER", 103, 107], ["viral gene expression", "OBSERVATION", 108, 129], ["no", "UNCERTAINTY", 298, 300], ["viral gene expression", "OBSERVATION", 301, 322]]], ["This finding suggests the possibility that the excessive cytokine release observed in severe COVID-19 patients 18 could be driven by bystander cells, and that these cells could serve as a potential therapeutic target.Design and optimization of FD-seqIn Drop-seq, each single cell is partitioned with a uniquely barcoded ceramic bead inside nanoliter droplets in oil, using a microfluidic device 3 .", [["bystander cells", "ANATOMY", 133, 148], ["cells", "ANATOMY", 165, 170], ["cell", "ANATOMY", 275, 279], ["oil", "ANATOMY", 362, 365], ["COVID", "DISEASE", 93, 98], ["patients", "ORGANISM", 102, 110], ["bystander cells", "CELL", 133, 148], ["cells", "CELL", 165, 170], ["cell", "CELL", 275, 279], ["oil", "ORGANISM_SUBSTANCE", 362, 365], ["cytokine", "PROTEIN", 57, 65], ["bystander cells", "CELL_TYPE", 133, 148], ["FD-seqIn Drop-seq", "DNA", 244, 261], ["patients", "SPECIES", 102, 110], ["the excessive cytokine release", "PROBLEM", 43, 73], ["severe COVID", "PROBLEM", 86, 98], ["these cells", "PROBLEM", 159, 170], ["FD", "TEST", 244, 246], ["a uniquely barcoded ceramic bead inside nanoliter droplets", "TREATMENT", 300, 358], ["a microfluidic device", "TREATMENT", 373, 394], ["suggests the possibility", "UNCERTAINTY", 13, 37], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["ceramic bead", "OBSERVATION", 320, 332]]], ["The cells are lysed inside the droplets, and their 5 mRNAs are captured by the oligonucleotides on the beads.", [["cells", "ANATOMY", 4, 9], ["droplets", "ANATOMY", 31, 39], ["cells", "CELL", 4, 9], ["5 mRNAs", "RNA", 51, 58], ["droplets", "OBSERVATION_MODIFIER", 31, 39], ["oligonucleotides", "OBSERVATION", 79, 95]]], ["After this, the droplets are broken to recover the beads, and the beads are extensively washed to remove uncaptured mRNAs.", [["droplets", "ANATOMY", 16, 24], ["uncaptured mRNAs", "RNA", 105, 121], ["the droplets", "TREATMENT", 12, 24], ["the beads", "TREATMENT", 47, 56], ["the beads", "TREATMENT", 62, 71], ["beads", "OBSERVATION_MODIFIER", 51, 56]]], ["After pooling the beads, the barcoded mRNAs undergo reverse transcription, exonuclease I digestion of free bead oligonucleotides, and whole transcriptome amplification.", [["exonuclease I", "GENE_OR_GENE_PRODUCT", 75, 88], ["barcoded mRNAs", "RNA", 29, 43], ["exonuclease I", "PROTEIN", 75, 88], ["pooling the beads", "TREATMENT", 6, 23], ["reverse transcription", "TREATMENT", 52, 73], ["exonuclease I digestion of free bead oligonucleotides", "TREATMENT", 75, 128], ["whole transcriptome amplification", "TREATMENT", 134, 167], ["beads", "OBSERVATION_MODIFIER", 18, 23], ["free bead oligonucleotides", "OBSERVATION", 102, 128]]], ["Finally, the barcoded and amplified cDNAs are tagmented and sequenced.Design and optimization of FD-seqTo make Drop-seq suitable for PFA-fixed cells, it is critical that the reversal of cross-linked mRNAs should have a high RNA recovery rate and avoid cross-contamination, while being compatible with all downstream molecular biology steps.", [["cells", "ANATOMY", 143, 148], ["PFA", "CHEMICAL", 133, 136], ["FD-seqTo", "SIMPLE_CHEMICAL", 97, 105], ["Drop-seq", "SIMPLE_CHEMICAL", 111, 119], ["PFA", "SIMPLE_CHEMICAL", 133, 136], ["cells", "CELL", 143, 148], ["barcoded and amplified cDNAs", "DNA", 13, 41], ["FD-seqTo", "DNA", 97, 105], ["PFA-fixed cells", "CELL_LINE", 133, 148], ["cross-linked mRNAs", "RNA", 186, 204], ["FD", "TEST", 97, 99], ["Drop", "TEST", 111, 115], ["PFA-fixed cells", "PROBLEM", 133, 148], ["cross-linked mRNAs", "PROBLEM", 186, 204], ["cross-contamination", "PROBLEM", 252, 271]]], ["Thus, to modify Drop-seq in the least obtrusive way, FD-seq introduces a separate cross-link reversal step between droplet generation and the droplet breakage step.", [["Drop-seq", "DNA", 16, 24], ["FD-seq", "DNA", 53, 59], ["droplet generation", "TREATMENT", 115, 133], ["the droplet breakage step", "TREATMENT", 138, 163], ["droplet breakage", "OBSERVATION", 142, 158]]], ["This allows all other steps of the standard Drop-seq protocol to remain unchanged, while restricting the uncross-linked mRNAs from a given cell inside the droplet during the reversal step.Design and optimization of FD-seqFirst, we tested different conditions for cross-link reversal at bulk level by lysing PFAfixed cells with Drop-seq lysis buffer, and extracting the total RNA using a commercial kit ( Fig. S1 and S2a, see Methods).", [["cell", "ANATOMY", 139, 143], ["cells", "ANATOMY", 316, 321], ["cell", "CELL", 139, 143], ["FD-seqFirst", "SIMPLE_CHEMICAL", 215, 226], ["PFAfixed cells", "CELL", 307, 321], ["uncross-linked mRNAs", "RNA", 105, 125], ["PFAfixed cells", "CELL_LINE", 307, 321], ["total RNA", "RNA", 369, 378], ["S1", "PROTEIN", 409, 411], ["S2a", "PROTEIN", 416, 419], ["the standard Drop-seq protocol", "TREATMENT", 31, 61], ["the reversal step", "TREATMENT", 170, 187], ["FD", "TEST", 215, 217], ["lysing PFAfixed cells", "TREATMENT", 300, 321], ["Drop-seq lysis buffer", "TREATMENT", 327, 348], ["the total RNA", "TREATMENT", 365, 378], ["a commercial kit ( Fig", "TREATMENT", 385, 407], ["unchanged", "OBSERVATION_MODIFIER", 72, 81]]], ["We found that a 1-hour incubation at 56 o C was sufficient to reverse PFA cross-linking, which agreed with another study 5 .", [["PFA", "CHEMICAL", 70, 73], ["PFA", "SIMPLE_CHEMICAL", 70, 73], ["another study", "TEST", 107, 120]]], ["The RNA yield could be improved further by the addition of proteinase K to the lysis buffer (Fig. S2a) .", [["K", "CHEMICAL", 70, 71], ["proteinase K", "GENE_OR_GENE_PRODUCT", 59, 71], ["proteinase K", "PROTEIN", 59, 71], ["proteinase K", "TREATMENT", 59, 71], ["the lysis buffer", "TREATMENT", 75, 91], ["could be", "UNCERTAINTY", 14, 22], ["improved", "OBSERVATION_MODIFIER", 23, 31]]], ["However, there was an optimal concentration of 40 units/ml of proteinase K, above which the RNA yield actually decreased (Fig. S1a ).", [["K", "CHEMICAL", 73, 74], ["proteinase K", "GENE_OR_GENE_PRODUCT", 62, 74], ["proteinase K", "PROTEIN", 62, 74], ["proteinase K", "TREATMENT", 62, 74], ["the RNA", "TEST", 88, 95], ["decreased", "OBSERVATION_MODIFIER", 111, 120]]], ["We consistently obtained high quality total RNA for all tested concentrations of proteinase K, demonstrated by high RNA integrity numbers (above 8.0) (Fig. S1b,c) .", [["K", "CHEMICAL", 92, 93], ["proteinase K", "GENE_OR_GENE_PRODUCT", 81, 93], ["proteinase K", "PROTEIN", 81, 93], ["proteinase K", "TEST", 81, 93], ["high RNA integrity numbers", "PROBLEM", 111, 137]]], ["(The RNA integrity number is used to quantify the degree of total RNA degradation.)Design and optimization of FD-seqTo check for contamination from RNA across droplets, we performed species-mixing experiments on fresh live cells and fixed cells.", [["cells", "ANATOMY", 223, 228], ["cells", "ANATOMY", 239, 244], ["cells", "CELL", 223, 228], ["cells", "CELL", 239, 244], ["fixed cells", "CELL_TYPE", 233, 244], ["total RNA degradation", "TREATMENT", 60, 81], ["FD", "TEST", 110, 112], ["seqTo check", "TEST", 113, 124], ["contamination", "PROBLEM", 129, 142], ["RNA across droplets", "PROBLEM", 148, 167], ["fresh live cells", "TREATMENT", 212, 228], ["fixed cells", "PROBLEM", 233, 244], ["fixed cells", "OBSERVATION", 233, 244]]], ["For the live cell experiment, we used Drop-seq to 6 analyze a 1-to-1 mixture of BC3, a human PEL cell line, and mouse 3T3 cells.", [["cell", "ANATOMY", 13, 17], ["PEL cell line", "ANATOMY", 93, 106], ["3T3 cells", "ANATOMY", 118, 127], ["cell", "CELL", 13, 17], ["BC3", "SIMPLE_CHEMICAL", 80, 83], ["human", "ORGANISM", 87, 92], ["PEL cell line", "CELL", 93, 106], ["mouse", "ORGANISM", 112, 117], ["3T3 cells", "CELL", 118, 127], ["BC3", "CELL_LINE", 80, 83], ["human PEL cell line", "CELL_LINE", 87, 106], ["mouse 3T3 cells", "CELL_LINE", 112, 127], ["human", "SPECIES", 87, 92], ["mouse", "SPECIES", 112, 117], ["human", "SPECIES", 87, 92], ["mouse", "SPECIES", 112, 117], ["Drop", "TEST", 38, 42], ["a human PEL cell line", "TREATMENT", 85, 106], ["PEL", "ANATOMY", 93, 96], ["cell line", "OBSERVATION", 97, 106], ["3T3 cells", "OBSERVATION", 118, 127]]], ["For the fixed cells experiment, we fixed the BC3 and 3T3 cells with PFA and permeabilized them with Triton-X separately, and analyzed a 1-to-1 mixture of the two fixed and permeabilized cell samples with FD-seq.", [["cells", "ANATOMY", 14, 19], ["BC3", "ANATOMY", 45, 48], ["3T3 cells", "ANATOMY", 53, 62], ["cell samples", "ANATOMY", 186, 198], ["Triton-X", "CHEMICAL", 100, 108], ["PFA", "CHEMICAL", 68, 71], ["cells", "CELL", 14, 19], ["BC3", "CELL", 45, 48], ["3T3 cells", "CELL", 53, 62], ["PFA", "SIMPLE_CHEMICAL", 68, 71], ["Triton-X", "SIMPLE_CHEMICAL", 100, 108], ["cell samples", "CELL", 186, 198], ["BC3", "CELL_LINE", 45, 48], ["3T3 cells", "CELL_LINE", 53, 62], ["the fixed cells experiment", "PROBLEM", 4, 30], ["PFA", "TEST", 68, 71], ["Triton", "TREATMENT", 100, 106], ["fixed cells", "OBSERVATION", 8, 19], ["permeabilized cell samples", "OBSERVATION", 172, 198]]], ["For both experiments, the sequencing results were aligned to a combined human-mouse reference genome.", [["human", "ORGANISM", 72, 77], ["mouse", "ORGANISM", 78, 83], ["human-mouse reference genome", "DNA", 72, 100], ["human", "SPECIES", 72, 77], ["mouse", "SPECIES", 78, 83], ["human", "SPECIES", 72, 77], ["mouse", "SPECIES", 78, 83]]], ["The amount of human and/or mouse transcripts per single cell barcode was then calculated.", [["cell", "ANATOMY", 56, 60], ["human", "ORGANISM", 14, 19], ["mouse", "ORGANISM", 27, 32], ["cell", "CELL", 56, 60], ["human and/or mouse transcripts", "RNA", 14, 44], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 27, 32], ["human", "SPECIES", 14, 19], ["mouse", "SPECIES", 27, 32], ["human and/or mouse transcripts", "TREATMENT", 14, 44], ["single cell barcode", "TREATMENT", 49, 68], ["amount", "OBSERVATION_MODIFIER", 4, 10]]], ["Cells having both mouse and human transcripts, which indicate cross-droplet contamination and/or high multiplet (multiple cells captured in the same droplet) rate, were only minimally observed in both live and fixed experiments (~0.5% and ~1% mixed species rate for fresh live and fixed cells, respectively, Fig. S2b ).", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 122, 127], ["cells", "ANATOMY", 287, 292], ["Cells", "CELL", 0, 5], ["mouse", "ORGANISM", 18, 23], ["human", "ORGANISM", 28, 33], ["cells", "CELL", 122, 127], ["cells", "CELL", 287, 292], ["mouse", "SPECIES", 18, 23], ["human", "SPECIES", 28, 33], ["mouse", "SPECIES", 18, 23], ["human", "SPECIES", 28, 33], ["cross-droplet contamination", "PROBLEM", 62, 89], ["high multiplet (multiple cells", "PROBLEM", 97, 127], ["fresh live and fixed cells", "PROBLEM", 266, 292]]], ["This suggests that the modifications of FD-seq did not affect the single-cell capture feature of Drop-seq.", [["cell", "ANATOMY", 73, 77], ["cell", "CELL", 73, 77], ["Drop-seq", "GENE_OR_GENE_PRODUCT", 97, 105], ["FD-seq", "DNA", 40, 46], ["Drop-seq", "DNA", 97, 105]]], ["Furthermore, the number of genes detected in fixed cells was comparable to that of live cells across species (median of 640 genes in fixed cells compared to 675 genes in live cells for human cells, and median of 734 genes compared to 724 genes for mouse cells) (Fig. S2c) .", [["cells", "ANATOMY", 51, 56], ["cells", "ANATOMY", 88, 93], ["cells", "ANATOMY", 139, 144], ["cells", "ANATOMY", 175, 180], ["cells", "ANATOMY", 191, 196], ["cells", "ANATOMY", 254, 259], ["cells", "CELL", 51, 56], ["cells", "CELL", 88, 93], ["cells", "CELL", 139, 144], ["cells", "CELL", 175, 180], ["human", "ORGANISM", 185, 190], ["cells", "CELL", 191, 196], ["mouse", "ORGANISM", 248, 253], ["cells", "CELL", 254, 259], ["live cells", "CELL_TYPE", 83, 93], ["human cells", "CELL_TYPE", 185, 196], ["mouse cells", "CELL_TYPE", 248, 259], ["human", "SPECIES", 185, 190], ["mouse", "SPECIES", 248, 253], ["human", "SPECIES", 185, 190], ["mouse", "SPECIES", 248, 253], ["fixed cells", "PROBLEM", 45, 56], ["fixed cells", "PROBLEM", 133, 144], ["human cells", "PROBLEM", 185, 196], ["fixed cells", "OBSERVATION", 45, 56]]], ["Importantly, the relative expression levels of the detected genes correlated well between live and fixed cells (Fig. S2d) , even though fewer transcripts were recovered from fixed cells than from live cells on average (Fig. S2b, Fig. S3a ).", [["cells", "ANATOMY", 105, 110], ["cells", "ANATOMY", 180, 185], ["cells", "ANATOMY", 201, 206], ["cells", "CELL", 105, 110], ["cells", "CELL", 180, 185], ["cells", "CELL", 201, 206], ["live and fixed cells", "CELL_TYPE", 90, 110], ["fixed cells", "CELL_TYPE", 174, 185], ["live cells", "CELL_TYPE", 196, 206], ["fixed cells", "PROBLEM", 174, 185]]], ["FD-seq also did not affect the percentage of reads mapped to intron and exon regions (Fig. S3b) .", [["FD-seq", "DNA", 0, 6], ["intron", "DNA", 61, 67], ["exon regions", "DNA", 72, 84]]], ["Taken together, these results demonstrate that FD-seq is a reliable method for whole transcriptome analysis of PFA-fixed single cells.FD-seq reveals heterogeneity in KSHV reactivated single tumor cellsNext, we applied FD-seq to identify host factors that regulate KSHV reactivation.", [["cells", "ANATOMY", 128, 133], ["tumor cells", "ANATOMY", 190, 201], ["tumor", "DISEASE", 190, 195], ["PFA", "CHEMICAL", 111, 114], ["PFA", "SIMPLE_CHEMICAL", 111, 114], ["cells", "CELL", 128, 133], ["KSHV", "ORGANISM", 166, 170], ["single tumor cells", "CELL", 183, 201], ["KSHV", "ORGANISM", 264, 268], ["PFA-fixed single cells", "CELL_LINE", 111, 133], ["KSHV reactivated single tumor cells", "CELL_LINE", 166, 201], ["KSHV", "SPECIES", 166, 170], ["KSHV", "SPECIES", 264, 268], ["whole transcriptome analysis", "TEST", 79, 107], ["PFA", "TEST", 111, 114], ["fixed single cells", "PROBLEM", 115, 133], ["FD", "TEST", 134, 136], ["heterogeneity", "PROBLEM", 149, 162], ["KSHV reactivated single tumor cells", "PROBLEM", 166, 201], ["FD-seq", "TREATMENT", 218, 224], ["host factors", "PROBLEM", 237, 249], ["KSHV reactivation", "TREATMENT", 264, 281], ["heterogeneity", "OBSERVATION", 149, 162], ["KSHV", "OBSERVATION", 166, 170], ["tumor cells", "OBSERVATION", 190, 201], ["KSHV reactivation", "OBSERVATION", 264, 281]]], ["Upon primary infection, KSHV establishes latency that is characterized by the expression of a very limited set of viral gene products.", [["primary infection", "DISEASE", 5, 22], ["KSHV", "ORGANISM", 24, 28], ["viral gene products", "PROTEIN", 114, 133], ["KSHV", "SPECIES", 24, 28], ["primary infection", "PROBLEM", 5, 22], ["viral gene products", "TREATMENT", 114, 133], ["primary", "OBSERVATION_MODIFIER", 5, 12], ["infection", "OBSERVATION", 13, 22], ["viral gene", "OBSERVATION", 114, 124]]], ["Lytic reactivation involves expression of the complete viral genome and the 7 production of new viral particles 19 .", [["viral genome", "DNA", 55, 67], ["Lytic reactivation", "PROBLEM", 0, 18], ["the complete viral genome", "PROBLEM", 42, 67], ["new viral particles", "PROBLEM", 92, 111], ["viral genome", "OBSERVATION", 55, 67]]], ["Although many viral and host factors that regulate the reactivation process of KSHV have been identified 20 , the exact physiological triggers have remained elusive.", [["KSHV", "ORGANISM", 79, 83], ["KSHV", "SPECIES", 79, 83], ["many viral and host factors", "PROBLEM", 9, 36], ["the reactivation process of KSHV", "PROBLEM", 51, 83], ["many", "OBSERVATION_MODIFIER", 9, 13], ["viral", "OBSERVATION", 14, 19]]], ["Furthermore, only a small proportion of cells enter the lytic replication, even when treated with known chemical inducing agents such as sodium butyrate (NaBut) and tetradecanoyl phorbol acetate (TPA) 13 .", [["cells", "ANATOMY", 40, 45], ["sodium butyrate", "CHEMICAL", 137, 152], ["NaBut", "CHEMICAL", 154, 159], ["tetradecanoyl phorbol acetate", "CHEMICAL", 165, 194], ["TPA", "CHEMICAL", 196, 199], ["sodium butyrate", "CHEMICAL", 137, 152], ["NaBut", "CHEMICAL", 154, 159], ["tetradecanoyl phorbol acetate", "CHEMICAL", 165, 194], ["TPA", "CHEMICAL", 196, 199], ["cells", "CELL", 40, 45], ["sodium butyrate", "SIMPLE_CHEMICAL", 137, 152], ["NaBut", "SIMPLE_CHEMICAL", 154, 159], ["tetradecanoyl phorbol acetate", "SIMPLE_CHEMICAL", 165, 194], ["TPA", "SIMPLE_CHEMICAL", 196, 199], ["a small proportion of cells", "PROBLEM", 18, 45], ["the lytic replication", "TREATMENT", 52, 73], ["known chemical inducing agents", "TREATMENT", 98, 128], ["sodium butyrate (NaBut)", "TREATMENT", 137, 160], ["tetradecanoyl phorbol acetate (TPA)", "TREATMENT", 165, 200], ["small", "OBSERVATION_MODIFIER", 20, 25], ["lytic", "OBSERVATION_MODIFIER", 56, 61], ["replication", "OBSERVATION", 62, 73]]], ["The reason for this low-level reactivation is currently not well understood, and we hypothesized that differences in the expression of specific host factors between individual cells contribute to the propensity of the cells to enter lytic reactivation.", [["cells", "ANATOMY", 176, 181], ["cells", "ANATOMY", 218, 223], ["cells", "CELL", 176, 181], ["cells", "CELL", 218, 223], ["host factors", "PROTEIN", 144, 156], ["this low-level reactivation", "PROBLEM", 15, 42], ["individual cells", "PROBLEM", 165, 181], ["the cells", "PROBLEM", 214, 223], ["lytic reactivation", "PROBLEM", 233, 251], ["lytic", "OBSERVATION_MODIFIER", 233, 238]]], ["To test this hypothesis, we focused on the PEL cell line BC3 that is latently infected with KSHV.FD-seq reveals heterogeneity in KSHV reactivated single tumor cellsTo identify lytically reactivated cells, we performed flow cytometry analysis of the viral lytic cell-surface glycoprotein K8.1.", [["PEL cell line BC3", "ANATOMY", 43, 60], ["tumor cells", "ANATOMY", 153, 164], ["cells", "ANATOMY", 198, 203], ["cell", "ANATOMY", 261, 265], ["tumor", "DISEASE", 153, 158], ["PEL cell line BC3", "CELL", 43, 60], ["KSHV", "ORGANISM", 92, 96], ["KSHV", "ORGANISM", 129, 133], ["single tumor cells", "CELL", 146, 164], ["cells", "CELL", 198, 203], ["cell", "CELL", 261, 265], ["K8", "GENE_OR_GENE_PRODUCT", 287, 289], ["PEL cell line BC3", "CELL_LINE", 43, 60], ["KSHV reactivated single tumor cells", "CELL_LINE", 129, 164], ["lytically reactivated cells", "CELL_LINE", 176, 203], ["viral lytic cell-surface glycoprotein K8", "PROTEIN", 249, 289], ["KSHV", "SPECIES", 92, 96], ["KSHV", "SPECIES", 129, 133], ["the PEL cell line BC3", "TREATMENT", 39, 60], ["FD", "TEST", 97, 99], ["heterogeneity", "PROBLEM", 112, 125], ["KSHV reactivated single tumor cells", "PROBLEM", 129, 164], ["lytically reactivated cells", "PROBLEM", 176, 203], ["flow cytometry analysis", "TEST", 218, 241], ["the viral lytic cell", "TEST", 245, 265], ["PEL cell line", "OBSERVATION", 43, 56], ["latently", "OBSERVATION_MODIFIER", 69, 77], ["infected", "OBSERVATION", 78, 86], ["heterogeneity", "OBSERVATION", 112, 125], ["KSHV", "OBSERVATION", 129, 133], ["tumor cells", "OBSERVATION", 153, 164], ["viral lytic cell", "OBSERVATION", 249, 265]]], ["As expected, we did not observe any appreciable spontaneous reactivation, as evident by undetectable K8.1 expression in untreated BC3 cells (Fig. S4a) .FD-seq reveals heterogeneity in KSHV reactivated single tumor cellsHowever, treatment with NaBut and TPA resulted in 2-8% K8.1-positive, lytically reactivated cells after 36 hours (Fig. S4b) .", [["BC3 cells", "ANATOMY", 130, 139], ["tumor cells", "ANATOMY", 208, 219], ["cells", "ANATOMY", 311, 316], ["tumor", "DISEASE", 208, 213], ["NaBut", "CHEMICAL", 243, 248], ["TPA", "CHEMICAL", 253, 256], ["NaBut", "CHEMICAL", 243, 248], ["TPA", "CHEMICAL", 253, 256], ["K8.1", "GENE_OR_GENE_PRODUCT", 101, 105], ["BC3 cells", "CELL", 130, 139], ["KSHV", "ORGANISM", 184, 188], ["single tumor cells", "CELL", 201, 219], ["NaBut", "SIMPLE_CHEMICAL", 243, 248], ["TPA", "SIMPLE_CHEMICAL", 253, 256], ["K8.1", "GENE_OR_GENE_PRODUCT", 274, 278], ["cells", "CELL", 311, 316], ["K8.1", "PROTEIN", 101, 105], ["BC3 cells", "CELL_LINE", 130, 139], ["KSHV reactivated single tumor cells", "CELL_LINE", 184, 219], ["K8.1-positive, lytically reactivated cells", "CELL_LINE", 274, 316], ["KSHV", "SPECIES", 184, 188], ["any appreciable spontaneous reactivation", "PROBLEM", 32, 72], ["untreated BC3 cells", "PROBLEM", 120, 139], ["FD", "TEST", 152, 154], ["heterogeneity", "PROBLEM", 167, 180], ["KSHV reactivated single tumor cells", "PROBLEM", 184, 219], ["NaBut", "TREATMENT", 243, 248], ["TPA", "TREATMENT", 253, 256], ["lytically reactivated cells", "PROBLEM", 289, 316], ["reactivation", "OBSERVATION", 60, 72], ["BC3 cells", "OBSERVATION", 130, 139], ["heterogeneity", "OBSERVATION", 167, 180], ["KSHV", "OBSERVATION", 184, 188], ["tumor cells", "OBSERVATION", 208, 219]]], ["Enrichment of reactivated cells was thus required to obtain a sufficiently large population of reactivated cells to obtain sufficient statistical power.", [["cells", "ANATOMY", 26, 31], ["cells", "ANATOMY", 107, 112], ["cells", "CELL", 26, 31], ["cells", "CELL", 107, 112], ["reactivated cells", "CELL_LINE", 14, 31], ["reactivated cells", "CELL_LINE", 95, 112], ["reactivated cells", "PROBLEM", 14, 31], ["reactivated cells", "PROBLEM", 95, 112], ["reactivated cells", "OBSERVATION", 14, 31], ["reactivated cells", "OBSERVATION", 95, 112]]], ["Therefore, TPA-treated BC3 cells were fixed and sorted by FACS based on the expression level of K8.1 protein (Fig. S5) , and their transcriptomes were analyzed by FD-seq.", [["BC3 cells", "ANATOMY", 23, 32], ["TPA", "CHEMICAL", 11, 14], ["TPA", "CHEMICAL", 11, 14], ["TPA", "SIMPLE_CHEMICAL", 11, 14], ["BC3 cells", "CELL", 23, 32], ["K8.1", "GENE_OR_GENE_PRODUCT", 96, 100], ["S5", "GENE_OR_GENE_PRODUCT", 115, 117], ["BC3 cells", "CELL_LINE", 23, 32], ["K8.1 protein", "PROTEIN", 96, 108], ["S5", "PROTEIN", 115, 117], ["TPA", "TREATMENT", 11, 14], ["BC3 cells", "TREATMENT", 23, 32]]], ["We obtained 1,035 highquality K8.1+ single cells, as well as 286 high-quality K8.1-cells in the FACS-sorted population using FD-seq.", [["highquality K8.1+ single cells", "ANATOMY", 18, 48], ["high-quality K8.1-cells", "ANATOMY", 65, 88], ["K8.1+ single cells", "CELL", 30, 48], ["K8.1-cells", "CELL", 78, 88], ["FACS", "CELL", 96, 100], ["1,035 highquality K8.1+ single cells", "CELL_LINE", 12, 48], ["K8.1-cells", "CELL_LINE", 78, 88], ["FACS-sorted population", "CELL_LINE", 96, 118], ["FD-seq", "DNA", 125, 131], ["single cells", "TEST", 36, 48], ["the FACS", "TEST", 92, 100]]], ["High dimensional clustering and visualization showed clear separation between reactivated and non-reactivated cells (Fig. 1a) .", [["cells", "ANATOMY", 110, 115], ["cells", "CELL", 110, 115], ["non-reactivated cells", "CELL_LINE", 94, 115], ["clear separation between reactivated and non-reactivated cells", "PROBLEM", 53, 115], ["clear separation", "OBSERVATION", 53, 69]]], ["We confirmed that FD-seq indeed enriched the cell population of interest: the K8.1+ cells expressed much higher K8.1 mRNA levels compared to the K8.1-cells (Fig. 1b) .", [["cell", "ANATOMY", 45, 49], ["1+ cells", "ANATOMY", 81, 89], ["K8.1-cells", "ANATOMY", 145, 155], ["FD-seq", "GENE_OR_GENE_PRODUCT", 18, 24], ["cell", "CELL", 45, 49], ["K8", "GENE_OR_GENE_PRODUCT", 78, 80], ["K8.1", "GENE_OR_GENE_PRODUCT", 112, 116], ["K8.1-cells", "CELL", 145, 155], ["FD-seq", "DNA", 18, 24], ["K8", "PROTEIN", 78, 80], ["K8.1 mRNA", "RNA", 112, 121], ["K8.1-cells", "CELL_LINE", 145, 155], ["FD", "TEST", 18, 20], ["mRNA levels", "TEST", 117, 128], ["the K8.1-cells", "TEST", 141, 155], ["cell population", "OBSERVATION", 45, 60], ["+ cells", "OBSERVATION_MODIFIER", 82, 89]]], ["The K8.1+ cluster also expressed more viral transcripts (on average, approximately 69% of the total detected transcripts in the K8.1+ cluster were of viral origin, compared to 4% in the K8.1-cluster) (Fig. 1c) .", [["K8", "GENE_OR_GENE_PRODUCT", 4, 6], ["K8", "GENE_OR_GENE_PRODUCT", 128, 130], ["K8", "PROTEIN", 4, 6], ["viral transcripts", "RNA", 38, 55], ["K8", "PROTEIN", 128, 130], ["viral transcripts", "PROBLEM", 38, 55], ["viral origin", "PROBLEM", 150, 162], ["viral transcripts", "OBSERVATION", 38, 55], ["viral origin", "OBSERVATION_MODIFIER", 150, 162]]], ["8 Herpesvirus reactivation involves the highly regulated, sequential expression of immediate-early, early, and late viral genes 21 .", [["8 Herpesvirus", "ORGANISM", 0, 13], ["immediate-early, early, and late viral genes 21", "DNA", 83, 130], ["Herpesvirus reactivation", "PROBLEM", 2, 26], ["late viral genes", "PROBLEM", 111, 127], ["Herpesvirus reactivation", "OBSERVATION", 2, 26]]], ["We found that the relative abundance of immediateearly viral genes increased early, then flattened after reaching 50% total viral transcripts ( Fig. S6a) .", [["immediateearly viral genes", "DNA", 40, 66], ["viral transcripts", "RNA", 124, 141], ["immediateearly viral genes", "PROBLEM", 40, 66], ["total viral transcripts", "TREATMENT", 118, 141], ["abundance", "OBSERVATION_MODIFIER", 27, 36], ["viral genes", "OBSERVATION", 55, 66], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["early", "OBSERVATION_MODIFIER", 77, 82], ["flattened", "OBSERVATION_MODIFIER", 89, 98]]], ["Early viral transcripts also increased early and monotonically with the abundance of total viral transcripts, without flattening like the immediate-early genes.", [["Early viral transcripts", "RNA", 0, 23], ["viral transcripts", "RNA", 91, 108], ["immediate-early genes", "DNA", 138, 159], ["Early viral transcripts", "PROBLEM", 0, 23], ["total viral transcripts", "PROBLEM", 85, 108], ["flattening", "PROBLEM", 118, 128], ["viral transcripts", "OBSERVATION", 6, 23], ["increased", "OBSERVATION_MODIFIER", 29, 38], ["viral transcripts", "OBSERVATION", 91, 108], ["early genes", "OBSERVATION", 148, 159]]], ["On the other hand, late viral transcripts were only detected in cells with more than 25% total viral transcripts, and increased strongly with higher total viral transcript abundance.FD-seq reveals heterogeneity in KSHV reactivated single tumor cellsThe K8.1+ population was highly heterogeneous: the relative abundance of viral transcripts varied from below 50% to over 90% (Fig. 1d) , and the correlation between viral genes was very poor (Fig. S6b ).", [["cells", "ANATOMY", 64, 69], ["tumor cells", "ANATOMY", 238, 249], ["tumor", "DISEASE", 238, 243], ["cells", "CELL", 64, 69], ["KSHV", "ORGANISM", 214, 218], ["single tumor cells", "CELL", 231, 249], ["K8", "GENE_OR_GENE_PRODUCT", 253, 255], ["viral transcripts", "RNA", 24, 41], ["viral transcripts", "RNA", 95, 112], ["KSHV reactivated single tumor cells", "CELL_LINE", 214, 249], ["K8", "PROTEIN", 253, 255], ["viral transcripts", "RNA", 322, 339], ["viral genes", "DNA", 414, 425], ["KSHV", "SPECIES", 214, 218], ["late viral transcripts", "PROBLEM", 19, 41], ["higher total viral transcript abundance", "PROBLEM", 142, 181], ["FD", "TEST", 182, 184], ["heterogeneity", "PROBLEM", 197, 210], ["KSHV reactivated single tumor cells", "PROBLEM", 214, 249], ["viral transcripts", "PROBLEM", 322, 339], ["viral genes", "PROBLEM", 414, 425], ["viral transcripts", "OBSERVATION", 24, 41], ["viral transcripts", "OBSERVATION", 95, 112], ["viral transcript", "OBSERVATION", 155, 171], ["heterogeneity", "OBSERVATION", 197, 210], ["KSHV", "OBSERVATION", 214, 218], ["tumor cells", "OBSERVATION", 238, 249], ["population", "OBSERVATION", 259, 269], ["highly", "OBSERVATION_MODIFIER", 274, 280], ["heterogeneous", "OBSERVATION_MODIFIER", 281, 294], ["abundance", "OBSERVATION_MODIFIER", 309, 318], ["viral transcripts", "OBSERVATION", 322, 339], ["varied", "OBSERVATION_MODIFIER", 340, 346]]], ["This agrees with two recent studies that showed the single-cell heterogeneity in herpes simplex virus type 1 (HSV-1) infection 22 , and low correlation between viral gene expression in a murine gammaherpesvirus infection model 23 .", [["cell", "ANATOMY", 59, 63], ["herpes simplex virus", "DISEASE", 81, 101], ["infection", "DISEASE", 117, 126], ["gammaherpesvirus infection", "DISEASE", 194, 220], ["cell", "CELL", 59, 63], ["herpes simplex virus type 1", "ORGANISM", 81, 108], ["HSV-1", "ORGANISM", 110, 115], ["murine", "ORGANISM", 187, 193], ["gammaherpesvirus", "ORGANISM", 194, 210], ["herpes simplex virus type 1", "SPECIES", 81, 108], ["HSV-1", "SPECIES", 110, 115], ["murine", "SPECIES", 187, 193], ["herpes simplex virus type 1", "SPECIES", 81, 108], ["HSV-1", "SPECIES", 110, 115], ["murine gammaherpesvirus", "SPECIES", 187, 210], ["two recent studies", "TEST", 17, 35], ["the single-cell heterogeneity", "PROBLEM", 48, 77], ["herpes simplex virus type", "PROBLEM", 81, 106], ["HSV", "TEST", 110, 113], ["infection", "PROBLEM", 117, 126], ["viral gene expression", "PROBLEM", 160, 181], ["a murine gammaherpesvirus infection model", "PROBLEM", 185, 226], ["cell heterogeneity", "OBSERVATION", 59, 77], ["herpes simplex virus", "OBSERVATION", 81, 101], ["viral gene expression", "OBSERVATION", 160, 181]]], ["One partial explanation is that the K8.1+ cells were at different stages of reactivation.", [["1+ cells", "ANATOMY", 39, 47], ["K8", "GENE_OR_GENE_PRODUCT", 36, 38], ["K8", "PROTEIN", 36, 38], ["reactivation", "PROBLEM", 76, 88], ["partial", "OBSERVATION_MODIFIER", 4, 11], ["+ cells", "OBSERVATION", 40, 47], ["different stages", "OBSERVATION_MODIFIER", 56, 72], ["reactivation", "OBSERVATION", 76, 88]]], ["Indeed, K8.1 protein expression level of the positive population varied within one order of magnitude, as quantified by flow cytometry (Fig. S5 ).", [["K8.1", "GENE_OR_GENE_PRODUCT", 8, 12], ["K8.1", "PROTEIN", 8, 12], ["K8.1 protein expression level", "TEST", 8, 37], ["the positive population", "PROBLEM", 41, 64], ["flow cytometry", "TEST", 120, 134], ["positive", "OBSERVATION_MODIFIER", 45, 53], ["population", "OBSERVATION", 54, 64]]], ["However, this alone could not sufficiently explain the lack of correlation between viral genes, even among highly expressed viral genes (Fig. S6c,d) .", [["viral genes", "DNA", 83, 94], ["viral genes", "DNA", 124, 135], ["viral genes", "PROBLEM", 83, 94]]], ["In summary, we showed that FD-seq enables scRNA-seq of a rare cell population of interest after fixation and FACS-enrichment, and found that KSHV reactivation is a highly heterogeneous process at the single-cell level.TMEM119 facilitates KSHV reactivationNext, we sought to identify host genes that modulate KSHV reactivation.", [["cell", "ANATOMY", 62, 66], ["single-cell", "ANATOMY", 200, 211], ["TMEM119", "CHEMICAL", 218, 225], ["FD-seq", "GENE_OR_GENE_PRODUCT", 27, 33], ["cell", "CELL", 62, 66], ["KSHV", "ORGANISM", 141, 145], ["single-cell", "CELL", 200, 211], ["TMEM119", "GENE_OR_GENE_PRODUCT", 218, 225], ["KSHV", "ORGANISM", 238, 242], ["KSHV", "ORGANISM", 308, 312], ["scRNA-seq", "DNA", 42, 51], ["TMEM119", "PROTEIN", 218, 225], ["host genes", "DNA", 283, 293], ["KSHV", "SPECIES", 141, 145], ["KSHV", "SPECIES", 238, 242], ["KSHV", "SPECIES", 308, 312], ["FD", "TEST", 27, 29], ["scRNA", "TEST", 42, 47], ["fixation", "TREATMENT", 96, 104], ["FACS", "TEST", 109, 113], ["KSHV reactivation", "PROBLEM", 141, 158], ["a highly heterogeneous process", "PROBLEM", 162, 192], ["KSHV reactivation", "PROBLEM", 308, 325], ["rare cell", "OBSERVATION", 57, 66], ["KSHV reactivation", "OBSERVATION", 141, 158], ["highly", "OBSERVATION_MODIFIER", 164, 170], ["heterogeneous", "OBSERVATION_MODIFIER", 171, 184], ["KSHV", "OBSERVATION", 238, 242], ["KSHV reactivation", "OBSERVATION", 308, 325]]], ["However, due to the large variation in the proportion of viral transcripts between cells (~4% in the K8.1-population and up to 90% in highly reactivated cells, Fig. 1d) , reduced expression of a host gene can merely result from the lower coverage of host transcripts overall, and does not necessarily mean that it is 9 downregulated in the reactivated cells.", [["cells", "ANATOMY", 83, 88], ["cells", "ANATOMY", 153, 158], ["cells", "ANATOMY", 352, 357], ["cells", "CELL", 83, 88], ["cells", "CELL", 153, 158], ["cells", "CELL", 352, 357], ["viral transcripts", "RNA", 57, 74], ["reactivated cells", "CELL_TYPE", 141, 158], ["host gene", "DNA", 195, 204], ["host transcripts", "RNA", 250, 266], ["reactivated cells", "CELL_TYPE", 340, 357], ["the large variation", "PROBLEM", 16, 35], ["viral transcripts between cells", "PROBLEM", 57, 88], ["the K8.1", "TEST", 97, 105], ["large", "OBSERVATION_MODIFIER", 20, 25], ["variation", "OBSERVATION_MODIFIER", 26, 35], ["viral transcripts", "OBSERVATION", 57, 74], ["reactivated cells", "OBSERVATION", 340, 357]]], ["Indeed, the majority of differentially expressed genes were negatively correlated with the relative abundance of viral transcripts (Fig. S7a) .", [["S7a", "GENE_OR_GENE_PRODUCT", 137, 140], ["viral transcripts", "RNA", 113, 130], ["viral transcripts", "OBSERVATION", 113, 130]]], ["While it is known that overall transcriptional host shut-off is induced by KSHV 24 , we instead primarily focused on host genes that were upregulated in the reactivated population, since their higher expression level would not be confounded by the high amount of viral transcripts.TMEM119 facilitates KSHV reactivationWe found four host genes whose expression strongly correlated with the degree of KSHV reactivation: ISCU, CDH1, CORO1C and TMEM119 (q-value < 10 -100 for all four genes).", [["TMEM119", "CHEMICAL", 281, 288], ["KSHV 24", "ORGANISM", 75, 82], ["TMEM119", "GENE_OR_GENE_PRODUCT", 281, 288], ["KSHV", "ORGANISM", 301, 305], ["KSHV", "ORGANISM", 399, 403], ["CDH1", "GENE_OR_GENE_PRODUCT", 424, 428], ["CORO1C", "GENE_OR_GENE_PRODUCT", 430, 436], ["host genes", "DNA", 117, 127], ["viral transcripts", "RNA", 263, 280], ["TMEM119", "DNA", 281, 288], ["KSHV reactivationWe", "DNA", 301, 320], ["CDH1", "DNA", 424, 428], ["CORO1C", "DNA", 430, 436], ["TMEM119", "DNA", 441, 448], ["KSHV", "SPECIES", 75, 79], ["KSHV", "SPECIES", 301, 305], ["KSHV", "SPECIES", 399, 403], ["viral transcripts", "TREATMENT", 263, 280], ["KSHV reactivation", "PROBLEM", 399, 416], ["CDH1", "TEST", 424, 428], ["CORO1C", "TEST", 430, 436], ["TMEM119", "TEST", 441, 448], ["q-value", "TEST", 450, 457], ["viral transcripts", "OBSERVATION", 263, 280], ["KSHV reactivation", "OBSERVATION", 399, 416]]], ["We observed that the expression of ISCU was relatively low in non-reactivated cells, and increased significantly with the abundance of viral transcripts (Fig. 1e) .", [["cells", "ANATOMY", 78, 83], ["ISCU", "GENE_OR_GENE_PRODUCT", 35, 39], ["cells", "CELL", 78, 83], ["ISCU", "PROTEIN", 35, 39], ["non-reactivated cells", "CELL_TYPE", 62, 83], ["viral transcripts", "RNA", 135, 152], ["relatively low in non-reactivated cells", "PROBLEM", 44, 83], ["viral transcripts", "PROBLEM", 135, 152], ["viral transcripts", "OBSERVATION", 135, 152]]], ["On the other hand, CDH1, CORO1CTMEM119 facilitates KSHV reactivationand TMEM119 were mostly undetectable in non-reactivated cells, and increased by 1-2 orders of magnitude as reactivation progressed.", [["cells", "ANATOMY", 124, 129], ["CDH1", "GENE_OR_GENE_PRODUCT", 19, 23], ["CORO1CTMEM119", "GENE_OR_GENE_PRODUCT", 25, 38], ["KSHV", "ORGANISM", 51, 55], ["TMEM119", "GENE_OR_GENE_PRODUCT", 72, 79], ["cells", "CELL", 124, 129], ["CDH1", "DNA", 19, 23], ["CORO1CTMEM119", "DNA", 25, 38], ["TMEM119", "PROTEIN", 72, 79], ["non-reactivated cells", "CELL_TYPE", 108, 129], ["KSHV", "SPECIES", 51, 55], ["CDH1", "TEST", 19, 23], ["KSHV reactivationand TMEM119", "TEST", 51, 79], ["CDH1", "OBSERVATION", 19, 23]]], ["We also validated the upregulation of ISCU, CORO1C and TMEM119 in bulk cell samples by RT-qPCR (Fig. S7b,c) .TMEM119 facilitates KSHV reactivationBecause the higher abundance of these transcripts in highly reactivated cells may suggest that these genes modulate KSHV reactivation efficiency, we tested the effect of their overexpression on KSHV reactivation.", [["bulk cell samples", "ANATOMY", 66, 83], ["cells", "ANATOMY", 218, 223], ["TMEM119", "CHEMICAL", 109, 116], ["ISCU", "GENE_OR_GENE_PRODUCT", 38, 42], ["CORO1C", "GENE_OR_GENE_PRODUCT", 44, 50], ["TMEM119", "GENE_OR_GENE_PRODUCT", 55, 62], ["cell samples", "TISSUE", 71, 83], ["TMEM119", "GENE_OR_GENE_PRODUCT", 109, 116], ["KSHV", "ORGANISM", 129, 133], ["cells", "CELL", 218, 223], ["KSHV", "ORGANISM", 262, 266], ["KSHV", "ORGANISM", 340, 344], ["ISCU", "PROTEIN", 38, 42], ["CORO1C", "PROTEIN", 44, 50], ["TMEM119", "PROTEIN", 55, 62], ["TMEM119", "PROTEIN", 109, 116], ["KSHV", "SPECIES", 129, 133], ["KSHV", "SPECIES", 262, 266], ["KSHV", "SPECIES", 340, 344], ["CORO1C", "TEST", 44, 50], ["bulk cell samples", "TEST", 66, 83], ["RT", "TEST", 87, 89], ["qPCR", "TEST", 90, 94], ["KSHV reactivation", "PROBLEM", 129, 146], ["these transcripts in highly reactivated cells", "PROBLEM", 178, 223], ["these genes modulate KSHV reactivation efficiency", "PROBLEM", 241, 290], ["KSHV reactivation", "TREATMENT", 340, 357], ["KSHV reactivation", "OBSERVATION", 129, 146], ["KSHV reactivation", "OBSERVATION", 340, 357]]], ["To this end, we exogenously expressed these genes in HEK293T.rKSHV219 cells, which are latently infected with the recombinant KSHV.219 virus strain that constitutively expresses GFP and further encodes RFP under control of the viral lytic PAN promoter 25 .", [["HEK293T.rKSHV219 cells", "ANATOMY", 53, 75], ["HEK293T.rKSHV219 cells", "CELL", 53, 75], ["KSHV", "ORGANISM", 126, 130], ["GFP", "GENE_OR_GENE_PRODUCT", 178, 181], ["RFP", "GENE_OR_GENE_PRODUCT", 202, 205], ["HEK293T.rKSHV219 cells", "CELL_LINE", 53, 75], ["GFP", "PROTEIN", 178, 181], ["RFP", "PROTEIN", 202, 205], ["viral lytic PAN promoter 25", "DNA", 227, 254], ["KSHV", "SPECIES", 126, 130], ["219 virus", "SPECIES", 131, 140], ["these genes in HEK293T.rKSHV219 cells", "PROBLEM", 38, 75], ["219 virus strain", "PROBLEM", 131, 147], ["further encodes RFP", "PROBLEM", 186, 205], ["the viral lytic PAN promoter", "TREATMENT", 223, 251], ["latently", "OBSERVATION_MODIFIER", 87, 95], ["infected", "OBSERVATION", 96, 104], ["viral", "OBSERVATION_MODIFIER", 227, 232], ["lytic", "OBSERVATION_MODIFIER", 233, 238]]], ["Live-cell imaging showed a clear increase in RFP expression, which is indicative of viral reactivation, upon ectopic expression of TMEM119 relative to a GFP-encoding control vector, whereas overexpression of the other three genes had no significant effect on KSHV reactivation efficiency (Fig. 1f, Fig. S8a-c) .", [["Live-cell", "ANATOMY", 0, 9], ["RFP", "GENE_OR_GENE_PRODUCT", 45, 48], ["TMEM119", "GENE_OR_GENE_PRODUCT", 131, 138], ["GFP", "GENE_OR_GENE_PRODUCT", 153, 156], ["KSHV", "ORGANISM", 259, 263], ["S8a-c", "GENE_OR_GENE_PRODUCT", 303, 308], ["RFP", "PROTEIN", 45, 48], ["TMEM119", "PROTEIN", 131, 138], ["GFP-encoding control vector", "DNA", 153, 180], ["KSHV", "SPECIES", 259, 263], ["Live-cell imaging", "TEST", 0, 17], ["a clear increase in RFP expression", "PROBLEM", 25, 59], ["viral reactivation", "PROBLEM", 84, 102], ["ectopic expression of TMEM119", "PROBLEM", 109, 138], ["a GFP", "TEST", 151, 156], ["encoding control vector", "TREATMENT", 157, 180], ["KSHV reactivation efficiency", "PROBLEM", 259, 287], ["clear", "OBSERVATION_MODIFIER", 27, 32], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["RFP expression", "OBSERVATION", 45, 59], ["indicative of", "UNCERTAINTY", 70, 83], ["viral reactivation", "OBSERVATION", 84, 102], ["no", "UNCERTAINTY", 234, 236], ["significant", "OBSERVATION_MODIFIER", 237, 248]]], ["Conversely, silencing of endogenous TMEM119 reduced the level of KSHV reactivation in TPA-treated cells (Fig. 1g, Fig S8b,c) .", [["cells", "ANATOMY", 98, 103], ["TMEM119", "CHEMICAL", 36, 43], ["TPA", "CHEMICAL", 86, 89], ["TMEM119", "CHEMICAL", 36, 43], ["TMEM119", "GENE_OR_GENE_PRODUCT", 36, 43], ["KSHV", "ORGANISM", 65, 69], ["TPA", "SIMPLE_CHEMICAL", 86, 89], ["cells", "CELL", 98, 103], ["endogenous TMEM119", "PROTEIN", 25, 43], ["TPA-treated cells", "CELL_LINE", 86, 103], ["KSHV", "SPECIES", 65, 69], ["KSHV reactivation in TPA", "TREATMENT", 65, 89], ["KSHV reactivation", "OBSERVATION", 65, 82]]], ["Corroborating these results, RT-qPCR analysis of KSHV lytic gene expression showed that TMEM119 overexpression enhanced viral gene expression compared to the GFP control (Fig. 1h) , while TMEM119 silencing had the opposite effect (Fig. 1i) .TMEM119 facilitates KSHV reactivationTo determine the mechanism by which TMEM119 enhances KSHV reactivation, we performed bulk transcriptome analysis of HEK293T.rKSHV and na\u00efve HEK293T cells following ectopic expression of TMEM119.", [["HEK293T.rKSHV", "ANATOMY", 394, 407], ["HEK293T cells", "ANATOMY", 418, 431], ["TMEM119", "CHEMICAL", 188, 195], ["TMEM119", "CHEMICAL", 241, 248], ["TMEM119", "CHEMICAL", 314, 321], ["KSHV", "ORGANISM", 49, 53], ["TMEM119", "GENE_OR_GENE_PRODUCT", 88, 95], ["GFP", "GENE_OR_GENE_PRODUCT", 158, 161], ["TMEM119", "GENE_OR_GENE_PRODUCT", 188, 195], ["TMEM119", "GENE_OR_GENE_PRODUCT", 241, 248], ["KSHV", "ORGANISM", 261, 265], ["TMEM119", "GENE_OR_GENE_PRODUCT", 314, 321], ["KSHV", "ORGANISM", 331, 335], ["HEK293T.rKSHV", "CELL", 394, 407], ["HEK293T cells", "CELL", 418, 431], ["TMEM119", "GENE_OR_GENE_PRODUCT", 464, 471], ["TMEM119", "PROTEIN", 88, 95], ["TMEM119", "PROTEIN", 188, 195], ["TMEM119", "PROTEIN", 241, 248], ["TMEM119", "PROTEIN", 314, 321], ["HEK293T.rKSHV", "CELL_LINE", 394, 407], ["na\u00efve HEK293T cells", "CELL_LINE", 412, 431], ["TMEM119", "PROTEIN", 464, 471], ["KSHV", "SPECIES", 49, 53], ["KSHV", "SPECIES", 261, 265], ["KSHV", "SPECIES", 331, 335], ["HEK293T.rKSHV", "SPECIES", 394, 407], ["RT-qPCR analysis", "TEST", 29, 45], ["KSHV lytic gene expression", "TEST", 49, 75], ["TMEM119 overexpression enhanced viral gene expression", "PROBLEM", 88, 141], ["KSHV reactivation", "PROBLEM", 261, 278], ["bulk transcriptome analysis", "TEST", 363, 390], ["HEK293T.rKSHV", "TEST", 394, 407], ["ectopic expression of TMEM119", "PROBLEM", 442, 471], ["KSHV reactivation", "OBSERVATION", 261, 278]]], ["We found that in HEK293T cells, 202 genes were significantly upregulated upon TMEM119 overexpression ( Fig. 1j and Supplementary File 1) .", [["HEK293T cells", "ANATOMY", 17, 30], ["HEK293T cells", "CELL", 17, 30], ["TMEM119", "GENE_OR_GENE_PRODUCT", 78, 85], ["HEK293T cells", "CELL_LINE", 17, 30], ["TMEM119", "PROTEIN", 78, 85], ["HEK293T cells", "OBSERVATION", 17, 30]]], ["KEGG pathway analysis 26 showed that these genes were highly enriched for the MAPK signaling pathway (Fig. 1l ).", [["MAPK", "GENE_OR_GENE_PRODUCT", 78, 82], ["MAPK", "PROTEIN", 78, 82], ["KEGG pathway analysis", "TEST", 0, 21]]], ["In TMEM119 transfected HEK293T.rKSHV cells, 994 genes were upregulated and showed enrichment in the HSV-1 infection pathway, especially the many zinc finger protein-encoding genes (Fig. 1k,l and Supplementary File 2) .", [["HEK293T.rKSHV cells", "ANATOMY", 23, 42], ["infection", "DISEASE", 106, 115], ["zinc", "CHEMICAL", 145, 149], ["TMEM119", "CELL", 3, 10], ["HEK293T.rKSHV cells", "CELL", 23, 42], ["HSV-1", "ORGANISM", 100, 105], ["TMEM119 transfected HEK293T.rKSHV cells", "CELL_LINE", 3, 42], ["zinc finger protein", "PROTEIN", 145, 164], ["encoding genes", "DNA", 165, 179], ["HSV-1", "SPECIES", 100, 105], ["HEK293T.rKSHV", "SPECIES", 23, 36], ["HSV-1", "SPECIES", 100, 105], ["enrichment in the HSV", "PROBLEM", 82, 103], ["1 infection pathway", "PROBLEM", 104, 123], ["zinc finger protein", "TEST", 145, 164]]], ["This is probably because both HSV-1 and KSHV belong to the Herpesvirus family.", [["HSV-1", "ORGANISM", 30, 35], ["KSHV", "ORGANISM", 40, 44], ["Herpesvirus", "ORGANISM", 59, 70], ["HSV-1", "SPECIES", 30, 35], ["HSV-1", "SPECIES", 30, 35], ["KSHV", "SPECIES", 40, 44], ["HSV", "TEST", 30, 33], ["probably because", "UNCERTAINTY", 8, 24]]], ["While further study is needed to fully characterize the molecular mechanism by which TMEM119 modulates KSHV reactivation, our data suggests that TMEM119 promotes viral reactivation via the MAPK pathway, which has previously been implicated in KSHV reactivation 27, 28 .FD-seq reveals pro-inflammatory bystander cells after coronavirus OC43 infectionWe next applied FD-seq to study infection of the betacoronavirus OC43 in single human lung cells.", [["bystander cells", "ANATOMY", 301, 316], ["lung cells", "ANATOMY", 435, 445], ["TMEM119", "CHEMICAL", 85, 92], ["TMEM119", "CHEMICAL", 145, 152], ["infection", "DISEASE", 381, 390], ["TMEM119", "GENE_OR_GENE_PRODUCT", 85, 92], ["KSHV", "ORGANISM", 103, 107], ["TMEM119", "GENE_OR_GENE_PRODUCT", 145, 152], ["MAPK", "GENE_OR_GENE_PRODUCT", 189, 193], ["KSHV", "ORGANISM", 243, 247], ["bystander cells", "CELL", 301, 316], ["coronavirus", "ORGANISM", 323, 334], ["betacoronavirus OC43", "ORGANISM", 398, 418], ["human", "ORGANISM", 429, 434], ["lung cells", "CELL", 435, 445], ["TMEM119", "PROTEIN", 85, 92], ["TMEM119", "PROTEIN", 145, 152], ["MAPK", "PROTEIN", 189, 193], ["KSHV reactivation 27, 28 .FD-seq", "DNA", 243, 275], ["pro-inflammatory bystander cells", "CELL_TYPE", 284, 316], ["betacoronavirus OC43", "DNA", 398, 418], ["single human lung cells", "CELL_TYPE", 422, 445], ["human", "SPECIES", 429, 434], ["KSHV", "SPECIES", 103, 107], ["KSHV", "SPECIES", 243, 247], ["betacoronavirus", "SPECIES", 398, 413], ["human", "SPECIES", 429, 434], ["further study", "TEST", 6, 19], ["our data", "TEST", 122, 130], ["viral reactivation", "PROBLEM", 162, 180], ["the MAPK pathway", "TEST", 185, 201], ["KSHV reactivation", "TEST", 243, 260], ["pro-inflammatory bystander cells", "PROBLEM", 284, 316], ["coronavirus OC43 infectionWe", "PROBLEM", 323, 351], ["study infection", "TEST", 375, 390], ["the betacoronavirus OC43", "PROBLEM", 394, 418], ["viral reactivation", "OBSERVATION", 162, 180], ["pro-inflammatory bystander cells", "OBSERVATION", 284, 316], ["infection", "OBSERVATION", 381, 390], ["lung", "ANATOMY", 435, 439], ["cells", "OBSERVATION", 440, 445]]], ["OC43 is a human pathogen that causes the common cold, and also a close relative of SARS-CoV-2.", [["OC43", "CHEMICAL", 0, 4], ["SARS", "DISEASE", 83, 87], ["OC43", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 10, 15], ["SARS-CoV-2", "ORGANISM", 83, 93], ["OC43", "PROTEIN", 0, 4], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15], ["SARS-CoV", "SPECIES", 83, 91], ["a human pathogen", "PROBLEM", 8, 24]]], ["OC43 has been successfully used as a safer (BSL-2) model pathogen in COVID-19FD-seq reveals pro-inflammatory bystander cells after coronavirus OC43 infectionresearch.", [["bystander cells", "ANATOMY", 109, 124], ["OC43", "CHEMICAL", 0, 4], ["OC43", "GENE_OR_GENE_PRODUCT", 0, 4], ["COVID", "SIMPLE_CHEMICAL", 69, 74], ["bystander cells", "CELL", 109, 124], ["coronavirus", "ORGANISM", 131, 142], ["OC43", "GENE_OR_GENE_PRODUCT", 143, 147], ["OC43", "PROTEIN", 0, 4], ["COVID-19FD-seq", "DNA", 69, 83], ["pro-inflammatory bystander cells", "CELL_TYPE", 92, 124], ["model pathogen", "TEST", 51, 65], ["COVID", "TEST", 69, 74], ["pro-inflammatory bystander cells", "PROBLEM", 92, 124], ["coronavirus OC43 infectionresearch", "PROBLEM", 131, 165], ["pro-inflammatory bystander cells", "OBSERVATION", 92, 124], ["coronavirus OC43", "OBSERVATION", 131, 147]]], ["Drug screening studies showed that many drugs that inhibit replication of OC43 also inhibit SARS-CoV-2 in vitro 17 .", [["OC43", "CHEMICAL", 74, 78], ["OC43", "GENE_OR_GENE_PRODUCT", 74, 78], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 92, 102], ["OC43", "PROTEIN", 74, 78], ["SARS-CoV", "SPECIES", 92, 100], ["Drug screening studies", "TEST", 0, 22], ["many drugs", "TREATMENT", 35, 45], ["replication of OC43", "TREATMENT", 59, 78], ["SARS", "TEST", 92, 96], ["CoV", "TEST", 97, 100]]], ["First, we infected human lung epithelial A549 cells with coronavirus OC43 at a multiplicity of infection (MOI) of 1 and fixed the cells with PFA, along 11 with a fixed mock infected sample, and performed FD-seq.", [["lung epithelial A549 cells", "ANATOMY", 25, 51], ["cells", "ANATOMY", 130, 135], ["sample", "ANATOMY", 182, 188], ["multiplicity of infection", "DISEASE", 79, 104], ["PFA", "CHEMICAL", 141, 144], ["human", "ORGANISM", 19, 24], ["lung epithelial A549 cells", "CELL", 25, 51], ["coronavirus", "ORGANISM", 57, 68], ["OC43", "CELL", 69, 73], ["cells", "CELL", 130, 135], ["PFA", "SIMPLE_CHEMICAL", 141, 144], ["human lung epithelial A549 cells", "CELL_LINE", 19, 51], ["coronavirus OC43", "PROTEIN", 57, 73], ["human", "SPECIES", 19, 24], ["coronavirus", "SPECIES", 57, 68], ["human", "SPECIES", 19, 24], ["infected human lung epithelial A549 cells", "PROBLEM", 10, 51], ["coronavirus OC43", "PROBLEM", 57, 73], ["infection", "PROBLEM", 95, 104], ["PFA", "TEST", 141, 144], ["a fixed mock infected sample", "PROBLEM", 160, 188], ["infected", "OBSERVATION", 10, 18], ["lung", "ANATOMY", 25, 29], ["epithelial", "ANATOMY_MODIFIER", 30, 40], ["A549 cells", "OBSERVATION", 41, 51], ["coronavirus OC43", "OBSERVATION", 57, 73], ["infection", "OBSERVATION", 95, 104], ["PFA", "OBSERVATION_MODIFIER", 141, 144]]], ["This experiment emulated a scenario where researchers fix SARS-CoV-2-infected sample with PFA and store them for later analysis or international transportation to their collaborators.", [["PFA", "CHEMICAL", 90, 93], ["PFA", "SIMPLE_CHEMICAL", 90, 93], ["CoV", "TEST", 63, 66], ["PFA", "TREATMENT", 90, 93], ["later analysis", "TEST", 113, 127]]], ["We obtained 1,167 and 1,924 high-quality single cells from the mock infected and OC43-infected cells, respectively.", [["cells", "ANATOMY", 48, 53], ["cells", "ANATOMY", 95, 100], ["cells", "CELL", 48, 53], ["OC43", "CELL", 81, 85], ["cells", "CELL", 95, 100], ["single cells", "CELL_TYPE", 41, 53], ["OC43-infected cells", "CELL_LINE", 81, 100], ["infected", "OBSERVATION_MODIFIER", 68, 76], ["infected cells", "OBSERVATION", 86, 100]]], ["After regressing out the effects of cell cycle variations (Fig. S9a, b) , high dimensional clustering yielded three main clusters of cells (Fig. 2a) .", [["cell", "ANATOMY", 36, 40], ["cells", "ANATOMY", 133, 138], ["cell", "CELL", 36, 40], ["cells", "CELL", 133, 138], ["cell cycle variations", "TEST", 36, 57], ["high dimensional clustering", "PROBLEM", 74, 101]]], ["Cluster 0 mainly contained the mock infected cell, while clusters 1 and 2 mainly contained OC43-infected cells (Fig. 2b) .", [["cell", "ANATOMY", 45, 49], ["cells", "ANATOMY", 105, 110], ["cell", "CELL", 45, 49], ["OC43", "GENE_OR_GENE_PRODUCT", 91, 95], ["cells", "CELL", 105, 110], ["OC43-infected cells", "CELL_LINE", 91, 110], ["the mock infected cell", "PROBLEM", 27, 49], ["infected cell", "OBSERVATION", 36, 49], ["infected cells", "OBSERVATION", 96, 110]]], ["At MOI 1, more than 70% of the cells were infected (defined as cells showing non-zero expression of viral genes) (Fig. 2c) .", [["cells", "ANATOMY", 31, 36], ["cells", "ANATOMY", 63, 68], ["cells", "CELL", 31, 36], ["cells", "CELL", 63, 68], ["viral genes", "DNA", 100, 111], ["non-zero expression of viral genes", "PROBLEM", 77, 111], ["viral genes", "OBSERVATION", 100, 111]]], ["Interestingly, this infected population consists of two subpopulations based on the number of viral transcripts detected: a larger subpopulation containing a low number of viral transcripts (below 100 UMIs, median 2 UMIs) and a smaller subpopulation containing a much high number of viral transcripts (above 100FD-seq reveals pro-inflammatory bystander cells after coronavirus OC43 infectionUMIs, median 428 UMIs) (Fig 2d) .", [["bystander cells", "ANATOMY", 343, 358], ["bystander cells", "CELL", 343, 358], ["coronavirus", "ORGANISM", 365, 376], ["viral transcripts", "RNA", 94, 111], ["viral transcripts", "RNA", 172, 189], ["viral transcripts", "RNA", 283, 300], ["100FD", "PROTEIN", 308, 313], ["pro-inflammatory bystander cells", "CELL_TYPE", 326, 358], ["this infected population", "PROBLEM", 15, 39], ["viral transcripts", "PROBLEM", 94, 111], ["a larger subpopulation", "PROBLEM", 122, 144], ["viral transcripts", "PROBLEM", 172, 189], ["a smaller subpopulation", "PROBLEM", 226, 249], ["viral transcripts", "PROBLEM", 283, 300], ["pro-inflammatory bystander cells", "PROBLEM", 326, 358], ["coronavirus OC43 infectionUMIs", "PROBLEM", 365, 395], ["infected", "OBSERVATION", 20, 28], ["two", "OBSERVATION_MODIFIER", 52, 55], ["subpopulations", "OBSERVATION_MODIFIER", 56, 70], ["viral transcripts", "OBSERVATION", 94, 111], ["larger", "OBSERVATION_MODIFIER", 124, 130], ["subpopulation", "OBSERVATION_MODIFIER", 131, 144], ["low number", "OBSERVATION_MODIFIER", 158, 168], ["viral transcripts", "OBSERVATION", 172, 189], ["smaller", "OBSERVATION_MODIFIER", 228, 235], ["subpopulation", "OBSERVATION", 236, 249], ["viral transcripts", "OBSERVATION", 283, 300]]], ["This small subpopulation of highly infected cells corresponds to cluster 2 (Fig. 2e, Fig. S9c, d) .FD-seq reveals pro-inflammatory bystander cells after coronavirus OC43 infectionNext, we sought to investigate the expression profile of OC43 viral genes as a function of total viral gene level.", [["cells", "ANATOMY", 44, 49], ["bystander cells", "ANATOMY", 131, 146], ["cells", "CELL", 44, 49], ["bystander cells", "CELL", 131, 146], ["coronavirus", "ORGANISM", 153, 164], ["OC43", "GENE_OR_GENE_PRODUCT", 165, 169], ["OC43", "GENE_OR_GENE_PRODUCT", 236, 240], ["highly infected cells", "CELL_TYPE", 28, 49], ["pro-inflammatory bystander cells", "CELL_TYPE", 114, 146], ["OC43 viral genes", "DNA", 236, 252], ["highly infected cells", "PROBLEM", 28, 49], ["FD", "TEST", 99, 101], ["pro-inflammatory bystander cells", "PROBLEM", 114, 146], ["coronavirus OC43 infectionNext", "PROBLEM", 153, 183], ["OC43 viral genes", "PROBLEM", 236, 252], ["total viral gene level", "PROBLEM", 270, 292], ["small", "OBSERVATION_MODIFIER", 5, 10], ["subpopulation", "OBSERVATION_MODIFIER", 11, 24], ["highly", "OBSERVATION_MODIFIER", 28, 34], ["infected cells", "OBSERVATION", 35, 49], ["pro-inflammatory bystander cells", "OBSERVATION", 114, 146]]], ["Within cluster 2, gene N (which encodes the viral nucleocapsid protein 29 ) was uniformly highly expressed (Fig. 2f) .", [["cluster 2", "GENE_OR_GENE_PRODUCT", 7, 16], ["viral nucleocapsid protein 29", "GENE_OR_GENE_PRODUCT", 44, 73], ["gene N", "DNA", 18, 24], ["viral nucleocapsid protein 29", "PROTEIN", 44, 73], ["the viral nucleocapsid protein", "TEST", 40, 70]]], ["The expression of the remaining viral genes was more heterogeneous, with ORF1ab, M (membrane gene) and S (spike gene) being more highly expressed overall compared to E (envelope gene), HE (hemagglutinin-esterase gene) and ns12.9 (which encodes a 12.9 kDa non-structural protein). ns2 (which encodes the non-structural protein 2) was the least abundant viral gene.", [["ORF1ab", "GENE_OR_GENE_PRODUCT", 73, 79], ["M (membrane gene", "GENE_OR_GENE_PRODUCT", 81, 97], ["S (spike gene", "GENE_OR_GENE_PRODUCT", 103, 116], ["E (envelope gene", "GENE_OR_GENE_PRODUCT", 166, 182], ["HE (hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 185, 211], ["ns2", "GENE_OR_GENE_PRODUCT", 280, 283], ["non-structural protein 2", "GENE_OR_GENE_PRODUCT", 303, 327], ["viral genes", "DNA", 32, 43], ["ORF1ab, M (membrane gene", "DNA", 73, 97], ["S", "DNA", 103, 104], ["spike gene", "DNA", 106, 116], ["E (envelope gene", "DNA", 166, 182], ["HE (hemagglutinin-esterase gene", "DNA", 185, 216], ["ns12.9", "DNA", 222, 228], ["12.9 kDa non-structural protein", "PROTEIN", 246, 277], ["ns2", "DNA", 280, 283], ["non-structural protein 2", "PROTEIN", 303, 327], ["viral gene", "DNA", 352, 362], ["the remaining viral genes", "PROBLEM", 18, 43], ["ORF1ab, M (membrane gene) and S (spike gene)", "PROBLEM", 73, 117], ["ns", "TEST", 222, 224], ["ns2", "PROBLEM", 280, 283], ["the non-structural protein", "TEST", 299, 325], ["viral genes", "OBSERVATION", 32, 43], ["heterogeneous", "OBSERVATION_MODIFIER", 53, 66], ["abundant", "OBSERVATION_MODIFIER", 343, 351], ["viral gene", "OBSERVATION", 352, 362]]], ["These patterns of viral gene expression level were also true when looking at all infected cells (Fig. S10) .FD-seq reveals pro-inflammatory bystander cells after coronavirus OC43 infectionCluster 1 consisted of cells that were exposed to the virus but failed to express high levels of viral genes ( Fig. 2d and Fig. S9c, d) , and were thus either abortively-infected or uninfected bystander cells.", [["cells", "ANATOMY", 90, 95], ["bystander cells", "ANATOMY", 140, 155], ["cells", "ANATOMY", 211, 216], ["cells", "ANATOMY", 391, 396], ["cells", "CELL", 90, 95], ["bystander cells", "CELL", 140, 155], ["coronavirus", "ORGANISM", 162, 173], ["cells", "CELL", 211, 216], ["S9c", "GENE_OR_GENE_PRODUCT", 316, 319], ["bystander cells", "CELL", 381, 396], ["infected cells", "CELL_TYPE", 81, 95], ["pro-inflammatory bystander cells", "CELL_TYPE", 123, 155], ["viral genes", "DNA", 285, 296], ["uninfected bystander cells", "CELL_TYPE", 370, 396], ["coronavirus", "SPECIES", 162, 173], ["viral gene expression level", "PROBLEM", 18, 45], ["FD", "TEST", 108, 110], ["pro-inflammatory bystander cells", "PROBLEM", 123, 155], ["coronavirus OC43 infectionCluster", "TREATMENT", 162, 195], ["cells", "PROBLEM", 211, 216], ["the virus", "PROBLEM", 238, 247], ["high levels of viral genes", "PROBLEM", 270, 296], ["uninfected bystander cells", "PROBLEM", 370, 396], ["viral gene expression", "OBSERVATION", 18, 39], ["infected cells", "OBSERVATION", 81, 95], ["pro-inflammatory bystander cells", "OBSERVATION", 123, 155], ["viral genes", "OBSERVATION", 285, 296], ["bystander cells", "OBSERVATION", 381, 396]]], ["We found that these bystander cells were enriched in pro-inflammatory genes, such as CXCL1, CXCL5, CCL2 and NFKBIA (Fig. 2g, Fig. S11, and Supplementary File 3) .FD-seq reveals pro-inflammatory bystander cells after coronavirus OC43 infectionCXCL1 and CXCL5 encode the protein ligands of the CXC chemokine receptor 2 (CXCR2), and are crucial to neutrophil recruitment 30 .", [["bystander cells", "ANATOMY", 20, 35], ["bystander cells", "ANATOMY", 194, 209], ["neutrophil", "ANATOMY", 345, 355], ["bystander cells", "CELL", 20, 35], ["CXCL1", "GENE_OR_GENE_PRODUCT", 85, 90], ["CXCL5", "GENE_OR_GENE_PRODUCT", 92, 97], ["CCL2", "GENE_OR_GENE_PRODUCT", 99, 103], ["NFKBIA", "GENE_OR_GENE_PRODUCT", 108, 114], ["bystander cells", "CELL", 194, 209], ["coronavirus", "ORGANISM", 216, 227], ["OC43", "GENE_OR_GENE_PRODUCT", 228, 232], ["CXCL5", "GENE_OR_GENE_PRODUCT", 252, 257], ["CXC chemokine receptor 2", "GENE_OR_GENE_PRODUCT", 292, 316], ["CXCR2", "GENE_OR_GENE_PRODUCT", 318, 323], ["neutrophil", "CELL", 345, 355], ["bystander cells", "CELL_TYPE", 20, 35], ["pro-inflammatory genes", "DNA", 53, 75], ["CXCL1", "PROTEIN", 85, 90], ["CXCL5", "PROTEIN", 92, 97], ["CCL2", "PROTEIN", 99, 103], ["NFKBIA", "PROTEIN", 108, 114], ["pro-inflammatory bystander cells", "CELL_TYPE", 177, 209], ["coronavirus OC43 infectionCXCL1", "PROTEIN", 216, 247], ["CXCL5", "PROTEIN", 252, 257], ["CXC chemokine receptor 2", "PROTEIN", 292, 316], ["CXCR2", "PROTEIN", 318, 323], ["these bystander cells", "PROBLEM", 14, 35], ["CXCL1", "TEST", 85, 90], ["CXCL5", "TEST", 92, 97], ["CCL2", "TEST", 99, 103], ["NFKBIA", "TEST", 108, 114], ["FD", "TEST", 162, 164], ["pro-inflammatory bystander cells", "PROBLEM", 177, 209], ["coronavirus OC43 infectionCXCL1", "PROBLEM", 216, 247], ["CXCL5", "TEST", 252, 257], ["the protein ligands", "TEST", 265, 284], ["the CXC chemokine receptor", "TEST", 288, 314], ["CXCR2", "TEST", 318, 323], ["neutrophil recruitment", "TEST", 345, 367], ["bystander cells", "OBSERVATION", 20, 35], ["pro-inflammatory genes", "OBSERVATION", 53, 75], ["CXCL1", "ANATOMY", 85, 90], ["CXCL5", "ANATOMY", 92, 97], ["pro-inflammatory bystander cells", "OBSERVATION", 177, 209], ["neutrophil recruitment", "OBSERVATION", 345, 367]]], ["CCL2 encodes a different chemokine that is responsible for monocyte recruitment from the bone marrow 31 .", [["monocyte", "ANATOMY", 59, 67], ["bone marrow", "ANATOMY", 89, 100], ["CCL2", "GENE_OR_GENE_PRODUCT", 0, 4], ["monocyte", "CELL", 59, 67], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 89, 100], ["CCL2", "PROTEIN", 0, 4], ["chemokine", "PROTEIN", 25, 34], ["a different chemokine", "TREATMENT", 13, 34], ["monocyte recruitment", "TEST", 59, 79], ["the bone marrow", "TEST", 85, 100], ["responsible for", "UNCERTAINTY", 43, 58], ["monocyte recruitment", "OBSERVATION", 59, 79], ["bone marrow", "ANATOMY", 89, 100]]], ["NFKBIA encodes the inhibitor I\u03baB\u03b1 to the transcription factor NF-\u03baB, which is an important regulator of the immune response 32 .", [["NFKBIA", "GENE_OR_GENE_PRODUCT", 0, 6], ["I\u03baB\u03b1", "GENE_OR_GENE_PRODUCT", 29, 33], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 62, 67], ["NFKBIA", "PROTEIN", 0, 6], ["I\u03baB\u03b1", "PROTEIN", 29, 33], ["transcription factor", "PROTEIN", 41, 61], ["NF-\u03baB", "PROTEIN", 62, 67]]], ["KEGG pathway analysis showed that cluster 1 was enriched for three main pro-inflammatory pathways:FD-seq reveals pro-inflammatory bystander cells after coronavirus OC43 infectionTNF, IL-17 and NF-\u03baB signaling pathways (Fig. 2g) .", [["bystander cells", "ANATOMY", 130, 145], ["cluster 1", "GENE_OR_GENE_PRODUCT", 34, 43], ["FD-seq", "GENE_OR_GENE_PRODUCT", 98, 104], ["bystander cells", "CELL", 130, 145], ["coronavirus", "ORGANISM", 152, 163], ["OC43", "GENE_OR_GENE_PRODUCT", 164, 168], ["IL-17", "GENE_OR_GENE_PRODUCT", 183, 188], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 193, 198], ["pro-inflammatory bystander cells", "CELL_TYPE", 113, 145], ["KEGG pathway analysis", "TEST", 0, 21], ["FD", "TEST", 98, 100], ["pro-inflammatory bystander cells", "PROBLEM", 113, 145], ["coronavirus OC43 infectionTNF", "PROBLEM", 152, 181], ["IL", "TEST", 183, 185], ["NF", "TEST", 193, 195], ["pro-inflammatory bystander cells", "OBSERVATION", 113, 145]]], ["On the other hand, the ribosome biogenesis pathway is enriched in the upregulated genes in this cluster 2 (Fig. 2g) , most probably because the virus inside the cells in cluster 2 hijacks the host's machinery for their own RNA replication.", [["ribosome", "ANATOMY", 23, 31], ["cells", "ANATOMY", 161, 166], ["ribosome", "CELLULAR_COMPONENT", 23, 31], ["cells", "CELL", 161, 166], ["cluster 2", "CELL", 170, 179], ["upregulated genes", "DNA", 70, 87], ["the virus", "PROBLEM", 140, 149], ["ribosome", "OBSERVATION", 23, 31], ["biogenesis pathway", "OBSERVATION", 32, 50], ["enriched", "OBSERVATION_MODIFIER", 54, 62], ["upregulated genes", "OBSERVATION", 70, 87], ["most probably", "UNCERTAINTY", 118, 131], ["virus", "OBSERVATION", 144, 149]]], ["These findings are in agreement with our previous characterization of HSV-1 infection at the single-cell level 22 , which showed that most HSV-1 infected cells did not express high levels of viral genes, and that these abortively-infected cells were the main producers of antiviral gene transcripts and the initiators of the type I interferon signaling.ConclusionHere we present FD-seq, a novel method for high-throughput droplet-based sequencing of PFAfixed single cells.", [["single-cell", "ANATOMY", 93, 104], ["cells", "ANATOMY", 154, 159], ["cells", "ANATOMY", 239, 244], ["cells", "ANATOMY", 466, 471], ["infection", "DISEASE", 76, 85], ["HSV-1", "ORGANISM", 70, 75], ["single-cell", "CELL", 93, 104], ["HSV-1", "ORGANISM", 139, 144], ["cells", "CELL", 154, 159], ["cells", "CELL", 239, 244], ["type I interferon", "GENE_OR_GENE_PRODUCT", 325, 342], ["PFAfixed single cells", "CELL", 450, 471], ["viral genes", "DNA", 191, 202], ["abortively-infected cells", "CELL_TYPE", 219, 244], ["antiviral gene transcripts", "RNA", 272, 298], ["type I interferon", "PROTEIN", 325, 342], ["FD-seq", "DNA", 379, 385], ["PFAfixed single cells", "CELL_LINE", 450, 471], ["HSV-1", "SPECIES", 70, 75], ["HSV-1", "SPECIES", 139, 144], ["HSV-1", "SPECIES", 70, 75], ["HSV-1", "SPECIES", 139, 144], ["HSV", "PROBLEM", 70, 73], ["1 infection", "PROBLEM", 74, 85], ["the single-cell level", "TEST", 89, 110], ["HSV", "TEST", 139, 142], ["1 infected cells", "PROBLEM", 143, 159], ["high levels of viral genes", "PROBLEM", 176, 202], ["infected cells", "PROBLEM", 230, 244], ["antiviral gene transcripts", "TREATMENT", 272, 298], ["the type I interferon signaling", "PROBLEM", 321, 352], ["a novel method", "TEST", 387, 401], ["PFAfixed single cells", "PROBLEM", 450, 471], ["infection", "OBSERVATION", 76, 85], ["infected cells", "OBSERVATION", 145, 159], ["viral genes", "OBSERVATION", 191, 202], ["infected cells", "OBSERVATION", 230, 244]]], ["FD-seq is particularly useful for sequencing rare subpopulations of cells that require intracellular staining and FACS-enrichment, and for rendering BSL-3 samples safe for BSL-2 condition.", [["cells", "ANATOMY", 68, 73], ["intracellular", "ANATOMY", 87, 100], ["samples", "ANATOMY", 155, 162], ["cells", "CELL", 68, 73], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 87, 100], ["BSL-2", "GENE_OR_GENE_PRODUCT", 172, 177], ["BSL", "PROTEIN", 149, 152], ["sequencing rare subpopulations of cells", "PROBLEM", 34, 73], ["intracellular staining", "TEST", 87, 109], ["FACS", "TEST", 114, 118], ["BSL", "TEST", 149, 152], ["BSL", "TEST", 172, 175]]], ["We used FD-seq to study the process of KSHV lytic reactivation at the singlecell level, and found that reactivation is very heterogeneous, and that the expression levels of viral genes correlated poorly with one another.", [["KSHV", "ORGANISM", 39, 43], ["viral genes", "DNA", 173, 184], ["KSHV", "SPECIES", 39, 43], ["KSHV lytic reactivation", "PROBLEM", 39, 62], ["reactivation", "PROBLEM", 103, 115], ["KSHV", "OBSERVATION_MODIFIER", 39, 43], ["lytic", "OBSERVATION", 44, 49], ["reactivation", "OBSERVATION", 103, 115], ["very", "OBSERVATION_MODIFIER", 119, 123], ["heterogeneous", "OBSERVATION_MODIFIER", 124, 137]]], ["We found four host factors to be strongly correlated with viral reactivation, namely CDH1, CORO1C, ISCU and TMEM119.", [["CDH1", "GENE_OR_GENE_PRODUCT", 85, 89], ["CORO1C", "GENE_OR_GENE_PRODUCT", 91, 97], ["TMEM119", "GENE_OR_GENE_PRODUCT", 108, 115], ["CDH1", "DNA", 85, 89], ["CORO1C", "PROTEIN", 91, 97], ["ISCU", "DNA", 99, 103], ["TMEM119", "DNA", 108, 115], ["viral reactivation", "PROBLEM", 58, 76], ["four host", "OBSERVATION_MODIFIER", 9, 18], ["viral reactivation", "OBSERVATION", 58, 76]]], ["ISCU is involved in the production of the iron-sulfur cluster assembly enzyme, and a mutation in ISCU is linked to 13 myopathy 33 .", [["myopathy", "DISEASE", 118, 126], ["ISCU", "CANCER", 97, 101], ["iron-sulfur cluster assembly enzyme", "PROTEIN", 42, 77], ["ISCU", "PROTEIN", 97, 101], ["a mutation in ISCU", "PROBLEM", 83, 101], ["myopathy", "PROBLEM", 118, 126]]], ["CDH1 (E-cadherin) is an adhesion protein, and different mutations in CDH1 are associated with different cancer conditions 34 .", [["cancer", "ANATOMY", 104, 110], ["cancer", "DISEASE", 104, 110], ["CDH1", "GENE_OR_GENE_PRODUCT", 0, 4], ["E-cadherin", "GENE_OR_GENE_PRODUCT", 6, 16], ["CDH1", "GENE_OR_GENE_PRODUCT", 69, 73], ["cancer", "CANCER", 104, 110], ["CDH1", "DNA", 0, 4], ["E-cadherin", "PROTEIN", 6, 16], ["adhesion protein", "PROTEIN", 24, 40], ["CDH1", "DNA", 69, 73], ["CDH1", "PROBLEM", 0, 4], ["an adhesion protein", "PROBLEM", 21, 40], ["different mutations in CDH1", "PROBLEM", 46, 73], ["different cancer conditions", "PROBLEM", 94, 121], ["adhesion protein", "OBSERVATION", 24, 40], ["cancer", "OBSERVATION", 104, 110]]], ["CORO1C encodes a protein that belongs to the WD repeat protein family.", [["CORO1C", "GENE_OR_GENE_PRODUCT", 0, 6], ["CORO1C", "PROTEIN", 0, 6], ["WD repeat protein family", "PROTEIN", 45, 69]]], ["Lastly, TMEM119 is a transmembrane protein, and is a marker for human microglial cells 35 .", [["transmembrane", "ANATOMY", 21, 34], ["microglial cells", "ANATOMY", 70, 86], ["TMEM119", "GENE_OR_GENE_PRODUCT", 8, 15], ["transmembrane", "CELLULAR_COMPONENT", 21, 34], ["human", "ORGANISM", 64, 69], ["microglial cells", "CELL", 70, 86], ["TMEM119", "PROTEIN", 8, 15], ["transmembrane protein", "PROTEIN", 21, 42], ["human microglial cells 35", "CELL_LINE", 64, 89], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["a transmembrane protein", "TEST", 19, 42], ["human microglial cells", "TEST", 64, 86]]], ["Using live-cell imaging and time-course study, we found TMEM119 to have the most pronounced effect among the four genes in enhancing the degree of viral reactivation.", [["live-cell", "ANATOMY", 6, 15], ["cell", "CELL", 11, 15], ["TMEM119", "GENE_OR_GENE_PRODUCT", 56, 63], ["TMEM119", "PROTEIN", 56, 63], ["live-cell imaging", "TEST", 6, 23], ["time-course study", "TEST", 28, 45], ["viral reactivation", "PROBLEM", 147, 165], ["most pronounced", "OBSERVATION_MODIFIER", 76, 91], ["viral reactivation", "OBSERVATION", 147, 165]]], ["Bulk RNA-seq suggested that this effect of TMEM119 could be mediated through the MAPK signaling pathway.ConclusionWe showed a potential application of FD-seq for investigating the host response in a coronavirus infection in vitro model, which also suggests its possible use in COVID-19 pandemic research.", [["TMEM119", "CHEMICAL", 43, 50], ["coronavirus infection", "DISEASE", 199, 220], ["TMEM119", "GENE_OR_GENE_PRODUCT", 43, 50], ["MAPK", "GENE_OR_GENE_PRODUCT", 81, 85], ["coronavirus", "ORGANISM", 199, 210], ["TMEM119", "PROTEIN", 43, 50], ["MAPK", "PROTEIN", 81, 85], ["coronavirus", "SPECIES", 199, 210], ["FD-seq", "TREATMENT", 151, 157], ["a coronavirus infection in vitro model", "PROBLEM", 197, 235], ["coronavirus infection", "OBSERVATION", 199, 220], ["suggests its possible", "UNCERTAINTY", 248, 269]]], ["We found that most of the cells after exposure to the OC43 coronavirus were unable to support high level of viral gene expression, and instead upregulated pro-inflammatory signaling pathways.", [["cells", "ANATOMY", 26, 31], ["cells", "CELL", 26, 31], ["OC43 coronavirus", "ORGANISM", 54, 70], ["OC43 coronavirus", "SPECIES", 54, 70], ["the cells", "PROBLEM", 22, 31], ["the OC43 coronavirus", "PROBLEM", 50, 70], ["viral gene expression", "PROBLEM", 108, 129], ["viral gene expression", "OBSERVATION", 108, 129]]], ["Therefore, these bystander cells are the main producers of pro-inflammatory gene products such as cytokines during OC43 infection in vitro.", [["bystander cells", "ANATOMY", 17, 32], ["infection", "DISEASE", 120, 129], ["bystander cells", "CELL", 17, 32], ["OC43", "GENE_OR_GENE_PRODUCT", 115, 119], ["bystander cells", "CELL_TYPE", 17, 32], ["pro-inflammatory gene products", "PROTEIN", 59, 89], ["cytokines", "PROTEIN", 98, 107], ["these bystander cells", "TREATMENT", 11, 32], ["pro-inflammatory gene products", "TREATMENT", 59, 89], ["cytokines during OC43 infection", "PROBLEM", 98, 129], ["pro-inflammatory gene", "OBSERVATION", 59, 80]]], ["Because cytokine storm has been shown to be associated many viral infections 36 and with COVID-19 disease severity 18 , and because of the close relationship between OC43 and SARS-CoV-2, it would be interesting to investigate whether cytokine storm is indeed driven by these bystander cells in COVID-19 patients.", [["bystander cells", "ANATOMY", 275, 290], ["viral infections", "DISEASE", 60, 76], ["OC43", "GENE_OR_GENE_PRODUCT", 166, 170], ["SARS-CoV-2", "ORGANISM", 175, 185], ["bystander cells", "CELL", 275, 290], ["COVID-19", "CELL", 294, 302], ["patients", "ORGANISM", 303, 311], ["cytokine", "PROTEIN", 8, 16], ["cytokine", "PROTEIN", 234, 242], ["bystander cells", "CELL_TYPE", 275, 290], ["patients", "SPECIES", 303, 311], ["SARS-CoV", "SPECIES", 175, 183], ["cytokine storm", "PROBLEM", 8, 22], ["many viral infections", "PROBLEM", 55, 76], ["COVID-19 disease severity", "PROBLEM", 89, 114], ["OC43", "TEST", 166, 170], ["cytokine storm", "PROBLEM", 234, 248], ["many", "OBSERVATION_MODIFIER", 55, 59], ["viral", "OBSERVATION_MODIFIER", 60, 65], ["infections", "OBSERVATION", 66, 76]]], ["If this is true, the bystander cells can be a therapeutic target for these patients.FD-seq is a valuable tool for integrating protein activity with transcriptome information.Transcription factor expression levels and phosphorylation can be integrated with whole transcriptome analysis by combining intracellular protein staining with FD-seq.", [["bystander cells", "ANATOMY", 21, 36], ["intracellular", "ANATOMY", 298, 311], ["bystander cells", "CELL", 21, 36], ["patients", "ORGANISM", 75, 83], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 298, 311], ["bystander cells", "CELL_TYPE", 21, 36], ["FD-seq", "DNA", 84, 90], ["Transcription factor", "PROTEIN", 174, 194], ["patients", "SPECIES", 75, 83], ["the bystander cells", "PROBLEM", 17, 36], ["Transcription factor expression levels", "TEST", 174, 212], ["phosphorylation", "TREATMENT", 217, 232], ["whole transcriptome analysis", "TEST", 256, 284], ["combining intracellular protein staining", "PROBLEM", 288, 328]]], ["Furthermore, FDseq is compatible with RNA velocity analysis, which relies on detection of unspliced mRNA molecules 12 (Fig. S12) .", [["FDseq", "PROTEIN", 13, 18], ["unspliced mRNA molecules 12", "PROTEIN", 90, 117], ["Fig. S12", "PROTEIN", 119, 127], ["RNA velocity analysis", "PROBLEM", 38, 59], ["unspliced mRNA molecules", "PROBLEM", 90, 114], ["compatible with", "UNCERTAINTY", 22, 37], ["RNA velocity", "OBSERVATION", 38, 50]]], ["In future studies, FD-seq could potentially be improved for sequencing 14 formalin-fixed paraffin-embedded (FFPE) tissues, the achievement of which would enable highthroughput single-cell sequencing of readily available samples in tissue banks.Data availabilityThe raw data, metadata and count data are deposited in NBCI's Gene Expression Omnibus (accession number GSE156988).AcknowledgementWe thank Heather Eckart for providing advice on Drop-seq.", [["FFPE) tissues", "ANATOMY", 108, 121], ["cell", "ANATOMY", 183, 187], ["samples", "ANATOMY", 220, 227], ["tissue banks", "ANATOMY", 231, 243], ["formalin", "CHEMICAL", 74, 82], ["paraffin", "CHEMICAL", 89, 97], ["tissues", "TISSUE", 114, 121], ["samples", "TISSUE", 220, 227], ["tissue", "TISSUE", 231, 237], ["Drop-seq", "DNA", 439, 447], ["future studies", "TEST", 3, 17], ["sequencing 14 formalin", "TEST", 60, 82], ["fixed paraffin-embedded (FFPE) tissues", "TREATMENT", 83, 121], ["The raw data", "TEST", 261, 273], ["count data", "TEST", 288, 298]]], ["This study was supported in part by U.S. National Institutes of Health (NIH) grants (R21 AI118509 and R01 AI087846 to M.U.G.).Competing interestsThe authors declare no competing interests.", [["This study", "TEST", 0, 10]]], ["15 The microfluidic device was fabricated based on the AutoCAD file provided in Macosko et al. 3 The mold was made from SU8-3050 photoresist of 100 \u00b5m height.", [["SU8-3050", "CHEMICAL", 120, 128], ["SU8-3050", "CHEMICAL", 120, 128], ["The microfluidic device", "TREATMENT", 3, 26], ["SU8", "TEST", 120, 123], ["microfluidic device", "OBSERVATION", 7, 26]]], ["Then, polydimethylsiloxane (PDMS, Momentive RTV615) was cast on the mold to form the microfluidic devices.", [["polydimethylsiloxane", "CHEMICAL", 6, 26], ["polydimethylsiloxane", "CHEMICAL", 6, 26], ["PDMS", "CHEMICAL", 28, 32], ["polydimethylsiloxane", "SIMPLE_CHEMICAL", 6, 26], ["polydimethylsiloxane (PDMS", "TREATMENT", 6, 32], ["the microfluidic devices", "TREATMENT", 81, 105], ["microfluidic devices", "OBSERVATION", 85, 105]]], ["Plasma bonding was used to bond the PDMS device to a glass slide, and the microfluidic channels were coated with Aquapel.Optimization of RNA extraction condition for fixed and permeabilized cellsBC3 cells were harvested, centrifuged at 300g for 3 min to remove the cell media, and washed once with PBS and 1% BSA (molecular biology grade, Gemini Bio-Products).", [["cellsBC3 cells", "ANATOMY", 190, 204], ["cell", "ANATOMY", 265, 269], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["cellsBC3 cells", "CELL", 190, 204], ["cell", "CELL", 265, 269], ["BSA", "SIMPLE_CHEMICAL", 309, 312], ["cellsBC3 cells", "CELL_LINE", 190, 204], ["Plasma bonding", "TREATMENT", 0, 14], ["the PDMS device", "TREATMENT", 32, 47], ["a glass slide", "TREATMENT", 51, 64], ["the microfluidic channels", "TREATMENT", 70, 95], ["Aquapel", "TREATMENT", 113, 120], ["RNA extraction condition", "TREATMENT", 137, 161], ["fixed and permeabilized cellsBC3 cells", "TREATMENT", 166, 204], ["the cell media", "TREATMENT", 261, 275], ["PBS", "TEST", 298, 301]]], ["To fix the cells, 4% PFA in PBS (Santa Cruz Biotechnology) was added to the cells and incubated at room temperature for 15 minutes.", [["cells", "ANATOMY", 11, 16], ["cells", "ANATOMY", 76, 81], ["PFA", "CHEMICAL", 21, 24], ["cells", "CELL", 11, 16], ["PFA", "SIMPLE_CHEMICAL", 21, 24], ["PBS", "SIMPLE_CHEMICAL", 28, 31], ["cells", "CELL", 76, 81], ["cells", "ANATOMY", 11, 16]]], ["Next, the paraformaldehyde was discarded, and the cells was washed once with wash buffer (PBS with 1% BSA and 40 units/ml of RNase inhibitor, murine (NEB)).", [["cells", "ANATOMY", 50, 55], ["paraformaldehyde", "CHEMICAL", 10, 26], ["paraformaldehyde", "SIMPLE_CHEMICAL", 10, 26], ["cells", "CELL", 50, 55], ["BSA", "SIMPLE_CHEMICAL", 102, 105], ["RNase", "GENE_OR_GENE_PRODUCT", 125, 130], ["murine", "ORGANISM", 142, 148], ["RNase", "PROTEIN", 125, 130], ["murine", "SPECIES", 142, 148], ["the paraformaldehyde", "TREATMENT", 6, 26], ["the cells", "TREATMENT", 46, 55], ["wash buffer (PBS", "TREATMENT", 77, 93], ["1% BSA", "TREATMENT", 99, 105], ["RNase inhibitor", "TREATMENT", 125, 140], ["murine (NEB", "TREATMENT", 142, 153]]], ["To permeabilize the cells, 0.1% Triton X-100 (molecular biology grade, Acros Organics) diluted in the wash buffer was added to the cells, and incubated at room temperature for 15 minutes.", [["cells", "ANATOMY", 20, 25], ["cells", "ANATOMY", 131, 136], ["Triton X-100", "CHEMICAL", 32, 44], ["Triton X-100", "CHEMICAL", 32, 44], ["cells", "CELL", 20, 25], ["Triton X-100", "SIMPLE_CHEMICAL", 32, 44], ["cells", "CELL", 131, 136], ["Acros Organics", "TREATMENT", 71, 85], ["the wash buffer", "TREATMENT", 98, 113]]], ["Then, after adding the wash buffer, cells were pelleted, the supernatant was discarded, and the cells were wash once more with the wash buffer.", [["cells", "ANATOMY", 36, 41], ["supernatant", "ANATOMY", 61, 72], ["cells", "ANATOMY", 96, 101], ["cells", "CELL", 36, 41], ["cells", "CELL", 96, 101], ["the wash buffer", "TREATMENT", 19, 34], ["cells", "TREATMENT", 36, 41], ["the supernatant", "TREATMENT", 57, 72], ["the cells", "TREATMENT", 92, 101], ["the wash buffer", "TREATMENT", 127, 142]]], ["To mimic the condition of antibody staining, cells were resuspended in wash buffer and incubated on ice for 1 hour, washed twice with the wash buffer and finally stored in wash buffer.Optimization of RNA extraction condition for fixed and permeabilized cellsTo serve as a positive control, RNA from bulk live cells was extracted using the RNeasy Plus Mini Kit (Qiagen).", [["cells", "ANATOMY", 45, 50], ["cells", "ANATOMY", 253, 258], ["cells", "ANATOMY", 309, 314], ["cells", "CELL", 45, 50], ["cells", "CELL", 253, 258], ["cells", "CELL", 309, 314], ["permeabilized cells", "CELL_TYPE", 239, 258], ["bulk live cells", "CELL_TYPE", 299, 314], ["antibody staining", "PROBLEM", 26, 43], ["cells", "PROBLEM", 45, 50], ["the wash buffer", "TREATMENT", 134, 149], ["RNA extraction condition", "TREATMENT", 200, 224], ["fixed and permeabilized cells", "TREATMENT", 229, 258], ["a positive control", "TREATMENT", 270, 288], ["Mini Kit (Qiagen)", "TREATMENT", 351, 368], ["permeabilized cells", "OBSERVATION", 239, 258]]], ["Cells were first suspended in a combination of the standard Drop-seq lysis buffer with PBS at equal volume ratio (to make the lysis buffer's final concentration the same as that in droplets), incubated at room temperature for 10 minutes, and placed on ice for at least 5 minutes.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["the standard Drop-seq lysis buffer", "TREATMENT", 47, 81], ["PBS", "TREATMENT", 87, 90], ["the lysis buffer", "TREATMENT", 122, 138], ["ice", "TREATMENT", 252, 255]]], ["Next, the cell lysate was combined with 350 \u00b5l of RLT plus buffer from the RNeasy kit, and processed according to the manufacturer's protocol.Optimization of RNA extraction condition for fixed and permeabilized cellsTo extract RNA from bulk fixed cells, fixed and permeabilized cells (as described above)Optimization of RNA extraction condition for fixed and permeabilized cellswere suspended in a combination of Drop-seq lysis buffer spiked in with various concentrations of proteinase K (NEB), and PBS at equal volume ratio.", [["cell lysate", "ANATOMY", 10, 21], ["cells", "ANATOMY", 211, 216], ["cells", "ANATOMY", 247, 252], ["cells", "ANATOMY", 278, 283], ["K", "CHEMICAL", 487, 488], ["cell", "CELL", 10, 14], ["RLT", "SIMPLE_CHEMICAL", 50, 53], ["cells", "CELL", 211, 216], ["cells", "CELL", 247, 252], ["cells", "CELL", 278, 283], ["proteinase K", "GENE_OR_GENE_PRODUCT", 476, 488], ["NEB", "SIMPLE_CHEMICAL", 490, 493], ["permeabilized cells", "CELL_TYPE", 197, 216], ["bulk fixed cells", "CELL_TYPE", 236, 252], ["permeabilized cells", "CELL_TYPE", 264, 283], ["proteinase K", "PROTEIN", 476, 488], ["the cell lysate", "TREATMENT", 6, 21], ["RLT", "TREATMENT", 50, 53], ["the RNeasy kit", "TREATMENT", 71, 85], ["the manufacturer's protocol", "TREATMENT", 114, 141], ["RNA extraction condition", "TREATMENT", 158, 182], ["fixed and permeabilized cells", "TREATMENT", 187, 216], ["fixed and permeabilized cells", "PROBLEM", 254, 283], ["RNA extraction condition", "TREATMENT", 320, 344], ["fixed and permeabilized cellswere", "TREATMENT", 349, 382], ["Drop-seq lysis buffer", "TREATMENT", 413, 434], ["proteinase K (NEB", "TREATMENT", 476, 493], ["PBS at equal volume ratio", "TEST", 500, 525], ["cell lysate", "OBSERVATION", 10, 21], ["permeabilized cells", "OBSERVATION", 197, 216], ["bulk fixed cells", "OBSERVATION", 236, 252], ["fixed", "OBSERVATION_MODIFIER", 254, 259], ["permeabilized cells", "OBSERVATION", 264, 283]]], ["Next, the sample was at 56 o C for 1 hour, left at room temperature for 10 minutes, and placed on ice for at least 5 minutes.", [["sample", "ANATOMY", 10, 16], ["the sample", "TEST", 6, 16], ["ice", "TREATMENT", 98, 101], ["left", "ANATOMY_MODIFIER", 43, 47]]], ["Finally, the cell lysate was combined with 350 \u00b5l of RLT plus buffer, and processed according to the RNeasy Plus Mini Kit's protocol.Infection of A549 cellsOC43 (ATCC) were grown and titrated on A549 cells.", [["cell lysate", "ANATOMY", 13, 24], ["A549 cellsOC43", "ANATOMY", 146, 160], ["ATCC", "ANATOMY", 162, 166], ["A549 cells", "ANATOMY", 195, 205], ["cell", "CELL", 13, 17], ["RLT", "SIMPLE_CHEMICAL", 53, 56], ["A549 cellsOC43", "CELL", 146, 160], ["ATCC", "CELL", 162, 166], ["A549 cells", "CELL", 195, 205], ["A549 cellsOC43", "CELL_LINE", 146, 160], ["ATCC", "CELL_LINE", 162, 166], ["A549 cells", "CELL_LINE", 195, 205], ["the cell lysate", "TREATMENT", 9, 24], ["RLT plus buffer", "TREATMENT", 53, 68], ["Infection of A549 cellsOC43", "PROBLEM", 133, 160], ["ATCC", "TEST", 162, 166], ["A549 cells", "TREATMENT", 195, 205], ["A549 cells", "OBSERVATION", 195, 205]]], ["For FD-seq experiments, A549 cells were seeded in 6-well plates and infected with OC43 at an MOI of 1 the following day.", [["A549 cells", "ANATOMY", 24, 34], ["A549 cells", "CELL", 24, 34], ["A549 cells", "CELL_LINE", 24, 34], ["A549 cells", "PROBLEM", 24, 34], ["OC43", "PROBLEM", 82, 86]]], ["Cells were incubated at 33C for 4 days and were subsequently harvested for FD-seq.FD-seq protocolThe protocol for FD-seq is based on the McCaroll lab's online Drop-seq protocol 3 .", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5]]], ["In summary, there are only two significant differences: 40 units/ml proteinase K was added to the Drop-seq lysis, and a heating step was added between the droplet generation and droplet breakage steps.FD-seq protocolFirst, the barcoded beads were suspended at 120,000 beads/ml in a modified Drop-seq lysis buffer:FD-seq protocol200 mM Tris pH 7.5, 6% Ficoll type 400, 0.2% Sarkosyl, 20 mM EDTA, 50 mM DTT and 40 units/ml proteinase K (NEB).", [["K", "CHEMICAL", 79, 80], ["Sarkosyl", "CHEMICAL", 373, 381], ["Sarkosyl", "CHEMICAL", 373, 381], ["EDTA", "CHEMICAL", 389, 393], ["DTT", "CHEMICAL", 401, 404], ["proteinase K", "GENE_OR_GENE_PRODUCT", 68, 80], ["Sarkosyl", "SIMPLE_CHEMICAL", 373, 381], ["EDTA", "SIMPLE_CHEMICAL", 389, 393], ["proteinase K", "GENE_OR_GENE_PRODUCT", 421, 433], ["NEB", "GENE_OR_GENE_PRODUCT", 435, 438], ["proteinase K", "PROTEIN", 68, 80], ["proteinase K", "TEST", 68, 80], ["the Drop-seq lysis", "TREATMENT", 94, 112], ["a heating step", "TREATMENT", 118, 132], ["the droplet generation and droplet breakage steps", "TREATMENT", 151, 200], ["the barcoded beads", "TREATMENT", 223, 241], ["a modified Drop-seq lysis buffer", "TREATMENT", 280, 312], ["Tris pH", "TEST", 335, 342], ["Ficoll type", "TEST", 351, 362], ["Sarkosyl", "TREATMENT", 373, 381], ["proteinase K (NEB)", "TREATMENT", 421, 439], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["droplet breakage", "OBSERVATION", 178, 194]]], ["Cells were suspended in PBS with 0.01% BSA at 100,000 cells/ml.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 54, 59], ["BSA", "CHEMICAL", 39, 42], ["Cells", "CELL", 0, 5], ["BSA", "SIMPLE_CHEMICAL", 39, 42], ["cells", "CELL", 54, 59], ["Cells", "TEST", 0, 5], ["PBS", "TEST", 24, 27]]], ["For droplet generation, the cells, beads and oil were injected at flow rates of 3, 3 and 12 ml/h, respectively, using syringe pumps.", [["cells", "ANATOMY", 28, 33], ["beads", "ANATOMY", 35, 40], ["oil", "ANATOMY", 45, 48], ["cells", "CELL", 28, 33], ["beads", "ORGANISM_SUBSTANCE", 35, 40], ["oil", "ORGANISM_SUBSTANCE", 45, 48], ["droplet generation", "TREATMENT", 4, 22], ["the cells, beads", "TREATMENT", 24, 40], ["oil", "TREATMENT", 45, 48], ["syringe pumps", "TREATMENT", 118, 131]]], ["After droplet generation, the droplets were heated on a heat block at 56 o C for 1 hour to reverse the PFA cross-links, then incubated at room temperature for 10 minutes and kept on ice for at least 5 minutes.", [["droplets", "ANATOMY", 30, 38], ["PFA", "CHEMICAL", 103, 106], ["the droplets", "TREATMENT", 26, 38], ["a heat block", "TREATMENT", 54, 66], ["ice", "TREATMENT", 182, 185]]], ["After this, the droplets were broken, the beads were 18 collected, washed, and subjected to reverse transcription and exonuclease I digestion as per standard Drop-seq protocol.FD-seq protocolFor whole transcriptome amplification (WTA), the beads were distributed into a 96-well plate such that each well contained 5,000 beads.", [["droplets", "ANATOMY", 16, 24], ["beads", "ANATOMY", 240, 245], ["exonuclease I", "GENE_OR_GENE_PRODUCT", 118, 131], ["exonuclease I", "PROTEIN", 118, 131], ["the droplets", "TREATMENT", 12, 24], ["the beads", "TREATMENT", 38, 47], ["exonuclease I digestion", "TREATMENT", 118, 141], ["standard Drop-seq protocol", "TREATMENT", 149, 175], ["whole transcriptome amplification", "TREATMENT", 195, 228], ["the beads", "TREATMENT", 236, 245], ["beads", "OBSERVATION_MODIFIER", 320, 325]]], ["A 50 ul PCR reaction was set up in each well (1X KAPA HiFi Hotstart Readymix, 0.8 uM TSO_PCR primer) using the following thermal cycle program: 95C 3 min; 4 cycles of 98C 20s, 65C 45s, 72C 3 min; 10 cycles of 98C 20s, 67C 20s, 72C 3 min; 72C 5 min; 4C hold.", [["A 50 ul PCR reaction", "PROBLEM", 0, 20], ["1X KAPA HiFi Hotstart Readymix", "TREATMENT", 46, 76]]], ["After PCR finishes, the WTA products were cleaned up with 0.6X Ampure XP beads (Beckman Coulter), pooled and quantified with TapeStation (Agilent).FD-seq protocolTo prepare the sequencing library, 450pg of WTA products were used for each tagmentation reaction (Nextera XT DNA Library Prep Kit, Illumina).", [["DNA", "CELLULAR_COMPONENT", 272, 275], ["WTA products", "PROTEIN", 24, 36], ["WTA products", "PROTEIN", 206, 218], ["PCR", "TEST", 6, 9], ["the WTA products", "TREATMENT", 20, 36], ["Ampure XP beads", "TREATMENT", 63, 78], ["the sequencing library", "TREATMENT", 173, 195], ["WTA products", "TREATMENT", 206, 218], ["each tagmentation reaction", "TREATMENT", 233, 259]]], ["First, the WTA products were incubated with the tagment enzyme at 55C for 5 min.", [["55C", "SIMPLE_CHEMICAL", 66, 69], ["WTA products", "PROTEIN", 11, 23], ["tagment enzyme", "PROTEIN", 48, 62], ["the WTA products", "TREATMENT", 7, 23], ["the tagment enzyme", "TEST", 44, 62]]], ["Next, the neutralization buffer was added, and the sample was incubated at room temperature for 5 min, in order to neutralize the enzyme.", [["sample", "ANATOMY", 51, 57], ["enzyme", "PROTEIN", 130, 136], ["the neutralization buffer", "TREATMENT", 6, 31], ["the enzyme", "TEST", 126, 136]]], ["After this, the Nextera PCR Master Mix and custom primers P5-TSO_Hybrid and Nextera_N70X were added, and the sample was thermocycled as following: 95C 30s; 12 cycles of 95C 10s, 55C 30s, 72C 30s; 72C 5 min; 4C hold.", [["sample", "ANATOMY", 109, 115], ["Nextera_N70X", "SIMPLE_CHEMICAL", 76, 88], ["Nextera PCR Master Mix and custom primers P5-TSO_Hybrid", "DNA", 16, 71], ["Nextera_N70X", "DNA", 76, 88], ["the Nextera PCR Master Mix", "TREATMENT", 12, 38], ["custom primers P5", "TREATMENT", 43, 60], ["TSO_Hybrid", "TREATMENT", 61, 71], ["Nextera_N70X", "TREATMENT", 76, 88]]], ["Finally, the tagmentation products were cleaned up with 0.6X Ampure XP beads and quantified with TapeStation.", [["the tagmentation products", "TREATMENT", 9, 34], ["0.6X Ampure XP beads", "TREATMENT", 56, 76], ["TapeStation", "TREATMENT", 97, 108]]], ["The sequences of the primers are given in Table S1 .Plasmids and transfectionsExpression plasmids encoding human CDH1, TMEM119, ISCU and CORO1C, as well as KSHVReverse transcription and real-time PCR (RT-qPCR)Total RNA was extracted from cells using the HP Total RNA Kit (OMEGA Bio-Tek) following the manufacturer's instructions.", [["plasmids", "ANATOMY", 89, 97], ["cells", "ANATOMY", 238, 243], ["human", "ORGANISM", 107, 112], ["CDH1", "GENE_OR_GENE_PRODUCT", 113, 117], ["TMEM119", "GENE_OR_GENE_PRODUCT", 119, 126], ["ISCU", "GENE_OR_GENE_PRODUCT", 128, 132], ["CORO1C", "GENE_OR_GENE_PRODUCT", 137, 143], ["cells", "CELL", 238, 243], ["Expression plasmids", "DNA", 78, 97], ["CDH1", "DNA", 113, 117], ["TMEM119", "DNA", 119, 126], ["ISCU", "DNA", 128, 132], ["CORO1C", "DNA", 137, 143], ["KSHVReverse", "DNA", 156, 167], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112], ["the primers", "TREATMENT", 17, 28], ["Plasmids", "TREATMENT", 52, 60], ["KSHVReverse transcription", "TREATMENT", 156, 181], ["PCR", "TEST", 196, 199], ["RT", "TEST", 201, 203], ["Total RNA", "PROBLEM", 209, 218], ["the HP Total RNA Kit (OMEGA Bio-Tek", "TREATMENT", 250, 285], ["transfections", "OBSERVATION", 65, 78]]], ["RT-qPCR was performed using either a one-step or a two-step protocol.", [["RT-qPCR", "TEST", 0, 7], ["a two-step protocol", "TREATMENT", 49, 68]]], ["For the one-step protocol, RT-qPCR were performed with equal amounts (25- For the two-step protocol, reverse transcription was performed using the ProtoScript II First Strand cDNA Synthesis Kit (NEB) according to the manufacturer's protocol.", [["RT-qPCR", "TEST", 27, 34], ["reverse transcription", "TREATMENT", 101, 122], ["the ProtoScript II First Strand cDNA Synthesis Kit (NEB", "TREATMENT", 143, 198], ["the manufacturer's protocol", "TREATMENT", 213, 240]]], ["The kit's oligo-dT primer was used as the primer in this step.", [["oligo-dT", "CHEMICAL", 10, 18], ["kit", "GENE_OR_GENE_PRODUCT", 4, 7], ["kit's oligo-dT primer", "DNA", 4, 25], ["The kit's oligo-dT primer", "TREATMENT", 0, 25]]], ["Next, the RT products were diluted by 20-fold in water, and used as the input for qPCR (Luna Universal qPCR Master Mix, NEB).", [["the RT products", "TREATMENT", 6, 21], ["qPCR", "TEST", 82, 86]]], ["The primers' sequences are given in Table S2 .", [["primers' sequences", "DNA", 4, 22], ["The primers' sequences", "TEST", 0, 22]]], ["Relative expression level of each target gene was calculated by 20 normalizing for GAPDH or 18S levels using the Comparative Ct Method (\u0394\u0394Ct Method) and presented relative to the control sample.Live-cell imaging experimentsHEK293T.rKSHV were seeded in 24-well plates and transfected with plasmids for overexpression or siRNA for knock-down experiments.", [["Live-cell", "ANATOMY", 194, 203], ["plasmids", "ANATOMY", 288, 296], ["GAPDH", "GENE_OR_GENE_PRODUCT", 83, 88], ["Live-cell", "CELL", 194, 203], ["target gene", "DNA", 34, 45], ["GAPDH or 18S levels", "PROBLEM", 83, 102], ["the Comparative Ct Method", "TEST", 109, 134], ["plasmids", "TREATMENT", 288, 296], ["overexpression", "PROBLEM", 301, 315], ["siRNA", "TREATMENT", 319, 324]]], ["Cells were then imaged on a Nikon Ti-Eclipse containing an environmental chamber (37C, 100% humidity, 5% CO2).", [["Cells", "ANATOMY", 0, 5], ["CO2", "CHEMICAL", 105, 108], ["CO2", "CHEMICAL", 105, 108], ["Cells", "CELL", 0, 5], ["CO2", "SIMPLE_CHEMICAL", 105, 108], ["a Nikon Ti-Eclipse", "TREATMENT", 26, 44], ["100% humidity", "TREATMENT", 87, 100], ["environmental chamber", "OBSERVATION", 59, 80]]], ["Images were acquired every 4 hours for 4 days.Bulk RNA-seqTotal RNA was extracted from cells with the HP Total RNA Kit as above, and quantified using NanoDrop. mRNA was isolated from 100 ng of total RNA per sample using oligo dT magnetic beads (NEB) according to the manufacturer's protocol.", [["cells", "ANATOMY", 87, 92], ["sample", "ANATOMY", 207, 213], ["oligo dT", "CHEMICAL", 220, 228], ["cells", "CELL", 87, 92], ["Bulk RNA", "RNA", 46, 54], ["seqTotal RNA", "RNA", 55, 67], ["mRNA", "RNA", 160, 164], ["Images", "TEST", 0, 6], ["Bulk RNA", "TEST", 46, 54], ["seqTotal RNA", "PROBLEM", 55, 67], ["NanoDrop", "TREATMENT", 150, 158], ["mRNA", "TEST", 160, 164], ["total RNA", "TREATMENT", 193, 202], ["oligo dT magnetic beads (NEB", "TREATMENT", 220, 248], ["the manufacturer's protocol", "TREATMENT", 263, 290], ["seqTotal RNA", "OBSERVATION", 55, 67]]], ["The isolated mRNA was then used to prepare sequencing libraries using NEBNext Ultra II Non-directional RNA Library Prep Kit for Illumina and NEBNext Multiplex Oligos for Illumina (Index sets 1 and 2) (NEB).", [["mRNA", "RNA", 13, 17], ["The isolated mRNA", "TREATMENT", 0, 17], ["NEBNext Ultra II", "TREATMENT", 70, 86], ["Illumina", "TEST", 128, 136], ["NEBNext Multiplex Oligos", "TREATMENT", 141, 165], ["Illumina (Index sets", "TEST", 170, 190]]], ["Next, the sequencing libraries were quantified using High Sensitivity Fragment Analyzer (Agilent), normalized to 30 nM, pooled at equimolar, and sequenced with NextSeq High-output kit (singleread 75 bp).Sequencing and alignmentDrop-seq and FD-seq libraries were sequenced on a NextSeq 550 machine with the following read distribution: 20 bp for read 1, 60 bp for read 2, and 8 bp for index 1 read.", [["NextSeq", "PROTEIN", 160, 167], ["Drop-seq and FD-seq libraries", "DNA", 227, 256], ["NextSeq 550 machine", "DNA", 277, 296], ["the sequencing libraries", "TEST", 6, 30], ["NextSeq", "TEST", 160, 167], ["bp", "TEST", 199, 201], ["Sequencing", "TEST", 203, 213], ["alignmentDrop", "TEST", 218, 231], ["bp", "TEST", 338, 340], ["bp", "TEST", 356, 358], ["bp", "TEST", 377, 379], ["30 nM", "OBSERVATION_MODIFIER", 113, 118]]], ["The custom read 1 sequencing primer Read1CustomSeqB was used in place of Illumina's read 1 primer (Table S1) .Sequencing and alignmentAlignment was performed using Drop-seq tools version 1.13.21Bulk RNA-seq libraries were sequenced on a NextSeq 550 machine with the following read distribution: 75 bp for read 1, and 6 bp for index 1 read.", [["custom read 1 sequencing primer Read1CustomSeqB", "DNA", 4, 51], ["Illumina's read 1 primer", "DNA", 73, 97], ["Bulk RNA-seq libraries", "DNA", 194, 216], ["NextSeq 550 machine", "DNA", 237, 256], ["Illumina's", "TEST", 73, 83], ["Sequencing and alignmentAlignment", "TEST", 110, 143], ["Drop", "TEST", 164, 168], ["bp", "TEST", 298, 300], ["bp", "TEST", 319, 321]]], ["Alignment was performed using STAR aligner (version 2.7.3a) and counted using featureCounts.", [["STAR aligner", "DNA", 30, 42]]], ["Alignemnt was performed to a concatenated version of the human genome GRCh38 and OC43 genome NC_006213.1 29 .scRNA-seq data analysisData analysis was done using R packages Monocle 2 37-39 q and Seurat 3 40, 41 .", [["human", "ORGANISM", 57, 62], ["human genome", "DNA", 57, 69], ["GRCh38", "DNA", 70, 76], ["OC43 genome", "DNA", 81, 92], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["OC43 genome NC", "TEST", 81, 95], [".scRNA", "TEST", 108, 114], ["Data analysis", "TEST", 132, 145], ["R packages Monocle", "TEST", 161, 179], ["Seurat", "TEST", 194, 200]]], ["Data visualization was done using R and Python.", [["Data visualization", "TEST", 0, 18]]], ["For species mixing data, a cell is classified as human or mouse if more than 90% of the detected transcripts are mapped to human or mouse, respectively. dropEst pipeline 42 was used with argument -L eiEIBA to annotate reads mapping to exon, intron or exon/intron spanning regions.", [["cell", "ANATOMY", 27, 31], ["cell", "CELL", 27, 31], ["human", "ORGANISM", 49, 54], ["mouse", "ORGANISM", 58, 63], ["human", "ORGANISM", 123, 128], ["mouse", "ORGANISM", 132, 137], ["L eiEIBA", "DNA", 197, 205], ["exon", "DNA", 235, 239], ["intron", "DNA", 241, 247], ["exon/intron spanning regions", "DNA", 251, 279], ["human", "SPECIES", 49, 54], ["mouse", "SPECIES", 58, 63], ["human", "SPECIES", 123, 128], ["mouse", "SPECIES", 132, 137], ["human", "SPECIES", 49, 54], ["mouse", "SPECIES", 58, 63], ["human", "SPECIES", 123, 128], ["mouse", "SPECIES", 132, 137], ["Est pipeline", "TEST", 157, 169], ["argument -L eiEIBA", "TREATMENT", 187, 205], ["exon, intron or exon/intron spanning regions", "PROBLEM", 235, 279]]], ["For the BC3 data, we first discarded cells with more than 3,000 genes detected, and cells with fewer than 1,000 UMIs or more than 10,000 UMIs.", [["cells", "ANATOMY", 37, 42], ["cells", "ANATOMY", 84, 89], ["cells", "CELL", 37, 42], ["cells", "CELL", 84, 89], ["BC3", "DNA", 8, 11], ["the BC3 data", "TEST", 4, 16], ["cells", "TEST", 84, 89]]], ["Then we discarded genes detected in fewer than 5 cells.", [["cells", "ANATOMY", 49, 54], ["cells", "CELL", 49, 54]]], ["To find the relative expression of each gene, we first normalized the cells using Monocle 2.", [["cells", "ANATOMY", 70, 75], ["cells", "CELL", 70, 75]]], ["To cluster the cells, we first performed dimension reduction with t-SNE using the first 4 principal components, then clustered the cells by setting rho_threshold = 17 and delta_threshold = 11.", [["cells", "ANATOMY", 15, 20], ["cells", "ANATOMY", 131, 136], ["cells", "CELL", 15, 20], ["cells", "CELL", 131, 136], ["t-SNE", "PROTEIN", 66, 71], ["dimension reduction", "TREATMENT", 41, 60], ["t-SNE", "TREATMENT", 66, 71], ["rho_threshold", "TEST", 148, 161], ["delta_threshold", "TEST", 171, 186]]], ["We then set the percentage of viral transcripts as the pseudotime parameter, and performed a \"pseudotime analysis\" in order to find genes correlated with the abundance of viral transcripts.", [["viral transcripts", "RNA", 30, 47], ["viral transcripts", "RNA", 171, 188], ["a \"pseudotime analysis", "TEST", 91, 113], ["viral transcripts", "PROBLEM", 171, 188], ["viral transcripts", "OBSERVATION", 30, 47], ["viral transcripts", "OBSERVATION", 171, 188]]], ["For the A549 data, we discarded cells with fewer than 1,000 UMIs or more than 20,000 UMIs.", [["A549", "ANATOMY", 8, 12], ["cells", "ANATOMY", 32, 37], ["A549", "CELL", 8, 12], ["cells", "CELL", 32, 37], ["the A549 data", "TEST", 4, 17]]], ["We then discarded genes detected in fewer than 5 cells.scRNA-seq data analysisWe then used Seurat 3 to remove the cell cycle effects, normalize and scale the data.", [["cells", "ANATOMY", 49, 54], ["cell", "ANATOMY", 114, 118], ["cells", "CELL", 49, 54], ["cell", "CELL", 114, 118], ["scRNA", "PROTEIN", 55, 60], ["scRNA", "TEST", 55, 60], ["the cell cycle effects", "TREATMENT", 110, 132], ["scale the data", "TEST", 148, 162]]], ["To cluster the cells, we used the first 10 principal components for the FindNeighbors and RunTSNE functions, and resolution=0.2 for the FindClusters function.", [["cells", "ANATOMY", 15, 20], ["cells", "CELL", 15, 20], ["RunTSNE", "PROTEIN", 90, 97], ["the FindNeighbors", "TEST", 68, 85], ["RunTSNE functions", "TEST", 90, 107], ["resolution", "TEST", 113, 123], ["the FindClusters function", "TEST", 132, 157]]], ["To find the cluster markers, we used min.pct=0.25 and logfc.threshold=0.25 for the FindAllMarkers function.Bulk RNA-seq data analysisBulk RNA-seq data was analyzed using the R package DESeq2 43 .", [["R package DESeq2 43", "DNA", 174, 193], ["min.pct", "TEST", 37, 44], ["threshold", "TEST", 60, 69], ["the FindAllMarkers function", "TEST", 79, 106], ["Bulk RNA", "TEST", 107, 115], ["RNA", "TEST", 138, 141], ["the R package DESeq2", "TREATMENT", 170, 190]]], ["To find the enriched KEGG pathways, we uploaded the list of genes that were upregulated in TMEM119 overexpression versus GFP overexpression (log2 fold change > 1, FDR < 0.05) to g:Profiler 26 .RNA velocity analysisThe output files of Drop-seq tools DetectBeadSynthesisErrors function were processed with the dropEst pipeline 42 to tag spliced and unspliced transcripts, and the results were analyzed with Python velocyto package 12 .", [["TMEM119", "GENE_OR_GENE_PRODUCT", 91, 98], ["GFP", "GENE_OR_GENE_PRODUCT", 121, 124], ["TMEM119", "PROTEIN", 91, 98], ["Drop-seq tools", "DNA", 234, 248], ["unspliced transcripts", "RNA", 347, 368], ["GFP overexpression", "TEST", 121, 139], ["log2 fold change", "TEST", 141, 157], ["RNA velocity analysis", "TEST", 193, 214], ["The output files", "TEST", 214, 230], ["Drop", "TEST", 234, 238], ["Errors function", "PROBLEM", 268, 283], ["Est pipeline", "TREATMENT", 312, 324], ["Python velocyto package", "TREATMENT", 405, 428], ["velocity", "OBSERVATION_MODIFIER", 197, 205], ["output", "OBSERVATION_MODIFIER", 218, 224]]]], "PMC7480584": [["BackgroundA recent publication described a high number of deaths among street-connected young people (SCY) in an urban setting in Kenya, mostly from HIV and violence [1], and another described an HIV prevalence of 4.1% in the same population [2].", [["deaths", "DISEASE", 58, 64], ["HIV and violence", "DISEASE", 149, 165], ["people", "ORGANISM", 94, 100], ["people", "SPECIES", 94, 100], ["HIV", "SPECIES", 149, 152], ["HIV", "SPECIES", 149, 152], ["HIV", "SPECIES", 196, 199], ["an HIV prevalence", "TEST", 193, 210], ["publication", "OBSERVATION", 19, 30]]], ["SCY, broadly defined as young people who live and work on the streets or for whom the streets are a central part of their identity, experience a high burden of morbidity related to infectious diseases, mental health, substance use, and sexual health [3].", [["infectious diseases", "DISEASE", 181, 200], ["people", "ORGANISM", 30, 36], ["people", "SPECIES", 30, 36], ["a high burden of morbidity", "PROBLEM", 143, 169], ["infectious diseases", "PROBLEM", 181, 200]]], ["Primary causes of homelessness among young people are poverty, family conflict, and child abuse/neglect [4].", [["homelessness", "DISEASE", 18, 30], ["poverty", "DISEASE", 54, 61], ["abuse/neglect", "DISEASE", 90, 103], ["people", "ORGANISM", 43, 49], ["people", "SPECIES", 43, 49], ["neglect", "PROBLEM", 96, 103]]], ["UNICEF estimates that there are tens to hundreds of millions of homeless or street-connected young people globally [5].BackgroundDespite evidence suggesting high mortality, there are currently no published estimates of mortality rates in populations of SCY in Kenya, or other countries in sub-Saharan Africa (SSA).", [["people", "ORGANISM", 99, 105], ["people", "SPECIES", 99, 105], ["high mortality", "PROBLEM", 157, 171], ["tens", "OBSERVATION_MODIFIER", 32, 36], ["suggesting", "UNCERTAINTY", 146, 156], ["high", "OBSERVATION_MODIFIER", 157, 161], ["mortality", "OBSERVATION", 162, 171]]], ["The absence of data limits our ability to understand the burden of preventable death among SCY and develop evidence-based policies to reduce morbidity and mortality.", [["death", "DISEASE", 79, 84], ["SCY", "DISEASE", 91, 94], ["preventable death", "PROBLEM", 67, 84], ["morbidity", "PROBLEM", 141, 150]]], ["The aim of this study is to estimate mortality rates among SCY in an urban setting in Kenya and calculate standardized mortality ratios to assess excess mortality among SCY compared to the general Kenyan population of the same age.Study setting ::: MethodsEldoret, 2019 population 475,716 [6], is home to Moi University, Moi Teaching and Referral Hospital, and the Academic Model Providing Access to Healthcare (AMPATH), which currently provides HIV care and other healthcare to over 80,000 people across Western Kenya.Study population ::: MethodsSCY were defined as individuals aged 0\u201329 years who either (a) spent both days and nights on the streets and had limited/no contact with caregivers, or (b) spent some/most of their time on the street and returned to caregivers at night [7].", [["people", "ORGANISM", 491, 497], ["people", "SPECIES", 491, 497], ["HIV", "SPECIES", 446, 449], ["this study", "TEST", 11, 21], ["standardized mortality ratios", "TEST", 106, 135], ["excess mortality", "PROBLEM", 146, 162], ["Healthcare (AMPATH)", "TREATMENT", 400, 419], ["HIV care", "TREATMENT", 446, 454]]], ["The United Nations defines \u2018youth\u2019 as people aged 15\u201324 years [5]; however, we included individuals aged 0\u201329 years due to the difficulty confirming age in this population and setting.Study design ::: MethodsData on the size of the total population of SCY in Eldoret were collected in 2016 via a point-in-time (PIT) count.", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44], ["MethodsData", "TREATMENT", 201, 212], ["size", "OBSERVATION_MODIFIER", 220, 224], ["total", "OBSERVATION_MODIFIER", 232, 237], ["population", "OBSERVATION_MODIFIER", 238, 248]]], ["PIT counts are a census-type approach to counting homeless individuals at a given time point.", [["PIT counts", "TEST", 0, 10]]], ["In brief, after extensive community consultation, four teams were stationed at sites where SCY are known to gather.", [["SCY", "DNA", 91, 94]]], ["Participant\u2019s fingerprints were digitally captured to prevent double-counting, and participants were connected to HIV testing and counseling [2].Study design ::: MethodsData on deaths among SCY in Eldoret were collected between 2010 and 2015.", [["deaths", "DISEASE", 177, 183], ["Participant", "SPECIES", 0, 11], ["participants", "SPECIES", 83, 95], ["HIV", "SPECIES", 114, 117], ["HIV testing", "TEST", 114, 125]]], ["Briefly, between 2010 and 2013, a community advocate with in-depth knowledge of Eldoret\u2019s community of SCY recorded deaths among SCY, including age, sex, and cause of death.", [["deaths", "DISEASE", 116, 122], ["SCY", "DISEASE", 129, 132], ["death", "DISEASE", 167, 172], ["death", "PROBLEM", 167, 172]]], ["From 2013 to 2015, deaths among SCY were recorded via standardized forms when reported to a community advocate or identified at the Eldoret mortuary.", [["deaths", "DISEASE", 19, 25]]], ["Completeness of the data may be limited given that some deaths among SCY may not have been reported, and some young persons may not have been identified as SCY at the mortuary.", [["deaths", "DISEASE", 56, 62], ["SCY", "DISEASE", 69, 72], ["SCY", "CANCER", 69, 72], ["persons", "ORGANISM", 116, 123], ["persons", "SPECIES", 116, 123]]], ["Only deaths identified between 2010 and 2015 among SCY aged 0\u201329 years with known sex were included.", [["deaths", "DISEASE", 5, 11]]], ["WPP provides annual estimates for Kenya\u2019s population and 5-year period estimates for deaths by age category (0\u20134, 5\u20139, 10\u201314, 15\u201319, 20\u201324, and 25\u201329 years).", [["deaths", "DISEASE", 85, 91]]], ["WPP estimates are based on analyses of all available information and relevant historical demographic trends, including national census data [8].Statistical methods ::: MethodsAge- and sex-stratified standardized mortality ratios (SMRs) were calculated by dividing the observed by expected number of deaths in the population of SCY from 2010 to 2015.", [["deaths", "DISEASE", 299, 305], ["WPP estimates", "TEST", 0, 13], ["MethodsAge", "TEST", 168, 178]]], ["The expected number of deaths were calculated by multiplying the Kenyan population death rate from 2010 to 2015 by the total age-equivalent population of SCY in 2013.", [["deaths", "DISEASE", 23, 29], ["death", "DISEASE", 83, 88], ["number", "OBSERVATION_MODIFIER", 13, 19], ["deaths", "OBSERVATION", 23, 29]]], ["The total population of SCY in Eldoret in 2013 was back-calculated by applying the rate of change in the Kenyan <30 population from 2013 to 2016 to the 2016 SCY PIT count data, since only one PIT count has ever been conducted among SCY in Eldoret.", [["PIT count data", "TEST", 161, 175], ["one PIT count", "TEST", 188, 201], ["total", "OBSERVATION_MODIFIER", 4, 9], ["population", "OBSERVATION_MODIFIER", 10, 20]]], ["Ninety-five per cent confidence intervals (CI) were calculated in R version 3.6.1 using the exact two-sided Poisson test (Package exactci version 1.1\u20133) [9].ResultsBetween 2010 and 2015, there were 69 deaths among SCY aged 0\u201329 years: 23 females (33%) and 46 males (67%).", [["deaths", "DISEASE", 201, 207], ["SCY", "DISEASE", 214, 217], ["CI", "TEST", 43, 45], ["Package exactci version", "TREATMENT", 122, 145]]], ["The total 2016 population of SCY <30 years of age was 1,327: 360 females (27%) and 967 males (73%).", [["SCY", "TEST", 29, 32]]], ["The estimated population of SCY <30 years of age in 2013 was 1,248: 341 females (27%) and 907 males (73%).", [["SCY", "TEST", 28, 31], ["population", "OBSERVATION_MODIFIER", 14, 24]]], ["Population and deaths by age are presented in Table 1.", [["deaths", "DISEASE", 15, 21]]]], "84976a6507cbf0da1757937ce0fa7f627fd868f1": [["En este art\u00edculo de Salud P\u00fablica, describimos los esfuerzos de colaboraci\u00f3n como antrop\u00f3logos, m\u00e9dicos, l\u00edderes ind\u00edgenas y funcionarios locales para desarrollar e implementar un plan multifase de prevenci\u00f3n y contenci\u00f3n para el COVID-19, centrado en el aislamiento colectivo voluntario y rastreo de los contactos entre los Tsimane recolectoreshorticultores en la Amazonia boliviana.", [["para el COVID", "TEST", 222, 235]]], ["La Fase I involucra educaci\u00f3n, alcances y preparaci\u00f3n.", [["La Fase I involucra educaci\u00f3n", "TREATMENT", 0, 29]]], ["1 Sus formas de vida, su idioma y su cultura han estado amenazadas por las muchas facetas del colonialismo y la globalizaci\u00f3n, y sus medios de subsistencia y sus vidas est\u00e1n ahora nuevamente en juego en medio de la pandemia del coronavirus 2019 .", [["Sus", "ORGANISM", 2, 5]]], ["El s\u00edndrome respiratorio agudo grave del coronavirus 2 (SARS-CoV-2) ha causado el COVID-19 en m\u00e1s de 200 pa\u00edses y territorios, con el n\u00famero de casos confirmados y muertes m\u00e1s altas en los Estados Unidos y Europa.", [["El s\u00edndrome", "TEST", 0, 11], ["respiratorio", "TEST", 12, 24], ["grave del coronavirus", "PROBLEM", 31, 52], ["SARS", "TEST", 56, 60], ["CoV", "TEST", 61, 64], ["ha", "PROBLEM", 68, 70], ["el COVID", "TEST", 79, 87]]], ["2 Los pueblos ind\u00edgenas de todo el mundo comparten caracter\u00edsticas comunes que los hacen especialmente vulnerables a COVID-19.", [["a COVID", "TEST", 115, 122]]], ["Como un claro indicador de lo que podr\u00eda ocurrir, la pandemia de influenza H1N1 de 2009 result\u00f3 en una mortalidad 3-6 veces mayor entre las poblaciones ind\u00edgenas comparado con las poblaciones no-ind\u00edgenas de las Am\u00e9ricas y el Pac\u00edfico.", [["influenza H1N1", "DISEASE", 65, 79], ["mortalidad", "TEST", 103, 113]]], ["4 Al 7 de mayo de 2020, Bolivia ten\u00eda 2,081 casos confirmados COVID-19 y 102 muertes, en gran parte concentradas en La Paz Santa Cruz.", [["COVID", "TEST", 62, 67]]], ["5 A pesar del hecho de que casi la mitad de los bolivianos se considera que es de origen ind\u00edgena, no hay directrices espec\u00edficas descritas para los grupos ind\u00edgenas de \u00e1reas remotas que habitan en territorios comunales nativos (Tierras Comunitarias de Origen).Introducci\u00f3nEn este art\u00edculo, en primer lugar destacaremos aspectos generales de las poblaciones ind\u00edgenas pertinentes a la pandemia actual del COVID-19, despu\u00e9s describiremos nuestra experienciaPoblaciones ind\u00edgenas: vulnerabilidades y resilienciaEl exceso de mortalidad por enfermedades infecciosas tiene una larga historia entre las poblaciones ind\u00edgenas.", [["COVID", "TEST", 405, 410]]], ["La viruela, el sarampi\u00f3n y otras enfermedades importadas eliminaron hasta el 80% de las poblaciones nativas en las Am\u00e9ricas y el Caribe despu\u00e9s del contacto europeo .", [["La viruela", "TEST", 0, 10]]], ["6 ,7 Hasta ahora , COVID-19 ya ha impactado fuertemente a la naci\u00f3n Navajo en los Estados Unidos.", [["COVID", "TEST", 19, 24]]], ["Aunque Nuevo M\u00e9xico tiene una poblaci\u00f3n 13 veces mayor que la naci\u00f3n Navajo, esta \u00faltima tiene muchas m\u00e1s muertes que Nuevo Mexico.", [["Aunque", "TEST", 0, 6], ["una poblaci\u00f3n", "TREATMENT", 26, 39]]], ["Tuberculosis pulmonar, infecciones respiratorias de v\u00edas a\u00e9reas inferiores) 10 , pueden aumentar el riesgo de muerte por COVID-19.", [["Tuberculosis", "DISEASE", 0, 12], ["Tuberculosis", "PROBLEM", 0, 12]]], ["11 Las poblaciones ind\u00edgenas experimentan una vulnerabilidad \u00fanica a COVID-19 por varias razones.", [["a COVID", "TREATMENT", 67, 74]]], ["La imposibilidad de pagar los servicios m\u00e9dicos dificulta a\u00fan m\u00e1s el acceso cuando no estan cubiertos por los seguros p\u00fablicos de salud del gobierno.Poblaciones ind\u00edgenas: vulnerabilidades y resilienciaLas normas locales tambi\u00e9n pueden promover la transmisi\u00f3n del virus.", [["m\u00e9dicos", "TEST", 40, 47], ["Poblaciones", "TEST", 149, 160]]], ["Esta colectividad es clave para la capacidad de recuperaci\u00f3n a largo plazo, pero puede obstaculizar el cumplimiento a corto plazo de las medidas de distanciamiento f\u00edsico, en comparaci\u00f3n con otras poblaciones con culturas m\u00e1s individualistas y familias nucleadas.Poblaciones ind\u00edgenas: vulnerabilidades y resilienciaMuchos grupos ind\u00edgenas en \u00e1reas rurales han desarrollado importantes lazos con mercados y ciudades, especialmente donde los medios de subsistencia tradicionales est\u00e1n desapareciendo.", [["Poblaciones", "TEST", 263, 274]]], ["Hipertensi\u00f3n arterial), discapacidad e inmunosenescencia.", [["arterial", "ANATOMY", 13, 21], ["Hipertensi\u00f3n arterial", "MULTI-TISSUE_STRUCTURE", 0, 21], ["discapacidad e inmunosenescencia", "PROBLEM", 24, 56], ["arterial", "ANATOMY", 13, 21], ["inmunosenescencia", "OBSERVATION", 39, 56]]], ["Estos miembros de la comunidad act\u00faan como \u00bfAislamiento colectivo voluntario como una mejor respuesta a COVID-19 para las poblaciones ind\u00edgenas?", [["a COVID", "TEST", 102, 109]]], ["Por ejemplo, se cree que la minera ilegal es responsable de muchas muertes relacionadas con infecciones desde la d\u00e9cada de 1980 entre los yanomami -en el norte de Brasil y Venezuela, incluyendo muertes por infecciones como sarampi\u00f3n y malaria recientes (2019) 15 , 16 .", [["malaria recientes", "DISEASE", 235, 252]]], ["Los l\u00edderes yanomami ahora alegan que la primera muerte de COVID-19 se debi\u00f3 a la exposici\u00f3n a mineros de oro infectados 9 .", [["Los l\u00edderes", "TEST", 0, 11]]], ["La extracci\u00f3n ilegal de recursos tambi\u00e9n puede aumentar durante la pandemia debido a una menor vigilancia y aplicaci\u00f3n de la ley por parte del gobierno, lo que resulta en una explotaci\u00f3n a\u00fan mayor de los territorios ind\u00edgenas y en conflictos fatales con las comunidades ind\u00edgenas comparados con tiempos anteriores a la pandemia.", [["a la pandemia", "PROBLEM", 314, 327], ["la pandemia", "OBSERVATION", 316, 327]]], ["13 La historia tr\u00e1gica pasada y la vulnerabilidad actual han aumentado el temor a la devastaci\u00f3n masiva por COVID-19 entre las comunidades ind\u00edgenas de todo el mundo.", [["a la devastaci\u00f3n masiva", "TREATMENT", 80, 103]]], ["21Prevenci\u00f3n de la propagaci\u00f3n de la pandemia en las tierras bajas de Bolivia, departamento de BeniLos Tsimane de Bolivia est\u00e1n distribuidos en m\u00e1s de 100 comunidades, muchas de las cuales se encuentran a lo largo de los r\u00edos Maniqui o Quiquibey, o en las regiones selv\u00e1ticas cercanas.", [["Prevenci\u00f3n de la propagaci\u00f3n", "TREATMENT", 2, 30]]], ["Los Tsimane producen casi todos sus alimentos (> 90% de calor\u00edas en la dieta) 22 , y no tienen acceso a agua corriente o saneamiento.", [["Los Tsimane", "TEST", 0, 11]]], ["[23] [24] [25] Mucha de su morbilidad y mortalidad se debe a infecciones, particularmente infecciones respiratorias.", [["respiratorias", "PROBLEM", 102, 115]]], ["La tuberculosis pulmonar sigue siendo generalizada y la bronquiectasia es muy com\u00fan.", [["La tuberculosis pulmonar sigue", "PROBLEM", 0, 30], ["tuberculosis", "OBSERVATION", 3, 15]]], ["La atenci\u00f3n m\u00e9dica por especialistas requiere el transporte a grandes ciudades, incluida la capital de Beni, Trinidad (aproximadamente 6 -8 horas por carretera desde San Borja).", [["Trinidad (aproximadamente", "TREATMENT", 109, 134]]], ["Los Tsimane, por lo tanto, son una poblaci\u00f3n altamente vulnerable a COVID-19 con opciones limitadas de tratamiento.Prevenci\u00f3n de la propagaci\u00f3n de la pandemia en las tierras bajas de Bolivia, departamento de BeniEl Proyecto de Salud y Ciclo de la Vida Tsimane (THLHP) ha estado trabajando con las comunidades Tsimane desde el a\u00f1o 2002, estudiando la salud y el envejecimiento, al mismo tiempo que proporciona atenci\u00f3n primaria en salud y realiza vigilancia epidemiol\u00f3gica de las enfermedades prevalentes.", [["al mismo tiempo que proporciona", "TREATMENT", 377, 408]]], ["27, 28 Nosotros ofrecemos una descripci\u00f3n general de nuestra experiencia trabajando con el gobierno, las comunidades Tsimane, y los funcionarios locales y gubernamentales de salud en el municipio de San Borja para ayudar a evitar que el SARS-CoV-2 llegue a las comunidades de Tsimane.Prevenci\u00f3n de la propagaci\u00f3n de la pandemia en las tierras bajas de Bolivia, departamento de BeniEn general, nuestro enfoque en el desarrollo de una estrategia COVID-19 se basa en dos principios.", [["basa en dos principios", "TREATMENT", 456, 478]]], ["Hemos dividido el plan en dos fases: Fase I, en la que SARS COV-2 se est\u00e1 extendiendo r\u00e1pidamente en Bolivia, pero no existen casos confirmados en el Departamento de Beni; y la Fase II, la situaci\u00f3n actual, cuando la propagaci\u00f3n de la pandemia se distribuye en la regi\u00f3n en la que viven los Tsimane (Tabla).Tabla 1.", [["Tabla 1", "GENE_OR_GENE_PRODUCT", 307, 314], ["COV", "TEST", 60, 63], ["la situaci\u00f3n actual", "TEST", 186, 205], ["cuando la propagaci\u00f3n", "TREATMENT", 207, 228]]], ["Elementos esenciales, consideraciones locales y de la implementaci\u00f3n en un plan de prevenci\u00f3n y contenci\u00f3n de Covid-19Fase Elementos esenciales Implementaci\u00f3n Consideraciones locales Fase 1Coordinaci\u00f3n con los l\u00edderes ind\u00edgenasDebates sobre planes existentes, evaluaci\u00f3n de la percepci\u00f3n local de la enfermedad, asistencia requerida de fuentes no tribales \u00bfExiste una comunidad centralizada o muchas comunidades aisladas?", [["Covid", "TEST", 110, 115], ["aisladas", "PROBLEM", 412, 420]]], ["\u00bfCu\u00e1l es su relaci\u00f3n con el gobierno central?Educaci\u00f3n / Concientizaci\u00f3nReuniones comunitarias en idioma nativo, volantes, transmisi\u00f3n de mensajes radiales, \" Whatsapp \" y redes socialesEducaci\u00f3n / Concientizaci\u00f3nModalidades de comunicaci\u00f3n disponibles, conocimiento local sobre Covid-19, comprensi\u00f3n de la transmisi\u00f3n de la enfermedad, idioma (s) hablado (s)Toma de decisiones colectivasReuniones comunitarias, consideraci\u00f3n del aislamiento colectivo, formaci\u00f3n de comit\u00e9s para hacer cumplir las decisiones, documentaci\u00f3n de las decisiones colectivas.Toma de decisiones colectivasEstatus legal del territorio ind\u00edgena y capacidad de aislamiento colectivo, pr\u00e1cticas culturales sobre la toma de decisiones, la capacidad y los derechos de usar la tierra para producir sus propios alimentos.Toma de decisiones colectivasCoordinaci\u00f3n con el gobierno regional y las autoridades de salud p\u00fablica.Reporte de casos a poblaci\u00f3n ind\u00edgenaRed de contactos dentro de cada pueblo, grupos de redes sociales, tel\u00e9fono celular, radio de comunicaciones, apoyo financiero para la comunicaci\u00f3n.Reporte de casos a poblaci\u00f3n ind\u00edgenaDisponibilidad de modalidades de comunicaci\u00f3n, naturaleza de las interacciones internas y entre comunidades.Informe de casos a las autoridades localesComunicaci\u00f3n con el equipo local de respuesta de Covid para investigar casos sospechosos.Informe de casos a las autoridades localesInfraestructura local para la investigaci\u00f3n de casos, recursos humanos existentes, confianza entre la poblaci\u00f3n local y las autoridades.Mapeo de casos sospechosos y confirmadosGenere un mapa de casos, hogares / comunidades afectadas, ajuste el plan de contenci\u00f3n a los 'puntos calientes' locales Disponibilidad de censo e informaci\u00f3n geogr\u00e1fica, fluidez de comunicaci\u00f3n con las comunidades locales.Mapeo de casos sospechosos y confirmados\u00bfAislamiento colectivo voluntario como una mejor respuesta a COVID-19 para las poblaciones ind\u00edgenas?", [["mensajes radiales", "DISEASE", 138, 155], ["Educaci\u00f3n", "TREATMENT", 45, 54], ["Aislamiento", "TEST", 1832, 1843], ["a COVID", "TEST", 1890, 1897]]], ["Un estudio de caso y protocolo de la Amazon\u00eda BolivianaCoordinar respuestas de aislamientoComunicaci\u00f3n por radio, tel\u00e9fono y en persona para aislar a las personas afectadas, familias de otras familias y para aislar a las comunidades no afectadas de las comunidades afectadasCoordinar respuestas de aislamientoTodas las consideraciones anteriores, distribuci\u00f3n geogr\u00e1fica de hogares y comunidades, obst\u00e1culos para el aislamiento a nivel individual, familiar y comunitario.Pruebas y seguimiento de contactosInvestigue cada caso, c\u00f3mo ingres\u00f3 a la comunidad y pruebe a todas las personas potencialmente afectadasPruebas y seguimiento de contactosDisponibilidad de pruebas diagn\u00f3sticas, recursos humanos para la investigaci\u00f3n de casos, frecuencia de contactos entre familias y con el mundo exterior.El manejo del pacienteAislamiento de pacientes menos enfermos, medici\u00f3n peri\u00f3dica de ox\u00edgeno en sangre de pacientes sintom\u00e1ticos, soporte de ox\u00edgeno de alto flujo, pronaci\u00f3n , antivirales y otros tratamientos a medida que est\u00e9n disponibles.El manejo del pacienteTodas las consideraciones anteriores, cambiando las mejores pr\u00e1cticas y la disponibilidad de modalidades de tratamiento.Fase I: Concientizaci\u00f3n y Prevenci\u00f3nCoordinaci\u00f3n con los l\u00edderes ind\u00edgenas que representan a las poblaciones ind\u00edgenas.Fase I: Concientizaci\u00f3n y Prevenci\u00f3nLa poblaci\u00f3n Tsimane tiene dos consejos de gobierno, el Gran Consejo Tsimane y el Consejo Regional Tsimane y Moseten.", [["pronaci\u00f3n", "TREATMENT", 959, 968], ["antivirales", "TREATMENT", 971, 982], ["Concientizaci\u00f3n y Prevenci\u00f3nLa poblaci\u00f3n", "TREATMENT", 1304, 1344]]], ["3 y 4 en ingl\u00e9s y pag.", [["pag", "DNA", 18, 21]]], ["El primer paso fue educar y entrenar a nuestro equipo y al secretario de salud del Gran Consejo sobre el SARS-CoV-2 (sobre el origen, transmisi\u00f3n, s\u00edntomas) y los obst\u00e1culos para obtener un tratamiento efectivo.", [["el SARS", "TEST", 102, 109], ["CoV", "TEST", 110, 113]]], ["Tres m\u00e9dicos del THLHP y los directores del proyecto trabajaron con los miembros Tsimane del equipo en la traducci\u00f3n y adaptaci\u00f3n de los posters informativos del Centro para el Control de Enfermedades de Estados Unidos al idioma Tsimane.", [["del proyecto trabajaron con los miembros Tsimane del equipo en la traducci\u00f3n", "TREATMENT", 40, 116]]], ["29 Dado que actualmente no hay casos conocidos o sospechosos en la poblaci\u00f3n de Tsimane, y que el transporte fue limitado por el gobierno boliviano, el equipo junto con los miembros del Gran Consejo (todos asintom\u00e1ticos para COVID-19 o cualquier s\u00edntoma similar a la gripe durante al menos dos semanas) viajaron en motocicleta a 60 comunidades para realizar reuniones comunitarias, a partir del 25 de marzo de 2020 (Apendice p.", [["Consejo", "TEST", 191, 198], ["COVID", "TEST", 225, 230], ["viajaron en motocicleta", "TREATMENT", 303, 326]]], ["Las presentaciones incluyeron informaci\u00f3n sobre c\u00f3mo se propaga el SARS-CoV-2 en todo el mundo, el per\u00edodo de incubaci\u00f3n y los riesgos de contagio, la naturaleza a \u00bfAislamiento colectivo voluntario como una mejor respuesta a COVID-19 para las poblaciones ind\u00edgenas?", [["CoV", "TEST", 72, 75], ["a COVID", "TEST", 223, 230]]], ["Un estudio de caso y protocolo de la Amazon\u00eda Boliviana menudo asintom\u00e1tica del virus, las vulnerabilidades \u00fanicas de las personas mayores y las personas con otras condiciones de salud, as\u00ed como de la falta de una vacuna y la disponibilidad tratamientos espec\u00edficos, y el papel de la cuarentena en la prevenci\u00f3n de la transmisi\u00f3n del virus.", [["Boliviana menudo asintom\u00e1tica del virus", "TREATMENT", 46, 85], ["vacuna y la disponibilidad tratamientos espec\u00edficos", "TREATMENT", 214, 265]]], ["Tambi\u00e9n hubo una discusi\u00f3n sobre c\u00f3mo el SARS-CoV-2 podr\u00eda extenderse a trav\u00e9s de la poblaci\u00f3n Tsimane a trav\u00e9s de interacciones de comercio y otros encuentros con extra\u00f1os.Fase I: Concientizaci\u00f3n y Prevenci\u00f3nToma de decisiones colectiva.", [["a trav\u00e9s", "TREATMENT", 70, 78]]], ["26 Los Tsimane en todas las comunidades visitadas reconocieron r\u00e1pidamente los riesgos de la enfermedad, y sus propias vulnerabilidades.", [["Los Tsimane en todas", "TREATMENT", 3, 23]]], ["Hist\u00f3ricamente, la respuesta Tsimane tradicional a las epidemias fue huir y aislarse en lo profundo de sus territorios, lejos de los extra\u00f1os.", [["Hist\u00f3ricamente", "TREATMENT", 0, 14], ["los extra\u00f1os", "OBSERVATION", 129, 141]]], ["Como se observ\u00f3 en un n\u00famero creciente de poblaciones ind\u00edgenas [17] [18] [19] , la poblaci\u00f3n de Tsimane llego a un amplio consenso de que el aislamiento colectivo es la estrategia m\u00e1s viable para minimizar la exposici\u00f3n a COVID-19 hasta que las vacunas o los tratamientos est\u00e9n disponibles.", [["la poblaci\u00f3n", "TEST", 81, 93], ["a COVID", "TEST", 221, 228]]], ["Tambi\u00e9n hubo acuerdo sobre la necesidad de una cuarentena de 14 d\u00edas en varios puntos clave de entrada al territorio Tsimane para cualquier comunario que se saliera o regresara a la comunidad.", [["Tambi\u00e9n", "TREATMENT", 0, 7], ["en varios puntos clave", "TREATMENT", 69, 91]]], ["Estas actas constituyen una prueba formal para presentar a las autoridades gubernamentales acerca de los procesos de decisi\u00f3n colectiva.Fase I: Concientizaci\u00f3n y Prevenci\u00f3nLas reuniones de las comunidades tambi\u00e9n resultaron en solicitudes de ayuda de parte de los miembros de la comunidad para lograr el aislamiento colectivo.", [["Estas", "TEST", 0, 5]]], ["Estos incluyeron: 1) dotaci\u00f3n de sal para complementar los alimentos que los Tsimane producen localmente y jab\u00f3n para el higiene de manos para eliminar virus de manos; 2) suficientes medicamentos para las dolencias comunes, de manera que los Tsimane puede evitar dejar su territorio para buscar atenci\u00f3n m\u00e9dica; 3) suministros para los ambientes de cuarentena (por ejemplo mosquiteros y utensilios para comer), y 4) apoyo para armar las trancas (por ejemplo, cerraduras y cadenas) y asegurar las barricadas f\u00edsicas que se crearon recientemente para lograr el aislamiento de la comunidad.Fase I: Concientizaci\u00f3n y Prevenci\u00f3nLas decisiones de estas reuniones formaron la base del plan de prevenci\u00f3n para todas las aldeas.Fase I: Concientizaci\u00f3n y Prevenci\u00f3nCoordinaci\u00f3n con el gobierno regional y las autoridades de salud p\u00fablica.", [["Tsimane", "TEST", 77, 84], ["Tsimane", "TEST", 242, 249]]], ["Un elemento cr\u00edtico de la Fase I ha sido la coordinaci\u00f3n con las autoridades locales, el hospital local y la red de respuesta al COVID-19, el gobernador del Beni y los Tsimane representantes en la Asamblea Nacional, as\u00ed como con los polic\u00edas y militares que hacen cumplir la cuarentena ordenada por el gobierno nacional (por ejemplo, la prohibici\u00f3n de viajes interprovinciales).", [["la prohibici\u00f3n de viajes interprovinciales", "TREATMENT", 334, 376]]], ["Esto permiti\u00f3 a nuestro equipo conseguir permisos aprobados por el gobierno para viajar r\u00e1pidamente a las comunidades Tsimane para celebrar reuniones, y para transportar a los m\u00e9dicos, medicamentos y equipo de protecci\u00f3n personal (PPE) al \u00bfAislamiento colectivo voluntario como una mejor respuesta a COVID-19 para las poblaciones ind\u00edgenas?", [["a COVID", "TEST", 298, 305]]], ["Nuestro equipo est\u00e1 coordinando con la oficina del Gobernador del Beni para incluir nuestra compra de jab\u00f3n y sal en la distribuci\u00f3n de comida para cada comunidad, conforme a lo solicitado en las reuniones de la comunidad.", [["Nuestro", "TREATMENT", 0, 7]]], ["Tambi\u00e9n estamos equipando con mosquiteros y utensilios para comer a cada comunidad que construye viviendas de cuarentena seg\u00fan lo solicitado por los comunarios, adem\u00e1s de candados y cadenas en caso necesario.Fase I: Concientizaci\u00f3n y Prevenci\u00f3nCompra de equipos de protecci\u00f3n personal (EPP) para la distribuci\u00f3n local.", [["Tambi\u00e9n", "TREATMENT", 0, 7], ["Concientizaci\u00f3n y Prevenci\u00f3nCompra de equipos de protecci\u00f3n personal (EPP) para la distribuci\u00f3n local", "TREATMENT", 216, 317]]], ["Estamos actualmente comprando m\u00e1scaras N95, gafas y guantes para donar al hospital local de San Borja, a los profesionales de salud, y al personal del THLHP.", [["Estamos", "TEST", 0, 7]]], ["Tambi\u00e9n se donar\u00e1n m\u00e1scaras y guantes quir\u00fargicos a cada comunidad seg\u00fan sea necesario.", [["Tambi\u00e9n", "TREATMENT", 0, 7], ["a cada comunidad", "TREATMENT", 50, 66]]], ["Tambi\u00e9n se proporcionar\u00e1 capacitaci\u00f3n sobre el uso apropiado de EPP seg\u00fan las pautas de la OMS.Fase I: Concientizaci\u00f3n y Prevenci\u00f3nPrestaci\u00f3n de atenci\u00f3n m\u00e9dica para pacientes no COVID -19 dentro del territorio Tsimane.", [["OMS", "DISEASE", 91, 94], ["Tambi\u00e9n se proporcionar\u00e1 capacitaci\u00f3n", "TREATMENT", 0, 37]]], ["Debido a la naturaleza de su entorno y la escaza infraestructura de salud p\u00fablica, los Tsimane padecen innumerables enfermedades infecciosas, incluidos par\u00e1sitos intestinales, enfermedades diarreicas y enfermedades respiratorias.", [["infecciosas", "PROBLEM", 129, 140], ["incluidos par\u00e1sitos intestinales", "PROBLEM", 142, 174]]], ["Tambi\u00e9n hemos adquirido medicamentos anticipadamente para la fase II, para cuando viajar hacia y desde el territorio probablemente significar\u00e1 mayor riesgo de infecci\u00f3n por SARS-Cov-2 o ser\u00e1 imposible debido a las inclemencias del tiempo.Fase I: Concientizaci\u00f3n y Prevenci\u00f3nResumen de la Fase I. Antes de participar en la Fase I, la mayor\u00eda de los Tsimane ten\u00edan poco conocimiento sobre el riesgo de COVID-19.", [["Tambi\u00e9n", "TEST", 0, 7]]], ["Esperamos que estos primeros pasos ayuden a prepararse para la fase II, que ser\u00e1 mucho m\u00e1s desafiante.Fase II: Contenci\u00f3n de COVID-19 y manejo del pacienteLa fase II comenz\u00f3 cuando los primeros casos de COVID-19 fueron diagnosticados y confirmados en el Beni, donde viven los Tsimane (20 de Abril del 2020) al momento de escribir este art\u00edculo no se han encontrado casos confirmados en San Borja, el municipio m\u00e1s cercano a las comunidades Tsimane.", [["casos", "TEST", 194, 199], ["COVID", "TEST", 203, 208]]], ["Desde esta base, el personal de THLHP realizar\u00e1 el rastreo de contactos en comunidades con casos sospechosos y confirmados de COVID-19, utilizando la estaci\u00f3n de radio Tsimane (capaz de llegar a la mayor\u00eda de las comunidades Tsimane) y otros modos de comunicaci\u00f3n (por ejemplo, radio de onda corta, tel\u00e9fono celular).", [["utilizando la estaci\u00f3n de radio Tsimane (capaz de llegar a la mayor\u00eda de las comunidades Tsimane)", "TREATMENT", 136, 233]]], ["Nuestro equipo seguir\u00e1 proporcionando \u00bfAislamiento colectivo voluntario como una mejor respuesta a COVID-19 para las poblaciones ind\u00edgenas?", [["Nuestro", "TEST", 0, 7], ["a COVID", "TEST", 97, 104]]], ["Un estudio de caso y protocolo de la Amazon\u00eda Boliviana informaci\u00f3n actualizada, y tambi\u00e9n coordinar\u00e1 la ayuda del gobierno local y la respuesta de salud p\u00fablica en el territorio Tsimane.Fase II: Contenci\u00f3n de COVID-19 y manejo del pacienteInforme de casos a la poblaci\u00f3n de Tsimane.", [["Boliviana informaci\u00f3n actualizada", "TREATMENT", 46, 79]]], ["Una vez que el COVID-19 sea detectado en el territorio Tsimane, las sesiones informativas ser\u00e1n m\u00e1s detalladas e incluir\u00e1n sugerencias para las respuestas estrat\u00e9gicas.", [["Una", "TEST", 0, 3], ["COVID", "TEST", 15, 20]]], ["Los miembros del equipo que hablan Tsimane estar\u00e1n disponibles para recibir informaci\u00f3n sobre los casos sospechosos de las comunidades ya sea por tel\u00e9fono o por radio de comunicaciones.", [["comunicaciones", "CHEMICAL", 170, 184]]], ["Vincularemos los informes sobre casos confirmados y sospechosos de COVID-19 a estos datos SIG para rastrear la propagaci\u00f3n del virus y los posibles centros de infecci\u00f3n.", [["a estos datos", "TEST", 76, 89], ["centros de infecci\u00f3n", "PROBLEM", 148, 168]]], ["Esta informaci\u00f3n se utilizar\u00e1 para coordinar las respuestas de aislamiento entre las comunidades afectadas y no afectadas, teniendo cuidado de no estigmatizar a las personas o familias afectadas por COVID-19; la estigmatizaci\u00f3n obstaculiz\u00f3 los esfuerzos de control del Ebola en el \u00c1frica Subsahariana 30, 31 , as\u00ed como el tratamiento del VIH en los Estados Unidos .", [["COVID", "TEST", 199, 204], ["la estigmatizaci\u00f3n obstaculiz\u00f3 los esfuerzos", "TREATMENT", 209, 253], ["Subsahariana", "TEST", 288, 300]]], ["31 Para reducir la estigmatizaci\u00f3n de los casos sospechosos o confirmados de COVID-19, enfatizaremos la inclusi\u00f3n y la solidaridad con los casos de COVID-19 en mensajes de radio y otros tipos de comunicaciones.", [["comunicaciones", "CHEMICAL", 195, 209], ["comunicaciones", "SIMPLE_CHEMICAL", 195, 209], ["enfatizaremos la", "TREATMENT", 87, 103]]], ["Tambi\u00e9n, enviamos el mensaje que solo con la unidad de los comunarios, la comunidad puede estar protegida.", [["Tambi\u00e9n", "CHEMICAL", 0, 7], ["Tambi\u00e9n", "TREATMENT", 0, 7]]], ["Mensajes similares de parte de los l\u00edderes de la comunidad reforzaran y legitimaran a\u00fan m\u00e1s estas ideas.Fase II: Contenci\u00f3n de COVID-19 y manejo del pacienteCoordinar las respuestas de aislamiento dentro de las comunidades afectadas y no afectadas.Fase II: Contenci\u00f3n de COVID-19 y manejo del pacienteUtilizando datos de SIG y haciendo un seguimiento de casos sospechosos utilizaremos todas las modalidades de comunicaci\u00f3n para ayudar a las comunidades a responder a la propagaci\u00f3n del SARS-CoV-2.Fase II: Contenci\u00f3n de COVID-19 y manejo del pacienteLa sospecha o confirmaci\u00f3n de casos de COVID-19 en una comunidad iniciar\u00e1 las medidas de distanciamiento f\u00edsico y de aislamiento a nivel individual y de familia.", [["afectadas", "PROBLEM", 238, 247]]], ["Apoyaremos a esas familias con consejos detallados y materiales impresos y radiales que sean cultural y ling\u00fc\u00edsticamente espec\u00edficos sobre c\u00f3mo usar el EPP y poner en cuarentena con \u00e9xito a los miembros de la familia que presenten s\u00edntomas.", [["Apoyaremos", "SIMPLE_CHEMICAL", 0, 10]]], ["29 \u00bfAislamiento colectivo voluntario como una mejor respuesta a COVID-19 para las poblaciones ind\u00edgenas?", [["Aislamiento", "TEST", 4, 15], ["a COVID", "TEST", 62, 69]]], ["Tambi\u00e9n se aconsejar\u00e1 a esos pueblos que se preparen para el aislamiento a nivel familiar en sus otras casas ubicadas en sus parcelas.Fase II: Contenci\u00f3n de COVID-19 y manejo del pacientePruebas y seguimiento de contactos.", [["Tambi\u00e9n", "TREATMENT", 0, 7], ["a esos pueblos", "TREATMENT", 22, 36]]], ["Un sistema de diagn\u00f3stico r\u00e1pido local de casos sospechosos de COVID-19 es una herramienta clave en la contenci\u00f3n de la propagaci\u00f3n de la infecci\u00f3n.", [["una herramienta clave", "TREATMENT", 75, 96]]], ["Estamos buscando activamente pruebas moleculares que puedan implementarse en los punto de atenci\u00f3n m\u00e9dica para ayudar a confirmar los diagn\u00f3sticos.", [["Estamos", "TEST", 0, 7]]], ["Un esfuerzo coordinado entre nuestro equipo y los trabajadores de salud del gobierno encargados del diagn\u00f3stico, el procesamiento adecuado de la muestra a nivel local, nuestro censo actualizado, y los traductores Tsimane como buscadores de contactos de casos (que se encuentra tanto en nuestra base y dentro de las comunidades, para evitar los viajes entre la ciudad y las comunidades), permitir\u00e1 contener los brotes de la enfermedad antes de que se diseminen a otras comunidades.", [["que se encuentra tanto en nuestra base", "TREATMENT", 260, 298]]], ["A diferencia de muchas otras enfermedades infecciosas, el tratamiento antiviral basado en evidencia para el SARS-COVID-2 todav\u00eda est\u00e1 bajo investigaci\u00f3n en todo el mundo.", [["A diferencia de muchas otras enfermedades infecciosas", "TREATMENT", 0, 53], ["el tratamiento antiviral basado", "TREATMENT", 55, 86]]], ["Puede ser necesario el uso de tratamiento antibi\u00f3tico en casos de posible sobreinfecci\u00f3n bacteriana.", [["sobreinfecci\u00f3n bacteriana", "PROBLEM", 74, 99], ["sobreinfecci\u00f3n bacteriana", "OBSERVATION", 74, 99]]], ["Con una tasa de mortalidad del 50-80% de los pacientes intubados en los pa\u00edses industrializados 2 , la intubaci\u00f3n probablemente ser\u00e1 in\u00fatil en este contexto sin cuidados m\u00e9dicos especializados.", [["la intubaci\u00f3n probablemente ser\u00e1", "TREATMENT", 100, 132]]], ["Como estrategia principal para manejar los casos de COVID-19 con una saturaci\u00f3n de ox\u00edgeno inadecuada (evaluada utilizando ox\u00edmetros de pulso disponibles), el ox\u00edgeno suplementario tiene el potencial de ser administrado fuera del hospital en los cinco puestos de salud mencionados anteriormente.", [["con una saturaci\u00f3n de ox\u00edgeno inadecuada", "TREATMENT", 61, 101]]], ["El suministro de ox\u00edgeno durante veinticuatro horas puede ser provisto por c\u00e1nulas nasales con reservorios de ox\u00edgeno.", [["El suministro de ox\u00edgeno durante veinticuatro horas", "TREATMENT", 0, 51]]], ["Esto permitir\u00eda proporcionar un tratamiento efectivo, sin la intubaci\u00f3n, cercano a la comunidad del paciente y en un espacio mucho menos congestionado comparado con un entorno hospitalario.", [["Esto", "TEST", 0, 4]]], ["Para cualquier rechazo, el aislamiento ser\u00e1 cr\u00edtico, combinado con alivio de los s\u00edntomas con analg\u00e9sicos y monitoreo de hipoxia.Fase II: Contenci\u00f3n de COVID-19 y manejo del pacienteEn el futuro, si se descubre tratamientos para COVID-19 , como antivirales e inmunomoduladores intravenosos, que sean efectivos y est\u00e9n disponibles en el \u00e1rea, el tratamiento regional de pacientes hospitalizados puede ayudar a prevenir la progresi\u00f3n de la enfermedad y mitigar la mortalidad.Una estrategia de prevenci\u00f3n r\u00e1pida para otras poblaciones ind\u00edgenas.Los riesgos, desaf\u00edos y opciones para las respuestas estrat\u00e9gicas que enfrentan las comunidades ind\u00edgenas comparten muchas caracter\u00edsticas con las que enfrentan las poblaciones de todo el mundo, debido a las caracter\u00edsticas del propio COVID-19.", [["como antivirales e inmunomoduladores intravenosos", "TREATMENT", 240, 289], ["Una estrategia", "PROBLEM", 473, 487]]], ["Sin embargo, existen algunas \u00bfAislamiento colectivo voluntario como una mejor respuesta a COVID-19 para las poblaciones ind\u00edgenas?", [["a COVID", "TEST", 88, 95]]], ["Un estudio de caso y protocolo de la Amazon\u00eda Boliviana circunstancias comunes entre muchos pueblos ind\u00edgenas que presentan diferentes riesgos y oportunidades.Una estrategia de prevenci\u00f3n r\u00e1pida para otras poblaciones ind\u00edgenas.Con respecto al riesgo, es probable que las \u00e1reas urbanas afectadas en todo el mundo agoten los suministros m\u00e9dicos, las instalaciones de laboratorio y las camas de hospital, dejando poco para las poblaciones ind\u00edgenas.", [["Una estrategia", "PROBLEM", 159, 173]]], ["La capacidad de producir diariamente alimentos de subsistencia es vital para el aislamiento colectivo.", [["La capacidad", "TREATMENT", 0, 12]]], ["Las normas culturales basadas en fuertes lazos familiares y reuniones comunitarias, como los que hemos llevado a cabo, son el contexto para la toma de decisiones colectivas.", [["Las normas culturales", "TEST", 0, 21]]], ["Estas fuentes de resistencia se pueden aplicar al desarrollo de estrategias para la prevenci\u00f3n y mitigaci\u00f3n de la mortalidad por COVID-19 en las poblaciones ind\u00edgenas.Una estrategia de prevenci\u00f3n r\u00e1pida para otras poblaciones ind\u00edgenas.La tabla proporciona un marco general para los elementos esenciales, implementaci\u00f3n de estrategias y consideraciones del contexto local para los planes de prevenci\u00f3n y contenci\u00f3n en otras poblaciones ind\u00edgenas.", [["COVID", "TEST", 129, 134], ["Una estrategia", "PROBLEM", 167, 181]]], ["As\u00ed mismo, los detalles deber\u00e1n adaptarse a las circunstancias locales en muchos otros entornos ind\u00edgenas.Una estrategia de prevenci\u00f3n r\u00e1pida para otras poblaciones ind\u00edgenas.La evaluaci\u00f3n de los conocimientos y educaci\u00f3n locales sobre COVID-19 son fundamentales.", [["Una estrategia", "PROBLEM", 106, 120]]], ["Otro elemento fundamental es la promoci\u00f3n y el respeto de la toma de decisiones activa colectiva por la propia comunidad, que incluye todas las partes interesadas, incluidos los l\u00edderes comunitarios y miembros, gobierno local y autoridades de salud p\u00fablica, y cualquier otra entidad que participa en la gesti\u00f3n de la respuesta a la pandemia.", [["a la pandemia", "PROBLEM", 327, 340], ["la pandemia", "OBSERVATION", 329, 340]]], ["La adquisici\u00f3n y capacitaci\u00f3n en el uso de EPP es otro elemento esencial, as\u00ed como lo es tener un plan para el tratamiento de enfermedades cr\u00f3nicas o agudas que no sean COVID -19 que garantice que se traten los casos emergentes, mientras se mantiene el plan de aislamiento.Una estrategia de prevenci\u00f3n r\u00e1pida para otras poblaciones ind\u00edgenas.Para la Fase II, se deben implementar estrategias de comunicaci\u00f3n para informar a las personas sobre d\u00f3nde se encuentran los casos sospechosos y / o confirmados, sin crear un estigma que evite que las personas busquen atenci\u00f3n m\u00e9dica 31 (Ap\u00e9ndice 7-8 en ingl\u00e9s y 13-14 en ingl\u00e9s ) .", [["casos sospechosos y / o confirmados, sin crear un estigma que evite que las personas busquen atenci\u00f3n m\u00e9dica 31 (Ap\u00e9ndice 7-8 en ingl\u00e9s y 13-14 en ingl\u00e9s", "SPECIES", 467, 620], ["La adquisici\u00f3n y capacitaci\u00f3n", "TREATMENT", 0, 29], ["COVID", "TEST", 169, 174], ["Una estrategia", "PROBLEM", 273, 287], ["m\u00e9dica", "TEST", 569, 575], ["Ap\u00e9ndice", "TEST", 580, 588]]], ["Deber\u00eda haber estrategias para prevenir la propagaci\u00f3n del virus a \u00e1reas y familias no afectadas.", [["afectadas", "PROBLEM", 87, 96]]], ["Se podr\u00eda proporcionar apoyo de telemedicina de especialistas locales o extranjeros para ayudar al personal de salud local, en particular a medida que se conozca m\u00e1s sobre las posibles terapias y las mejores pr\u00e1cticas de apoyo al paciente a medida que COVID-19 se propaga a nivel mundial.", [["a medida que COVID", "TREATMENT", 239, 257]]], ["Si las terapias intravenosas resultan eficaces, como los agentes antivirales y / o inmunomoduladores, las oportunidades de hospitalizaci\u00f3n ser\u00e1n importantes.Una estrategia de prevenci\u00f3n r\u00e1pida para otras poblaciones ind\u00edgenas.Otros aspectos de la Fase II tambi\u00e9n pueden tener que adaptarse a las condiciones locales.", [["inmunomoduladores", "PROBLEM", 83, 100], ["Una estrategia", "PROBLEM", 157, 171], ["Otros", "TEST", 226, 231]]], ["El alcance en el que una poblaci\u00f3n ind\u00edgena depende de los bienes comprados en los mercados puede \u00bfAislamiento colectivo voluntario como una mejor respuesta a COVID-19 para las poblaciones ind\u00edgenas?", [["mercados", "TEST", 83, 91], ["Aislamiento", "TEST", 99, 110], ["a COVID", "TEST", 157, 164]]], ["Este proceso se est\u00e1 aplicando actualmente entre los Moseten, un grupo ind\u00edgena m\u00e1s aculturados que son cultural y ling\u00fc\u00edsticamente similar a la Tsimane.", [["Este", "TEST", 0, 4]]], ["En d\u00edas determinados, las mercanc\u00edas podr\u00edan ser transportados a la zona designada con vendedores y compradores que mantienen el distanciamiento f\u00edsico y el uso de EPP.Conclusi\u00f3n: Actuar ahora para prevenir desastresNuestro objetivo para esta contribuci\u00f3n es promover estrategias generales y adaptables para mitigar los efectos de la pandemia del COVID-19 en las poblaciones ind\u00edgenas.", [["a la zona designada", "TREATMENT", 63, 82], ["COVID", "TEST", 347, 352]]], ["El momento de actuar es ahora, antes de que COVID-19 produzca una devastaci\u00f3n en las poblaciones ind\u00edgenas.ColaboradoresDER, JCA, RQG, MGC, RMM y LMM fueron fundamentales para organizar e implementar el plan COVID-19 en el territorio de Tsimane.", [["JCA", "DISEASE", 125, 128], ["COVID", "TEST", 44, 49], ["produzca una devastaci\u00f3n", "TREATMENT", 53, 77], ["MGC", "TREATMENT", 135, 138], ["JCA", "ANATOMY", 125, 128]]], ["HSK y MDG concibieron la idea del art\u00edculo.", [["HSK", "DISEASE", 0, 3], ["HSK", "PROBLEM", 0, 3], ["del art\u00edculo", "OBSERVATION", 30, 42]]], ["HSK, BCT, JS, GST, DEM, DER y MGD redactaron el documento.", [["HSK", "DISEASE", 0, 3], ["DEM", "CHEMICAL", 19, 22], ["DEM", "CHEMICAL", 19, 22], ["GST", "GENE_OR_GENE_PRODUCT", 14, 17], ["DEM", "SIMPLE_CHEMICAL", 19, 22], ["HSK", "TEST", 0, 3], ["BCT", "TEST", 5, 8], ["JS", "ANATOMY", 10, 12]]], ["Todos los autores declaran no tener intereses en competencia.Agradecimientos.", [["Agradecimientos", "CHEMICAL", 61, 76], ["Agradecimientos", "SIMPLE_CHEMICAL", 61, 76]]], ["JS tambi\u00e9n reconoce la financiaci\u00f3n IAST de la Agencia Nacional de Investigaci\u00f3n (ANR) de Francia en el marco del programa Inversiones para el Futuro (Investissements d'Avenir) (ANR-17-EURE-0010).", [["JS", "TEST", 0, 2], ["ANR", "TEST", 178, 181]]], ["Agradecemos al equipo THLHP por sus incansables esfuerzos de prevenci\u00f3n, especialmente Arnulfo Cari Ista, Bernabe Nate A\u00f1ez, Bacilio Vie TayoFUNCIONES DEL COMIT\u00c9 DE VIGILANCIAa) Implementar normas internas de la comunidad para manejo de casos sospechosos b) Dirigir la construcci\u00f3n de ambientes de cuarentena para contactos probables y casos sospechosos c) Definir las condiciones de contacto con caso sospechoso y contactos probables d) Coordinar con centros de salud y con equipo de epidemiologia del proyecto Tsimane para reporte de casos y contactos. e) Reuniones con la comunidad para dar informes y coordinar actividades durante la epidemiaDEFINICIONES OPERATIVASDefinici\u00f3n de caso sospechoso Una vez que se haya iniciado la epidemia, se considerara como caso sospechoso a toda persona que presente tos y fiebre con o sin problemas para respirar y que este viniendo de una zona que ya se haya notificado casos confirmados de COVID 19.Definici\u00f3n de probables contactos\u00bfAislamiento colectivo voluntario como una mejor respuesta a COVID-19 para las poblaciones ind\u00edgenas?", [["Aislamiento", "TEST", 974, 985], ["a COVID", "TEST", 1032, 1039]]], ["Los individuos que cumplan con la definici\u00f3n de caso sospechoso y contacto probable En que consistir\u00e1 la cuarentena?", [["probable", "UNCERTAINTY", 75, 83]]], ["Tambi\u00e9n se le dar\u00e1 detergente para que laven sus manos, ropa y utensilios de cocina.Tiempo de duraci\u00f3n de la cuarentenaLos posibles contactos deben estar en cuarentena para su observaci\u00f3n durante 12 d\u00edas para ver si presentan s\u00edntomas, de no presentar s\u00edntomas pueden integrarse a su familia y comunidad.", [["Tambi\u00e9n", "TREATMENT", 0, 7]]], ["Los casos sospechosos deben asistir a la atenci\u00f3n m\u00e9dica (Centro de salud m\u00e1s cercano) y deben estar separados en la cuarentena hasta que remitan sus s\u00edntomas.", [["a la atenci\u00f3n m\u00e9dica (Centro de salud m\u00e1s cercano)", "TREATMENT", 36, 86]]], ["Se les proveer\u00e1 la alimentaci\u00f3n y la medicaci\u00f3n necesaria durante su enfermedad, as\u00ed como evaluaciones diarias para ver la progresi\u00f3n de la enfermedad y la necesidad de transferencia a centros de salud m\u00e1s especializados.INSUMOS PARA CADA COMIT\u00c9 DE VIGILANCIAa) Comprar detergente, plato, cuchara y vaso para los comit\u00e9s para que usen los contactos cuando interact\u00faen con los casos sospechosos. b) Botiqu\u00edn para IRAS de comunidad c) Coordinar con centros de salud para evitar que los pacientes con enfermedades tratables en primer nivel vayan a SB", [["SB", "CHEMICAL", 545, 547], ["SB", "ANATOMY", 545, 547]]]], "f746c812c39e7685944fa61ecbec816b684415c1": [["JC virus (JCV), which belongs to the polyomavirus family of non-enveloped DNA viruses, is known to be a causative agent of the progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the central nervous system (CNS).", [["PML", "ANATOMY", 171, 174], ["central nervous system", "ANATOMY", 208, 230], ["CNS", "ANATOMY", 232, 235], ["multifocal leukoencephalopathy", "DISEASE", 139, 169], ["PML", "DISEASE", 171, 174], ["demyelinating disease of the central nervous system", "DISEASE", 179, 230], ["JC virus", "ORGANISM", 0, 8], ["JCV", "ORGANISM", 10, 13], ["polyomavirus", "ORGANISM", 37, 49], ["DNA", "CELLULAR_COMPONENT", 74, 77], ["multifocal leukoencephalopathy", "CANCER", 139, 169], ["PML", "CANCER", 171, 174], ["central nervous system", "ANATOMICAL_SYSTEM", 208, 230], ["CNS", "ANATOMICAL_SYSTEM", 232, 235], ["JC virus", "SPECIES", 0, 8], ["JC virus", "SPECIES", 0, 8], ["JCV", "SPECIES", 10, 13], ["JC virus (JCV", "PROBLEM", 0, 13], ["non-enveloped DNA viruses", "PROBLEM", 60, 85], ["the progressive multifocal leukoencephalopathy (PML", "PROBLEM", 123, 174], ["a demyelinating disease of the central nervous system", "PROBLEM", 177, 230], ["DNA viruses", "OBSERVATION", 74, 85], ["progressive", "OBSERVATION_MODIFIER", 127, 138], ["multifocal", "OBSERVATION_MODIFIER", 139, 149], ["leukoencephalopathy", "OBSERVATION", 150, 169], ["PML", "OBSERVATION", 171, 174], ["demyelinating disease", "OBSERVATION", 179, 200], ["central", "ANATOMY_MODIFIER", 208, 215], ["nervous system", "ANATOMY", 216, 230], ["CNS", "ANATOMY", 232, 235]]], ["PML affects mainly immunosuppressed patients, such as those with acquired immunodeficiency syndrome (AIDS) or following organ transplantation, and has increased in prevalence with the spread of transplantations and AIDS.", [["PML", "ANATOMY", 0, 3], ["organ", "ANATOMY", 120, 125], ["PML", "DISEASE", 0, 3], ["acquired immunodeficiency syndrome", "DISEASE", 65, 99], ["AIDS", "DISEASE", 101, 105], ["AIDS", "DISEASE", 215, 219], ["PML", "GENE_OR_GENE_PRODUCT", 0, 3], ["patients", "ORGANISM", 36, 44], ["organ", "ORGAN", 120, 125], ["patients", "SPECIES", 36, 44], ["PML", "PROBLEM", 0, 3], ["acquired immunodeficiency syndrome", "PROBLEM", 65, 99], ["AIDS", "PROBLEM", 101, 105], ["organ transplantation", "TREATMENT", 120, 141], ["transplantations", "TREATMENT", 194, 210], ["AIDS", "PROBLEM", 215, 219], ["mainly", "OBSERVATION_MODIFIER", 12, 18], ["immunosuppressed", "OBSERVATION", 19, 35], ["increased", "OBSERVATION_MODIFIER", 151, 160]]], ["However, there is still no effective treatment for PML.", [["PML", "ANATOMY", 51, 54], ["PML", "DISEASE", 51, 54], ["PML", "CANCER", 51, 54], ["effective treatment", "TREATMENT", 27, 46], ["PML", "PROBLEM", 51, 54], ["no", "UNCERTAINTY", 24, 26], ["effective", "OBSERVATION_MODIFIER", 27, 36], ["treatment", "OBSERVATION", 37, 46], ["PML", "OBSERVATION", 51, 54]]], ["The major target cells of JCV infection in the CNS are the glial cells, such as oligodendrocytes and astrocytes [1] .", [["cells", "ANATOMY", 17, 22], ["CNS", "ANATOMY", 47, 50], ["glial cells", "ANATOMY", 59, 70], ["oligodendrocytes", "ANATOMY", 80, 96], ["astrocytes", "ANATOMY", 101, 111], ["infection", "DISEASE", 30, 39], ["cells", "CELL", 17, 22], ["JCV", "ORGANISM", 26, 29], ["CNS", "ANATOMICAL_SYSTEM", 47, 50], ["glial cells", "CELL", 59, 70], ["oligodendrocytes", "CELL", 80, 96], ["astrocytes", "CELL", 101, 111], ["glial cells", "CELL_TYPE", 59, 70], ["oligodendrocytes", "CELL_TYPE", 80, 96], ["astrocytes", "CELL_TYPE", 101, 111], ["JCV", "SPECIES", 26, 29], ["JCV infection", "PROBLEM", 26, 39], ["major", "OBSERVATION_MODIFIER", 4, 9], ["target cells", "OBSERVATION", 10, 22], ["JCV infection", "OBSERVATION", 26, 39], ["CNS", "ANATOMY", 47, 50], ["glial cells", "OBSERVATION", 59, 70]]], ["The first step in the establishment of JCV infection is attachment of the viral capsid to receptors on host cells.", [["cells", "ANATOMY", 108, 113], ["JCV infection", "DISEASE", 39, 52], ["JCV", "ORGANISM", 39, 42], ["host cells", "CELL", 103, 113], ["viral capsid to receptors", "PROTEIN", 74, 99], ["host cells", "CELL_TYPE", 103, 113], ["JCV", "SPECIES", 39, 42], ["JCV infection", "PROBLEM", 39, 52], ["the viral capsid to receptors", "PROBLEM", 70, 99], ["JCV infection", "OBSERVATION", 39, 52], ["viral capsid", "OBSERVATION", 74, 86], ["host cells", "OBSERVATION", 103, 113]]]], "1e222abe270a949acb795d73086a2164f99001db": [["Introduction and paper positioningOn December 31, 2019, the Wuhan Municipal Health Commission (China) reported to the World Health Organization a cluster of pneumonia cases of unknown etiology in the city of Wuhan, in the Chinese province of Hubei.", [["pneumonia", "DISEASE", 157, 166], ["pneumonia cases", "PROBLEM", 157, 172], ["pneumonia", "OBSERVATION", 157, 166]]], ["On January 9, 2020, the Chinese Center for Disease Control and Prevention reported that a new coronavirus 5 (SARS-CoV-2, later called COVID- 19) was identified as the cause of such respiratory diseases.", [["respiratory", "ANATOMY", 181, 192], ["coronavirus", "DISEASE", 94, 105], ["respiratory diseases", "DISEASE", 181, 201], ["coronavirus 5", "ORGANISM", 94, 107], ["SARS-CoV-2", "ORGANISM", 109, 119], ["COVID- 19", "CELL", 134, 143], ["SARS-CoV", "SPECIES", 109, 117], ["Disease Control", "TREATMENT", 43, 58], ["a new coronavirus", "PROBLEM", 88, 105], ["CoV", "TEST", 114, 117], ["such respiratory diseases", "PROBLEM", 176, 201], ["respiratory diseases", "OBSERVATION", 181, 201]]], ["On March 11, 2020 , the World Health Organization declared the COVID-19 viral disease a pandemic.", [["viral disease", "DISEASE", 72, 85], ["the COVID", "TEST", 59, 68], ["viral disease", "PROBLEM", 72, 85], ["viral disease", "OBSERVATION", 72, 85]]], ["Since then, the COVID-19 has affected the whole world, with about ten millions of confirmed cases and five hundred thousand of confirmed deaths up to August 2020 over more than two hundred countries, areas, or territories, 10 thus becoming one of the most relevant pandemics in the recent decades [1] .", [["deaths", "DISEASE", 137, 143], ["COVID-19", "DNA", 16, 24]]], ["Like other Coronaviruses (e.g., SARS and MERS), the COVID-19 appears to be controllable using basic Non-Pharmaceutical Interventions (NPIs), particularly social-distancing and the use of face-masks in public (especially when implemented in combinations).", [["SARS", "DISEASE", 32, 36], ["other Coronaviruses", "PROBLEM", 5, 24], ["SARS", "PROBLEM", 32, 36], ["the COVID", "TEST", 48, 57], ["basic Non-Pharmaceutical Interventions", "TREATMENT", 94, 132], ["Coronaviruses", "OBSERVATION", 11, 24]]], ["The factors that are obviously critically-important to the success of the anti-COVID-19 con- 15 trol efforts are the early implementation (and enhancement of effectiveness) of these measures, and ensuring their high adherence/coverage in the community [2] .", [["the anti-COVID-19 con- 15 trol efforts", "TREATMENT", 70, 108], ["these measures", "TREATMENT", 176, 190]]], ["However, despite the adoption of these measures, it is still possible that secondary waves of contagion occur.", [["these measures", "TREATMENT", 33, 47]]], ["In effect, although the adopted countermeasures appear to have reduced the number of reported cases, the absence of herd immunity against COVID-19 suggests that contagions could easily rise again when these interventions are relaxed, as business, factory operations, and schools resume [3] .Introduction and paper positioningAs a consequence, in recent months there has been a growing research interest 25 on COVID-19 mitigation in different scientific fields.", [["COVID", "TEST", 138, 143], ["COVID", "TREATMENT", 409, 414], ["growing", "OBSERVATION_MODIFIER", 377, 384]]], ["In effect, predicting the trend of the epidemic is of paramount importance to plan effective control strategies [5] to limit or block the spread of the epidemic.", [["effective control strategies", "TREATMENT", 83, 111]]], ["Broadly speaking, since a vaccine is not yet available, two main control strategies can be applied 30 [6], [7] : (1) mitigation, consisting in slowing but not necessarily stopping the epidemic spread (e.g., through isolation of suspect cases and social distancing of the elderly), so that the peak healthcare demand is reduced and individuals that are most at risk of severe disease from infection can be protected, and (2) suppression, which is aimed at reversing the epidemic growth, so that the number of cases is reduced, and kept low.", [["infection", "DISEASE", 388, 397], ["a vaccine", "TREATMENT", 24, 33], ["mitigation", "TREATMENT", 117, 127], ["the epidemic spread", "PROBLEM", 180, 199], ["severe disease", "PROBLEM", 368, 382], ["infection", "PROBLEM", 388, 397], ["severe", "OBSERVATION_MODIFIER", 368, 374], ["disease", "OBSERVATION", 375, 382], ["infection", "OBSERVATION", 388, 397], ["reduced", "OBSERVATION_MODIFIER", 517, 524]]], ["For instance, most countries have attempted to control the effect of COVID-19 by adopting a total lockdown of their population at a relevant economic cost, while few other countries have preferred timed interventions aimed at 40 reducing the number of infected people to a manageable level, depending on the capacity of the healthcare system to absorb and treat the newly infected [8] .", [["people", "ORGANISM", 261, 267], ["people", "SPECIES", 261, 267], ["COVID", "TREATMENT", 69, 74], ["timed interventions", "TREATMENT", 197, 216], ["the newly infected", "PROBLEM", 362, 380]]], ["In this regard, it is evident that the proper selection of which strategic action (or which combination of them) should be adopted to ensure the best outcomes is a challenging task.Introduction and paper positioningIn the pertinent literature, several models have been developed to describe the pan- 45 demic dynamics, which are based on the classic compartmental epidemiological models [9] , [10] , and adapting them to the specific case of COVID-19.", [["COVID", "TEST", 442, 447]]], ["Briefly said, epidemiological models, describing disease transmission within a population, provide important insights to understand which control mechanisms can lead, under what circumstances, to remove, or at least reduce, the infection [11] .", [["infection", "DISEASE", 228, 237], ["the infection", "PROBLEM", 224, 237], ["infection", "OBSERVATION", 228, 237]]], ["More in detail, according to 50 the work in [9] , compartmental epidemiological models are typically classified on the basis of the considered compartments of individuals and the related flow patterns.", [["flow patterns", "OBSERVATION", 187, 200]]], ["In particular, labels such as M (i.e., infants with passive immunity), S (that is, the class of Susceptible people, i.e., those who can become infected), E (the class of Exposed, i.e., those who are infected but not yet infectious), I (the class of Infective individuals,i.e., 55 those who are capable of transmitting the infection), and R (the Recovered class, i.e., those with permanent infection-acquired immunity) are often used for epidemiological classes, and the threshold for most epidemiological models is the basic reproduction number R 0 , defined as the average number of secondary infections produced when one infected individual is introduced into a population of Susceptible individuals [9] .", [["infection", "DISEASE", 322, 331], ["infection", "DISEASE", 389, 398], ["infections", "DISEASE", 594, 604], ["people", "ORGANISM", 108, 114], ["infants", "SPECIES", 39, 46], ["people", "SPECIES", 108, 114], ["the infection", "PROBLEM", 318, 331], ["permanent infection", "PROBLEM", 379, 398], ["secondary infections", "PROBLEM", 584, 604], ["infection", "OBSERVATION", 322, 331], ["secondary", "OBSERVATION_MODIFIER", 584, 593], ["infections", "OBSERVATION", 594, 604]]], ["60 Depending on the specific features of the disease to be modeled, some of the above compartments can be omitted (as an example, as shown in [12], the Exposed compartment is generally used only when the disease has a significant latent period relative to the infectious period), as well as further compartments can be identified and represented, nevertheless three of the recalled compartments should be always included in detected infected with life-threatening symptoms), H (Healed, i.e., recovered), and E (Extinct, i.e., dead).", [["the disease", "PROBLEM", 41, 52], ["the disease", "PROBLEM", 200, 211], ["threatening symptoms", "PROBLEM", 452, 472], ["disease", "OBSERVATION", 45, 52], ["significant", "OBSERVATION_MODIFIER", 218, 229], ["latent", "OBSERVATION_MODIFIER", 230, 236], ["infectious", "OBSERVATION_MODIFIER", 260, 270]]], ["90 The recalled works focus on the analysis of the COVID-19 in a country at a national level; however, given the heterogeneity of economic and social features at regional level in almost any country, and particularly in Italy, it is actually essential to assess the evolution of the pandemic when applying suitable local post-lockdown strategies (that is, once the epidemic is brought under control, or in the so-called Phase 2).", [["economic and social features at regional level", "PROBLEM", 130, 176], ["the pandemic", "PROBLEM", 279, 291], ["suitable local post-lockdown strategies", "TREATMENT", 306, 345]]], ["Nonetheless, only few contributions in the related literature take into account the spatial dynamics of the epidemic, among which we recall the work in [14] , where a spatial SEIR model for the ongoing COVID-19 emergency in Italy is developed as a baseline support tool to plan 100 the inter-regional mobility and to deploy medical supplies and staff based on the local epidemiological conditions.", [["the ongoing COVID", "TEST", 190, 207], ["few", "OBSERVATION_MODIFIER", 18, 21]]], ["Similarly, in [17] a SEIIR model (i.e., including classes of Susceptible, Exposed, pre-symptomatic and symptomatic Infectious, and Removed individuals) is adopted to evaluate the impact of school closure and telework during the COVID-19 lockdown in the three most affected France regions (i.e., le-de-France, 105 Hauts-de-France, Grand Est) through a stochastic age-structured data-driven analysis.", [["a SEIIR model", "TEST", 19, 32], ["school closure", "TREATMENT", 189, 203], ["the COVID", "TEST", 224, 233], ["symptomatic", "OBSERVATION_MODIFIER", 103, 114], ["Infectious", "OBSERVATION", 115, 125]]], ["A generalized multi-region SIR model is proposed in [18] , as well as a multi-region SI 2 R 2 extension (where the considered classes are Susceptible, Infectious but not yet diagnosed, Infectious diagnosed, Removed undiagnosed, and Removed diagnosed individuals), albeit only the mathematical formulation of the models is reported while 110 the validation is not yet available.", [["A generalized multi-region SIR model", "PROBLEM", 0, 36], ["generalized", "OBSERVATION_MODIFIER", 2, 13], ["Infectious", "OBSERVATION", 151, 161]]], ["Finally, in [16] a model including the Susceptible, Infected, Quarantined, Hospitalized, Recovered, and Deceased compartments for the Italian regions is presented to evaluate the effectiveness and impact level of differentiated but coordinated local actions during Phase 2, to avoid future recurrence of the epidemic, while taking into account the specific regional healthcare systems' charac-115 teristics.", [["the epidemic", "PROBLEM", 304, 316], ["Infected", "OBSERVATION", 52, 60]]], ["The main finding of these studies is that the expected impact of mitigation measures deeply varies across different regions.", [["these studies", "TEST", 20, 33], ["mitigation measures", "TREATMENT", 65, 84], ["main", "OBSERVATION_MODIFIER", 4, 8], ["mitigation", "OBSERVATION", 65, 75]]], ["Therefore, it is essential to correctly parameterize the model to the specific characteristics of each region under examination.Introduction and paper positioningAll the above recalled approaches, while being able to model the pandemic dynamics, do not provide a feedback control method to properly select the most beneficial 120 action(s) (for instance, based on the number of infected or of hospitalized patients) to be applied in a post-lockdown framework.", [["patients", "ORGANISM", 406, 414], ["patients", "SPECIES", 406, 414], ["examination", "TEST", 116, 127], ["a feedback control method", "TREATMENT", 261, 286]]], ["In fact, these methods can be classified as open-loop techniques that typically require what-if analyses (through scenario-based evaluations or Monte Carlo simulations) to identify the most effective actions.", [["open-loop techniques", "TREATMENT", 44, 64], ["based evaluations", "TEST", 123, 140]]], ["In this perspective, it is fundamental to provide a tool for a feedback-based selection of the 125 mitigation strategy that continuously adapts to the contagion evolution.", [["a feedback", "TEST", 61, 71], ["the 125 mitigation strategy", "TREATMENT", 91, 118], ["contagion", "OBSERVATION", 151, 160]]], ["This is possible by constantly measuring and monitoring the pandemics values and adapting the policy accordingly [19] .", [["the pandemics values", "TEST", 56, 76]]], ["It has been proven that an open-loop optimal control policy is successful to evaluate simple policies under the assumption of exact model knowledge, while in a more realistic scenario with uncertain data and model mismatch, a feedback 130 strategy that periodically updates the policy is much more effective [19] .", [["an open-loop optimal control policy", "TREATMENT", 24, 59]]], ["In effect, the use of feedback control theory represents a powerful tool to support managing the COVID-19 outbreak [7] .", [["feedback control theory", "TREATMENT", 22, 45]]], ["Unfortunately, most of the existing literature contributions on the control of previous epidemics involves vaccines or treatments, which are currently not available for COVID-19.Introduction and paper positioningIn addition, in the recalled contributions, the lockdown periods are typically driven by a periodic switching logic.", [["previous epidemics involves vaccines", "TREATMENT", 79, 115], ["treatments", "TREATMENT", 119, 129], ["COVID", "TEST", 169, 174]]], ["On the contrary, in order to ensure an active and effective support to the decision-making process, it is essential to tune the parameters of the mitigation strategy over larger time periods, providing a robust outer supervisory feedback loop to the process [8] .", [["the mitigation strategy", "TREATMENT", 142, 165], ["a robust outer supervisory feedback loop", "TREATMENT", 202, 242], ["active", "OBSERVATION", 39, 45]]], ["To this aim, the contribution in [8] proposes a fast switching 140 policy, consisting in multi-shot interventions based on the outcomes of two SIR-based models (i.e., the SIQR and the SIDARTHE) to switch between quarantine (i.e., social isolation) and work days (that is, normal behavior).Introduction and paper positioningGiven the obvious uncertainties in the spreading of the virus and in the disease progression, an effective feedback control strategy can be obtained by joining a SIR-based 145 epidemic model with other techniques, thus providing a hybrid model.", [["multi-shot interventions", "TREATMENT", 89, 113], ["the virus", "PROBLEM", 375, 384], ["the disease progression", "PROBLEM", 392, 415], ["an effective feedback control strategy", "TREATMENT", 417, 455], ["a hybrid model", "TREATMENT", 552, 566], ["obvious", "OBSERVATION_MODIFIER", 333, 340], ["uncertainties", "OBSERVATION", 341, 354], ["disease", "OBSERVATION_MODIFIER", 396, 403], ["progression", "OBSERVATION_MODIFIER", 404, 415]]], ["Hence, the final aim is to combine a disease transmission model with a feedback control mechanism of the epidemics, which allows controlling the whole network rather than only predicting the recovery 150 time or the proportion of infected individuals.", [["a disease transmission model", "PROBLEM", 35, 63], ["the epidemics", "PROBLEM", 101, 114], ["infected individuals", "PROBLEM", 230, 250], ["infected", "OBSERVATION", 230, 238]]], ["Indeed, optimal control theory has been already successfully applied to identify the best action strategies for other diseases, typically by simply introducing into the predictive model a new control variable representing the vaccination rate at time t (see, e.g., the work in [21] , where a SIR model for dengue is proposed, and that in [22] , where a SIR model for Ebola is presented), 155 or other specifically defined control variables (such as, for instance, in [23], where an ad-hoc model for the optimal control of tuberculosis is suggested by including in the model reinfection and post-exposure interventions).Introduction and paper positioningIn this perspective, Model Predictive Control (MPC) is a control technique including both feedback control and optimization that allows to take into account the devia-160 tions of the predictive model from the real progress of the disease [24] , [25] .", [["dengue", "DISEASE", 306, 312], ["Ebola", "DISEASE", 367, 372], ["tuberculosis", "DISEASE", 522, 534], ["Ebola", "ORGANISM", 367, 372], ["other diseases", "PROBLEM", 112, 126], ["dengue", "PROBLEM", 306, 312], ["Ebola", "PROBLEM", 367, 372], ["an ad-hoc model", "TREATMENT", 479, 494], ["tuberculosis", "PROBLEM", 522, 534], ["post-exposure interventions", "TREATMENT", 590, 617], ["Model Predictive Control (MPC)", "TREATMENT", 674, 704], ["a control technique", "TREATMENT", 708, 727], ["both feedback control", "TREATMENT", 738, 759], ["the devia", "TEST", 810, 819], ["the disease", "PROBLEM", 880, 891], ["tuberculosis", "OBSERVATION", 522, 534], ["reinfection", "OBSERVATION", 574, 585]]], ["Although implementing the MPC controller typically requires a large amount of computational resources, which can lead to long computation time [26] , this is not a concern when the optimization is performed at a strategic level, as is the case of the decision-making process for the definition of the proper strategies to tackle epidemiological diseases.165The basic idea here is to keep the true system state (that is, the predicted future output of the model) in line with the selected target.", [["the MPC controller", "TREATMENT", 22, 40], ["tackle epidemiological diseases", "PROBLEM", 322, 353]]], ["This is achieved based on past control inputs and the optimal predicted control input over a prediction horizon by solving an optimization problem aimed at minimizing a cost function [27] .", [["past control inputs", "TREATMENT", 26, 45], ["a prediction horizon", "TREATMENT", 91, 111], ["solving an optimization problem", "TREATMENT", 115, 146]]], ["Basically, at regular time intervals, the values of the state variables in the prediction model are updated, 170 hence the control is re-optimized and the new strategy is applied to the system until the next update time, thus ensuring that the approximate model and the control strategy closely match at each time interval [24] .", [["the control strategy", "TREATMENT", 266, 286]]], ["The main strength of this procedure is that it allows to directly take into account the unavoidable uncertainties in the model [27] .", [["this procedure", "TREATMENT", 21, 35], ["main", "OBSERVATION_MODIFIER", 4, 8], ["strength", "OBSERVATION_MODIFIER", 9, 17]]], ["In effect, MPC has been already applied, in conjunction with some SIR-based predictive model, in some previous studies on epidemiological models, showing that coupling feedback control with simulation models can help designing effective and robust action strategies for managing epidemics [24] .", [["MPC", "TREATMENT", 11, 14], ["epidemiological models", "TEST", 122, 144], ["simulation models", "TREATMENT", 190, 207], ["robust action strategies", "TREATMENT", 241, 265], ["managing epidemics", "PROBLEM", 270, 288]]], ["For instance, the contribution in [20] investi-gates the dynamical control of a generic SIS (i.e., Susceptible-Infectious-Susceptible) epidemic model through a non-linear MPC method aimed at minimizing an objective 180 function (which includes the predicted future outputs of the model) over a finite predictive horizon (which is moved forward at each control step).", [["a generic SIS", "PROBLEM", 78, 91], ["epidemic model", "PROBLEM", 135, 149], ["a non-linear MPC method", "TREATMENT", 158, 181], ["a finite predictive horizon", "TREATMENT", 292, 319]]], ["The work in [20] shows that the MPC algorithm allows to guide the system to the desired target once the values of the control parameters are carefully chosen.", [["the MPC algorithm", "TEST", 28, 45]]], ["A robust economic MPC for the containment of a generic stochastic SEIV (i.e., Susceptible-Exposed-Infected-Vigilant) 185 epidemic process is presented in [28] , with the final aim of deciding who to quarantine, and for how long, in the presence of an epidemic contagion.", [["A robust economic MPC", "TREATMENT", 0, 21], ["a generic stochastic SEIV", "PROBLEM", 45, 70], ["an epidemic contagion", "PROBLEM", 248, 269], ["robust", "OBSERVATION_MODIFIER", 2, 8], ["economic MPC", "OBSERVATION", 9, 21], ["epidemic", "OBSERVATION", 251, 259]]], ["Furthermore, the work in [24] studies a generic stochastic SIR model to optimally allocate vaccination resources while minimizing the costs of an epidemics, showing that the use of MPC allows improving the disease management, reducing cost, and ensuring more robustness 190 to uncertainty, thus performing well on complex models.165In the COVID-19 framework, to the best of the authors' knowledge, the joint use of predictive epidemiological models and MPC has been studied in just very few papers.", [["MPC", "CHEMICAL", 181, 184], ["vaccination resources", "TREATMENT", 91, 112], ["an epidemics", "PROBLEM", 143, 155], ["MPC", "TREATMENT", 181, 184], ["the disease management", "TREATMENT", 202, 224], ["joint", "ANATOMY", 402, 407]]], ["More in detail, the work in [27] proposes a methodology based on an extended SEIRmodel and MPC to determine the optimal government strategy to tackle the in Belgium under dynamic circumstances.", [["an extended SEIRmodel and MPC", "TREATMENT", 65, 94]]], ["First, the model is calibrated by means of the available data over time on the number of active cases and that of deaths.", [["deaths", "DISEASE", 114, 120]]], ["Then, the MPC is used to optimize the time course of social measures with respect to the available Intensive Care Units under three different scenarios: no government action; the current policy (i.e., with mild social restrictions); on-off strategy and immunization 200 of the herd.", [["the MPC", "TREATMENT", 6, 13], ["social measures", "TREATMENT", 53, 68], ["strategy", "TREATMENT", 240, 248], ["immunization", "TREATMENT", 253, 265]]], ["Similarly, the contribution in [19] combines a SIDARTHE model and a robust MPC approach that adapts the social distancing measures to minimize the number of fatalities over a range of two years when measurements are inaccurate and infection rates cannot be precisely evaluated.", [["fatalities", "DISEASE", 157, 167], ["infection", "DISEASE", 231, 240], ["a SIDARTHE model", "TREATMENT", 45, 61], ["a robust MPC approach", "TREATMENT", 66, 87], ["infection rates", "PROBLEM", 231, 246], ["infection", "OBSERVATION", 231, 240]]], ["First, the model parameters and the initial conditions are calibrated according to the COVID-19 outbreak in Germany.", [["the COVID", "TEST", 83, 92]]], ["Then, the 205 outcomes obtained through a closed-loop control via MPC are compared with those obtained when a multi-objective open-loop optimal control is performed, showing that the latter approach may lead to intermediate increases in the number of new infections, thus requiring an additional lockdown period, while the former method is able to avoid such a behavior, thus significantly reducing the number of fatalities.210Against this background, this paper presents a multi-region SIRQTHE model in conjunction with a non-linear MPC approach which is able to simultaneously take into account both the specific strategies undertaken at the regional level (i.e., restrictions on the intra-region activity) and the actions taken at the upper level in terms of border activities between the regions (i.e., restrictions on the inter-region activity).", [["infections", "DISEASE", 255, 265], ["fatalities", "DISEASE", 413, 423], ["a closed-loop control via MPC", "TREATMENT", 40, 69], ["a multi-objective open-loop optimal control", "TREATMENT", 108, 151], ["new infections", "PROBLEM", 251, 265], ["an additional lockdown period", "TREATMENT", 282, 311], ["a multi-region SIRQTHE model", "TREATMENT", 472, 500], ["a non-linear MPC approach", "TREATMENT", 521, 546], ["intermediate", "OBSERVATION_MODIFIER", 211, 223], ["increases", "OBSERVATION_MODIFIER", 224, 233], ["number", "OBSERVATION_MODIFIER", 241, 247], ["new", "OBSERVATION_MODIFIER", 251, 254], ["infections", "OBSERVATION", 255, 265], ["upper", "ANATOMY_MODIFIER", 738, 743]]], ["We remark 215 that, in this paper, we refer to the control actions to be undertaken in order to mitigate the effect of secondary waves of pandemic, that is, we are assuming that the basic non-pharmaceutical interventions (such as, for instance, social-distancing and the use of face-masks) have been ineffective or measures have been relaxed, and as such some more restrictive (but still non-pharmaceutical) measures, such as restrictions on the 220 intra-region and on inter-region activities, are needed.210The analysis is conducted in Italy, since this is one of the countries where the pandemic effect has been the most significant, particularly in some regions (such as in Lombardy), as well as diversified in the territory.", [["pandemic", "PROBLEM", 138, 146], ["the basic non-pharmaceutical interventions", "TREATMENT", 178, 220], ["face-masks", "TREATMENT", 278, 288], ["The analysis", "TEST", 509, 521], ["pandemic", "OBSERVATION", 590, 598], ["most significant", "OBSERVATION_MODIFIER", 619, 635], ["diversified", "OBSERVATION_MODIFIER", 700, 711], ["territory", "ANATOMY_MODIFIER", 719, 728]]], ["The presented approach can be easily applied to different levels of the spatial scale, provided the availability of data to calibrate the model.210With respect to the existing state of the art, the novel contributions of this paper are as follows:230\u2022 We define a networked SIR-based model (a SIRQTHE model) to represent the spread of COVID-19 in multi-region areas where the economic and healthcare systems are characterized by strong regional heterogeneity.", [["a SIRQTHE model", "TREATMENT", 291, 306], ["COVID", "TEST", 335, 340], ["strong regional heterogeneity", "PROBLEM", 429, 458], ["spread", "OBSERVATION_MODIFIER", 325, 331], ["economic", "OBSERVATION_MODIFIER", 376, 384], ["strong", "OBSERVATION_MODIFIER", 429, 435], ["regional", "OBSERVATION_MODIFIER", 436, 444], ["heterogeneity", "OBSERVATION", 445, 458]]], ["More in detail, we extend the model proposed by [18] by defining a more accurate single-region epidemic model, where seven compartments are introduced (namely, Susceptible,235Infected, Removed, Quarantined, Threatened, Healed, and Extinct).", [["Healed", "OBSERVATION_MODIFIER", 219, 225]]], ["We remark that, differently from the six-compartment model presented in [16] , in this work we split the compartment of recovered individual into two classes: the class of Healed people (i.e., recognized individuals that heal after transition in the status of Quarantined or Threatened), and that of Removed people (i.e., completely 240 recovered people that have never been detected).", [["people", "ORGANISM", 179, 185], ["people", "ORGANISM", 308, 314], ["people", "ORGANISM", 347, 353], ["people", "SPECIES", 179, 185], ["people", "SPECIES", 308, 314], ["people", "SPECIES", 347, 353], ["Healed", "OBSERVATION", 172, 178]]], ["Moreover, while in [16] the model parameters are dynamically identified by splitting the fitting period, in our 245 work we identify time-varying functions to model time-varying parameters, such as the recovery and the death rate.", [["death", "DISEASE", 219, 224], ["the death rate", "TEST", 215, 229]]], ["Finally, another improvement with respect to the model presented in [16] is that we leverage on the Google mobility reports to better take into account the time-dependency of the infection rate.235\u2022 While in the related literature modeling and controlling the pandemic contagion 250 is typically addressed on a national basis, this paper proposes an optimal control approach that supports governments in defining the most effective strategies to be adopted during post-lockdown mitigation phases in a diversified multi-region scenario.", [["infection", "DISEASE", 179, 188], ["the infection rate", "PROBLEM", 175, 193], ["an optimal control approach", "TREATMENT", 347, 374], ["infection", "OBSERVATION", 179, 188]]], ["The proposed approach allows policy makers taking targeted intervention decisions on different regions by an integrated and structured model, 255 thus both respecting the specific regional healthcare systems characteristics and improving the system-wide performance by the avoidance of uncoordinated behavior by individual regions.235\u2022 Differently from the related literature, where the addressed control strategies aim at minimizing the number of fatalities or ensuring that the healthcare systems is 260 not overloaded, this paper also focuses on the economic impact of the control strategies.", [["fatalities", "DISEASE", 448, 458], ["the control strategies", "TREATMENT", 572, 594]]], ["Indeed, the approach aims at minimizing the cost of the mitigation strategies on a multi-region area, while ensuring that the capacity of the network of regional healthcare systems is not violated.235\u2022 By applying the proposed methodology to the network of Italian regions, we 265 show its effectiveness and flexibility in properly supporting the definition of effective regional strategies for managing the COVID-19 disease under different government policies.", [["the mitigation strategies", "TREATMENT", 52, 77], ["a multi-region area", "TREATMENT", 81, 100], ["effective regional strategies", "TREATMENT", 361, 390], ["the COVID-19 disease", "PROBLEM", 404, 424], ["capacity", "OBSERVATION_MODIFIER", 126, 134]]], ["We discuss the results achieved by the MPC scheme when control actions within and on the border of regions are applied both by a regionby-region basis or by an inter-region coordination mechanism.", [["the MPC scheme", "TREATMENT", 35, 49]]], ["In particular, we 270 analyze and compare the following scenarios: uniform intra-region activity and inter-region travel restrictions, differentiated intra-region activity restrictions and uniform inter-region travel restrictions, and differentiated intra-region activity and inter-region travel restrictions.235The rest of this work is structured as follows.", [["uniform intra-region activity", "PROBLEM", 67, 96], ["intra-region activity", "OBSERVATION", 150, 171], ["uniform", "OBSERVATION_MODIFIER", 189, 196], ["differentiated", "OBSERVATION_MODIFIER", 235, 249], ["intra-region activity", "OBSERVATION", 250, 271]]], ["In Section 2, we first present the 275 single-region SIRQTHE model, providing the formulation of the dynamic equations and the description of the parameters' identification process; subsequently we focus on the extension of the SIRQTHE model to a multi-region framework.", [["the dynamic equations", "TEST", 97, 118]]], ["Finally, in Section 5, we conclude the paper and discuss an outlook for future works.Model of the COVID-19 dynamicsCurrently, governments all around the world are struggling to contain the COVID-19 pandemic.", [["the COVID", "TREATMENT", 94, 103], ["the COVID", "TEST", 185, 194], ["pandemic", "PROBLEM", 198, 206]]], ["In this context, mathematical models are extremely valuable to simulate and control the spread of the pandemic.", [["mathematical models", "PROBLEM", 17, 36], ["the pandemic", "PROBLEM", 98, 110]]], ["In fact, mathematical models are widely used to estimate the contagion parameters and predict the effects of any control action on 295 populations.Basics on SIR-based epidemiological modelsCompartmental models are traditionally considered suitable to model the spread of a virus within a large population [9] .", [["the contagion parameters", "TEST", 57, 81], ["a virus", "PROBLEM", 271, 278], ["large", "OBSERVATION_MODIFIER", 288, 293]]], ["In these models, the overall population is divided into different compartments, where people can flow from one compartment to another based on specific rate values.", [["people", "ORGANISM", 86, 92], ["people", "SPECIES", 86, 92], ["overall", "OBSERVATION_MODIFIER", 21, 28], ["population", "OBSERVATION", 29, 39]]], ["In particular, in the SIR-based models, we can assume that the dynamics of the pandemic is quicker than the dynamics of birth and death, therefore, the latter two events are usually omitted.", [["death", "DISEASE", 130, 135]]], ["Hence, the simplest SIR model can be expressed by the following set of ordinary differential equations [9] :Basics on SIR-based epidemiological modelswhere N denotes the overall population, S, I, and R represent respectively the compartments of the Susceptible, Infected, and Removed (dead or recovered) individuals , \u03b2 \u2208 R + is the infection rate, and \u03b3 \u2208 R + is the recovery rate.", [["infection", "DISEASE", 333, 342], ["\u03b2 \u2208 R", "GENE_OR_GENE_PRODUCT", 318, 323], ["\u03b3 \u2208 R", "GENE_OR_GENE_PRODUCT", 353, 358], ["the infection rate", "TEST", 329, 347], ["Infected", "OBSERVATION", 262, 270], ["infection", "OBSERVATION", 333, 342]]], ["Since N corresponds to 300 the sum of compartments populations, it holds:Basics on SIR-based epidemiological modelsConsequently, in (1)-(3) it is sufficient to analyze only two equations since the third is dependent.", [["dependent", "OBSERVATION_MODIFIER", 206, 215]]], ["Independently from the choice of the time domain, the SIR model is able to characterize in broad terms the spread of a pandemic, thus disregarding the multiple and complex facets of a real pandemic.", [["a pandemic", "PROBLEM", 117, 127]]], ["Consequently, several models have been proposed in the related literature to improve the classical SIR model for a specific 310 pandemic, for instance, by adding additional compartments and by better modeling the relation among them.Single-region SIRQTHE modelThe proposed epidemiological model for the COVID-19 is a novel time-varying discrete-time model, named SIRQTHE, which distinguishes between detected and un-315 detected infected people, healed, dead, and hospitalized.", [["people", "ORGANISM", 438, 444], ["COVID-19", "DNA", 303, 311], ["people", "SPECIES", 438, 444], ["Single-region SIRQTHE model", "TREATMENT", 233, 260], ["the COVID", "TEST", 299, 308], ["healed", "OBSERVATION_MODIFIER", 446, 452]]], ["As a major assumption, we suppose that the probability of becoming susceptible after being healed is negligible, which seems reasonable based on the current level of knowledge [31] .Single-region SIRQTHE modelMore in detail, in our model, the overall population in a given region is divided into the following compartments: The overall interconnections between the above compartments are shown in Fig.1 .", [["Single-region SIRQTHE model", "TREATMENT", 182, 209], ["healed", "OBSERVATION", 91, 97]]], ["The SIRQTHE model is composed by seven time-varying difference equations, which characterize the flows of the individuals between the different compartments.", [["flows", "OBSERVATION_MODIFIER", 97, 102]]], ["More in detail, by designating all the state variables (the fraction of the overall population) by a Latin letter, and denoting the time step as k, the model is described as follows:Single-region SIRQTHE modelR(k + 1) =R(k) + \u03b3\u0128(k) (7)Single-region SIRQTHE modelT (k + 1) = T (k) + \u00b5 Q(k) + \u03bb I(k) \u2212 (\u03c0(k) + \u03b5(k)) T (k)Single-region SIRQTHE modelwhere the state variables indicated with a tilde are those that cannot be directly observed with a reasonable confidence, i.e., there are no data from official sources [13] .", [["k", "TEST", 211, 212], ["k", "TEST", 221, 222], ["k", "TEST", 229, 230], ["Single-region SIRQTHE", "TEST", 235, 256], ["modelT", "TEST", 257, 263], ["k", "TEST", 265, 266], ["k", "TEST", 277, 278], ["k", "TEST", 295, 296], ["T", "TEST", 314, 315], ["k", "TEST", 317, 318], ["Single", "TEST", 319, 325]]], ["As shown in Fig. 1 , the seven classes are related by different parameters, which are able to capture the system dynamics.", [["Fig", "OBSERVATION", 12, 15], ["different parameters", "OBSERVATION", 54, 74]]], ["In particular, \u03b2(k) is the time-varying infection rate, whose value is strongly dependent on the population behavior and the social distancing measures.", [["infection", "DISEASE", 40, 49], ["\u03b2(k)", "GENE_OR_GENE_PRODUCT", 15, 19], ["varying infection rate", "PROBLEM", 32, 54], ["varying", "OBSERVATION_MODIFIER", 32, 39], ["infection", "OBSERVATION", 40, 49]]], ["In Appendix A, we show that this parameter may be highly correlated with people's mobility.", [["people", "ORGANISM", 73, 79], ["people", "SPECIES", 73, 79], ["Appendix", "ANATOMY", 3, 11]]], ["Parameter \u03b8 is the rate of 335 infected that are recognized and Quarantined, \u03b3 is the rate of healing when the Infected and unrecognized people do not need to be hospitalized, \u03b4 is the rate of healing of Quarantined people, \u03bb is the rate of people that have been recognized only when a strong symptomatic condition occurs and therefore an immediate hospitalization is needed.", [["people", "ORGANISM", 137, 143], ["people", "ORGANISM", 216, 222], ["people", "ORGANISM", 241, 247], ["people", "SPECIES", 137, 143], ["people", "SPECIES", 216, 222], ["people", "SPECIES", 241, 247], ["the rate", "TEST", 15, 23], ["a strong symptomatic condition", "PROBLEM", 284, 314], ["an immediate hospitalization", "TREATMENT", 336, 364], ["infected", "OBSERVATION", 31, 39], ["healing", "OBSERVATION_MODIFIER", 94, 101], ["Infected", "OBSERVATION", 111, 119]]], ["Moreover, \u00b5 is the rate of Quarantined people that need to be hospitalized, \u03c0 is the rate 340 of healing of the Threatened people and \u03b5 is the death rate.Single-region SIRQTHE modelThe justification of this model construction lies in achieving a good compromise between the model accuracy, which allows representing all the facets of the pandemic diffusion, and the simplicity that helps identifying the characteristic parameters from the available data.", [["death", "DISEASE", 143, 148], ["people", "ORGANISM", 39, 45], ["people", "ORGANISM", 123, 129], ["people", "SPECIES", 39, 45], ["people", "SPECIES", 123, 129], ["the death rate", "PROBLEM", 139, 153], ["Single-region SIRQTHE model", "TREATMENT", 154, 181], ["this model construction", "TREATMENT", 202, 225], ["the pandemic diffusion", "PROBLEM", 334, 356], ["good", "OBSERVATION_MODIFIER", 246, 250], ["compromise", "OBSERVATION", 251, 261], ["model", "OBSERVATION_MODIFIER", 274, 279], ["accuracy", "OBSERVATION_MODIFIER", 280, 288], ["facets", "OBSERVATION_MODIFIER", 324, 330], ["pandemic", "OBSERVATION", 338, 346]]], ["For instance, we consider simply a Quarantined people class not discerning from those asymptomatic and those with mild or strong symptoms.", [["people", "ORGANISM", 47, 53], ["people", "SPECIES", 47, 53], ["mild or strong symptoms", "PROBLEM", 114, 137]]], ["Moreover, we ignore that hospitalized individuals may in fact require different treatments; in fact, several models divide this class considering 355 an additional class that takes into account people needing intensive care treatments.", [["individuals", "ORGANISM", 38, 49], ["people", "ORGANISM", 194, 200], ["people", "SPECIES", 194, 200], ["different treatments", "TREATMENT", 70, 90], ["intensive care treatments", "TREATMENT", 209, 234]]], ["In addition, we partially neglect the incubation time of the virus.", [["the virus", "PROBLEM", 57, 66]]], ["Lastly, we do not use the so-called Exposed compartment, which contains the people that have been infected while they are not yet contagious.", [["people", "ORGANISM", 76, 82], ["people", "SPECIES", 76, 82], ["infected", "OBSERVATION", 98, 106]]], ["Despite these hypotheses, as shown in Appendix A, the proposed SIRQTHE model shows its effectiveness in the identification phase 360 based on a minimal set of measurable epidemiological data that are commonly available across countries.Multi-region SIRQTHE modelIn order to correctly represent the COVID-19 spread, a multi-region variant of the model in (5)-(11) is here proposed.", [["SIRQTHE model", "DNA", 249, 262], ["COVID-19", "DNA", 298, 306], ["the proposed SIRQTHE model", "TEST", 50, 76], ["Appendix", "ANATOMY", 38, 46]]], ["In effect, a multi-region model is more reliable than a centralized model to reproduce the heterogeneous situation in multi-region areas with high-fidelity.", [["the heterogeneous situation in multi-region areas", "PROBLEM", 87, 136], ["heterogeneous", "OBSERVATION_MODIFIER", 91, 104], ["situation", "OBSERVATION", 105, 114], ["high-fidelity", "OBSERVATION_MODIFIER", 142, 155]]], ["By assuming the area under analysis is composed by M regions, whose index i varies in the set M = {1, . . . , M }, the equations related to the i-th region can be written as follows:Multi-region SIRQTHE modelComparing equations (5)-(11) with (12)- (18), we remark that in the latter formulation we mark the state variables related to region i with the corresponding index, and we 365 add a further term in the right-hand side of the first two difference equations to take the migration of individuals between regions into account.", [["right-hand", "ANATOMY", 410, 420], ["whose index i", "TEST", 62, 75], ["the set M", "TEST", 86, 95], ["the equations", "TEST", 115, 128], ["right", "ANATOMY_MODIFIER", 410, 415]]], ["In particular, we use the timevarying coefficients \u03be i,j (k), \u2200i, j \u2208 M to represent the inter-region mobility:Multi-region SIRQTHE modelrepresents the rate of people leaving the region i at time k.", [["people", "ORGANISM", 160, 166], ["SIRQTHE", "PROTEIN", 124, 131], ["people", "SPECIES", 160, 166]]], ["We assume that all 370 the parameters \u03be i,j (k) (\u2200j = i) get non-negative values; thus, \u03be i,i (k) has a non-positive value equal to:Multi-region SIRQTHE modelNote that (19) is derived by imposing the balance of the migrations flows between all the regions:Multi-region SIRQTHE modelThe complete model for a network composed by M regions can be written in matrix 375 form.", [["SIRQTHE model", "DNA", 269, 282], ["the parameters", "TEST", 23, 37]]], ["First we define:Multi-region SIRQTHE modelas the vectors containing all the state variables for each region.", [["Multi-region SIRQTHE modelas", "DNA", 16, 44], ["Multi-region SIRQTHE modelas the vectors", "TREATMENT", 16, 56]]], ["Then, we define the model parameters matrices as:Multi-region SIRQTHE modelwhere all the parameter matrices are diagonal, except for matrix \u039e(k) of the migration coefficients between regions.", [["Multi-region SIRQTHE modelwhere", "TREATMENT", 49, 80], ["diagonal", "ANATOMY_MODIFIER", 112, 120], ["migration coefficients", "OBSERVATION", 152, 174]]], ["Finally, the overall multi-region SIRQTHE model can be written as follows:Multi-region SIRQTHE modelwhere the symbol \u2022 represents the operator of the component-wise product (i.e, the Hadamard product).385For the sake of clarity, Fig. 2 shows the schematic diagram of the multi-region SIRQTHE model, where the links between the different single-region SIRQTHE models highlight the migration fluxes in terms of exchanged Susceptible and Infected individuals.390Before introducing the multi-region MPC framework we preliminarily recall that the aim of this paper is to support decision makers in identifying the optimal control actions to mitigate the effect of secondary pandemic waves, when the basic NPIs actions (e.g., in terms of social-distancing and use of face-masks) are ineffective or such measures are relaxed, thus requiring some more restrictive measures.", [["SIRQTHE", "DNA", 87, 94], ["the Hadamard product", "TREATMENT", 179, 199], ["the migration fluxes", "PROBLEM", 376, 396], ["the multi-region MPC framework", "TREATMENT", 478, 508], ["secondary pandemic waves", "PROBLEM", 659, 683], ["face-masks", "TREATMENT", 761, 771], ["some more restrictive measures", "TREATMENT", 834, 864], ["migration fluxes", "OBSERVATION", 380, 396], ["Infected", "OBSERVATION", 435, 443]]], ["As an example, in China, restrictions were eased as cases declined, but by the mid of May 2020, new pandemic clusters were reported.", [["new pandemic clusters", "PROBLEM", 96, 117]]], ["In effect, although the adopted NPIs countermeasures reduced the number of reported cases, the absence of herd immunity against COVID-19 suggests that contagions could easily rise again when these interventions are relaxed, as business, factory operations, and schools resume.", [["COVID-19", "CHEMICAL", 128, 136], ["COVID", "TEST", 128, 133]]], ["Therefore, as no vaccine is cur-400 rently available, we assume that any long term management of the COVID-19 spread should aim at reaching the heard immunity while not exceeding the regional healthcare capacity and limiting the loss of the regional economic systems.", [["vaccine", "TREATMENT", 17, 24], ["any long term management", "TREATMENT", 69, 93], ["the COVID", "TEST", 97, 106], ["the loss of the regional economic systems", "PROBLEM", 225, 266]]], ["This goal can be reached by applying some interventions that are more restrictive than the basic NPIs [6] in accordance with an optimal control strategy, whose aim is to keep low the num-405 ber of fatalities while minimizing the effects on the economic framework.", [["some interventions", "TREATMENT", 37, 55], ["the basic NPIs", "TREATMENT", 87, 101], ["an optimal control strategy", "TREATMENT", 125, 152]]], ["In addition, in multi-region areas with a strong regional heterogeneity, it is crucial to find targeted and coordinated optimal exit and restarting strategies on a regional basis to effectively cope with the possible onset of further epidemic waves, while efficiently returning economic activities to their standard level of intensity.", [["a strong regional heterogeneity", "PROBLEM", 40, 71], ["further epidemic waves", "PROBLEM", 226, 248], ["strong", "OBSERVATION_MODIFIER", 42, 48], ["regional", "OBSERVATION_MODIFIER", 49, 57], ["heterogeneity", "OBSERVATION", 58, 71]]], ["As a consequence, in this section 410 we present an optimal control approach based on a receding horizon scheme, which supports regional governments in defining the most effective strategies to be adopted during post-lockdown mitigation phases in a multi-region scenario.390Throughout the rest of the paper, we consider the same length for both the prediction and control horizon.", [["an optimal control approach", "TREATMENT", 49, 76], ["a receding horizon scheme", "TREATMENT", 86, 111], ["regional governments", "OBSERVATION", 128, 148]]], ["In particular, at the generic time instant h \u2208 Z + the horizonPossible control and mitigation actionsIn this section, we introduce some different control actions that can be used to contain the impacts of the COVID-19 pandemic.", [["the horizonPossible control", "TREATMENT", 51, 78], ["mitigation actions", "TREATMENT", 83, 101], ["some different control actions", "TREATMENT", 131, 161], ["the COVID", "TEST", 205, 214], ["pandemic", "PROBLEM", 218, 226]]], ["On the other hand, we assume that any control action is focused only on reducing the parameters \u03b2 i (k) and \u03be i,j (k), i.e., the intra-region infection rate and the inter-region migration coefficient at each time k, respectively.", [["infection", "DISEASE", 142, 151], ["the intra-region infection rate", "PROBLEM", 125, 156], ["the inter-region migration", "PROBLEM", 161, 187], ["infection", "OBSERVATION", 142, 151]]], ["These parameters are indeed controllable in some way.", [["controllable", "OBSERVATION_MODIFIER", 28, 40]]], ["For instance, a reduction of the internal activities of region i would reduce significantly the corresponding \u03b2 i (k), whilst travel restrictions between region i and region j will reduce coefficients \u03be i,j (k).", [["reduction", "OBSERVATION_MODIFIER", 16, 25], ["internal", "OBSERVATION_MODIFIER", 33, 41]]], ["Therefore, we model two classes of control and mitigation interventions:Possible control and mitigation actions\u2022 intra-region activity restrictions;Possible control and mitigation actions\u2022 inter-region travel restrictions.430As for the first class, for each region i we preliminarily define a vector of control variables u i := u i (h : h + K \u2212 1) that models the interventions on the activities performed within the given region (in terms of percentage reduction) over the given control horizon.", [["mitigation interventions", "TREATMENT", 47, 71], ["mitigation actions", "TREATMENT", 93, 111], ["intra-region activity restrictions", "TREATMENT", 113, 147], ["u i", "TEST", 328, 331], ["K \u2212", "TEST", 341, 344], ["the activities", "TEST", 381, 395], ["percentage reduction", "TREATMENT", 443, 463]]], ["For 435 instance, when U i = {0, 0.2, 0.8}, u i (k) = 0.8 corresponds to a complete lockdown, u i (k) = 0 is the normal condition, and u i (k) = 0.2 corresponds to telework and closure of schools and universities in region i at time k.", [["u i (k)", "TEST", 44, 51], ["a complete lockdown, u i (k)", "TEST", 73, 101], ["u i (k)", "TEST", 135, 142], ["closure", "OBSERVATION", 177, 184]]], ["Subsequently, we assume that a reduction of the activity level linearly produces a decrease of the infection coefficient for all the regions [6] .", [["infection", "DISEASE", 99, 108], ["a reduction of the activity level", "PROBLEM", 29, 62], ["the infection", "PROBLEM", 95, 108], ["reduction", "OBSERVATION_MODIFIER", 31, 40], ["decrease", "OBSERVATION_MODIFIER", 83, 91], ["infection", "OBSERVATION", 99, 108]]], ["Hence, we correlate the intra-region infection rate for time slot 440 k with the intra-region activity restriction measures in accordance with the following linear equation:430where \u03b2 0 i is the infection rate when no measures are applied.", [["infection", "DISEASE", 37, 46], ["infection", "DISEASE", 195, 204], ["the intra-region infection rate", "PROBLEM", 20, 51], ["the intra-region activity restriction measures", "TREATMENT", 77, 123], ["the infection rate", "PROBLEM", 191, 209], ["infection", "OBSERVATION", 37, 46], ["infection", "OBSERVATION", 195, 204]]], ["For each region i we preliminarily define a vector of control variables r i := r i (h : h + K \u2212 1) 445 that models the restrictions on the mobility from and towards the given region over the given control horizon.", [["K \u2212", "TEST", 92, 95], ["mobility", "OBSERVATION", 139, 147]]], ["For instance, in the case of on/off strategy, R i = {0, 1}: r i (k) = 1 corresponds to the situation where inbound and outbound mobility is forbidden, whilst r i (k) = 0 means that no inter-region travel restriction are imposed to region i at time k.", [["strategy", "TEST", 36, 44], ["inter-region travel restriction", "TREATMENT", 184, 215]]], ["Subsequently, we assume that a reduction of the inter-region mobility produces a linear decrease in the Susceptible and Infectedin region i (see [18] ) in accordance with the following linear equation:430where \u03be 0 i,j denotes the coefficient of migration from the region j to the region i when 455 no mobility restrictions are applied.", [["Susceptible and Infectedin region", "DNA", 104, 137], ["the inter-region mobility", "PROBLEM", 44, 69], ["a linear decrease", "PROBLEM", 79, 96], ["the Susceptible and Infectedin region i", "PROBLEM", 100, 139], ["mobility restrictions", "TREATMENT", 301, 322], ["reduction", "OBSERVATION_MODIFIER", 31, 40], ["linear", "OBSERVATION_MODIFIER", 81, 87], ["decrease", "OBSERVATION_MODIFIER", 88, 96], ["Susceptible", "OBSERVATION_MODIFIER", 104, 115], ["migration", "OBSERVATION", 245, 254], ["mobility restrictions", "OBSERVATION", 301, 322]]], ["Finally, we denote as u := (u 1 , . . . , u M ) and r := (r 1 , . . . , r M ) the vectors collecting the intra-region activity and inter-region restriction strategies over all the regions in M, respectively.", [["the vectors", "TREATMENT", 78, 89], ["inter-region restriction strategies", "TREATMENT", 131, 166], ["intra-region activity", "OBSERVATION", 105, 126], ["regions", "ANATOMY_MODIFIER", 180, 187]]], ["We assume that the intra-region activity and inter-region restrictions can be either applied on a region-by-region basis or by an inter-region co-460 ordination mechanism.", [["the intra-region activity", "PROBLEM", 15, 40], ["inter-region restrictions", "TREATMENT", 45, 70], ["an inter-region co", "TEST", 127, 145], ["activity", "OBSERVATION_MODIFIER", 32, 40]]], ["Such a kind of policies can be reflected in the control system by properly defining constraint sets U and R on the given decision variables:430For instance, the control actions could be applied to the whole network of regions in accordance with the following policies:430\u2022 Uniform intra-region activity and inter-region travel restrictions.", [["the control actions", "TREATMENT", 157, 176]]], ["This case is 465 applicable to a multi-region structure controlled by an upper-level government that does not allow each individual region to implement differentiated control actions.", [["an upper-level government", "TREATMENT", 70, 95]]], ["Under such a policy, the definition of the constraint sets U and R is given by:430An example of application of this policy was implemented by the Italian gov-470 ernment during the so-called COVID-19 Phase 1: the lockdown and the boundary closure was simultaneously imposed to each Italian region, i.e.:430\u2022 Differentiated intra-region activity restrictions and uniform inter-region travel restrictions.", [["the lockdown", "TREATMENT", 209, 221], ["the boundary closure", "TREATMENT", 226, 246], ["Differentiated intra-region activity restrictions", "PROBLEM", 308, 357], ["closure", "OBSERVATION", 239, 246], ["intra-region activity", "OBSERVATION", 323, 344], ["uniform", "OBSERVATION_MODIFIER", 362, 369], ["inter-region", "OBSERVATION_MODIFIER", 370, 382]]], ["Under such a policy, the definition of the constraint sets U and R is characterized by coupling between the control variables related to different regions:430An example of applying this policy was implemented by the Italian govern-480 ment during the so-called Phase 2: all the regional boundaries were kept closed (r i (k) = 0, \u2200i \u2208 M), while each region determined the restarting strategies on a local basis.430\u2022 Differentiated intra-region activity and inter-region travel restrictions.", [["Differentiated", "OBSERVATION_MODIFIER", 415, 429], ["intra-region activity", "OBSERVATION", 430, 451]]], ["This is the most general case of a multi-region structure where the regional jurisdiction 485 allows implementing individual control actions both on regional internal activities and boundaries.", [["individual control actions", "TREATMENT", 114, 140]]], ["Under such a policy, in the definition of the constraint sets U and R there is no coupling between the control variables related to different regions: We finally remark that, to avoid too frequent and unpractical changes in the strategies, the control actions can be kept constant over a given period equal to \u2206l = \u03c9 \u2206k (i.e., for \u03c9 time slots).", [["coupling between the control variables", "PROBLEM", 82, 120], ["too frequent and unpractical changes", "PROBLEM", 184, 220], ["the strategies", "TREATMENT", 224, 238]]], ["For instance, if \u2206k is one day, it could be meaningful to set the periodicity of the control actions to one week (i.e., \u03c9 = 7).", [["\u2206k", "DNA", 17, 19]]], ["Assuming that K = L \u03c9, with L \u2208 N, the following additional constraints on the control actions are then introduced:430In Fig. 3 we show the different time intervals used to update the state model and the control actions.Control multiple objectivesThe proposed MPC approach aims at simultaneously optimizing the objectives of all the regions.", [["L \u2208 N", "CHEMICAL", 28, 33], ["K", "TEST", 14, 15], ["L \u2208 N", "TREATMENT", 28, 33], ["The proposed MPC approach", "TREATMENT", 247, 272], ["MPC", "OBSERVATION_MODIFIER", 260, 263], ["regions", "ANATOMY_MODIFIER", 333, 340]]], ["In turn, the objective function related to region i -denoted as J i (\u2200i \u2208 M) -is composed by multiple cost terms as follows:Control multiple objectiveswhere vectors S i ,Control multiple objectivescollect the predicted values of compartment members in region i over the control horizon (e.g., S i = S i (k : k + K \u2212 1)).", [["k", "TEST", 308, 309]]], ["Note that 505 coefficients C T , C u i , and C r i have a twofold function: on the one hand, they provide a prioritization among the multiple cost terms in (37) ; on the other hand, they ensure that these terms are homogeneous (namely, they make the three terms dimensionless).Control multiple objectivesMore in detail, the first term in (37) -weighted by coefficient C T -represents the cost incurred by the healthcare system of region i, which is consequent to the predicted 510 epidemic evolution over the whole control horizon.", [["homogeneous", "OBSERVATION_MODIFIER", 215, 226]]], ["By properly assigning a very large value to C T , we ensure that the number of Threatened individuals T i (k) related to region i is lower than a prefixed maximum T max i for each time slot k.", [["C T", "GENE_OR_GENE_PRODUCT", 44, 47], ["C T", "CELL_TYPE", 44, 47]]], ["The second term in (37) -weighted by coefficient C u i -is the cost incurred by the regional economic system, as a result of applying the intra-region activity restriction 515 in region i over the entire control horizon.", [["the intra-region activity restriction", "TREATMENT", 134, 171]]], ["It assumes that there is a linear correlation between the level of restriction imposed to the internal activities and the loss of the regional economic productivity.Control multiple objectivesThe third term in (37) -weighted by coefficient C r i -represents the cost incurred by the regional economic system, as a result of regulating the closure of boundaries 520 to region i over the entire control horizon.", [["the regional economic productivity", "PROBLEM", 130, 164], ["the closure of boundaries", "TREATMENT", 335, 360], ["linear", "OBSERVATION_MODIFIER", 27, 33], ["internal", "OBSERVATION_MODIFIER", 94, 102], ["activities", "OBSERVATION_MODIFIER", 103, 113], ["loss", "OBSERVATION_MODIFIER", 122, 126], ["regional", "OBSERVATION_MODIFIER", 134, 142], ["economic", "OBSERVATION_MODIFIER", 143, 151], ["productivity", "OBSERVATION_MODIFIER", 152, 164], ["closure", "OBSERVATION", 339, 346]]], ["It assumes that there is a linear correlation between the level of restriction applied to the in-and out-bound mobility and the loss of the regional economic productivity, according to (30) .Control multiple objectivesSumming up, the objective function defined in (37) allows finding a control policy that minimizes the economic loss -quantified through the last two terms of (37)-and 525 simultaneously keeps the number of Threatened under a safety threshold -thanks to the presence of the first term of (37) .Control multiple objectivesFinally, note that weighting coefficients C u i and C r i are region-dependent: this ensures that regional policy makers can adjust these coefficient in accordance with the importance and priority that can be assigned to the above mentioned costs in each re-530 gion depending on local scenarios, according to (31) .The proposed multi-region optimal control problemHaving defined the state model, the control variables with the corresponding constraint set, and the objective function related to the online optimization, the optimal control problem is formulated as follows:The proposed multi-region optimal control problemconstraints on control variables (32) and (36) .", [["the regional economic productivity", "PROBLEM", 136, 170], ["the economic loss", "PROBLEM", 316, 333], ["The proposed multi-region optimal control problem", "TREATMENT", 854, 903], ["the online optimization", "TREATMENT", 1034, 1057], ["linear", "OBSERVATION_MODIFIER", 27, 33], ["loss", "OBSERVATION_MODIFIER", 128, 132], ["regional", "OBSERVATION_MODIFIER", 140, 148], ["economic", "OBSERVATION_MODIFIER", 149, 157], ["productivity", "OBSERVATION_MODIFIER", 158, 170]]], ["(38) The optimization problem (38) has 2M K integer and 7M K real decision variables (i.e., u, r and S i ,The proposed multi-region optimal control problemrespectively); furthermore, it presents non-linearities both in the objective function and state model.", [["2M K integer", "TEST", 39, 51]]], ["Consequently, the optimization problem (38) is a mixed-integer non-linear programming (MINLP) problem.540Due to (36) , the optimization problem (38) is iteratively solved every \u03c9 time slots in accordance with the receding horizon paradigm (see Fig. 3 ), based on the most recent input data.", [["a mixed-integer non-linear programming (MINLP) problem", "TREATMENT", 47, 101]]], ["Then, for the next group of \u03c9 time slots, a new optimization problem is solved using the updated information 545 on forecasts and system states.", [["a new optimization problem", "PROBLEM", 42, 68]]], ["This results in the closed-loop control scheme shown in Fig. 4 .", [["the closed-loop control scheme", "TREATMENT", 16, 46]]], ["Note that the presented closed-loop feedback control technique may rely both on directly measurable and not directly measurable quantities.", [["closed-loop feedback control technique", "TREATMENT", 24, 62]]], ["In fact, since not all SIRQTHE classes may be directly estimable, at each time shift a procedure for the identification of 550 the model parameters should be conducted.", [["a procedure", "TREATMENT", 85, 96], ["the identification", "TEST", 101, 119]]], ["More in detail, at each time shift, the latest data related to the available classes should be used to update the remaining SIRQTHE parameters by employing the dynamical identification procedure (e.g., referring to the Italian scenario, see the identification description defined in Appendix A).540The MPC integrates both the control actions and multi-region epidemic models 555 (described in the previous sections), taking into account the mutual interaction between the effects of the intra-region activity and the inter-region mobility restrictions and the multi-region epidemic dynamics.", [["The MPC", "TREATMENT", 298, 305]]], ["The MPC law is defined in accordance with an output-feedback formulation.", [["an output", "TEST", 42, 51], ["feedback formulation", "TREATMENT", 52, 72], ["MPC law", "OBSERVATION", 4, 11]]], ["The optimization problem aims at determining the control actions (e.g., intra-region activity restrictions and the inter-region mobility re-560 strictions) for each region, whilst the measured responses coincide with the main epidemic parameters (e.g., number of hospitalized or Quarantined, level of mobility, etc.) monitored by the regional government agencies.", [["intra-region activity restrictions", "TREATMENT", 72, 106], ["the inter-region mobility", "TREATMENT", 111, 136]]], ["Obviously, the estimation of all the variables influencing the epidemic dynamics in the network of regions (i.e., the variables that are not monitored by sensors), as well as the presence of disturbances, can 565 affect the accuracy of the model response.", [["disturbances", "PROBLEM", 191, 203]]], ["The application of the MPC strategy allows limiting the effects of such uncertainties thanks to the computation of feedback control actions that are based on periodical updates of the actual system state and on the prediction of its evolution in a rolling horizon approach.Numerical experiments on the Italian scenario 570In order to validate the optimal control approach of the COVID-19 outbreak, we test the proposed multi-region methodology on the Italian scenario.", [["the MPC strategy", "TREATMENT", 19, 35], ["feedback control actions", "TREATMENT", 115, 139], ["a rolling horizon approach", "TREATMENT", 246, 272]]], ["In particular, in this section we report and analyze the results of the optimal mitigation strategies on the network of M = 20 Italian regions, i.e., the second level administrative body in Italy.", [["body", "ORGANISM_SUBDIVISION", 182, 186]]], ["In effect, the Italian scenario suits well the proposed control approach due to two main 575 aspects.", [["the proposed control approach", "TREATMENT", 43, 72]]], ["In fact, all the regions have a different level of quality for the healthcare facilities; in addition, each region has different regulations and policies regarding swabs, hospitalization, treatment, and prevention.", [["swabs", "TREATMENT", 164, 169], ["treatment", "TREATMENT", 188, 197]]], ["On the other hand, the spread of COVID-19, and the consequently adopted containment measures, produced extremely heterogeneous 580 effects on the Italian regions: while the North of Italy, and particularly Lombardy, has been facing a tremendous amount of COVID-19 cases (with about one hundred thousand of confirmed cases and sixteen thousand of confirmed deaths as of August 13, 2020 [32] ), the South of Italy is experiencing a relatively stable situation.Numerical experiments on the Italian scenario 570First, based on the real data available for the Italian pandemic (see [29] ), we esti-585 mate the model parameters for both the single-region and the multi-region SIRQTHE model.", [["deaths", "DISEASE", 356, 362], ["COVID", "TEST", 33, 38], ["heterogeneous", "OBSERVATION_MODIFIER", 113, 126], ["stable", "OBSERVATION", 441, 447]]], ["Then, we discuss the long-term outcomes that can be achieved by applying the proposed optimal control approach for different restriction policies.", [["different restriction policies", "TREATMENT", 115, 145]]], ["We also provide a comparison with respect to the results obtained with three performance evaluation benchmarks, that is: (1) the minimization of the economic cost;Numerical experiments on the Italian scenario 570(2) the minimization 590 of the Threatened; (3) the threshold rule-based feedback control scheme inspired by the Italian government's existing protocol [33] .Definition and set-up of test scenariosThis section reports the main results of the identification to be used as initial conditions for the considered control schemes.", [["three performance evaluation benchmarks", "TEST", 71, 110], ["the threshold rule", "TEST", 260, 278], ["test scenarios", "TEST", 395, 409]]], ["The detailed description of the fitting pro-595 cedure is reported in Appendix A.Definition and set-up of test scenariosThe time slot \u2206k is set to one day, whilst the simulation period is one year.", [["Appendix", "ANATOMY", 70, 78]]], ["Moreover, since a daily application of the restrictive measures would be unrealistic and impossible to be implemented in real-life, we assume that the control actions are implemented on a weekly basis (i.e., \u2206l = \u03c9 \u2206k, with \u03c9 = 7).600The initial number of Quarantined, Threatened, Recovered, and Extinct individuals are set to the values of August 13, 2020, according to the real data in [29] .", [["the restrictive measures", "TREATMENT", 39, 63]]], ["Consequently, the corresponding number of Susceptible, Infected, and Removed individuals is estimated according to the identification procedure reported in Appendix A for the considered date.", [["the identification procedure", "TREATMENT", 115, 143], ["number", "OBSERVATION_MODIFIER", 32, 38], ["Susceptible", "OBSERVATION_MODIFIER", 42, 53], ["Infected", "OBSERVATION", 55, 63], ["Appendix", "ANATOMY", 156, 164]]], ["605 We highlight that, since the aim of our work is to reduce the infection rate \u03b2(k) so as to contain the number of Threatened people under a well-defined maximum level T max i , we assume that \u03b2(k) is a function of the mobility level, computed on the basis of the daily Google mobility reports [34] .", [["infection", "DISEASE", 66, 75], ["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134], ["the infection rate", "PROBLEM", 62, 80], ["infection", "OBSERVATION", 66, 75]]], ["Note that T max i is specifically defined for each region, due to the high heterogeneity of the Italian healthcare system.", [["T max i", "TEST", 10, 17]]], ["Moreover, 610 we assume that parameters \u03b3, \u03b4, \u03b8, \u03bb, and \u00b5 are constant over the prediction horizon and are computed by means of the identification procedure described in Appendix A. Parameters \u03c0(k) and \u03b5(k) are time-dependent; however, in the simulations, we set their value to the last fitted value.", [["\u03b4", "PROTEIN", 43, 44], ["\u03b8", "PROTEIN", 46, 47], ["\u03bb", "PROTEIN", 49, 50], ["\u00b5", "PROTEIN", 56, 57], ["parameters", "TEST", 29, 39], ["the identification procedure", "TREATMENT", 128, 156], ["Appendix", "ANATOMY", 170, 178]]], ["This hypothesis is reasonable because, although these two parameters are highly variable during the first stage of the pandemic, for long-time 615 observations they settle to a stable value, as shown in Appendix A. Finally, the timevarying migration coefficients \u03be i,j (k) (\u2200i, j \u2208 M) are adapted from [35] .600The optimal control problem (38) is implemented in the Matlab environment [36] using the Global Optimization toolbox on a laptop equipped with a 1.3 GHz Intel Core i5 CPU and 8 GB RAM.", [["the timevarying migration coefficients", "TREATMENT", 224, 262], ["Appendix", "ANATOMY", 203, 211], ["GB RAM", "ANATOMY", 488, 494]]], ["Since problem (38) falls into the class of MINLP problems, its resolution is non trivial due both to its combinatorial complexity and non-linearity.", [["MINLP problems", "PROBLEM", 43, 57]]], ["Therefore, a two-step genetic algorithm approach is here applied for the resolution of (38) .", [["a two-step genetic algorithm approach", "TREATMENT", 11, 48]]], ["In the first phase, being n the number of control variables, we perform 1, 000 n parallel computations of the genetic algorithm with 1, 000 n generations, i.e., an initial population size of 1, 000 n.", [["the genetic algorithm", "TEST", 106, 127], ["size", "OBSERVATION_MODIFIER", 183, 187]]], ["In the second phase, the outcomes of the first phase are 625 used as the initial population of an additional genetic optimization process.600As for the objective function of (38), the cost coefficients C u i and C r i are set for each region based on the corresponding per capita regional Gross Domestic Product (GDP) normalized by the per capita national GDP (see Appendix B).", [["GDP", "SIMPLE_CHEMICAL", 356, 359], ["an additional genetic optimization process", "TREATMENT", 95, 137], ["the objective function", "TEST", 148, 170], ["the cost coefficients C u i and C r i", "TREATMENT", 180, 217], ["Domestic Product", "OBSERVATION", 295, 311]]], ["In fact, we assume 630 that C T is much higher than the other coefficients because our objective is to keep the number of Threatened cases below a maximum level T max i , i.e., the first term represents a soft constraint.", [["C T", "GENE_OR_GENE_PRODUCT", 28, 31]]], ["We do not impose such a condition by means of an explicit additional constraint because, with some settings for the model (e.g., a high infection rate), the problem may become infeasible.", [["infection", "DISEASE", 136, 145], ["a high infection rate", "PROBLEM", 129, 150]]], ["Note that, on the basis of the Italian data [32] , we 635 set T max i equal to three times the number of Intensive Care Units (ICUs), reported in Appendix B.600Finally, we assume that three different intra-region activity restrictions can be implemented by each region at each time k: lockdown (i.e., u i (k) = 0.8), partial lockdown corresponding to the closure of specific activities, such as universities and schools645In this section we show the results obtained by the proposed MPC over the given simulation period of one year using a prediction horizon of eight weeks (i.e., K = 56, L = 8) with the application of the following restriction policies:645\u2022 U-U policy : Uniform intra-region activity restrictions and Uniform inter-region travel restrictions.650\u2022 D-U policy: Differentiated intra-region activity restrictions and Uniform interregion travel restrictions.650\u2022 D-D policy: Differentiated intra-region activity restrictions and Differentiated inter-region travel restrictions.650As a first outcome, we analyze all the considered restriction policies using several 655 sets of weights by changing the relative importance of intra-region activities with respect to inter-region mobility (that is, by varying parameter \u03b1 in C r i = \u03b1C u i , \u2200i \u2208 M).", [["partial lockdown", "PROBLEM", 317, 333], ["K", "TEST", 581, 582], ["Uniform intra-region activity restrictions", "TREATMENT", 673, 715], ["Appendix", "ANATOMY", 146, 154], ["intra-region activity", "OBSERVATION", 793, 814]]], ["Figures 5-7 show the results obtained for the three above policies when \u03b1 = 1.", [["Figures", "TEST", 0, 7]]], ["The blue line represents the time evolution of the Threatened cases, the red line represents the time evolution of the intra-region control actions, and the green dotted line represents the time evolution of the inter-region travel restrictions, while the black line represents the maximum number of Threatened cases that can be treated by the i-th region (i.e., T max i ).650In particular, Fig. 5 highlights that, by adopting the U-U policy, the trend of the control actions is the same for all regions, while the time evolution of the Threatened 665 cases largely varies depending on the considered region.", [["blue line", "CELL", 4, 13], ["U-U", "GENE_OR_GENE_PRODUCT", 431, 434], ["green dotted line", "CELL_LINE", 157, 174], ["The blue line", "TREATMENT", 0, 13], ["the red line", "TREATMENT", 69, 81], ["the green dotted line", "PROBLEM", 153, 174], ["the black line", "PROBLEM", 252, 266], ["blue line", "OBSERVATION", 4, 13], ["Threatened", "OBSERVATION_MODIFIER", 51, 61], ["cases", "OBSERVATION", 62, 67], ["red line", "OBSERVATION", 73, 81], ["black line", "OBSERVATION", 256, 266], ["maximum", "OBSERVATION_MODIFIER", 282, 289], ["number", "OBSERVATION_MODIFIER", 290, 296], ["Threatened", "OBSERVATION", 300, 310]]], ["Note that such a policy seems to be unnecessary in some regions, such as Aosta and Trentino-South Tyrol that present a very small amount of Threatened cases with respect to the remaining regions.", [["very", "OBSERVATION_MODIFIER", 119, 123], ["small", "OBSERVATION_MODIFIER", 124, 129], ["amount", "OBSERVATION_MODIFIER", 130, 136], ["Threatened", "OBSERVATION", 140, 150], ["remaining", "ANATOMY_MODIFIER", 177, 186], ["regions", "ANATOMY_MODIFIER", 187, 194]]], ["We highlight that with this policy only the intra-region control policy are applied.", [["the intra-region control policy", "TREATMENT", 40, 71]]], ["670 Figure 6 (D-U policy, with \u03b1 = 1) shows that the trend of the control actions differs from region to region and the time evolution of the Threatened cases still largely varies depending on the considered region.", [["D-U policy", "TEST", 14, 24], ["the Threatened cases", "PROBLEM", 138, 158], ["Threatened", "OBSERVATION", 142, 152]]], ["It has to be noticed that, similarly to Policy U-U, Policy D-U imposes that the regional borders must be open during the observing period.", [["D-U", "GENE_OR_GENE_PRODUCT", 59, 62]]], ["On the contrary, differently from Policy U-U, the intra-region control actions 675 are set coherently to the specific pandemic evolution occurring in each region.", [["U-U", "GENE_OR_GENE_PRODUCT", 41, 44], ["specific", "OBSERVATION_MODIFIER", 109, 117], ["pandemic", "OBSERVATION", 118, 126]]], ["In fact, in Aosta no unnecessary restrictions are applied on the intra-region activities.", [["unnecessary restrictions", "TREATMENT", 21, 45], ["unnecessary", "OBSERVATION_MODIFIER", 21, 32], ["restrictions", "OBSERVATION", 33, 45]]], ["680 Moreover, Fig. 7 (D-D policy, with \u03b1 = 1) shows that the control actions vary from region to region as well as the time evolution of the Threatened cases, but the trend now differs from the previous policies because also the inter-regional control actions are applied.", [["D-D", "SIMPLE_CHEMICAL", 22, 25]]], ["In this case, both intra-region and inter-region control actions are coherently applied depending on the specific pandemic evolution occurring in each 685 region and depending on its economic framework.", [["both intra-region and inter-region control actions", "TREATMENT", 14, 64]]], ["In effect, the differentiated intra-and inter-region control actions are coherently set, thus leading to the minimum objective function value for the regional healthcare and economic system.", [["the differentiated intra-and inter-region control actions", "TREATMENT", 11, 68], ["differentiated", "OBSERVATION_MODIFIER", 15, 29], ["intra-and", "OBSERVATION_MODIFIER", 30, 39]]], ["Indeed, the D-D policy presents the least restricted control action set with respect to the D-U and U-U policies, thus leading to a global objective function value that is lower than or equal to that of the other policies (i.e., from a global perspective, the D-D policy generally outperforms the other two policies).", [["D-D", "SIMPLE_CHEMICAL", 12, 15], ["U-U", "GENE_OR_GENE_PRODUCT", 100, 103], ["the D-D policy", "TREATMENT", 8, 22], ["a global objective function value", "PROBLEM", 130, 163], ["the D-D policy", "TREATMENT", 256, 270]]], ["Nevertheless, since the objective func-695 tion (37) is composed by the weighted summation of multiple terms, this conclusion is no more valid when analyzing and comparing the single contributions of the objective function for the three policies.", [["the objective func", "TEST", 20, 38]]], ["Consequently, the various policies have to be evaluated using further performance indicators different from the composite objective function value, such as the average number of Threatened people and the duration of the control 700 actions.", [["people", "ORGANISM", 189, 195], ["people", "SPECIES", 189, 195]]], ["Such a comparative analysis is indeed very useful to policy-makers in supporting the choice of the most suitable strategy to be implemented.", [["a comparative analysis", "TEST", 5, 27]]], ["Therefore, in order to effectively evaluate the different control policies, in Tables \u2022 the average number of Threatened individuals over the control horizon for all the regions and the whole Italy;650\u2022 the duration of the lockdown (measured in days) for all the regions;715\u2022 the duration of the partial lockdown (measured in days) for all the regions;715\u2022 the total number of control action switches, both for intra-and inter-region control actions;715\u2022 the duration of the border closure (measured in days) for all the regions;715\u2022 the overall cost of the policies over the control horizon for all the regions and the 720 whole Italy.715By analyzing Table 1 , it can be observed that, if a similar importance weight is assigned to both the intra-and inter-region actions (i.e., for \u03b1 = 1), then the average number of Threatened people assumes the lowest value with the U-U policy, thus making it preferable from a social perspective, whereas the average duration of the 725 lockdown is the highest with the lowest number of control actions switches.", [["people", "ORGANISM", 830, 836], ["people", "SPECIES", 830, 836], ["the control horizon", "TREATMENT", 138, 157], ["the partial lockdown", "TREATMENT", 292, 312], ["control action switches", "TREATMENT", 377, 400], ["intra-and inter-region control actions", "TREATMENT", 411, 449], ["the border closure", "TREATMENT", 471, 489], ["the control horizon", "TREATMENT", 572, 591]]], ["As a result, we can conclude that, although the D-D policy, thanks to differentiated actions on intra-region activity and inter-region mobility restrictions, ensures the lowest global objective function value, it does not guarantee the lowest number of Threatened cases.", [["D-D", "SIMPLE_CHEMICAL", 48, 51], ["inter-region mobility restrictions", "TREATMENT", 122, 156]]], ["Figure 6 : Policy D-U , \u03b1 = 1: Threatened cases (blue line), intra-region activity (red line) and inter-region travel (green dotted line) restrictions, the maximum number of Threatened cases that can be treated by the region (black line).", [["Threatened cases (blue line", "TREATMENT", 31, 58], ["intra-region activity (red line", "PROBLEM", 61, 92], ["green dotted line)", "TREATMENT", 119, 137], ["Threatened cases", "TREATMENT", 174, 190], ["red line", "OBSERVATION", 84, 92], ["black line", "OBSERVATION", 226, 236]]], ["For each region, the x-axis reports the time in days, the left y-axis represents the number of Threatened individuals, and the right y-axis represents the value of the control actions.A comparison with benchmark control strategiesIn this section, we introduce some reference strategies to compare the examining the effectiveness of the proposed optimal control approach.", [["benchmark control strategies", "TREATMENT", 202, 230], ["the proposed optimal control approach", "TREATMENT", 332, 369], ["left", "ANATOMY_MODIFIER", 58, 62], ["number", "OBSERVATION_MODIFIER", 85, 91], ["Threatened", "OBSERVATION", 95, 105], ["right", "ANATOMY_MODIFIER", 127, 132]]], ["In particular, three simple 735 benchmark strategies are defined:A comparison with benchmark control strategies\u2022 Benchmark control strategy 1: No restrictions are applied for the whole simulation period, ignoring the impact on the healthcare system.A comparison with benchmark control strategies\u2022 Benchmark control strategy 2: All restrictions are applied for the whole simulation period, i.e., all the intra-region and inter-region restrictions are used at 740 their maximum value to control and flatten the number of cases, ignoring any economic impact.A comparison with benchmark control strategies\u2022 Benchmark control strategy 3: At the beginning of each week, all restrictions are applied in a single region if the number of Threatened is higher than a safety threshold.745Note that the first two strategies represent two ideal extreme cases, since they correspond to take only the economic or the health perspective into account, respectively.", [["benchmark control strategies", "TREATMENT", 83, 111], ["Benchmark control strategy", "TREATMENT", 113, 139], ["benchmark control strategies", "TREATMENT", 267, 295], ["Benchmark control strategy", "TREATMENT", 297, 323], ["All restrictions", "TREATMENT", 327, 343], ["benchmark control strategies", "TREATMENT", 573, 601], ["Benchmark control strategy", "TREATMENT", 603, 629], ["all restrictions", "TREATMENT", 664, 680], ["Threatened", "OBSERVATION", 729, 739], ["higher", "OBSERVATION_MODIFIER", 743, 749]]], ["Instead, the third strategy is a simple but at the same time realistic feedback control strategy to mitigate the COVID-19 outbreak.", [["the COVID", "TEST", 109, 118]]], ["Figures 8-10 show the results obtained for the three benchmark control strategies.", [["Figures", "TEST", 0, 7], ["the three benchmark control strategies", "TREATMENT", 43, 81]]], ["The blue line represents the time evolu-750 tion of the Threatened cases, the red line represents the time evolution of the intraregion control actions, and the green dotted line represents the time evolution of the inter-region travel restrictions, while the black line represents the maximum number of Threatened cases that can be treated by the i-th region (i.e., T max i ).", [["blue line", "CELL", 4, 13], ["green dotted line", "CELL_LINE", 161, 178], ["The blue line", "TREATMENT", 0, 13], ["the red line", "TREATMENT", 74, 86], ["the green dotted line", "PROBLEM", 157, 178], ["the black line", "PROBLEM", 256, 270], ["blue line", "OBSERVATION", 4, 13], ["red line", "OBSERVATION", 78, 86], ["black line", "OBSERVATION", 260, 270], ["maximum", "OBSERVATION_MODIFIER", 286, 293], ["number", "OBSERVATION_MODIFIER", 294, 300], ["Threatened", "OBSERVATION", 304, 314]]], ["In Fig. 8 we show the results of benchmark control strategy 1, i.e., the case where 755 no restrictions are applied and the control actions at each week are null (u i (k) = 0 and r i (k) = 0 for each region i for each time k).", [["benchmark control strategy", "TREATMENT", 33, 59]]], ["The reported graph highlights that with the current model parameters, applying no control actions would result in an overload of the national healthcare system in almost all Italian regions.", [["control actions", "TREATMENT", 82, 97], ["an overload of the national healthcare system", "PROBLEM", 114, 159], ["overload", "OBSERVATION", 117, 125]]], ["At the same time, this solution corresponds to the minimization of only the last two terms of (37), i.e., only 760 the economic part.745Conversely, in Fig. 9 we show the results of benchmark control strategy 2, i.e., the case where all the restrictions are applied at their maximum value (u i (k) = 0.8 and r i (k) = 1 for each region i at each time k of the simulation period).", [["this solution", "TREATMENT", 18, 31], ["benchmark control strategy", "TREATMENT", 181, 207]]], ["In this case the number of Infected falls to zero; however, the economic cost is the highest (i.e., 765 19603.17).745Finally, in Fig. 10 , we show the results of benchmark control strategy 3.", [["Infected falls", "PROBLEM", 27, 41], ["benchmark control strategy", "TREATMENT", 162, 188], ["Infected", "OBSERVATION_MODIFIER", 27, 35], ["falls", "OBSERVATION", 36, 41]]], ["In this approach, the control actions are applied when the number of Threatened cases is higher than a predetermined threshold.", [["higher", "OBSERVATION_MODIFIER", 89, 95]]], ["More in detail, at the end of each week, if the Threatened cases are higher than the threshold level, all the measures (intra and inter-region 770 control actions) are applied in the subsequent week.", [["intra and inter-region 770 control actions", "TREATMENT", 120, 162]]], ["In fact, the current Italian protocol considers safety thresholds on the number of infected and Threatened.", [["the current Italian protocol", "TREATMENT", 9, 37], ["infected", "OBSERVATION", 83, 91]]], ["When these thresholds are exceeded in a specific region, the restrictive measures are applied to reduce the number of cases.", [["the restrictive measures", "TREATMENT", 57, 81], ["restrictive", "OBSERVATION", 61, 72]]], ["The threshold directly influences the total economic cost and 775 the number of Threatened people.", [["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97]]], ["In fact, a high threshold leads to a large number of Threatened cases that may exceed the maximum capacity.", [["Threatened cases", "TREATMENT", 53, 69], ["large", "OBSERVATION_MODIFIER", 37, 42]]], ["Conversely, a low threshold would keep the number of cases low by having a higher economic cost.", [["a higher economic cost", "PROBLEM", 73, 95]]], ["In our simulation, we assume a safety level for all the regions equal to 0.8T max i ; this results in an economic cost of 830.33., i.e., only the last two terms of (37).", [["a safety level", "TEST", 29, 43]]], ["Moreover, the figure 780 shows that this strategy is ineffective in containing the number of Threatened cases.", [["ineffective", "OBSERVATION_MODIFIER", 53, 64]]], ["Figure 9 : Benchmark control strategy 2: Threatened cases (blue line), intra-region activity (red line) and inter-region travel (green dotted line) restrictions, and the maximum number of Threatened that can be treated by the region (black line).", [["Benchmark control strategy", "TREATMENT", 11, 37], ["Threatened cases (blue line", "TREATMENT", 41, 68], ["intra-region activity (red line", "PROBLEM", 71, 102], ["green dotted line", "TREATMENT", 129, 146], ["red line", "OBSERVATION", 94, 102], ["Threatened", "OBSERVATION", 188, 198], ["black line", "OBSERVATION", 234, 244]]], ["For each region, the x-axis reports the time in days, the left y-axis represents the number of Threatened, and the right y-axis represents the value of the control actions.", [["left", "ANATOMY_MODIFIER", 58, 62], ["number", "OBSERVATION_MODIFIER", 85, 91], ["Threatened", "OBSERVATION", 95, 105], ["right", "ANATOMY_MODIFIER", 115, 120]]], ["Figure 10 : Benchmark control strategy 3: Threatened cases (blue line), intra-region activity (red line) and inter-region travel (green dotted line) restrictions, and the maximum number of Threatened that can be treated by the region (black line).", [["Benchmark control strategy", "TREATMENT", 12, 38], ["Threatened cases (blue line", "TREATMENT", 42, 69], ["intra-region activity (red line", "PROBLEM", 72, 103], ["green dotted line", "TREATMENT", 130, 147], ["red line", "OBSERVATION", 95, 103], ["Threatened", "OBSERVATION", 189, 199], ["black line", "OBSERVATION", 235, 245]]], ["For each region, the x-axis reports the time in days, the left y-axis represents the number of Threatened, and the right y-axis represents the value of the control actions.745We now compare the results of the MPC approach (Section 4.2) with respect to the above results.", [["left", "ANATOMY_MODIFIER", 58, 62], ["number", "OBSERVATION_MODIFIER", 85, 91], ["Threatened", "OBSERVATION", 95, 105], ["right", "ANATOMY_MODIFIER", 115, 120]]], ["Disregarding the difference between the three different policies (i.e., U-U, D-U, and D-D), the objective function value is always significantly lower than that of all the benchmark control strategies, due to different factors as detailed in the 785 sequel.745Comparing the proposed MPC results with the benchmark control strategy 1, it is apparent that, since no restrictions are applied, the number of Threatened largely exceeds the maximum limit in all the regions in the latter case.", [["D-U", "GENE_OR_GENE_PRODUCT", 77, 80], ["D-D", "GENE_OR_GENE_PRODUCT", 86, 89], ["the objective function value", "TEST", 92, 120], ["the benchmark control strategy", "TREATMENT", 300, 330], ["Threatened", "OBSERVATION", 404, 414], ["maximum", "OBSERVATION_MODIFIER", 435, 442]]], ["Hence, although the economic cost is null, the global objective function value is much higher than that of 790 the proposed MPC approach.745Referring to the benchmark control strategy 2, the number of Threatened is kept at the lowest value.", [["the global objective function value", "TEST", 43, 78], ["the proposed MPC approach", "TREATMENT", 111, 136]]], ["Nevertheless, since the economic aspect is ignored, the last two parts of the objective function largely arise, thus leading to a higher global objective function value with respect to that of the presented MPC method.795The comparison between the proposed MPC and the benchmark control strategy 3 is of particular interest.", [["a higher global objective function value", "PROBLEM", 128, 168], ["the proposed MPC", "TREATMENT", 244, 260], ["the benchmark control strategy", "TREATMENT", 265, 295]]], ["The latter shows an economic cost, which is computed by taking into account only the last two parts of the objective function, four times higher than that of the D-D policy and two times higher than that of the U-U one.", [["D-D", "SIMPLE_CHEMICAL", 162, 165], ["U-U", "GENE_OR_GENE_PRODUCT", 211, 214], ["the D-D policy", "TREATMENT", 158, 172], ["economic", "OBSERVATION_MODIFIER", 20, 28], ["cost", "OBSERVATION", 29, 33]]], ["In addition, since the benchmark strategy 3 is unable to keep the number of Threatened below the 800 maximum limit in all the regions, the first part of the objective function makes the total cost much higher than the proposed MPC approach.795Summing up, from the above simulations it arises that the proposed optimal control approach provides the best compromise between the two most important governmental aspects (that is, the economic and the social features of interventions), being able to 805 keep the number of Threatened cases below a maximum limit while minimizing the economic cost of the eventually required lockdown periods.", [["the proposed MPC approach", "TREATMENT", 214, 239], ["the proposed optimal control approach", "TREATMENT", 297, 334], ["lockdown periods", "TREATMENT", 620, 636]]], ["Consequently, the proposed methodology represents a useful support tool for policy-makers to mitigate the COVID-19 outbreak in case of secondary pandemic waves.", [["pandemic", "DISEASE", 145, 153], ["the COVID", "TEST", 102, 111], ["secondary pandemic waves", "PROBLEM", 135, 159], ["pandemic waves", "OBSERVATION", 145, 159]]], ["810 In this paper, we propose a novel feedback control strategy aimed at supporting policy-makers in efficiently mitigating the effects of COVID-19 pandemic contagions in multi-region areas, such as Italy, where the contagion peak has been reached and, in a post-lockdown phase, coordinated regional restarting strategies are needed.Conclusions and future worksThe presented methodology makes joint use of an epidemiological SIR-based model815(namely a SIRQTHE model) in conjunction with a non-linear Model Predictive Control (MPC) approach, with the final aim of minimizing the cost of the adopted mitigation strategies, while ensuring that the capacity of the regional healthcare systems is not violated.", [["a novel feedback control strategy", "TREATMENT", 30, 63], ["COVID", "TREATMENT", 139, 144], ["coordinated regional restarting strategies", "TREATMENT", 279, 321], ["a non-linear Model Predictive Control (MPC) approach", "TREATMENT", 488, 540], ["the adopted mitigation strategies", "TREATMENT", 587, 620], ["joint", "ANATOMY", 393, 398]]], ["First, the SIRQTHE model allows to consider seven compartments of individuals (that is, Susceptible,Infected, Removed, Quarantined, Threatened, Healed, and 820 Extinct), thus ensuring a detailed representation of the pandemic dynamics, which is further guaranteed thanks to the definition of time-varying parameters.", [["the SIRQTHE model", "TREATMENT", 7, 24], ["Healed", "OBSERVATION_MODIFIER", 144, 150]]], ["On the one hand, the proposed 825 approach fills a gap in the existing literature, where in reference to a multi-region scenario there is a lack of investigations on optimal control approaches aimed at effectively coping with possible onset of further epidemic waves, while efficiently returning economic activities to the standard level of intensity.", [["optimal control approaches", "TREATMENT", 166, 192], ["further epidemic waves", "PROBLEM", 244, 266]]], ["On the other hand, the application to the network of Italian regions based on real data-sets highlights the planning utility 830 and flexibility of the proposed MPC approach in determining differentiated, as well as coordinated, optimal control actions over all the given regions.", [["real data", "TEST", 78, 87], ["the proposed MPC approach", "TREATMENT", 148, 173]]], ["Whilst in the presented numerical experiments we choose the network of Italian regions as the multi-region area under control, an interesting devel-835 opment of the research can be to apply the MPC approach to determine the differentiated, as well as coordinated, optimal control policies of higher-and lower-granularity networks, such as, for instance, the counties in the European Union or the districts within the same region.815Nonetheless, this study is not without limitations, which still need to be investi-840 gated in future works.", [["investi-840", "CHEMICAL", 508, 519], ["the MPC approach", "TREATMENT", 191, 207], ["this study", "TEST", 446, 456], ["not without", "UNCERTAINTY", 460, 471]]], ["In particular, the main limitation of the proposed framework relies on the centralized computation of the regional optimal control policies.", [["main", "OBSERVATION_MODIFIER", 19, 23]]], ["Due to economical, political, and societal reasons, a centralized control approach may not be appealing in the epidemic control of a multi-region framework.", [["a centralized control approach", "TREATMENT", 52, 82]]], ["Hence, the optimization of the regional strategies may be preferably performed through a cooperative distributed framework.815Therefore, our future work will mainly be devoted to define an iterative mechanism to determine the regional optimal control policies in a cooperative distributed setting.815Finally, one may observe that results and implications are derived from a simple model of control and mitigation actions, since we consider a finite set of intra-region activity and inter-region mobility restrictions producing additive effects on the reduction of infection.", [["infection", "DISEASE", 564, 573], ["a simple model of control", "TREATMENT", 372, 397], ["intra-region activity", "TREATMENT", 456, 477], ["inter-region mobility restrictions", "TREATMENT", 482, 516], ["infection", "PROBLEM", 564, 573], ["infection", "OBSERVATION", 564, 573]]], ["Actually, this limitation is only apparent, since the proposed model can be easily generalized to more complex cases by adding other terms in the objective 855 function and constraints to deal with the eventual finer control and mitigation actions producing combined non-linear effects on the analyzed epidemic dynamics.Appendix A. Parameters identificationIn this Appendix we explain how we calibrate the SIRQTHE model for the considered numerical experiments.", [["mitigation actions", "TREATMENT", 229, 247], ["combined non-linear effects", "PROBLEM", 258, 285], ["the SIRQTHE model", "TREATMENT", 402, 419]]], ["Data availability in the Italian scenario and main assumptionsThe Italian State body largely responsible for the management of natural disasters 865 and catastrophes is the Protezione Civile [32] (i.e., the Italian Civil Protection Department) [32] .", [["body", "ANATOMY", 80, 84], ["body", "ORGANISM_SUBDIVISION", 80, 84], ["catastrophes", "PROBLEM", 153, 165]]], ["During a pandemic emergency, the Protezione Civile is responsible for collecting and elaborating all the data related with the pandemic.", [["the Protezione Civile", "TREATMENT", 29, 50], ["the pandemic", "PROBLEM", 123, 135]]], ["More in detail, several data (and analyses) on a daily basis are available for the COVID-19 pandemic [29] :870\u2022 total cases: cumulative number of people infected, also comprehending healed and dead;870\u2022 hospitalized in a non-critical situation: number of people that are identified as currently infected and as such they are hospitalized, although their situation is not critical;875\u2022 hospitalized in a critical situation: number of people that are currently hospitalized in an Intensive Care Unit because of their severe situation;875\u2022 in quarantine: number of people recognized as infected; however, due to their mild or absent symptoms, they are legally obliged to stay in isolation at home;875\u2022 healed: number of people recognized as infected, but dismissed because healed;880\u2022 deceased: number of people dead because of COVID-19;880\u2022 swabs: number of swabs made by the national healthcare system.880Besides the above data, in order to perform a realistic and fruitful selection of the model parameters for the whole Italian outbreak (i.e., from February until to the post-lockdown restarting phase in June) we should not neglect that all parameters are 885 variable and time-dependent, especially during the first spread of the virus in a country.880In the literature, a pragmatic and widely adopted approach to overcome this limitation consists in fitting the model by employing different time windows, which reflect the different stages of the epidemic, and to set the parameters constant within each of these periods [37] .", [["people", "ORGANISM", 146, 152], ["people", "ORGANISM", 255, 261], ["people", "ORGANISM", 433, 439], ["people", "ORGANISM", 562, 568], ["people", "ORGANISM", 717, 723], ["people", "ORGANISM", 802, 808], ["people", "SPECIES", 146, 152], ["people", "SPECIES", 255, 261], ["people", "SPECIES", 433, 439], ["people", "SPECIES", 562, 568], ["people", "SPECIES", 717, 723], ["people", "SPECIES", 802, 808], ["their mild or absent symptoms", "PROBLEM", 609, 638], ["COVID", "TEST", 825, 830], ["healed", "OBSERVATION_MODIFIER", 182, 188], ["infected", "OBSERVATION", 738, 746], ["different stages", "OBSERVATION_MODIFIER", 1427, 1443]]], ["For instance, it is possible to add constraints on the parameters based on the available scientific knowledge.880Conversely, in this paper, we fit the model by assuming that the required parameters can be predicted with some time-dependent functions.", [["the parameters", "TEST", 51, 65]]], ["Moreover, the following assumptions are made on the parameters:895\u2022 \u03b2 i (k) (i.e., the infection rate of region i at time k): in the related literature (see, e.g., the work in [35] ), this parameter typically ranges between 0.35 and 0.55 in the absence of social distancing policies and people awareness.", [["infection", "DISEASE", 87, 96], ["people", "ORGANISM", 287, 293], ["people", "SPECIES", 287, 293], ["the infection rate of region", "PROBLEM", 83, 111], ["this parameter", "TEST", 184, 198]]], ["However, this value highly decreases during lockdown periods.", [["this value", "TEST", 9, 19], ["decreases", "OBSERVATION_MODIFIER", 27, 36]]], ["In our work, to perform a continuous fitting of the COVID-19 from March to June (that is, during the post-900 lockdown phase), we correlate the evolution of \u03b2 with the evolution of people's mobility computed on the basis of the daily Google mobility reports [34] , aggregated on a weekly basis.", [["people", "ORGANISM", 181, 187], ["COVID-19", "DNA", 52, 60], ["\u03b2", "PROTEIN", 157, 158], ["people", "SPECIES", 181, 187], ["the COVID", "TREATMENT", 48, 57]]], ["Therefore, the infection rate at the week w is defined as:895where \u03b2 0 i is the infection rate in region i when no containment measures are 905 applied, M i (\u00b7) is the weekly mobility level (i.e., M i (\u00b7) is a function of weeks and it ranges between 0 and 1) in region i, and d i is the delay of effects that mobility has on the contagion in region i.", [["infection", "DISEASE", 15, 24], ["infection", "DISEASE", 80, 89], ["the infection rate", "PROBLEM", 11, 29], ["the infection rate", "PROBLEM", 76, 94], ["containment measures", "TREATMENT", 115, 135], ["infection", "OBSERVATION", 15, 24], ["infection", "OBSERVATION", 80, 89], ["mobility", "OBSERVATION_MODIFIER", 309, 317]]], ["Note that, since the effects of social restrictions are not immediate, after a sensitivity analysis on the available data we consider a delay of one week in all the regions.", [["a sensitivity analysis", "TEST", 77, 99]]], ["Hence, we set d i = 1, \u2200i \u2208 M. Also note 910 that the use of a different \u03b2 0 i for each region would help the model fitting model, since \u03b2 0 i is likely to increase in the regions with a higher population density (we refer the interested reader to the work in [38] ).", [["\u03b2 0 i", "DNA", 73, 78], ["a higher population density", "PROBLEM", 185, 212], ["likely to", "UNCERTAINTY", 146, 155], ["increase", "OBSERVATION_MODIFIER", 156, 164], ["higher", "OBSERVATION_MODIFIER", 187, 193], ["population", "OBSERVATION_MODIFIER", 194, 204], ["density", "OBSERVATION", 205, 212]]], ["Nevertheless, for the sake of limiting the number of parameters, we set for all the Italian regions a uniform value for this parameter: \u03b2 0 i = \u03b2 0 , \u2200i \u2208 M.915\u2022 \u03b3 and \u03b4 (i.e., the rate of healing of unrecognized infected people who do not need hospitalization and the rate of healing of Quarantined people who do not need hospitalization, respectively): the value assigned to these parameters can be approximated by a constant since currently there is no proof that the virus has mutated.", [["people", "ORGANISM", 222, 228], ["people", "ORGANISM", 300, 306], ["people", "SPECIES", 222, 228], ["people", "SPECIES", 300, 306], ["\u03b3", "TEST", 162, 163], ["\u03b4", "TEST", 168, 169], ["the rate", "TEST", 177, 185], ["the virus", "PROBLEM", 467, 476], ["no proof", "UNCERTAINTY", 453, 461], ["virus", "OBSERVATION", 471, 476]]], ["In theory, these two parameters have different values: in several 920 countries, someone may leave the quarantine only after two negative swabs, i.e., a person may be forced to be in quarantine even after clinically healed.", [["person", "SPECIES", 153, 159]]], ["Nevertheless, for the sake of reducing the model parameters in the identification phase, we assume, without loss of generality, that these two parameters equal.", [["loss of generality", "PROBLEM", 108, 126]]], ["In particular, the literature findings show that setting \u03b3 = 1/14 is appropriate (see, e.g., 925 the work in [39] ) and therefore we assume this value for all the regions.915\u2022 \u03b8 i (i.e., the rate of infected people that are recognized and Quarantined of region i): this parameter is mainly related with the specific policy adopted by each region and the number of laboratory testing capacities (e.g., in terms of tested swabs).", [["people", "ORGANISM", 208, 214], ["people", "SPECIES", 208, 214], ["laboratory testing capacities", "TEST", 364, 393], ["tested swabs", "TEST", 413, 425], ["infected", "OBSERVATION", 199, 207]]], ["However, when the laboratory limits were reached at the beginning of 930 March the number of tested swabs became constant.", [["swabs", "ANATOMY", 100, 105]]], ["Therefore, we assume this parameter as time-independent, but variable from region to region.915\u2022 \u03bb and \u00b5 (i.e., the rate of people recognized only when strong symptomatic conditions occur and the rate of Quarantined people to be hospitalized, respectively): both parameters represent the rates of people that need to be hospitalized.", [["people", "ORGANISM", 124, 130], ["people", "ORGANISM", 216, 222], ["people", "ORGANISM", 297, 303], ["people", "SPECIES", 124, 130], ["people", "SPECIES", 216, 222], ["people", "SPECIES", 297, 303], ["strong symptomatic conditions", "PROBLEM", 152, 181]]], ["As 935 these parameters are only related with the virus nature, we assume they are both constant and equal for all the regions.915\u2022 \u03c0 i (k) (i.e., the recovery rate of region i at time k): this parameter is far from being constant during the spread of COVID-19.", [["COVID-19", "CHEMICAL", 252, 260], ["the virus nature", "PROBLEM", 46, 62], ["COVID", "TEST", 252, 257], ["constant", "OBSERVATION_MODIFIER", 88, 96]]], ["The national healthcare system may not be prepared and does not have therapeutic procedures for patients with 940 symptoms that have never been seen before.", [["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 96, 104], ["therapeutic procedures", "TREATMENT", 69, 91], ["940 symptoms", "PROBLEM", 110, 122]]], ["This means that initially the evolution of the number of recoveries can be slow until a constant value is reached, i.e., when the healthcare system becomes ready and prepared.", [["a constant value", "TEST", 86, 102]]], ["In particular, on the basis of the performed analyses, we impose the parameter \u03c0 to be time-dependent with the following formulation for each region:915\u2022 \u03b5 i (k) (i.e., the death rate of region i at time k): the number of deaths is not constant and hopefully decreases with time.", [["death", "DISEASE", 173, 178], ["deaths", "DISEASE", 222, 228]]], ["This is mainly due to the availability of new clinical treatments.", [["new clinical treatments", "TREATMENT", 42, 65]]], ["Furthermore, at the beginning of an epidemic, when the screening of infected people is low, only the sever symptoms cases are recognized and treated.", [["people", "ORGANISM", 77, 83], ["people", "SPECIES", 77, 83], ["the screening", "TEST", 51, 64], ["the sever symptoms", "PROBLEM", 97, 115], ["infected", "OBSERVATION", 68, 76]]], ["With the ongoing of the pandemic, more cases are recognized 950 as infected, and hence the percentage of severe symptoms cases becomes lower.", [["severe symptoms", "PROBLEM", 105, 120], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["symptoms", "OBSERVATION", 112, 120], ["lower", "OBSERVATION_MODIFIER", 135, 140]]], ["Therefore, taking into account the performed analyses, we set parameter \u03b5 i as time-dependent with the following formulation for each region:915\u03b5 i (k) = a 4,i + exp (\u2212a 5,i (k + a 6,i )) (A.3)915\u2022 \u03be i,j (k) (i.e., the inter-region mobility coefficient between regions i and j at time k): these parameters are adapted from [35] due to the different model assump-955 tions; in detail, the aforementioned work considers the interaction between the people between different regions.", [["people", "ORGANISM", 446, 452], ["people", "SPECIES", 446, 452], ["the inter-region mobility", "PROBLEM", 215, 240], ["these parameters", "TEST", 289, 305]]], ["In contrast, we consider physical migration between different classes.Appendix A.2.", [["Appendix", "TEST", 70, 78]]], ["Parameters identification for Single-region SIRQTHE modelsIn order to estimate the parameters for the Single-region SIRQTHE model, we adopt 960 a pragmatic approach with a least-squares optimization technique based on the real data combined with hard constraints to enforce the prior knowledge on the system.Appendix A.2.", [["Parameters identification", "TEST", 0, 25], ["Single-region SIRQTHE models", "TREATMENT", 30, 58], ["optimization technique", "TREATMENT", 186, 208], ["the real data", "TEST", 218, 231], ["Appendix", "TEST", 308, 316]]], ["Parameters identification for Single-region SIRQTHE modelsThe containment measures of the pandemic in Italy can be divided into two main phases, one following February 23, which mainly concerned Northern Italy, and a second one following March 09, including the more restrictive measures affecting the 965 whole national territory.", [["Parameters identification", "TEST", 0, 25], ["Single-region SIRQTHE models", "TREATMENT", 30, 58], ["containment", "OBSERVATION_MODIFIER", 62, 73], ["more", "OBSERVATION_MODIFIER", 262, 266], ["restrictive", "OBSERVATION", 267, 278]]], ["The first restrictive measures, which comprehend the closure of schools, universities, and bars and restaurants after 6 p.m., had limited effects on the contagion dynamics and, as the crisis worsened, the need for more severe restrictions motivated the second phase, which turned into a total lockdown where all the non-essential production activities were shut down.", [["The first restrictive measures", "TREATMENT", 0, 30], ["the crisis", "PROBLEM", 180, 190], ["more severe restrictions", "PROBLEM", 214, 238], ["a total lockdown", "TREATMENT", 285, 301], ["restrictive", "OBSERVATION_MODIFIER", 10, 21], ["closure", "OBSERVATION_MODIFIER", 53, 60]]], ["Since two of these equations are highly non-linear, the fitting procedure is highly non-convex; indeed, as proposed in [16] , improved results can be obtained by splitting each regional model into two simpler sub-models and thus performing a two-stage fitting procedure.980In the first stage we analyze the following sub-model:980where C(k) = Q(k) + T (k) + H(k) + E(k) is the cumulative number of Infected people.", [["people", "ORGANISM", 407, 413], ["people", "SPECIES", 407, 413], ["the fitting procedure", "TREATMENT", 52, 73], ["a two-stage fitting procedure", "TREATMENT", 240, 269], ["k", "TEST", 345, 346], ["Infected", "OBSERVATION", 398, 406]]], ["It is clear that \u03b2 0 , \u03c4 = \u03b8 + \u03bb, and the initial condition\u0128(0) are the only parameters to be estimated.", [["clear", "OBSERVATION", 6, 11]]], ["The estimation of such parameters consists in minimizing the mean squared error (MSE) of the model with respect to the real data, which is defined as: In the second stage, we analyze the following sub-model:980T (k + 1) = T (k) + \u00b5 Q(k) + \u03bb I(k) \u2212 (\u03c0(k) + \u03b5(k)) T (k) (A.9)980H(k + 1) = H(k) + \u03b3 Q(k) + \u03c0(k) T (k) (A.10)980where we assume that the parameters \u03c0(k) and \u03b5(k) are time-dependent.", [["H(k) + \u03b3 Q(k) + \u03c0(k) T (k) (A.10)980", "CHEMICAL", 287, 323], ["The estimation of such parameters", "TEST", 0, 33], ["k", "TEST", 213, 214], ["k", "TEST", 225, 226], ["k", "TEST", 243, 244], ["k", "TEST", 251, 252], ["k", "TEST", 258, 259], ["k", "TEST", 265, 266], ["k", "TEST", 278, 279], ["k", "TEST", 289, 290], ["k", "TEST", 298, 299], ["k", "TEST", 305, 306], ["k", "TEST", 311, 312], ["the parameters", "TEST", 344, 358], ["k", "TEST", 361, 362], ["k", "TEST", 370, 371], ["dependent", "OBSERVATION", 382, 391]]], ["The estimation of the parameters of the Multi-region SIRQTHE model follows a two-stage fitting procedure similar to that described in Appendix A.2, except for the differences highlighted in the sequel.", [["Multi-region SIRQTHE model", "CELL_LINE", 40, 66], ["Appendix A.2", "CELL_LINE", 134, 146], ["a two-stage fitting procedure", "TREATMENT", 75, 104], ["Appendix", "ANATOMY", 134, 142]]], ["First, we note that, since the multi-region model takes the migrations between regions into account, the corresponding fitting window includes also periods when the inter-region borders are opened in Italy (i.e., from February 29 to June 3).", [["migrations", "OBSERVATION_MODIFIER", 60, 70], ["fitting window", "OBSERVATION", 119, 133]]], ["These coefficients are adapted from [16] : in particular, the authors in [16] use two sets of average number of people migrated from region i to region j, respectively referred the lockdown and post-lockdown phases; in our model we normalize the data used in [16] with respect to the regional population in order to determine the migration rate \u03be i,j (k) (\u2200i = j \u2208 M) and we compute \u03be i,i (k) (\u2200i \u2208 M) through (19) .", [["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118], ["the migration rate", "TEST", 326, 344]]]]}